<SEC-DOCUMENT>0001829126-24-000192.txt : 20240116
<SEC-HEADER>0001829126-24-000192.hdr.sgml : 20240116
<ACCEPTANCE-DATETIME>20240112182831
ACCESSION NUMBER:		0001829126-24-000192
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		36
FILED AS OF DATE:		20240116
DATE AS OF CHANGE:		20240112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEONC TECHNOLOGIES HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001979414
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				921954864
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276124
		FILM NUMBER:		24533144

	BUSINESS ADDRESS:	
		STREET 1:		8335 SUNSET BOULEVARD
		STREET 2:		SUITE 240
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
		BUSINESS PHONE:		310 663 7831

	MAIL ADDRESS:	
		STREET 1:		8335 SUNSET BOULEVARD
		STREET 2:		SUITE 240
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>neonctechnologies_s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As filed with the Securities and Exchange Commission on January 12, 2024.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">276124</FONT></B> </P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington, D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 14pt"><B>AMENDMENT
NO. 1</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 14pt"><B>TO</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>FORM S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92-1954864</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation or organization)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary Standard Industrial</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Classification Code Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S. Employer<BR> Identification No.)</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address including zip code, telephone number, including area code, of Registrant&rsquo;s Principal Executive Offices)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8335 Sunset Boulevard, Suite 240<BR> </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Los Angeles, CA 90069<BR> (310) 663-7831</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name, address including zip code, telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr. Thomas C. Chen</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8335 Sunset Boulevard, Suite 240</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los Angeles, CA 90069</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(310) 663-7831</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Copies To:</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas J. Poletti, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Veronica Lah, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manatt, Phelps &amp; Phillips LLP</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>695 Town Center Drive, 14<SUP>th</SUP> Floor</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Costa Mesa, CA 92626</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(714) 371-2500</B></FONT></P></TD>
    <TD STYLE="text-align: center; width: 34%">
        <P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amir Farrokh Heshmatpour<BR> Patrick Walters<BR> Keithly Garnett<BR> 8335 Sunset Boulevard, Suite 240<BR> Los Angeles, CA 90069<BR> (310) 663-7831</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mitchell S. Nussbaum, Esq.<BR> Angela M. Dowd, Esq.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loeb &amp; Loeb LLP<BR> 345 Park Avenue<BR> New York, NY 10154<BR> (212) 407-4000</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act, check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act (Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #D81E05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #D81E05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 46%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 54%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT TO COMPLETION, DATED JANUARY 12, 2024</B></FONT> </TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">NEONC TECHNOLOGIES HOLDINGS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This is the initial public offering of ______ shares of common stock of NeOnc Technologies Holdings, Inc., based on an assumed public offering price of $____ per share, which is the midpoint of the range discussed below. Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price will be between $____ and $____ per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have applied to have our shares of common stock listed on the Nasdaq Capital Market under the symbol &ldquo;NTHI&rdquo;. The closing of this offering is contingent upon our listing on the Nasdaq Capital Market. No assurance can be given that our application will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are an &ldquo;emerging growth company,&rdquo; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See &ldquo;<I>Prospectus Summary&#8212; Implications of Being an Emerging Growth Company</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing in our common stock involves a high degree of risk. See the section entitled &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 12 to read about factors you should consider before buying shares of our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither the Securities and Exchange Commission in the United States nor any other regulatory body has approved or disapproved of these common shares or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per Share</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial public offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds, before expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;<I>Underwriting</I>&rdquo; for additional disclosure regarding underwriting discounts and commissions and estimated offering expenses payable to the underwriters. The Company has separately retained Maxim Group LLC (&ldquo;Maxim&rdquo;) as a financial advisor in connection with this offering. Such financial advisory services are separate from those services to be performed by Maxim as an underwriter in connection with this offering. The Company has agreed to pay Maxim a separate cash fee equal to three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have granted the underwriters a 45-day option from the date of this prospectus to purchase up to ______ additional shares of common stock from us at the initial public offering price less the underwriting discounts and commissions, solely to cover the underwriters&rsquo; option to purchase additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriters expect to deliver the shares of common stock to purchasers against payment in New York, New York on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024.</FONT> </P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole Bookrunning Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Loop Capital Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Co-Managers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 12pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left; width: 33%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Maxim Group LLC</B></FONT> </TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 34%"></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 33%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Brookline
    Capital Markets,</B></FONT> </TD> </TR>
  <TR STYLE="font: 12pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a division of Arcadia Securities, LLC</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="toc1"></A>Table of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">INDUSTRY AND MARKET DATA</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">THE OFFERING </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">RISK FACTORS </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">78</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">80</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">82</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DILUTION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">83</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">BUSINESS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">MANAGEMENT</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">PRINCIPAL SHAREHOLDERS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">169</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">SHARES ELIGIBLE FOR FUTURE SALE</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">179</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">181</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">188</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">188</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">188</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we nor the underwriters take responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through and including ____, 2024 (the 25<SUP>th</SUP> day after the date of this prospectus), all dealers that buy, sell or trade in our common shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For investors outside of the United States neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about, and to observe any restrictions relating to, this offering and the distribution of this prospectus outside of the United States. See the section of this prospectus entitled &ldquo;<I>Underwriting</I>&rdquo; for additional information on these restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, information in this prospectus concerning economic conditions, our industries and our markets is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. This information involves a number of assumptions, estimates and limitations. The industry publications, surveys and forecasts and other public information generally indicate or suggest that their information has been obtained from sources believed to be reliable. None of the third-party industry publications used in this prospectus were prepared on our behalf. The industries in which we operate are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;<I>Risk Factors</I>&rdquo; in this prospectus. These and other factors could cause results to differ materially from those expressed in these publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our businesses. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&rsquo; trademarks, service marks and trade names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the &reg;, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_001"></A>INDUSTRY AND MARKET DATA</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We obtained the industry, market, and competitive position data used throughout this prospectus from our own internal estimates and research, as well as from independent market research, industry, and general publications and surveys, governmental agencies, and publicly available information in addition to research, surveys, and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research, and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market, and competitive position data included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &ldquo;<I>Risk Factors</I>.&rdquo; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_002"></A>PROSPECTUS SUMMARY</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>This summary highlights certain significant aspects of our business and this offering and is a summary of information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Business&rdquo; and our financial statements and related notes thereto included in this prospectus, before making an investment decision. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless otherwise indicated, all share and per share information in this prospectus has been retroactively restated to give effect to a 1.222 for-1 forward split of our outstanding shares of common stock in April 2023 and the subsequent issuance of 10,500,000 shares of our common stock to shareholders of NeOnc Technologies, Inc. in April 2023 in a share exchange.</I></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless the context otherwise requires, the terms &ldquo;NeOnc&rdquo;, &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to NeOnc Technologies Holdings, Inc., a Delaware corporation, and its wholly-owned subsidiary NeOnc Technologies, Inc., and &ldquo;this prospectus&rdquo; refers to the offering contemplated this prospectus.</I></FONT></P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (&ldquo;POH&rdquo;) which is administered to brain cancer patients via intranasal delivery. <U>Ongoing activities for intranasal delivery of NEO100</U>: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> We have completed human testing in a Phase 1 clinical trial and are currently conducting a Phase
    2a trial with recurrent malignant glioma (Grade IV, IDH1 mutant and Grade III Astrocytoma, IDH1 mutant) patients. </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A similar Phase 2a trial of intranasal NEO100 (NEO 100-02) for patients with malignant skull-based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Separate from this single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&rsquo;s preclinical studies suggest evidence that the combination of NEO100 with other drugs may enable a patient&rsquo;s improved brain tumor delivery via the intranasal route. Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&rsquo;s disease (PD). NeOnc&rsquo;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase 1 clinical trial is planned to study the impact on human patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our initial application for the Phase I/IIa trial for NEO 100 focused on an enrollment population with recurrent glioblastoma. Based on our Phase I results, NEO 100 showed more promise in patients with IDH1,2 mutant Grade IV astrocytomas. However, this patient population represented less than 5-10 percent of all patients with recurrent glioblastoma. As we planned for a total of 31 patients for Phase IIa in our initial analysis, enrollment of recurrent Grade IV, IDH1,2 mutants was limited due to the fact that only 5-10 percent of Grade IV astrocytomas have IDH1,2 mutations. Independent biostatistical review of clinical progression patterns of recurrent IDH1,2 mutated Grade III astrocytomas compared to recurrent IDH1,2 mutated Grade IV astrocytomas revealed that these two tumors have the same prognosis. As a result, in June 2023 we requested that the FDA not object to the inclusion of patients with recurrent Grade III IDH1,2 mutant astrocytomas in the Phase IIa trial. The FDA did not object and, as a result, the population of patients available to be enrolled is now much larger. Because the prognosis of recurrent Grade III IDH1,2 mutants is similar to recurrent IDH1,2 Grade IV astrocytomas, the number of patients needed to be enrolled in the Phase IIa trial to assess the clinical efficacy of NEO100 in the population of high grade astrocytomas did not change. The expanded patient population means that there are a significant number of additional patients that can be targeted for potential enrollment in the Phase IIa study; in an initial review, we have identified approximately 80 grade III IDH1,2 mutation-positive candidates. Patients with residual measurable disease are now followed via MRI scans to determine if there is progression, (recurrent disease), making them eligible for enrollment. We believe this targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite our trial process and we project that the readout for our Phase 2 studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> Our second lead product,
NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical
testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA), i.e., it
has been authorized to proceed to clinical testing in cancer patients. We have designed a Phase 1/2 trial for oral NEO212, which began
in the fourth quarter of 2023. In this trial, NEO212 will be administered orally to patients with primary brain tumors (i.e., malignant
gliomas) and secondary brain tumors (i.e., brain metastases derived from peripheral tumors, such as tumors of the lung, breast, skin/melanoma,
etc.). Furthermore, NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain
metastases derived from peripheral tumors (lung, breast, skin, etc.), but has not yet been studied in human patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, none of our product candidates have been approved for sale in the United States or elsewhere. We have no commercial products nor do we have a sales or marketing infrastructure. In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations elsewhere in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have not generated any revenue from product sales and from January&nbsp;1, 2021 to September 30, 2023 have only generated revenue of $90,462. We do not anticipate generating significant revenues for the foreseeable future. We had net loss of $8,765,816 for the nine months ended September 30, 2023 and $3,046,757 for the year ended December&nbsp;31, 2022. At September 30, 2023, we had an accumulated deficit of $32,554,732.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The World Health Organization (WHO) has estimated that CNS diseases affect nearly 2 billion people globally, making up approximately 40%of total disease burden (based on disability adjusted life years),compared with 13% for cancer and 12% for cardiovascular disease. According to Fortune Business Insights, the CNS treatment market is estimated to grow at 9.4% CAGR to $166.5 billion by 2028 and the global brain tumor drug market to grow at CAGR of 9.0% to $4.4 billion by 2029.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iHeathcareAnalys has reported that the malignant Glioblastoma Multiforme (GBM) drug market is expected to grow at 12.7% CAGR to $2.3 billion by 2029. According to the book, <I>Glioblastoma</I> by Ahmad Faleh Tamimi and Malik Juweid (2017), GBM accounts for up to 54% of gliomas and 16% of all primary brain cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our strategy is to leverage our considerable industry experience, understanding of the CNS and GBM markets and development expertise to identify, develop and commercialize product candidates with significant market potential that can fulfill unmet medical needs in the treatment of brain cancers and CNS diseases. We have assembled a management team along with both scientific and business advisors, including recognized experts in the fields of neuro-oncology, with significant industry and regulatory experience to lead and execute the development and commercialization of our NEO platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We plan to further develop NEO100 and NEO212 as our priority programs. We have generated and plan to continue to generate intellectual property (IP) that will further protect our products from competition. We will continue to prioritize our product development activities after considering the resources we have available, market dynamics and potential for adding value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual Property Portfolio and Market Exclusivity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have exclusively licensed a large worldwide patent portfolio from the University of Southern California (USC) consisting of both issued patents and pending patent applications related to NEO100, NEO212 and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that the key elements for our market success include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compelling lead product opportunity, with NEO100 currently in Phase 2 trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed large patent portfolio for NEO100 with currently issued patents expiring between 2030-2038; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential in additional multiple indications in underserved markets with large patient populations.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implications of Being an Emerging Growth Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As an emerging growth company, we are eligible to take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies and may elect to take advantage of other exemptions from reporting requirements in our future filings with the Securities Exchange Commission (&ldquo;SEC&rdquo;). In particular, in this prospectus, these exemptions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">presenting only two years of audited financial statements and only two years of related selected financial data and Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our registration statement of which this prospectus forms a part;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about our executive compensation arrangements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the requirements to hold non-binding advisory votes on executive compensation (&ldquo;Say on Pay&rdquo;);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended transition periods for complying with new or revised accounting standards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;); and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the auditor not being required to comply with the requirement in Public Company Accounting Oversight Board Auditing Standard 3101, <I>The Auditor&rsquo;s Report on an Audit of Financial Statements When the Auditor Expresses an Unqualified Opinion</I>, to communicate critical audit matters in the auditor&rsquo;s report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of this offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in annual revenue, we have more than $700 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form&nbsp;10-K) or we issue more than $1 billion of non-convertible debt securities over a three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of certain reduced reporting obligations in this prospectus. Further, pursuant to Section&nbsp;107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock, and our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. See &ldquo;<I>Risk Factors&#8212;Risks Related to this offering and Ownership or Our Common Stock</I>&rdquo; which describes that we are an emerging growth company, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Risks Related to Our Business</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business is subject to numerous risks and uncertainties, including those described in &ldquo;<I>Risk Factors</I>&rdquo; and elsewhere in this prospectus. You should carefully consider these risks before making an investment. These risks include, among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to our Financial Position and Need for Additional Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred significant losses since our inception and anticipate that we will incur significant and increasing losses for the foreseeable future and we may never achieve or maintain profitability.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we complete this offering, we will require additional financing to advance the development of our product candidates. Failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our operations.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never generated any revenue from product sales and may never become profitable. Raising additional capital may cause dilution to our shareholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. The report of our independent registered public accounting firm included a &ldquo;going concern&rdquo; explanatory paragraph.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to Product Discovery, Development and Regulatory Approval</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our development of product candidates based on our technology platform is limited, and we do not know whether we will be able to develop any products of commercial value.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have two clinical development product candidates (NEO100 and NEO212). The failure of one of these two product candidates in clinical development would adversely affect our business. It may require us to discontinue developing other product candidates based on the same therapeutic approach.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical development involves a lengthy and expensive process with an uncertain outcome and stringent regulations, and delays can occur for a variety of reasons.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we experience delays or difficulties in the enrolment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim, topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious adverse events, undesirable side effects (including emergent drug-drug interactions between NEO100 and any of the other therapeutic agents given to the clinical trial subjects) or other unexpected properties of our current or future product candidates may be identified during development or after approval, which could halt their development or lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that many of our product candidates, if approved, may be used in combination with third-party drugs and/or devices, some of which may still be in development, and we have limited or no control over the supply, regulatory status or regulatory approval of such drugs and/or devices.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not achieve our product development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and as a result our share price may decline.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the commercialization of NEO100 and any other product candidate we develop.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of any products for unapproved or &ldquo;off-label&rdquo; uses, resulting in damage to our reputation and business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to Manufacturing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in product candidate manufacturing or formulation may result in additional costs or delay, including due to requirements for additional regulatory approvals.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or our contract manufacturing partner(s) are unable to manufacture product candidates in the volumes that we require on a timely basis, or fail to comply with regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, any product candidates, and may lose potential revenues.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to Commercialization</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we, or our collaboration partners, are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in others discovering, developing or commercializing competing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success. The revenues that we generate from their sales may be limited, and we may never become profitable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates we develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to Our Intellectual Property&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual property rights are inadequate, our competitive position could be harmed.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to protect our intellectual property and proprietary rights throughout the world.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect NEO100, NEO212 and our other product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign regulatory authority.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as pharmacological products may face competition sooner than anticipated.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks Related to Our Business and Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the commercialization of any approved products and/or our product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc Technologies, Inc. was incorporated in Delaware in 2008 as NAS-ONC, Inc. In April&nbsp;2023, shareholders of NeOnc Technologies, Inc. completed a share exchange (the &ldquo;Share Exchange&rdquo;) with NeOnc Technologies Holdings, Inc. pursuant to which all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. Our executive offices are located at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90069 and our telephone number is (310) 633-7831. Our corporate website is www.neonctech.com. Information appearing on our corporate website is not incorporated as part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On December&nbsp;19, 2022, NeOnc Technologies, Inc. entered into an engagement agreement with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;). Amir Heshmatpour is the sole member and managing director of AFH and a member of NeOnc&rsquo;s Board of Directors. AFH was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing. AFH was retained to assist NeOnc Technologies, Inc. with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering, and was paid a fee of $500,000. AFH agreed to advance costs of up to $500,000 to the Company for fees paid to service providers related to a financing transaction and are to be repaid out of proceeds from the short-term loan provided to the company by HCWG LLC. As of September 30, 2023, no amounts were outstanding further to such agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On April&nbsp;7, 2023, NeOnc Technologies, Inc. and its shareholders entered into a Share Exchange Agreement (the &ldquo;Share Exchange&rdquo;) with NeOnc Technologies Holdings, Inc., whereby all of the shareholders of NeOnc Technologies, Inc. exchanged their stock in NeOnc Technologies, Inc. for a total of 10,500,000 shares of common stock in NeOnc Technologies Holdings, Inc. As a result, all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. At the consummation of this transaction, Amir Heshmatpour, AFH, and their affiliated entities, individuals, or assignees owned an aggregate of 34.4% of the fully diluted issued and outstanding common shares of NeOnc Technologies Holdings, Inc. NeOnc Technologies Holdings, Inc. was not formed until January 2023. As of the date of incorporation, NeOnc Technologies Holdings, Inc. had no operations or assets other than cash paid by its shareholders for their shares ($450 in the aggregate), no commitments and contingencies and liabilities of $50,000 pertaining to an amount owing to Mr. Heshmatpour for a professional retainer paid by him on our behalf. For this reason, no separate audited financial statements for the year ended December 31, 2022 are presented herein for NeOnc Technologies Holdings, Inc. and consolidated financial statements for such year ended with NeOnc Technologies, Inc. are not required to be filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition, NeOnc Technologies, Inc. agreed to retain AFH as its exclusive advisor on all financing and mergers and acquisitions for a period of two (2) years from the closing of a public offering. Further to the advisory arrangement, AFH shall be paid in cash an aggregate fee in an amount equal to 2% of the post-money valuation of NeOnc Technologies Holdings, Inc. immediately after the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Listing</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have applied to list our common stock on the Nasdaq Capital Market. There is no assurance that our listing application will be approved by Nasdaq. The approval of our listing on the Nasdaq Capital Market is a condition of closing. If our application to the Nasdaq Capital Market is not approved or we otherwise determine that we will not be able to secure the listing of the common stock on the Nasdaq Capital Market, we will not complete the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>The Offering</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    of Common Stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares (or ___ shares if the underwriters exercise the over-allotment option to purchase additional shares in full).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock to be outstanding after this Offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___
    shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        have granted to the underwriters a 45-day option to purchase from us up to an additional 15% of the shares of common stock sold
        in the offering at the initial public offering price, less the underwriting discounts and commissions to cover over-allotments.</FONT></P> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advisory
    Agreement</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has separately retained Maxim as a financial advisor in connection with this offering., Such financial advisory services
    are separate from those services to be performed by Maxim as an underwriter in connection with this offering. The Company has agreed
    to pay Maxim a separate cash fee equal to three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common
    stock in this Offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of Proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        estimate that our net proceeds from the sale of our common stock that we are offering will be approximately $___ (or approximately
        $___ if the over-allotment option is exercised in full), assuming an initial public offering price of $____ per share, the midpoint
        of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
        and commissions and estimated offering expenses.</FONT></P> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    principal purposes of this offering are to increase our capitalization and financial flexibility and create a public market for our
    common stock. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds
    to us of this offering. However, we currently intend to use approximately $23.7 million of the net proceeds for clinical trials,
    $11.4 million of the net proceeds for research and development, $10.0 million of the net proceeds to repay a short term loan provided
    to us by HCWG LLC, an entity substantially beneficially owned by our officers and directors, $913 thousand of the net proceeds to
    pay accrued salaries, and $30.5 million of the net proceeds for general corporate purposes and working capital, of which we will
    pay (i) AFH a cash fee in an amount equal to 2.0% of the post-money valuation of our company immediately after the consummation of
    this offering, (ii) Maxim an advisory fee of three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common
    stock in this, (iii) $600,000 in connection with a settlement of a dispute with a former licensee, and (iv) $230,000 to the University
    of Southern California for past due amounts under our license agreement with the University. See the section titled &ldquo;<I>Use
    of Proceeds</I>&rdquo; for additional information.</FONT>

</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common stock involves a high degree of risk. You should carefully read and consider the information set forth under &ldquo;Risk Factors&rdquo; and all other information in this prospectus before investing in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up Agreements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We, and all of our directors, officers and beneficial owners of 1% or more of our outstanding common stock (and all holders of securities exercisable for or convertible into shares of Common Stock) have agreed with the representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of six (6) months from the effective date of this prospectus. See &ldquo;<I>Underwriting</I>&rdquo; on page&nbsp;181.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer Agent</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VStock Transfer LLC.</FONT></P> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;NTHI.&rdquo; The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The number of shares of common stock that will be outstanding after this offering set forth above is based on 16,560,000 shares of common stock outstanding as of January __, 2024, and excludes the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">3,221,250 shares of common stock issuable upon
    the vesting of restricted stock units that were granted in January 2024; and </FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">3,440,000 shares of common stock (which includes the 3,221,250 shares
    issuable upon the vesting of the restricted stock units described above) currently reserved for future grant or issuance under our
    2023 Incentive Stock Plan (the &ldquo;2023 Plan&rdquo;), of which 218,750 shares would be available for future grant or issuance
    assuming the vesting of all restricted stock units that were granted in January 2024.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless specifically stated otherwise, all information in this prospectus assumes no exercise of the underwriters&rsquo; over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Financial Data</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>The following tables set forth selected summary financial data as of the dates and for the periods indicated. We have derived the summary statement of operations data for the years ended December 31, 2022 and 2021 from our audited financial statements and the summary balance sheet data as of September 30, 2023 and the summary statement of operations data for the nine months ended September 30, 2023 and 2022 from our unaudited interim consolidated financial statements included elsewhere in this prospectus. In our opinion, the unaudited interim financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair statement of such financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The historical results presented below are not necessarily indicative of the results to be expected for any future period and our interim results are not necessarily indicative of the results that may be expected for a full year. The following summaries of our financial data for the periods presented should be read in conjunction with the sections of this prospectus entitled &ldquo;Risk Factors,&rdquo; &ldquo;Capitalization,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and the related notes included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended<BR> September 30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<BR> December 31,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2023</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2022</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>2022<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>(Unaudited)</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>(Unaudited)</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top">Revenue</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 52%; vertical-align: top">Revenue</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">20,000</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating expenses:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">989,239</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">766,260</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,163,330</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">674,558</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Legal and professional</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,586,661</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">319,294</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">318,205</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">217,951</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,291,909</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,219,333</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">General and administrative</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,047,771</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">53,479</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">84,160</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">159,841</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advisory fee </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement expense </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">License expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,737,773</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total operating expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,461,444</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,971,283</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,857,604</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,271,683</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss from operations</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(7,390,982</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,971,283</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(2,837,604</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(3,271,683</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other expense:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in fair value of note payable &ndash; Chairman of the Board</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(9,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(9,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">9,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Interest expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,374,834</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200,153</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,919</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total other expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,374,834</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(209,153</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(103,919</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,765,816</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,980,283</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,046,757</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,375,602</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Diluted net loss per share</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.62</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.22</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.36</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.41</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Weighted average shares outstanding</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">14,044,444</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,853,126</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,480,860</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,305,331</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance Sheet Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of <BR> September&nbsp;30,<BR> 2023</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As Adjusted<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">769</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred offering costs</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">620,486</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,208,674</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable related party</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,318,727</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Litigation settlement payable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">600,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued compensation</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">913,404</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred revenue</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fair value of common stock payable for license fee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2,507,773</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Bridge loan &ndash; related party</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">4,144,604</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Paid-in capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">22,213,955</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accumulated deficit</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(32,554,732</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&rsquo; equity (deficit)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(10,340,777</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents summary financial data for NeOnc Technologies, Inc.</FONT></P> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    adjusted amounts reflect the sale of shares in this offering at the assumed initial public offering price of $____ per share, which
    is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting the estimated
    underwriting discounts and commissions and estimated offering expenses payable by us, and an advisory fee payable to Maxim of three-quarters
    of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering. Does not reflect certain payments
    to be made with a portion of the net proceeds of this offering as follows: (i) an amount equal to 2.0% of the post-money valuation
    of our company immediately after the consummation of this offering payable to AFH, (ii) $600,000 in connection with a settlement
    of a dispute with a former licensee, and (iii) $230,000 to the University of Southern California for past due amounts under our license
    agreement with the University. A $1.00 increase (decrease) in the assumed initial public offering price of $____ per share, which
    is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the
    as adjusted amount of each of cash, working capital, total assets and total shareholders&rsquo; equity by approximately $___, assuming
    that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated
    underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0
    million shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $___, assuming
    the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U><A NAME="a_004"></A>Risk Factors</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this prospectus, before deciding whether to invest in shares of our common stock. If any of the following risks actually occurs, our business, results of operations and financial condition could be materially adversely affected. In this case, the trading price of our common stock would likely decline, and you might lose part or all your investment in our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to our Financial Position and Need for Additional Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have incurred significant losses since our inception and anticipate that we will incur significant and increasing losses for the foreseeable future and we may never achieve or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical company, and our operations to date have been focused substantially on organizing and staffing our company, business planning, raising capital, creating, assessing, and developing our technology, establishing our intellectual property portfolio, identifying potential product candidates, undertaking preclinical studies, commencing clinical trials and manufacturing. Additionally, as an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product, or conduct sales and marketing activities necessary for successful commercialization. We have never generated any significant revenue and have incurred significant operating losses. Our net loss was $8,765,816, $3,046,757 and $3,375,602 for the nine months ended September 30, 2023 and the years ended December&nbsp;31, 2022 and 2021, respectively. As of September&nbsp;30, 2023, we had an accumulated deficit of $32,554,732. We expect to continue to incur significant and increasing operating losses for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&rsquo; deficit and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that it will be several years, if ever, before we have a commercialized product. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance the Phase 2 clinical trial for our lead product candidate, NEO100;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate planned and future clinical trials of NEO100 or NEO212 in other cancer indications;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discover and develop new product candidates, and conduct research and development activities, preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture preclinical, clinical and commercial supplies of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broaden and strengthen our internal manufacturing capabilities, including the expansion and upgrade of our in-house manufacturing facility;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect our intellectual property portfolio;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional research and development, clinical, scientific and management personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">add operational, financial and management information systems and personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain regulatory approval and we commercialize on our own or in collaboration with others; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional legal, accounting and other expenses operating as a public company following the completion of this offering.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials, obtaining regulatory approval for product candidates and manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We are only in the development stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even if we complete this offering, we will require substantial additional financing to advance the development of our product candidates, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, potential commercialization efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The development of biopharmaceutical product candidates is capital-intensive. Our operations have consumed substantial amounts of cash since inception. As of September&nbsp;30, 2023, we had $769 in cash. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of, and seek regulatory approval for, our current and future product candidates. If we are able to gain marketing approval of any product candidate that we develop, including NEO100 and NEO212, we will require significant additional amounts of cash in order to launch and commercialize such product either alone or in collaboration with others. Because the design and outcome of our ongoing, anticipated and any future clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future capital requirements depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of researching and developing NEO100, NEO212 and our other product candidates and programs, and of conducting preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of, and the costs involved in, obtaining marketing approvals for NEO100, NEO212 and future product candidates we develop if clinical trials are successful;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of any future collaborations;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of commercialization activities for any approved product, including marketing, sales and distribution costs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of establishing, equipping, and operating our current and planned manufacturing activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing NEO100, NEO212 and future product candidates for clinical trials in preparation for marketing approval and commercialization;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcome of seeking FDA and any other regulatory approvals for any future product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation or other patent challenge costs and the outcome of such litigation or other patent challenges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain healthcare coverage and adequate reimbursement for our future products, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt, and amount of sales of, or royalties on, our future products, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the emergence of competing cancer therapies and other adverse market developments;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with being a public company;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need and ability to retain key management and hire scientific, technical, medical and business personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with expanding our facilities or building out our laboratory space; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and the overall impact of the COVID-19 pandemic.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings and debt financings, or other capital sources such as potential collaborations, strategic alliances, licensing arrangements and other arrangements. Based on our research and development plans, we expect that the net proceeds from this offering, together with our existing cash balance, will enable us to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, because the design and outcome of our anticipated and any future clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of NEO100, NEO212 or any future product candidates. The net proceeds of this offering, together with our existing cash balance, may not be sufficient to complete development of NEO100, NEO212 or any other product candidate. Accordingly, we will be required to obtain further funding to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have never generated any revenue from product sales other than for humanitarian uses of less than $71,000 per year and may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognized point-in-time revenue of $70,462, $20,000 and $0 for the nine months ended September 30, 2023 and for the years ended December 31, 2022 and 2021, respectively. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with future partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our development programs. We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate revenue and achieve profitability depends heavily on our success in achieving a number of goals, including:</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completing research regarding, and preclinical and clinical development of, product candidates and programs, including NEO100 and NEO212, and identifying and developing new product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining marketing approvals for any product candidates for which we complete clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approval to use and sell products generated by our existing or future manufacturing processes for NEO100, NEO212 and future product candidates, including at our existing manufacturing facility and/or by establishing and maintaining supply and manufacturing relationships with third parties;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching and commercializing product candidates for which we obtain marketing approvals, either directly by establishing a sales force and marketing, medical affairs and distribution infrastructure or, alternatively, with a collaborator or distributor;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining healthcare coverage and adequate reimbursement for our future products, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of product candidates that we develop as viable treatment options;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing any competing technological and market developments;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing, acquiring and developing new product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trademarks, trade secrets, and know-how; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring, and retaining qualified personnel.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if NEO100, NEO212 or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any such product candidate that we commercialize on our own or in collaboration with others. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities, to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are successful in obtaining regulatory approvals to market NEO100, NEO212 or any future product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indications approved by regulatory authorities are narrower than we expect, the labels for our product candidates contain significant safety warnings, regulatory authorities impose burdensome or restrictive distribution requirements, or the reasonably accepted patient populations for treatment are narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest may be diluted. Any future debt financings we undertake, if available, are likely to involve restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. We also could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations, stock price and prospects. Securing additional financing could also require a substantial amount of time from our management and may divert a disproportionate amount of their attention away from daily activities, which may adversely affect our management&rsquo;s ability to oversee the development of NEO100, NEO212 or any future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The report of our independent registered public accounting firm included a &ldquo;going concern&rdquo; explanatory paragraph.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The report of our independent registered public accounting firm on our financial statements for the years ended December&nbsp;31, 2022 and 2021 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. If we are unable to raise additional capital as and when needed, our business, financial condition and results of operations will be materially and adversely affected, and we may be forced to delay our development efforts, limit our activities and reduce research and development costs. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The inclusion of a going concern explanatory paragraph by our independent registered public accounting firm, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into licensing and collaboration arrangements or other contractual relationships with third parties and otherwise execute our development strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Product Discovery, Development and Regulatory Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our development of product candidates based on our technology platform is limited, and we do not know whether we will be able to develop any products of commercial value.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The success of our business depends primarily upon our ability to identify novel product candidates and to successfully develop and commercialize those product candidates. While we have had preclinical and clinical study results for NEO100 and preclinical results for NEO212, to date, these remain our only product candidates that have moved into clinical trials. We have not yet succeeded and may not succeed in demonstrating efficacy and safety in order to be able to commercialize NEO100 or NEO212. We also may be unsuccessful in identifying additional product candidates beyond NEO100 and NEO212, and any of our product candidates may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. Similarly, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value and potential of our discovery platform and resulting product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of these events occur, our ability to successfully discover, develop and commercialize any product candidates may be impaired and the value of our company could decline significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All of our product candidates are in research, preclinical or clinical development. We have not completed the development of any product candidates, we currently generate no revenue, and we may never be able to develop a marketable product. We intend to use the net proceeds from this offering to fund the Phase 2a portion of our clinical trial of NEO100, Phase 1 of the clinical trial for NEO212, and a Phase 1/2a trial of intranasal NEO100 (NEO 100-03) for a pediatric indication. Other ongoing research on pipeline drugs will use the remainder of working capital and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Enrollment in NEO100 Phase 1 was completed in September&nbsp;2019, and we reported multiple data readouts in 2020. Our Phase 1 clinical trial &ndash; an open-label, single-arm study, of our lead product candidate, NEO100, in patients with recurrent malignant glioma (Grade IV, IDH1 mutation) &ndash; has been completed. Our Phase 2a trial of NEO100 is currently enrolling patients. We plan to enroll a total of 30 patients; 5 patients are currently enrolled. We plan to have a total of 12 sites for enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating plan may change due to many unknown factors, and we may need to seek additional funds sooner than planned through equity and debt financing. We may consider new collaborations or selectively partner with our technology or programs. Even if we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The success of our current and future product candidates will depend on several factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful completion of preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials and to pursue the necessary regulatory approval processes;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of INDs/IND amendments for our planned clinical trials or future clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrollment and completion of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">generating successful data from our clinical trials that support FDA conclusion of an acceptable risk-benefit profile of our product candidates in the intended populations;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt of regulatory and marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approval to use our existing or future manufacturing processes for the clinical and commercial manufacture of our product candidates at our existing or future manufacturing facilities or at the facilities of one or more third-party manufacturers with whom we would need to establish supply arrangements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of any products we develop and their benefits and uses, if and when approved, by patients, the medical community and third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively competing with other therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a continued acceptable safety profile of the products following approval; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">maintaining compliance with all pre-approval and post-approval regulatory requirements.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We currently have two clinical development product candidates, both of which rely in whole or in part on perillyl acid (NEO100 and NEO212). The failure of one of these two product candidates in clinical development would adversely affect our business. It may require us to discontinue developing other product candidates based on the same therapeutic approach.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our business and future success substantially depend on our ability to obtain regulatory approval and license our lead product candidates successfully. Both NEO100 and NEO212 are in the early stages of clinical development. Our product candidates will require additional clinical and nonclinical development, regulatory review, and approval in one or more jurisdictions, a substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate revenue from product sales. In addition, because NEO100 and NEO212, our most advanced product candidates are both perillyl acid-based products and because all of our other future product candidates will likely be based on similar technology, if either encounters safety or efficacy problems, developmental delays, regulatory issues, or other problems, our development plans and business for our other product candidates would be significantly harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are currently advancing our lead product candidates, NEO100, and NEO212, through clinical development and other product candidates through preclinical development. We are still recruiting for NEO100 Phase 2a and aim to finish that trial in 2 years. After Phase 2a is completed, Phase 2b or Phase 3 may still have to be performed depending on the results of the studies. Oral NEO212 has been submitted for an IND for a Phase 1 trial in patients with primary brain cancer and brain metastasis. Twelve patients will be recruited for the Phase 1 trial. Afterward, a Phase 2a trial is planned to be performed for primary gliomas and metastatic brain cancer. Intranasal NEO212 is still in development and an IND will be submitted for a Phase 1 trial for brain metastasis. We are also working on an intranasal delivery of a chemotherapeutic agent for midline primary pediatric intracranial tumor. This development is still preliminary but is in development with multi-center pediatric neuro-oncology consortiums. Any development problems we experience in the future may cause significant delays or unanticipated costs, and we may not be able to solve any such development problems. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA or foreign regulatory authorities may place all, or part, of our clinical development on hold or refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs. Moreover, even if we are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates. We may also experience delays in developing and obtaining regulatory approval for a sustainable, reproducible and scalable manufacturing process, or developing or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely manner, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. We may need to devote significant time and resources to satisfy these requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome and stringent regulations, and delays can occur for a variety of reasons.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to obtain FDA approval to market a new small molecule drug product, we must demonstrate proof of safety and efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs in the United States. We cannot be certain of the timely completion or outcome of our clinical trials and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our clinical trials will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin and we cannot be sure that our planned clinical trials will begin on time, that our ongoing clinical trials will be completed on schedule, or that the results of any of our clinical trials will be sufficient to support regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting clinical development is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. We may experience delays in initiating or completing clinical trials. We also may experience numerous unforeseen events during, or as a result of, any ongoing or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize NEO100 or any future product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators or institutional review boards (IRBs), may not authorize us or our investigators to commence a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and/or contract research organizations (CROs);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the unsuccessful development of nasal inhaler devices used to deliver NEO100;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate, or may elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays or failures related to the COVID-19 pandemic or similar future pandemics, which may result in clinical site closures, delays to patient enrollment, patients withdrawing prior to receiving treatment (e.g., catheter implantation failure), patients discontinuing their treatment or follow up visits or changes to trial protocols;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party clinical trial sites or individual clinical investigators may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing delays;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, emergent drug-drug interactions between NEO100 and any of the other therapeutic agents given to the clinical trial subjects or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a pharmacologically, chemically or mechanistically similar therapeutic or therapeutic candidate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statutes or regulations could be amended, or new ones could be adopted;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes could be adopted in the regulatory review process for submitted product applications;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical trials of our product candidates may be greater than we anticipate, or we may have insufficient funds for a clinical trial or product manufacture or to pay the substantial user fees required by the FDA upon the submission of a NDA or equivalent authorizations from comparable foreign regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data, or preclinical trials, or we may abandon product development programs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and the FDA or comparable foreign regulatory authorities may require changes to our study designs that make further study impractical or not financially prudent;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not support product candidate approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be regulatory questions or disagreements regarding interpretations of data and results, or new information may emerge regarding our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our trial design, including endpoints, or our interpretation of data from preclinical studies and clinical trials or find that a product candidate&rsquo;s benefits do not outweigh its safety risks;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our intended indications;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our contract manufacturing facilities for clinical and future commercial supplies;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a New Drug Application or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development, including, for example due to a longer-and/or-higher-than-expected response rate determination in the active comparator group or a shorter-and/or-lower-than-expected response rate determination in the experimental drug group.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product development costs will also increase if we experience delays in clinical testing or marketing approvals, and we may not have sufficient funding to complete the testing and approval process for any of our current or future product candidates. We may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials beyond what we currently have planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant delays relating to any preclinical studies or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of our product candidates. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability and efficacy of approved therapies for the disease under investigation;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient eligibility criteria for the trial in question;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks that enrolled subjects will drop out before completion of the trial, including as a result of emergent drug-drug interactions between NEO100 and any of the other therapeutic agents given to the clinical trial subjects, contracting COVID-19 or other health conditions or being forced to quarantine;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived risks and benefits of the product candidate under study;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts to facilitate timely enrollment in clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient referral practices of physicians;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity and availability of clinical trial sites for prospective patients;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdraw of consent for any reasons;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen limitations of protocol design; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protocol amendment by the sponsor and/or as requested by applicable regulatory authorities.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, our planned clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a competing clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our inability to enroll a sufficient number of patients for our anticipated and any future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which could have an adverse effect on our business, financial condition, results of operations, and prospects. In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter patient enrollment difficulties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For our lead product candidate, NEO100, we completed Phase 1 enrollment and reported multiple data readouts in 2021 and 2022. For our Phase 2a clinical trial, we expect the final readout by the end of 2024. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. NEO100 may not perform as we expect in clinical trials, particularly in our open label, randomized, and controlled Phase 2 clinical trial, may ultimately have a different or no impact on malignant gliomas, may have another mechanism of action than we expect, and may not ultimately prove to be safe and effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The results of previous clinical trials of NEO100 and NEO212 and results of preclinical studies or early clinical trials of any other product candidate we may develop, may not be predictive of the results of subsequent and later-stage clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We do not have experience in designing a registration-stage clinical trial and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols, variations in conducting clinical trial at different sites, changes in medical practice, FDA requirements based on agency guidelines or precedence which may be more strict for a Phase 2 clinical trial, the rate of dropout among clinical trial participants and changes in the manufacturing process. Moreover, should there be an issue with the design of any of our clinical trials, our results may be impacted. We may not discover such a flaw until the clinical trial is at an advanced stage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim, topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials, based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline, or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, topline, and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, such data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim, topline, and preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, interim or topline data and final data could significantly harm our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability, or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate, or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize NEO100 and any future product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious adverse events, undesirable side effects (including emergent drug-drug interactions between NEO100 and any of the other therapeutic agents given to the clinical trial subjects) or other unexpected properties of our current or future product candidates may be identified during development or after approval, which could halt their development or lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, NEO100 is the only product candidate we have tested in humans. As we continue our development of NEO100 and initiate clinical trials of any future product candidates, serious adverse events, undesirable side effects or unexpected characteristics may emerge or be reported, causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Even if our product candidates initially show promise in early clinical trials, the side effects of therapies are frequently only detectable after they are tested in large, Phase 2 or phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development and are determined to be attributed to our product candidates, or the result of drug-drug interactions between our product candidate and any of the concomitant therapies given to the trial subjects, we, the FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, could interrupt, delay, or halt clinical trials and could result in a more restrictive label, a Risk Evaluation and Mitigation Strategy (REMS) or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may also require, or we may voluntarily develop strategies for managing adverse events during clinical development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study&rsquo;s design, or the monitoring of safety data by a data monitoring committee, among other strategies. Any requests from the FDA or comparable foreign regulatory authority for additional data or information could also result in substantial delays in the approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw approvals of such product;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require additional warnings on the label;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product may become less competitive, and our reputation may suffer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We anticipate that many of our product candidates may be tested and, if approved, used in combination with third-party drugs and/or devices, some of which may still be in development, and we have limited or no control over the supply, regulatory status or regulatory approval of such drugs and/or devices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate developing our product candidates for use in combination with other oncology pharmaceutics, including chemotherapies and cellular and targeted therapies (e.g., immune checkpoint inhibitors). In particular, our development of NEO100 as a solvent (carrier) of other drugs and biologics to the brain will depend on our ability to access such drugs and devices on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or devices on commercially reasonable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing platinum-based and other chemotherapies, or any other combination products, or any devices in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. For our product candidates that may be used in combination with platinum-based and other chemotherapies, or any other combination products or any devices, the FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that there are adverse events tied to the interaction of NEO100 with any of the other therapies, or that any positive previous trial results are attributable to the combination therapy and not our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, following product approval, the FDA may require that products or devices used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product or device, this may require us to work with a third party to satisfy such a requirement. The ability to obtain cooperation from the third party may impact our ability to respond to the FDA&rsquo;s requests which could impact our ability to achieve regulatory approval. Moreover, developments related to the other product or device may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the safety or efficacy profile of the other product or device, changes to the availability of the approved product or device, and changes to the standard of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that any future collaborator or supplier of platinum-based and other chemotherapies, or any other products administered in combination, or any devices used, with our product candidates does not supply their products on commercially reasonable terms or in a timely fashion, we would need to identify alternatives for accessing these products. This could cause our clinical trials to be delayed and limit the commercial opportunities for our product candidates, in which case our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may not be successful in our efforts to expand our pipeline of product candidates and develop marketable products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect initially to develop our lead product candidate, NEO100. We anticipate pursuing clinical development of other product candidates, alone or in collaboration with our partners. Research programs to identify new product candidates require substantial technical, financial and human resources. Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial additional funding beyond the net proceeds of this offering and will be subject to the risks of failure inherent in medical product development. We cannot assure you that we will be able to successfully advance any of these additional product candidates through the development process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our product candidates on the potential treatment of certain indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially-viable products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring product candidates requires substantial technical, financial, and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&rsquo;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we do not achieve our product development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and as a result our share price may decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug development is inherently risky and uncertain. We cannot be certain that we will be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete IND-enabling preclinical studies or develop manufacturing processes and associated analytical methods that meet current good manufacturing practice (cGMP) requirements in time to initiate or to complete our anticipated or future clinical trials in the timeframes we announce;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain sufficient clinical supply of our product candidates to support our anticipated or future clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate clinical trials within the timeframes we announce;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enroll and maintain a sufficient number of subjects to complete or timely complete any clinical trials; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collect and analyze the data from any completed clinical trials in the timeframes we announce.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual timing of our development milestones could vary significantly compared to our estimates, in some cases for reasons beyond our control. If we are unable to achieve our goals within the timeframes we announce, the commercialization of our product candidates may be delayed and, as a result, the stock price of our common stock could fall and you may lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the commercialization of NEO100 and any other product candidate we develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any current or future product candidate we may develop, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we may seek to develop in the future will ever obtain regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&rsquo;s safety and efficacy for that indication. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities. If we do not receive approval from the FDA and comparable foreign regulatory authorities for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in other jurisdictions. If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions, our business, financial condition, results of operations, stock price and prospects will be materially harmed. Even if our product candidates are approved, they may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other conditions of approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain significant safety warnings, including boxed warnings;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain significant contraindications, and precautions which could reduce the size of the patient population;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not be approved with label statements necessary or desirable for successful commercialization;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a REMS to monitor the safety or efficacy of the products; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be withdrawn from the market because of a serious safety issue becomes know after approval is granted.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, takes many years even if successful, and can vary substantially in and among jurisdictions based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. It is possible that our product candidates will never obtain the appropriate regulatory approvals necessary for us to commence product sales, or any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we experience delays in obtaining approval or if we fail to obtain approval of any current or future product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of any products for unapproved or &ldquo;off-label&rdquo; uses, resulting in damage to our reputation and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to pharmaceuticals are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human Services&rsquo; Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for desired uses or indications for our product candidates, we may not market or promote them for those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock price and prospects will be materially harmed. We also must sufficiently substantiate any claims that we make for any products we develop, including claims comparing our products to other companies&rsquo; products, and must abide by the FDA&rsquo;s strict requirements regarding the content of promotion and advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine, physicians may in their independent medical judgment choose to prescribe products for uses that are not described in the product&rsquo;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities. Regulatory authorities do, however, limit communications by biopharmaceutical companies concerning off-label use. Therefore, we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are found to have impermissibly promoted any products that we may develop, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The federal government has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional statements. If after one or more of our product candidates obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging in the impermissible promotion of our products, in the United States, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These False Claims Act (FCA) lawsuits against manufacturers of drugs and small molecule products have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, up to $3.0 billion, pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose manufacturers to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. If we obtain approval for any product candidate and ultimately commercialize that product in foreign markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA or comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, and GCPs for any clinical trials that we conduct post-approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a product&rsquo;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Any such restrictions could limit sales of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, later discovery of previously unknown adverse events or of the product being less effective than previously thought or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various negative results, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on manufacturing, distribution, or marketing of such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the labeling, including required additional warnings, such as New Drug Application boxed warnings, contraindications, precautions, and restrictions on the approved indication or use;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">modifications to promotional pieces;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of corrective information;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements to conduct post-marketing studies or other clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical holds or termination of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements to establish or modify a REMS or similar strategy;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the way the product candidate is administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability for harm caused to patients or subjects;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational harm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product becoming less competitive;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters or untitled letters alleging violations;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension of marketing or withdrawal of the products from the market;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product candidate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls of products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal of marketing approvals;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to permit the import or export of our products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties, including imprisonment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidate(s), if approved, or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its marketing and sale. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA&rsquo;s policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, limit the marketability of our product candidates, or impose additional regulatory obligations on us. Changes in medical practice and standard of care may also impact the marketability of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The manufacture of active pharmaceutical ingredients (API) and finished dosage form (FDF) drug products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturing must strictly comply with regulatory requirements governing current Good Manufacturing Practices (cGMP). The process of manufacturing API and FDF products, including our product candidates, is complex, time-consuming, highly-regulated and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers of small molecule API and FDFs often encounter difficulties in production, particularly in scaling up initial production, with such risks including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality control, including stability of the product candidate and quality assurance testing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shortages of qualified personnel or key raw materials or components;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor and raw material shortages, natural disasters, power failures and numerous other factors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product candidate batches that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such manufacturing changes may require separate regulatory approvals before being implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes in product candidate manufacturing or formulation may result in additional costs or delay.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate relying on contract manufacturing organizations (CMOs) to conduct large-scale manufacture of NEO100 and NEO212 API and FDF in the future. The inability to identify and contract with suitable CMOs or their failure to meet their obligations to us could affect our ability to develop or commercialize NEO100 in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the FDA, state or a comparable foreign regulatory authority does not approve our manufacturing facility for the manufacture of our product candidates or if it withdraws any such approval in the future, or our current facility is unable to meet our volume requirements to fail to comply with cGMP regulations, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any alternative manufacturing facility would require obtaining the necessary equipment and materials and, if a third-party manufacturer, the necessary manufacturing know-how, which may take substantial time and investment. We must also receive FDA approval to use any manufacturing facility for commercial supply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In such an instance, we may need to enter into an appropriate third-party relationship. We may fail to establish manufacturing relationships or alternative arrangements for our product candidates or programs. Any product candidates we develop compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers operating under cGMP regulations capable of manufacturing and filling our viral product for us and willing to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If we are unable to have manufactured and release any product candidates in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, any product candidates, and may lose potential revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We do not own or operate manufacturing facilities for the production of NEO100 nor do we plan to develop our own manufacturing operations in the foreseeable future. We currently depend on third party contract manufacturers for all of our required raw materials, active pharmaceutical ingredient and finished products for our preclinical and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our clinical product supply may be limited, interrupted, or of unsatisfactory quality or not continue to be available at acceptable prices.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Any delays in obtaining adequate supplies of our product candidates that meet the necessary quality standards may delay our development or commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or our contract manufacturer(s) may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory requirements of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our contract manufacturers&rsquo; manufacturing equipment and processes. We may not be able to develop, retain or acquire the internal expertise and resources necessary for managing our ongoing contract manufacturing operations and complying with these requirements. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing. If we cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, we will not be able to secure or maintain regulatory approval for our manufacturing facility. Any such deviations may also require remedial measures that may be costly and/or time-consuming for us to implement, particularly in areas relating to operations, quality, regulatory, facilities and information technology. Any such remedial measures imposed upon us may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of our facility and could materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement actions against us or our raw material and component suppliers (including fines and civil and criminal penalties, including imprisonment) suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities. If the safety of any quantities supplied is compromised due to our failure or our raw material and component suppliers&rsquo; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any problems or delays we experience in commercial-scale manufacturing of a product candidate or component may result in a delay in product development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of clinical development and commercialization of any product candidates and may materially harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We rely, and expect to continue to rely, on third parties to supply and quality-test the ingredients for our product candidates and components for our manufacturing process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While we are responsible for the manufacturing of our product candidates, drug substance and drug product, reliance on raw material and component suppliers entails risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control for certain aspects of our contracted manufacturing activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination or nonrenewal of the applicable supplier and service agreements in a manner or at a time that is costly or damaging to us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possible breach by our third-party suppliers and service providers of our agreements with them;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of our third-party suppliers and service providers to comply with applicable regulatory requirements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions to the operations of our third-party suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. In addition, we do not have any long-term commitments or guaranteed prices from our suppliers of raw materials, manufacturing equipment components or devices or combination products. In particular, any change in our suppliers could require significant effort and expertise because there may be a limited number of qualified replacements. Further, the terms of any new arrangement could be less favorable and transfer costs relating to technology and processes could be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, impact our ability to successfully commercialize any of our product candidates or otherwise harm our business, financial condition, results of operations, stock price and prospects. Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure or total or partial suspension of product manufacture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely, and will rely, on third-party CROs, study sites and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities would be delayed and our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must also ensure that our preclinical trials are conducted in accordance with the FDA&rsquo;s Good Laboratory Practice (GLP) regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred to as GCP guidelines, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions. For example, the data generated in our trials may not have been appropriately collected or documented, and thereby be deemed unreliable and the FDA or comparable foreign regulatory authorities may conclude the study findings are not adequate and require us to perform additional studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials complies with the applicable regulatory requirements. In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on one or more government-sponsored databases, e.g., ClinicalTrials.gov, within specified timeframes. Failure to do so can result in enforcement actions and adverse publicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm our competitive position. In addition, such third parties are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates; we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates; or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will also rely on other third parties to store and distribute our product candidates for the clinical trials that we conduct. Any performance failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates, which could result in additional losses and deprive us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have entered into, and may in the future enter into, certain collaboration agreements and strategic alliances to maximize the potential of our product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&rsquo;s time and attention in order to manage a collaboration. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into the arrangement. Additionally, the success of any collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we are not able to establish future collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans for one or more of our other development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face significant competition in seeking appropriate additional collaborators. Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any future collaborations are not a guarantee of success, and all collaborations are as risky, or more risky, than undertaking the activities ourselves.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any potential future collaborations we might enter into for NEO100, NEO212 or our other product candidates, may pose a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not perform their obligations as expected;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&rsquo; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators could fail to make timely regulatory submissions for a product candidate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of any of our current or future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any collaborations we have entered into or might enter into do not result in the successful development and commercialization of products or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, if any collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, delay their ability to review and act on our regulatory submissions, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately, the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to the COVID-19 pandemic or similar future pandemics that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we, or our collaboration partners, are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we, or our collaboration partners, are successful in obtaining marketing approval from applicable regulatory authorities for NEO100 or any other product candidate, our ability to generate revenues from any such products will depend on our success in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching commercial sales of such products, whether alone or in collaboration with others;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations that would impede our ability to market such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating market demand for such products through marketing, sales and promotion activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring, training, and deploying a sales force or contracting with third parties to commercialize such products in the United States;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating partnerships with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining patent and trade secret protection and regulatory exclusivity for such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving market acceptance of such products by patients, the medical community, and third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving coverage and adequate reimbursement from third-party payors for such products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving patients&rsquo; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing with other therapies; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a continued acceptable safety profile of such products following launch.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. There are a number of large biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of solid tumors, including viral immunotherapy and cancer vaccine approaches. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While certain of our product candidates may be used in combination with other drugs with different mechanisms of action, if and when marketed they will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors when used alone or in combination with other drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign regulatory authorities&rsquo; approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by third-party payors&rsquo; coverage and reimbursement decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently do not have a commercial infrastructure for the marketing, sale, and distribution of any products that we may develop. If and when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own or in collaboration with others and potentially with pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products, we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services. We may not be successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure. If a commercial launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product candidates, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves, which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates, which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations, stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to effectively oversee a geographically dispersed sales and marketing team;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with training personnel, including sales and marketing personnel, on compliance matters and monitoring their actions;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an inability to secure coverage and adequate reimbursement by third-party payors, including government and private health plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the unwillingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which the products are approved and the claims that we may make for the products;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings, including distribution or use restrictions, contained in the products&rsquo; approved labeling;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a mandatory REMS or voluntary risk management plan;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability for our personnel, including sales or marketing personnel, who fail to comply with applicable law;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success. The revenues that we generate from their sales may be limited, and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive marketing approval will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy of our product, including in combination with other cancer therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commercial success of any cancer therapies with which our product may be co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of adverse events associated with our product or those products with which it is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which our product is approved and the approved claims that we may make with respect to the product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings contained in the FDA-approved labeling of the product or the labeling approved by comparable foreign regulatory authorities, including potential limitations or warnings for our product that may be more restrictive than other competitive products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the standard of care for the targeted indications for our product, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative convenience and ease of administration of our product and any products with which it is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of coverage and adequate reimbursement by third-party payors, such as private insurance companies and government healthcare programs, including Medicare and Medicaid;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to have our product placed on approved formularies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&rsquo; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price concessions required by third-party payors to obtain coverage and adequate reimbursement;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent and strength of our marketing and distribution of our product;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product or to which we agree as part of a REMS or voluntary risk management plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of market introduction of our product, as well as competitive products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to offer our product for sale at competitive prices;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent and strength of our raw material supplier and service provider support;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the actions of companies that market any products with which our product is co-administered;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of other new products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse publicity about our product or any products with which it is co-administered, or favorable publicity about competitive products; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential product liability claims.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates we develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are co-administered and the success of competing therapies and therapeutic approaches. Our estimates of the potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. Additionally, because of the potential that any product candidates we develop could cure a target disease, we may not receive recurring revenues from patients and may deplete the patient population prevalence through curative therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may face early and aggressive generic competition for any of our product candidates for which we obtain regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Drug Price Competition and Patent Term Restoration Act of 1984 (the &ldquo;Hatch-Waxman Amendments&rdquo;) established a streamlined and expedited regulatory approval pathway, known as an Abbreviated New Drug Application or ANDA, for identical generic versions of drug products initially approved pursuant to full clinical trials and the New Drug Application (NDA) process. This process is explained in more detail later in this document. Using this pathway, generic drug companies aggressively seek to market approved generic versions of small molecule drug products, including by challenging patents covering the original drug product. Generic drugs approved under an ANDA usually are deemed by FDA to be &ldquo;therapeutically equivalent&rdquo; to the original version of the drug that they copy, and accordingly, such generic products may be automatically substituted by pharmacies for patients who present a prescription for the original brand-name version of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a generic drug company files an ANDA that includes a challenge to one or more of our patents covering any of our approved drugs, a specialized type of patent litigation may ensue, which may result in a court ruling that our patent(s) are invalid, unenforceable, or would not be infringed by the proposed generic version of our product. In such cases, we may face direct competition from equivalent generic versions of our product before the expiration date of our patents. Moreover, because patent litigation is inherently uncertain, many such patent cases are settled with the patent holder agreeing to allow market entry of the generic product at some point prior to expiration of the patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market entry of generic versions of approved drugs generally has a rapid and dramatic adverse impact on the pricing that can be realized by the maker of the original drug product. If we are unable to obtain and enforce patents and regulatory exclusivities on our drug candidates, earlier than expected market entry of generic competitors could significantly adversely affect our business.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual property rights are inadequate, our competitive position could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology, including NEO100, NEO212 and our other product candidates. We also rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent positions of biotechnology and pharmaceutical companies generally are uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation or patent challenges in the United States Patent and Trademark Office or in corresponding patent offices. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we may own are highly uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, the examination process may require us to narrow the claims for our pending patent applications, which may significantly limit the scope of patent protection that may be obtained if these applications issue. Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates. In addition, the scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. If we are unable to obtain and maintain patent protection for our technology or for NEO100, NEO212 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours in a non-infringing manner, and our ability to successfully commercialize NEO100, NEO212 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail to identify any patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. It is also possible that we will fail to identify patentable aspects of our research and development efforts in time to obtain any patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications with a claim that covers infringing third-party activity. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition proceedings, derivation proceedings, post-grant review, <I>inter partes </I>review, post-grant review, derivation proceedings, interference proceedings or litigation. Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection for our technology. Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to obtain licenses from others to advance our research and development activities or allow the commercialization of our current or future product candidates. We expect any such license agreements will impose various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by the intellectual property under any such license agreements. If such in-licenses were to be terminated, or if the underlying patents were to fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues and our respective compliance therewith;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the priority of invention of patented technology.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and other proprietary information. To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators, contractors, and other third parties who have access to our trade secrets. Our agreements with employees and consultants also provide that any inventions conceived by the individual employee or consultant in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property or that of our licensor. In addition, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information including a breach of our confidentiality agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. In addition, some courts in and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other third party would impair our competitive position and may materially harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial success depends on our ability and the ability of any future collaborators to develop, manufacture, market and sell NEO100, NEO212 and our other product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any other future product candidates, including interference proceedings, post-grant review, <I>inter partes</I> review and derivation proceedings before the USPTO (or similar proceedings in foreign jurisdictions). Third parties may assert infringement or other intellectual property claims against us based on existing patents or patents that may be granted in the future. Numerous U.S. and foreign-issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. If we are found to infringe a third party&rsquo;s intellectual property rights, and we are unsuccessful in demonstrating that such intellectual property rights are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing and commercializing NEO100, NEO212 and our other product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing NEO100, NEO212 or our other product candidates. In addition, in any such proceeding or litigation, we could be found liable for significant monetary damages, including treble damages and attorneys&rsquo; fees, if we are found to have willfully infringed a patent or other intellectual property right. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material adverse effect on our business. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, we plan to develop our product candidates in combination with products developed by companies that may be covered by patents or licenses held by those entities to which we do not have a license or a sublicense. In the event that a labeling instruction is required in product packaging recommending that combination, we could be accused of, or held liable for, infringement of the third-party patents covering the product candidate or product recommended for administration with NEO100, NEO212 or our other product candidates. In such a case, we could be required to obtain a license from the other company or institution to use the required or desired package labeling, which may not be available on commercially reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world.</I></B></FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing, prosecuting and defending patents on our technology throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own products, and may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the granting or enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to obtain patent rights or stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally in those countries. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to protect and enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the laws of certain foreign countries may not protect our rights to the same extent as the laws of the United States, and those foreign laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries. Furthermore, competitors may challenge the scope, validity and enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business and results of operations may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and to maintain patents after they are issued. For example, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents and patent applications often must be paid to the USPTO and foreign patent agencies over the lifetime of our licensed patents or any patents we own. In certain circumstances, we may rely on future licensing partners to take the necessary action to comply with these requirements with respect to licensed intellectual property. Although an unintentional lapse may be curable, depending on the jurisdiction, for a period of time by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to NEO100, NEO212 or our other product candidates, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect NEO100, NEO212 and our other product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or other jurisdictions in which we have or seek patent protection could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in the United States on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <I>inter partes</I> review, and derivation proceedings. After March&nbsp;2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors may infringe our licensed patents or any patent we own, or misappropriate or otherwise violate our intellectual property rights. Litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets, or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. If we were to initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Our licensed patents and any patents we own in the future may become involved in priority or other intellectual property related disputes. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. Also, third parties may initiate legal proceedings against us to challenge the validity or scope of our owned or licensed intellectual property rights. These proceedings can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to conduct intellectual property related litigations or proceedings than we can. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Litigation and other intellectual property related proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or other intellectual property related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any such proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock, and could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. Any of the foregoing may have a material adverse effect our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may be subject to claims by third parties asserting that we, our employees or any future collaborators have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these people, including each member of our senior management team, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment or consulting agreements, that assigned ownership of intellectual property relating to work performed under such agreements to the contracting third party. Although we try to ensure that our employees, as well as those of our licensor and contractors, do not use, claim as theirs, or misappropriate the intellectual property, proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&rsquo;s current or former employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of third parties or are in breach of non-competition or non-solicitation agreements with our competitors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We could be subject to claims that we or our employees, including senior management, have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors or others. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we caused an employee to breach the terms of their non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor or other party. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to NEO100, NEO212 and our other product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers, competitors or other parties. An inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully commercializing NEO100, NEO212 and our other product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or consultants. A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize NEO100, NEO212 and our other product candidates, which could have an adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign regulatory authority.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other things, an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, <I>inter partes</I> review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect NEO100, NEO212 and our other product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. For example, with respect to the validity of our licensed patents or any patents we obtain in the future, we cannot be certain that there is no invalidating prior art of which we, our patent counsel or our licensing partner&rsquo;s patent counsel(s), and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on NEO100, NEO212 and our other product candidates. Such a loss of patent protection could have a material adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as pharmacological products may face competition sooner than anticipated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, such as NEO100 and our other product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent for the patent term lost during the FDA regulatory review process. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other non-U.S. jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents that we believe are eligible for such extension. We also intend to seek patent term extensions in other jurisdictions where these are available. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their products earlier than might otherwise be the case, which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some intellectual property which we have licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &ldquo;march-in&rdquo; rights, certain reporting requirements, and a preference for United States industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intellectual property rights we licensed from USC has been generated through the use of United States government funding and is therefore be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our future products and product candidates pursuant to the Bayh-Dole Act of 1980. These United States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &ldquo;march-in rights&rdquo;). The United States government also has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the United States government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the United States government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our license agreement with USC, under which we license all of our current patent rights and a significant portion of our technology for our product candidates, imposes royalty and other financial obligations on us and other substantial performance obligations. We also may enter into additional licensing and funding arrangements with third parties that may impose diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under current or future license and collaboration agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product or product candidate that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could diminish the value of our products or product candidates. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, it is possible that USC may conclude that we have materially breached the USC licensing agreement and might therefore terminate the agreement, thereby removing our ability to market products covered by our license agreement with USC. If the USC licensing agreement is terminated, or if the underlying patents fail to provide the intended market exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products similar or identical to ours. Moreover, if our license agreement with USC is terminated, USC may be able to prevent us from utilizing the technology covered by the licensed patents and patent applications. If we breach the agreement (including by failing to meet our payment obligations) and do not adequately cure such breach, the rights in the technology licensed to us under the USC license agreement will revert to USC at no cost to USC. This could have a material adverse effect on our competitive business position, our financial condition, our results of operations and our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the agreement under which we currently license intellectual property is complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected products or product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names, and evaluation of whether the proposed name implies an unapproved use or a level of safety or efficacy that is not supported by relevant data. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we fail to comply with federal and state healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, financial condition, results of operations, stock price and prospects will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable healthcare fraud and abuse, and other healthcare laws, which may constrain the business or financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil and criminal false claims laws, including, without limitation, the civil FCA, and the federal Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Federal Food, Drug and Cosmetic Act, and its implementing regulations, which prohibits, among other things, the adulteration or misbranding of drugs, small molecule products and medical devices.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal physician payment transparency requirements, sometimes referred to as the Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) and its implementing regulations, which require certain manufacturers of drugs, devices, small molecule products and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous state and foreign anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; and state and local laws requiring the registration of pharmaceutical sales representatives.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, imprisonment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S. federal or state health care programs, additional reporting requirements and/or oversight if we become subject to corporate integrity agreements or similar agreement to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to significant criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in U.S. federal or state healthcare programs, which could also materially affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with such laws may prove costly. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s attention from the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better value, our revenue and prospects for profitability will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and adequate reimbursement from third-party payors or placement on approved product formularies. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently become available, even if our products are alone in a class. Third-party payors establish reimbursement levels. Therefore, even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. Our failure to obtain or maintain timely or adequate pricing or formulary placement of our products, or failure to obtain such formulary placement at favorable pricing may negatively impact our revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved small molecule products. Marketing approvals, pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A significant trend within the healthcare industry is cost containment, both in the United States and elsewhere. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs, including use of formularies. Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the overall cost of the therapy. Certain third-party payors are requiring that companies provide them with predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals. In addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, seeking performance-based discounts, and challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate. If payors subject our product candidates to maximum payment amounts, or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any products to the satisfaction of hospitals, other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Such delays have made it increasingly common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated into existing payments for other services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An inability to promptly obtain coverage and adequate reimbursement from third-party payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For example, the ACA was passed in March&nbsp;2010 and substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the United States pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been executive, judicial and congressional challenges to certain aspects of the ACA. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017 (the Tax Act), includes a provision repealing, effective January&nbsp;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April&nbsp;2013 and, following passage of the Bipartisan Budget Act of 2018 (BBA) and the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry. For instance, the Drug Quality and Security Act of 2013 imposes obligations on manufacturers of biopharmaceutical products related to product tracking and tracing. Further, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may determine to change our </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in presidential executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&rsquo;s proposals. The FDA concurrently released a final rule and guidance in September&nbsp;2020, implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the U.S. Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until 2032. On March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&rsquo;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In July&nbsp;2021, the Biden administration released an executive order, &ldquo;Promoting Competition in the American Economy,&rdquo; with multiple provisions aimed at prescription drugs. In response to Biden&rsquo;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under the Program, the Secretary of HHS will publish a list of &ldquo;selected drugs,&rdquo; and will then negotiate maximum fair prices (MFP) with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &ldquo;selected drug&rdquo; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &ldquo;selected drug&rdquo; up to 95% and the potential of civil monetary penalties. In August 2023, HHS released the first list of 10 drugs subject to this negotiation process. Several pharmaceutical companies had previously filed lawsuits challenging the legality of the program, but subsequently, many of those lawsuits were withdrawn as the companies decided to, at least initially, participate in the negotiation process. The possibility of renewed lawsuits could create further uncertainty about this program in the future. Further, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. In addition, the Biden administration released an additional executive order on October&nbsp;14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any new laws or regulations, including those that may result in additional reductions in Medicare and other healthcare funding, could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products, decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate revenue, and we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, and other consequences, which could adversely affect our business, financial condition, results of operations, stock price and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other anti-corruption laws generally prohibit us and our employees and intermediaries from authorizing, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. We can be held liable for the corrupt or other illegal activities of our personnel or intermediaries, even if we do not explicitly authorize or have prior knowledge of such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also subject to other laws and regulations governing our international operations, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. An investigation of any potential violations of anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, we process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, and patient information. Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject to or affected by evolving federal, state and foreign data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g. Section&nbsp;5 of the Federal Trade Commission Act). For example, HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. We may obtain health information or other personal information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&rsquo;s criminal provisions if it knowingly receives individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&rsquo;s requirements for disclosure of individually identifiable health information under aiding-and-abetting or conspiracy principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain states have also adopted data privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on covered businesses. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we may maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), which became effective January&nbsp;1, 2023, will expand the CCPA. The CPRA establishes a new California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of enforcement. Other states have enacted data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which become effective in 2023. In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&rsquo;s General Data Protection Regulation (EU GDPR), the United Kingdom&rsquo;s GDPR (UK GDPR), and the Swiss Federal Act on Data Protection impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals or consumer protection organizations authorized at law to represent their interests may initiate litigation related to processing of individuals&rsquo; personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, in addition to direct compliance obligations under those laws. We may be directly or contractually subject to data privacy and security obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations in the future. For example, certain privacy laws, such as the EU GDPR and the CCPA, require companies to impose specific contractual restrictions on their service providers. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, Europe has significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although there are currently various mechanisms that may be used to transfer personal data from Europe to the United States in compliance with law, such as the EU and UK&rsquo;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If there is no lawful manner for us to transfer personal data from Europe or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, which could limit our ability to conduct clinical trial activities in Europe or elsewhere, and injunctions against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies from transferring personal data out of Europe for allegedly violating the GDPR and EU&rsquo;s cross-border data transfer limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. Additionally, we publish privacy policies, self-certifications, and other documentation regarding our collection, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies, certifications, and documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations. Such failures can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to numerous federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the controlled production, storage, use and disposal of hazardous and flammable materials, including chemicals. We would incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties, as well as our curtailment of the use of these materials or even shutting down our facilities and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although we maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Our Business and Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are highly dependent on our key personnel, including our Chief Executive Officer and Chairman. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management and particularly on the services of our personnel including Dr. Thomas C. Chen, our Chief Executive Officer and Chairman. We believe that his drug discovery and development experience and overall biopharmaceutical company management experience, would be difficult to replace. Any of our executive officers could leave our employment at any time, as all of our employees are &ldquo;at-will&rdquo; employees. We currently do not have &ldquo;key person&rdquo; insurance on any of our employees. The loss of the services of our key personnel and any of our other executive officers, key employees, and scientific and medical advisors, and our inability to find suitable replacements, could result in delays in our research and development objectives and harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. We conduct our operations at our facilities in Southern California, a region that is home to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employee agreements with our key employees, these agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &ldquo;key person&rdquo; insurance policies on the lives of all of these individuals or the lives of any of our other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management team has limited public company experience.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management team has limited public company experience. Our entire management team, as well as other of our personnel, will need to devote substantial time to compliance, and may not effectively or efficiently manage our transition into a public company. If we are unable to effectively comply with the regulations applicable to public companies or if we are unable to produce accurate and timely financial statements, which may result in misstatements that may be material in our financial statements or possible restatement of financial results, our stock price may be materially adversely affected. Any such failures could also result in litigation or regulatory actions by the SEC or other regulatory authorities, loss of investor confidence, delisting of our securities, harm to our reputation and diversion of financial and management resources from the operation of our business, any of which could materially adversely affect our business, financial condition, results of operations, and growth prospects. Additionally, the failure of a key employee to perform in his or her current position could result in our inability to continue to grow our business or to implement our business strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We will need to continue to expand the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing our internal development efforts effectively, including the clinical, FDA and comparable foreign regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving our operational, financial and management controls, reporting systems and procedures.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future financial performance and our ability to commercialize NEO100, NEO212 and any other product candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of NEO100and our other product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize NEO100, NEO212 and our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses and cash requirements;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional indebtedness or contingent liabilities;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity securities;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&rsquo;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unfavorable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock price and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Public health crises such as pandemics, including the ongoing COVID-19 pandemic, or similar future outbreaks could materially and adversely affect our preclinical studies and clinical trials, business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March&nbsp;2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our office, clinical trial sites and third parties on whom we rely. As the COVID-19 pandemic started to spread in the first half of 2020, our clinical trial sites reported it had the most impact on patient care as facilities were generally ill prepared to conduct business as usual; adequate clinical evaluations, physical exams and tests were either absent or drastically reduced. Our clinical trial sites further reported that their institutions better adjusted to pandemic conditions beginning in the second half of 2020. Additionally, we have experienced disruption to our manufacturing supply chain which has delayed receipt of ordered materials and delayed our manufacturing timeline; while we now have received all ordered materials, we do not have insight into whether, or to what extent, there may be future delays.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any further negative impact on our clinical development timelines could materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work-from-home policy allowing employees who can work from home to do so, while those needing to work in laboratory and manufacturing facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the COVID-19 pandemic, or similar pandemics, and related governmental orders and other public health guidance measures, we have and may in the future experience disruptions that could materially and adversely impact our preclinical studies, clinical trials, business, financial condition and results of operations. Potential disruptions might include but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties in enrolling patients in our clinical trials;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or disruptions in preclinical experiments and studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of, or delays in receiving, supplies of our product candidates from third-party providers due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent to which the ongoing COVID-19 global pandemic may affect our preclinical activities, clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs or vaccine rollout in the United States, business closures or business disruptions and the effectiveness of actions taken in the United States to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of our business, we may process, collect, store, and transmit proprietary, confidential, and sensitive data, including de-identified personal data (such as health-related data), intellectual property, proprietary business information and trade secrets (collectively, sensitive information). We may rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of information technology infrastructure, cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&rsquo; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive information with or from third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyber-attacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &ldquo;hackers,&rdquo; &ldquo;hacktivists,&rdquo; threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruption of clinical trials, loss of data (including data related to clinical trials), and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&rsquo; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and our services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&rsquo; systems and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While we have established physical, electronic and organizational security measures to safeguard and secure our systems against security incidents, and rely on commercially-available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and address vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the commercialization of any approved products and/or our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even greater risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue from decreased demand for our products and/or product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of our business reputation or financial stability;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of related litigation;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to patients or other claimants;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management attention;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize our product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant negative media attention;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreases in our stock price;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation of investigations and enforcement actions by regulators; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include clinical trials and the sale of commercial products if we obtain FDA or comparable foreign regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. Failure to obtain and retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop. On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our employees, independent contractors, consultants, commercial partners, principal investigators, contract manufacturing organizations (CMOs), or contract research organizations (CROs) may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners or principal investigators could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required by federal programs, report financial information or data accurately or disclose unauthorized activities to us. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Moreover, it is possible for a whistleblower to pursue a FCA case against us even if the government considers the claim unmeritorious and/or declines to intervene, which could require us to incur costs defending against such a claim. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in U.S. federal healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have generated significant net operating loss (NOL) carryforwards and research and development tax credits, and our ability to utilize our net operating loss carryforwards and research and development tax credits to reduce future tax payments may be limited or restricted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have generated significant NOL carryforwards and research and development tax credits (R&amp;D credits) due to our incurrence of losses and our conduct of research activities since inception. As of December 31, 2022, we had federal NOL carryforwards of approximately $13.3 million. We do not anticipate generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve profitability. Our U.S. federal NOL carryforwards developed in taxable years beginning before January&nbsp;1, 2018, can be carried forward to each of the 20 taxable years following the year of the loss. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under current law, U.S. federal NOLs incurred in tax years beginning after December&nbsp;31, 2017, totaling $9.4 million, may be carried forward indefinitely, but the utilization of U.S. federal NOLs generated in tax years beginning after December&nbsp;31, 2020, is limited. Our U.S. federal R&amp;D credit carryforwards can be carried forward for 20 taxable years. If not utilized in that period, these R&amp;D credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under current law, the California state R&amp;D credits carry forward indefinitely until utilized. These R&amp;D credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under Sections&nbsp;382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &ldquo;ownership change,&rdquo; the corporation&rsquo;s ability to use its pre-change NOL carryforwards and R&amp;D credits to offset its post-change income and taxes, respectively, may be limited. For purposes of these rules, an &ldquo;ownership change&rdquo; generally occurs if one or more shareholders or groups of shareholders who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The application of these rules could limit the amount of NOLs or R&amp;D credit carryforwards that we can utilize annually to offset future taxable income or tax liabilities. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Although the Company has not undertaken a formal analysis, an ownership change may have occurred prior to September 30, 2023, which would reduce the NOL available for use in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by U.S. and state tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If our listing application for our common stock is not approved by Nasdaq, we will not be able to consummate this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;NTHI.&rdquo; Our initial public offering is conditioned upon the approval of our listing by Nasdaq, which approval may not be granted. If our listing is not approved by Nasdaq, we will not be able to complete this initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An active trading market for our common stock may not develop, and you may not be able to resell your shares at or above the initial public offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although we have applied to list our common stock on The Nasdaq Capital Market, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock was determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to enter into collaborations or acquire other companies or technologies using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our stock price is likely to be volatile. The stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile, and we note recent instances of extreme stock price run-ups followed by rapid price declines and stock price volatility seemingly unrelated to company performance following a number of recent initial public offerings, particularly among companies with relatively smaller public floats. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, as a relatively small-capitalization company with limited public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than companies with larger market capitalization. In particular, our common shares may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices. In addition, if the trading volumes of our common shares are low, persons buying or selling in relatively small quantities may easily influence prices of our common shares. This low volume of trades could also cause the price of our common shares to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our common shares may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. A decline in the market price of our common shares also could adversely affect our ability to issue additional shares of common shares or other securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our common shares will develop or be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price for our common stock may be influenced by many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results from, and any delays in, our clinical trials for NEO100 and NEO212, our preclinical studies and any other future clinical development programs, including any delays related to the COVID-19 pandemic;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement or termination of collaboration, licensing or similar arrangements for our development programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure or discontinuation of any of our development programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize NEO100, NEO212 and our other product candidates, if approved, inside and outside of the United States, either independently or working with third parties;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our partners&rsquo; and collaborators&rsquo; ability to successfully commercialize their licensed product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or setbacks related to drugs that are co-administered with any of our product candidates, such as cellular and targeted therapies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or legal developments in the United States and other countries;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recruitment or departure of key personnel;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of expenses related to the development of NEO100, NEO212 and any other product candidate we may develop;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the competitive landscape in our industry, including results of clinical trials of existing and potential future products that compete with NEO100, NEO212 and our other product candidates;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to adequately support future growth;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our financial results or those of companies that are perceived to be similar to us;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future accounting pronouncements or changes in our accounting policies;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements or expectations of additional financing efforts by us;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us, our insiders or other shareholders;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration of market stand-off or lock-up agreements;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations and changes in estimates or recommendations by securities analysts, if any, that cover our stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the structure of healthcare payment systems;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market conditions in the pharmaceutical and biotechnology sectors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, including the COVID-19 pandemic; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&rsquo; general perception of us and our business.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate rapidly and substantially, including any stock price run-up, regardless of our actual or expected operating performance and financial condition or prospects, which may limit, prevent or make it difficult for prospective investors to assess the rapidly changing value of our common stock or to sell their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You will suffer immediate and substantial dilution with respect to the common stock you purchase in this offering. Based on an assumed initial public offering price of $____ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, purchasers of common stock in this offering will experience immediate dilution of $____ per share, representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the assumed initial public offering price, and, following the completion of this offering, investors purchasing common stock in this offering will have contributed ___% of the total amount invested by shareholders since inception but will only own ____% of the shares of common stock outstanding. See &ldquo;<I>Dilution</I>&rdquo; for a more detailed description of the dilution to new investors in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will have considerable discretion in the application of the net proceeds of this offering. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. Management might not apply our net proceeds in ways that ultimately increase the value of your investment. While we expect to use the net proceeds from this offering as set forth in &ldquo;<I>Use of Proceeds</I>,&rdquo; we are not obligated to do so. As a result, investors will be relying upon management&rsquo;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our shareholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You should not rely on an investment in our common stock to provide dividend income. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to shareholders will therefore be limited to the appreciation of their stock, which may never occur, as the only way to realize any return on their investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our executive officers, directors, and shareholders and their affiliates who beneficially own more than 5% of our common stock will continue to exercise significant influence over our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based upon the number of shares of our common stock outstanding as of September 30, 2023, the existing holdings of our executive officers, directors, and shareholders and their affiliates who beneficially own more than 5% of our common stock are expected to represent beneficial ownership, in the aggregate, of approximately 50% of our outstanding common stock (assuming no exercise of the underwriters&rsquo; option to purchase additional shares and no purchases by such holders in this offering). As a result, these shareholders, if they act together, will be able to exercise significant influence over our management and affairs and the outcome of matters submitted to our shareholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These shareholders acquired their shares of common stock at prices per share that were substantially less than the per share price of the shares of common stock being sold in this offering, these shareholders may have interests with respect to their common stock that are different from those of investors in this offering, and the concentration of voting power among these shareholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying, deferring or preventing a change of control of our company;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding a merger, consolidation, takeover or other business combination involving our company; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">See &ldquo;<I>Principal Shareholders</I>&rdquo; in this prospectus for more information regarding the ownership of our outstanding common stock by our executive officers, directors, principal shareholders and their respective affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Conflicts of interest may arise because some members of our board of directors are representatives of our principal shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain of our principal shareholders or their affiliates are investment funds or other investment vehicles that could invest in companies that directly or indirectly compete with us. As a result of these relationships, conflicts may arise between the interests of the principal shareholders or their affiliates and the interests of other shareholders, and members of our board of directors that are representatives of such principal shareholders may not be disinterested in such conflicts. We expect that all decisions made by our executive officers and directors will be made in accordance with their duties and obligations to deal fairly and in good faith and to act in the best interests of us and our shareholders, as well as in compliance with our Code of Conduct, which will be adopted in connection with this offering and includes a &ldquo;conflicts of interest&rdquo; section applicable to all employees, executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sales of a substantial number of shares of our common stock by our existing shareholders in the public market could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on shares of common stock outstanding as of January __, 2024 upon the closing of this offering, we will have an outstanding total of ______ shares of common stock (assuming no exercise of the over-allotment option to purchase additional shares). Of these shares, only the shares of common stock sold in this offering by us, including any upon exercise of the underwriters&rsquo; option to purchase additional shares, will generally be freely tradable without restriction in the public market immediately following this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All of our directors, officers and beneficial owners of over one percent of our outstanding common stock have agreed that, until 180 days after the date of this prospectus, subject to certain exceptions, we and they will not, without the prior written consent of the Representatives, offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any of our shares of common stock, any options or warrants to purchase any of our shares of common stock or any securities convertible into or exchangeable for or that represent the right to receive shares of our common stock; the Representatives may release any of the securities subject to these lock-up agreements at any time, subject to applicable notice requirements. After the lock-up agreements expire, up to 16,560,000 shares of common stock will be eligible for sale in the public market, of which 7,964,726 shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements, and Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our shareholders and could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will need significant additional capital in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities, and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our failure to meet Nasdaq&rsquo;s continued listing requirements could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the listing requirements of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the past, securities class action litigation has often been brought against public companies following declines in the market prices of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and our resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure in this prospectus, not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these exemptions until the last day of the fiscal year ending after the fifth anniversary of this offering or until we are no longer an emerging growth company, whichever is earlier. We will cease to be an emerging growth company prior to the end of such five-year period if certain earlier events occur, including if we become a &ldquo;large accelerated filer&rdquo; as defined in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also a &ldquo;smaller reporting company&rdquo; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company, which would allow us to take advantage of many of the same exemptions available to emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. We will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our shareholders, more difficult and may prevent attempts by our shareholders to replace or remove our current management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws that will become effective immediately prior to the completion of this offering and provisions of Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a classified board of directors such that not all members of the board are elected at one time;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit the manner in which shareholders can remove directors from the board;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our shareholders by written consent;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit our shareholders from calling a special meeting of our shareholders;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &ldquo;poison pill,&rdquo; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require the approval of the holders of at least 66 2/3% of the votes that all our shareholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our amended and restated bylaws will provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our amended and restated bylaws that will become effective immediately prior to the completion of this offering will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any derivative action or proceeding brought on our behalf;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a breach of fiduciary duty;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our certificate of incorporation or our bylaws; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action asserting a claim against us that is governed by the internal affairs doctrine.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and the provisions may be enforced by a court in those other jurisdictions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could harm our business, financial condition, results of operations, and prospects. Further, this exclusive forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees or make it more difficult or expensive to litigate the foregoing matters, which may discourage lawsuits against us and our directors, officers and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We will incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &ldquo;say on pay&rdquo; and proxy access. Emerging growth companies and smaller reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If we fail to maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are required to maintain internal controls over financial reporting. Commencing with our fiscal year ending the year after this offering is completed, we must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form&nbsp;10-K filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We have identified material weaknesses in our intern</I></B>al <B><I>control over financial reporting and may identify additional material weaknesses in the future. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. If we fail to establish and maintain effective internal controls over financial reporting, our operating results and our ability to operate our business could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As a private company, our company has not been required to document and test its internal controls over financial reporting, nor has management been required to certify the effectiveness of its internal controls, and our auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Similarly, our company has not been subject to the SEC&rsquo;s internal control reporting requirements. Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In connection with the audit of NeOnc Technologies, Inc. for the years ended December&nbsp;31, 2022 and 2021, our company and its independent registered public accounting firm identified material weaknesses in its internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The material weaknesses that NeOnc Technologies, Inc. and its independent registered public accounting firm identified in NeOnc Technologies, Inc.&rsquo;s financial statements for the years ended December&nbsp;31, 2022 and 2021 occurred because our company was a private company that had not previously been audited and had maintained a complement of resources with various levels of accounting knowledge, experience, and expertise that are not commensurate with our prospective financial reporting needs. These material weaknesses relate to the fact that we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting to reduce the risk of publishing materially misstated financial statements, as well as defined responsibilities and segregated incompatible duties to reduce the risk of unauthorized transactions. Collectively, this could result in difficulties in meeting our internal reporting needs and our external reporting requirements and assessing the appropriate accounting treatment for various events and/or transactions.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have initiated various remediation efforts, including the hiring of additional financial personnel/consultants with the appropriate public company and technical accounting expertise. We cannot reasonably estimate the cost of such remediation plan at this time. We can give no assurance that such efforts will remediate these material weaknesses internal control over financial reporting or that additional material weaknesses in its internal control over financial reporting will not be identified in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We may discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company, we will operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of the Nasdaq Capital Market, the rules and regulations of the Securities and Exchange Commission, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. Commencing with our fiscal year ending the year after this offering is completed, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form&nbsp;10-K filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Prior to this offering, we have never been required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that the process of building our accounting and financial functions and infrastructure will require significant additional professional fees, internal costs and management efforts. For example, we expect that we will need to implement new systems to enhance and streamline the management of our financial, accounting, human resources and other functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However, such systems will likely require us to complete many processes and procedures for the effective use of the systems, which may result in substantial costs. Any disruptions or difficulties in implementing or using these systems could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to implement proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_005"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus includes forward-looking statements within the meaning of the federal securities laws. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the operating results and financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management&rsquo;s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our projected financial position and estimated cash burn rate;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates of the size of our market opportunities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to effectively manage our growth;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success, cost and timing of our clinical trial;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on third parties in the conduct of our clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential that results of pre-clinical and clinical trials indicate our current product candidates or any future product candidates we may seek to develop are unsafe or ineffective;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain intellectual property protection for our current product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market acceptance of our product candidates, the size and growth of the potential markets for our current product candidates and any future product candidates we may seek to develop, and our ability to serve those markets;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing therapies and products that are or become available;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the successful development of our commercialization capabilities, including sales and marketing capabilities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expected use of proceeds from this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential lack of liquidity and trading of our securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential ability to obtain additional financing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain the listing of our common stock on the Nasdaq Capital Market;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant disruption in, or breach in security of, our information technology systems and resultant interruptions in service and any related impact on our reputation;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the attraction and retention of qualified employees and key personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our internal controls and disclosure controls;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws and government regulation affecting our business;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of adverse economic conditions;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sufficiency of our cash and cash equivalents to meet our liquidity needs and service our indebtedness; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">outcomes of legal or administrative proceedings.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in this prospectus, the words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; and similar expressions, as they relate to our Company, our business and our management, are intended to identify forward-looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking statements speak only as of the date of this prospectus. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_006"></A>USE OF PROCEEDS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $___, assuming an initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and an advisory fee payable to Maxim of three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The principal purposes
of this offering are to increase our capitalization and financial flexibility, increase our visibility in the marketplace and create
a public market for our common stock. As of the date of this prospectus, we cannot specify with certainty all of the particular uses
for the net proceeds to us of this offering. However, we currently intend to use approximately $23.7 million of the net proceeds for
clinical trials, $11.4 million of the net proceeds for research and development, $10.0 million of the net proceeds to repay a short term
loan (the &ldquo;HCWG Loan&rdquo;) provided to us by HCWG LLC, an entity substantially beneficially owned by our officers and directors,
$913 thousand of the net proceeds to pay accrued salaries, and $30.5 million of the net proceeds for general corporate purposes and working
capital, of which we will pay (i) AFH a cash fee in an amount equal to 2.0% of the post-money valuation of our company immediately after
the consummation of this offering, (ii) Maxim an advisory fee of three-quarters of one percent (0.75%) of the gross proceeds from the
sale of the common stock in this, (iii) $600,000 in connection with a settlement of a dispute with a former licensee, and (iv) $230,000
to the University of Southern California for past due amounts under our license agreement with the University. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We intend to allocate the net proceeds used for clinical trials and research and development to develop the program candidates until the development stages detailed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1pt solid; vertical-align: bottom; width: 33%; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Program
    Candidate</B></FONT> </TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; width: 34%; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Allocated
    Proceeds</B></FONT> </TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; width: 33%; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Expected
    Development Phase from Use of Allocated Proceeds</B></FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">NEO100
    (NEO100-01/02)</FONT> </TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">$11.0
    million</FONT> </TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">Phase
    2a</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">NEO212
    (Oral and Intranasal)</FONT> </TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">$19.0
    million</FONT> </TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">Phase
    1/2a</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">Pediatric
    (NEO100-03)</FONT> </TD>
    <TD STYLE="border-right: black 1pt solid; vertical-align: top; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">$5.1
    million</FONT> </TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: center"> <FONT STYLE="font-size: 10pt">Phase
    1/2a</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have primarily used the proceeds of the HCWG Loan to prepare the company for an offering of its securities and activities related thereto, while payment for operating activities have been deferred. This short term loan does not bear interest, matures after twelve months after the date of issuance and is repayable with a 1x return in full from the proceeds of this offering. For more information, see &ldquo;<I>Certain Relationships and Related Party Transactions &ndash; Letter of Intent &ndash; AFH Holdings and Advisory, LLC</I>&rdquo; and &ldquo;<I>Certain Relationships and Related Party Transactions &ndash; Short-term loans</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While we have not allocated a specific amount of the remaining net proceeds from this offering to any particular purpose, we may use such remaining net proceeds for the acquisitions of additional businesses or technologies. We do not have any understandings or agreements for any acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds we actually expend for the acquisition of additional businesses may vary significantly depending on a number of factors, including our ability to locate such companies and enter into a binding acquisition agreement on favorable terms and the negotiated purchase price. In addition, the net proceeds we actually expend for general corporate purposes may vary significantly depending on a number of factors, including future revenue growth and our cash flows. As a result, we will retain broad discretion over the allocation of the remaining net proceeds from this offering. Pending use of the net proceeds from this offering, we intend to invest the net proceeds in short-term, investment-grade securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each $1.00 increase or decrease in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $___, assuming that the number of shares of our common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions payable by us. An increase or decrease of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $___, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The foregoing represents our current intentions to use and allocate the net proceeds of this offering based upon our present plans and business conditions. We will have broad discretion over how to use the net proceeds to us from this offering. We intend to invest the net proceeds to us from the offering that are not used as described above in investment-grade, interest-bearing instruments. See &ldquo;<I>Risk Factors&#8212;Risks Related to this Offering and Our Common Stock &#8212; Our management has broad discretion in the use of the net proceeds from this offering and may not use the net proceeds effectively.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_007"></A>DIVIDEND POLICY</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors or any authorized committee thereof after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors or such committee deems relevant, and subject to the restrictions contained in our current or future financing instruments. <FONT STYLE="background-color: white">See also &ldquo;</FONT><I>Risk Factors&#8212; Risks Related to this Offering and Our Common Stock <FONT STYLE="background-color: white">&#8212; We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.&rdquo;</FONT></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_008"></A>CAPITALIZATION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth our cash and capitalization as of September&nbsp;30, 2023 (i) on an actual basis and (ii) on an as adjusted basis, giving effect to our receipt of estimated net proceeds from the sale of shares of common stock that we are offering at an assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses, and (b) the issuance in October 2023 of 560,000 shares of common stock to be issued to USC further to the terms of our license agreement with the university as amended on April 5, 2023 (&ldquo;Amended License Agreement&rdquo;). You should read this table together with the section titled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo; and our consolidated financial statements and related notes included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of<BR> September&nbsp;30,<BR> 2023</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjusted<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">769</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indebtedness, including current portion</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right">4,<FONT STYLE="font-family: Times New Roman, Times, Serif">194,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding actual and as adjusted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, $0.0001 par value, 100,000,000 shares authorized, 16,000,000 shares issued and outstanding actual and ________shares issued and outstanding as adjusted</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,600</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paid-in capital</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,212,355</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,554,732</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total shareholders&rsquo; equity (deficit)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,340,777</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,146,173</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not reflect certain payments to be made with a portion of the net proceeds of this offering as follows: (i) an amount equal to 2.0%
    of the post-money valuation of our company immediately after the consummation of this offering payable to AFH, (ii) $600,000 in connection
    with a settlement of a dispute with a former licensee, and (iii) $230,000 to the University of Southern California for past due amounts
    under our license agreement with the University.</FONT> </TD></TR>

<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares
    of our common stock reflected in the discussion and table above excludes the following:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">3,221,250 shares of common stock issuable upon the vesting of restricted
    stock units that were granted in January 2024;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">560,000 shares of common stock to be issued to USC in accordance with the Amended License Agreement (issued in October 2023); and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">3,440,000 shares of common stock (which include the 3,221,250 shares
    issuable upon the vesting of the restricted stock units described above) currently reserved for future grant or issuance under our
    2023 Plan of which, 218,750 shares would be available for future grant or issuance assuming the vesting of all restricted stock units
    that were granted in January 2024.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each $1.00 increase or decrease in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our cash, and total shareholders&rsquo; equity and total capitalization by approximately $___, assuming that the number of shares of our common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions payable by us. Each increase or decrease of 1.0 million shares in the number of shares offered by us would increase or decrease the amount of our cash, total shareholders&rsquo; equity and total capitalization by approximately $___, assuming an initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_009"></A>DILUTION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If you invest in our common stock, your interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock after this offering. <FONT STYLE="background-color: white">Dilution in net tangible book value per share to new investors is the amount by which the offering price paid by the purchasers of the shares sold in this offering exceeds the as adjusted net tangible book value per </FONT>share of common stock <FONT STYLE="background-color: white">after this offering. Net tangible book value per share is determined at any date by subtracting our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of </FONT>our common stock <FONT STYLE="background-color: white">deemed to be outstanding at that date.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our historical net tangible book value (deficit) as of September&nbsp;30, 2023 was $($8,765,816), or $(0.62) per share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to our sale of _____ shares of our common stock in this offering at an assumed initial public offering price of $___ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions payable by us and an advisory fee payable to Maxim of three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering, and (b) the issuance in October 2023 of 560,000 shares of common stock to be issued to USC further to the terms of our Amended License Agreement with the university, (recorded as Common stock payable for license fee, at fair value of $2,507,773 in the accompanying condensed consolidated balance sheet as of September 30, 2023), our as adjusted net tangible book value as of September&nbsp;30, 2023, would have been $___, or $___ per share<SUP>(1)</SUP>. This represents an immediate increase in as adjusted net tangible book value of $___per share to our existing shareholders and an immediate dilution of $___per share to new investors purchasing shares of common stock in this offering. The following table illustrates this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed initial public offering price per share</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value (deficit) per share as of September&nbsp;30, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(___</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value (deficit) per share after this offering<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution in as adjusted net tangible book value per share to new investors in this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"> (1) </TD>
    <TD STYLE="text-align: justify"> Does not reflect certain payments to be made with a portion of the net proceeds of this offering
    as follows: (i) an amount equal to 2.0% of the post-money valuation of our company immediately after the consummation of this offering
    payable to AFH, (ii) $600,000 in connection with a settlement of a dispute with a former licensee, and (iii) $230,000 to the University
    of Southern California for past due amounts under our license agreement with the University. </TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of our common stock reflected in the discussion and table above excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">3,221,250 shares of common stock issuable upon
    the vesting of restricted stock units that were granted in January 2024; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">3,440,000 shares of common stock (which include
    the 3,221,250 shares issuable upon the vesting of the restricted stock units described above) currently reserved for future grant
    or issuance under our 2023 Plan, of which 218,750 shares would be available for future grant or issuance assuming the vesting of
    all restricted stock units that were granted in January 2024.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each $1.00 increase or decrease in the assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our as adjusted net tangible book value by approximately $____, or approximately $____per share, and would increase or decrease, as applicable, dilution per share to new investors in this offering by $____, assuming that the number of shares of our common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions payable by us. An increase or decrease of 1,000,000 shares in the number of shares offered by us would increase or decrease, as applicable, our as adjusted net tangible book value by approximately $___, or approximately $____ per share. An increase of 1,000,000 shares in the number of shares offered by us would decrease dilution per share to new investors in this offering by approximately $____ and a decrease of 1,000,000 shares in the number of shares offered by us would increase dilution per share to new investors in this offering by approximately $____ per share, assuming an initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. If the underwriters exercise their option to purchase additional shares in full, the as adjusted net tangible book value per share would be $____ per share, and the dilution per share to new investors in this offering would be $____ per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following table summarizes as of the date of this prospectus the differences between the existing shareholders and new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid or to be paid to us at an assumed initial public offering price of $____ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us and an advisory fee payable to Maxim of three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering:</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total Consideration</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Average<BR> Price</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares Purchased</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amount</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percent</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Per Share</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing shareholders</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 1%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,560,000</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 1%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 9%; text-align: right"></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT>&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%<SUP>(2)</SUP></FONT>&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New investors</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Totals</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the underwriters exercise their option to purchase additional shares in full, the percentage of shares of our common stock held by existing shareholders would be ____% and the percentage of shares of our common stock held by new investors would be ____%.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not reflect certain
    payments to be made with a portion of the net proceeds of this offering as follows: (i) an amount equal to 2.0% of the post-money
    valuation of our company immediately after the consummation of this offering payable to AFH, (ii) $600,000 in connection with a settlement
    of a dispute with a former licensee, and (iii) $230,000 to the University of Southern California for past due amounts under our license
    agreement with the University.</FONT> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_010"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus entitled &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Statement Concerning Forward-Looking Statements&rdquo;. Financial information as of and for the year ended December 31, 2022 and 2021 is for NeOnc Technologies, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing superior treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc&rsquo;s lead product candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical trial and are currently conducting preliminary efficacy testing in a Phase 2a trial with recurrent malignant glioma (Grade IV IDH1 mutant and Grade III Astrocytoma IDH1 mutant) patients. NeOnc is also developing a second product candidate, NEO212, which has completed preclinical testing and an investigational new drug (IND) application has been filed and accepted with the United States Food and Drug Administration (FDA). The company has started Phase 1 clinical trials with patients harboring primary and secondary malignant brain cancer types. Several additional drug candidates are in the pipeline and are undergoing preclinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, acquiring and developing our technology, establishing our intellectual property portfolio, identifying potential product candidates and undertaking preclinical and clinical studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product sales other than for humanitarian usage. From inception through September 30, 2023, we had raised an aggregate of approximately $13.1 million of gross proceeds through the sale and issuance of preferred stock and common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its inception, we have incurred significant operating losses. Our net loss was $8,765,816, $3,046,757 and $3,375,602 for the nine months ended September 30, 2023 and the years ended December&nbsp;31, 2022 and 2021, respectively. We had an accumulated deficit of $32,554,732 at September 30, 2023. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing, and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The report of our independent registered public accounting firm on our financial statements as of and for the year ended December&nbsp;31, 2022 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. See Note 1 to our annual financial statements appearing at the end of this prospectus for additional information on our assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In December 2022, we signed a Letter of Intent (&ldquo;LOI&rdquo;) with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;) to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&ldquo;NTHI&rdquo;) to facilitate future fundraising transactions. On April 7, 2023, we entered into Share Exchange Agreements with NTHI, whereby all of the common and preferred shareholders of NeOnc Technologies, Inc. exchanged their shares of common stock for a total of 10,500,000 shares of common stock in NTHI (the &ldquo;Share Exchange&rdquo;). At the consummation of the Share Exchange, AFH and its affiliated entities, individuals, or assignees owned an aggregate of 34.4% (5,500,000 shares) of the fully diluted issued and outstanding common shares of NTHI. AFH will also act as an investment advisor in future financing transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2023, we had a cash balance of $769, and $30,000 available to borrow from our loan with HCWG that will be available through the date of this offering and will be repaid with a portion of the net proceeds of this offering. On December 4, 2023, the maximum available borrowings under the loan with HCWG was increased to up to $10,000,000. We believe that our existing cash, together with the aforementioned credit facility and with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We occasionally receive a fee from a patient for a &ldquo;right to try&rdquo; humanitarian program. Such revenues are not part of our core business.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have deferred payments received for the license of our products to third parties &#8211; See collaboration agreement accounting policy below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating expenses consist of (i) research and development expenses and (ii) legal and professional expenses and (iii) general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts and preclinical and clinical studies under our research programs, which include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related expenses, including salaries, benefits and stock-based compensation expense for our research and development personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on our behalf;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of manufacturing drug product and drug supply related to our current or future product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of conducting preclinical studies and clinical trials of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting and professional fees related to research and development activities, including equity-based compensation to non-employees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of maintaining our laboratory, including purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to compliance with clinical regulatory requirements; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical and clinical studies or other services performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The successful development of our product candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete development of our current or future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if they are approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies and clinical trials and other research and development activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing an appropriate safety profile;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrollment in and completion of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether our product candidates show safety and efficacy in our clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt of marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued acceptable safety profile of the products following any regulatory approval.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly change the costs and timing associated with the development of those product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we commence clinical trials and continue the development of our current and future product candidates. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and professional expenses consist of costs related to corporate and intellectual property legal costs and accounting and auditing fees. We also anticipate increased expenses associated with being a public company, including costs for audit, legal, regulatory and tax-related services related to compliance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and listing standards applicable to companies listed on a national securities exchange, director and officer insurance premiums, and investor relations costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses include salaries and other compensation-related costs, including stock-based compensation, for personnel in executive, finance and accounting, business development, operations and administrative roles. Other significant costs include insurance costs, travel costs, facility and office-related costs not included in research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth in research and development activities, including our future clinical programs. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside service providers, among other expenses. In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Advisory Fee Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The advisory fee expenses results from the advisory arrangement with AFH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>License Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The license expense results from the Amended License Agreement with USC whereby we agreed to issue USC 560,000 additional shares of our common stock. We have recorded a liability at September&nbsp;30, 2023 equal to the estimated value of such shares; upon issuance of the shares in October 2023, such liability was recorded as a credit to additional paid in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Interest Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense results from the bridge loan from a related party. Borrowings under the note carry a 50% (or 1 times amounts borrowed) original issue discount (&ldquo;OID&rdquo;) on principal. The OID to be earned under the bridge loan is recognized ratably over the term of each draw-down under the loan through the maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison of the nine months Ended September 30, 2023 and 2022</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following table summarizes our results of operations for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended<BR> September&nbsp;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top">Revenues</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 64%; vertical-align: top">Revenue</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating expenses:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">989,239</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">766,260</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">222,979</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Legal and professional</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,586,661</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">319,294</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,267,367</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Share based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(832,250</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">General and administrative</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,047,771</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">53,479</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">994,292</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advisory fee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement expense</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">License expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,737,773</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,737,773</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total operating expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,461,444</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,971,283</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,490,161</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss from operations</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(7,390,982</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,971,283</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(5,419,699</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other expense:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in fair value of note payable &ndash; Chairman of the Board</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(9,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">9,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Interest expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,374,834</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,374,834</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,765,816</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,980,283</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,785,533</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue was generated for fees for a &ldquo;right to try&rdquo; humanitarian program during 2023 and sale of product to a licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the components of our research and development expenses for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the<BR> nine months ended<BR> September&nbsp;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Research and development costs by project:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top">NEO100</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">354,364</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">215,324</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">NEO212</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">238,041</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">132,035</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Pediatric IND</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">131,230</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Laboratory</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">240,732</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">340,853</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top">Other</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,872</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,048</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Total</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">989,239</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">766,260</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended<BR> September&nbsp;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Clinical trial expense</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">748,507</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">425,407</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">323,100</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Research and laboratory</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">240,732</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">340,853</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(100,121</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total research and development expense</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">989,239</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">766,260</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">222,979</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses were $989,239 and $766,260 for the nine months ended September&nbsp;30, 2023 and 2022, respectively. A portion of these expenses are from the University of Southern California (USC), where Dr. Chen is a member of the faculty, amounted to approximately $240,732 and $340,853 for the nine months ended September&nbsp;30, 2023 and 2022, respectively. The total increase of $222,979 was primarily due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The addition of clinical trial site for NEO100&rsquo;s clinical trial. </FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The completion of the IND for NEO212 and preparation for the clinical trial.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preparation of an IND for NEO100-03 for a Pediatric Indication.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Share-Based Compensation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Share-based compensation expenses decreased from $832,250 to $0 for the nine months ended September 30, 2023, as all outstanding awards were fully vested prior to January 1, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Advisory Fee </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advisory fee expense of $500,000 for the nine months ended September 30, 2023 resulted from the advisory arrangement with AFH. No such fees were incurred during the nine months ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Litigation Settlement Expense </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Litigation settlement expense of $600,000 for the nine months ended September 30, 2023 resulted from the settlement of a legal matter with a former licensee. No such settlements were incurred during the nine months ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>License Expense </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">License expense of $2,737,773 for the nine months ended September 30, 2023, resulted from the estimated fair value of the shares to be issued to USC in accordance with the USC Amended License Agreement in the amount of $2,507,773, and $230,000 to cure deficiencies in the existing USC Restated Agreement related to unpaid sub-license fees. No such fees were incurred during the nine months ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and professional expenses were $1,586,661 and $319,294 for the nine months ended September&nbsp;30, 2023 and 2022, respectively. The increase of $1,267,367 was primarily due to conducting our audits of the financial statements and preparation thereof, increased legal expenses as a result of terminating certain license agreements and corporate restructurings, and increased legal expense related to filing new patents and maintenance of current patent portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expense were $1,047,771 and $53,479 for the nine months ended September&nbsp;30, 2023 and 2022, respectively. The increase of $994,292 was primarily due to the commencement of incurring salaries of approximately $581,000 (there were no such costs approved by the Board of Directors in 2022) and public relations and travel costs of approximately $314,000 related to potential fund-raising meetings and corporate visibility conferences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended<BR> September&nbsp;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net cash provided by (used in):</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; width: 64%; text-align: left">Operating activities</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(1,508,146</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(645,764</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(862,382</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Financing activities</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">875,617</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">725,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,617</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(632,529</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">79,236</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(711,765</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the nine months ended September&nbsp;30, 2023, net cash used in operating activities was $1,508,146, consisting primarily of our net loss of $8,765,816 less the non-cash charge for license expense payable in stock of $2,507,773 and accretion of original issue discount of $1,374,084 and an offset by an increase in accounts payable of $1,185,808, accrued compensation of $500,904 and litigation settlement payable of $600,000. During the nine months ended September&nbsp;30, 2022, net cash used in operating activities was $645,764, consisting primarily of our net loss of $1,980,283 less the non-cash charge for share based compensation of $832,250 and an increase in accounts payable of $505,269. We have primarily used the proceeds of the bridge loan to prepare the company for an offering of its securities and activities related thereto, while payment for operating activities have been deferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the nine months ended September&nbsp;30, 2023, cash provided by financing activities was $875,617 consisting primarily of net proceeds of $2,432,866 from the bridge loans, offset by the repayment of bridge loans of $1,199,588 and the payment of deferred offering costs of $358,111. At September&nbsp;30, 2023, the debt outstanding consisted of a $50,000 convertible promissory note from a stockholder and bridge loans with outstanding principal of $4,144,604 (including OID) due at the earlier of the IPO date or July&nbsp;26, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September&nbsp;30, 2022, cash provided by financing activities was $725,000. We received $1,300,000 from the sale of common stock, and $125,000 of borrowings from related parties, and repaid $700,000 of notes payables and advances primarily from our Chairman.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison of the Years Ended December&nbsp;31, 2022 and 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes our results of operations for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended December&nbsp;31.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">488,772</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal and professional</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">318,205</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">217,951</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,254</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,376,069</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,379,174</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,003,105</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,857,604</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,271,683</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(414,079</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from operations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,837,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,271,683</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">434,079</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other (expense) income:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of note payable &ndash; Chairman of the Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(200,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(112,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(87,234</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total other expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(209,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(103,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(105,234</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">328,845</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue was a one-time fee received for a &ldquo;right to try&rdquo; humanitarian program during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the components of our research and development expenses for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the<BR> year ended <BR> December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development costs by project:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">348,285</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">159,018</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">240,808</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,734</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Laboratory</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">512,709</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">421,869</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,528</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,937</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended December&nbsp;31,</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical trial expense</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">650,621</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">252,689</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">397,932</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and laboratory</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">512,709</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">421,869</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90,840</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total research and development expense</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">488,772</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses were $1,163,330 and $674,558 for the years ended December&nbsp;31, 2022 and 2021, respectively. A portion of these expenses are from USC where Dr. Chen is a member of the faculty and amounted to approximately $442,000 and $372,000 for the years ended December&nbsp;31, 2022 and 2021, respectively. The increase of $488,772 was primarily due to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacture of capsules in preparation for the NEO212 oral clinical trial of $150,800</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in expenses for the preparation of the NEO212 and related expenses for the preparation of IND.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and professional expense were $318,205 and $217,951 for the years ended December&nbsp;31, 2022 and 2021, respectively. The increase of $100,254 was primarily due to conducting our audits of the financial statements and preparation thereof and increased legal expense related to filing new patents and maintenance of current patent portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expense were $1,376,069 and $2,379,174 for the years ended December&nbsp;31, 2022 and 2021, respectively. The decrease of $1,003,105 was primarily due to the decrease in stock based compensation expense of $927,424 from 2021 to 2022, because options were not issued in 2022, and a decrease of $150,000 of accrued compensation to officers and consultants (there were no such costs approved by the Board of Directors in 2022).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest Expense and change in fair value of the note payable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense in 2021 relates primarily to the fair value of a stock option granted to Dr. Chen in 2021 in connection with the issuance of a promissory note. Interest expense in 2022 primarily relates to charges associated with the settlement of advances made by Dr. Chen. At December&nbsp;31, 2022, we have a $50,000 promissory note outstanding. The note was recorded at fair value and was repaid in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following table summarizes our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by (used in):</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating activities</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(881,736</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(396,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(485,043</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,490,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,240,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">608,264</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">754,957</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Operating Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the year ended December&nbsp;31, 2022, net cash used in operating activities was $881,736, consisting primarily of our net loss of $3,046,757 less the non-cash charge for share based compensation expense of $1,291,909 and an offset by an increase in accounts payable of $804,147. During the year ended December&nbsp;31, 2021, net cash used in operating activities was $396,693, consisting primarily of our net loss of $3,375,602 less the non-cash charge for share based compensation of $2,219,333, an increase in accounts payable of $423,172, and an increase in accrued compensation of $150,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Financing Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the year ended December&nbsp;31, 2022, cash provided by financing activities was $1,490,000 consisting primarily of net proceeds of $2,400,000 from the sale of our common stock, $125,000 from related parties, offset by the repayment of advances made by Dr. Chen of $700,000 and the net repayment of loans from related parties, including Dr. Chen&rsquo;s promissory note of $250,000. At December&nbsp;31, 2022, the debt outstanding consisted of a $50,000 convertible promissory note from a stockholder due August&nbsp;2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the year ended December&nbsp;31, 2021, cash provided by financing activities was $250,000, consisting primarily of a note from our Chairman. This was fully repaid in 2022.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sources of Liquidity/ Going Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since our inception, we have funded our operations through the sale and issuance of preferred and common stock. From inception through December&nbsp;31, 2022, we raised an aggregate of approximately $13,117,000 in gross proceeds from the sales of our stock. In April 2023, we entered into a non-interest bearing, non-convertible promissory note with HCWG LLC (a related party) payable at the earlier of the IPO date or April 27, 2024. The note was amended December 4, 2023 to increase the maximum borrowings up to $10,000,000, which may be drawn upon at any time during the term of the note. As of September&nbsp;30, 2023, we had drawn $3,970,109 under such facility. As of September&nbsp;30, 2023, we had cash on hand in the amount of $769.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Since our inception, we have not generated any revenue from product sales or any other sources, except humanitarian use, and we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. As reflected in the accompanying financial statements, we have incurred recurring net losses since our inception. During the nine months ended September&nbsp;30, 2023, we incurred a net loss of $8,765,816 and used cash in operations of $1,508,146 and had a shareholders&rsquo; deficit of $10,340,777 as of September&nbsp;30, 2023. During the year ended December&nbsp;31, 2022, we incurred a net loss of $3,046,757 and used cash in operations of $881,736 and had a shareholders&rsquo; deficit of $ 1,575,411 as of December&nbsp;31, 2022 These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise additional funds and implement our strategies, such as executing additional licensing contracts. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ability to continue as a going concern is dependent on us raising additional capital and attaining and maintaining profitable operations in the future to meet our obligations and repay our liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and licensing income and we expect to continue to rely on these sources of capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing, or grant unfavorable terms in licensing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Funding Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development, initiate and conduct preclinical studies and clinical trials, and seek marketing approval for our current and any of our future product candidates. In addition, if we obtain marketing approval for any of our current or our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, which costs we may seek to offset through entry into collaboration agreements with third parties. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that our existing cash, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of conducting preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of discovery, preclinical development, laboratory testing, and clinical trials for product candidates we may develop, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing, and outcome of regulatory review of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain collaborations on favorable terms, if at all;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the achievement of milestones or occurrence of other developments that trigger payments under any license or collaboration agreements we might have at such time;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our headcount growth and associated costs as we expand our business operations and research and development activities; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of operating as a public company.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds of this offering, together with our existing cash, will be sufficient to progress our Phase 2 registration trial of development of NEO100, but will not be sufficient to progress trials in other indications or the development of any other product candidate. Accordingly, we will be required to obtain further funding to achieve our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we raise funds through potential collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Bridge Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In April 2023, we entered into a non-interest bearing, non-convertible promissory note with HCWG LLC (a related party). Borrowings under the note carry a 50% (or 1 times amounts borrowed) original issue discount (&ldquo;OID&rdquo;) on principal. The note initially allowed for maximum borrowings of $1,600,000 (amended on June 26, 2023, to increase the maximum borrowings to $2,800,000, on July 26, 2023 to increase the maximum borrowings to $4,000,000, on October&nbsp;19, 2023 to increase the maximum borrowings to $5,000,000 and again on December 4, 2023 to increase the maximum borrowings up to $10,000,000), which may be drawn upon at any time during the term of the note. All outstanding interest and principal are payable at the earlier of the IPO date or December 4, 2024 (the &ldquo;Maturity Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have the option to prepay this note with no penalties at any time and prior to the Maturity Date in an amount equal to the sum of: (A) the then principal balance of this note plus (B) all other amounts, costs, and expenses then due in respect of this note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of September&nbsp;30, 2023, we had received $3,970,109 under the bridge loan. Accretion of the OID for the nine months ended September&nbsp;30, 2023, amounted to $1,374,084. Summary of the bridge loan activity through September&nbsp;30, 2023 is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended<BR> September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Bridge loan payable &ndash; draw downs</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">3,970,109</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">OID on draw downs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,970,109</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less repayments of draw downs</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,199,588</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance June 30, 2023</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,740,630</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">At<BR> September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Principal outstanding</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">6,740,630</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less unrecognized OID</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,596,026</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Total</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,604</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have incurred $500,904 and $0 for the nine months ended September&nbsp;30, 2023 and 2022 for compensation to the three officers of our company, two of whom are shareholders. We have incurred $0 and $150,000 for the years ended December&nbsp;31, 2022 and 2021 for compensation to the Chairman and a consultant, both of whom are shareholders. This compensation is recorded in the statement of operations as part of general and administrative expenses. Accrued compensation payable to the Chairman and the consultant was $412,500 and $462,000 as of December&nbsp;31, 2022 and 2021, respectively. At September&nbsp;30, 2023, accrued compensation was $913,404.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In 2022, we issued $50,000 of convertible notes to a shareholder due August 30, 2023 (&ldquo;Note&rdquo;). The Note bears interest at 2% per annum. This Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by us in our next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering (&ldquo;IPO&rdquo;), of equity securities by the Company to investors for cash. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without further action on the part of the noteholder or us, into the class and series of stock issued by us, at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have elected to account for the Note under the fair value option. The fair value of the Note approximated the face amount of $50,000 at both September&nbsp;30, 2023 and December 31, 2022. As such, no adjustment was made to the carrying value of the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-term loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&nbsp;2022, we entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022 from Martin Schmieg, a former executive officer of NeOnc Technologies, Inc. The loan was fully paid off in December&nbsp;2022. Interest expense paid related to this loan for the year ended December&nbsp;31, 2022 was approximately $1,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances from Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have periodically received cash advances from the Chairman or have had certain costs incurred by the USC on our behalf paid for by the Chairman. These advances were non-interest bearing and had no stated maturity. At December&nbsp;31, 2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, we repaid in cash $700,000 of such advances to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022. The fair value of the common stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891 was recorded as interest expense in the statement of operations for the year ended December&nbsp;31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder advances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically certain of our shareholders have advanced us funds to support operations under informal loan arrangements (the &ldquo;Shareholder Advances&rdquo;). These Shareholder Advances bear no interest and have no specified maturity date. There were Shareholder Advances outstanding totaling $0 and $10,000 as of December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, we repaid all outstanding Shareholder Advances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note payable &#8211; Chairman of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&nbsp;18, 2021, we entered into a loan agreement with the Chairman with a principal amount of $250,000 (the &ldquo;Chairman Note&rdquo;). The Chairman Note bore no interest and was payable when we received funding in excess of $1,000,000. We received funding in excess of $1,000,000 during the year ended December&nbsp;31, 2022, at which time the Chairman Note was repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Contractual Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We enter into agreements in the normal course of business for sponsored research, preclinical studies, contract manufacturing, and other services and products for operating purposes, which are generally cancellable upon written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>USC License</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On March&nbsp;9, 2009, Nas-Onc, Inc. (k/n/a NeOnc Technologies, Inc.) entered into an exclusive, worldwide license agreement with USC, pursuant to which USC granted us a license to use certain patents and patent applications for the treatment and therapies of disease symptoms in mammals (the &ldquo;USC Agreement&rdquo;). The license is exclusive except for the rights granted to the US government pursuant to the Bayh-Dole Act and the right of USC and other non-profit academic research institutions to practice and improve the licensed patents for educational and research purposes. Pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC 117,236 shares of common stock, (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) have paid and will continue to pay annual maintenance royalties of: $5,000 due January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1, 2013, and $20,000 due January&nbsp;1 yearly thereafter. Annual maintenance royalties paid to USC are creditable toward earned royalties. We are also responsible for paying all reasonable patent expenses incurred by USC for filing prosecution and maintaining the licensed patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the event of suspected patent infringement, the parties may agree to jointly institute suit, wherein the parties will share equally all costs and any recovery, with control of such lawsuit being by agreement between us and USC. Absent an agreement to jointly institute a suit, USC has the sole right to institute suit, at its option, where USC will bear the cost of such litigation and retain all recovery. In the event that USC does not institute the lawsuit, we may bring suit, at its option, and bear all such costs. Any recovery obtain by us must be shared with USC, after litigation costs reimbursement, as royalties on Net Sales for the remaining recovery. These rights and obligations were changed pursuant to the Amended License Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The USC Agreement is sublicensable subject to the same terms, except that (1) sublicensees may not grant sublicenses, (2) the earned royalty may be increased as to sublicensees, (3) the sublicense reverts to USC in the event the USC Agreement is terminated as to us and, (4) additional issue and maintenance fees are owed to USC for each sublicense. These rights and obligations were changed pursuant to the Second Amendment and the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We may challenge the licensed patents upon 90 days&rsquo; notice and payment of all royalties due. If we are unsuccessful in its challenge, the earned royalty will thereafter be increased by a factor of three. These rights and obligations were changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Term of the USC Agreement extends until the last to expire of the licensed patents. The Term of the USC Agreement was changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The USC Agreement may be terminated by either party upon 30 days&rsquo; notice or upon material breach, wherein the breaching party is permitted 30 days to remedy such breach. USC may terminate immediately if (1) we attempt to sublicense, transfer or assign its rights contrary to the terms of the agreement, (2) we do not maintain the required insurance coverage, or (3) we are determined to be insolvent. These rights and obligations were changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The parties amended the USC Agreement on April&nbsp;5, 2023 (&ldquo;Amended License Agreement&rdquo;). The Amended License Agreement added NeOnc Technologies Holdings, Inc., our parent company, as a licensee. The Amended License Agreement also added additional patents and patent applications to the prior license grant and requires us to obtain and record fully executed assignments of the added patents demonstrating USC&rsquo;s ownership in all relevant jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Amended License Agreement, we agreed to issue USC 560,000 additional shares of our common stock. We issued such shares on October 11, 2023. We recorded a liability at September&nbsp;30, 2023 equal to the estimated value of such shares; upon issuance, such liability was recorded as a credit to additional paid in capital. For more information, see &ldquo;<I>Business &ndash; Exclusive Patent License Agreement between USC and our Company</I>.&rdquo; In addition, the Amended License Agreement provides for an 4% earned royalty on Net Sales on licensed products protected by the newly added patents on a country by-country basis. In the event that a licensed product is protected by patents from both the USC Agreement and the Amended License Agreement, the higher royalty will apply. The Amended License Agreement also recognizes a Royalty Credit, in the event that we must obtain additional licenses from third parties in order to sell the licensed products. The Amended License Agreement also grants us control the prosecution of any patent application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the licensed patents. The Amendment also changed the parties enforcement obligations. Specifically, we shall have the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were Sublicense Revenue as defined in the USC Agreement. USC must consent to any settlement that is detrimental to USC or USC&rsquo;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The parties further amended the USC Agreement on May 30, 2023 (&ldquo;Second Amendment&rdquo;). The Second Amendment revised the license agreement to permit Sublicensees to sublicense the patents pursuant to specific terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &ldquo;Restated Agreement&rdquo;). The Restated Agreement addressed and clarified certain reporting obligations of the Company under the USC Agreement and addressed certain financial and other obligations, defaults, and deficiencies in connection with the Company&rsquo;s performance under the USC Agreement. In satisfaction prior unpaid sublicense issue royalties and annual maintenance royalties due for sublicensees, the Company must pay USC $230,000 by March 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Restated Agreement provides for the same annual maintenance royalties of $20,000 per year noted above as well as the earned royalty of 2% or 4% on Net Sales on Licensed Products based on patent coverage (with the higher royalty applied when the Licensed Product is protected by patents from both the USC Agreement and the Amended License Agreement) and on a country by-country basis. As above, the Restated Agreement recognizes the Royalty Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that we, or our sublicensee (other than OEP (discussed below)), challenges a Licensed Patent the annual maintenance royalty, milestone payments and the earned royalty percentage rated will be doubled during the pendency of such challenge. At the conclusion of such challenge, if a Valid Claim that covers the Licensed Product, Licensed Service or Licensed Process is held valid and enforceable then such ongoing royalty payments will be tripled. We must also reimburse USC for all costs incurred in connection with such challenge. Further, we must provide USC at least 180 day&rsquo;s written notice prior to our, or our sublicensee (excluding OEP) challenging a Licensed Patent. The notice is required to contain the prior art and a description of the facts and arguments that support the invalidity or unenforceability contention. We are required to discuss same with USC in an attempt to resolve the issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As above, we may grant sublicenses and our sublicensees may further grant licenses through one tier. As to our sublicense and collaboration agreement with OEP (discussed below) the Restated Agreement waives any prior breach by us of the USC Agreement and permits the OEP sublicense despite inconsistencies with certain terms of the Restated Agreement. We are responsible for OEP&rsquo;s compliance with the collaboration agreement and any future amendments to the OEP Agreement shall either comply with the terms and conditions of the Restated Agreement as to all other sublicensees or shall require USC&rsquo;s written consent in each instance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As above, pursuant to the Restated Agreement we maintain sole control of the prosecution of any patent application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the Licensed Patents. In addition, the parties enforcement obligations as described in the Amended License Agreement remain unchanged. Specifically, we have the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were sublicense revenue. USC must consent to any settlement that is detrimental to USC or USC&rsquo;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Restated Agreement changes the Term of the license. Specifically, the term is now tied to our royalty obligations under the Restated Agreement. We are obligated to pay royalties as to each Licensed Product, Licensed Service or Licensed Process on a country-by-country basis until (a) the last to expire Licensed Patent covering such product/service/process or (b) for 15 years after the date of first commercial sale of such product/service/process where such product/service/process is not covered by a Valid Claim of a Licensed Patent but such product/service/process was developed or made using any Licensed Process. The Term of the license ends when no further royalty obligations are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Last, as to termination, the Restated Agreement provides that the parties may mutually agree to terminate. Further, USC may immediately terminate if (a) we do not make payments when due and fail to cure, (b) we default on our indemnification or insurance obligations, (c) we are determined to be insolvent, (d) if any of our officers, directors or employees are convicted of a felony related to the development, manufacture use, marketing, distribution or sale of the Licensed Product, (e) if an audit shows an underpayment by us or a sublicensee of 15% or more for any 12 month period, or (f) we default in the performance of our other obligations in the agreement, and in each case fail to cure. We may terminate the license by giving 180 days advance written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon any termination of the license (other than expiration of the Term), then the Restated Agreement grants to USC a non-exclusive worldwide fully paid license, with the right to sublicense, to the Licensed Product Data, which includes all pre-clinical, clinical and other regulatory data generated by or on behalf of the Company relating to the Licensed Product and generated after the effective date of the USC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Collaboration Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2013, we entered into a collaboration agreement (&ldquo;Agreement&rdquo;) with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license to OEP the right to commercialize our drug NEO100, a highly purified form of perillyl alcohol (&ldquo;Licensed Product&rdquo;), in the territories specified in the license agreement (&ldquo;Territory&rdquo;). Pursuant to the terms of the Agreement, OEP will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the Licensed Products, and bear the cost of and be responsible for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval for Licensed Products in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined that the arrangement is within the scope of ASC 808, <I>Collaborative Arrangements, </I>as both NeOnc and OEP are active participants in the activity, and they are both exposed to significant risks and rewards dependent on the commercial success of the activity. We have determined two performance obligations under the arrangement &ndash; product development and the license of the completed product. We have deferred recognition of revenue on the $200,000 paid upon signing the agreement and the $300,000 milestone payment received in 2020 as the product development obligation had not yet been completed as of December 31, 2022. Accordingly, deferred revenue as of December 31, 2022 and 2021 was $500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OEP is also obligated to pay potential milestone payments to us totaling up to $6,000,000 for the achievement of certain sales milestones. In addition, during the Royalty Term (as defined in the underlying Agreement), OEP is obligated to pay us tiered royalties between 1-5% of net sales of Licensed Products in the Territory. However, under certain conditions, royalties will not be paid if (i) no patent covering the Licensed Products is issued to NeOnc in counties defined within the collaboration agreement, and (ii) a generic version of the Licensed Products has launched in such country, and (iii) the gross profit margin for the Licensed Products in such country is less than 50%. No consideration has been received as of December 31, 2022 for the license of the completed product, as it is still under development. Despite OEP not having an obligation to pay royalties in certain circumstances, we remain obligated to pay earned royalties to USC for Licensed Products sold in such country as set forth in the Restated Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A company&rsquo;s internal control over financial reporting is a process designed by, or under the supervision of, that company&rsquo;s principal executive and principal financial officers, or persons performing similar functions, and effected by that company&rsquo;s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness in future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have concluded that there were material weaknesses in internal control over financial reporting. Historically, we were a private company that had not previously been audited and had maintained a complement of resources with various levels of accounting knowledge, experience, and expertise that are not commensurate with our prospective financial reporting needs. These material weaknesses relate to the fact that we do not maintain a comprehensive policies and procedures manual designed to establish internal controls over financial reporting to reduce the risk of publishing materially misstated financial statements, as well as define responsibilities and segregate incompatible duties to reduce the risk of unauthorized transactions. Collectively, this could result in difficulties in meeting our internal reporting needs and our external reporting requirements and assessing the appropriate accounting treatment for various events and/or circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have initiated various remediation efforts, including the hiring of additional financial personnel/&#8203;consultants with the appropriate public company and technical accounting expertise and other actions that are more fully described below. As such remediation efforts are still ongoing, we have concluded that the material weaknesses have not been fully remediated. Our remediation efforts to date have included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have assessed our current accounting personnel, financial reporting, and information system environments and capabilities. Based on our preliminary findings, we have found these resources and systems lacking and have concluded that these resources and systems will need to be supplemented and/or upgraded. We have hired a Chief Financial Officer and implemented accounting procedures and controls, such as a two-signature policy for all disbursements and vendor invoice/contract review processes. We have also instituted procedures to store and maintain vendor invoices, contracts and agreements for efficient retrieval, and analysis of financial reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We engaged external consultants with public company and technical accounting experience to facilitate accurate and timely accounting closes and to accurately prepare and review the financial statements of NeOnc Technologies Holdings, Inc. and related footnote disclosures. We plan to retain these financial consultants until such a time that our internal resources have been upgraded and the required financial controls have been fully implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actions that have been taken are subject to continued review, implementation, and testing by management, as well as audit committee oversight. While we have implemented a variety of steps to remediate these weaknesses, we cannot assure you that we will be able to fully remediate them, which could impair our ability to accurately and timely meet our public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the assessment that our internal controls over financial reporting are not effective and that material weaknesses exist, we believe that we have employed supplementary procedures to ensure that the financial statements contained in this filing fairly present our financial position, results of operations, and cash flows for the reporting periods covered herein in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notes payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have elected to account for the $250,000 (original principal amount) note payable to the Chairman of the Board (Chairman) and the $50,000 (original principal amount) note payable to a shareholder using the fair value option in accordance with the guidance contained in Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) 825-10-25. The fair value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities, unrecognized firm commitments, and written loan commitments. See Note 3 for additional information. Our company accounted for the fair value of the stock options issued in connection with the note payable to the Chairman as additional interest expense on the grant date, using the same methodology to determine the fair value of the stock option as discussed in the share-based compensation policy footnote below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Original Issue Discount (&ldquo;OID&rdquo;) to be earned under the bridge loan is recognized ratably over the term of each draw-down under the loan through the maturity date.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Common stock payable for license fee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have estimated the fair value of the common stock issued to USC in October 2023 under the Amended License Agreement at the date of the amendment (April 5, 2023). We based the estimate of the fair value of such shares based upon the most recent share price of common stock sold to third parties, as adjusted for the impact of the Share Exchange.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair value measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">FASB ASC Topic 820, &ldquo;<I>Fair Value Measurements and Disclosures</I>&rdquo; (&ldquo;ASC 820&rdquo;), defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of our company. Unobservable inputs reflect our company&rsquo;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The carrying value of our company&rsquo;s accounts receivable, accounts payable, shareholder advances, and advances from the Chairman approximate fair value because of the short-term nature of these financial instruments. Our company&rsquo;s note payable to Chairman was reported at fair value (see Note&nbsp;3). The promissory note payable is reported at face value as the fair value difference is not material (see Note 4).</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that our company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree of judgment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &#8212; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by the market through correlation or other means.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &#8212; Valuations based on unobservable inputs and significant to the overall fair value measurement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Determination of the Fair Value of Equity-Based Awards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of stock option awards granted using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and subjective assumptions we make, including expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. Due to the lack of a public market for the trading of our common stock and a lack of company-specific historical and implied volatility data, we base the estimate of expected stock price volatility on the historical volatility of a representative group of publicly traded companies for which historical information is available. The historical volatility is generally calculated based on a period of time commensurate with the expected term assumption. We use the simplified method to calculate the expected term for options granted to employees and directors. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, we utilize the contractual term. The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero, as we have never paid dividends and do not have current plans to pay any dividends on our common stock. We determine the fair value of common stock awards based on the fair value of our common stock on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As there has been no public market for our common stock, the estimated fair value of our common stock has been approved by our board of directors, with input from management, as of the date of each award grant, considering our most recently available sale of our common stock to independent investors and our board of directors&rsquo; assessment of additional objective and subjective factors deemed relevant that may have changed from the date of the most recent determination through the date of the grant. The additional objective and subjective factors considered by our board of directors in determining the fair value of our common stock included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices of our common stock and preferred stock sold to outside investors in arm&rsquo;s length transactions, if any, and the rights, preferences and privileges of our preferred stock as compared to those of our common stock, including the liquidation preferences of our preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress of our research and development efforts, including the status of preclinical studies and planned clinical trials for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of liquidity of our equity as a private company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stage of development and business strategy and the material risks related to our business and industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the valuation of publicly traded companies in the biotechnology industry, as well as recently completed mergers and acquisitions of peer companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any external market conditions affecting the biotechnology industry, and trends within the biotechnology industry;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of achieving a liquidity event, such as an IPO or a sale of our company in light of prevailing market conditions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the analysis of IPOs and the market performance of similar companies in the biotechnology industry.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions underlying our board of directors&rsquo; valuation determinations represented our board&rsquo;s best estimates, which involved inherent uncertainties and the application of our board&rsquo;s judgment. As a result, if factors or expected outcomes had changed or our board of directors had used significantly different assumptions or estimates, our equity-based compensation expense could have been materially different. Following the completion of this offering, our board of directors will determine the fair value of our common stock based on the quoted market prices of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the nine months ended September&nbsp;30, 2023 and the years ended December&nbsp;31, 2022 and 2021, we did not have, and we do not currently have, any off-balance sheet arrangements (as defined under SEC rules).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the nine months ended September&nbsp;30, 2023 or the years ended December&nbsp;31, 2022 or 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_011"></A>BUSINESS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify; width: 78%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company was originally formed in Delaware in 2008 under the name NAS-ONC, Inc. and was renamed to NeOnc Technologies, Inc. in 2009. In 2015, the Delaware entity was merged with and into NeOnc Technologies California, Inc., a California corporation, and the surviving California corporation was renamed to NeOnc Technologies, Inc. Our company is devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NeOnc has two lead products in development: NEO100 and NEO212. NEO100, a purified form of perillyl alcohol (&ldquo;POH&rdquo;), is planned to be administered to brain cancer patients via intranasal delivery. <U>Ongoing activities for intranasal delivery of NEO100</U>:</P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><IMG SRC="img_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have completed human testing in a Phase 1 clinical trial and are currently conducting a Phase 2a trial with recurrent malignant glioma (Grade IV, IDH1 mutant) patients (further details are provided below).</P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 20%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A similar Phase 2a trial of intranasal NEO100 (NEO100-02) for patients with malignant skull based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 20%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Separate from this single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&rsquo;s preclinical studies suggest evidence that the combination of NEO100 with other drugs may enable a patient&rsquo;s improved brain tumor delivery via the intranasal route. Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&rsquo;s disease (PD). NeOnc&rsquo;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase 1 clinical trial is planned to study the impact on human patients.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 20%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In our ongoing effort to streamline
        our clinical trials, we have identified approximately 80 grade III IDH1 mutation-positive patients as potential candidates for
        our clinical trial. We believe this targeted enrolment pool may significantly expedite our trial process. With this refined focus,
        we are revising our protocol inclusion criteria to include Residual Measurable Disease (RMD) grade III IDH1 mutant patients.
        We believe this amendment to our enrolment criteria may markedly accelerate patient accrual, enhance the efficiency of our trials
        and may lead to quicker&nbsp;results. As a result of these changes, we project that the readout for our Phase 2 studies with
        respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025. </P></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 2%"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 20%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 78%; font-size: 10pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">Separate from this
    single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&rsquo;s preclinical
    studies suggest that the combination of NEO100 with other drugs may enable a patient&rsquo;s improved brain tumor delivery via the
    intranasal route. Our second lead product, NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide
    with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United
    States Food and Drug Administration (FDA), i.e., it has been authorized to proceed to clinical testing in cancer patients. We have
    designed a Phase 1/2 trial for oral NEO212, which began in the fourth quarter of 2023. In this trial, NEO212 will be administered
    orally to patients with primary brain tumors (i.e., malignant gliomas) and secondary brain tumors (i.e., brain metastases originating
    from peripheral tumors, such as tumors of the lung, breast, skin/melanoma, etc.). Furthermore, NEO212 is undergoing development towards
    intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast,
    skin, etc.), but has not yet been studied in human patients.</FONT> </TD>
    <TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 20%; font-size: 10pt; text-align: right"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Pipeline of NeOnc Drug</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_002.jpg" ALT="" STYLE="height: 405px; width: 750px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lead Product: NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEO100 is our most advanced product candidate based on perillyl alcohol (POH). This naturally occurring monoterpenoid can be found as a constituent of essential oils from various botanicals, including peppermint, spearmint, lavender, bergamot, lemongrass, sage, thyme, cherries, and others. POH has been used in cosmetics, fragrances, and some cleaning products and as an ingredient in baked goods, frozen dairy, gelatine, puddings, beverages, and candies. However, clinical trials by other companies with an oral POH formulation administered to cancer patients were not successful for two presumed reasons: (i) after ingestion, not enough POH entered the bloodstream, because the liver (portal vein) quickly metabolized and thereby eliminated POH; in fact, it was not possible to demonstrate the presence of POH in the blood of these patients; and (ii) in an effort to overcome the rapid depletion of POH, physicians attempted to administer increasing amounts of oral POH, which resulted in significant gastrointestinal toxicity that became dose-limiting. As a result, efforts to introduce oral POH into the clinic were abandoned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Under the direction of
NeOnc, a novel manufacturing and delivery pathway was investigated which we believe may avoid the drawbacks of oral POH. Using derivatization
of POH with a crystalline intermediate enabled the production of ultra-pure, pharmaceutical-grade NEO100. NEO100 received fast-track
status in 2016 and orphan-drug designation in 2011 from the FDA. NeOnc&rsquo;s novel approach uses intranasal, rather than oral, delivery.
Our completed Phase 1 trial of intranasal NEO100 suggested that when given via the intranasal route: (i) the drug appeared to be well
tolerated with no severe adverse effects being observed, despite consistent treatment over several months; and (ii) patients&rsquo; reported
quality of life was unchanged. In one patient, we were able to obtain brain tumor tissue (based on surgery immediately following intranasal
delivery of a dose of NEO100), which we analyzed for the presence of NEO100 (POH). The presence of NEO100 (POH) was confirmed in the
tumor tissue, thus providing proof of principle that intranasal delivery of NEO100 reaches its tumor target in the brain. This is in
contrast to the above-mentioned studies with oral POH, where the presence of drug could not be demonstrated in blood or tumor tissue
of any patient. Among the group of 12 patients in our Phase 1 trial, there were several long-term survivors: At two years after start
of intranasal NEO100 treatment, five patients (37%) were still alive, which is noteworthy, because recurrent glioblastoma patients (that
is, patients where the tumor has returned after one or more rounds of traditional treatment) have an average life expectancy of about
six months, and 24-month survival is rare. Another result from our Phase 1 trial is the fact that three patients (i.e., 25% of the original
cohort of 12 patients), were still alive after 3 years. These outcomes will have to be investigated with a larger number of patients
to establish statistical significance. This is currently being pursued in our Phase 2a trial, where we are planning to expand our clinical
trial sites and potentially enrolling the remaining Phase 2a patients. A data read out for any patient enrolled in the clinical trial
is expected beginning six months from the enrollment of such patient. </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 338px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above chart illustrates what is currently known about NEO100&rsquo;s mechanism of action. The manner by which NEO100 may block tumor growth is thought to result from its pleiotropic (multi-faceted) impact on tumor cells. In <I>in vitro</I> tests: (i) NEO100 has been shown to inhibit the activity of the Ras protein. Ras is a (proto)onco-protein that stimulates mitogenic (growth-stimulatory) pathways inside cells. In tumor cells, it is often mutated, resulting in its increased activity and uncontrolled cell growth. Inhibition of Ras by NEO100 is thought to remove this aberrant growth stimulus from tumor cells, causing cell cycle arrest. (ii) NEO100 has been shown to block the activity of sodium/potassium (Na/K) adenosine triphosphatase (ATPase). Na/K-ATPase is an ion pump that sits in the plasma membrane and regulates the flux of ions across the membrane. In cancer cells, it can have abnormal activity and not only helps cancer cells resist chemotherapy, but also stimulates them to spread to other locations in the body. We believe that NEO100 may stunt these advantages for cancer cells. (iii) NEO100 has been shown to intercalate into the plasma membrane to disturb membrane fluidity and the function of some proteins that are located at or near the plasma membrane (including Ras and Na/K-ATPase). Among the consequences is an electrolyte imbalance that triggers endoplasmic reticulum (ER) stress. Cancer cells in general are less resistant to withstand prolonged ER stress. As a result, in combination with cell cycle arrest, they undergo apoptosis (cell death).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Therapeutic applications of NEO100 that are under development by NeOnc</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Intranasal delivery that we hypothesize may bypasses the blood-brain barrier (BBB), which could permit delivery of drugs to the brain via cranial nerves I and V, and possibly allow delivery of other pharmaceutics to the brain. Proof of this principle has been observed in animal models, but has not yet been tested in human patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">At high concentrations, we are investigating whether intranasal NEO100 may be used as a therapeutic for treating brain cancers. In a Phase 1 trial there were preliminary signs of activity, based on several (25%) patients who have survived for at least 4 years, but validation of activity will have to await results from the ongoing Phase 2a and possible additional clinical trials.</P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">At low concentrations, NEO100 might act as a solvent and delivery vehicle for traditional large-molecule pharmaceutics, which could potentially bypass the BBB and enter the brain. Proof of this principle has been observed in animal models but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Intra-arterial delivery of NEO100 could possibly create a temporary opening in the BBB, which might allow traditional large-molecule pharmaceutics to pass through and enter the brain. Proof of this principle has been observed in animal models, but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">NEO100 could potentially be covalently conjugated with other pharmaceutics to create novel fusion compounds that might enable superior BBB penetration ability and, potentially higher activity against brain cancer. Proof of this principle has been observed in animal models but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intranasal NEO100 for the treatment of malignant glioma</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma in 2011. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. Upon approval, the exclusivity granted to orphan drugs provides seven years during which FDA may not approve any other sponsor&rsquo;s application for the same drug for the same designated orphan disease or condition, regardless of whether such other sponsor files an Abbreviated New Drug Application (ANDA) for a generic version of the drug, or if another sponsor files a &ldquo;full&rdquo; new drug application (NDA). Orphan Drug Exclusivity does not, however, prevent FDA approval of applications for the same drug for a different indication, nor applications for a different drug for the same orphan indication. In limited circumstances, such as showing clinical superiority to the product with orphan drug exclusivity, FDA may approve a competing application during the Orphan Drug Exclusivity period. However, the process of clinical development is inherently uncertain and there is no guarantee that orphan drug designation will accelerate the timeline for approval or make it more likely that NEO100 will be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For clinical testing of NEO100, a combined Phase 1/2a trial was conducted, with the first patient enrolled in April&nbsp;2017. NEO100 was administered intranasally 4-times a day to patients with recurrent glioblastoma. Patients enrolled in this trial had already undergone standard therapy, but the disease had returned and was deemed untreatable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among the inclusion criteria were the following: (i) Radiographically confirmed progression or recurrent grade IV glioma, and on a stable dose of steroid for at least 5 days; (ii) Patients must have failed previous radiation and temozolomide treatment; (iii) Age &ge; 18 years; (iv) ECOG performance status of 0-2, or KPS &ge; 60; (v) An expected survival of at least 3 months; (vi) Baseline MRI with gadolinium within two weeks of entry into the trial; and (vii) Seizures controlled on a stable dose of anti-epileptics for two weeks prior to enrollment. Furthermore, patients were screened with MR perfusion scan if there was a possibility that progression seen on a MRI scan represented pseudo-progression. Response assessment was performed by gadolinium-enhanced MRI and assessment by RANO (Response Assessment in Neuro-Oncology) criteria every two months. Adverse events were graded for severity using NCI Common Terminology Criteria for Adverse Events v.4.0.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The institutions that participated in the trial were Cleveland Clinic, University of Washington/Seattle, University of Wisconsin, and the University of Southern California. It was sponsored by NeOnc Technologies, Inc. (Los Angeles, CA) with ClinDatrix, Inc. (Irvine, CA), as the Clinical Data Management CRO (Contract Research Organization). A total of 12 patients were enrolled in Phase 1, which was completed in 2020. The patients were divided into four cohorts, three patients per cohort in a dose escalating trial (384-1152 mg/day). Patients received the intranasal dosage using a nebulizer mask four times a day. The results suggested that intranasal NEO100, even at the highest dose given, appeared to be well tolerated, and there were no serious adverse events reported in any of the patients, i.e., there were only minor side effects, such as a runny nose or nasal discomfort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Results from Phase 1 preliminarily
suggested that intranasal NEO100 might have exerted therapeutic activity in some of these patients, although statistical analysis was
limited by the small number of 12 patients, which means that statistically firm conclusions cannot be drawn. Most patients (55%) survived
for more than one year, four patients (33%) survived for over two years, and three patients (25%) remained alive at the 3-year mark. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Primary endpoints for Phase 1 were to determine maximum tolerated dose (MTD) and progression free survival (PFS). NEO100 did not reach MTD, as results suggested that NEO100 was well tolerated by the cohort 4 patients. The recommended Phase 2 dose was therefore at 1152 mg/day. PFS at 6 months was 33%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Survival Data from NeOnc&rsquo;s Phase 1 Clinical Trial with Intranasal NEO100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_004a.jpg" ALT="" STYLE="height: 301px; width: 600px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patient Survival: Comparison of NeOnc&rsquo;s Phase 1 Trial to Other Cancer Trials</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Secondary endpoints were evaluated for: a) pharmacokinetic endpoints of POH and perillic acid (PA) metabolism, b) objective tumor response according to RANO criteria, and c) adverse events. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pharmacokinetic measurements were performed in patients at the time of trial entry and used to measure the ability of patients to properly inhale NEO100. All patients had the expected rapid elimination of NEO100 within 30 minutes from serum, and elimination of its PA within 2 hours. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Objective tumor response to NEO100 was determined by RANO criteria. NEO100 performance by RANO criteria was reported as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_004c.jpg" ALT="" STYLE="height: 400px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The third secondary endpoint was adverse events, as characterized by type, frequency, and severity (NCI common terminology for adverse events were reported as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <IMG SRC="img_004d.jpg" ALT="" STYLE="height: 400px; width: 600px"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Moreover, our Phase 1 clinical trial indicated that patients harboring an IDH1 mutation in their tumor cells responded to treatment more favorably than those without the mutation. Among the 12 patients, five presented with IDH1 mutant status. Among these five, four patients (80%) survived longer than the seven patients without IDH 1 mutation. As of February&nbsp;12, 2021 three of them were still alive four years after the recurrence of their original tumor and initiation of NEO100 treatment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Comparison of our Phase I survival data compared with current standard of care for recurrent malignant gliomas is set forth below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="img_004b.jpg" ALT="" STYLE="height: 294px; width: 600px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above chart compares the survival of patients with recurrent glioblastoma in different treatment groups of other clinical trials. All of these patients had failed prior treatment, and their tumors had returned. <U>The blue line represents survival of patients treated with intranasal NEO100 in our Phase 1 trial</U>. Overall survival at 12 months (58% (n=7) of patients) and 24 months (37% (n=~11) of patients) was better than current standard of care for recurrent GBM. Mean length of overall survival was greater than 22.5 months, as two of the patients are still alive (August 1, 2023). It is compared to six representative published studies by other groups that were also performed with recurrent glioblastoma patients. In red, we show two studies with the oral DNA alkylator agent lomustine. Both studies used lomustine as a reference control arm to compare the efficacy of either a new drug (cediranib; <FONT STYLE="color: red">Batchelor TT et al., <I>Journal of Clinical Oncology </I>31:3212; <B>2013)</B></FONT> or in combination with a new drug (regorafenib; <FONT STYLE="color: red">Lombardi G et al., <I>Lancet Oncology</I> 20:110, <B>2019</B></FONT>). Batchelor et al. conducted a Phase III trial comparing the efficacy of cediranib alone or in combination with lomustine vs lomustine alone in 325 patients. Progression free survival (PFS; 82 vs 92days) was not significantly different between the arms. Lombardi et al. conducted an open Phase II multicenter trial in 119 patients comparing the tyrosine kinase inhibitor regorafenib with lomustine. Overall survival (OS) was increased in the regorafenib group (7.4 months) vs the lomustine group (5.6 months).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">In purple, we show two studies with intravenous bevacizumab (Avastin&reg;). Desjardins et al. reported a single institution retrospective report from Duke University for bevacizumab in recurrent GBM in 74 patients, with a median overall survival of 11.1 months and PFS of 6.4 months (<FONT STYLE="color: red">Desjardins A et al., <I>Health Science Reports</I> 2:e114, <B>2019</B></FONT><B>)</B>. Similar results were demonstrated by Heiland et al. in a retrospective study examining PFS and OS in patients with recurrent GBM treated with last-line bevacizumab vs bevacizumab/lomustine. Combination therapy lead to an increase of 2 months of PFS (6.11 months) and OS (6.59 months) vs bevacizumab alone (<FONT STYLE="color: red">Heiland DH et al., <I>Journal of Neurooncology</I> 126:567, <B>2016</B></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The green curve shows a single arm retrospective study with intravenous BCNU for recurrent GBM in 35 patients with recurrent GBM. Median PFS was only 11 weeks and OS was 22 weeks (<FONT STYLE="color: red">Reithmeier T et al., <I>BMC Cancer</I> 10:30, <B>2010</B></FONT>). The brown curve shows a prospective study examining the role of second surgical resections of recurrent GBM in 46 patients. Median OS was 36 weeks, with improvement in overall quality of life in selected patients (<FONT STYLE="color: red">Barker FG et al., <I>Neurosurgery</I> 42:709, <B>1998</B></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This chart illustrates the following: (i) In our study with NEO100 (blue line), overall survival at 12 months (OS-12) was 58%, whereas in all comparison studies OS-12 was below 50%. (ii) In our study with NEO100, overall survival at 24 months (OS-24) was 37%, whereas in all comparison studies it was much less, and in fact some of the other studies had no patients reaching 24 months of survival.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A potential advantage of intranasal NEO100 is that intranasal delivery via a nebulizer device does not require surgeries, infusions, or other invasive procedures that would require medical visits. Rather, intranasal delivery could be done conveniently at home (or while traveling) by the patients themselves. Compared to the well-known toxicities of many chemotherapeutic agents, NEO100 appeared to be well tolerated at the doses tested in the limited Phase 1 trial, and none of the typical side effects of other cancer pharmaceutics (nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss, etc.) were observed. It, therefore, suggests that NEO100 may not lead to deterioration of quality of life for patients (<FONT STYLE="color: red">Sch&ouml;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc
Phase 2a studies describe the first time NEO100 is given to the intended treatment population. The studies are undertaken to confirm
dosing requirements identified in Phase 1 testing (such as how much, how often and  to whom the drug should be given) are correct.
They are sufficiently powered (statistically) to determine how well the drug performs at the prescribed dose and for the intended
outcome. Work in future trials may be needed to further understand results obtained in Phase 2a testing (i.e., dosing, effect on a
patient sub-population) and randomized, controlled Phase 3 testing may be required prior to marketing authorization. Details
regarding the ongoing Phase 2a trials of NEO100 and the ongoing Phase 1/2 trial of oral NEO212 are as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>&ldquo;An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or IV Gliomas with IDH1 Mutation&rdquo; (NEO100-01)</U></I></FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enrollment </B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated: </B>25</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested: </B>Radiographically-confirmed progression of, or recurrent, primary or secondary Grade IV glioma (the original study population) and radiographically-confirmed progression of, or recurrent, primary or secondary Grade III astrocytoma.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary Endpoint:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Progression free survival at six months.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secondary Endpoints:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Objective tumor response to NEO100 as determined by RANO criteria.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Progression free survival.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Overall survival.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Perillic acid measurement.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety Endpoint:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Adverse Events characterized by type, frequency, severity, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0), seriousness and relationship to study therapy NEO100.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Changes from&nbsp;baseline in vital signs and clinical laboratory parameters (hematology and chemistry), as well as ECOG performance status will be assessed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&nbsp;&ndash; Cannot be reported until completion of the Phase 2a portion of the study.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled: 6</B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>&ldquo;An Open-Label, Phase 2 Study of NEO100 in Participants with Residual, Progressive or Recurrent High-Grade Meningioma&rdquo; (NEO100-02)</U></I></B></FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated: </B>29</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested: </B>Radiographically-confirmed progression of, or recurrent, WHO Grade II or III meningioma</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary and Secondary Endpoints:</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary Endpoint: Progression free survival at 6 months</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secondary Endpoint: </B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objective tumor response by RANO criteria</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progression free survival</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall survival</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perillic acid measurement and level</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled:&nbsp;</B>2</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>&ldquo;An Open-Label, Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-Mutant, Glioblastoma IDH-Wildtype or Uncontrolled Metastasis to the Brain in Patients with Select Solid Tumors (NEO212-01)</U></I></B></FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated:</B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 1:</B> Up to 36</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2a: </B>12</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2b: </B>27 per cohort</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested:&nbsp;</B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 1:</B> Radiographically-confirmed astrocytoma IDH-mutant, glioblastoma IDH-wildtype following previously radiation therapy or treatment with temozolomide and radiation or a select solid tumor with uncontrolled brain metastases (e.g., melanoma, NSCLC, SCLC, HNSCC, urothelial carcinoma, gastric cancer, renal cell cancer, colorectal cancer)</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2a:</B>&nbsp;Radiographically-confirmed astrocytoma IDH-mutant, glioblastoma IDH-wildtype following previously radiation therapy or treatment with temozolomide and radiation</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2b:</B>&nbsp;Select solid tumor with uncontrolled brain metastases (e.g., melanoma, NSCLC, SCLC, HNSCC, urothelial carcinoma, gastric cancer, renal cell cancer, colorectal cancer)</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary and Secondary Endpoints</B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary Objectives &#9679;</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assess the safety and tolerability of increasing dose levels of orally administered NEO212 in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype and patients with select solid tumors with uncontrolled metastases to the brain. </FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the maximum tolerated dose (MTD) of NEO212. </FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the recommended Phase 2 dose (RP2D) of NEO212. </FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary Objectives</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characterize the pharmacokinetics (PK) of NEO212. </FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate anti-tumor activity of NEO212 in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype and patients with select solid tumors with uncontrolled brain metastases.</FONT> </TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled:</B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 1:</B> 2</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2a:</B>&nbsp;Not Open to Accrual</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase 2b:</B>&nbsp;Not Open to Accrual</FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pipeline Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%">
        <P STYLE="text-align: justify; text-indent: 0.5in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212 (chemical structure shown on the right) was designed as a hybrid compound where NEO100 was covalently conjugated to temozolomide (TMZ), an alkylating agent that represents the current standard of chemotherapeutic care for patients with glioblastoma. Based on the recognition that amphipathic NEO100 in research has suggested it may permeate biological barriers and cellular membranes, we hypothesized that this novel covalent molecule might penetrate the blood-brain barrier, possibly enabling a dual approach against malignant lesions in the brain. Our preclinical characterization of NEO212 in various mouse tumor models suggests that this multifunctional agent may show activity against a variety of cancer types. In preclinical studies, results suggested that NEO212 demonstrated activity against primary and secondary brain cancers as well as cancer types that were chemoresistant to other commonly used cancer therapeutics <FONT STYLE="color: red">(Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014; Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018)</FONT>. So far, the activity of NEO212 has not yet been studied in humans.</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 102px; width: 250px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEO212 demonstrates an interesting feature that its demonstrated activity in preclinical studies may be greater than the sum of its parts. That is: merely applying its individual constituents, NEO100 and TMZ, as a mix of two independent compounds (akin to the conventional combination therapy mode) may not mimic the potential of the conjugated hybrid molecule. The toxicological studies in rodents and dogs suggest that NEO212 was tolerated. When administered at the same dosages as those that suggest activity in mouse cancer models, there were no detectable side effects in mice, rats, or dogs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The demonstrated activity in preclinical studies of NEO212, along with its low toxicity profile, contributed to our IND application for oral administration that was approved by the FDA in 2023. FDA approval provides an opportunity for Phase 1/2a clinical trials, primarily focusing on patients with intracranial malignancies. We are designing clinical trials that evaluate two different modes of NEO212 delivery: oral and intranasal. Oral NEO212 during Phase 1 will be administered to patients with brain malignancies that include primary and secondary brain cancers (so-called &ldquo;all comers&rdquo;). Phase 2a will focus on newly diagnosed, primary glioblastoma. Intranasal NEO212 will be used in a Phase 1/2a trial in patients with metastatic brain cancer, i.e., where brain lesions originated from cells that were disseminated by tumors from outside the brain, such as lung cancer, breast cancer, or melanoma. All these patients represent a cohort in dire need of better therapies, and NEO212 may hold the potential that might improve their prognosis and survival.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma (2014), (ii) brain metastases from breast cancer (2017), and (iii) nasopharyngeal carcinoma (2017). As stated above, if a product that has ODD subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years (except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity). However, the process of clinical development is inherently uncertain and there is no guarantee that orphan drug designation will accelerate the timeline for approval or make it more likely that NEO212 will be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Drug Delivery Pathways Potentially Enabled by NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancerous tissue in the brain is protected from systemically circulating drugs by the blood-brain barrier (BBB), which prevents the brain entry of most pharmaceutical agents. We are using NEO100 to develop three different methods of overcoming the obstacle placed by the BBB:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I><U>Intranasal delivery</U>: </I>As part of a direct nose-to-brain route, this pathway could potentially allow direct brain access without interference from the BBB.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Monotherapy with NEO100</U>: </I> At higher dosages, intranasal delivery of NEO100 is in clinical testing for patients with glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><U>Combination therapy with NEO100</U>: </I>At lower dosages, intranasal NEO100 might be used as a carrier for the co-delivery of established therapeutics to the brain. This has been observed in animal models, but it has not yet been studied in humans.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><I><U>Conjugated delivery</U>:</I> Stable conjugation of NEO100 to other therapeutic agents (such as temozolomide, creating NEO212) indicated a possible increase in the ability of the fused compound to penetrate the BBB and enter the brain. This has been observed in animal models, but it has not yet been studied in humans.</P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><I><U>Permeable delivery</U>: </I></FONT>Intra-arterial delivery of NEO100 may create temporary (up to 4 hours) openings in the BBB, that we believe could potentially enable drugs (Adriamycin&reg;, Velcade&reg;, etc.) and therapeutic antibodies (Herceptin&reg;, Opdivo&reg;, etc.) to enter the brain and reach the tumor bed. This has been observed in animal models, but it has not yet been studied in humans.</P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 78%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">All three drug delivery pathways potentially enabled by NEO100 are being investigated by NeOnc and are at different stages of development. Only one of these pathways, monotherapy with intranasal NEO100, has moved into clinical testing, where Phase 1 studies have been completed and Phase 2a studies are ongoing. The other pathways, including combination therapy with NEO100, conjugated delivery (e.g., NEO212), and permeable delivery have not yet reached the clinical stage and have not yet been studied in humans. In these latter pathways, preclinical studies are currently ongoing to provide further results and IND-enabling data, so that in the future these principles can be studied in human cancer patients.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> We believe these
        three delivery areas (details below) may be key to a potential shift in physicians&rsquo; ability to treat brain diseases. They
        represent potential pathways for possible reliable delivery of pharma-therapeutics to the brain, potentially mitigating problems
        and side effects from current methodologies, and potentially providing an alternative treatment protocols to existing pharma
        manufacturers for their drugs. </P>

</TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_009.jpg" ALT="" STYLE="height: 328px; width: 300px"></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>Intranasal Delivery of NEO100</U>: Administration of NEO100 into the nose is accomplished by a standard nebulizer that aerosolizes NEO100 into fine particles that reach the olfactory mucosa and its embedded nerve endings in the nasal cavity. Uptake by these and other nerve cells enables direct nose-to-brain transport of NEO100 so it can reach the tumor sites without interference from the BBB. This direct mode of brain-targeted drug administration is thought to deliver higher levels of the drug to the brain tumor site as compared to oral delivery of a given drug, also because this route of transport avoids drug breakdown in the liver. It also lowers total drug exposure to the rest of the body; therefore, it&rsquo;s hypothesized there may be fewer side effects. This principle was observed in the Phase 1 clinical trial with glioblastoma patients above-mentioned (<FONT STYLE="color: red">Sch&ouml;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>). And the actual presence of NEO100 (perillyl alcohol), along with its major metabolite, perillic acid, has been observed in brain tumor tissue (<FONT STYLE="color: red">Sch&ouml;nthal AH et al., <I>J. Neurosurg. Case Lessons</I> 4:case22215, 2022</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Ongoing activities for intranasal delivery of NEO100</U>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase 2a component of our clinical trial is ongoing in patients with recurrent Grade IV glioma (further details are provided below).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A similar Phase 2a trial of intranasal NEO100 (NEO100-02) for patients with malignant skull based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&rsquo;s disease (PD). NeOnc&rsquo;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase 1 clinical trial is planned to study the impact on human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Stable Conjugation of NEO100 to Other Therapeutic Agents</U>: Many drugs work quite well for diseases in the rest of the body but do not reach the brain due to the BBB obstacle. Our pre-clinical results suggested that stable conjugation of several such drugs to NEO100 may increase their ability to reach lesions located in the brain. Temozolomide (TMZ) is widely used to treat malignant glioma&mdash;even though it enters the brain sub-optimally, its modest therapeutic impact is an expression of this limitation. However, when conjugated to NEO100, creating NEO212, the molecule may cross the BBB, and in preclinical mouse models, various types of brain malignancies have shown therapeutic activity. NEO212&rsquo;s IND application was approved by the FDA in May&nbsp;2023. (Further details on NEO212 are provided below.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 78%">
        <P STYLE="margin-top: 0; margin-bottom: 0"><U>Intra-arterial Injection of NEO100</U>: Our preclinical studies in mouse models with brain cancer suggest that intra-arterial delivery of NEO100 might open the BBB up to four hours, which could allow other therapeutic agents to enter the brain from the bloodstream or a catheter in those models. The mechanism appears to be via a transient opening of the tight junctions between the brain endothelial cells. Catheters can be used to deliver NEO100 to specific parts of the brain, particularly to the sites where the tumor bed is located, so that co-delivered pharmaceutics can immediately access the malignant tissue. In this manner, NEO100 and any other co-delivered therapeutic agent might impact the tumor. While this principle has been established in our preclinical studies, it has not yet been tested in human patients., Well-known side effects of the brain cancer agent temozolomide (TMZ) are bone marrow suppression and resulting infections. We believe these side effects may be reduced or possibly avoided if the bone marrow can be spared from whole-body exposure to TMZ, as is a consequence of the typical oral ingestion of TMZ. This catheter-based approach is based on the co-delivery of another agent (as a mix). It is distinct from the above described stable conjugation of NEO100 to another compound, such as TMZ, which creates a single fusion molecule (as in NEO212).</P> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_010.jpg" ALT="" STYLE="height: 253px; width: 300px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 78%">
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The global central nervous system (CNS) treatment market is expected to grow at 9.4% CAGR to reach $166.5 billion by 2028, and the global brain tumor drug market is expected to grow at CAGR of 9.0% reach $4.4 billion by 2029, according to Fortune Business Insights.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation therapy still accounts for 38% of the brain cancer treatment market, while drug treatment remains second mostly due to current inefficiencies of drug delivery, according to Grandview Research.</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_011.jpg" ALT="" STYLE="height: 350px; width: 407px"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_012.jpg" ALT="" STYLE="height: 350px; width: 186px"></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%">
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also address the malignant glioblastoma multiforme (GBM) treatment market. The GBM drug market is expected to grow at 12.7% CAGR to $2.3 billion by 2029, according to iHealthcare Analyst, with the market being driven by rising geriatric population, growing incidence cases, and a pipeline of new products.</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GBM accounts for up to 54% of gliomas and 16% of all primary brain cancers, according to research published in the journal, <I>Glioblastoma</I>. By creating an alternative delivery mechanism for GBM drug therapy, we believe we can significantly impact market demand in this sector.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our goal is to change the cancer therapeutic landscape by developing novel therapeutic approaches leveraging dual approaches of novel drug delivery methods in combination with novel drug candidates that potentially lead to better therapeutic results with low side effects.</P>
        <P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
        <P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following five clinical applications of our drugs are at different stages of preclinical or clinical development:</FONT></P></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO100 to patients with IDH mutant malignant glioma (Phase 2a clinical trial has started).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO212 to patients with brain metastasis (IND approved).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO100 alone, and in combination with doxorubicin for pediatric brain tumors (IND is in the process of being prepared).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal co-delivery of NEO100 with levodopa for Parkinson&rsquo;s disease (preclinical stage).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intra-arterial delivery of NEO100 to open the patient&rsquo;s blood-brain barrier, allowing brain entry of BBB-impermeable pharmaceuticals or biologics (preclinical stage).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral NEO212 for primary brain cancer, including glioblastoma (IND approved).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD> </TR>
  </TABLE>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details: <B>1. </B>Intranasal delivery of NEO100 to patients with IDH mutant malignant glioma (Phase 2a clinical trial has started)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">NEO100 is our most advanced product candidate. Its chemical structure (<B>Figure 1</B>) is based on the natural compound perillyl alcohol (POH). We have investigated a novel manufacturing and delivery pathway that avoided the drawbacks of oral POH and capitalized on its recognized properties. The FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_014.jpg" ALT="" STYLE="height: 175px; width: 305px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure [X]: Chemical structure of NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NeOnc sponsored a Phase 1 clinical trial, where NEO100 was administered to patients with recurrent glioblastoma. All enrolled patients had already undergone standard therapy for this disease, consisting of radiation treatment combined with chemotherapy. Still, this standard therapy had stopped working, and patients were no longer benefiting from it. At this stage of the re-emerging glioblastoma disease, there is no clear clinical recommendation for specific further treatment because effective treatments do not exist for this patient group. Rather, the prognosis is dismal, and the average median survival is only 6-9 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After enrollment in our study, patients received intranasal NEO100 four times daily, using a standard nebulizer and nasal mask. After initial instructions by a nurse, patients can self-administer this treatment at the convenience of their home. Four cohorts of 3 patients each received the following dosages: 96 mg/dose (384 mg/day), 144 mg/dose (576 mg/day), 192 mg/dose (768 mg/day), and 288 mg/dose (1152 mg/day). Completion of 28 consecutive days of treatment was recorded as one cycle. Adverse events were documented, and radiographic response <I>via </I>RANO criteria was evaluated every two months. Progression-free and overall survival were determined after 6 and 12 months, respectively (PFS-6, OS-12).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trial was completed in 2020, and after peer review, the results obtained from these 12 patients were published in 2021 (<FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT>). Data analysis suggested that intranasal NEO100 may be well tolerated at all four dose levels, and even at the highest dose levels, no severe adverse events were noted. Minor side effects included a runny nose or nasal discomfort. PFS-6 was 33%, OS-12 was 55%, and of the three cohorts&rsquo; median survival was 15 months (<B>Figure 2</B>, left panel). Four patients (33%) survived &gt;24 months. Thus, compared to historical controls and what is commonly observed in clinical practice, average patient survival in our clinical trial with these 12 patients might be improved (see further comparison details below). As important, there were none of the typically harsh side effects of many conventional chemotherapies, such as nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss, etc.). Treatment with intranasal NEO100, therefore, did not lead to deterioration of quality of life for patients. However, further research is needed to confirm these results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 2: Survival of all 12 patients (left) and survival in relation to IDH status (right).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_015.jpg" ALT="" STYLE="height: 213px; width: 675px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from: <FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Detailed further analysis of our Phase 1 trial suggested that patients with the highest response to intranasal NEO100 were those whose tumor harbored a mutation in the gene for isocitrate dehydrogenase 1 (IDH1) (<B>Figure 2</B>, right panel). In the five patients with this mutation, 4 (80%) survived a minimum of 24 months while being treated with intranasal NEO100. In contrast, seven patients without this mutation succumbed to disease earlier&mdash;although their average median survival of 11 months was still longer than what might have been expected based on historical experience in the clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Prompted by these observations from our Phase 1 clinical trial, a Phase 2a continuation of intranasal NEO100 was started in 2021 for high-grade glioma patients with IDH1 mutations. As with Phase 1, the trial is being conducted as a multicenter study. A total of 12 institutions will be recruited to enroll 31 patients for our Phase 2a trial, of which five have been recruited. The potential mechanism by which these IDH1 mutant patients may have a specific survival advantage in response to NEO100 is the subject of our current laboratory investigations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details: <B>2.</B> Intranasal delivery of NEO212 to patients with brain metastasis (IND submission scheduled for late 2023)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEO212 is a hybrid compound where NEO100 is covalently conjugated to temozolomide (TMZ) via a carbamate bridge (<B>Figure 3</B>). While TMZ has been widely used as the standard of care for the treatment of glioblastoma, it does not penetrate the BBB effectively; unsurprisingly, its clinical efficacy is relatively modest. Also, its activity could be further reduced when applied to tumors that are positive for O6-methylguanine methyltransferase (MGMT). This DNA repair protein protects tumor cells from killing by TMZ. Our preclinical studies suggest that NEO212 may potentially be able to overcome these drawbacks and exert its activity even against tumor cells that are positive for MGMT. The FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma, (ii) brain metastases from breast cancer, and (iii) nasopharyngeal carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 3: Chemical structure of NEO212: NEO100 conjugated to temozolomide.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_016.jpg" ALT="" STYLE="height: 175px; width: 367px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEO212 was initially designed as a therapeutic molecule with potential enhanced capability of crossing the blood-brain barrier to address the urgent clinical need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. In mouse models data indicated that orally-administered<SUP>1 </SUP> NEO212 enters the brain in higher quantities than oral TMZ alone. While NEO212 has been investigated in multiple preclinical studies, it has so far not been studied in humans. Based on preclinical studies, the following potential beneficial features of this compound can be summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">NEO212 might exert greater activity than the sum of its parts; i.e., a mere combination of the individual components, TMZ plus POH at equimolar ratios, does not appear to mimic the activity of the conjugated compound, both <I>in vitro</I> and in mouse tumor models <I>in vivo</I> (<FONT STYLE="color: red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014; Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In mouse tumor models, NEO212 displayed intracranial therapeutic activity not only against glioblastoma (<FONT STYLE="color: Red">Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018; Minea RO et al., <I>PLoS One</I> 15(9):e0238238, 2020</FONT>) but also against brain-metastatic breast cancer xenografts (<FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT>) (<B>Figure 4</B>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Besides intracranial tumors in mouse tumor models, NEO212 showed activity against peripheral cancers in mouse tumor models, including subcutaneous melanoma (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters</I> 358:144, 2015</FONT>), nasopharyngeal carcinoma (<FONT STYLE="color: red">Chen TC et al., <I>Journal of Biomedical Sciences </I>22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016</FONT>) ovarian carcinoma (<FONT STYLE="color: red">Song X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019</FONT>), lung cancer (<FONT STYLE="color: red">Song X et al., <I>Cell Death &amp; Disease</I> 9:202, 2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal of Experimental and Clinical Cancer Research </I>37:250, 2018</FONT>), cutaneous T-cell lymphoma (<FONT STYLE="color: red">Silva-Hirschberg C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019</FONT>), and cytosine arabinoside-resistant leukemia (<FONT STYLE="color: red">Sch&ouml;nthal AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The activity of NEO212 was also documented with the use of primary patient samples implanted into mice, including glioblastoma stem cells (<FONT STYLE="color: red">Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience</I> 5:148, 2018</FONT>) as well as xenografts of a variety of TMZ-resistant glioma and melanoma lines, where drug resistance was based on different molecular mechanisms (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">In all tested in <I>vivo</I> models, NEO212 was administered orally in the range of 5-50 mg/kg (once per day, repeat dosing). This dose range seemed well tolerated by mice, rats, and dogs and did not result in detectable signs of toxicity.</P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD>
    <TD STYLE="text-align: justify">Confirm oral route.</TD> </TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 4: Representative result showing survival of mice with brain-metastatic breast cancer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_017.jpg" ALT="" STYLE="height: 231px; width: 450px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">source: <FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The observed activity of NEO212, which was recapitulated in a variety of preclinical tumor models, along with its low observed toxicity profile, led to our IND application to the FDA which was approved in May&nbsp;2023. FDA approval allowed us to proceed for Phase 1/2a clinical trials, primarily focusing on patients with intracranial malignancies (metastatic and malignant primary brain cancer types). Although NEO212 also showed activity against peripheral cancer types (melanoma, lung cancer, breast cancer, and others) in pre-clinical studies, our first clinical trial will focus on patients with aggressive brain cancer types because the clinical need is the greatest here; due to the significant clinical need because no therapies exist. Because NEO212 was designed for blood-brain barrier penetration, we would expect that it might reveal its most valuable impact in patients with brain malignancies. However, studies with NEO212 in humans have not yet started.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details: <B>3.</B> Intranasal co-delivery of NEO100 with levodopa for Parkinson&rsquo;s disease (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our preclinical research in mouse brain tumor models indicated that intranasal delivery of NEO100 may facilitate nose-to-brain transport of NEO100 itself and potentially enabled co-delivered pharmaceutics to be carried along this axis and enter the brain as well. For example, intranasal co-delivery of NEO100 with bortezomib (a drug marketed under the trade name Velcade<SUP>&reg;</SUP>) seemed to allow bortezomib to enter the mouse&rsquo;s brain resulting in activity against brain cancer. Without NEO100, bortezomib could not enter the brain (<FONT STYLE="color: red">Wang W et al., <I>Journal of Neurosurgery</I> 132(3):959, 2019</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Given preclinical results of NEO100&rsquo;s ability to act as a vehicle to carry other pharmaceutics into the brain, we considered its application to neurological diseases, such as Parkinson&rsquo;s disease (PD) or Alzheimer&rsquo;s disease (AD), which are increasing in numbers as the U.S. population is aging. PD Patients are treated with levodopa (L-Dopa) pills, which must be dosed precisely. These pills have common side effects, such as hypotension, nausea, confusion, and dyskinesia. Therefore, intranasal delivery with direct nose-to-brain transport would be highly desirable because it is could potentially offer better brain-directed delivery without exposing the entire body to the drug, minimizing the undesirable side effects. As well, smaller doses can be given. In our work, we used mice with PD-type lesions in their brains and co-administered NEO100 together with L-Dopa by intranasal delivery. Our results suggest that intranasal co-delivery of NEO100 and L-Dopa suppresses PD symptoms in these mice. Intranasal delivery of L-Dopa without the added NEO100 did not achieve this beneficial effect (<B>Figure 5</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 5: Mixture of NEO100 with L-Dopa (red underline), when given intranasally, could potentially restore healthy brain function of PD in mice as does a subcutaneous injection of apomorphine (blue underline).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_018.jpg" ALT="" STYLE="height: 615px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Wang W et al., <I>manuscript in preparation.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The health benefits of this approach in the mice were analyzed by determining the physical activity of the mice, in particular their ability to rotate to one side. Untreated PD mice are sick and unable to perform rotations, which is a symptom of the disease. But mice receiving intranasal NEO100 combined with L-Dopa appear to be physically active and perform rotations (bar graphs of mice in <B>Figure 5</B> with the label underlined in red). The figure also shows that mice injected with apomorphine recover from PD (label underlined in blue). However, compared to the ease of intranasal delivery, injections are invasive and do not support brain-targeted delivery due to the resulting systemic distribution of the injectate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details to <B>4.</B> Intra-arterial delivery of NEO100 to open the patient&rsquo;s blood-brain barrier will allow brain entry of BBB-impermeable pharmaceuticals or biologics (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While intranasal applications of NEO100 may exploit direct nose-to-brain access routes and thereby circumvent the obstacle placed by the blood-brain barrier (BBB), an intra-arterial path of administering NEO100 has suggested that it also might directly confront the BBB and &ldquo;open&rdquo; it, diminishing its barrier function to potentially enable mostly unrestricted permeation of otherwise BBB-impermeable compounds. We established this procedure, characterized it in preclinical mouse tumor models, and shown that it may have advantages over the currently established clinical method of opening the BBB with mannitol (<FONT STYLE="color: red">Wang W et al., <I>Neuro-Oncology</I> 23(1):63, 2021</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We used mouse models of brain-metastatic breast cancer positive for human epidermal growth factor receptor 2 (HER2). In humans, HER2+ breast cancer is usually treated with trastuzumab (Herceptin), a humanized monoclonal antibody, and this treatment often shows success. However, HER2+ breast cancer has a propensity to metastasize to the brain, and trastuzumab may not work as effectively because it cannot effectively penetrate the BBB. Our work has established that intra-arterial NEO100 might open the BBB of mice for a few hours, potentially allowing a brain influx of therapeutic agents that are circulating in the bloodstream. In the case of mice with HER2+ metastases in their brains, a single application of BBB opening with NEO100 seems to enable brain influx of trastuzumab that had been given by intravenous injection, and this approach resulted in the recovery of several of the animals (<B>Figure 6</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 6: BBB opening by intra-arterial (IA) NEO100 achieves the absence of brain cancer of several brain-metastatic mice treated with intravenous (IV) trastuzumab.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_019.jpg" ALT="" STYLE="height: 362px; width: 500px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from: <FONT STYLE="color: Red">Wang W et al., <I>Neuro-Oncology</I> 23(10):1656, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent cancer therapy breakthroughs have introduced immune checkpoint-inhibitory antibodies as novel tools to treat cancer. However, as with other antibody-based therapies, these biologics&rsquo; applications may be limited due to the BBB, which prevents their brain entry, i.e., brain metastases and primary malignant brain tumors such as glioblastoma. Therefore, we utilized our BBB opening method with intra-arterial NEO100 to a glioblastoma mouse model, where mice received a one-time dose of a checkpoint-inhibitory antibody within the mixture of intra-arterially applied NEO100. The outcome showed that all six mice treated in this fashion showed absence of brain cancer (blue line in <B>Figure 7</B>). In contrast, all other mice died within 4-7 weeks, including those treated with checkpoint-inhibitory antibodies in the absence of NEO100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 7: BBB opening by intra-arterial (IA) NEO100 achieves the absence of brain cancer for all glioblastoma mice treated with checkpoint-inhibitory antibodies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_020.jpg" ALT="" STYLE="height: 338px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Wang W et al., <I>Journal of Neurosurger</I>y, Feb 3:1-9, 2023 [online ahead of print]<I>.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other recent breakthroughs in cancer therapy include the production of CAR T cells, where T lymphocytes are being modified to harbor a chimeric antigen receptor (CAR). While such cells have yielded impressive therapeutic advances, their activity&mdash;similar to the case of therapeutic antibodies&mdash;may be limited by their poor entry into the brain. Therefore, we applied our BBB opening method with intra-arterial NEO100 to a mouse model with intracranial lymphoma (lymphoma in the brain), where mice received a one-time dose of intravenous lymphoma-targeted CAR T cells, along with BBB opening by intra-arterial NEO100. The outcome showed that all six mice treated in this fashion showed absence of brain lymphoma (blue line in <B>Figure 8</B>). In comparison, most mice that received CAR T cells without BBB opening with intra-arterial NEO100 died within the first three weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 8: BBB opening by intra-arterial (IA) NEO100 shows the absence of brain cancer in all brain-lymphoma mice treated with lymphoma-directed CAR T cells.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_021.jpg" ALT="" STYLE="height: 299px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">From: <FONT STYLE="color: red">Wang W et al., <I>manuscript submitted.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Details to <B>5.</B> Oral NEO212 for advanced cancer types, including leukemia (preclinical stage)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NEO212 was initially designed as a therapeutic molecule with enhanced capability of crossing the blood-brain barrier to address the urgent clinical need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. At the same time, however, NEO212 has demonstrated potential potency, along with low toxicity, against cancer types outside the brain, such as lung cancer, melanoma, ovarian cancer, leukemia, and others (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters </I>358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016; Song X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019; Song X et al., <I>Cell Death &amp; Disease</I> 9:202, 2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal of Experimental and Clinical Cancer Research </I>37:250, 2018; Silva-Hirschberg C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019; Sch&ouml;nthal AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Among the most striking examples of NEO212&rsquo;s potential therapeutic impact on peripheral cancer types, as established in mouse tumor models, is its effect on leukemia, particularly drug-resistant acute myeloid leukemia (AML), which in daily clinical practice remains very difficult to treat and often is fatal. First-line treatment of AML usually includes intravenous cytarabine. Still, often the tumor becomes resistant to this drug, which precludes further cytarabine treatment and generally requires subsequent hematopoietic stem cell transplantation. In our experiments, treatment of mice harboring cytarabine-resistant AML with NEO212 suggested a positive result and tolerability. Oral NEO212 was administered once daily for five days, followed by 7-14 days of a treatment holiday; this cycle was repeated twice more for three cycles in total (green arrows in <B>Figure 9</B>); there were no further treatments after week 8. All mice in this treatment group survived beyond 200 days, which might be interpreted as a positive outcome (<B>Figure 9</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Figure 9: Treatment of mice harboring cytarabine-resistant AML with NEO212 results in the absence of brain cancer in all treated animals.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_022.jpg" ALT="" STYLE="height: 212px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from: <FONT STYLE="color: Red">Sch&ouml;nthal AH et al., <I>Cancers</I> 13(14):3385, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the activity of NEO212 against a variety of tumor types studied in mouse tumor models, the initial Phase 1 clinical trial will be conducted with patients harboring brain cancers, including primary brain cancers (such as recurrent glioblastoma) and secondary brain cancers (metastases derived from lung, breast, and melanoma). NeOnc has received the IND approval for this Phase 1 trial. Phase 1 is expected to last up to one year, followed by Phase 2, which is expected to last about two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Extending the above, we are also designing a Phase 1/2a trial of oral NEO212 that will specifically focus on patients with newly-diagnosed glioblastoma. With current standard of care, these patients have an average life expectancy of only 15 months after initial diagnosis. Based on the encouraging results from our extensive preclinical studies, our extensive preclinical studies suggest that NEO212 may provide some benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition and Competitive Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">NEO100 and NEO212 address different aspects of the </FONT> global central nervous system (CNS) treatment market and the brain tumor drug markets which are highly competitive, dynamic, and rapidly evolving areas of the pharmaceutical and healthcare industries. In both markets, success often hinges on a combination of clinical effectiveness, regulatory approvals, market access, pricing strategies, and effective marketing. The competition is further intensified by ongoing advances in medical science and technology, making it essential for companies to stay at the forefront of innovation and research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">Our NEO100 and NEO212 candidates will need to differentiate themselves based on efficacy, safety, cost, ease of administration, and other therapeutic benefits. As we continue our research and development, we are cognizant of these competitive dynamics and are strategizing accordingly to ensure our products bring unique and tangible benefits to patients. As a clinical company, we face many of the challenges outlined below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Central Nervous System Treatment Market:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The competitive conditions in this market are:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Wide Range of Indications: The CNS treatment market encompasses a broad range of neurological and psychiatric disorders, including epilepsy, Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease, multiple sclerosis, schizophrenia, and more. Each indication has its own set of competing treatments.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Established Players: Large pharmaceutical companies, such as Pfizer, Roche, and Novartis, have a strong presence in the CNS market, with well-established drugs and therapies for various conditions.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Generics and Biosimilars: Many older CNS drugs have lost patent protection, leading to the availability of generic and biosimilar versions. This has intensified competition, particularly in the treatment of common conditions like depression and anxiety.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">R&amp;D Investment: Companies invest heavily in research and development to discover and develop new CNS drugs. Advancements in neuroscience are driving innovative therapies, including novel mechanisms of action and targeted treatments.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Regulatory Challenges: Developing CNS drugs can be challenging due to the complexity of the brain and the potential for side effects. Companies must navigate stringent regulatory processes to gain approvals from agencies like the FDA and EMA.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Biologics and Gene Therapies: Emerging treatments, such as gene therapies and biologics, are becoming more prevalent in the CNS market. These advanced therapies often come with high costs and complex manufacturing processes.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Market Access and Pricing: Reimbursement and pricing challenges exist, and companies must demonstrate cost-effectiveness to secure market access, especially for novel, high-cost treatments.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Brain Tumor Drug Market:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">The competitive conditions in this market are:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Tumor Type Variability: The market for brain tumor drugs is highly diverse due to the various types of brain tumors, including glioblastoma multiforme (GBM), meningioma, and astrocytoma, each requiring different treatment approaches.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Surgery and Radiation Therapy: Brain tumors often require a combination of surgery and radiation therapy. Competition can be intense among medical device manufacturers and radiation therapy providers, as well as pharmaceutical companies offering adjuvant therapies.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Targeted Therapies: Developing targeted therapies that focus on specific genetic mutations or signaling pathways associated with brain tumors is an active area of competition. Personalized medicine approaches are increasingly relevant.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Immunotherapy: Immunotherapies are being explored for brain tumors, and competition revolves around developing effective immunotherapeutic strategies to harness the body&rsquo;s immune system against the tumor.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Clinical Trials: Companies often compete based on the strength of their clinical trial results and their ability to bring new drugs to market. The effectiveness and safety of brain tumor drugs are critical factors.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Orphan Drug Designations: Some brain tumor treatments may qualify for orphan drug designations, which can provide certain advantages, including extended exclusivity and incentives for development.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Patient Advocacy: Patient advocacy organizations play a significant role in raising awareness and influencing drug development. Collaboration with these groups can enhance a company&rsquo;s competitive position.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Research and Innovation: Continuous research and innovation in areas such as drug delivery, biomarker discovery, and imaging technologies contribute to the competitive landscape.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Combination Therapies: Companies explore combination therapies that can enhance treatment effectiveness. Combining surgery, radiation, and chemotherapy, for example, is a common approach in brain tumor treatment.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Global Expansion: Companies that can navigate international regulatory frameworks and secure approvals in various markets have a competitive edge.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">There are numerous other pharmaceutical and biotech companies, as well as academic institutions, involved in brain tumor research and drug development, including:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Bristol Myers Squibb (BMS): Makers of Opdivo<SUP>&reg;</SUP> (nivolumab) which has been explored for glioblastoma.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Merck &amp; Co., Inc.: Their drug, Temozolomide (Temodar<SUP>&reg;</SUP> in the US, Temodal<SUP>&reg; </SUP>in Europe), is a primary treatment for glioblastoma and anaplastic astrocytoma.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Roche: They have received accelerated US approval for Avastin<SUP>&reg;</SUP> (bevacizumab) for recurrent glioblastoma.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Novocure: Developers of the Optune<SUP>&reg;</SUP> device, a non-invasive treatment for glioblastoma.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">AstraZeneca are engaged in various stages of research, development, and commercialization of treatments for brain tumors.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Eli Lilly and Company: Conducting research in targeting brain tumors.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Pfizer: Involvement in the development of treatments for various types of cancers, including brain tumors.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Celldex Therapeutics: Working on drug candidates for glioblastoma.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The competition in this sector extends beyond just drug therapies. Various modalities, including radiation, surgery, and newer non-drug technologies, also vie for market share in the brain tumor treatment domains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="background-color: white">We
believe NEO100 may have three distinctive competitive advantages over the current treatment for high grade gliomas. First, it is delivered
intranasally. Unlike standard chemotherapy which is delivered orally (i.e. temozolomide) or intravenously (i.e. Avastin<SUP>&reg;</SUP>)
it has demonstrated minimal side-effects such as nasal irritation, and one case of initial nose bleeding, and to date has not induced
myelotoxicity, nausea/vomiting, or poor wound healing. Secondly, with respect to the treatment of IDH1 mutant recurrent Grade IV gliomas
in our Phase I trial, three recurrent Grade IV IDH1 mutant glioma patients having survival times greater than 3 years (Schonthal et al).
Recently, NeOnc has obtained permission from the FDA to expand the enrollment of Phase 2a to include not only recurrent Grade IV IDH1
mutants, but also Grade III gliomas with IDH1 mutations. Lastly, pre-clinical results indicate that it may be capable of dissolving drugs
that do not normally cross the blood brain barrier (i.e. velcade), and delivering them via the intranasal route to the brain (Wang et
al). This property would enable a potential platform delivery method, bypassing the blood brain barrier. The main new competitive landscape
to NEO100 is the development of vorasidenib (Servier Pharmaceuticals; Suresnes, France) for patients with low grade gliomas who have
IDH1,2 mutations (Mellinghoff 2023). Although the trial was in patients with low grade gliomas (Grade II), it has already been adopted
(without a clinical trial) for higher grade gliomas (Grade III, IV) with IDH mutations.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wang et al. JNS 132: 959, 2019</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Schonthal et al. Neuro-oncology Advances 3(1): 1, 2021.</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Mellinghoff IK et al. NEJM 389: 589, 2023</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>NEO100 vs. Current Standard of Care for Recurrent High-Grade Gliomas</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_023.jpg" ALT="" STYLE="height: 281px; width: 700px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEO212</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NEO212 is a temozolomide conjugate that is given orally. Its main competitive landscape will be standard of care alkylating agents such as temozolomide and lomustine. It is intended that NEO212 will have an oral formulation for primary brain cancers and may also be used for metastatic brain cancers. These cancers are treated currently by surgery or radiosurgery only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future Growth Drivers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We anticipate several goals and plans that may potentially support our long-term growth, with some supported by additional high-growth global markets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Potential commercial launch of NEO100 following FDA market approval.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Possible clinical trials &amp; FDA approval of other POH compounds in our product pipeline.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exploration of NEO100 pediatric indication.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are currently investigating several additional proprietary chemotherapy agents that have shown preliminary positive effects in laboratory tests on various types of cancers, i.e., NEO212 oral and intranasal delivery for primary and metastatic brain cancer.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatments for other CNS diseases and disorders based on our POH technology, such as Alzheimer&rsquo;s, Parkinson&rsquo;s and Epilepsy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not own or operate manufacturing facilities for the production of NEO100 nor do we plan to develop our own manufacturing operations in the foreseeable future. We currently depend on third party contract manufacturers for all of our required raw materials, active pharmaceutical ingredient and finished products for our preclinical and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&rsquo;s current good manufacturing practice standards (&ldquo;cGMP&rdquo;) regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA/NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have exclusively licensed a large worldwide patent portfolio from USC consisting of both issued patents and pending patent applications related to NEO100, NEO212 and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. In the United States, the Company has exclusive rights to 28 issued patents and 14 pending patent applications. Internationally, we have 65 patents issued and 28 patents applications pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The patent families of our product candidates are briefly described in the table below. All patents are owned by USC and exclusively licensed to us from USC. Patent Term Extension (PTE) may be available on certain patents after product approval.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1pt solid; text-align: left; width: 12%; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Candidate</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 30%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title [description]</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US Application #</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US Patent</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration Date</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 22%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign Counterparts</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising Monoterpenes</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Ultra Pure]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/040,059</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/939,834</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/817,286</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/843,097</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/040,002</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/220,135</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/575,587</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/749,293</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,507,734<SUP>1,2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,133,085<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,480,659<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,498,448<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,700,524<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,457,618<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,899,691<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/29/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/5/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031*</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada, China, China, EU (France, Germany, United Kingdom, Ireland, and Italy)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to temozolomide (TMZ)]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/566,731</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/455,371</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/818,972</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/408,866</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,916,545<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,580,372<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,499,461<SUP>1,2,3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,092,562<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil, China, EU (Germany, Spain, France, United Kingdom Switzerland, Ireland, Italy, Netherlands, Sweden), Japan, Hong Kong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 214</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to rolipram]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/123,729</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/388,535</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/306,167</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,077,104<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,013,804<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>2,3</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan, EU (Spain, France, United Kingdom, Ireland, Italy, Netherlands, Sweden)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 216</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives and Methods of Use</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to valproic acid]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/606,520</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/150,933</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,559,508<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/24/2038</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/18/2038*</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pending in both)</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 218</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Perillyl Alcohol-3-Bromopyruvate Conjugate and Methods of Treating Cancer</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to 3- Bromopyruvate]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/465,081</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,858,305<SUP>1,2,3</SUP></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/29/2037</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU, Japan (pending in all)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 400</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated with linoleic acid (LA)]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/251,452</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/313,258</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/573,693</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>2</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pending in both)</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 412</FONT></TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising Perillyl Alcohol Derivatives</FONT></P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Triple conjugation of perillyl alcohol, linoleic acid, and temozolomide]</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/041,743</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/126,586</FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,522,918<SUP>1,2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,696,680<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2036</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2036</FONT></P> </TD>
    <TD STYLE="text-align: left; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia, China, EU (Germany, France, United Kingdom, Ireland), Japan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD>
    <TD STYLE="text-align: justify">Method of making pharmaceutical composition</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD>
    <TD STYLE="text-align: justify">Pharmaceutical composition</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD>
    <TD STYLE="text-align: justify">Method of using pharmaceutical composition</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">*</TD>
    <TD STYLE="text-align: justify">20 years from the earliest filing date, subject to patent term adjustment</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology, including NEO100, NEO212 and our other product candidates. We also rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we own are highly uncertain. The steps we and our licensor have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, the examination process may require us to narrow the claims for our licensed pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. Our pending licensed and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which prevent others from commercializing competitive product candidates. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. Even if patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. If we are unable to obtain and maintain patent protection for our technology or for NEO100 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours in a non-infringing manner, and our ability to successfully commercialize NEO100 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. It is also possible that we will fail to identify patentable aspects of our research and development efforts in time to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our licensed pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications with a claim that covers infringing third-party activity. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition proceedings, derivation proceedings, post-grant review, <I>inter partes </I>review, interference proceedings or litigation. Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection for our technology. Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exclusive Patent License Agreement between USC and our Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;9, 2009, Nas-Onc, Inc. (k/n/a NeOnc Technologies, Inc). entered into an exclusive, worldwide license agreement with USC, pursuant to which USC granted us a license to use certain patents and patent applications for the treatment and therapies of disease symptoms in mammals (the &ldquo;USC Agreement&rdquo;). The license is exclusive except for the rights granted to the US government pursuant to the Bayh-Dole Act and the right of USC and other non-profit academic research institutions to practice and improve the licensed patents for educational and research purposes. Pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC 117,236 shares of common stock, (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) has paid and will continue to pay annual maintenance royalties of: $5,000 due January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1, 2013, and $20,000 due January&nbsp;1 yearly thereafter. Annual maintenance royalties paid to USC are creditable toward earned royalties. We are also responsible for paying all reasonable patent expenses incurred by USC for filing prosecution and maintaining the licensed patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the USC Agreement, payments will not be due to USC upon reaching certain development milestones. As of May 3, 2023, we have paid USC $479,621. Of the $479,621 paid to USC, $240,000 was a maintenance royalty payment. In the event of suspected patent infringement, the parties may agree to jointly institute suit, wherein the parties will share equally all costs and any recovery, with control of such lawsuit being by agreement between us and USC. Absent an agreement to jointly institute a suit, USC has the sole right to institute suit, at its option, where USC will bear the cost of such litigation and retain all recovery. In the event that USC does not institute the lawsuit, we may bring suit, at its option, and bear all such costs. Any recovery obtain by us must be shared with USC, after litigation costs reimbursement, as royalties on Net Sales for the remaining recovery. These rights and obligations were changed pursuant to the Amended License Agreement discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USC Agreement is sublicensable subject to the same terms, except that (1) sublicensees may not grant sublicenses, (2) the earned royalty may be increased as to sublicensees, (3) the sublicense reverts to USC in the event the USC Agreement is terminated as to us and, (4) additional issue and maintenance fees are owed to USC for each sublicense. These rights and obligations were changed pursuant to the Second Amendment and Restated Agreement discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may challenge the licensed patents upon 90 days&rsquo; notice and payment of all royalties due. If we are unsuccessful in its challenge, the earned royalty will thereafter be increased by a factor of three. These rights and obligations were changed pursuant to the Restated Agreement discussed below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of the USC Agreement extends until the last to expire of the licensed patents. The Term of the Agreement was changed pursuant to the Restated Agreement discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USC Agreement may be terminated by either party upon 30 days&rsquo; notice or upon material breach, wherein the breaching party is permitted 30 days to remedy such breach. USC may terminate immediately if (1) we attempt to sublicense, transfer or assign its rights contrary to the terms of the agreement, (2) we do not maintain the required insurance coverage, or (3) we are determined to be insolvent. These rights and obligations were changed pursuant to the Restated Agreement discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties amended the USC Agreement on April&nbsp;5, 2023 (&ldquo;Amended License Agreement&rdquo;). The Amended License Agreement added NeOnc Technologies Holdings, Inc. as a licensee. The Amended License Agreement also added additional patents and patent applications to the prior license grant and requires us to obtain and record fully executed assignments of the added patents/applications demonstrating USC&rsquo;s ownership in all relevant jurisdictions. Pursuant to the Amended License Agreement, we agreed to issue USC 560,000 additional shares of our common stock. The 560,000 shares were issued to USC on October 11, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Amended License Agreement provides for an 4% earned royalty on Net Sales on licensed products protected by the newly added patents on a country by-country basis. In the event that a licensed product is protected by patents from both the USC Agreement and the Amended License Agreement, the higher royalty will apply. The Amended License Agreement also recognizes a Royalty Credit, in the event that we must obtain additional licenses from third parties in order to sell the licensed products. The Amended License Agreement also grants us control the prosecution of any patent application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the licensed patents. The Amendment also changed the parties enforcement obligations. Specifically, we shall have the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were Sublicense Revenue as defined in the USC Agreement. USC must consent to any settlement that is detrimental to USC or USC&rsquo;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties further amended the USC Agreement on May 30, 2023 (&ldquo;Second Amendment&rdquo;). The Second Amendment revised the license agreement to permit sublicensees to sublicense the patents pursuant to specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &ldquo;Restated Agreement&rdquo;). The Restated Agreement addressed and clarified certain reporting obligations of the Company under the USC Agreement and addressed certain financial and other obligations, defaults, and deficiencies in connection with the Company&rsquo;s performance under the USC Agreement. In satisfaction prior unpaid sublicense issue royalties and annual maintenance royalties due for sublicensees, the Company must pay USC $230,000 by March 31, 2024. In connection with the Restated Agreement, the Company recorded the settlement amount of $230,000 in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2023, and accounts payable to USC in the accompanying condensed consolidated balance sheet as of September 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Restated Agreement provides for the same annual maintenance royalties of $20,000 per year above as well as the earned royalty of 2% or 4% on Net Sales on Licensed Products based on patent coverage (with the higher royalty applied when the Licensed Product is protected by patents from both the USC Agreement and the Amended License Agreement) and on a country-by-country basis. As above, the Restated Agreement recognizes the Royalty Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that we, or our sublicensee (other than OEP (discussed below)), challenges a Licensed Patent the annual maintenance royalty, milestone payments and the earned royalty percentage rated will be doubled during the pendency of such challenge. At the conclusion of such challenge, if a Valid Claim that covers the Licensed Product, Licensed Service or Licensed Process is held valid and enforceable then such ongoing royalty payments will be tripled. We must also reimburse USC for all costs incurred in connection with such challenge. Further, we must provide USC at least 180 day&rsquo;s written notice prior to our, or our sublicensee (excluding OEP) challenging a Licensed Patent. The notice is required to contain the prior art and a description of the facts and arguments that support the invalidity or unenforceability contention. We are required to discuss same with USC in an attempt to resolve the issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As above, we may grant sublicenses and our sublicensees may further grant licenses through one tier. As to our sublicense and collaboration agreement with OEP (discussed below) the Restated Agreement waives any prior breach by us of the USC Agreement and permits the OEP sublicense despite inconsistencies with certain terms of the Restated Agreement. We are responsible for OEP&rsquo;s compliance with the collaboration agreement and any future amendments to the OEP Agreement shall either comply with the terms and conditions of the Restated Agreement as to all other sublicensees or shall require USC&rsquo;s written consent in each instance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As above, pursuant to
the Restated Agreement we maintain us sole control the prosecution of any patent application and maintenance of any patent included within
licensed patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the licensed patents.
In addition, the parties enforcement obligations as described in the Amended License Agreement remain unchanged. Specifically, we have
the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any
Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were sublicense
revenue. USC must consent to any settlement that is detrimental to USC or USC&rsquo;s intellectual property rights. If we elect not to
file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action,
and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Restated Agreement changes the Term of the license. Specifically, the term is now tied to our royalty obligations under the Restated Agreement. We are obligated to pay royalties as to each Licensed Product, Licensed Service or Licensed Process on a country-by-country basis until (a) the last to expire Licensed Patent covering such product/service/process or (b) for 15 years after the date of first commercial sale of such product/service/process where such product/service/process is not covered by a Valid Claim of a Licensed Patent but such product/service/process was developed or made using any Licensed Process. The Term of the license ends when no further royalty obligations are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Last, as to termination, the Restated Agreement provides that the parties may mutually agree to terminate. Further, USC may immediately terminate if (a) we do not make payments when due and fail to cure, (b) we default on our indemnification or insurance obligations, (c) we are determined to be insolvent, (d) if any of our officers, directors or employees are convicted of a felony related to the development, manufacture use, marketing, distribution or sale of the Licensed Product, (e) if an audit shows an underpayment by us or a sublicensee of 15% or more for any 12 month period, or (f) we default in the performance of our other obligations in the agreement, and in each case fail to cure. We may terminate the license by giving 180 days advance written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon any termination of the license (other than expiration of the Term), then the Restated Agreement grants to USC a non-exclusive worldwide fully paid license, with the right to sublicense to the Licensed Product Data, which includes all pre-clinical, clinical and other regulatory data generated by or on behalf of the Company relating to the Licensed Product and generated after the effective date of the USC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Collaboration and License Agreement between NeOnc and Orient EuroPharma Co., Ltd. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">On November 8, 2013, NeOnc entered into the Collaboration and License Agreement (the &ldquo;OEP Agreement&rdquo;) with Orient EuroPharma Co., Ltd (&ldquo;OEP&rdquo;) to form a strategic relationship in which the parties collaboratively develop, and NeOnc licenses to OEP the right to commercialize, any pharmaceutical or medicinal item, substance, formulation, composition, article of manufacture, or other product (a) that is comprised of or contains the compound, (S)-perillyl alcohol having a purity of greater than 98.5% weight by weight (the &ldquo;Compound&rdquo;); (b) that is to be used in connection with the management, treatment, prevention, cure, or delayed progression of brain cancer and other cancers of the central nervous system; and (c) that does not comprise or contain perillyl alcohol covalently linked or conjugated in any manner with any therapeutic agent. The OEP Agreement details development costs and clinical trials of the licensed product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"> The term of the OEP Agreement
began on November 8, 2013 and continues until the later of (i) the expiration of the last to expire of the licensed patents in Taiwan,
China, Hong Kong, Macau, Korea, Cambodia, Laos, Myanmar, Thailand, Vietnam, Brunei, East Timor, Indonesia, Philippines, Malaysia, Singapore,
Australia, and New Zealand (collectively, the &ldquo;OEP Licensed Territory&rdquo;) that includes a valid claim, or (ii) November 8,
2033. Each party may terminate the OEP Agreement (i) if the other party fails in any material respect to perform or observe any term,
covenant, or understanding contained in the OEP Agreement, and any such failure remains unremedied for sixty (60) days after written
notice to the failing party or (ii) if any written representation or warranty by the other party made under or in connection with the
OEP Agreement proves to have been incorrect in any material respect when made. In addition, OEP may terminate the OEP Agreement if (i)
NeOnc elects to discontinue the development of the licensed product or (ii) the validity of the NeOnc patent rights is litigated and
no NeOnc patent rights survive final adjudication. Lastly, if OEP challenges of the validity directly or indirectly of any of NeOnc&rsquo;s
patent rights anywhere in the world, all rights granted to OEP under the OEP Agreement will immediately terminate and cease. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The OEP Agreement provides for tiered royalty rates payable by OEP to NeOnc based on net sales of the licensed product in the OEP Licensed Territory as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the total annual net sales of all licensed product in the OEP Licensed Territory is less than $3,000,000, then OEP pays a royalty rate of 1%;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the total annual net sales of all licensed product in the OEP Licensed Territory is equal to or greater than $3,000,000 and less than $30,000,000, then OEP pays a royalty rate of 1.5%;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the total annual net sales of all licensed product in the OEP Licensed Territory is equal to or greater than $30,000,000 and less than $50,000,000 then OEP pays a royalty rate of 2%; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the total annual net sales of all licensed product in the OEP Licensed Territory is equal to or greater than $50,000,000, then OEP pays a royalty rate of 5%.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Despite OEP not having an obligation to pay royalties in certain circumstances (for example, in countries within the territory where no patent has issued covering the Licensed Products and (ii) a generic version of the Licensed Products has launched in such country, and (iii) the gross profit margin for the Licensed Products [(Net Sales- cost of goods sold/Net Sales) in such country is less than 50%) we remain obligated to pay earned royalties to USC for Licensed Products sold in such country as set forth in the Restated Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">OEP also agrees to make the following milestone payments to NeOnc upon the first achievement of the corresponding milestones:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">A <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of $100,000 for the approval by the relevant Taiwanese regulatory authority of an IND application for any licensed product;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;
    <TD STYLE="text-align: justify">A <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of $300,000 for the satisfactory completion of a Phase I Clinical Trial in the United States for any licensed product;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;
    <TD STYLE="text-align: justify">A&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of $500,000 for the satisfactory completion of a Phase 2 Clinical Trial in the United States for any licensed product;</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">A <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of $500,000 for the Filing of NDA in Taiwan for any licensed product; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">A <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of $500,000 for the Filing of NDA in China for any licensed product.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">OEP has the right of first negotiation for an exclusive license on commercially reasonable business terms to make, have made, use, sell, offer to sell, and import products under such patent or patents if any patent or patents are issued to NeOnc or any of its affiliates in either the OEP Licensed Territory relating to perillyl alcohol conjugated with a therapeutic agent. NeOnc agrees to provide written notice to OEP of the issuance of any such patent within 5 business days of the issuance of the patent, and to thereafter negotiate with OEP exclusively, and in good faith, for 90 days for an exclusive license for rights under such patent. If no agreement has been reached after the expiration of those ninety (90) days, then NeOnc may negotiate with third parties without any further obligation to OEP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">The OEP Agreement may not be assigned by either party, except that: (i) each party may perform through its affiliates to the extent permitted in the OEP Agreement, and (ii) each party may assign the OEP Agreement and its rights and interests, in whole or in part, to any of its affiliates, any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger or consolidation with or into such corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government Regulation and Product Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the PHSA, and regulations and guidance documents implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving pharmaceutical products. Consent from the FDA is required before conducting human clinical testing of drug products. FDA approval of a new drug application (NDA) or a biologics license application (BLA) also must be obtained before marketing a new drug or biological product. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the continued expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Small Molecule New Drug Product Development Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any new drug product must be approved by the FDA before it may be legally marketed in the United States. FDA approval is also required before marketing an approved drug product for a new indication or condition of use. The process required by the FDA before a new drug product candidate may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical laboratory tests and in vivo studies in accordance with the FDA&rsquo;s Good Laboratory Practice (GLP) regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Submission to the FDA of an investigational new drug (IND) application, which allows human clinical trials to begin unless FDA objects (issues a &ldquo;clinical hold&rdquo;) within 30 calendar days;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Approval by an independent institutional review board (IRB), reviewing each proposed clinical trial and clinical site before each clinical trial may be initiated;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Performance of adequate and well-controlled human clinical trials in accordance with the protocol contained in the approved IND and in accordance with the FDA&rsquo;s Good Clinical Practice (GCP) regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed product candidate for its intended use;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Preparation and submission to the FDA of a new drug application (NDA) for marketing approval that includes substantial evidence of safety and efficacy from results of nonclinical testing and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Review of the product by an FDA advisory committee, if applicable;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product candidate is produced to assess compliance with current Good Manufacturing Practice (cGMP) requirements and to assure that the facilities, methods and controls are adequate to preserve the product candidate&rsquo;s identity, safety, strength, quality, potency and purity;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">Payment of user fees and FDA review and approval of the NDA.</P> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA&rsquo;s pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Before testing any product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vivo animal studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes active 30 calendar days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose partial or full clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not begin, or recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, that issues arise that partially or fully suspend or terminate such studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Human Clinical Trials Under an IND</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials must be conducted under written study protocols detailing, among other things, the objectives of the trial, subject selection and exclusion, the trial procedures, the parameters to be used in monitoring safety, the criteria to be evaluated, and a statistical analysis plan. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval by an IRB at each study site participating in the clinical trial or a central IRB. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 1.</I> The product candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its value in treating patients. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 2</I>. The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase 3</I>.</FONT> Phase 3 clinical trials are commonly referred to as &ldquo;pivotal&rdquo; or &ldquo;registrational&rdquo; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product. In Phase 3 studies, the product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically demonstrate the efficacy and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</P> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be required by FDA, or may be voluntarily conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings from other studies, in vivo laboratory tests or in vitro testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&rsquo;s initial receipt of the information. Relevant additional information obtained by the sponsor that pertains to a previously submitted IND safety report must be submitted as a follow-up IND safety report. Such report should be submitted within 15 calendar days after the sponsor receives the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information about certain clinical trials, including a description of the study and, in some cases, study results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their clinicaltrials.gov website. Manufacturers or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious or life-threatening diseases or conditions where no other comparable or satisfactory therapeutic options exist must also have a publicly available policy on evaluating and responding to requests for expanded access, sometimes called &ldquo;compassionate use,&rdquo; requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor that regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of the trial. This group, known as a Data and Safety Monitoring Board (DSMB) or Data and Safety Monitoring Committee (DSMC), may also review interim data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determined there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&rsquo;s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compliance with Current Good Manufacturing Practices (cGMP) Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers of pharmaceutical products must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved NDA, and may extend to requiring withdrawal of the product from the market. The FDA will not approve a NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of small molecule products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In relation to the clinical trials that may be conducted in other countries with a view to obtaining a marketing authorization, there are comparable cGMP requirements and other regulatory rules that are implemented nationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S. FDA Review and Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming successful completion of the required clinical and preclinical testing, the results of the preclinical tests and clinical trials together with detailed information relating to the product&rsquo;s CMC, including negative or ambiguous results as well as positive findings, and proposed labeling, among other things, are submitted to the FDA for NDA (new drug application) approval to market the product for one or more indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved therapeutic products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, under the Pediatric Research Equity Act (PREA), an NDA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and potential of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe. Also, applications for product candidates intended for the treatment of adult cancer which are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place of the PREA investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, using appropriate formulations, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA reviews a NDA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA reviews the NDA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&rsquo;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel therapeutic products or therapeutic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, (REMS) is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before approving a NDA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate if it determines that the manufacturing processes and facilities are not in compliance with cGMP requirements or otherwise are not adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a NDA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the basis of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA may also require post-marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a product&rsquo;s safety, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every five years, the FDA agrees to specified performance goals in the review of NDAs under the PDUFA. One such current goal is to review standard NDAs in ten months after the FDA accepts the NDA for filing, and priority NDAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expedited Development and Review Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but ideally no later than the pre-NDA or pre-BLA meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product may be eligible for priority review if it is intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A product may also be eligible for accelerated approval if it is intended to treat a serious or life-threatening condition and generally provide a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a drug may be eligible for designation as a Breakthrough Therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After approval, there also are continuing annual program user fee requirements for approved products, excluding, under certain circumstances, orphan products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rigorous and extensive FDA regulation of pharmaceutical products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other post-approval requirements applicable to pharmaceutical products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency of pharmacological products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with current cGMP and other requirements, which impose certain procedural and documentation requirements upon us and third-party manufacturers. Manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with current cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, changes to the manufacturing process or facility generally require prior FDA approval or notification before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, the Drug Quality and Security Act imposes obligations on manufacturers of pharmaceutical products related to product tracking and tracing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Adverse event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval of a NDA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license suspension or revocation, imposition of a partial or full clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and result in adverse publicity, among other adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor also must comply with the FDA&rsquo;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are inconsistent with the product&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;). The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Violations relating to the promotion of off-label uses may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Companies, however, may generally share truthful and non-misleading information that is otherwise consistent with a product&rsquo;s FDA approved labeling. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal actions and adverse publicity. These actions could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension or termination of a clinical trial by an IRB, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadly equivalent requirements and controls typically apply in other countries to the submission of marketing authorization applications and, post-approval, to the holding of such marketing authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Hatch-Waxman Amendments and Generic Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orange Book Listing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a drug product is approved under an NDA, the product is listed in the FDA&rsquo;s publication, &ldquo;Approved Drug Products with Therapeutic Equivalence Evaluations,&rdquo; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug (RLD). Sponsors of approved NDAs are required to list with the FDA patents whose claims cover the product&rsquo;s active ingredient, formulation, or an approved method of using the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent Term Extensions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments to the FDCA (Hatch-Waxman&rdquo;). Hatch-Waxman permits a patent restoration term of up to five years as compensation for patent term lost during drug product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&rsquo;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ANDA Approval Process for Generic Drugs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hatch-Waxman also established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application, or ANDA, with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. In some cases involving drugs with no or limited systemic absorption, an ANDA must include clinical endpoint (efficacy) studies in order to demonstrate bioequivalence. Drugs approved in this way are commonly referred to as &ldquo;generic equivalents&rdquo; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 505(b)(2) NDA Approval Process</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA under a &ldquo;full&rdquo; NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and enables the applicant to rely, in part, on the FDA&rsquo;s previous approval of a similar product, and/or published literature, in support of the safety and/or efficacy of its drug product. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&rsquo;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ANDA and 505(b)(2) NDA Patent Certification Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is, in the applicant&rsquo;s opinion, invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA or 505(b)(2) NDA is submitted to FDA with a Paragraph IV Certification, the applicant must also provide a &ldquo;Paragraph IV Notification&rdquo; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the applicant, providing a detailed written statement of the bases for the applicant&rsquo;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA or 505(b)(2) NDA will be automatically stayed for 30 months, or until 7-1/2 years after the RLD&rsquo;s NDA approval date if the ANDA or 505(b)(2) NDA was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &ldquo;section viii&rdquo; statement with respect to a listed method of use patent, certifying that the proposed ANDA or 505(b)(2) product&rsquo;s labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory Exclusivities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Chemical Entity Exclusivity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Hatch-Waxman Amendments provide a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&ldquo;NCE&rdquo;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &ldquo;active moiety&rdquo; is defined as the molecule or ion responsible for the drug substance&rsquo;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2 years after the approval of the reference drug NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Clinical Trial (3-Year) Exclusivity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the 3-year exclusivity period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan Drug Designation and Orphan Exclusivity Under the Orphan Drug Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&rsquo;s product for the same indication or disease. If one of our products is designated as an orphan drug and receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pediatric Exclusivity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to support a label change for pediatric use; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&rsquo;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other Healthcare Laws and Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities following product approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services (HHS) and its various divisions, including the Office of Inspector General, the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Healthcare providers and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources, including healthcare providers, are subject to broadly applicable fraud and abuse laws and regulations, and these laws and regulations may constrain the business or financial arrangements and relationships through which manufacturers conduct clinical research, market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other individuals and entities on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to commit a violation;</P> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil and criminal false claims, including the civil FCA, and Civil Monetary Penalties Laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, therapeutic products and medical supplies for which payment is available under Medicare, Medicaid, or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers and drug pricing and/or marketing expenditures; and state and local laws requiring the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, we may be subject to data privacy and security regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (HITECH), and its respective implementing regulations imposes certain requirements, including mandatory contractual terms, on covered entities, business associates and their covered subcontractors relating to the privacy, security, and transmission of certain individually identifiable health information known as protected health information. Among other things, HITECH, through its implementing regulations, makes HIPAA&rsquo;s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&rsquo;s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, subcontractors, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be pre-empted by HIPAA, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the EU, the data privacy laws are generally perceived to be stricter than those which apply in the United States and include specific requirements for the transfer of personal data outside the EU to the United States to ensure that EU standards of data privacy will be applied to such data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation of the laws described above or any other governmental laws and regulations may result in significant penalties, including administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, and additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly for manufacturers of branded prescription products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of FDA-approved drugs for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party payors are increasingly challenging the price and examining the medical necessity and cost of medical products and services, in addition to their safety and efficacy. New metrics frequently are used as the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. In order to obtain coverage and reimbursement for any product that might be approved for sale, it may be necessary to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and rational of the cost of the products, in addition to the costs required to obtain regulatory approvals. If third-party payors do not consider a product to be cost saving when compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost of a particular product candidate to currently available therapies. EU member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health Reform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By way of example, in March&nbsp;2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our business are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension of a manufacturer&rsquo;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&rsquo;s Medicaid rebate liability;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical research, along with funding for such research.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, in August&nbsp;2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April&nbsp;2013 and, following passage of the BBA and the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, President Trump used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders, and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&rsquo;s proposals. The FDA concurrently released a final rule and guidance in September&nbsp;2020 implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until 2032. Additionally, on March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&rsquo;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In July&nbsp;2021, the Biden administration released an executive order, &ldquo;Promoting Competition in the American Economy,&rdquo; with multiple provisions aimed at prescription drugs. In response to Biden&rsquo;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under the Program, the Secretary of HHS will publish a list of &ldquo;selected drugs,&rdquo; and will then negotiate maximum fair prices (MFP) with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &ldquo;selected drug&rdquo; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &ldquo;selected drug&rdquo; up to 95% and the potential of civil monetary penalties. Further, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. In addition, the Biden administration released an additional executive order on October&nbsp;14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the state level, individual states in the United States have increasingly passed legislation and implemented regulations designed to control pharmaceutical and therapeutic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare providers that use such therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data Privacy and Security</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of our business, we collect, process and store confidential and sensitive information, including personal information, intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third parties upon whom we rely, use sophisticated information technology, software and services to process, store, use, generate, transfer and disclose information, as well as other sensitive information controlled by ourselves or other third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third parties on whom we rely. The legislative and regulatory framework related to the collection, use, retention, safeguarding, disclosure, sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection laws and regulations is changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions, or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements, including our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data security laws and regulations will involve substantial costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain health care providers, health plans and health care clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even when HIPAA does not apply, according to the FTC, violating consumers&rsquo; privacy rights or failing to take appropriate steps to keep consumers&rsquo; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5 of the FTC Act. The FTC expects a company&rsquo;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 (CCPA), which has been characterized as the first &ldquo;GDPR-like&rdquo; privacy statute to be enacted in the United States. Although the CCPA exempts certain data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal information we maintain about California residents. The CCPA among other effects, creates individual privacy rights for California consumers (as defined in the law), places increased privacy and security obligations on entities handling certain personal data of consumers or households, requires covered companies to provide disclosures to consumers regarding data collection, use and sharing practices, requires covered companies to allow users to opt-out of certain sales or transfers of personal information, and provides consumers with a private right of action for certain data breaches. The CCPA became effective on January&nbsp;1, 2020, and the California Attorney General&rsquo;s authority to begin bringing enforcement actions began July&nbsp;1, 2020. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Further, the California Privacy Rights Act (CPRA) was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA went into effect on January&nbsp;1, 2023, and become enforceable on July&nbsp;1, 2023. A similar law, the Consumer Data Protection Act (CDPA), was recently passed in Virginia and went into effect on January&nbsp;1, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also are or will become subject to privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection, control, processing, and other use of personal data (i.e. data relating to an identified or identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical information of these participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to cross-border transfers of personal data out of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States, e.g. on July&nbsp;16, 2020, the Court of Justice of the European Union (CJEU), invalidated the EU-U.S. Privacy Shield Framework, or the Privacy Shield, under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June&nbsp;4, 2021, the European Commission adopted new standard contractual clauses under the GDPR for data transfers from entities that are subject to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including the obligation to conduct a transfer impact assessment and, depending on a party&rsquo;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers, we may be required to incur significant time and resources to update our contractual arrangements and to comply with new obligations. Additionally, on September&nbsp;8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner) concluded that the Swiss-U.S. Privacy Shield does not provide an adequate level of protection for personal data transfer from Switzerland to the U.S. pursuant to the Swiss Federal Act on Data Protection. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20.0 million or 4% of total global annual turnover. Further, following the withdrawal of the United Kingdom from the EU on January&nbsp;31, 2020, pursuant to the transitional arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, each regime having the ability to fine up to the greater of &#8364;20 million / &pound;17 million or 4% of global turnover. Following December&nbsp;31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and EU, although it is likely that the data protection obligations of the GDPR will continue to apply to UK-related processing of personal data in substantially unvaried form and fashion, for at least the short term thereafter, the relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United Kingdom will be the subject of a so-called adequacy decision of the European Commission, and it is therefore unclear how data transfers between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to the UK and EU position regarding aspects of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions, or potential civil claims including class action type litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, we use third-party service providers and subprocessors to help us operate our business and engage in processing on our behalf. If we, our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our (or their) information technology, software, services, communications or data, it may result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions. Furthermore, applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security breaches, including affected individuals, customers, and regulators. Such disclosures are costly, and the disclosure or the failure to comply with such requirements, could result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For more information on the potential impact of the GDPR, and associated EEA data protection laws, on our business, see the section titled &ldquo;<I>Risk Factors&#8212;Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S. Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value, directly or indirectly, to any foreign government official, government staff member, official or employee of a public international organization, or a political party or political candidate for the purpose of influencing any act or decision of the foreign entity in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with healthcare professionals of foreign state-owned or affiliated hospitals, universities, or research institutions. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivalent laws have been adopted in other foreign countries that impose similar or arguably broader obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of September&nbsp;30,
2023, we had three full-time employees. There are also four PhD professionals and one lab technician who are paid by USC which is then
reimbursed by us. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We
consider our relationship with our employees to be good. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not currently own or lease any properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">We may in the future be involved in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and data protection, privacy and other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On July 1, 2022, NeOnc Technologies, Inc. and Fox Infused, LLC, a Delaware limited liability company (&ldquo;Fox Infused&rdquo;), entered into an Intellectual Property License and Supply Agreement effective July 1, 2022 (the &ldquo;Agreement&rdquo;) whereby NeOnc agreed to supply certain products to Fox Infused and license certain of our patents. We terminated the Agreement with Fox Infused on April 25, 2023. On June 6, 2023, Fox Infused filed a complaint against NeOnc in the Central District of California alleging that the termination was improper (Civil Action No. 2:23-04431). Fox Infused also filed an ex parte application for a temporary restraining order and an order to show cause on a preliminary injunction against us seeking to have the court stop the termination of the contract. Fox Infused&rsquo;s temporary restraining order application was denied and the case dismissed without prejudice. Fox Infused refiled the case in arbitration before the American Arbitration Association (Case No. 01-23-0002-5020). The parties engaged in settlement discussions, and agreed to settle the dispute for a $600,000 payment by us to Fox Infused within 5 business days of the closing date of this offering or March 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_012"></A>MANAGEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Director Nominees</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our directors, executive officers and director nominees are listed below as of the date of this prospectus. The executive officers are full-time employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
    and Executive Officers:</B></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas C. Chen, M.D., Ph.D.</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Walters</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keithly
    Garnett<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Heshmatpour</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman and Secretary</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
    Nominees:</B></FONT> </TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 44%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 9%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasim
    Shomali</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Sikirat
    Iyabo Tinubu-Karch, M.D.</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Victoria
    Medvec, Ph.D.</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Nanula</FONT> </TD>
    <TD STYLE="text-align: left; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Keithly Garnett will resign as a director on or prior to the effective date of this offering.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our directors holds office until the next annual meeting of our shareholders or until his/her successor has been elected and qualified, or until his/her death, resignation, or removal. Our executive officers are appointed by our board of directors and hold office until their death, resignation, or removal from office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Experience</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a brief overview of the education and business experience of each of our directors, executive officers and director nominees during at least the past five years, including their principal occupations or employment during the period, the name and principal business of the organization by which they were employed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Directors and Executive Officers:</FONT> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dr. Thomas C. Chen, M.D., Ph.D.,</I> has served as NeOnc Technologies Holdings, Inc.&rsquo;s Chief Executive Officer since April&nbsp;2023 and Chairman since May&nbsp;2023. Dr. Chen has served as NeOnc Technologies, Inc.&rsquo;s Chief Executive Officer, Chairman and Chief Medical Officer of the Board since its inception. Since July 1997, Dr. Chen has worked as a Neurosurgeon at Keck Medicine of USC and a Professor Neurological Surgery at the University of Southern California Keck School of Medicine (&ldquo;USC&rdquo;). He has been the Director of Surgical Neuro-Oncology and Professor of Neurosurgery &amp; Pathology. Dr. Chen&rsquo;s work is widely published, including 148+ peer-reviewed clinical studies. He maintains a clinical practice in both surgical neuro-oncology and spine surgery, as well as heads a research laboratory focused on glioma biology. He graduated summa cum laude from the University of Illinois at Urbana-Champaign with Bronze Tablet honors and Phi Beta Kappa. He graduated from University of California San Francisco with M.D. degree, and was in the top 10% of his class, awarded Alpha Omega Alpha. He earned his Ph.D. in pathobiology from University of Southern California where he wrote his thesis on the role of immunotherapy in malignant brain tumors. We believe that Dr. Chen&rsquo;s extensive knowledge of NeOnc&rsquo;s business and his extensive corporate and leadership experience as the founder of NeOnc and its Chief Executive Officer qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patrick Walters</I> has served as NeOnc Technologies Holdings, Inc.&rsquo;s Chief Operating Officer since April&nbsp;2023. Mr. Walters has served as NeOnc Technologies, Inc.&rsquo;s Chief Financial Officer from 2009 to January&nbsp;2023. Mr. Walters has served as NeOnc Technologies, Inc.&rsquo;s Chief Operating Officer and Director from January&nbsp;2023 to April&nbsp;2023. For over 30 years, Mr. Walters has held senior management positions in corporate finance, financial reporting, planning analysis, operations, business development, and strategic planning. He started his career at Deloitte &amp; Co., earning his CPA license. He has spent 16 years as a senior financial executive at Sony Pictures as the SVP of Worldwide Finance for Theatrical Films. He also spent five years managing a Forbes 400 family office as the managing director. His vast industry experience includes Biotech, Retail, Service, Entertainment, Publishing, Start-up, Banking, Venture Capital, and a Family Office. Mr. Walters is in the process of reactivating his CPA license. Mr. Walters holds a Bachelor of Arts degree in Economics Accounting from California State University, Northridge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Keithly Garnett</I> has served as NeOnc Technologies Holdings, Inc.&rsquo;s Chief Financial Officer since April&nbsp;2023 and director since January&nbsp;2023. Mr. Garnett spent over 17 years with Ernst &amp; Young LLP in their Transaction Advisory Services practice. During that time, he specialized in business valuation modelling and strategy. His services were provided in support of audit related work for financial reporting, tax planning and management planning. His client list included companies such as Amgen, Edwards Life Sciences, Medtronic, etc. In any given year, he led over 50 transaction analyses and/or review for publicly traded companies, in connection with their SEC financial reporting requirements. From March 2017 to January 2023, Mr. Garnett was a Director at Sycamore Valuation. Since January 2021, Mr. Garnett has worked as the Chief Financial Officer of AFH Holding &amp; Advisory, a single member family office based in Malibu. From 2018 to 2022, he was involved with the Shuttle Pharmaceutical Holdings public offering, which was successfully listed on the Nasdaq in 2022. Mr. Garnett holds a Master&rsquo;s in Business Administration with a concentration in Corporate Financial Management, and a Bachelor of Science degree in Business Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Amir Heshmatpour</I> has served on NeOnc Technologies Holdings, Inc.&rsquo;s board of directors since January&nbsp;2023. Mr. Heshmatpour founded AFH Holding and Advisory LLC (&ldquo;AFH&rdquo;) in July 2005. Since July 2005, Mr. Heshmatpour has been the Managing Director of AFH. Mr. Heshmatpour, through AFH, his family office, has been involved in multiple biotech transactions from private to public. From 2018 to 2022, through a special purpose vehicle, Shuttle Pharmaceuticals Holdings Inc. (&ldquo;SPH&rdquo;), Mr. Heshmatpour restructured the board of directors, management, and recapitalized an IPO of a Georgetown phase 2 oncology asset. The SPV was created in 2018 and eventually was successfully listed on NASDAQ in 2022. Since then, he has been involved in NeOnc Technologies Inc., where he has provided strategic advisory services. Mr. Heshmatpour has a certification from the UCLA Anderson School of Business in corporate governance. He is also involved in the UCLA Anderson School of Business Management, Price Center, as a member of the Board of Advisors. We believe that Mr. Heshmatpour&rsquo;s extensive corporate and leadership experience qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B> Director Nominees:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasim Shomali</I>. Since April 2013, Ms. Shomali has served as Sustainability Strategy Senior Manager at Accenture. At Accenture, she partners with senior executives from Fortune 500 companies to help them tackle operational challenges and drive innovation and growth. Ms. Shomali is responsible for managing and growing Accenture&rsquo;s US divisions&rsquo; Software, Platform, and Technology industries sustainability book of business, and also serves as one of Accenture&rsquo;s leading data center experts, driving operational efficiencies and future state design for her global hyperscale clients. Ms. Shomali earned her MBA at UCLA. She holds a dual degree in Bio-engineering and Mathematics at University of Washington. She completed the prestigious World Business Council for Sustainable Development Executive Leadership Program in partnership with Yale School of Business. We believe that Ms. Nasim Shomali&rsquo;s extensive corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr. Sikirat Iyabo Tinubu-Karch</I>. Dr. Tinubu-Karch, <I>M.D.</I>, is a geriatric medicine specialist in Seattle, Washington with over thirty years of experience in the field. Dr. Tinubu-Karch received her M.D. from St. Georges School of Medicine, and completed a residency at Lenox Hill Hospital. Thereafter, Dr. Tinubu-Karch completed a M.D. fellowship in critical care medicine at the University of Washington and later earned her Master of Health Administration from the same university. Since 2019, Dr. Tinubu-Karch has been a member as the Board of Governors of Sidra Medicine, in Doha, Qatar, and she became the CEO in November 2022. Dr. Tinubu-Karch also serves on Sidra Medicine&rsquo;s audit committee. In 2019, Dr. Tinubu-Karch founded 6M Geriatrics &amp; Hospital Medicine (&ldquo;6M&rdquo;), where she was CEO until October 2022. 6M is affiliated with Swedish Edmonds Campus. Dr. Tinubu-Karch is also a member of the board of directors of Rippl Care. We believe that Dr. Iyabo Tinubu-Karch&rsquo;s extensive corporate and leadership experience qualify her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dr. Victoria Medvec, Ph.D</I>. Since 1995, Dr. Victoria Medvec has been the Adeline Barry Davee Professor of Management and Organizations at the Kellogg School of Management at Northwestern University. In addition, Dr. Medvec is a co-founder and the Executive Director of the Center for Executive Women at the Kellogg School. Since 2002 Dr. Medvec has served as the CEO of Medvec and Associates, a consulting firm focused on high stakes negotiations and strategic decisions. Dr. Medvec received her Ph. D in psychology from Cornell University and Bachelor of Arts degree in Economics, Management, and Psychology from Bucknell University. Dr Medvec is a renowned expert in the areas of negotiations, executive decision making, influence, and corporate governance. Dr. Medvec&rsquo;s research is published in top academic journals and she is the author of the best-selling book, Negotiate Without Fear. Dr. Medvec has served on both public and private company Boards across many industries, including banking, human resources and benefits administration. She also is a Ringleader in Ringleader Ventures, a unique venture fund matching start up technologies with corporate needs. We believe that Dr. Victoria Medvec&rsquo;s extensive corporate and leadership experience qualify her to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Richard Nanula.</I> A Harvard Business School graduate, Mr. Nanula was the long-time EVP &amp; CFO at the Walt Disney Company, and later the President
and COO of Starwood Hotels before turning his career focus to the biosciences. From 2001 to 2007, Mr. Nanula was EVP of Finance and Strategy
at Amgen where he scrupulously restructured the company to bring down capital costs and concentrate equity, and architected what was
the largest acquisition in the history of the biotech industry at the time. From 2019 to 2023, Mr. Nanula served as CEO of PureForm Global,
Inc., a tech-focused biosciences company. Since 2023, Mr. Nanula has served as the Executive Chairman at Lucy Scientific Discovery, a
drug manufacturer with heavy emphasis on research and development. We believe that Mr. Richard Nanula&rsquo;s extensive corporate and
leadership experience qualify him to serve on our Board of Directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family Relationships</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasim Shomali, one of our director nominees, is Amir Heshmatpour&rsquo;s niece. Other than the foregoing, there are no other family relationships among any of our executive officers, directors or director nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Involvement in Certain Legal Proceedings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item&nbsp;401(f) of Regulation S-K in the past ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CORPORATE GOVERNANCE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition of our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current Board of Directors consists of Dr. Thomas C. Chen, Amir Heshmatpour and Keithly Garnett</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Nasim Shomali, Dr. Iyabo
Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D., will become directors on the effective date of this offering and
Keithly Garnett will resign on or prior to the effective date of this offering. Our board of directors may establish the authorized number
of directors from time to time by resolution. In accordance with our amended and restated certificate of incorporation, our board of
directors will be divided into three classes with staggered three-year terms. At each annual meeting of shareholders, the successors
to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting
following election. Our directors are divided among the three classes as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Class I director is Nasim Shomali, and her term will expire at the annual meeting of shareholders to be held in 2024;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the Class II directors are Richard Nanula and Dr.
    Victoria Medvec, Ph.D., and their terms will expire at the annual meeting of shareholders to be held in 2025; and</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">the Class III directors
are Dr. Iyabo Tinubu-Karch, M.D., Amir Heshmatpour and Dr. Thomas C. Chen, M.D., Ph.D., and their terms will expire at the annual meeting
of shareholders to be held in 2026.</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Under the listing requirements
and rules of the Nasdaq Stock Market LLC (Nasdaq Listing Rules), a majority of our directors must be independent directors. Nasim Shomali,
Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D., are considered independent based on the listing
standards of Nasdaq. In order to promote open discussion among independent directors, our Board intends to adopt a policy of regularly
conducting executive sessions of independent directors at scheduled meetings led by the lead independent director and at such other times
requested by other independent directors. Executive sessions shall not include Dr. Thomas Chen, M.D., Ph.D., or Mr. Amir Heshmatpour. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees of our Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate pursuant to a charter to be adopted by our Board of Directors and will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The Board of Directors may also establish other committees from time to time to assist our company and the board of directors. Upon the effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq Capital Market and SEC rules and regulations, if applicable. Upon our listing on the Nasdaq Capital Market, our committees&rsquo; charters will be available on our website at www.NeOnctech.com. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our audit committee will
consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D. Our Board of Directors
has determined that each of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D., satisfies
the independence requirements under Nasdaq listing standards and Rule&nbsp;10A-3(b)(1) of the Exchange Act. The chair of our audit committee
will be Richard Nanula, who our Board of Directors has determined is an &ldquo;audit committee financial expert&rdquo; within the meaning
of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable
requirements. In arriving at these determinations, our Board of Directors has examined each audit committee member&rsquo;s scope of experience
and the nature of their employment in the corporate finance sector. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal duties and responsibilities of our audit committee will include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending, based upon the audit committee&rsquo;s review and discussions with management and our independent registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form&nbsp;10-K;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing quarterly earnings releases.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our compensation committee
will consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D. The chair of our
compensation committee will be Nasim Shomali. Our Board of Directors has determined that each of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch,
M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D., is independent under Nasdaq listing standards, a &ldquo;non-employee director&rdquo;
as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The principal duties and responsibilities of our compensation committee will include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation: (i) recommending to the board of directors the cash compensation of our Chief Executive Officer, and (ii) reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors the cash compensation of our other executive officers;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and establishing our overall management compensation, philosophy, and policy;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and administering our compensation and similar plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retaining and approving the compensation of any compensation advisors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving our policies and procedures for the grant of equity-based awards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors the compensation of our directors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our nominating and corporate
governance committee will consist of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D.
The chair of our nominating and corporate governance committee will be Dr. Victoria Medvec, Ph.D. Our Board of Directors has determined
that each of Nasim Shomali, Dr. Sikirat Iyabo Tinubu-Karch, M.D., Richard Nanula, and Dr. Victoria Medvec, Ph.D. is independent under
Nasdaq listing standards. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The nominating and corporate governance committee&rsquo;s responsibilities include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and recommending to the board of directors&rsquo; criteria for board and committee membership;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying individuals qualified to become members of the board of directors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the board&rsquo;s committees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors&rsquo; appropriate corporate governance guidelines; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the evaluation of our board of directors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the effectiveness of the registration statement of which this prospectus is a part, we will adopt a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions. Following the effectiveness of the registration statement of which this prospectus is a part, a current copy of this code will be posted on the Corporate Governance section of our website, which is located at www.NeOncco.com. The information on our website is deemed not to be incorporated in this prospectus or to be a part of this prospectus. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have assembled a scientific advisory board with expertise in oncology and clinical trials. The members of our scientific advisory board have made significant scientific contributions in their individual fields. Members of our scientific advisory board provide strategic advice to us in fields pertinent to gynecologic oncology and perform other such services as may be mutually determined by us and the scientific advisory board member. Our scientific advisory board meets on an as-needed basis, based on our need for advice in their fields of expertise from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We provide compensation for their time and on a per meeting basis to members of our scientific advisory board. We also reimburse each member of our scientific advisory board for all reasonable and necessary travel expenses in connection with the performance of his services. Our scientific advisory board includes: Dr. Steven L. Giannotta, M.D., Axel H. Sch&ouml;nthal, Ph.D., Dr. Iyabo Tinubu-Karch, M.D., Dr. David M. Peereboom, Dr. Daniel Levin and Dr. Ming-Fu (Alan) Chiang, M.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board Leadership Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our Board of Directors
and management believe that the choice of whether the Chair of our Board of Directors should be an executive of our company, or a non-executive
or independent director, depends upon a number of factors, taking into account the candidates for the position and the best interests
of our company and our shareholders. Dr. Chen serves as the Board Chair. Dr. Chen&rsquo;s operating and leadership experience as an officer
and director of our company since its inception made him a compelling choice for Board Chair. Mr. Richard Nanula will serve as lead independent
director of our Board of Directors. As lead independent director, Mr. Richard Nanula will preside over executive sessions of the independent
directors and serves as a liaison between the independent directors and our management team. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board oversees a company-wide approach to risk management. Our Board will determine the appropriate risk level for us generally, assess the specific risks faced by us and review the steps taken by management to manage those risks. While our Board has ultimate oversight responsibility for the risk management process, its committees will oversee risk in certain specified areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically, our compensation committee will be responsible for overseeing the management of risks relating to our executive compensation plans and arrangements, and the incentives created by the compensation awards it administers. Our audit committee will oversee management of enterprise risks and financial risks, as well as potential conflicts of interest. Our Board is responsible for overseeing the management of risks associated with the independence of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more officers serving as a member of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director and Officer Indemnification Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to enter into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our certificate of incorporation and bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&rsquo; fees, judgments, penalties, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at our request. The indemnification agreements and our certificate of incorporation and bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXECUTIVE COMPENSATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information regarding compensation awarded to, earned by or paid to persons serving as our principal
executive officer and our principal financial officer during the year ended December&nbsp;31, 2023 and 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name
    and Principal Position</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fiscal<BR>
    Year</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Salary<BR>
    Paid<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bonus<BR>
    ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock<BR>
    Awards<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option<BR>
    Awards<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-Equity<BR>
    Incentive<BR> Plan<BR> Compensation<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-<BR>
    Qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other<BR>
    Compensation<BR> ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total<BR>
    ($)</FONT> </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 29%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Dr. Thomas C.
    Chen &ndash; <BR> Chief Executive Officer</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 6%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">194,333</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="width: 5%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">194,333</FONT> </TD><TD STYLE="width: 1%; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Patrick Walters &ndash;
    <BR>
    Chief Operating Officer<SUP>(1)</SUP></FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">178,750</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">178,750</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">50,000</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Keithly Garnett &ndash;<BR>
    Chief Financial Officer</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2023</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">164,083</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">164,083</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2022</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT> </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0</FONT> </TD><TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Walters served as
    our Chief Financial Officer until April 7, 2023. </FONT> </TD> </TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 800,000 restricted stock units were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock units will
    be time vested; one-third (1/3) will vest seven months after the effective date of this offering and one-third will vest in equal
    monthly installments over a one (1) year period commencing on the eighth month from the effective date of this offering. The remaining
    one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth
    in Dr. Chen&rsquo;s individual grant agreement.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 300,000 restricted stock units were granted to Patrick Walters. Two-thirds of such restricted stock units will be time vested;
    one-third (1/3) will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments
    over a one (1) year period commencing on the eighth month from the effective date of this offering. The remaining one-third will
    be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&rsquo;s
    individual grant agreement.</FONT> </TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 360,000 restricted stock units were granted to
    Keithly Garnett. Two-thirds of such restricted stock units will be time vested; one-third (1/3) will vest seven months after the
    effective date of this offering and one-third will vest in equal monthly installments over a one (1) year period commencing on the
    eighth month from the effective date of this offering. The remaining one-third will be performance-based, the vesting of which will
    be predicate on certain performance metrics being met as set forth in Mr. Garnett&rsquo;s individual grant
    agreement.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Employment Agreements</B> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On January 4, 2024, the Company entered
into an employment agreement (&ldquo;Employment Agreement&rdquo;) with Dr. Thomas C. Chen to serve as Chief Executive Officer and Chief
Scientific Officer of the Company. The term of the Employment Agreement will commence upon the effective date of the initial public offering
and continue for a period of seven months. The term will automatically renew for successive one-year periods until either party delivers
written notice of their intent not to renew at least fifteen days prior to the expiration of the then effective term. The Employment
Agreement provided for a base salary of $212,000. In addition, Dr. Chen shall be eligible to participate in any bonus or incentive programs
established by the Company. The Employment Agreement may be terminated by either the Company or Dr. Chen at any time and for any reason
or for no reason at all, subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement
by Dr. Chen, Dr. Chen shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any
cash remuneration paid to Dr. Chen during the severance period, and (ii) benefits. Dr. Chen&rsquo;s employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause
of the Employment Agreement by the Company, Dr. Chen shall be entitled to receive (i) his base salary until the end of the severance
period, and (ii) accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Dr.
Chen shall be entitled to receive payments equal to the base salary for the severance period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On January 4, 2024, the Company entered
into an employment agreement (&ldquo;Employment Agreement&rdquo;) with Patrick Walters to serve as Chief Operating Officer of the Company.
The term of the Employment Agreement will commence upon the effective date of the initial public offering and continue for a period of
seven months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent
not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary
of $195,000. In addition, Mr. Walters shall be eligible to participate in any bonus or incentive programs established by the Company.
The Employment Agreement may be terminated by either the Company or Mr. Walters at any time and for any reason or for no reason at all,
subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement by Mr. Walters, Mr. Walters
shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid
to Mr. Walters during the severance period, and (ii) benefits. Mr. Walters&rsquo;s employment may also be terminated by the Company at
any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment
Agreement by the Company, Mr. Walters shall be entitled to receive (i) his base salary until the end of the severance period, and (ii)
accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Mr. Walters shall
be entitled to receive payments equal to the base salary for the severance period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> On January 4, 2024, the Company entered
into an employment agreement (&ldquo;Employment Agreement&rdquo;) with Keithly Garnett to serve as Chief Financial Officer of the Company.
The term of the Employment Agreement will commence upon the effective date of the initial public offering and continue for a period of
seven months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent
not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary
of $179,000. In addition, Mr. Garnett shall be eligible to participate in any bonus or incentive programs established by the Company.
The Employment Agreement may be terminated by either the Company or Mr. Garnett at any time and for any reason or for no reason at all,
subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement by Mr. Garnett, Mr. Garnett
shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid
to Mr. Garnett during the severance period, and (ii) benefits. Mr. Garnett&rsquo;s employment may also be terminated by the Company at
any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment
Agreement by the Company, Mr. Garnett shall be entitled to receive (i) his base salary until the end of the severance period, and (ii)
accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Mr. Garnett shall
be entitled to receive payments equal to the base salary for the severance period. </P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> &nbsp; </P>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee Director Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 1,000,000
restricted stock units were granted to Amir Heshmatpour. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Nasim Shomali. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 750,000
restricted stock units, subject to adjustment, were granted to Dr. Sikirat Iyabo Tinubu-Karch, M.D. The forgoing restricted stock units
will vest upon certain financial metrics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Richard Nanula. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock units will vest one hundred percent (100%)
seven months following the effective date of this offering. </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023 Incentive Stock Plan</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have adopted a 2023
Incentive Stock Plan (the &ldquo;2023 Plan&rdquo;). <FONT STYLE="background-color: white">An aggregate of 3,440,000 shares of our common
stock is currently reserved for issuance and available for awards under the 2023 Plan, including incentive stock options granted under
the 2023 Plan, which amount will increase, if necessary, to twenty percent (20%) of the fully diluted capitalization of the Company on
the closing of this offering. The 2023 Plan administrator may grant awards to any employee, director, consultant, or other person providing
services to us or our affiliates. In January 2024,</FONT> 3,221,250 restricted stock units were granted to our executive officers and
directors further to the 2023 Plan as described below. The 2023 Plan is currently administered by the Board. The 2023 Plan administrator
has the authority to determine, within the limits of the express provisions of the 2023 Plan, the individuals to whom awards will be
granted, the nature, amount and terms of such awards and the objectives and conditions for earning such awards. The Board may at any
time amend or terminate the 2023 Plan, provided that no such action may be taken that adversely affects any rights or obligations with
respect to any awards previously made under the 2023 Plan without the consent of the recipient. No awards may be made under the 2023
Plan after the tenth anniversary of its effective date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards under the 2023 Plan may include incentive stock options, nonqualified stock options, restricted shares of common stock and restricted stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock Options</I>. The 2023 Plan administrator may grant to a participant options to purchase our common stock that qualify as incentive stock options for purposes of Section&nbsp;422 of the Internal Revenue Code (&ldquo;incentive stock options&rdquo;), options that do not qualify as incentive stock options (&ldquo;non-qualified stock options&rdquo;) or a combination thereof. The terms and conditions of stock option grants, including the quantity, price, vesting periods, and other conditions on exercise will be determined by the 2023 Plan administrator. The exercise price for stock options will be determined by the 2023 Plan administrator in its discretion, but non-qualified stock options and incentive stock options may not be less than 100% of the fair market value of one share of our company&rsquo;s common stock on the date when the stock option is granted. Additionally, in the case of incentive stock Options granted to a holder of more than 10% of the total combined voting power of all classes of our stock on the date of grant, the exercise price may not be less than 110% of the fair market value of one share of common stock on the date the stock option is granted. Stock options must be exercised within a period fixed by the 2023 Plan administrator that may not exceed ten years from the date of grant, except that in the case of incentive stock options granted to a holder of more than 10% of the total combined voting power of all classes of our stock on the date of grant, the exercise period may not exceed five years. At the 2023 Plan administrator&rsquo;s discretion, payment for shares of common stock on the exercise of stock options may be made in cash, shares of our common stock held by the participant or in any other form of consideration acceptable to the 2023 Plan administrator (including one or more forms of &ldquo;cashless&rdquo; or &ldquo;net&rdquo; exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Restricted Shares and Restricted Units</I>. The 2023 Plan administrator may award to a participant shares of common stock subject to specified restrictions. Restricted shares, or restricted stock units, are subject to forfeiture if the participant does not meet certain conditions such as continued employment over a specified forfeiture period and/or the attainment of specified performance targets over the forfeiture period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 800,000
restricted stock units were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock units will be time vested;
one-third (1/3) will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments
over a one (1) year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&rsquo;s individual grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 300,000
restricted stock units were granted to Patrick Walters. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&rsquo;s individual grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 360,000
restricted stock units were granted to Keithly Garnett. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&rsquo;s individual grant
agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 1,000,000
restricted stock units were granted to Amir Heshmatpour. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Nasim Shomali. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 750,000
restricted stock units, subject to adjustment, were granted to Dr. Sikirat Iyabo Tinubu-Karch, M.D. The forgoing restricted stock units
will vest upon certain financial metrics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Richard Nanula. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock units will vest one hundred percent (100%)
seven months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">With respect to that potion of the aforementioned restricted stock units that vest based upon performance criteria, the Board determined that it would be to the competitive advantage and interest of the Company and its stockholders to grant an award of restricted stock units the vesting of which will be predicate on certain performance metrics being met as a whole, as an inducement to remain in the service of our Company and as an incentive for increased efforts during such service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The number of restricted stock units issued with performance criteria vesting metrics that are ultimately vested with respect to each grantee will depend upon the achievement of such performance metrics, taken as a whole, as set forth in each individual grant agreement. The actual number of such restricted stock units vested with respect to each grantee will be determined at meetings of the Compensation Committee of the Board (the &ldquo;Committee&rdquo;) to be held semi-annually following the completion of the six month period ended June 30 and the year ended December 31 at which time the Committee will certify whether it believes in its sole discretion that sufficient performance criteria have been satisfied to justify the vesting, in whole or in part, of such restricted stock units. The Committee may certify in its sole discretion that all, none or a percentage of such performance based grants should be deemed vested and the grantee will acknowledge that certification shall be binding and non-appealable and that he/she shall have no legal right to contest such certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Committee is permitted to waive any vesting conditions applicable to any stock award or grant of restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_013"></A>PRINCIPAL SHAREHOLDERS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following table sets forth information with respect to the beneficial ownership of our shares as of January __, 2024 by: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each named executive officer;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and director nominees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our directors, director nominees and executive officers as a group; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person or entity known by us to own beneficially more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Applicable percentage ownership before the offering is based on 16,560,000 shares of common stock outstanding. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60 days of January __, 2024. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o NeOnc Technologies Holdings, Inc., 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90069:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name and Address of Beneficial Owner</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> shares<BR> beneficially<BR> owned</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage<BR> of shares<BR> beneficially<BR> owned <BR> before <BR> Offering</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage <BR> of shares <BR> beneficially <BR> owned after <BR> Offering</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Directors, Director Nominees and Executive Officers:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 67%; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Thomas C. Chen, M.D., Ph.D.<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">2,839,321</TD>
    <TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP>&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">17.15</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD> </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Patrick Walters<SUP>(3)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">587,905</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Keithly Garnett<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Amir Heshmatpour<SUP>(5)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">4,950,000</TD>
    <TD STYLE="text-align: left"><SUP>(6)</SUP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">29.89</TD>
    <TD STYLE="text-align: left">%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">%</TD> </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Nasim Shomali<SUP>(7)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Sikirat Iyabo Tinubu-Karch, M.D.<SUP>(8)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Richard Nanula<SUP>(9)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Victoria Medvec, Ph.D.<SUP>(10)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> All executive
    officers, directors and director nominees as a group (8 persons) </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 8,377,226 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 50.59 </TD>
    <TD STYLE="text-align: left"> % </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other 5% of greater shareholders:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <FONT STYLE="font-size: 10pt">Neucen
    Biomedical Co. LTD<SUP>(11)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 888,148 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 5.36 </TD>
    <TD STYLE="text-align: left"> % </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 25%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">January 2024, 800,000 restricted stock units were
    granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock units will be time vested; one-third (1/3) will vest
    seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1) year
    period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
    the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&rsquo;s individual grant
    agreement.</FONT> </TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents shares of our common stock held of record by TR Chen Third Family Limited Partnership over which Dr. Chen and Dr. Chen&rsquo;s spouse, Rosa Chen, exercise sole voting and investment control. The address of TR Chen Third Family Limited Partnership is c/o NeOnc Technologies Holding, Inc., 8335 Sunset Blvd., Suite 240, Los Angeles CA 90069.</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 300,000 restricted stock units were granted to
    Patrick Walters. Two-thirds of such restricted stock units will be time vested ; one-third (1/3) will vest seven months after the
    effective date of this offering and one-third will vest in equal monthly installments over a one (1) year period commencing on the
    eighth month from the effective date of this offering. The remaining one-third will be performance-based, the vesting of which will
    be predicate on certain performance metrics being met as set forth in Mr. Walter&rsquo;s individual grant agreement.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">On January 2024, 360,000 restricted stock units were granted to
    Keithly Garnett. Two-thirds of such restricted stock units will be time vested; one-third (1/3) will vest seven months after the
    effective date of this offering and one-third will vest in equal monthly installments over a one (1) year period commencing on the
    eighth month from the effective date of this offering. The remaining one-third will be performance-based, the vesting of which will
    be predicate on certain performance metrics being met as set forth in Mr. Garnett&rsquo;s individual grant agreement.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">(5)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 1,000,000 restricted stock units were granted to
    Amir Heshmatpour. The forgoing restricted stock units will vest one hundred percent (100%) seven months following the effective date
    of this offering.</FONT> </TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes (i) 3,712,500 shares of our common stock held of record by AFH Holding and Advisory, LLC, of which Mr. Heshmatpour is the sole member and over which he has sole voting and investment control; (ii) 550,000 shares of our common stock held of record by KIG LLC of which Mr. Heshmatpour&rsquo;s spouse, Kathy Heshmatpour, exercises sole voting and investment control; (iii) 275,000 shares held by Angelina Heshmatpour, the minor daughter of Mr. Heshmatpour, (iv) 275,000 shares held by Amir Heshmatpour, and (v) 137,500 shares held by Amir &amp; Kathy Heshmatpour Family Fund. The address of AFH Holding and Advisory, LLC is c/o NeOnc Technologies Holding, Inc., 8335 Sunset Blvd., Suite 240, Los Angeles CA 90069.</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px"> <FONT STYLE="font-size: 10pt">(7)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 3,750 restricted stock units were granted to Nasim
    Shomali. &nbsp;The forgoing restricted stock units will vest one hundred percent (100%) seven months following the effective date
    of this offering.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">(8)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 750,000 restricted stock units, subject to adjustment,
    were granted to Dr. Sikirat Iyabo Tinubu-Karch, M.D. The forgoing restricted stock units will vest upon certain financial metrics.
    </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">(9)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 3,750 restricted stock units were granted to Richard
    Nanula. The forgoing restricted stock units will vest one hundred percent (100%) seven months following the effective date of this
    offering.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">(10)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">In January 2024, 3,750 restricted stock units were granted to Dr.
    Victoria Medvec, Ph.D. The forgoing restricted stock units will vest one hundred percent (100%) seven months following the effective
    date of this offering.</FONT> </TD></TR>
  </TABLE>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px"> <FONT STYLE="font-size: 10pt">(11)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Reflects the shares of common stock held by Neucen Biomedical Co.
    LTD, of which Ming Biomed. Co. Ltd, Dr. Thomas C. Chen, Austin Lin, Paul Yang and OP Nano Pharm Co. Ltd. own over a majority of the
    ownership interest. Dr. Thomas C. Chen owns approximately 5% of the ownership interest of Neucen Biomedical Co. LTD. The address
    of Neucen Biomedical Co. LTD is 5-1F, No. 88, Sec. 2, Chong-Qing N. Rd., Taipei 10345, Taiwan.</FONT> </TD></TR>
  </TABLE>
<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_014"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than as disclosed below, and except for the compensation arrangements and regular salary and bonus payments made to our directors and officers in the ordinary course of business as described in &ldquo;<I>Executive Compensation</I>,&rdquo; there have been no transactions since January&nbsp;1, 2021, or any currently proposed transaction or series of similar transactions to which our company was or is to be a party, in which the amount involved exceeds $120,000 and in which any current or former director or officer of our company, any 5% or greater shareholder of our company or any member of the immediate family of any such persons had or will have a direct or indirect material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Letter of Intent &#8211; AFH Holdings and Advisory, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;19, 2022, NeOnc Technologies, Inc. entered into an engagement agreement with AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;). Amir Heshmatpour is the sole member and managing director of AFH and a member of NeOnc&rsquo;s Board of Directors. AFH was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing. AFH was retained to assist NeOnc Technologies, Inc. with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering, and earned $500,000 during the nine months ended September 30, 2023. AFH agreed to advance costs of up to $500,000 for such professionals on our behalf to be to be paid off with proceeds of the short term loan provided to us by HCWG LLC. As of September 30, 2023, no amounts were outstanding further to such agreement. NeOnc Technologies, Inc. also agreed to effect a share exchange with NeOnc Technologies Holdings, Inc., a special purpose entity substantially beneficially owned by Amir Heshmatpour and his affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&nbsp;7, 2023, NeOnc Technologies, Inc. entered into a Share Exchange Agreement (the &ldquo;Share Exchange&rdquo;) with NeOnc Technologies Holdings, Inc., whereby all of the shareholders of NeOnc Technologies, Inc. exchanged their stock in NeOnc Technologies, Inc. for a total of 10,500,000 shares of common stock in NeOnc Technologies Holdings, Inc. As a result, all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. At the consummation of this transaction, Amir Heshmatpour, AFH, and their affiliated entities, individuals, or assignees owned an aggregate of 34.4% of the fully diluted issued and outstanding common shares of NeOnc Technologies Holdings, Inc. For the year ended December 31, 2022, NeOnc Technologies Holdings, Inc. had no operations or assets other than cash paid by its shareholders for their shares ($450 in the aggregate) and liabilities of $50,000 pertaining to an amount owing to Mr. Heshmatpour for a professional retainer paid by him on behalf of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NeOnc Technologies, Inc. agreed to retain AFH as an exclusive advisor on all financing and mergers and acquisitions for a period of two (2) years from the closing of a public offering. Further to the advisory arrangement, AFH shall be paid in cash an aggregate fee in an amount equal to 2% of the post-money valuation of NeOnc Technologies Holdings, Inc. immediately after the consummation of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder advances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodically certain of our shareholders have advanced us funds to support operations under informal loan arrangements (the &ldquo;Shareholder Advances&rdquo;). These Shareholder Advances bear no interest and have no specified maturity date. There were Shareholder Advances outstanding totaling $0 and $10,000 as of December&nbsp;31, 2022 and 2021, respectively. During the year ended December&nbsp;31, 2022, we repaid all outstanding Shareholder Advances of $10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note payable &#8211; Chairman of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&nbsp;18, 2021, we entered into a loan agreement with the Chairman with a principal amount of $250,000 (the &ldquo;Chairman Note&rdquo;). The Chairman Note bore no interest and was payable when we received funding in excess of $1,000,000. We received funding in excess of $1,000,000 during the year ended December&nbsp;31, 2022, at which time the Chairman Note was repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances from Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have periodically received cash advances from the Chairman or has had certain costs incurred USC on our behalf paid for by the Chairman. These advances were non-interest bearing and had no stated maturity. At December&nbsp;31, 2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, we repaid in cash $700,000 of such advances to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022. The fair value of the common stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891 was recorded as interest expense in the statement of operations for the year ended December&nbsp;31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions with USC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&nbsp;9, 2009, we entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related to the use of monoterpenes as a solvent, specifically perillyl alcohol. This technology is the basis of the current products under development by us. We agreed to issue USC 560,000 additional shares of our common stock and issued such shares in October 2023. Additionally, pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC 117,236 shares of common stock, (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) has paid and will continue to pay annual maintenance royalties of: $5,000 due January&nbsp;1, 2011, $5,000 due January&nbsp;1, 2012, $10,000 due January&nbsp;1, 2013, and $20,000 due January&nbsp;1 thereafter. We have not paid any earned royalties date, since no products are being sold using such technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &ldquo;Restated Agreement&rdquo;). The Restated Agreement addressed and clarified certain reporting obligations of the Company&nbsp;<FONT STYLE="background-color: white">under the</FONT>&nbsp;license agreement with USC dated March 9, 2009, and addressed&nbsp;<FONT STYLE="background-color: white">certain financial and other obligations, defaults, and deficiencies in connection with the Company&rsquo;s performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Restated Agreement, the Company recorded additional license fees in the amount of $230,000 to cure deficiencies in the existing license agreement related to unpaid sub-license fees within license expense in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2023, and accrued within accounts payable &ndash; related parties in the accompanying condensed consolidated balance sheet as of September 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also utilize laboratory services from USC. We have incurred approximately $442,000 and $372,000 of research and development-related costs from USC for the years ended December&nbsp;31, 2022 and 2021, respectively. We incurred approximately $39,666, $20,100 and $12,000 of patent maintenance and legal-related expenses for the nine months ended September 30, 2023 and the years ended December&nbsp;31, 2022 and 2021, respectively. At September 30, 2023, and at December&nbsp;31, 2022 and 2021, we owed USC approximately $47,344, $75,600 and $51,000, respectively. From time to time, we have been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty at USC to satisfy the amounts due from us to USC. Such amounts deducted from the Chairman&rsquo;s USC faculty compensation are recorded as Advances from the Chairman on December&nbsp;31, 2022 and 2021. Additionally, included in accounts payable-related parties at September 30, 2023 and at December&nbsp;31, 2022 and 2021 are approximately $1,041,383, $800,700 and $365,000, respectively, due to the Chairman related to such deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the nine months ended September 30, 2023 we incurred $500,904, for compensation to the Chairman and two consultants who were also shareholders. For the years ended December&nbsp;31, 2022 and 2021, we incurred $0 and $150,000 for compensation to the Chairman and a consultant. who is also a shareholder. This compensation is recorded in the statement of operations as part of general and administrative expenses. The amount accrued for the Chairman and the consultants were $913,404, $412,500 and $462,000 as of September 30, 2023, December&nbsp;31, 2022 and 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-term loans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&nbsp;2022, we entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022 from a Martin Schmieg, a former executive officer of NeOnc Technologies, Inc. The loan was paid off in December&nbsp;2022. Interest expense paid related to this loan for the year ended December&nbsp;31, 2022 was approximately $1,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2023, we entered into a non-interest bearing, non-convertible promissory note with HCWG LLC. HCWG LLC is owned 31.25% by Amir Heshmatpour, 18.75% by Dr. Thomas Chen, 18.75% by Dr. Alan Chiang (a former director), 15.625% by Patrick Walters and 15.625% by The Hilkiah Group LLC (an entity wholly-owned by Keithly Garnett, our Chief Financial Officer). Borrowings under the note do not bear interest and carry a 50% (or 1 times amounts borrowed) original issue discount (&ldquo;OID&rdquo;) on principal. The note initially allowed for maximum borrowings of $1,600,000 (amended on June 26, 2023, to increase the maximum borrowings to $2,800,000, on July 26, 2023 to increase the maximum borrowings to $4,000,000, on October 19, 2023 to increase the maximum borrowings to $5,000,000, and again on December&nbsp;4, 2023 to increase the maximum borrowings to $10,000,000), which may be drawn upon at any time during the term of the note. All outstanding principal is payable at the earlier of the IPO date or December&nbsp;4, 2024 (the &ldquo;Maturity Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have the option to prepay this note with no penalties at any time and prior to the Maturity Date in an amount equal to the sum of: (A) the then principal balance of this note plus (B) all other amounts, costs, and expenses then due in respect of this note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2023, we had received $3,970,109 under the bridge loan. Accretion of the OID for the nine months ended September 30, 2023, amounted to approximately $1,374,084. A summary of the bridge loan activity through September 30, 2023 is summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine months ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,<BR> 2023</B></P></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Bridge loan payable &ndash; draw downs</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">3,970,109</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">OID on draw downs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,970,109</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less repayments of draw downs</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,199,588</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Balance June 30, 2023</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,740,630</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">At<BR> September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Principal outstanding</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">6,740,630</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less unrecognized OID</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,596,026</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Total</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,604</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December&nbsp;31, 2021 NeOnc Technologies, Inc. issued stock options pursuant to its 2013 Stock Option Plan for 7,250,000 shares of common stock to directors and advisors and, in connection with the Chairman Note, 250,000 options to the Dr. Thomas Chen at an exercise price of $0.66 per share. On December&nbsp;31, 2022, all of the option holders converted the then aggregate outstanding options to acquire 18,705,451 shares into 9,150,051 shares of common stock pursuant to the cashless exercise provision of the 2013 Option Plan. A portion of the outstanding options (those with an exercise price of $1.25 per share) were repriced to an exercise price of $1.00 immediately before the cashless exercise. This modification of the stock option resulted in a charge to share-based compensation of $182,243, which is recorded within general and administrative expenses on the statement of consolidated operations during the year ended December&nbsp;31, 2022. The remaining outstanding stock options to acquire 166,060 shares of common stock were cancelled during 2023 per cancellation agreements. The 2013 Stock Option Plan has been terminated and no other options remain outstanding under the plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 800,000
restricted stock units were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock units will be time vested;
one-third (1/3) will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments
over a one (1) year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&rsquo;s individual grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 300,000
restricted stock units were granted to Patrick Walters. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&rsquo;s individual grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 360,000
restricted stock units were granted to Keithly Garnett. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&rsquo;s individual grant
agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> In
January 2024, 1,000,000 restricted stock units were granted to Amir Heshmatpour. The forgoing restricted stock units will vest one hundred
percent (100%) seven months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> In
January 2024, 3,750 restricted stock units were granted to Nasim Shomali. The forgoing restricted stock units will vest one hundred percent
(100%) seven months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> In
January 2024, 750,000 restricted stock units, subject to adjustment, were granted to Dr. Sikirat Iyabo Tinubu-Karch, M.D. The forgoing
restricted stock units will vest upon certain financial metrics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> In
January 2024, 3,750 restricted stock units were granted to Richard Nanula. The forgoing restricted stock units will vest one hundred
percent (100%) seven months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> In
January 2024, 3,750 restricted stock units were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock units will vest one
hundred percent (100%) seven months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Collaboration and License Agreement between NeOnc and Orient EuroPharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&nbsp;8, 2013, we entered into a Collaboration and License Agreement with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;), which is partially owned by Alan Chiang, a former director, pursuant to which NeOnc licensed OEP the right to commercialize NEO100. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License Agreement by and between NeOnc Technologies and Neucen Biomedical Co., Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;5, 2015, we previously entered into a License Agreement with Neucen Biomedical Co. Ltd. (&ldquo;Neucen&rdquo;), which is owned in part by the spouse of Dr. Alan Chiang and Thomas Chen, pursuant to which NeOnc licensed to Neucen the right to commercialize NEO212. We terminated this License Agreement on May&nbsp;30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_015"></A>DESCRIPTION OF SECURITIES</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following description summarizes the most important terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws that will become effective immediately prior to the completion of this offering. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to the Registration Statement of which this prospectus is a part, and by the applicable provisions of Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Currently and upon filing of our amended and restated certificate of incorporation, our authorized capital stock consists of 110,000,000 shares of capital stock, of which (i) 100,000,000 shares are common stock with a par value $0.0001 per share and (ii) 10,000,000 shares are preferred stock with a par value of&thinsp;$0.0001 per share. All of our authorized shares of preferred stock will be undesignated. As of January__, 2024, there were 16,560,000 shares of common stock and no shares of preferred stock issued and outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Rights</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock are entitled to one vote per share on all matters to be voted upon by the shareholders, including the election of directors. Such holders are not entitled to vote cumulatively for the election of directors. Our amended and restated certificate of incorporation that will become effective immediately prior to the completion of this offering establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only the directors in one class will be subject to election by a plurality of the votes cast at each annual meeting of our shareholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, shareholder notices, actions by written consent, and exclusive jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to preferences that may be applicable to any outstanding preferred stock, our common shareholders are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available for that purpose. We have never declared or paid any cash dividends on our capital stock. We currently expect to retain future earnings, if any, to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future. See the section titled &ldquo;<I>Dividend Policy</I>&rdquo; for further information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation, dissolution or winding up, our common shareholders are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No Preemptive or Similar Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shareholders have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon filing of our amended and restated certificate of incorporation that will become effective immediately prior to the completion of this offering, our board of directors is authorized, without action by the shareholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more series and to designate the powers, preferences and rights of each series, which may be greater than the rights of the common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of the common stock until the board of directors determines the specific rights of the holders of such preferred stock. However, the effects might include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing dividend rights of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting the voting power of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing the liquidation rights of the common stock; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying or preventing a change in control of us without further action by the shareholders</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, NeOnc Technologies, Inc. issued a $50,000 convertible note to a shareholder due August&nbsp;30, 2023 (&ldquo;Note&rdquo;). The Note bears interest at 2% per annum and is convertible. The Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by us in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering, of equity securities by us to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets tous. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of the Note plus accrued interest by (ii) the Financing Transaction conversion price, which shall be equal to 75% of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest of the Note shall automatically be converted, without further action on the part of the noteholder or us, into the class and series of stock issued by us, at the closing of an initial public offering. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of the Note plus accrued interest by (ii) the initial public offering conversion price, which shall be equal to 75% of the price paid for one share of Conversion Stock by the investors in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Takeover Provisions<FONT STYLE="font-weight: normal"> </FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our shareholders do not have cumulative voting rights, our shareholders holding a majority of the outstanding shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and our amended and restated bylaws, each to be effective immediately prior to the closing of this offering, will provide for shareholder actions at a duly called meeting of shareholders. A special meeting of shareholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our amended and restated bylaws will establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described above in &ldquo;<I>Management&#8212;Corporate Governance,&rdquo;</I> in accordance with our amended and restated certificate of incorporation to be filed in connection with this offering, our board of directors will be divided into three classes with staggered three-year terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing provisions will make it more difficult for our existing shareholders to replace our Board of Directors as well as for another party to obtain control of us by replacing our Board of Directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These provisions are intended to enhance the likelihood of continued stability in the composition of our Board of Directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;203 of the Delaware General Corporation Law</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested shareholder for a period of three years after the date that such shareholder became an interested shareholder, with the following exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">upon closing of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested shareholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the shareholders, and not by written consent, by the affirmative vote of at least 66 2&#8725;3% of the outstanding voting stock that is not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203 defines business combination to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any merger or consolidation involving the corporation and the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested shareholder; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the receipt by the interested shareholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203 defines an &ldquo;interested shareholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested shareholder status did own, 15% or more of the outstanding voting stock of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive forum for adjudication of disputes provision which limits the forum to the Delaware Court of Chancery for certain shareholder litigation matters actions against us, which may limit an investor&rsquo;s ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our amended and restated bylaws, that will become effective immediately prior to the completion of this offering, dictate that, unless we consent in writing to the selection of an alternative forum, the Delaware Court of Chancery (or, if the Delaware Court of Chancery does not have jurisdiction, the federal district court for the State of Delaware) is, to the fullest extent permitted by law, the sole and exclusive forum for certain actions including derivative action or proceeding brought on our behalf; an action asserting a breach of fiduciary duty owed by an officer, director, employee or to the shareholders of our company; any claim arising under Delaware corporate law, our certificate of incorporation or our bylaws; and any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of our company shall be deemed to have notice of and consented to the provisions of our amended and restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, this provision of our amended and restated bylaws will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated thereunder. We note, however, that Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Delaware corporation is allowed to mandate in its corporate governance documents a chosen forum for the resolution of state law-based shareholder actions, derivative suits and other intra-corporate disputes. With respect to such state law claims, our management believes limiting state law based claims to Delaware will provide the most appropriate outcomes as the risk of another forum misapplying Delaware law is avoided, Delaware courts have a well-developed body of case law and limiting the forum will preclude costly and duplicative litigation and avoids the risk of inconsistent outcomes. Additionally, Delaware Chancery Courts can typically resolve disputes on an accelerated schedule when compared to other forums.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The choice of forum provisions contained in our amended and restated bylaws may limit a shareholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company or any of our directors, officers, other employees or shareholders, which may discourage lawsuits with respect to such claims. Alternatively, the enforceability of similar choice of forum provisions in other issuers&rsquo; bylaws and certificates of incorporation has been challenged in legal proceedings, and it is possible that in connection with any applicable action brought against our company, a court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. As a result, we could incur additional costs associated with resolving such actions in other jurisdictions, which could harm our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have appointed VStock Transfer LLC, 18 Lafayette Pl Woodmere, NY 11598, telephone: (212) 828-8436, as the transfer agent for our common stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol and Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering, we have applied to have our shares of common stock listed on the Nasdaq Capital Market under the symbol &ldquo;NTHI&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_016"></A>SHARES ELIGIBLE FOR FUTURE SALE</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before the closing of this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to raise equity capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Based on our shares outstanding as of January__, 2024, upon the closing of this offering, a total of ______shares of common stock will be outstanding. Of these shares, all of the common stock sold in this offering by us will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by &ldquo;affiliates,&rdquo; as that term is defined in Rule&nbsp;144 under the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remaining shares of common stock will be, and shares of common stock subject to stock options will be on issuance, &ldquo;restricted securities,&rdquo; as that term is defined in Rule&nbsp;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules&nbsp;144 or 701 under the Securities Act, which are summarized below. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule&nbsp;904 of Regulation S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the lock-up agreements described below and the provisions of Rule&nbsp;144 or Regulation S under the Securities Act, as well as our insider trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&nbsp;144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;144 as currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible shareholder is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule&nbsp;144, subject to compliance with the public information requirements of Rule&nbsp;144. To be an eligible shareholder under Rule&nbsp;144, such shareholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule&nbsp;144, subject to the expiration of the lock-up agreements described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such shareholders may sell a number of shares that does not exceed the greater of:</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of shares of common stock then outstanding, which will equal approximately _____ shares immediately after this offering; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading volume of our common stock on the Nasdaq Capital Market during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to such sale.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales under Rule&nbsp;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&nbsp;701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;701 generally allows a shareholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule&nbsp;144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule&nbsp;144. Rule&nbsp;701 also permits affiliates of our company to sell their Rule&nbsp;701 shares under Rule&nbsp;144 without complying with the holding period requirements of Rule&nbsp;144. All holders of Rule&nbsp;701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule&nbsp;701, subject to the expiration of the lock-up agreements described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form S-8 Registration Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to file one or more registration statements on Form S-8 under the Securities Act with the SEC to register the offer and sale of shares of our common stock that are issuable under our 2023 Plan. This registration statement will become effective immediately on filing. Shares covered by this registration statement will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described below, and Rule&nbsp;144 limitations applicable to affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, our executive officers and directors, and beneficial owners of over one percent of our outstanding common stock have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired, without the prior written consent of the representative, for a period of 180 days from the date of this prospectus. These agreements are described in &ldquo;<I>Underwriting&mdash;Lock-Up Agreements.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_017"></A>UNDERWRITING</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering our common stock described in this prospectus through the underwriters named below. Loop Capital Markets LLC, or Loop or the representative, is acting as representative of the underwriters. We have entered into an underwriting agreement with the representative. Subject to the terms and conditions of the underwriting agreement, the underwriters have agreed to purchase, and we have agreed to sell to the underwriters, the number of common stock listed next to its name in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number&nbsp;of<BR> Shares</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%"><FONT STYLE="font-size: 10pt">Loop Capital Markets LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Maxim Group LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Brookline Capital Markets, a division of Arcadia Securities, LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriters are offering the shares of our common stock subject to their acceptance of the shares of our common stock from us and subject to prior sale. The underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the shares of our common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of our common stock if any such shares of our common stock are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with this offering, the underwriters or securities dealers may distribute prospectuses electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have granted to the underwriters an option exercisable not later than 45 days after the date of this prospectus to purchase up to a number of additional shares of our common stock equal up to 15% of the shares of common stock at the public offering price per share set forth on the cover page hereto less the underwriting discounts and commissions. The underwriters may exercise the option solely to cover overallotments, if any, made in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting Discounts and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares sold by the underwriters to the public will initially be offered at the initial offering price set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. The representative may offer the shares through one or more of their affiliates or selling agents. If all the shares are not sold at the initial public offering price, the representative may change the offering price and the other selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to pay the underwriters a cash fee equal to eight percent (8.0%) of the aggregate gross proceeds from the sale of the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the underwriting discount and commission to be paid to the underwriters by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per Share</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR> with Full<BR> Exercise of<BR> Overallotment</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting discount to be paid to the underwriters by us</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds to us (before expenses)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to pay the representative&rsquo;s out-of-pocket accountable expenses, including the representative&rsquo;s legal fees, up to a maximum amount of $375,000 if this offering is completed. We have paid $25,000 to the underwriters as an advance to be applied towards out-of-pocket expenses, or the Advance. Any portion of the Advance shall be returned back to us to the extent not actually incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that the total expenses of the offering payable by us, not including the underwriting discount, will be approximately $___. We expect the net proceeds from this offering to be approximately $__ million after deducting $_____in underwriting commissions and $_____in our other estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. If we are unable to provide this indemnification, we have agreed to contribute to payments the underwriter may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our directors and officers and any other holders of one percent (1.0%) or more of our outstanding common stock as of the effective date of the registration statement which this prospectus forms a part of (and all holders of securities exercisable for or convertible into one percent (1.0%) or more of our common stock) have entered into customary &ldquo;lock-up&rdquo; agreements in favor of Loop pursuant to which such persons and entities have agreed, for a period of six (6) months after the effective date of the registration statement related to this offering, that they shall neither offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any our securities without Loop&rsquo;s prior written consent, including the issuance of shares of common stock upon the exercise of currently outstanding options approved by Loop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisory Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has separately retained Maxim Group LLC (&ldquo;Maxim&rdquo;) as a financial advisor in connection with this offering. Such financial advisory services are separate from those services to be performed by Maxim as an underwriter in connection with this offering. The Company has agreed to pay Maxim a separate cash fee equal to three-quarters of one percent (0.75%) of the gross proceeds from the sale of the common stock in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriter and its affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No Public Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to this offering, there has not been a public market for our securities in the U.S. and the public offering price for our common stock will be determined through negotiations between us and the underwriter. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriter believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We offer no assurances that the initial public offering price will correspond to the price at which our common stock will trade in the public market subsequent to this offering or that an active trading market for our common stock will develop and continue after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have applied to list our common stock on the Nasdaq Capital Market, under the symbol &ldquo;NTHI&rdquo; There can be no assurance that we will be successful in listing our common stock on the Nasdaq Capital Market.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A prospectus in electronic format may be made available on websites or through other online services maintained by the underwriter of this offering, or by their affiliates. Other than the prospectus in electronic format, the information on any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price Stabilization, Short Positions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with this offering, the underwriter may engage in activities that stabilize, maintain or otherwise affect the price of our common stock during and after this offering, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stabilizing transactions;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases to cover positions created by short sales;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of penalty bids; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">syndicate covering transactions.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing transactions consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price of our common stock while this offering is in progress. Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. These transactions may also include making short sales of our common stock, which involve the sale by the underwriter of a greater number of common stock than they are required to purchase in this offering and purchasing common stock on the open market to cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo; which are short positions in an amount not greater than the underwriter&rsquo;s option to purchase additional shares referred to above, or may be &ldquo;naked short sales,&rdquo; which are short positions in excess of that amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriter may close out any covered short position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriter will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naked short sales are short sales made in excess of the over-allotment option. The underwriter must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchased in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriter a portion of the underwriting
discount received by it because the representative Loop has repurchased shares sold by or for the account of that underwriter in stabilizing
or short covering transactions.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These stabilizing transactions, short sales, purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result of these activities, the price of our common stock may be higher than the price that otherwise might exist in the open market. The underwriter may carry out these transactions on the Nasdaq Capital Market, in the over-the-counter market or otherwise. Neither we nor the underwriter make any representation or prediction as to the effect that the transactions described above may have on the price of the shares. Neither we, nor the underwriter make any representation that the underwriter will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no public market for our common stock. The initial public offering price will be determined by negotiation
between us and Loop. The principal factors to be considered in determining the initial public offering price include, but not limited
to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information set
    forth in this prospectus and otherwise available to Loop;</FONT> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history and prospects and the history and prospects for the industry in which we compete;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present financial performance;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our prospects for future earnings and the present state of our development;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general condition of the securities market at the time of this offering;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market prices of, and demand for, publicly traded shares of generally comparable companies; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed relevant by the underwriter and us.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated public offering price range set forth on the cover page of this preliminary prospectus is subject to change as a result of market conditions and other factors. Neither we nor the underwriter can assure investors that an active trading market will develop for our common stock or that the common stock will trade in the public market at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriter and its respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and its affiliates may from time to time in the future engage with us and perform services for us or in the ordinary course of their business for which they will receive customary fees and expenses. In the ordinary course of their various business activities, the underwriter and its respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of us. The underwriter and its respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of these securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in these securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the common stock the possession, circulation or distribution of this prospectus or any other material relating to us or the common stock in any jurisdiction where action for that purpose is required. Accordingly, the common stock may not be offered or sold, directly or indirectly, and neither this prospectus nor any other material or advertisements in connection with the common stock may be distributed or published, in or from any country or jurisdiction except in compliance with any applicable laws, rules and regulations of any such country or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Restrictions</B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B>. The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 <I>Prospectus Exemptions</I> or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31 103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to section&nbsp;3A.3 of National Instrument 33 105 <I>Underwriting Conflicts</I> (NI 33 105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European Economic Area. </I></B>In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &ldquo;Relevant Member State&rdquo;) an offer to the public of any securities may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any securities may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by us or any underwriters of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United Kingdom.</I></B> Each underwriter has represented and agreed that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (the FSMA)) received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Switzerland. </I></B>The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the <I>SIX</I>) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither this document nor any other offering or marketing material relating to the offering, or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (<I>CISA</I>). Accordingly, no public distribution, offering or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does not extend to acquirers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Australia. </I></B>No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (<I>ASIC</I>), in relation to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the <I>Corporations Act</I>) and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any offer in Australia of the securities may only be made to persons (the <I>Exempt Investors</I>) who are &ldquo;sophisticated investors&rdquo; (within the meaning of section&nbsp;708(8) of the Corporations Act), &ldquo;professional investors&rdquo; (within the meaning of section&nbsp;708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section&nbsp;708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section&nbsp;708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice to Prospective Investors in the Cayman Islands.</I></B> No invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taiwan</I></B>. The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice to Prospective Investors in Hong Kong</I></B>. The contents of this prospectus have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. Please note that (i) our securities may not be offered or sold in Hong Kong, by means of this prospectus or any document other than to &ldquo;professional investors&rdquo; within the meaning of Part I of Schedule&nbsp;1 of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) (SFO) and any rules made thereunder, or in other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong) (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO, and (ii) no advertisement, invitation or document relating to our securities may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere) which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the SFO and any rules made thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice to Prospective Investors in the People&rsquo;s Republic of China</I></B>. This prospectus may not be circulated or distributed in the PRC and the shares may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan and the special administrative regions of Hong Kong and Macau.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice to prospective investors in Japan.</I></B> The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &ldquo;resident&rdquo; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice to prospective investors in Israel.</I></B> In the State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728&mdash;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&ndash;1968, including, inter alia, if: (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors, or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&mdash;1968, subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&mdash;1968. We have not and will not distribute this prospectus supplement or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#8212;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i) that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8212;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8212;1968 regarding Qualified Investors is applicable to it; (iii) that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#8212;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#8212;1968: (a) for its own account; (b) for investment purposes only; and (c) not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#8212;1968; and (v) that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&rsquo;s name, address and passport number or Israeli identification number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_018"></A>LEGAL MATTERS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Manatt, Phelps &amp; Phillips, LLP, Costa Mesa, California. Certain legal matters in connection with this offering will be passed upon for the underwriters by Loeb &amp; Loeb LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_019"></A>EXPERTS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of NeOnc Technologies, Inc as of December 31, 2022 and 2021 and for the years then ended, appearing in this prospectus have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, appearing elsewhere in this prospectus, and are included in reliance on the report of such firm given upon their authority as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A NAME="a_020"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also maintain a website at www.NeOncco.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 193 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; width: 90%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed Consolidated Financial Statements</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#c_002">Condensed Consolidated Balance Sheets as of September&nbsp;30, 2023 (Unaudited) and December&nbsp;31, 2022</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#c_003">Condensed Consolidated Statements of Operations for the nine months ended September&nbsp;30, 2023 and September&nbsp;30, 2022 (Unaudited)</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#c_004">Condensed Consolidated Statements of Changes in Shareholders&rsquo; Deficit for the nine months ended September&nbsp;30, 2023, and September&nbsp;30, 2022 (Unaudited)</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#c_005">Condensed Consolidated Statements of Cash Flows for the nine months ended September&nbsp;30, 2023 and September&nbsp;30, 2022 (Unaudited)</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#c_006">Notes to Condensed Consolidated Financial Statements</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6 &ndash; F-17</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 194; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c_002"></A>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed Consolidated Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">September&nbsp;30,</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top">Assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 76%; vertical-align: top">Cash</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">769</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">633,298</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred offering costs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">620,486</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Prepaid expenses and other</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">281,150</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">95,384</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Current Assets</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">902,405</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">728,682</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">902,405</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">728,682</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Liabilities and Shareholders&rsquo; Deficit</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,208,674</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">465,309</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable &ndash; related parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,318,727</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">876,284</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement payable</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">913,404</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">412,500</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred revenue</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock payable for license fee, at fair value</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,507,773</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Bridge loan &ndash; related party </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 4,144,604 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"> Note payable
    &ndash; related party, at fair value </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 50,000 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 50,000 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,243,182</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,304,093</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitments and contingencies</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&rsquo; Deficit:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares were issued and outstanding as of September 30, 2023 and December 31, 2022</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Common stock, $0.0001 par value, 100,000,000 shares authorized; 16,000,000 and 10,500,000 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,600</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,050</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid in capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">22,212,355</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">22,212,455</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,554,732</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(23,788,916</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo; Deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,340,777</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,575,411</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&rsquo; Deficit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">902,405</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">728,682</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c_003"></A>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed Consolidated Statements of Operations (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the<BR> nine months ended</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR> 2022</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Revenues:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; width: 76%">Revenue</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating Expenses:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">989,239</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">766,260</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Legal and professional</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,586,661</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">319,294</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">General and administrative</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,047,771</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">53,479</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advisory fee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement expense</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">License expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,737,773</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Operating Expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,461,444</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,971,283</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss From Operations</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(7,390,982</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,971,283</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other Expense:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Change in fair value of note payable
    &ndash; Chairman of the Board </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> (9,000 </TD>
    <TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Interest expense</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,374,834</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,765,816</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,980,283</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">Loss per share:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt"> Net loss
    per share &ndash; basic and diluted </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.62 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.22 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding during the period- basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,044,444</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,853,126</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c_004"></A>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed Consolidated Statements of Changes in Shareholders&rsquo; Deficit (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Additional</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Total</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Paid In</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Shareholders&rsquo;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; padding-left: 0.125in; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Capital</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Deficit</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Deficit</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold; vertical-align: top"> Balance
    &ndash; January 1, 2022 </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right"> 8,749,405 </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 875 </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 18,124,938 </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> (20,742,159 </TD>
    <TD STYLE="width: 1%; text-align: left"> ) </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> (2,616,346 </TD>
    <TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">190,508</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">19</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,299,981</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,300,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Share based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,980,283</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,980,283</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Balance
    &ndash; September 30, 2022 </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 8,939,913 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 894 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 20,257,169 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (22,722,442 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,464,379 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"> Balance &ndash;
    January 1, 2023 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 10,500,000 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 1,050 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 22,212,455 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> (23,788,916 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> (1,575,411 </TD>
    <TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Share exchange</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,500,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">550</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(100</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">450</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,765,816</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,765,816</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top"> Balance
    &ndash; September 30, 2023 </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 16,000,000 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,600 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 22,212,355 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (32,554,732 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (10,340,777 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c_005"></A>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed Consolidated Statements of Cash Flows (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the<BR> Nine Months Ended</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR> 2022</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from operating activities:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(8,765,816</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(1,980,283</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left"> Change in fair value of note payable &ndash; Chairman
    of the Board </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 9,000 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left"> Increase in bridge loan &ndash; expenses paid by bridge
    loan provider on behalf of the Company </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 1,075,196 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left"> Accretion of original issue discount on bridge loan
    &ndash; related party </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> 1,374,084 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in">Share-based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">832,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Common stock payable for license fee, at fair value</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,507,773</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Prepaid expenses</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,905</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(12,000</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Accrued compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">500,904</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Litigation settlement payable</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">600,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Accounts payable</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,185,808</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">505,269</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">Net cash used in operating activities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,508,146</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(645,764</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from financing activities:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from related party loans</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,432,866</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">125,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of related party loans</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,199,588</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(250,000</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred offering costs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(358,111</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from sale of common stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">450</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,300,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Repayment of advances from the Chairman of the Board</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(450,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">Net cash provided by financing activities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">875,617</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">725,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net (decrease) increase in cash</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(632,529</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">79,236</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1pt"> Cash &ndash; beginning of period </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 633,298 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 25,034 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt"> Cash &ndash; end of period </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 769 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 104,270 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental disclosure of non-cash financing activities:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Original issue discount on bridge loan &ndash; related
    party </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 3,970,109 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Increase in bridge loan payable &ndash; prepaid and
    deferred offering costs paid directly by bridge loan provider on behalf of the Company </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 462,046 </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c_006"></A>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 1 &ndash; Description of Business and Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc Technologies, Inc. (&ldquo;NTI&rdquo;) was incorporated on April 13, 2005, as a California corporation. On April 7, 2023, NTI merged into NeOnc Technologies Holdings, Inc. (&ldquo;NTHI&rdquo; and the combined entities &ldquo;NeOnc&rdquo; or the &ldquo;Company&rdquo;). NTHI was incorporated January 5, 2023, as a Delaware Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc&nbsp;is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The Company&rsquo;s lead product, NEO100, commenced Phase 2a clinical trials in July of 2019 (which is still ongoing as of September 30, 2023), treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (&ldquo;FDA&rdquo;). The Company licensed the underlying technology from the University of Southern California. (&ldquo;USC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2023, the Company had cash totaling $769. For the nine months ended September 30, 2023, the Company has incurred a net loss of $8,765,816 and has an accumulated deficit of $32,554,732 at September 30, 2023. The Company has financed its working capital requirements to date primarily through the issuance of common stock, preferred stock, shareholder loans and a short-term bridge loan. The Company had the ability to draw approximately $30,000 on the bridge loan as of September 30, 2023 (see Note 4). Subsequent to September 30, 2023, the bridge loan was amended to allow for an additional $1,000,000 of borrowings (see Note 9). As of September 30, 2023, the Company is preparing for an initial public offering (&ldquo;IPO&rdquo;) of its common stock, however, there is no certainty that the IPO can be completed. The Company does not have sufficient available capital to fund operations for a period of twelve months from the issuance date of these financial statements. The Company will need to raise additional funding to complete the development of its products and commence the market launch, assuming regulatory approval is obtained. The Company does not know whether additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. These factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, the Company signed a Letter of Intent (&ldquo;LOI&rdquo;) with an investment advisory firm AFH Holdings and Advisory, LLC (&ldquo;AFH&rdquo;) to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&ldquo;NTHI&rdquo;) to facilitate future fundraising transactions (see Note 3). On April 7, 2023, the Company entered into share exchange agreements whereby all of the common shareholders of NTI exchanged all of their stock in NTI for a total of 10,500,000 shares of NTHI common stock in the share exchange (&ldquo;Share Exchange&rdquo;). At the consummation of the Share Exchange transaction, AFH and its affiliated entities, individuals, or assignees owned an aggregate of 34.4% (5,500,000 shares) of the fully diluted issued and outstanding common shares of the Company. AFH will also act as an investment advisor in future financing transactions and be able to appoint a majority of the Board of Directors of NTHI.&nbsp;Except for the completed exchange transaction described above, there is no assurance of consummation of any of the transactions contemplated by the LOI. There can be no assurance that a fundraising transaction can be completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other risks and uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to biopharmaceutical companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, and the uncertainty of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third-party suppliers and, in some cases, single-source suppliers. The Company&rsquo;s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions where the Company may license or sell its products. There can be no assurance that the Company&rsquo;s products will receive all required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There can be no assurance that the Company&rsquo;s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost with appropriate performance characteristics or that such products will be successfully marketed, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) was reported in Wuhan, China. The World Health Organization declared COVID-19 a &ldquo;Public Health Emergency of International Concern&rdquo; on January 30, 2020, and a global pandemic on March 11, 2020. In March 2020, individual states mandated &ldquo;stay-at-home orders,&rdquo; restricted access to hospitals, prohibited elective surgeries, and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on the Company&rsquo;s operational and financial performance will depend on future developments, including access to products, potential disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity of the COVID-19 outbreak.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 2 &ndash; Basis of Presentation and Summary of Significant Accounting Policies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements contained herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to SEC rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, the condensed consolidated financial statements reflect all normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results of interim periods and may not include all disclosures required by accounting principles generally accepted in the United States (&ldquo;GAAP&rdquo;). The information as of September&nbsp;30, 2023, and for the nine months ended September&nbsp;30, 2023, and September 30, 2022, is unaudited, whereas the condensed consolidated balance sheet as of December&nbsp;31, 2022, is derived from the Company&rsquo;s audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto included in the audited financial statements for the year ended December 31, 2022. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for any other interim period or for the year as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements and related notes to the condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in one segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company&rsquo;s financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, from time to time during the period covered by these financial statements, may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. For the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents include all cash balances on hand and highly liquid investments having original maturities of three months or less when purchased. At September 30, 2023 and December 31, 2022, the Company did not have any cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred offering costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&ldquo;SAB&rdquo;) Topic 5A &ldquo;Expenses of Offering&rdquo;. Offering costs consist principally of professional and registration fees incurred through the balance sheet dated September 30, 2023 that are related to the planned public offering of its securities (See Note 3). These costs have been capitalized and are expected to be recognized in equity upon the completion of the securities offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes payable </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to account for notes payable to a shareholder using the fair value option in accordance with the guidance contained in Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) 825-10-25. The fair value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities, unrecognized firm commitments, and written loan commitments. See Note 4 for additional information. The Company accounted for the fair value of the stock options issued in connection with the note payable to the Chairman of the Board (&ldquo;Chairman&rdquo;) as additional interest expense on the grant date, using the same methodology to determine the fair value of the stock option as discussed in the share-based compensation policy footnote below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Original Issue Discount (&ldquo;OID&rdquo;) to be earned under the bridge loan is recognized ratably over the term of each draw-down under the loan through the maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC Topic 820, &ldquo;<I>Fair Value Measurements and Disclosures</I>&rdquo; (&ldquo;ASC 820&rdquo;), defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company&rsquo;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s accounts payable approximates its fair value because of the short-term nature of these financial
instruments. The note payable &ndash; related party is reported at fair value as the Company elected the fair value option for such note
(see Note 4).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Level 1 &mdash; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree of judgment.</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Level 2 &mdash; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by the market through correlation or other means.</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Level 3 &mdash; Valuations based on unobservable inputs and significant to the overall fair value measurement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses of intellectual property (&ldquo;IP&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates intellectual property licensing agreements in accordance with ASC 808, <I>Collaborative Arrangements.</I> If the license to the Company&rsquo;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measurement of performance and related revenue recognition. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&rsquo;s license and collaboration agreements in Note 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones. The Company estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&rsquo;s control or the licensee&rsquo;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore, revenue recognized is constrained as management cannot assert that a revenue reversal would not be possible. The transaction price is then allocated to each performance obligation on a residual basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development milestones and any related constraints. The Company adjusts its estimate of the overall transaction price if necessary. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the adjustment period. To date, the Company has not recognized any milestone revenue resulting from any of its agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When performance obligations are not required of the Company or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reclassification of Prior Year Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Certain prior year balance sheet amounts have been reclassified to conform with the current year presentation. These reclassifications had no effect on the reported total assets, liabilities, and shareholders&rsquo; deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized point-in-time revenue of $70,462 and $0 for the nine months ended September 30, 2023 and 2022, respectively, for the sale/license of technology where the Company has no further performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors performing research, conducting clinical trials, and manufacturing drug supplies and materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock options and common shares to employees, non-employee consultants and non-employee members of our Board of Directors. The Company measures the compensation cost associated with all share-based payments based on the grant date fair values. The Company recognizes share-based compensation expense over the requisite service period of each award, which generally equals the vesting period, using the straight-line method for awards that contain only service conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option is estimated on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the Company&rsquo;s stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. For grants of stock options, the Company uses a blend of historical and implied volatility for similar companies in order to estimate the expected volatility assumption required in the Black-Scholes model. The Company&rsquo;s use of a blended volatility estimates in computing the expected volatility assumption for stock options is based on its belief that while the implied volatility is representative of expected future volatility, the historical volatility over the expected term of the award is also an indicator of expected future volatility. The expected term of stock options granted is estimated using historical experience. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the Company&rsquo;s stock options. The dividend yield assumption is based on the Company&rsquo;s history and expectation of no dividend payouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation costs associated with grants of common shares are measured at fair value at the date of grant, which has historically been the most recent price paid by investors to purchase shares of the Company&rsquo;s common stock prior to such grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patent-related costs incurred in filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as legal and professional expenses in the accompanying condensed consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net loss per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares outstanding during the period. For periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, there are no potentially dilutive securities outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2022, the number of shares excluded from diluted net loss per share included outstanding options to purchase 2,765,514 common shares. The shares issuable upon exercise of the stock options are not included in the denominator since their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income taxes </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes federal, state, and foreign current tax liabilities or assets based on its estimate of taxes payable to or refundable by tax authorities in the current fiscal year. The Company also recognizes federal and state deferred tax liabilities or assets based on the Company&rsquo;s estimate of future tax effects attributable to temporary differences and carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more likely than not that some portion of the deferred tax asset will not be realized. The Company evaluates deferred income taxes quarterly to determine if valuation allowances are required by considering available evidence. If the Company is unable to generate sufficient future taxable income in certain tax jurisdictions, or if there is a material change in the actual effective tax rates or time period within which the underlying temporary differences become taxable or deductible, the Company could be required to increase its valuation allowance against its deferred tax assets which could result in an increase in the Company&rsquo;s effective tax rate and an adverse impact on operating results. The Company will continue to evaluate the necessity of the valuation allowance based on the remaining deferred tax assets. The difference between the statutory and effective rates for the nine months ended September 31, 2023 and 2022 is a result of the Company applying a full valuation allowance against any deferred tax assets as a result of net operating losses due to uncertainties surrounding the usability of such net operating losses.&rsquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the accounting guidance related to financial statement recognition, measurement and disclosure of uncertain tax positions. The Company recognizes the impact of an uncertain income tax position on an income tax return at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it is less than 50% likely to be sustained. Uncertain tax positions are recognized in the first subsequent financial reporting period in which that threshold is met or from changes in circumstances such as the expiration of applicable statutes of limitations. The Company will recognize interest and penalties related to tax positions in income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 3 &ndash; Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AFH Holdings and Advisory, LLC advisory agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2022, the Company entered into an advisory agreement with AFH to assist the Company in connection with its intent to affect a public listing. AFH was retained to assist the Company with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTI agreed to affect a share exchange with a special purpose entity (NTHI) substantially owned by AFH, whereby AFH retained approximately 34.4% of the shares of the combined entity after the Share Exchange. The Share Exchange occurred on April 7, 2023 (see Note 1). The Company has accounted for the Share Exchange transaction as a reverse recapitalization with NTI as the accounting acquirer. At the time of the Share Exchange, NTHI had no operations and did not meet the definition of a &ldquo;business&rdquo; as defined under U.S. GAAP. Since NTI is the accounting acquirer, its historical financial statements became the Company&rsquo;s historical financial statements and such assets and liabilities continued to be recorded at their historical carrying values. The historical common and preferred stock of NTI have been retroactively adjusted for all periods presented to reflect the conversion of preferred stock of NTI to common stock of NTI prior to the Share Exchange and the exchange ratio from the Share Exchange (0.1465 shares of common stock of NTHI for 1 share of common stock of NTI).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, AFH earned a fee of $500,000 for its advisory work, which is included in the condensed consolidated statement of operations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company agreed to retain&nbsp;AFH as an exclusive advisor to the Company on all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities offering. Further to the advisory arrangement, AFH shall be paid an aggregate fee in an amount equal to 2% of the post-money valuation of the Company immediately after the effective time of the public offering.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, AFH agreed to advance costs of up to $500,000 to the Company for fees paid to service providers related to a financing transaction and are to be repaid out of proceeds from the short-term loan provided to the company by HCWG LLC. As of September 30, 2023 and December 31, 2022, no amounts were outstanding further to such agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances from Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has periodically received cash advances from the Chairman or has had certain costs incurred by the University of Southern California (&ldquo;USC&rdquo;) on behalf of the Company paid for by the Chairman. These advances were non-interest bearing and had no stated maturity. During the nine months ended September 30, 2022, the Company repaid in cash $450,000 of such advances to the Chairman, and as of September 30, 2023 and December 31, 2022 there were no amounts outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions with USC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2009, the Company entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related to the use of monoterpenes as a solvent, specifically <I>perillyl alcohol</I>. This technology is the basis of the current products under development by the Company. The Company granted USC 117,236 shares of common stock in exchange for the license. Additionally, the Company is required to pay an annual patent maintenance cost of $20,000 and a 2% royalty on all net sales, as defined. The Company has not paid any earned royalties through September 30, 2023, since no products are being sold using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2023, NeOnc amended the license agreement with USC dated March 9, 2009 (&ldquo;Amended License Agreement&rdquo;) to include all of the worldwide patents developed by the Company related to the biotechnology under development by the Company. The Amended License Agreement also had added the Company as an additional licensee. In addition, the Amended License Agreement contained the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">The Company issued to USC 560,000 shares of common stock of NTHI on October 11, 2023. The Company has received a waiver from USC to forgo any material breach of the Amended License Agreement for failure to issue such shares within 15 days of the effective date of the Amended License Agreement, as required by the Amended Agreement. The fair value of the common stock to be issued for the license was valued based upon the pricing from a recent financing round adjusted for the dilution from the Share Exchange. The Company recorded license expense in the amount of $2,507,773 in the accompanying condensed consolidated statement of operations equal to the estimated fair value of the shares to be issued to USC. The fair value of the liability is recorded as &ldquo;common stock payable for license fee, fair value&rdquo; in the accompanying condensed consolidated balance sheets as of September 30, 2023.</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">The Company will pay USC nonrefundable earned royalties of 4% on Net Sales (as defined in the Amended License Agreement) of Licensed Products covered by the licensed patents in all countries in which the manufacture, use, sale, offer for sale, or import of such Licensed Products, as such capitalized terms are defined in the Amended License Agreement. To date, no sales have been made using Licensed Products, and no royalties are due to USC.</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">The Company will assume responsibility for patent-related costs.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &ldquo;Restated Agreement&rdquo;). The Restated Agreement addressed and clarified certain reporting obligations of the Company&nbsp;under the&nbsp;license agreement with USC dated March 9, 2009, and addressed&nbsp;certain financial and other obligations, defaults, and deficiencies in connection with the Company&rsquo;s performance under the&nbsp;Amended License Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> The Restated Agreement
provides that the parties may mutually agree to terminate. Further, USC may immediately terminate if (a) we do not make payments when
due and fail to cure, (b) we default on our indemnification or insurance obligations, (c) we are determined to be insolvent, (d) if any
of our officers, directors or employees are convicted of a felony related to the development, manufacture use, marketing, distribution
or sale of the Licensed Product, (e) if an audit shows an underpayment by us or a sublicensee of 15% or more for any 12 month period, or
(f) we default in the performance of our other obligations in the agreement, and in each case fail to cure. We may terminate the license
by giving 180 days advance written notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Restated Agreement, the Company recorded additional license fees in the amount of $230,000 to cure deficiencies in the existing license agreement related to unpaid sub-license fees within license expense in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2023, and accrued within accounts payable &ndash; related parties in the accompanying condensed consolidated balance sheet as of September 30, 2023.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also utilizes laboratory services from USC. The Company has incurred approximately $240,732 and $340,853 of research and development-related costs from USC for the nine months ended September 30, 2023 and 2022, respectively. The Company incurred approximately $39,666 and $13,311 of patent maintenance and legal-related expenses for the nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company owes USC approximately $47,344 and $75,633, respectively, which is included in accounts payable - related parties in the accompanying condensed consolidated balance sheet. From time to time, the Company has been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty at USC to satisfy the amounts due from the Company to USC. Such amounts deducted from the Chairman&rsquo;s USC faculty compensation are recorded as Advances from the Chairman on September 30, 2023 and December 31, 2022. Additionally, included in accounts payable &ndash; related parties in the accompanying condensed consolidated balance sheet at September 30, 2023 and December 31, 2022 is $1,041,383 and $800,651, respectively, due to the Chairman related to such deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred $500,904 and $0 for the nine months ended September 30, 2023 and 2022, respectively for compensation to the management team, Chairman, COO and CFO, all of whom are shareholders<B>. </B> This compensation is recorded in the condensed consolidated statement of operations as part of general and administrative expenses. The amount accrued for the management team was $913,404 and $412,500 as of September 30, 2023 and December 31, 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 4 &ndash; Related Party Loans Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company issued $50,000 of convertible notes to a shareholder due August 30, 2023 (&ldquo;Note&rdquo;). The Note bears interest at 2% per annum. This Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by the Company in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering (&ldquo;IPO&rdquo;), of equity securities by the Company to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company, at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to account for the Note under the fair value option (See Note 2). The fair value of the Note (classified within Level 3 of the fair value hierarchy) approximated the face amount of $50,000 at both December 31, 2022 and September 30, 2023. As such, no adjustment was made to the carrying value of the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridge Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company entered into a non-interest bearing, non-convertible promissory note with HCWG LLC (an entity owned by certain shareholders, directors, and officers of the Company). Borrowings under the note carry a 50% (or 1 times cash amounts borrowed) original issue discount (&ldquo;OID&rdquo;) on principal. The note initially allowed for maximum cash borrowings of $1,600,000 (amended on June 26, 2023, to increase the maximum cash borrowings to $2,800,000, and again on July 26, 2023 to increase the maximum cash borrowings to $4,000,000, which may be drawn upon at any time during the term of the note). The outstanding amounts under this bridge loan are payable at the earlier of the IPO date or July 26, 2024 (the &ldquo;Maturity Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 19, 2023, the bridge loan was amended to increase the maximum borrowings from $4,000,000 to $5,000,000 and extend the maturity date to the earlier of the IPO date or October 24, 2024 and again on December 4, 2023 to increase the maximum borrowings up to $10,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall have the option to prepay this note with no penalties at any time and prior to the Maturity Date in an amount equal to the sum of: (A) the then principal balance of this note plus (B) all other amounts, costs, and expenses then due in respect of this note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the Company has received $3,970,109 under the bridge loan. The OID will be recognized ratably over the term of each draw-down under the loan through the Maturity Date unless paid down earlier, at which point the accretion is accelerated. Accretion of the OID for the nine months ended September 30, 2023, amounted to $1,374,084, which is included in interest expense in the accompanying condensed consolidated statement of operations. Summary of the bridge loan activity through September 30, 2023 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">9 months ended<BR> September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Bridge loan payable - draw downs</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">3,970,109</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">OID - draw downs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,970,109</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less repayments of draw downs</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,199,588</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance September 30, 2023</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,740,630</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">At<BR> September&nbsp;30,<BR> 2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Principal outstanding</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">6,740,630</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less unrecognized OID</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,596,026</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,604</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-term loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Company entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August 2022 from a related party. The loan was fully repaid off in December 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 5 &ndash; Common and Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeOnc Technologies Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of common stock available for issue by NTHI is 100,000,000 shares of common stock at $0.0001 par value per share and the total number of shares of preferred stock is 10,000,000 at a par value of $0.0001. See Note 1 for discussion of the issuance of common shares pursuant to the Share Exchange. As of September 30, 2023, no preferred shares have been issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The board of directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of shares of Preferred Stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware<I>,</I> to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences, and rights of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereof. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock, without a vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to the terms of any Preferred Stock Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeOnc Technologies Inc</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the share exchange, the total number of shares of common stock available for issue by the Company was 100,000,000 shares at $0.001 par value per share and the total number of preferred stock available to issue was 3,030,303 shares at $0.001 par value per share. The Company issued 1,300,000 (190,508 shares as adjusted for the impact of the Share Exchange) shares of common stock for proceeds totaling $1,300,000 as part of a series of private placements during nine months ended September 30, 2022 (unaudited).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the then outstanding 3,030,303 preferred shares of NeOnc Technologies Inc. were converted into NTI common stock at a ratio of 1 common share for every preferred share outstanding immediately prior to the Share Exchange Agreement (see Note 1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 6 &ndash; Collaboration and License Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License Agreement - Orient EuroPharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 8, 2013, the Company entered into a collaboration agreement (&ldquo;Agreement&rdquo;) with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license OEP the right to commercialize the Company&rsquo;s drug NEO100, a highly purified form of <I>perillyl alcoho</I>l (&ldquo;Licensed Product&rdquo;), in the territories specified in the license agreement (&ldquo;Territory&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Agreement, OEP will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the Licensed Products, and bear the cost of and be responsible for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval for Licensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Agreement, OEP agreed to compensate the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Reimbursement of the costs related to an Investigational New Drug Application filing with the FDA, which was received in 2014 and 2016;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">$200,000 paid upon signing the agreement in 2013; and</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify">Specified clinical milestone payments of up to $1,900,000. The Company received a milestone payment of $300,000 during the year ended December 31, 2020 upon completion of the first phase of clinical trials. The Company has received no other clinical milestone payments through September 30, 2023.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that the arrangement is within the scope of ASC 808, <I>Collaborative Arrangements,</I> as both NeOnc and OEP are active participants in the activity, and they are both exposed to significant risks and rewards dependent on the commercial success of the activity. The Company has determined two performance obligations under the arrangement &ndash; the scientific development phase and the clinical trial evaluation phase. The Company has deferred recognition of revenue on the $200,000 paid upon signing the agreement and the $300,000 milestone payment received in 2020 as the clinical trial evaluation phase had not yet been completed as of September 30, 2023. Deferred revenue of $500,000 as of September 30, 2023 and December 31, 2022 is recorded on the accompanying condensed consolidated balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OEP is also obligated to pay potential milestone payments to the Company totaling up to $6,000,000 for the achievement of certain sales milestones. In addition, during the Royalty Term (as defined in the underlying Agreement), OEP is obligated to pay the Company tiered royalties between 1-5% of net sales of Licensed Products in the Territory. However, under certain conditions, royalties will not be paid if (i) no patent covering the Licensed Products is issued to NeOnc in counties defined within the collaboration agreement, and (ii) a generic version of the Licensed Products has launched in such country, and (iii) the gross profit margin for the Licensed Products in such country is less than 50%. No consideration has been received as of September 30, 2023 for the license of the completed product, as it is still under development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either party may terminate the Agreement for material breach upon a party&rsquo;s insolvency, bankruptcy, or safety reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, after completion of Phase II clinical trials, the Company enters into one or more agreements to license any of the patent rights or Licensed Products to a party other than OEP, then the Company will reimburse specified amounts based upon amounts paid by OEP to the Company, not to exceed $3,000,000 to be paid as various milestones are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 14, 2023, the Company terminated the licensing agreement with OEP. The Company and OEP were in mediation to resolve the settlement or potential re-negotiation terms of such license agreement. On October 31, 2023, the Company rescinded the termination of the OEP license agreement and therefore the original terms of the license with OEP remain in effect. The reinstatement of the license agreement may result in litigation or mediation, and the impact cannot yet be determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 208; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>License Agreement &ndash; Neucen Biomedical Co., Ltd. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 5, 2015, the Company entered into a license agreement with Neucen Biomedical Co., Ltd. (&ldquo;NB&rdquo;), a shareholder of NeOnc Technologies, Inc., in which NeOnc will license to NB the right to commercialize the Company&rsquo;s drug NEO212, a conjugate of perillyl alcohol and temozolomide (&ldquo;NB Licensed Product&rdquo;) in the territories specified in the license agreement (&ldquo;NB Territory&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Agreement, NB will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the NB Licensed Products, and bear the cost of, and be responsible for, among other things, preparing and filing applications for regulatory approval in the NB Territory and for commercializing NB Licensed Products in the NB Territory, and obtain pricing approval for NB Licensed Products in the NB Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NB must pay the Company tiered royalties of 1-5% on net sales of NB Licensed Products in the NB Territory. The Company received no sales milestones or royalties through December 31, 2022, as no commercialized products are using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2023, NB and NTHI mutually agreed to terminate this license agreement, and no consideration was paid or received related to such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 7 &ndash; Stock-Based Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company&rsquo;s 2013 Stock Incentive Plan (the &ldquo;2013 Option Plan&rdquo;), up to 2,930,000 shares of NTI&rsquo;s common stock may be issued pursuant to awards granted in the form of incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance shares, and performance units to employees, directors and consultants of the Company and its affiliates. As of December 31, 2022 there were 24,328 vested stock options outstanding under the 2013 Option Plan, which were cancelled in January 2023. These options had a weighted average exercise price of $0.36 per share. There were no grants during the nine months ended September 30, 2023 and 2022. As of September 30, 2023, there were no stock options outstanding. There is no further activity expected under the 2013 Option Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of stock option awards is estimated using the Black-Scholes option-pricing model. The estimated fair value of each stock option is then expensed over the vesting period, approximately three years. The determination of fair value using the Black-Scholes model is affected by the Company&rsquo;s share price and assumptions regarding a number of complex and subjective variables, including expected price volatility and the risk-free interest rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation expense related to vesting stock options was $0 and $554,833 for the nine months ended September 30, 2023 and 2022, respectively. The weighted average fair value of stock options vested in the nine months ended September 30, 2022 was approximately $0.92 per share. At September 30, 2023, there was no unrecognized compensation cost related to non-vested options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &ldquo;2023 Plan&rdquo;), which allows the issuance of up to 4,000,000 shares of the Company&rsquo;s authorized and unissued common stock in the form of incentive stock options, non-qualified stock options, restricted stock units, performance share units, or other forms of equity as may be added in the future to employees, directors and consultants of the Company and its affiliates. As of September 30, 2023, there were no awards issued under the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 209; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes to Condensed Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 8 &ndash; Commitments and Contingencies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Underwriter</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">In December 2023, the Company entered into an agreement with a firm to act as the lead managing underwriter and book runner (&ldquo;Underwriter&rdquo;) in connection with the planned IPO. The agreement provides for an 8% underwriter discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; margin: 0pt; font: 10pt Times New Roman, Times, Serif">The Company paid a $25,000 advance to the Underwriter, which is included in deferred offering costs in the accompanying condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Litigation </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company is involved in various disputes, claims, liens and litigation matters arising out of the normal course of business which could result in a material adverse effect on the Company&rsquo;s combined financial position, results of operations or cash flows. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. As of September 30, 2023 and December 31, 2022, the Company had no liabilities recorded for loss contingencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 6, 2023, a former licensee filed a complaint against the Company for breach of contract in the Central District of California. The former licensee alleged that the Company improperly terminated an Intellectual Property License and Supply Agreement (&ldquo;IPLSA&rdquo;) and that the Company also defrauded the former licensee in connection with the IPLSA. This matter was settled on October 16, 2023, and the Company agreed to pay the former licensee $600,000 within 5 business days of the close of the IPO or March 31, 2024, whichever occurs first. The Company recognized this as a litigation settlement expense in the accompanying condensed consolidated statement of operations and a litigation settlement payable in the accompany condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 9 &ndash; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through December 18, 2023, the date the financial statements were available to be issued and determined that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements, except as disclosed in Notes 4 and 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 210; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DECEMBER&nbsp;31, 2022 AND 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A HREF="#b_001">Report of Independent Registered Public Accounting Firm (PCAOB ID#688)</A></B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-20</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial Statements</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_003">Balance Sheets as of December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_004">Statements of Operations for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-22</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_005">Statements of Changes in Shareholders&rsquo; Deficit for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-23</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_006">Statements of Cash Flows for the years ended December&nbsp;31, 2022 and 2021</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-24</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_007">Notes to Financial Statements</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-25 &ndash; F-36</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="b_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Shareholders and Board of Directors of<BR> NeOnc Technologies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion on the Financial Statements</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have audited the accompanying balance sheets of NeOnc Technologies, Inc. (the &ldquo;Company&rdquo;) as of December&nbsp;31, 2022 and 2021, the related statements of operations, changes in shareholders&rsquo; deficit and cash flows for each of the two years in the period ended December&nbsp;31, 2022, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2022, in conformity with accounting principles generally accepted in the United States of America<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going Concern</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis for Opinion</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcum LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&rsquo;s auditor since 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">May&nbsp;1, 2023, except for the presentation of loss per share on the statements of operations, the net loss per share accounting policy disclosed in Note 2, and Note 10, as to which the date is August 2, 2023.

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_003"></A><FONT STYLE="font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Assets</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">633,298</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">95,384</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,457</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Current Assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Assets</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities and Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Liabilities</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,341,593</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">537,446</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">412,500</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">462,500</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred revenue</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory note payable, at fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder advance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note payable - Chairman of the Board, at fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">241,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advances from Chairman of the Board</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">897,891</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Current Liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,304,093</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,648,837</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments and contingencies</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo; Deficit:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock, $0.001 par value, 3,030,303 shares authorized; 3,030,303 Series A shares issued and outstanding as of December 31, 2022 and 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, $0.001 par value, 100,000,000 shares authorized; 68,620,340 and 59,674,906 shares issued and outstanding as of December 31, 2022 and 2021, respectively</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,621</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid in capital</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,141,854</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,066,108</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,788,916</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,742,159</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,575,411</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,616,346</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Liabilities and Shareholders&rsquo; Deficit</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,682</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,491</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 214; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_004"></A><FONT STYLE="font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">For the<BR> years ended<BR> December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenues</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 76%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,163,330</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">674,558</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal and professional</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">318,205</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">217,951</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,376,069</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,379,174</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Operating Expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,857,604</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,271,683</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss From Operations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,837,604</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,271,683</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other (Expense) Income:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of note payable - Chairman of the Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(200,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(112,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Other Expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(209,153</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(103,919</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net Loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Loss per share:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss per share - basic and diluted</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(0.05</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(0.06</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Weighted average common shares outstanding - basic and diluted</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">57,592,166</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">56,674,506</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 215; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_005"></A><FONT STYLE="font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements of Changes in Shareholders&rsquo; Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Additional</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total</B></FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Preferred Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Paid In </B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Accumulated</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shareholders&rsquo;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 30%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance - December 31, 2020</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,674,506</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,733,856</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17,366,557</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,572,996</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expense related to options granted to related party debtholder in conjunction with debt issuance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance - December 31, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,674,506</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,675</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,066,108</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,742,159</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,616,346</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sale of common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,397,600</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares issued upon cashless exercise of stock options</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,150,051</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,150</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,150</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Charge associated with settlement of shareholder advances through the issuance of shares of common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,783</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">396</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,387</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">395,783</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance - December 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,620,340</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">68,621</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030,303</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,030</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,141,854</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23,788,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,575,411</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the financial statements. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 216; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_006"></A><FONT STYLE="font-size: 10pt"><B>NEONC TECHNOLOGIES, INC.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the<BR> year ended<BR> December&nbsp;31,</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from operating activities:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,046,757</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,375,602</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash used in operating activities</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of note payable - Chairman of the Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss on conversion of advances from Chairman of the Board to common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,891</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expense related to options granted to related party debtholder in conjunction with debt issuance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">112,919</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share based compensation expense</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,291,909</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,219,333</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Grant receivable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,748</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(87,926</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(263</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts receivable</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(50,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">150,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">804,147</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">423,172</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(881,736</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(396,693</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from financing activities:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from note payable - Chairman of the Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from note payable - related parties</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">125,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment of notes payable - related parties</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(335,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from sale of common stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,400,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment of advances from the Chairman of the Board</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(700,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,490,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">608,264</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(146,693</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash - beginning of year</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171,727</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash - end of year</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">633,298</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,034</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental cash flow disclosures:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest paid</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,261</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental disclosure of non-cash financing activities:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable settled by the Chairman of the Board, reclassified</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">176,404</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of advances from Chairman of the Board to common stock</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">197,891</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 217; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_007"></A><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Note 1 &#8211; Description of Business and Liquidity</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEONC Technologies, Inc. (&ldquo;NeOnc&rdquo; or the &ldquo;Company&rdquo;) was incorporated on April&nbsp;13, 2005, as a California corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The Company&rsquo;s lead product, NEO100, commenced Phase 2a clinical trials in July of 2019 (which is still ongoing as of December&nbsp;31, 2022), treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (&ldquo;FDA&rdquo;). The Company licensed the underlying technology from the University of Southern California. (&ldquo;USC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At December&nbsp;31, 2022, the Company had cash totaling $633,298. For the year ended December&nbsp;31, 2022, the Company has incurred a net loss of $3,046,757 and has an accumulated deficit of $23,788,916 at December&nbsp;31, 2022. The Company has financed its working capital requirements to date primarily through the issuance of common stock, preferred stock and shareholder loans. As of December&nbsp;31, 2022, the Company had not raised sufficient funds to finance the operating requirements for at least the next 12 months from the issuance date of these financial statements. The Company has engaged with an investment bank to assist with additional financing activities. However, there can be no assurance that financing can be completed on terms acceptable to the Company. These factors raise substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December&nbsp;2022, the Company signed a Letter of Intent (&ldquo;LOI&rdquo;) with AFH Holdings and Advisory, LLC, an investment advisory firm (&ldquo;AFH&rdquo;) to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&ldquo;Newco&rdquo;) (formed January 5, 2023) to facilitate future fundraising transactions (see Note 3). On April&nbsp;7, 2023, the shareholders of the Company exchanged their shares for shares of Newco. (see Note 10). AFH will assist the Company in a fundraising transaction, which may include bridge financing before an Initial Public Offering (IPO) or private financing. AFH will also act as an investment advisor in future financing transactions and be able to appoint a majority of the Board of Directors of Newco. Except for the completed exchange transaction described above, there is no assurance of consummation of any of the transactions contemplated by the LOI. There can be no assurance that a fundraising transaction can be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other risks and uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to biopharmaceutical companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, and the uncertainty of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third-party suppliers and, in some cases, single-source suppliers. The Company&rsquo;s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions where the Company may license or sell its products. There can be no assurance that the Company&rsquo;s products will receive all required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There can be no assurance that the Company&rsquo;s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost with appropriate performance characteristics or that such products will be successfully marketed, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December&nbsp;2019, a novel strain of coronavirus (&ldquo;COVID-19&rdquo;) was reported in Wuhan, China. The World Health Organization declared COVID-19 a &ldquo;Public Health Emergency of International Concern&rdquo; on January&nbsp;30, 2020, and a global pandemic on March&nbsp;11, 2020. In March&nbsp;2020, individual states mandated &ldquo;stay-at-home orders,&rdquo; restricted access to hospitals, prohibited elective surgeries, and instituted other restrictions in connection with the COVID-19 outbreak. The extent of the impact of COVID-19 on the Company&rsquo;s operational and financial performance will depend on future developments, including access to products, potential disruption in global freight networks, domestic and foreign government actions and changes in demand based on the duration and severity of the COVID-19 outbreak.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 218; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;), including all pronouncements of the U.S. Securities and Exchange Commission applicable to annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company&rsquo;s financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, from time to time during the period covered by these financial statements, may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. For the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents include all cash balances on hand and highly liquid investments having original maturities of three months or less when purchased. At December&nbsp;31, 2022 and 2021, the Company did not have any cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to account for the $250,000 (original principal amount) note payable to the Chairman of the Board (Chairman) and the $50,000 (original principal amount) note payable to a shareholder using the fair value option in accordance with the guidance contained in Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) 825-10-25. The fair value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities, unrecognized firm commitments, and written loan commitments. See Note 3 for additional information. The Company accounted for the fair value of the stock options issued in connection with the note payable to the Chairman as additional interest expense on the grant date, using the same methodology to determine the fair value of the stock option as discussed in the share-based compensation policy footnote below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC Topic 820, &ldquo;<I>Fair Value Measurements and Disclosures</I>&rdquo; (&ldquo;ASC 820&rdquo;), defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company&rsquo;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company&rsquo;s accounts receivable, accounts payable, shareholder advances, and advances from the Chairman approximate fair value because of the short-term nature of these financial instruments. The Company&rsquo;s note payable to Chairman is reported at fair value (see Note 3). The promissory note payable is reported at face value as the fair value difference is not material (see Note 4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 219; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree of judgment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &#8212; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by the market through correlation or other means.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &#8212; Valuations based on unobservable inputs and significant to the overall fair value measurement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses of intellectual property (&ldquo;IP&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates intellectual property licensing agreements in accordance with ASC 808, <I>Collaborative Arrangements.</I> If the license to the Company&rsquo;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measurement of performance and related revenue recognition. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&rsquo;s license and collaboration agreements in Note 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones. The Company estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&rsquo;s control or the licensee&rsquo;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Therefore, revenue recognized is constrained as management cannot assert that a revenue reversal would not be possible. The transaction price is then allocated to each performance obligation on a residual basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development milestones and any related constraints. The Company adjusts its estimate of the overall transaction price if necessary. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the adjustment period. To date, the Company has not recognized any milestone revenue resulting from any of its agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When performance obligations are not required of the Company or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized point-in-time revenue of $20,000 and $0 for the years ended December&nbsp;31, 2022 and 2021, respectively, for the sale/license of technology where the Company has no further performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors performing research, conducting clinical trials, and manufacturing drug supplies and materials. The Company recognizes the proceeds from the National Institute of Health (&ldquo;NIH&rdquo;) grant as a reduction of research and development expenses when the costs related to the grant are incurred. Grant receivables consist of unbilled amounts due from the NIH for costs incurred under the grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 220; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock options and common shares to employees, non-employee consultants and non-employee members of our Board of Directors. The Company measures the compensation cost associated with all share-based payments based on the grant date fair values. The Company recognizes share-based compensation expense over the requisite service period of each award, which generally equals the vesting period, using the straight-line method for awards that contain only service conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each stock option is estimated on the date of grant using an option pricing model. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the Company&rsquo;s stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. For grants of stock options, the Company uses a blend of historical and implied volatility for similar companies in order to estimate the expected volatility assumption required in the Black-Scholes model. The Company&rsquo;s use of a blended volatility estimate in computing the expected volatility assumption for stock options is based on its belief that while the implied volatility is representative of expected future volatility, the historical volatility over the expected term of the award is also an indicator of expected future volatility. The expected term of stock options granted is estimated using historical experience. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the Company&rsquo;s stock options. The dividend yield assumption is based on the Company&rsquo;s history and expectation of no dividend payouts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation costs associated with grants of common shares are measured at fair value at the date of grant, which has historically been the most recent price paid by investors to purchase shares of the Company&rsquo;s common stock prior to such grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patent-related costs incurred in filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as legal and professional expenses in the accompanying statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Net loss per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of unrestricted common shares outstanding during the year. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares outstanding during the year. For years in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2022 and 2021, the number of shares excluded from diluted net loss per share included outstanding options to purchase 166,060 and 18,871,511 common shares, respectively. For the years ended December 31, 2022 and 2021, the number of shares excluded from diluted net loss per share also included 3,030,303 shares of common stock issuable upon conversion of 3,030,303 shares of preferred stock. Both the shares issuable upon exercise of the stock options and conversion of 3,030,303 shares of preferred stock are not included in the denominator since their inclusion would be anti-dilutive.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes federal, state, and foreign current tax liabilities or assets based on its estimate of taxes payable to or refundable by tax authorities in the current fiscal year. The Company also recognizes federal and state deferred tax liabilities or assets based on the Company&rsquo;s estimate of future tax effects attributable to temporary differences and carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more likely than not that some portion of the deferred tax asset will not be realized. The Company evaluates deferred income taxes quarterly to determine if valuation allowances are required by considering available evidence. If the Company is unable to generate sufficient future taxable income in certain tax jurisdictions, or if there is a material change in the actual effective tax rates or time period within which the underlying temporary differences become taxable or deductible, the Company could be required to increase its valuation allowance against its deferred tax assets which could result in an increase in the Company&rsquo;s effective tax rate and an adverse impact on operating results. The Company will continue to evaluate the necessity of the valuation allowance based on the remaining deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the accounting guidance related to financial statement recognition, measurement and disclosure of uncertain tax positions. The Company recognizes the impact of an uncertain income tax position on an income tax return at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it is less than 50% likely to be sustained. Uncertain tax positions are recognized in the first subsequent financial reporting period in which that threshold is met or from changes in circumstances such as the expiration of applicable statutes of limitations. The Company will recognize interest and penalties related to tax positions in income tax expense. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 221; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 3 &#8211; <FONT STYLE="background-color: white">Related Party Transactions</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Intent &#8211; AFH Holdings and Advisory, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;19, 2022, the Company entered into an engagement agreement with AFH. AFH was engaged to assist the Company in connection with its intent to effect a public listing. AFH was retained to assist the Company with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering. AFH agreed to advance costs of up to $500,000 for such professionals on behalf of the company to be repaid out of proceeds from the initial public offering. As of December&nbsp;31, 2022, no such advances have taken place. The Company agreed to effect a share exchange with a special purpose entity substantially owned by AFH, whereby AFH retained approximately 34.4% of the shares of the combined entity after the share exchange. In addition, the Company agreed to retain AFH as an exclusive advisor to the Company on all financing and mergers and acquisitions for a period of two (2) years from the closing of a public securities offering. Further to the advisory arrangement, AFH shall be paid an aggregate fee in an amount equal to 2% of the post-money valuation of the Company immediately after the effective time of the public offering. The share exchange occurred on April&nbsp;7, 2023 (see Note 10).</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder advances</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically certain shareholders of the Company have advanced the Company funds to support operations under informal loan arrangements (the &ldquo;Shareholder Advances&rdquo;). These Shareholder Advances bear no interest and have no specified maturity date. There were Shareholder Advances outstanding totaling $0 and $10,000 as of December&nbsp;31, 2022 and 2021, respectively. During the year ended December&nbsp;31, 2022, the Company repaid all outstanding Shareholder Advances of $10,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable &#8211; Chairman of the Board</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August&nbsp;18, 2021, the Company entered into a loan agreement with the Chairman with a principal amount of $250,000 (the &ldquo;Chairman Note&rdquo;). The Chairman Note bore no interest and was payable when the Company received funding in excess of $1,000,000. The Company received funding in excess of $1,000,000 during the year ended December&nbsp;31, 2022, at which time the Chairman Note was repaid. The Company has elected to account for the Chairman Note under the fair value option (See Note 2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Chairman Note is classified within Level 3 of the fair value hierarchy. In order to calculate the fair value of the Chairman Note, the Company utilized the following inputs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>December&nbsp;31,<BR> 2021</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>August&nbsp;18,<BR> 2021<BR> (initial measurement)</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underlying principal amount of note payable</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flow discount rate</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.89</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.21</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Term (years)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.37</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.73</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The discount rate was based on a 3-month CCC debt yield based upon a comparative credit rating for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairman Note was repaid on May&nbsp;12, 2022. The changes in the fair value of the Chairman Note from the inception through December&nbsp;31, 2022 are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible promissory note at inception, August 18, 2021</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible promissory note, December 31, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">241,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repayment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(250,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible promissory note, December 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 222; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the issuance of the Chairman Note, the Chairman received a stock option grant from the Company to purchase 250,000 shares of common stock at an exercise price of $0.66 per share. The stock option vested immediately and was valued using the Black-Scholes option-pricing model utilizing the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">82.0</FONT></TD>
    <TD STYLE="width: 1%; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free interest rate</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected dividend yield</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected life of options in years</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per share fair value of common stock</FONT></TD>
    <TD STYLE="color: windowtext"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="color: windowtext; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.47</FONT></TD>
    <TD STYLE="color: windowtext; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total fair value of the stock option grant was $112,919, recognized as interest expense for the year ending December&nbsp;31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances from Chairman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has periodically received cash advances from the Chairman or has had certain costs incurred by the University of Southern California (&ldquo;USC&rdquo;) on behalf of the Company paid for by the Chairman. These advances were non-interest bearing and had no stated maturity. At December&nbsp;31, 2021, the balance outstanding was $897,891. During the year ended December&nbsp;31, 2022, the Company repaid in cash $700,000 of such advances to the Chairman and $197,891 was converted to 395,782 shares of common stock on December&nbsp;31, 2022. The fair value of the common stock issued of $395,782 exceeded the remaining balance due the Chairman. Such excess fair value of $197,891 was recorded as interest expense in the statement of operations for the year ended December&nbsp;31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with USC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;9, 2009, the Company entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related to the use of monoterpenes as a solvent, specifically <I>perillyl alcohol</I>. This technology is the basis of the current products under development by the Company. The Company granted USC 800,000 shares of common stock in exchange for the license. Additionally, the Company is required to pay an annual patent maintenance cost of $20,000 and a 2% royalty on all net sales, as defined. The Company has not paid any royalties through December&nbsp;31, 2022, since no products are being sold using such technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also utilizes laboratory services from USC. The Company has incurred approximately $442,000 and $372,000 of research and development-related costs from USC for the years ended December&nbsp;31, 2022 and 2021, respectively. The Company incurred approximately $20,100 and $12,000 of patent maintenance and legal-related expenses for the years ended December&nbsp;31, 2022 and 2021, respectively. At December&nbsp;31, 2022 and 2021, the Company owes USC approximately $75,633 and $51,000, respectively. From time to time, the Company has been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty at USC to satisfy the amounts due from the Company to USC. Such amounts deducted from the Chairman&rsquo;s USC faculty compensation are recorded as Advances from the Chairman on December&nbsp;31, 2022 and 2021. Additionally, included in accounts payable at December&nbsp;31, 2022 and 2021 are approximately $800,651 and $365,000, respectively, due to the Chairman related to such deductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred $0 and $150,000 for the years ended December&nbsp;31, 2022 and 2021 for compensation to the Chairman and a consultant, both of whom are shareholders. This compensation is recorded in the statement of operations as part of general and administrative expenses. The amount accrued for the Chairman and the consultant were $412,500 and $462,000 as of December&nbsp;31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&nbsp;2022, the Company entered into a $75,000 loan agreement bearing interest at 2.5% per annum with a maturity date of August&nbsp;2022 from a related party. The loan was paid off in December&nbsp;2022. Interest expense paid related to this loan for the year ended December&nbsp;31, 2022 was approximately $1,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 223; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4 &#8211; <FONT STYLE="font-variant: small-caps">Convertible Promissory Note Offering</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company issued $50,000 of convertible notes to a shareholder due August&nbsp;30, 2023 (&ldquo;Note&rdquo;). The Note bears interest at 2% per annum. This Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by the Company in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering (&ldquo;IPO&rdquo;), of equity securities by the Company to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company, at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected to account for the Note under the fair value option (See Note 2). The fair value of the Note (classified within Level 3 of the fair value hierarchy) approximated the face amount of $50,000 at both the issuance date of March&nbsp;28, 2022 and at December&nbsp;31, 2022. As such, no adjustment was made to the carrying value of the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 5 &#8211; Common and Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of common stock available for issue is 100,000,000 shares at $0.001 par value per share and the total number of preferred stock available to issue is 3,030,303 shares at $0.001 par value per share. The Company issued 2,400,000 shares of common stock for proceeds totaling $2,400,000 as part of a series of private placements during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common shareholders are entitled to one vote for each share of common stock held at the record date of the vote. Each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of such Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. The holders of Series A Preferred Stock shall vote together with the common shareholders as a single class. When the holders of Series A Preferred Stock hold 5% (on a fully diluted basis) of the outstanding common shares, such holders shall be entitled to vote for one director of the Company and all remaining directors shall be elected by common shareholders. For so long as any shares of Series A Preferred Stock remain outstanding, the vote or written consent of the holders of the majority of the outstanding shares of Series A Preferred Stock is necessary for the Company to conduct certain corporate actions. These include, but are not limited to, the sale of the Company, certain amendments to the certificate of incorporation or bylaws that adversely affect the power, preferences, or rights of the Series A preferred shareholders, or authorizing the issuance of any dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the holders of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its shareholders before any payment shall be made to the holders of common stock. The amount per share equals 1.0 times the Series A Original Issue Price ($0.33 per share as of December&nbsp;31, 2022, as defined), plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution, or winding up of the Company, the proceeds available for distribution shall be insufficient to pay the preferred stockholders the full amount to which they are entitled, the holders share ratably in the distribution of available proceeds. The liquidation preference of such preferred shares at December&nbsp;31, 2022 and 2021 is $1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no stated dividends on the common or Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time and from time to time into shares of common stock at a conversion rate which is computed by dividing the Series A Original Issue Price by the Series A Conversion Price. Series A Original Issue Price initially means $0.33 per share and Series A Conversion Price initially means $0.33 per share, as defined. The conversion price may be adjusted for certain dilutive events such as down-round provision, stock splits and combinations, certain dividends and distributions, or any merger or reorganization. Conversion to common stock shall be mandatory upon closing an initial public offering resulting in net proceeds of at least $20,000,000. A down round occurs when shares are offered at less than the Series A Original Issue Price ($0.33 per share). If a down round occurred, the holders of the Series A preferred stock would be entitled to an adjustment in the number of preferred shares. As of December&nbsp;31, 2021, no down round has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 224; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 6 &#8211; Collaboration and License Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License Agreement - Orient Europharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November&nbsp;8, 2013, the Company entered into a collaboration agreement (&ldquo;Agreement&rdquo;) with Orient EuroPharma Co., Ltd. (&ldquo;OEP&rdquo;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license OEP the right to commercialize the Company&rsquo;s drug NEO100, a highly purified form of perillyl alcohol (&ldquo;Licensed Product&rdquo;), <FONT STYLE="background-color: white">in the territories specified in the license agreement (&ldquo;Territory&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Agreement, OEP will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the Licensed Products, and bear the cost of and be responsible for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval for Licensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the Agreement, OEP agreed to compensate the Company as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement of the costs related to an <FONT STYLE="background-color: white">Investigational New Drug Application</FONT> filing with the FDA, which was received in 2014 and 2015;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000 paid upon signing the agreement in 2013; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specified development milestone payments of up to $1,900,000. The Company received a milestone payment of $300,000 during the year ended December&nbsp;31, 2020 upon completion of the first phase of clinical trials. The Company has received no other development milestone payments through December&nbsp;31, 2022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that the arrangement is within the scope of ASC 808, <I>Collaborative Arrangements,</I> as both NeOnc and OEP are active participants in the activity, and they are both exposed to significant risks and rewards dependent on the commercial success of the activity. The Company has determined two performance obligations under the arrangement &#8211; product development and the license of the completed product. The Company has deferred recognition of revenue on the $200,000 paid upon signing the agreement and the $300,000 milestone payment received in 2020 as the product development obligation had not yet been completed as of December&nbsp;31, 2022. Deferred revenue as of December&nbsp;31, 2022 and 2021 of $500,000 is recorded on the accompanying balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OEP is also obligated to pay potential milestone payments to the Company totaling up to $6,000,000 for the achievement of certain sales milestones. In addition, during the Royalty Term (as defined in the underlying Agreement), OEP is obligated to pay the Company tiered royalties between 1-5% of net sales of Licensed Products in the Territory. However, under certain conditions, royalties will not be paid if (i) no patent covering the Licensed Products is issued to NeOnc in countries defined within the collaboration agreement, and (ii) a generic version of the Licensed Products has launched in such countries, and (iii) the gross profit margin for the Licensed Products in such country is less than 50%. No consideration has been received as of December&nbsp;31, 2022 for the license of the completed product, as it is still under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either party may terminate the Agreement for material breach upon a party&rsquo;s insolvency, bankruptcy, or safety reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, after completion of Phase II clinical trials, the Company enters into one or more agreements to license any of the patent rights or Licensed Products to a party other than OEP, then the Company will reimburse specified amounts based upon amounts paid by OEP to the Company, not to exceed $3,000,000 to be paid as various milestones are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 225; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>License Agreement &#8211; Neucen Biomedical Co.., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&nbsp;5, 2015, the Company entered into a license agreement with Neucen Biomedical Co., Ltd. (&ldquo;NB&rdquo;), a shareholder of NeOnc Technologies, Inc., in which NeOnc will license to NB the right to commercialize the Company&rsquo;s drug NEO212, a conjugate of perillyl alcohol and <FONT STYLE="background-color: white">temozolomide (&ldquo;NB Licensed Product&rdquo;) in the territories specified in the license agreement (&ldquo;NB Territory&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Agreement, NB will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the NB Licensed Products, and bear the cost of, and be responsible for, among other things, preparing and filing applications for regulatory approval in the NB Territory and for commercializing NB Licensed Products in the NB Territory, and obtain pricing approval for NB Licensed Products in the NB Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NB must pay the Company tiered royalties of 1-5% on net sales of NB Licensed Products in the NB Territory. The Company received no sales milestones or royalties through December&nbsp;31, 2022, as no commercialized products are using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 7 &#8211; Grant from the National Institute of Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&nbsp;2020, the Company was awarded a grant of $336,000 from the NIH for developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. The project period for the grant was from April&nbsp;1, 2020 to March&nbsp;31, 2021, which was subsequently extended to March&nbsp;31, 2022. The Company received approximately $156,000 during the year ended December&nbsp;31, 2021 from the NIH. The Company contracted with USC to perform a portion of the work related to this grant totaling $180,000. As of December&nbsp;31, 2021, all work required for the grant was complete and all NIH funding had been received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income related to this NIH grant totaled approximately $98,000 during the year ended December&nbsp;31, 2021, and was classified as a reduction of research and development costs in the accompanying Statement of Operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 8 &#8211; Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company&rsquo;s 2013 Stock Incentive Plan (the &ldquo;2013 Option Plan&rdquo;), up to 20,000,000 shares of the Company&rsquo;s common stock may be issued pursuant to awards granted in the form of incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, restricted stock, performance shares, and performance units to employees, directors and consultants of the Company and its affiliates. The 2013 Option Plan requires the exercise price of stock options to be not less than the fair value of the Company&rsquo;s common stock on the date of grant or 110% of fair value in the case of incentive options granted to a ten-percent stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December&nbsp;31, 2021, the Company issued stock options for 7,250,000 shares of common stock to directors and advisors and 250,000 to the Chairman (See Note 3) at an exercise price of $0.66 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&nbsp;31, 2022, all of the option holders converted the then aggregate outstanding options to acquire 18,705,451 shares into 9,150,051 shares of common stock pursuant to the cashless exercise provision of the 2013 Option Plan. A portion of the outstanding options (those with an exercise price of $1.25 per share) were repriced to an exercise price of $1.00 immediately before the cashless exercise. This modification of the stock option resulted in a charge to share-based compensation of $182,243, which is recorded within general and administrative expenses on the statement of consolidated operations during the year ended December&nbsp;31, 2022. The remaining outstanding stock options to acquire 166,060 shares of common stock were canceled during 2023 per cancellation agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 226; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December&nbsp;31, 2022, the Company has 1,128,489 options remaining available to be issued under the 2013 Option Plan. The following table summarizes stock-based activities, including the 250,000 options issued to the Chairman as part of the Chairman Note (see Note 3):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Shares<BR> Underlying<BR> Options</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Weighted<BR> Average<BR> Exercise<BR> Price</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Weighted<BR> Average<BR> Contractual<BR> Term to<BR> expiration<BR> (years)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding at December 31, 2020</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">11,371,511</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.60</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">5.82</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Granted</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">7,500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.66</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">9.17</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding at December 31, 2021</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">18,871,511</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercised</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(18,705,451</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Outstanding at December 31, 2022</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">166,060</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercisable Options at December 31, 2022</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">166,060</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.36</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Exercisable Options at December 31, 2021</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">16,454,844</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">$</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">0.63</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">6.55</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of stock option awards is estimated using the Black-Scholes option-pricing model. The estimated fair value of each stock option is then expensed over the vesting period, approximately three years. The determination of fair value using the Black-Scholes model is affected by the Company&rsquo;s share price and assumptions regarding a number of complex and subjective variables, including expected price volatility and the risk-free interest rate. Stock options granted in 2022 and 2021 were 0 and 7,500,000, respectively. Stock options granted during the year ended December&nbsp;31, 2021 were valued using the Black-Scholes option-pricing model with the following weighted average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 88%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">82.16</FONT></TD>
    <TD STYLE="width: 1%; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Risk free interest rate</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">1.50</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected dividend yield</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">0.00</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Expected life of options in years</FONT></TD>
    <TD STYLE="font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-style: italic; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">6.4</FONT></TD>
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value of stock options granted during 2021 was approximately $0.46. The weighted average fair value of stock options vested in 2022 and 2021 was approximately $0.92 and $0.92, respectively. Share-based compensation expense related to vesting stock options was $1,958,151 and $2,219,333 for the years ended December&nbsp;31, 2022 and 2021, respectively, and is recorded in the accompanying statements of operations within general and administrative expenses. The intrinsic value of stock options outstanding and exercisable at December&nbsp;31, 2022 was approximately $111,000. At December&nbsp;31, 2022, there was no unrecognized compensation cost related to non-vested options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 227; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 9 &#8211; Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no significant current income taxes due because of the losses generated in each period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and those used for income tax purposes. The Company&rsquo;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance to fully offset the gross deferred tax asset because it is not &ldquo;more likely than not&rdquo; that the Company will realize future benefits associated with these deferred tax assets at December&nbsp;31, 2022 and 2021. The valuation allowance increased by approximately 851,000 and $948,000 for the years ended December&nbsp;31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of the Company&rsquo;s deferred tax assets at December&nbsp;31, 2022 and 2021 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December&nbsp;31,</FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax assets:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net operating losses</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,732,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,578,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share based compensation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,405,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,044,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued wages</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">116,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">130,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred research and development costs</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">293,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred revenue and costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total deferred tax assets</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,773,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,924,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,773,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5,924,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax asset, net of valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The difference between income taxes at the statutory federal income tax rate and income taxes reported in the Statements of Operations is attributable to a full valuation allowance recorded in all periods since inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision for income taxes for the taxable periods ended December&nbsp;31, 2022 and 2021 differs from the statutory federal income tax rate for the years ended December&nbsp;31, 2022 and 2021 as follows: 2022 to be reviewed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax benefit at the Federal statutory rate</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">State tax, net of Federal benefit</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Permanent differences</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.4</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.4</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in the valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(27.6</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28.4</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective income tax rate</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December&nbsp;31, 2022, the Company had Federal net operating loss carryforwards of approximately $13,300,000, which will begin to expire in 2035. Of the total Federal net operating losses, the amounts incurred after 2017 of approximately $6,200,000 will carry forward indefinitely. Sections&nbsp;382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any year may be limited. Although the Company has not undertaken a formal analysis, it is likely that such an ownership change occurred prior to 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&rsquo;s financial statements as of December&nbsp;31, 2022 or 2021. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. No tax audits were commenced or were in process for the taxable periods that ended December&nbsp;31, 2022 and 2021. No tax related interest or penalties were incurred during the years ended December&nbsp;31, 2022 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 228; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Note 10 &#8211; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through August&nbsp;2, 2023, the date the financial statements were available to be issued and determined that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements except for the transactions described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>USC License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;5, 2023, NeOnc amended the exclusive license agreement with USC dated March&nbsp;9, 2009 (see Note 3) (&ldquo;Amended Agreement&rdquo;) to include all of the worldwide patents developed by the Company related to the biotechnology under development by the Company. The Amended Agreement also had NeOnc Technologies Holding Company, Inc. (&ldquo;Newco&rdquo;) as a licensee. In addition, the Amended Agreement contained the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; color: #222222; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company will issue to USC, within fifteen (15) days of the Amended Agreement, shares of common stock of the Company which (when combined with shares previously held by USC) represents three and one-half percent (3.5%) of the fully diluted capitalization of Newco after completion of the transactions contemplated in the LOI. (see Note 1). The Company expects to record the estimated fair value of the shares to be issued as a liability until the shares are issued.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; color: #222222; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">The Company will pay USC nonrefundable earned royalties of 4% on Net Sales of Licensed Products covered by the licensed patents in all countries in which the manufacture, use, sale, offer for sale, or import of such Licensed Products, as such capitalized terms are defined in the Amended Agreement. To date, no sales have been made using the Licensed Products, and no royalties are due to USC.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company will assume responsibility for patent-related costs.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Share Exchange</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;7, 2023, the Company entered into Share Exchange Agreements with Newco, whereby all of the common and preferred shareholders of the Company exchanged their stock in the Company for a total of 10,500,000 shares of common stock in Newco. At the consummation of this transaction, AFH, its affiliated entities, individuals, or assignees owned an aggregate of 34.6% of the fully diluted issued and outstanding common shares of Newco. The Company expects to account for this transaction as a reverse capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options Cancelled</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January&nbsp;2023, the remaining 166,060 options to acquire shares of common stock were canceled pursuant to cancellation agreements with the option holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><U>Legal Matters</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is involved in various disputes, claims, liens and litigation matters arising out of the normal course of business which could result in a material adverse effect on the Company&rsquo;s combined financial position, results of operations or cash flows. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. As of December 31, 2022 and 2021, the Company had no liabilities recorded for loss contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 6, 2023, a vendor filed a complaint against the Company for breach of contract in the Central District of California. The vendor alleged that the Company improperly terminated an Intellectual Property License and Supply Agreement (&ldquo;IPLSA&rdquo;) and that the Company also defrauded the vendor in connection with the IPLSA. The vendor made an initial settlement demand of $12 million, which was rejected by the Company. The Company denies that it breached the IPLSA or defrauded the vendor and does not believe the matter will have a material impact on the financial condition of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 14, 2023, the Company terminated its collaboration agreement with OEP. OEP retained counsel which informed the Company that it believed that the collaboration agreement was improperly terminated by the Company and intended to take legal action in connection therewith. The Company and OEP are discussing possible settlement, including the possibility of a new agreement between the parties, of this matter prior to arbitration. As of the date of this report, the matter remains unresolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.15pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>NB License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2023, the Company terminated the NB license agreement, and no consideration was paid or received related to such termination.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 229; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">NEONC TECHNOLOGIES HOLDINGS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">PRELIMINARY PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole Bookrunning Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Loop Capital Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><I>Co-Managers</I></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 12pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 33%"><P STYLE="margin: 0; font: 12pt Times New Roman, Times, Serif"> <B>Maxim Group LLC</B> </P></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 34%"></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; width: 33%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Brookline
    Capital Markets,</B></FONT> </TD> </TR>
  <TR STYLE="font: 12pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a division of Arcadia Securities, LLC</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024</FONT> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or any sale of these securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024 (25 days after the commencement of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this prospectus, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 230; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION NOT REQUIRED IN PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the costs and expenses payable by us (the Registrant), other than underwriting discounts and commissions, in connection with the issuance and distribution of the securities being registered hereunder. All of the amounts shown are estimates, except for the SEC Registration Fee and FINRA filing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amounts<BR> to be Paid</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%"><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Nasdaq filing fee</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Printing fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">100,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">600,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">250,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Transfer agent and registrar fees</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">10,000</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Miscellaneous fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be completed by amendment.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;14. INDEMNIFICATION OF OFFICERS AND DIRECTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides that no director of the registrant shall be personally liable to it or its shareholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our bylaws authorize the indemnification of our officers and directors, consistent with Section&nbsp;145 of the DGCL, as amended. Reference is made to Section&nbsp;102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director&rsquo;s fiduciary duty, except (i) for any breach of the director&rsquo;s duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section&nbsp;174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (iv) for any transaction from which a director derived an improper personal benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 231; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&rsquo; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM&nbsp;15. RECENT SALES OF UNREGISTERED SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set forth below is information regarding shares of capital stock issued by us within the past three years. Also included is the consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December&nbsp;31, 2021 NeOnc Technologies, Inc. issued stock options for 7,250,000 shares of common stock to directors and advisors and, in connection with the Chairman Note, 250,000 options to the Chairman at an exercise price of $0.66 per share. On December&nbsp;31, 2022, all of the option holders converted the then aggregate outstanding options to acquire 18,705,451 shares into 9,150,051 shares of common stock pursuant to the cashless exercise provision of the 2013 Option Plan. A portion of the outstanding options (those with an exercise price of $1.25 per share) were repriced to an exercise price of $1.00 immediately before the cashless exercise. This modification of the stock option resulted in a charge to share-based compensation of $182,243, which is recorded within general and administrative expenses on the statement of consolidated operations during the year ended December&nbsp;31, 2022. The remaining outstanding stock options to acquire 166,060 shares of common stock were cancelled during 2023 per cancellation agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between January&nbsp;2022 and December&nbsp;2022, 2.4 million shares of our NeOnc Technologies, Inc.&rsquo;s common stock were issued for $1 per share in private placements, amounting to net proceeds of $2.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&nbsp;2022, NeOnc Technologies, Inc. issued a $50,000 convertible note to a shareholder due August&nbsp;30, 2023 (&ldquo;Note&rdquo;). The Note bears interest at 2% per annum and is convertible. This Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&ldquo;Conversion Stock&rdquo;) that is sold by the Company in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering (&ldquo;IPO&rdquo;), of equity securities by the Company to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company, at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January&nbsp;2023, NeOnc Technologies Holdings, Inc. issued 4,500,000 shares of its common stock to seven accredited investors at a per share price of $0.0001. In April&nbsp;2023, NeOnc Technologies Holdings, Inc. effected a 1.222222-for-1 forward split of the outstanding shares of its common stock, resulting in 5,500,000 shares of common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April&nbsp;2023, following effectiveness of the forward split, NeOnc Technologies Holdings, Inc. issued 10,500,000 shares of its common stock to sixty-seven (67) accredited investors in exchange for shares of stock in NeOnc Technologies, Inc. held by such investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 232; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to an amendment to our license agreement with the University of Southern California, we issued the university 560,000 shares of our common stock in September 2023 in consideration for amending the terms of such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 800,000
restricted stock units were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock units will be time vested;
one-third (1/3) will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments
over a one (2.5) year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be
performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&rsquo;s individual
grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 300,000
restricted stock units were granted to Patrick Walters. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&rsquo;s individual grant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 360,000
restricted stock units were granted to Keithly Garnett. Two-thirds of such restricted stock units will be time vested; one-third (1/3)
will vest seven months after the effective date of this offering and one-third will vest in equal monthly installments over a one (1)
year period commencing on the eighth month from the effective date of this offering. The remaining one-third will be performance-based,
the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&rsquo;s individual grant
agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 1,000,000
restricted stock units were granted to Amir Heshmatpour. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Nasim Shomali. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 750,000
restricted stock units, subject to adjustment, were granted to Dr. Sikirat Iyabo Tinubu-Karch, M.D. The forgoing restricted stock units
will vest upon certain financial metrics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Richard Nanula. The forgoing restricted stock units will vest one hundred percent (100%) seven
months following the effective date of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In January 2024, 3,750
restricted stock units were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock units will vest one hundred percent (100%)
seven months following the effective date of this offering. </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule&nbsp;701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&nbsp;701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 233; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;16. Exhibits and Financial Statement Schedules.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See the Exhibit Index on the page immediately preceding the signature page for a list of exhibits filed as part of this registration statement on Form S-1, which Exhibit Index is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Financial Statement Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;17. Undertakings.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser each prospectus filed pursuant to Rule&nbsp;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A (&sect; 230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 234; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s annual report pursuant to section&nbsp;13(a) or section&nbsp;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes that:</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 235; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT INDEX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B><B><BR> Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: left; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Form of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">3.1**</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex3-1.htm">Certificate of Incorporation of NeOnc Technologies Holdings, Inc., as currently in effect</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">3.2</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex3-2.htm">Certificate of Amendment of NeOnc Technologies Holdings, Inc., as currently in effect</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Form of Amended and Restated Certificate of Incorporation </FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">3.4</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex3-4.htm">Bylaws of NeOnc Technologies Holdings, Inc., as currently in effect</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">3.5*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Form of Amended and Restated Bylaws</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">4.1</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex4-1.htm">Form of Common Stock Certificate</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">4.2</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex4-2.htm">Promissory Note, dated February&nbsp;17, 2022, by NeOnc Technologies, Inc. to R &amp; J Brownstone</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">4.3</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex4-3.htm">Fourth Amended &amp; Restated Promissory Note, dated December&nbsp;4, 2023, by NeOnc Technologies Holdings, Inc. and Holders</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Opinion of Manatt, Phelps &amp; Phillips, LLP</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.1<B>#</B></FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-1.htm">NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.2#</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-2.htm">Form of First Amendment to the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> 10.3#** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-3.htm">Form of Stock Option Agreement</A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> 10.4#** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-4.htm">Form of Option Exercise Agreement</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> 10.5#** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-5.htm">Form of Option Exercise Agreement</A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> 10.6#** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-6.htm">Form of Restricted Stock Agreement</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> 10.7#** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-7.htm">Form of Restricted Share Unit Agreement</A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">10.8<B>#*</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Form of Indemnity Agreement between NeOnc Technologies Holdings, Inc. and each of its directors and executive officers</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.9</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-9.htm">Amended and Restated Exclusive License Agreement by and between University of Southern California, and NeOnc Technologies, Inc.</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.10</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-10.htm">Engagement Agreement dated December 19, 2022, between NeOnc Technologies, Inc. and AFH Holdings and Advisory, LLC</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.11</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-11.htm">Form of Share Exchange Agreement dated April 7, 2023 between NeOnc Technologies, Inc. and NeOnc Technologies Holdings, Inc</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.12</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-12.htm">Financial Advisory Agreement dated October 16, 2023, between NeOnc Technologies Holdings, Inc. and Maxim Group LLC</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"> <FONT STYLE="font-size: 10pt">10.13</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex10-13.htm">Collaboration and License Agreement dated November 8, 2013, between Orient Europharma Co., LTD. and NeOnc Technologies, Inc.</A></FONT> </TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center; width: 9%"> <FONT STYLE="font-size: 10pt">10.14#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 90%"> <A HREF="neonctechnologies_ex10-14.htm">Employment Agreement
    dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Keithly Garnett</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.15#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="neonctechnologies_ex10-15.htm">Employment Agreement dated January
    4, 2024, between NeOnc Technologies Holdings, Inc. and Patrick Walters</A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.16#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="neonctechnologies_ex10-16.htm">Employment Agreement dated January
    4, 2024, between NeOnc Technologies Holdings, Inc. and Dr. Thomas C. Chen</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.17#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex10-17.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Dr. Richard Nanula</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.18#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex10-18.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Thomas C. Chen</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.19#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex10-19.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Amir Heshmatpour</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.20#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="neonctechnologies_ex10-20.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Keithly Garnett</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.21#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <A HREF="neonctechnologies_ex10-21.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Patrick Walters</A> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.22#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <A HREF="neonctechnologies_ex10-22.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Nasim Shomali</A> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.23#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex10-23.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Dr. Iyabo Tinubu-Karch, M.D.</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">10.24#</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex10-24.htm">Restricted Stock Award Agreement dated January 4, 2024, between NeOnc Technologies Holdings, Inc. and Dr. Victoria Medvec, Ph.D.</A></FONT> </TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center; width: 9%"> <FONT STYLE="font-size: 10pt">21.1</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 90%"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex21-1.htm">List of Subsidiaries of NeOnc Technologies Holdings, Inc.</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Manatt, Phelps &amp; Phillips LLP (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">23.2</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex23-2.htm">Consent of Marcum LLP</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">24.1</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_s1.htm#poa">Power of Attorney</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">99.1</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex99-1.htm">Consent of Nasim Shomali, director nominee</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">99.2</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex99-2.htm">Consent of Dr. Iyabo Tinubu-Karch, M.D., director nominee</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">99.3</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex99-3.htm">Consent of Richard Nanula, director nominee</A></FONT> </TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">99.4</FONT>** </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1979414/000182912623008101/neonctechnologies_ex99-4.htm">Consent of Dr. Victoria Medvec, Ph.D., director nominee</A></FONT> </TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-size: 10pt">107</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-size: 10pt"><A HREF="neonctechnologies_ex107.htm">SEC Filing Fee Table</A></FONT> </TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To be filed by amendment.</B></FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"></TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt"><B>**</B></FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt"><B>Previously filed.</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indicates management contract or compensatory plan.</B></FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 236; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT style="font: 10pt Times New Roman, Times, Serif"><a href="#toc1">Table of Contents</a></font></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SIGNATURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="background-color: white">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Los Angeles, California, on January 12, 2024.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dr. Thomas C. Chen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Dr. Thomas C. Chen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As required under the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dr. Thomas C. Chen</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">
        <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chairman</FONT> </P></TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> January 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Thomas C. Chen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Principal Executive Officer</I>)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Keithly Garnett</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">
        <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</FONT> </P></TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> January 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keithly Garnett</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Principal Accounting Officer</I>)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amir Heshmatpour</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman and Secretary</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> January 12, 2024 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir Heshmatpour</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 237; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>neonctechnologies_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.14</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EMPLOYMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Employment Agreement (the &ldquo;Agreement&rdquo;) is entered into as of the 4th day of January, 2024, by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Keithly A. Garnett, an individual residing at the address set forth on Schedule A hereto (the &ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>INTRODUCTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company is in the business of the development and commercialization of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain (the &ldquo;Business&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company wishes to employ the Executive under the title and capacity set forth on Schedule A hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Executive desires to be employed by the Company in such capacity, subject to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOW, THEREFORE, in consideration of the premises and mutual promises herein below set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Employment Period</U>. The initial term of the Executive&rsquo;s employment by the Company (directly or through its wholly-owned subsidiary NeOnc Technologies, Inc.) pursuant to this Agreement shall commence upon the effective date of the Company&rsquo;s initial public offering if such public offering occurs on or before June&nbsp;30, 2024 (the &ldquo;Effective Date&rdquo;) and shall continue for and shall continue through and expire on that date which is seven months from the Effective Date (the &ldquo;Employment Period&rdquo;). Thereafter, the Employment Period shall automatically renew for successive periods of one (1) year each, unless either party shall have given to the other at least fifteen (15) days&rsquo; prior written notice of their intention not to renew the Executive&rsquo;s employment prior to the end of the Employment Period or the then applicable renewal term, as the case may be. In any event, the Employment Period may be terminated as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Employment; Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Subject to the terms and conditions set forth herein, the Company hereby employs the Executive to act for the Company during the Employment Period in the capacity set forth on Schedule A hereto, and the Executive hereby accepts such employment. The duties and responsibilities of the Executive shall include such duties and responsibilities appropriate to such office and as are normally associated with and appropriate for such position and as the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) may from time to time reasonably assign to the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive recognizes that during the period of Executive&rsquo;s employment hereunder, Executive owes an undivided duty of loyalty to the Company, and Executive will use Executive&rsquo;s good faith efforts to promote and develop the business of the Company and its subsidiaries (the Company&rsquo;s subsidiaries from time to time, together with any other affiliates of the Company, the &ldquo;Affiliates&rdquo;). Executive shall devote all of Executive&rsquo;s business time, attention and skills to the performance of Executive&rsquo;s services as an executive of the Company. Recognizing and acknowledging that it is essential for the protection and enhancement of the brand name, reputation and business of the Company and the goodwill pertaining thereto, Executive shall perform the Executive&rsquo;s duties under this Agreement professionally, in accordance with the applicable laws, rules and regulations and such standards, policies and procedures established by the Company and the industry from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) However, the parties agree that: (i) Executive may devote a reasonable amount of his time to civic, community, or charitable activities and may serve as a director of other corporations (provided that any such other corporation is not a competitor of the Company, as determined by the Board) and to other types of business or public activities not expressly mentioned in this paragraph and (ii) Executive may participate as a non-employee director and/or investor in other companies and projects as disclosed by Executive to, and approved by, the Board, so long as Executive&rsquo;s responsibilities with respect thereto do not conflict or interfere with the faithful performance of his duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>Place of Employment</U>. The Executive&rsquo;s services shall be performed at the Company&rsquo;s offices located at 8335 Sunset Boulevard, Suite 240, Los Angeles, California, 90069, at any other location at which the Company now or hereafter has a business facility, at employee&rsquo;s home office, or at any other location where Executive&rsquo;s presence is necessary to perform his duties. The parties acknowledge that the Executive may be required to travel in connection with the performance of his duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Base Salary</U>. The Executive shall be entitled to receive a salary from the Company during the Employment Period at a rate per year indicated on Schedule A hereto (the &ldquo;Base Salary&rdquo;). Once the Board has established the Base Salary, such Base Salary shall be payable in monthly installments in accordance with the Company&rsquo;s customary payroll practices. The Executive&rsquo;s Base Salary may be increased on each anniversary of the Effective Date, at the Board&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Bonus</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive shall be eligible to participate in any bonus or incentive program established by the Company for executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. <U>Other Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Grant of Restricted Stock Units. The Executive shall be entitled to receive a number of restricted stock units (&ldquo;Restricted Stock Units&rdquo;) as in accordance with the terms of a separate Restricted Stock Unit Award Agreement set forth on Exhibit A hereto. Any additional equity awards to the Executive shall be at the option of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Restrictions. Any and all shares of stock, options, restricted stock units and other equity awards granted to or owned by the Executive will be subject to the share ownership guidelines and insider trading and blackout policies adopted from time to time by the Board of Directors for senior executives of the Company and will also be subject to applicable holding periods and transaction reporting requirements under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Insurance and Other Benefits. During the Employment Period, the Executive and the Executive&rsquo;s dependents shall be entitled to participate in any Company insurance programs and any applicable benefit plans, as the same may be adopted and/or amended from time to time (the &ldquo;Benefits&rdquo;). The Executive shall be bound by all of the policies and procedures relating to Benefits established by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) Vacation; Personal Days. During the Employment Period, the Executive shall be entitled to an annual vacation of such duration consistent with the Company&rsquo;s policies from time to time, as determined by the Board. The Executive shall be entitled to paid personal days on a basis consistent with the Company&rsquo;s other senior executives, as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) Expense Reimbursement. The Company shall reimburse the Executive for all reasonable business, promotional, travel, education (a minimum of 50% as agreed) and entertainment expenses (&ldquo;Reimbursable Expenses&rdquo;) incurred or paid by the Executive during the Employment Period in the performance of Executive&rsquo;s services under this Agreement on a basis consistent with the Company&rsquo;s other senior executives, as determined by the Board, provided that the Executive furnishes to the Company appropriate documentation required by the Code and/or other taxing authorities in a timely fashion in connection with such expenses and shall furnish such other documentation and accounting as the Company may from time to time reasonably request. For purposes of this Agreement, &ldquo;Code&rdquo; means the U.S. Internal Revenue Code of 1986 (as it has been and may be amended from time to time) and any regulations and guidance that has been promulgated or may be promulgated from time to time thereunder and any state law of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. <U>Termination; Compensation Due Upon Termination of Employment</U>. The Executive&rsquo;s employment with the Company shall be entirely &ldquo;at-will,&rdquo; meaning that either the Executive or the Company may terminate such employment relationship by terminating this Agreement in writing delivered to the other party at any time for any reason or for no reason at all, subject, however, to the terms of this Section&nbsp;7. The Executive&rsquo;s right to compensation for periods after the date his employment with the Company terminates shall be determined in accordance with the provisions of paragraphs (a) through (e) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Voluntary Resignation; Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Voluntary Resignation</U>. The Executive may terminate his employment at any time upon thirty (30) days prior written notice to the Company. In the event of the Executive&rsquo;s voluntary termination of employment other than for Good Reason (as defined below), the Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, except as otherwise required by this Agreement or by applicable law, to provide the benefits described in Section&nbsp;6 for periods after the date on which the Executive&rsquo;s employment with the Company terminates due to the Executive&rsquo;s voluntary resignation, except for the payment of the Executive&rsquo;s Base Salary accrued through the date of such resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(A) If the Executive&rsquo;s employment is terminated by the Company without Cause (as defined below): the Company shall (x) continue to pay the Executive the Base Salary (at the rate in effect on the date the Executive&rsquo;s employment is terminated) until the end of the Severance Period (as defined below), and (y) pay any other accrued compensation and Benefits. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(B) If, following a termination of employment without Cause, the Executive breaches the provisions of Section&nbsp;10 hereof or that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, the Executive shall not be eligible, as of the date of such breach, for the payments and benefits described in Section&nbsp;7(a)(ii)(A) above, and any and all obligations and agreements of the Company with respect to such payments shall thereupon cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">(b) Discharge for Cause. Upon written notice to the Executive, the Company may terminate the Executive&rsquo;s employment for &ldquo;Cause&rdquo; if any of the following events shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) any act or omission that constitutes a material breach by the Executive of any of his obligations under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) the willful and continued failure or refusal of the Executive to satisfactorily perform the duties reasonably required of him as an employee of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) the Executive&rsquo;s conviction of, or plea of nolo contendere to, (i) any felony or (ii) a crime involving dishonesty or moral turpitude or which could reflect negatively upon the Company or otherwise impair or impede its operations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the Executive&rsquo;s engaging in any misconduct, negligence, act of dishonesty (including, without limitation, theft or embezzlement), violence, threat of violence or any activity that could result in any violation of federal securities laws, in each case, that is injurious to the Company or any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) the Executive&rsquo;s material breach of a written policy of the Company or the rules of any governmental or regulatory body applicable to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vi) the Executive&rsquo;s refusal to follow the directions of the Board, unless such directions are, in the written opinion of legal counsel, illegal or in violation of applicable regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vii) any other willful misconduct by the Executive which is materially injurious to the financial condition or business reputation of the Company or any of its Affiliates, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(viii) the Executive&rsquo;s breach of his obligations under Section&nbsp;10 hereof or under that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">In the event Executive is terminated for Cause, the Company shall have no obligation to make payments to Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law, to provide the benefits described in Section&nbsp;6, for periods after the Executive&rsquo;s employment with the Company is terminated on account of the Executive&rsquo;s discharge for Cause except for the Executive&rsquo;s then applicable Base Salary accrued through the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Disability</U>. The Company shall have the right, but shall not be obligated to, terminate the Executive&rsquo;s employment hereunder in the event the Executive becomes disabled such that he is unable to discharge his duties to the Company for a period of ninety (90) consecutive days or one hundred twenty (120) days in any one hundred eighty (180) consecutive day period (unless longer periods are not required under applicable local labor regulations) (a &ldquo;Permanent Disability&rdquo;). In the event of a termination of employment due to a Permanent Disability, the Company shall be obligated to continue to make payments to the Executive in an amount equal to the then applicable Base Salary for the Severance Period (as defined below), payable in the form of salary continuation for the applicable Severance Period after the Executive&rsquo;s employment with the Company is terminated due to a Permanent Disability. A determination of a Permanent Disability shall be made by a physician satisfactory to both the Executive and the Company; provided, however, that if the Executive and the Company do not agree on a physician, the Executive and the Company shall each select a physician and those two physicians together shall select a third physician, whose determination as to a Permanent Disability shall be binding on all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Death</U>. The Executive&rsquo;s employment hereunder shall terminate upon the death of the Executive. The Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law or the terms of any applicable benefit plan, to provide the benefits described in Section&nbsp;6 for periods after the date of the Executive&rsquo;s death except for then applicable Base Salary earned and accrued through the date of death, payable to the Executive&rsquo;s beneficiary, as the Executive shall have indicated in writing to the Company (or if no such beneficiary has been designated, to Executive&rsquo;s estate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Termination for Good Reason</U>. The Executive may terminate this Agreement at any time for Good Reason. In the event of termination under this paragraph (e), the Company shall pay to the Executive severance in an amount equal to the Executive&rsquo;s then applicable Base Salary for a period equal to the number of months set forth on Schedule A hereto (the &ldquo;Severance Period&rdquo;), subject to the Executive&rsquo;s continued compliance with Section&nbsp;10 hereof and with that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, payable in the form of salary continuation for the applicable Severance Period following the Executive&rsquo;s termination, and subject to the Company&rsquo;s regular payroll practices and required withholdings. Such severance shall be reduced by any cash remuneration paid to the Executive because of the Executive&rsquo;s employment or self-employment during the Severance Period. The Executive shall continue to receive all Benefits (either through the Company or an Affiliate) during the Severance Period. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such resignation. For the purposes of this Agreement, &ldquo;Good Reason&rdquo; shall mean any of the following (without Executive&rsquo;s express written consent):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) ;the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) removal of the Executive from his position as indicated on Schedule A hereto, or the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed under this Agreement, within twelve (12) months after a Change of Control (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) a reduction by the Company in the Executive&rsquo;s then applicable Base Salary or other compensation, unless said reduction is pari passu with other senior executives of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the taking of any action by the Company that would, directly or indirectly, materially reduce the Executive&rsquo;s benefits, unless said reductions are pari passu with other senior executives of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) a breach by the Company of any material term of this Agreement that is not cured by the Company within thirty (30) days following receipt by the Company of written notice thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f) <U>Notice of Termination</U>. Any termination of employment by the Company or the Executive shall be communicated by a written &ldquo;Notice of Termination&rdquo; to the other party hereto given in accordance with Section&nbsp;18 of this Agreement. In the event of a termination by the Company for Cause, the Notice of Termination shall (i) indicate the specific termination provision in this Agreement relied upon, (ii) set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive&rsquo;s employment under the provision so indicated and (iii) specify the date of termination, which date shall be the date of such notice. The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive&rsquo;s or the Company&rsquo;s rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) <U>Resignation of Executive Officer</U>. The termination of the Executive&rsquo;s employment for any reason will constitute the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive has with the Company or any of its Affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive holds with respect to any employee benefit plans or trusts established by the Company. The Executive agrees that this Agreement shall serve as written notice of resignation in this circumstance, unless otherwise required by any plan or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. <U>Section&nbsp;409A</U>. It is intended that
all payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A
provided under Treasury Regulations Sections&nbsp;1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed
to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions
hereunder) will be construed in a manner that complies with Section&nbsp;409A. For all purposes of Code Section&nbsp;409A (including,
without limitation, for purposes of Treasury Regulations Sections&nbsp;1.409A 2(b)(2)(i) and (iii)), Executive&rsquo;s right to receive
any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to
receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate
and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time
of Executive&rsquo;s Separation from Service (for purposes of this Agreement, &ldquo;Separation from Service&rdquo; means a &ldquo;separation
from service&rdquo;, as defined under Treasury Regulation Section&nbsp;1.409A-1(h))to be a &ldquo;specified employee&rdquo; for purposes
of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other
agreement with the Company are deemed to be &ldquo;deferred compensation,&rdquo; then to the extent delayed commencement of any portion
of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to Executive prior to the earliest of (i) the first date following
expiration of the six-month period following the date of Executive&rsquo;s Separation from Service with the Company, (ii) the date of
Executive&rsquo;s death or (iii) such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon
the first business day following the expiration of such applicable Code Section&nbsp;409A(a)(2)(B)(i) period, all payments deferred pursuant
to this paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein
or in the applicable agreement. No interest shall be due on any amounts so deferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. <U>Section&nbsp;280G</U>. If any payment or benefit Executive will or may receive from the Company or otherwise (a &ldquo;<U>280G Payment</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section&nbsp;280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<U>Reduced Amount</U>&rdquo; hall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&rsquo;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &ldquo;<U>Reduction Method</U>&rdquo;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &ldquo;<U>Pro Rata Reduction Method</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &ldquo;deferred compensation&rdquo; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change in control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive&rsquo;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other reasonable time as requested by Executive or the Company.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If Executive receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. <U>Non-Competition; Non-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) For the duration of the Employment Period and, unless the Company terminates the Executive&rsquo;s employment without Cause, during the Severance Period (the &ldquo;Non-compete Period&rdquo;), the Executive shall not, directly or indirectly, except as specifically provided in the last sentence of Section&nbsp;2(c) hereof, engage or invest in, own, manage, operate, finance, control or participate in the ownership, management, operation, financing, or control of, be employed by, associated with, or in any manner connected with, lend any credit to, or render services or advice to, any business, firm, corporation, partnership, association, joint venture or other entity that engages or conducts any business the same as or substantially similar to the Business or any other business engaged in or proposed to be engaged in or conducted by the Company and/or any of its Affiliates during the Employment Period, or then included in the future strategic plan of the Company and/or any of its Affiliates, anywhere within North America; provided, however, that the Executive may own less than 5% in the aggregate of the outstanding shares of any class of securities of any enterprise (but without otherwise participating in the activities of such enterprise), other than any such enterprise with which the Company competes or is currently engaged in a joint venture, if such securities are of a class listed on any national or regional securities exchange or have been registered under Section&nbsp;12(b) or (g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) During the Employment Period and for a period of twelve (12) months following termination of the Executive&rsquo;s employment with the Company, the Executive shall not solicit or attempt to recruit any employee, or independent contractor of, or consultant to, the Company, or its Affiliates, to leave the employment (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is party to an employment agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) The Executive recognizes and agrees that because a violation by the Executive of his obligations under this Section will cause irreparable harm to the Company that would be difficult to quantify and for which money damages would be inadequate, the Company shall have the right to injunctive relief to prevent or restrain any such violation, without the necessity of posting a bond. The Non-compete Period will be extended by the duration of any violation by the Executive of any of his obligations under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) The Executive expressly agrees that the character, duration and scope of the covenant not to compete are reasonable in light of the circumstances as they exist at the date upon which this Agreement has been executed. However, should a determination nonetheless be made by a court of competent jurisdiction at a later date that the character, duration or geographical scope of the covenant not to compete is unreasonable in light of the circumstances as they then exist, then it is the intention of the Executive, on the one hand, and the Company, on the other, that the covenant not to compete shall be construed by the court in such a manner as to impose only those restrictions on the conduct of the Executive which are reasonable in light of the circumstances as they then exist and necessary to assure the Company of the intended benefit of the covenant not to compete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. <U>Inventions and Patents</U>. The Executive acknowledges that all inventions, innovations, improvements, know-how, plans, development, methods, designs, analyses, specifications, software, drawings, reports and all similar or related information (whether or not patentable or reduced to practice) which related to any of the Company&rsquo;s actual or proposed business activities and which are created, designed or conceived, developed or made by the Executive during the Executive&rsquo;s past or future employment by the Company or any Affiliates, or any predecessor thereof (&ldquo;Work Product&rdquo;), belong to the Company, or its Affiliates, as applicable. Any copyrightable work falling within the definition of Work Product shall be deemed a &ldquo;work made for hire&rdquo; and ownership of all right title and interest shall rest in the Company. The Executive hereby irrevocably assigns, transfers and conveys, to the full extent permitted by law, all right, title and interest in the Work Product, on a worldwide basis, to the Company to the extent ownership of any such rights does not automatically vest in the Company under applicable law. The Executive will promptly disclose any such Work Product to the Company and perform all actions requested by the Company (whether during or after employment) to establish and confirm ownership of such Work Product by the Company (including, without limitation, assignments, consents, powers of attorney and other instruments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. <U>Executive&rsquo;s Representation</U>. The Executive hereby represents that the Executive&rsquo;s entry into this Agreement and performance of the services hereunder will not violate the terms or conditions of any other agreement to which the Executive is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. <U>Arbitration of All Disputes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Agreement to Arbitrate</U>. To ensure the timely and economical resolution of disputes that may arise between Executive and the Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#xa7;1-16, and to the fullest extent permitted by applicable law, Executive and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or (ii) Executive&rsquo;s employment with the Company (including but not limited to all statutory claims); or (iii) the termination of Executive&rsquo;s employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EXECUTIVE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Arbitrator Authority</U>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Individual Capacity Only</U>. All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Arbitration Process</U>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS in Los Angeles, California, or as otherwise agreed to by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). Executive and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own expense. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute; (ii) issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Injunctive Relief and Final Orders</U>. Nothing in this Section is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. <U>Governing Law/Jurisdiction</U>. This Agreement and any disputes or controversies arising hereunder shall be construed and enforced in accordance with and governed by the internal laws of the State of California without regard to the conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. <U>Public Company Obligations; Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Executive acknowledges that the Company intends to become a publicly reporting company whose shares of common stock will be registered under the U.S. Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and whose common stock will be registered under the Exchange Act, and that, after the Company becomes a publicly reporting company, this Agreement will be subject to the public filing requirements of the Exchange Act. In addition, both parties acknowledge that the Executive&rsquo;s compensation and perquisites (each as determined by the rules of the US Securities and Exchange Commission (the &ldquo;SEC&rdquo;) or any other regulatory body or exchange having jurisdiction) (which may include benefits or regular or occasional aid/assistance, such as recreation, club memberships, meals, education for his family, vehicle, lodging or clothing, occasional bonuses or anything else he receives, during the Employment Period and any renewals thereof, in cash or in kind) paid or payable or received or receivable under this Agreement or otherwise, and his transactions and other dealings with the Company, may be required to be publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive acknowledges and agrees that the applicable insider trading rules, transaction reporting rules, limitations on disclosure of non-public information and other requirements set forth in the Securities Act, the Exchange Act and rules and regulations promulgated by the SEC may apply to this Agreement and Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Executive (on behalf of himself, as well as the Executive&rsquo;s executors, heirs, administrators and assigns) absolutely and unconditionally agrees to indemnify and hold harmless the Company and all of its past, present and future affiliates, executors, heirs, administrators, shareholders, employees, officers, directors, attorneys, accountants, agents, representatives, predecessors, successors and assigns from any and all claims, debts, demands, accounts, judgments, causes of action, equitable relief, damages, costs, charges, complaints, obligations, controversies, actions, suits, proceedings, expenses, responsibilities and liabilities of every kind and character whatsoever (including, but not limited to, reasonable attorneys&rsquo; fees and costs) in the event of Executive&rsquo;s breach of any obligation of Executive under the Securities Act, the Exchange Act, any rules promulgated by the SEC and any other applicable federal, state or foreign laws, rules, regulations or orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16. <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and thereof and supersedes and cancels any and all previous agreements, both written and oral, regarding the subject matter hereof between the parties hereto. This Agreement shall not be changed, altered, modified or amended, except by a written agreement signed by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">17. <U>Notices</U>. All notices, requests, demands and other communications called for or contemplated hereunder shall be in writing and shall be deemed to have been given when delivered to the party to whom addressed or when sent by telecopy (if promptly confirmed by registered or certified mail, return receipt requested, prepaid and addressed) to the parties, their successors in interest, or their assignees at the following addresses, or at such other addresses as the parties may designate by written notice in the manner aforesaid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(a)</TD>
    <TD STYLE="text-align: justify">to the Company at:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">NeOnc Technologies Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">8335 Sunset Boulevard, Suite 240</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Los Angeles, California, 90069</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: info@neonctech.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Manatt, Phelps and Phillips, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">695 Town Center Drive, 14th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Costa Mesa, CA 92629</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Thomas J. Poletti, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: tpoletti@manatt.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(b)</TD>
    <TD STYLE="text-align: justify">to the Executive as set forth on Schedule A hereto.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All such notices, requests and other communications will (i) if delivered personally to the address as provided in this Section, be deemed given upon delivery, (ii) if delivered by facsimile transmission to the facsimile number as provided for in this Section, be deemed given upon facsimile confirmation, (iii) if delivered by mail in the manner described above to the address as provided for in this Section, be deemed given on the earlier of the third business day following mailing or upon receipt and (iv) if delivered by overnight courier to the address as provided in this Section, be deemed given on the earlier of the first business day following the date sent by such overnight courier or upon receipt (in each case regardless of whether such notice, request or other communication is received by any other person to whom a copy of such notice is to be delivered pursuant to this Section). Either party may, by notice given to the other party in accordance with this Section, designate another address or person for receipt of notices hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18. <U>Severability</U>. If any term or provision of this Agreement, or the application thereof to any person or under any circumstance, shall to any extent be invalid or unenforceable, the remainder of this Agreement, or the application of such terms to the persons or under circumstances other than those as to which it is invalid or unenforceable, shall be considered severable and shall not be affected thereby, and each term of this Agreement shall be valid and enforceable to the fullest extent permitted by law. The invalid or unenforceable provisions shall, to the extent permitted by law, be deemed amended and given such interpretation as to achieve the economic intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">19. <U>Waiver</U>. The failure of any party to insist
in any one instance or more upon strict performance of any of the terms and conditions hereof, or to exercise any right or privilege
herein conferred, shall not be construed as a waiver of such terms, conditions, rights or privileges, but same shall continue to remain
in full force and effect. Any waiver by any party of any violation of, breach of or default under any provision of this Agreement by
the other party shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation of,
breach of or default under any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">20. <U>Successors and Assigns</U>. This Agreement shall be binding upon the Company and any successors and assigns of the Company. Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive. The Company may assign this Agreement and its right and obligations hereunder, in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">21. <U>Counterparts</U>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Additionally, a facsimile counterpart of this Agreement shall have the same effect as an originally executed counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">22. <U>Headings</U>. Headings in this Agreement are for reference purposes only and shall not be deemed to have any substantive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">23. <U>Opportunity to Seek Advice</U>. The Executive acknowledges and confirms that he has had the opportunity to seek such legal, financial and other advice and representation as he has deemed appropriate in connection with this Agreement, that the Executive is fully aware of its legal effect, and that Executive has entered into it freely based on the Executive&rsquo;s judgment and not on any representations or promises other than those contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">24. <U>Withholding and Payroll Practices</U>. All salary, severance payments, bonuses or benefits payments made by the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law and shall be paid in the ordinary course pursuant to the Company&rsquo;s then existing payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[SIGNATURES TO FOLLOW ON NEXT PAGE]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: left">NEONC TECHNOLOGIES HOLDINGS, INC.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Dr. Thomas Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Dr. Thomas Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">EXECUTIVE:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Keithly A. Garnett</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Keithly A. Garnett</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Financial Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">2.</TD>
    <TD STYLE="text-align: justify">Employment</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">a.</TD>
    <TD STYLE="text-align: justify">Title: Chief Financial Officer</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">3.</TD>
    <TD STYLE="text-align: justify">Base Salary: $179,000 per year.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6(e).</TD>
    <TD STYLE="text-align: justify"><U>Severance Period</U>: Three months</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">18(b).</TD>
    <TD STYLE="text-align: justify"><U>Executive Contact Information</U>:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Keithly A. Garnett</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">505 South Flower Street, Unit 71404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Los Angeles, California 90071</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Restricted Stock Award Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Employee Proprietary Information<BR>and Inventions Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>CONFIDENTIALITY AND PROPRIETARY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>AND INVENTIONS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">In consideration of my Service (as defined herein) with NeOnc Technologies Holdings, Inc., and the compensation now and later paid to me, directly and indirectly, I hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-variant: small-caps"><B>1.</B></FONT>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Definitions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.1.</B>&nbsp;<B>Company. </B>As used in this Agreement, the &ldquo;<B><I>Company</I></B>&rdquo; refers to NeOnc Technologies Holdings, Inc. and each of its subsidiaries or affiliated companies. I recognize and agree that my obligations under this Agreement and all terms of this Agreement apply to me regardless of whether I am engaged by, employed by, or work for the Company or any other subsidiary or affiliated company of the Company. Furthermore, I understand and agree that the terms of this Agreement will continue to apply to me even if my Service is transferred at some time from one subsidiary or affiliate of the Company to another.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.2.</B>&nbsp;<B>Company Business. </B>As used in this Agreement, &ldquo;<B><I>Company Business</I></B>&rdquo; shall mean: (i) the development, manufacturing, distribution, marketing and/or sale of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain and (ii) any other business, product or service in which the Company engages during my Services with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.3.</B>&nbsp;<B>Competing Business. </B>As used in this Agreement, &ldquo;<B><I>Competing Business</I></B>&rdquo; shall mean any person or entity that engages in a commercial business that is the same or substantially similar to the Company Business, and only that portion of the business that is in competition with the Company Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.4.</B>&nbsp;<B>Confidential Information. </B>As used in this Agreement, &ldquo;<B><I>Confidential Information</I></B>&rdquo; shall mean, collectively, all &ldquo;Proprietary Information&rdquo; and &ldquo;Trade Secrets&rdquo; of the Company and/or any affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.5.</B>&nbsp;<B>Intellectual Property Rights. </B>As used in this Agreement, the term &ldquo;<B><I>Intellectual Property Rights</I></B>&rdquo; means all trade secrets, copyrights, trademarks, mask work rights, moral rights, patents and other intellectual</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">property rights recognized by the laws of any jurisdiction or country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.6.</B>&nbsp;<B>Invention. </B>As used in this Agreement, the term &ldquo;<B><I>Invention</I></B>&rdquo; means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments, designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.7.</B>&nbsp;<B>Proprietary Information. </B>As used in this Agreement, &ldquo;<B><I>Proprietary Information</I></B>&rdquo; shall include, without limitation, all technical and non-technical data, compilations, programs and methods, techniques, drawings, processes, financial data, actual and prospective customer lists, customer route books and materials, documents containing names and addresses of current or former customers that includes their past or present buying patterns or habits, sales reports, service reports, price lists and discount lists, methods and/or procedures regarding pricing, product cost and profit strategies or structures, product formulae, methods and/or procedures related to sales or services, methods and/or procedures of operation, special training of sales representatives, continuous market updates and merchandising strategies relating to the Company, any affiliate of the Company, and the Company Business, which is communicated to, supplied to or observed by me, either directly or indirectly, at any time during the Service relationship, whether or not received from the Company, any affiliate of the Company, or from any actual or potential customer of the Company or any affiliate of the Company, or from any person with a business relationship, whether contractual or otherwise, with the Company or any affiliate of the Company. The term &ldquo;Proprietary Information&rdquo; shall not include any information that I can prove: (i) was known or independently developed by me prior to the time of receipt from the Company or any affiliate, as long as such information was not acquired, either directly or indirectly, from the Company or any affiliate; (ii) is or becomes</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">publicly known through no direct or indirect act, fault or omission of my own; (iii) is or becomes part of the public domain through no direct or indirect act, fault or omission of my own; or (iv) was received by me from a third party having the legal right to transmit the same without restriction as to use and disclosure and such receipt was not in connection with any business relationship or prospective business relationship with the Company or any affiliate; <I>provided</I>, <I>however</I>, that a combination of features shall not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or otherwise within such exceptions, as previously described, unless the combination itself is in the public domain or otherwise entirely within any one such exception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.8.</B>&nbsp;<B>Trade Secrets. </B>As used in this Agreement, &ldquo;<B><I>Trade Secrets</I></B>&rdquo; shall mean information not generally known about the Company&rsquo;s business which is the subject of efforts that are reasonable under the circumstances to maintain its secrecy or confidentiality and from which the Company and/or any affiliate derives economic value from the fact that the information is not generally known to other persons who can obtain economic value from its disclosure or use, and shall include any and all Proprietary Information which may be protected as a trade secret under any applicable law, even if not specifically designated as such. Unless told otherwise, I shall treat all Proprietary Information as Trade Secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.9.</B>&nbsp;<B>Service. </B>As used in this Agreement, &ldquo;<B><I>Service</I></B>&rdquo; means any responsibility, duty or authority consistent with the role of an employee, consultant, advisor, officer or director of the Company, including any other responsibility, duty or authority assigned from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.10.</B>&nbsp;<B>Work Product. </B>As used in this Agreement, &ldquo;<B><I>Work Product</I></B>&rdquo; shall mean all discoveries, improvements, techniques, designs, artwork, trade secrets, Confidential Information, trademarks, data, analyses, materials, formulas, strategic plans, acquisition strategies, research, documentation, computer programs, information technology systems, communication systems, manufacturing systems, system designs, inventions (whether or not patentable), copyrightable subject matter, works of authorship, and other confidential or proprietary information or work product (including all worldwide Intellectual Property Rights therein), whether or not patentable, and in whatever form, which I have made or conceived, or may make or conceive, either solely or jointly with others, while providing Services to the Company or any affiliate, or with the use of the time,</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">material, resources, or facilities of the Company or any affiliate or relating to any actual or anticipated Business of the Company, or suggested by or resulting from any task assigned to me or work performed by me for or on behalf of the Company or any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>2.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Confidentiality</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.1.</B>&nbsp;<B>Protection of Confidential Information. </B>I recognize the interest of the Company and its affiliates in maintaining the confidential nature of its Confidential Information. Accordingly, I covenant and agree that I will not, at any time, other than in the performance of my Service for the Company or any affiliate, both during and after my Service with the Company, communicate or disclose to any person or entity, or use for my benefit, or for the benefit of any other person or entity, either directly or indirectly, any Trade Secrets and/or Proprietary Information. For the purposes of this Agreement, the prohibition against the disclosure of Proprietary Information is prohibited until the information becomes publicly available through no direct or indirect fault or act of my own, or otherwise no longer qualifies as a Trade Secret. I understand that misappropriation of a trade secret of the Company in breach of this Agreement may subject me to liability under the Defend Trade Secrets Act of 2016 (the &ldquo;<B><I>DTSA</I></B>&rdquo;), entitle the Company to injunctive relief and require me to pay compensatory damages, double damages and attorneys&rsquo; fees. Nothing in the foregoing covenant shall in any way limit or impair any of the rights of the Company or any affiliate with respect to any trade secret information, including, without limitation, any information that qualifies as a trade secret under the DTSA. Notwithstanding any other provision of this letter agreement, I understand that I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, in each case solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. I further understand that if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the trade secrets of the Company to my attorney and use the trade secret information in the court proceeding if I file any document containing the trade secret under seal and do not disclose the trade secret except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.2.</B>&nbsp;<B>Third Party Information.</B> I understand, in addition, that Company has received and, in the future, will receive from third parties confidential or proprietary</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">information (&ldquo;<B><I>Third Party Information</I></B>&rdquo;) subject to a duty on Company&rsquo;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my Service and thereafter, I will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information, unless expressly authorized by an officer of the Company in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.3.</B>&nbsp;<B>No Improper Use of Information of Prior Employers and Others.</B> I represent that my Service with Company does not and will not breach any agreement with any former employer, including any non-compete agreement or any agreement to keep in confidence information acquired by me in confidence or trust prior to my Service with Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict herewith. During my Service with Company, I will not improperly use or disclose any confidential information or trade secrets of any former employer or other third party to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party to whom I have an obligation of confidentiality, unless consented to in writing by that former employer or person. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>3.</B>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Work
Product and</B></FONT><B> <FONT STYLE="font-variant: small-caps">Inventions</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.1.</B>&nbsp;<B>Protection of Work Product</B>. I acknowledge and agree that all Work Product produced by me during my Service with the Company or any affiliate shall be considered &ldquo;work for hire&rdquo; as such term is defined in 17 U.S.C. &#xa7; 101 <I>et seq</I>. I hereby assign to the Company and all affiliates all right, title and interest whatsoever in and to any and all Work Product, including all worldwide Intellectual Property Rights therein. If, for any reason, any of the Work Product does not constitute a &ldquo;work made for hire,&rdquo; I hereby irrevocably assign to the Company, in each case without additional consideration, all right, title and interest throughout the world in and to such Work Product, including all Intellectual Property Rights therein. I agree to promptly disclose any and all such Work Product to the Company and any affiliate, as requested, and to perform, during or after the termination of my Service and</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">without requiring the Company or any affiliate to provide any further consideration, such further acts as may be necessary or desirable to transfer, perfect, and defend the Company&rsquo;s ownership (or any affiliate&rsquo;s ownership) of the Work Product as requested by the Company or any affiliate, including, without limitation the execution of such patent applications (including continuations and related materials), confirmatory assignments, instruments and documents as the Company or any affiliate deems necessary or desirable in order to effect such assignment and to protect and enforce such rights. The Company and all affiliates shall have the right to obtain and hold in its and their own name copyrights, patents, registrations, and any other protection available in the Work Product. My obligation to execute materials to effect assignment of Work Product shall survive the termination of my Service with the Company of any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.2.</B>&nbsp;<B>Prior Inventions.</B> I agree that I will not incorporate, or permit to be incorporated, Prior Inventions (defined below) in any Company Inventions (defined below) without Company&rsquo;s prior written consent. In addition, I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU GPL or LGPL or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company. I have disclosed on <B>Exhibit A</B> a complete list of all Inventions that I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my Service with Company, in which I have an ownership interest or which I have a license to use, and that I wish to have excluded from the scope of this Agreement (collectively referred to as &ldquo;<B><I>Prior Inventions</I></B>&rdquo;). If no Prior Inventions are listed in <B>Exhibit A</B>, I warrant that there are no Prior Inventions. If, in the course of my Service with Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.3.</B>&nbsp;<B>Assignment of Company Inventions.</B> Subject to the section titled &ldquo;Government or Third Party&rdquo; and except for Inventions that I can prove qualify fully under the provisions of California Labor Code section&nbsp;2870 (or</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">any similar law in an applicable jurisdiction) and I have set forth in <B>Exhibit A</B>, I hereby assign and agree to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, in the course of my Service with the Company. Inventions assigned to Company or to a third party as directed by Company pursuant to the section titled &ldquo;Government or Third Party&rdquo; are referred to in this Agreement as <B>&ldquo;<I>Company Inventions</I>.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.4.</B>&nbsp;<B>Obligation to Keep Company Informed.</B> During the period of my Service and for one (1) year thereafter, I will promptly and fully disclose to Company in writing (a) all Inventions or Work Product authored, conceived, or reduced to practice by me, either alone or with others, including any that might be covered under California Labor Code section&nbsp;2870 (or any similar law in any applicable jurisdiction), and (b) all patent applications filed by me or in which I am named as an inventor or co-inventor, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.5.</B>&nbsp;<B>Government or Third Party.</B> I also agree to assign all my right, title, and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.6.</B>&nbsp;<B>Enforcement of Intellectual Property Rights and Assistance.</B> During the period of my Service and thereafter, I will assist Company in every proper way to obtain and enforce United States and foreign Intellectual Property Rights relating to Company Inventions in all countries. In the event Company is unable to secure my signature on any document needed in connection with such purposes, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>4.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Records.</FONT></B> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Inventions or Work Product made by me during the period of my Service with Company, if any, which records shall be available to, and remain the sole property of, Company at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>5.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Return Of Company Property.</FONT></B> Upon termination</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">of my Service or upon Company&rsquo;s request at any other time, I will deliver to Company all of Company&rsquo;s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information of Company, excepting only (i) my personal copies of records relating to my compensation; (ii) my personal copies of any materials previously distributed generally to stockholders of the Company; and (iii) my copies of my agreements with the Company. I agree that I will not copy, delete, or alter any Confidential Information contained upon my Company computer immediately before I return it to Company. I further agree that any property situated on Company&rsquo;s premises and owned by Company is subject to inspection by Company personnel at any time with or without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>6.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Notification Of New Employer</FONT>.</B> In the event that my Service with the Company terminates, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement, by Company&rsquo;s providing a copy of this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>7.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">General Provisions</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.1.</B>&nbsp;<B>Governing Law</B>. This Agreement will be governed by and construed according to the laws of the State of California, without reference to conflict of laws principles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.2.</B>&nbsp;<B>Severability.</B> If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the other provisions of this Agreement will be unimpaired and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.3.</B>&nbsp;<B>Survival.</B> This Agreement shall survive the termination of my Service and the assignment of this Agreement by Company to any successor-in-interest or other assignee and be binding upon my heirs and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.4.</B>&nbsp;<B>Continuation of Service.</B> I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of Service with Company, nor shall it interfere in any way with my right or Company&rsquo;s right to terminate my Service at any time, with or without cause and with or without advance notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.5.</B>&nbsp;<B>Notices</B>. Each party must deliver all notices or other communications required or permitted under this Agreement in writing to the other party at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">requested), or by a nationally-recognized express mail service. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, any such notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, any such notice shall be considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of such change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.6.</B>&nbsp;<B>Legal Remedies. </B>I acknowledge and agree that the Company and its affiliates, as applicable, will suffer irreparable loss and damage if I breach or violate any of the restrictions and agreements contained in this Agreement. I therefore agree that, in addition to any other remedies available, the Company and its affiliates, as applicable, shall be entitled to a temporary restraining order, preliminary injunction and/or permanent injunction, without any bond or other security being required, to prevent a breach or contemplated breach by me and by any person or entity to whom I provide or propose to provide any services in violation of any of the covenants or agreements contained in this Agreement. Any rights created by this Agreement shall be in addition to, and not in lieu of, any other remedies that may exist under any applicable law or in equity.</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.7.</B>&nbsp;<B>Waiver.</B> Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or of such provision on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.8.</B>&nbsp;<B>Export</B>. I agree not to export, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, to countries outside the United States, because such export could be in violation of the United States export laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.9.</B>&nbsp;<B>Entire Agreement.</B> The obligations pursuant to sections of this Agreement titled &ldquo;Confidentiality&rdquo; and &ldquo;Inventions&rdquo; shall apply to any time during which I was previously employed, or am in the future employed, by Company as an independent contractor if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matters hereof and supersedes and merges all prior communications between us with respect to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and a duly authorized officer of the Company. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0.5in; margin: 0">[<I>Remainder of Page Intentionally Left Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">This Agreement shall be effective as of the first day of my Service with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B><FONT STYLE="font-variant: small-caps">I have read, understand, and accept this agreement and have been given the opportunity to review it with independent legal counsel.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Print Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">Date:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-variant: small-caps"><B>Accepted and Agreed To:</B></FONT></TD>
    <TD STYLE="text-align: left; width: 50%"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B>, a Delaware corporation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>[Signature Page to Confidentiality
and Proprietary Information and Inventions Agreement]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">EXHIBIT A</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">INVENTIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD>
    <TD STYLE="text-align: justify"><B>Prior Inventions Disclosure.</B> The following is a complete list of all Prior Inventions:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">None</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">See immediately below:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD>
    <TD STYLE="text-align: justify"><B>Limited Exclusion Notification.</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B><FONT STYLE="font-variant: small-caps">This is to notify </FONT></B>you in accordance with California Labor Code section&nbsp;2870 (or any similar law in an applicable jurisdiction) that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&rsquo;s equipment, supplies, facilities or trade secret information, except for those Inventions that either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>a.</B>&nbsp;Relate at the time of conception or reduction to practice to Company&rsquo;s business actual or demonstrably anticipated research or development; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>b.</B>&nbsp;Result from any work performed by you for Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent permitted by applicable law, this limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>neonctechnologies_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EMPLOYMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Employment Agreement (the &ldquo;Agreement&rdquo;) is entered into as of the 4th day of January, 2024, by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Patrick Walters, an individual residing at the address set forth on Schedule A hereto (the &ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>INTRODUCTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company is in the business of the development and commercialization of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain (the &ldquo;Business&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company wishes to employ the Executive under the title and capacity set forth on Schedule A hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Executive desires to be employed by the Company in such capacity, subject to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOW, THEREFORE, in consideration of the premises and mutual promises herein below set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Employment Period</U>. The initial term of
the Executive&rsquo;s employment by the Company (directly or through its wholly-owned subsidiary NeOnc Technologies, Inc.) pursuant
to this Agreement shall commence upon the effective date of the Company&rsquo;s initial public offering if such public offering
occurs on or before June&nbsp;30, 2024 (the &ldquo;Effective Date&rdquo;) and shall continue for and shall continue through and
expire on that date which is seven months from the Effective Date (the &ldquo;Employment Period&rdquo;). Thereafter, the Employment
Period shall automatically renew for a successive period of one (1) year each, unless either party shall have given to the other at
least fifteen (15) days&rsquo; prior written notice of their intention not to renew the Executive&rsquo;s employment prior to the
end of the Employment Period or the then applicable renewal term, as the case may be. In any event, the Employment Period may be
terminated as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Employment; Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Subject to the terms and conditions set forth herein, the Company hereby employs the Executive to act for the Company during the Employment Period in the capacity set forth on Schedule A hereto, and the Executive hereby accepts such employment. The duties and responsibilities of the Executive shall include such duties and responsibilities appropriate to such office and as are normally associated with and appropriate for such position and as the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) may from time to time reasonably assign to the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive recognizes that during the period of Executive&rsquo;s employment hereunder, Executive owes an undivided duty of loyalty to the Company, and Executive will use Executive&rsquo;s good faith efforts to promote and develop the business of the Company and its subsidiaries (the Company&rsquo;s subsidiaries from time to time, together with any other affiliates of the Company, the &ldquo;Affiliates&rdquo;). Executive shall devote all of Executive&rsquo;s business time, attention and skills to the performance of Executive&rsquo;s services as an executive of the Company. Recognizing and acknowledging that it is essential for the protection and enhancement of the brand name, reputation and business of the Company and the goodwill pertaining thereto, Executive shall perform the Executive&rsquo;s duties under this Agreement professionally, in accordance with the applicable laws, rules and regulations and such standards, policies and procedures established by the Company and the industry from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) However, the parties agree that: (i) Executive may devote a reasonable amount of his time to civic, community, or charitable activities and may serve as a director of other corporations (provided that any such other corporation is not a competitor of the Company, as determined by the Board) and to other types of business or public activities not expressly mentioned in this paragraph and (ii) Executive may participate as a non-employee director and/or investor in other companies and projects as disclosed by Executive to, and approved by, the Board, so long as Executive&rsquo;s responsibilities with respect thereto do not conflict or interfere with the faithful performance of his duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>Place of Employment</U>. The Executive&rsquo;s services shall be performed at the Company&rsquo;s offices located at 8335 Sunset Boulevard, Suite 240, Los Angeles, California, 90069, at any other location at which the Company now or hereafter has a business facility, at employee&rsquo;s home office, or at any other location where Executive&rsquo;s presence is necessary to perform his duties. The parties acknowledge that the Executive may be required to travel in connection with the performance of his duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Base Salary</U>. The Executive shall be entitled to receive a salary from the Company during the Employment Period at a rate per year indicated on Schedule A hereto (the &ldquo;Base Salary&rdquo;). Once the Board has established the Base Salary, such Base Salary shall be payable in monthly installments in accordance with the Company&rsquo;s customary payroll practices. The Executive&rsquo;s Base Salary may be increased on each anniversary of the Effective Date, at the Board&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Bonus</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive shall be eligible to participate in any bonus or incentive program established by the Company for executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. <U>Other Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Grant of Restricted Stock Units. The Executive shall be entitled to receive a number of restricted stock units (&ldquo;Restricted Stock Units&rdquo;) as in accordance with the terms of a separate Restricted Stock Unit Award Agreement set forth on Exhibit A hereto. Any additional equity awards to the Executive shall be at the option of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Restrictions. Any and all shares of stock, options, restricted stock units and other equity awards granted to or owned by the Executive will be subject to the share ownership guidelines and insider trading and blackout policies adopted from time to time by the Board of Directors for senior executives of the Company and will also be subject to applicable holding periods and transaction reporting requirements under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Insurance and Other Benefits. During the Employment Period, the Executive and the Executive&rsquo;s dependents shall be entitled to participate in any Company insurance programs and any applicable benefit plans, as the same may be adopted and/or amended from time to time (the &ldquo;Benefits&rdquo;). The Executive shall be bound by all of the policies and procedures relating to Benefits established by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) Vacation; Personal Days. During the Employment Period, the Executive shall be entitled to an annual vacation of such duration consistent with the Company&rsquo;s policies from time to time, as determined by the Board. The Executive shall be entitled to paid personal days on a basis consistent with the Company&rsquo;s other senior executives, as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) Expense Reimbursement.
The Company shall reimburse the Executive for all reasonable business, promotional, travel and entertainment expenses
(&ldquo;Reimbursable Expenses&rdquo;) incurred or paid by the Executive during the Employment Period in the performance of
Executive&rsquo;s services under this Agreement on a basis consistent with the Company&rsquo;s other senior executives, as
determined by the Board, provided that the Executive furnishes to the Company appropriate documentation required by the Code and/or
other taxing authorities in a timely fashion in connection with such expenses and shall furnish such other documentation and
accounting as the Company may from time to time reasonably request. For purposes of this Agreement, &ldquo;Code&rdquo; means the
U.S. Internal Revenue Code of 1986 (as it has been and may be amended from time to time) and any regulations and guidance that has
been promulgated or may be promulgated from time to time thereunder and any state law of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. <U>Termination; Compensation Due Upon Termination of Employment</U>. The Executive&rsquo;s employment with the Company shall be entirely &ldquo;at-will,&rdquo; meaning that either the Executive or the Company may terminate such employment relationship by terminating this Agreement in writing delivered to the other party at any time for any reason or for no reason at all, subject, however, to the terms of this Section&nbsp;7. The Executive&rsquo;s right to compensation for periods after the date his employment with the Company terminates shall be determined in accordance with the provisions of paragraphs (a) through (e) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Voluntary Resignation; Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Voluntary Resignation</U>. The Executive may terminate his employment at any time upon thirty (30) days prior written notice to the Company. In the event of the Executive&rsquo;s voluntary termination of employment other than for Good Reason (as defined below), the Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, except as otherwise required by this Agreement or by applicable law, to provide the benefits described in Section&nbsp;6 for periods after the date on which the Executive&rsquo;s employment with the Company terminates due to the Executive&rsquo;s voluntary resignation, except for the payment of the Executive&rsquo;s Base Salary accrued through the date of such resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(A) If the Executive&rsquo;s employment is terminated by the Company without Cause (as defined below): the Company shall (x) continue to pay the Executive the Base Salary (at the rate in effect on the date the Executive&rsquo;s employment is terminated) until the end of the Severance Period (as defined below), and (y) pay any other accrued compensation and Benefits. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(B) If, following a termination of employment without Cause, the Executive breaches the provisions of Section&nbsp;10 hereof or that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, the Executive shall not be eligible, as of the date of such breach, for the payments and benefits described in Section&nbsp;7(a)(ii)(A) above, and any and all obligations and agreements of the Company with respect to such payments shall thereupon cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">(b) Discharge for Cause. Upon written notice to the Executive, the Company may terminate the Executive&rsquo;s employment for &ldquo;Cause&rdquo; if any of the following events shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) any act or omission that constitutes a material breach by the Executive of any of his obligations under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) the willful and continued failure or refusal of the Executive to satisfactorily perform the duties reasonably required of him as an employee of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) the Executive&rsquo;s conviction of, or plea of nolo contendere to, (i) any felony or (ii) a crime involving dishonesty or moral turpitude or which could reflect negatively upon the Company or otherwise impair or impede its operations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the Executive&rsquo;s engaging in any misconduct, negligence, act of dishonesty (including, without limitation, theft or embezzlement), violence, threat of violence or any activity that could result in any violation of federal securities laws, in each case, that is injurious to the Company or any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) the Executive&rsquo;s material breach of a written policy of the Company or the rules of any governmental or regulatory body applicable to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vi) the Executive&rsquo;s refusal to follow the directions of the Board, unless such directions are, in the written opinion of legal counsel, illegal or in violation of applicable regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vii) any other willful misconduct by the Executive which is materially injurious to the financial condition or business reputation of the Company or any of its Affiliates, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(viii) the Executive&rsquo;s breach of his obligations under Section&nbsp;10 hereof or under that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">In the event Executive is terminated for Cause, the Company shall have no obligation to make payments to Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law, to provide the benefits described in Section&nbsp;6, for periods after the Executive&rsquo;s employment with the Company is terminated on account of the Executive&rsquo;s discharge for Cause except for the Executive&rsquo;s then applicable Base Salary accrued through the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Disability</U>. The Company shall have the right, but shall not be obligated to, terminate the Executive&rsquo;s employment hereunder in the event the Executive becomes disabled such that he is unable to discharge his duties to the Company for a period of ninety (90) consecutive days or one hundred twenty (120) days in any one hundred eighty (180) consecutive day period (unless longer periods are not required under applicable local labor regulations) (a &ldquo;Permanent Disability&rdquo;). In the event of a termination of employment due to a Permanent Disability, the Company shall be obligated to continue to make payments to the Executive in an amount equal to the then applicable Base Salary for the Severance Period (as defined below), payable in the form of salary continuation for the applicable Severance Period after the Executive&rsquo;s employment with the Company is terminated due to a Permanent Disability. A determination of a Permanent Disability shall be made by a physician satisfactory to both the Executive and the Company; provided, however, that if the Executive and the Company do not agree on a physician, the Executive and the Company shall each select a physician and those two physicians together shall select a third physician, whose determination as to a Permanent Disability shall be binding on all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Death</U>. The Executive&rsquo;s employment hereunder shall terminate upon the death of the Executive. The Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law or the terms of any applicable benefit plan, to provide the benefits described in Section&nbsp;6 for periods after the date of the Executive&rsquo;s death except for then applicable Base Salary earned and accrued through the date of death, payable to the Executive&rsquo;s beneficiary, as the Executive shall have indicated in writing to the Company (or if no such beneficiary has been designated, to Executive&rsquo;s estate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Termination for Good Reason</U>. The Executive may terminate this Agreement at any time for Good Reason. In the event of termination under this paragraph (e), the Company shall pay to the Executive severance in an amount equal to the Executive&rsquo;s then applicable Base Salary for a period equal to the number of months set forth on Schedule A hereto (the &ldquo;Severance Period&rdquo;), subject to the Executive&rsquo;s continued compliance with Section&nbsp;10 hereof and with that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, payable in the form of salary continuation for the applicable Severance Period following the Executive&rsquo;s termination, and subject to the Company&rsquo;s regular payroll practices and required withholdings. Such severance shall be reduced by any cash remuneration paid to the Executive because of the Executive&rsquo;s employment or self-employment during the Severance Period. The Executive shall continue to receive all Benefits (either through the Company or an Affiliate) during the Severance Period. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such resignation. For the purposes of this Agreement, &ldquo;Good Reason&rdquo; shall mean any of the following (without Executive&rsquo;s express written consent):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) removal of the Executive from his position as indicated on Schedule A hereto, or the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed under this Agreement, within twelve (12) months after a Change of Control (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) a reduction by the Company in the Executive&rsquo;s then applicable Base Salary or other compensation, unless said reduction is pari passu with other senior executives of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the taking of any action by the Company that would, directly or indirectly, materially reduce the Executive&rsquo;s benefits, unless said reductions are pari passu with other senior executives of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) a breach by the Company of any material term of this Agreement that is not cured by the Company within thirty (30) days following receipt by the Company of written notice thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f) <U>Notice of Termination</U>. Any termination of employment by the Company or the Executive shall be communicated by a written &ldquo;Notice of Termination&rdquo; to the other party hereto given in accordance with Section&nbsp;18 of this Agreement. In the event of a termination by the Company for Cause, the Notice of Termination shall (i) indicate the specific termination provision in this Agreement relied upon, (ii) set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive&rsquo;s employment under the provision so indicated and (iii) specify the date of termination, which date shall be the date of such notice. The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive&rsquo;s or the Company&rsquo;s rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) <U>Resignation of Executive Officer</U>. The termination of the Executive&rsquo;s employment for any reason will constitute the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive has with the Company or any of its Affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive holds with respect to any employee benefit plans or trusts established by the Company. The Executive agrees that this Agreement shall serve as written notice of resignation in this circumstance, unless otherwise required by any plan or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. <U>Section&nbsp;409A</U>. It is intended that
all payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A
provided under Treasury Regulations Sections&nbsp;1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed
to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions
hereunder) will be construed in a manner that complies with Section&nbsp;409A. For all purposes of Code Section&nbsp;409A (including,
without limitation, for purposes of Treasury Regulations Sections&nbsp;1.409A 2(b)(2)(i) and (iii)), Executive&rsquo;s right to receive
any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to
receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate
and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time
of Executive&rsquo;s Separation from Service (for purposes of this Agreement, &ldquo;Separation from Service&rdquo; means a &ldquo;separation
from service&rdquo;, as defined under Treasury Regulation Section&nbsp;1.409A-1(h))to be a &ldquo;specified employee&rdquo; for purposes
of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other
agreement with the Company are deemed to be &ldquo;deferred compensation,&rdquo; then to the extent delayed commencement of any portion
of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to Executive prior to the earliest of (i) the first date following
expiration of the six-month period following the date of Executive&rsquo;s Separation from Service with the Company, (ii) the date of
Executive&rsquo;s death or (iii) such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon
the first business day following the expiration of such applicable Code Section&nbsp;409A(a)(2)(B)(i) period, all payments deferred pursuant
to this paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein
or in the applicable agreement. No interest shall be due on any amounts so deferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. <U>Section&nbsp;280G</U>. If any payment or benefit Executive will or may receive from the Company or otherwise (a &ldquo;<U>280G Payment</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section&nbsp;280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<U>Reduced Amount</U>&rdquo; hall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&rsquo;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &ldquo;<U>Reduction Method</U>&rdquo;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &ldquo;<U>Pro Rata Reduction Method</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &ldquo;deferred compensation&rdquo; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change in control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive&rsquo;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other reasonable time as requested by Executive or the Company.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If Executive receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. <U>Non-Competition; Non-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) For the duration of the Employment Period and, unless the Company terminates the Executive&rsquo;s employment without Cause, during the Severance Period (the &ldquo;Non-compete Period&rdquo;), the Executive shall not, directly or indirectly, except as specifically provided in the last sentence of Section&nbsp;2(c) hereof, engage or invest in, own, manage, operate, finance, control or participate in the ownership, management, operation, financing, or control of, be employed by, associated with, or in any manner connected with, lend any credit to, or render services or advice to, any business, firm, corporation, partnership, association, joint venture or other entity that engages or conducts any business the same as or substantially similar to the Business or any other business engaged in or proposed to be engaged in or conducted by the Company and/or any of its Affiliates during the Employment Period, or then included in the future strategic plan of the Company and/or any of its Affiliates, anywhere within North America; provided, however, that the Executive may own less than 5% in the aggregate of the outstanding shares of any class of securities of any enterprise (but without otherwise participating in the activities of such enterprise), other than any such enterprise with which the Company competes or is currently engaged in a joint venture, if such securities are of a class listed on any national or regional securities exchange or have been registered under Section&nbsp;12(b) or (g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) During the Employment Period and for a period of twelve (12) months following termination of the Executive&rsquo;s employment with the Company, the Executive shall not solicit or attempt to recruit any employee, or independent contractor of, or consultant to, the Company, or its Affiliates, to leave the employment (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is party to an employment agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) The Executive recognizes and agrees that because a violation by the Executive of his obligations under this Section will cause irreparable harm to the Company that would be difficult to quantify and for which money damages would be inadequate, the Company shall have the right to injunctive relief to prevent or restrain any such violation, without the necessity of posting a bond. The Non-compete Period will be extended by the duration of any violation by the Executive of any of his obligations under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) The Executive expressly agrees that the character, duration and scope of the covenant not to compete are reasonable in light of the circumstances as they exist at the date upon which this Agreement has been executed. However, should a determination nonetheless be made by a court of competent jurisdiction at a later date that the character, duration or geographical scope of the covenant not to compete is unreasonable in light of the circumstances as they then exist, then it is the intention of the Executive, on the one hand, and the Company, on the other, that the covenant not to compete shall be construed by the court in such a manner as to impose only those restrictions on the conduct of the Executive which are reasonable in light of the circumstances as they then exist and necessary to assure the Company of the intended benefit of the covenant not to compete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. <U>Inventions and Patents</U>. The Executive acknowledges that all inventions, innovations, improvements, know-how, plans, development, methods, designs, analyses, specifications, software, drawings, reports and all similar or related information (whether or not patentable or reduced to practice) which related to any of the Company&rsquo;s actual or proposed business activities and which are created, designed or conceived, developed or made by the Executive during the Executive&rsquo;s past or future employment by the Company or any Affiliates, or any predecessor thereof (&ldquo;Work Product&rdquo;), belong to the Company, or its Affiliates, as applicable. Any copyrightable work falling within the definition of Work Product shall be deemed a &ldquo;work made for hire&rdquo; and ownership of all right title and interest shall rest in the Company. The Executive hereby irrevocably assigns, transfers and conveys, to the full extent permitted by law, all right, title and interest in the Work Product, on a worldwide basis, to the Company to the extent ownership of any such rights does not automatically vest in the Company under applicable law. The Executive will promptly disclose any such Work Product to the Company and perform all actions requested by the Company (whether during or after employment) to establish and confirm ownership of such Work Product by the Company (including, without limitation, assignments, consents, powers of attorney and other instruments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. <U>Executive&rsquo;s Representation</U>. The Executive hereby represents that the Executive&rsquo;s entry into this Agreement and performance of the services hereunder will not violate the terms or conditions of any other agreement to which the Executive is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. <U>Arbitration of All Disputes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Agreement to Arbitrate</U>. To ensure the timely and economical resolution of disputes that may arise between Executive and the Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#xa7;1-16, and to the fullest extent permitted by applicable law, Executive and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or (ii) Executive&rsquo;s employment with the Company (including but not limited to all statutory claims); or (iii) the termination of Executive&rsquo;s employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EXECUTIVE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Arbitrator Authority</U>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Individual Capacity Only</U>. All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Arbitration Process</U>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS in Los Angeles, California, or as otherwise agreed to by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). Executive and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own expense. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute; (ii) issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Injunctive Relief and Final Orders</U>. Nothing in this Section is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. <U>Governing Law/Jurisdiction</U>. This Agreement and any disputes or controversies arising hereunder shall be construed and enforced in accordance with and governed by the internal laws of the State of California without regard to the conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. <U>Public Company Obligations; Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Executive acknowledges that the Company intends to become a publicly reporting company whose shares of common stock will be registered under the U.S. Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and whose common stock will be registered under the Exchange Act, and that, after the Company becomes a publicly reporting company, this Agreement will be subject to the public filing requirements of the Exchange Act. In addition, both parties acknowledge that the Executive&rsquo;s compensation and perquisites (each as determined by the rules of the US Securities and Exchange Commission (the &ldquo;SEC&rdquo;) or any other regulatory body or exchange having jurisdiction) (which may include benefits or regular or occasional aid/assistance, such as recreation, club memberships, meals, education for his family, vehicle, lodging or clothing, occasional bonuses or anything else he receives, during the Employment Period and any renewals thereof, in cash or in kind) paid or payable or received or receivable under this Agreement or otherwise, and his transactions and other dealings with the Company, may be required to be publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive acknowledges and agrees that the applicable insider trading rules, transaction reporting rules, limitations on disclosure of non-public information and other requirements set forth in the Securities Act, the Exchange Act and rules and regulations promulgated by the SEC may apply to this Agreement and Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Executive (on behalf of himself, as well as the Executive&rsquo;s executors, heirs, administrators and assigns) absolutely and unconditionally agrees to indemnify and hold harmless the Company and all of its past, present and future affiliates, executors, heirs, administrators, shareholders, employees, officers, directors, attorneys, accountants, agents, representatives, predecessors, successors and assigns from any and all claims, debts, demands, accounts, judgments, causes of action, equitable relief, damages, costs, charges, complaints, obligations, controversies, actions, suits, proceedings, expenses, responsibilities and liabilities of every kind and character whatsoever (including, but not limited to, reasonable attorneys&rsquo; fees and costs) in the event of Executive&rsquo;s breach of any obligation of Executive under the Securities Act, the Exchange Act, any rules promulgated by the SEC and any other applicable federal, state or foreign laws, rules, regulations or orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16. <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and thereof and supersedes and cancels any and all previous agreements, both written and oral, regarding the subject matter hereof between the parties hereto. This Agreement shall not be changed, altered, modified or amended, except by a written agreement signed by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">17. <U>Notices</U>. All notices, requests, demands and other communications called for or contemplated hereunder shall be in writing and shall be deemed to have been given when delivered to the party to whom addressed or when sent by telecopy (if promptly confirmed by registered or certified mail, return receipt requested, prepaid and addressed) to the parties, their successors in interest, or their assignees at the following addresses, or at such other addresses as the parties may designate by written notice in the manner aforesaid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(a)</TD>
    <TD STYLE="text-align: justify">to the Company at:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">NeOnc Technologies Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">8335 Sunset Boulevard, Suite 240</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Los Angeles, California, 90069</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: info@neonctech.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Manatt, Phelps and Phillips, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">695 Town Center Drive, 14th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Costa Mesa, CA 92629</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Thomas J. Poletti, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: tpoletti@manatt.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(b)</TD>
    <TD STYLE="text-align: justify">to the Executive as set forth on Schedule A hereto.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All such notices, requests and other communications will (i) if delivered personally to the address as provided in this Section, be deemed given upon delivery, (ii) if delivered by facsimile transmission to the facsimile number as provided for in this Section, be deemed given upon facsimile confirmation, (iii) if delivered by mail in the manner described above to the address as provided for in this Section, be deemed given on the earlier of the third business day following mailing or upon receipt and (iv) if delivered by overnight courier to the address as provided in this Section, be deemed given on the earlier of the first business day following the date sent by such overnight courier or upon receipt (in each case regardless of whether such notice, request or other communication is received by any other person to whom a copy of such notice is to be delivered pursuant to this Section). Either party may, by notice given to the other party in accordance with this Section, designate another address or person for receipt of notices hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18. <U>Severability</U>. If any term or provision of this Agreement, or the application thereof to any person or under any circumstance, shall to any extent be invalid or unenforceable, the remainder of this Agreement, or the application of such terms to the persons or under circumstances other than those as to which it is invalid or unenforceable, shall be considered severable and shall not be affected thereby, and each term of this Agreement shall be valid and enforceable to the fullest extent permitted by law. The invalid or unenforceable provisions shall, to the extent permitted by law, be deemed amended and given such interpretation as to achieve the economic intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">19. <U>Waiver</U>. The failure of any party to insist
in any one instance or more upon strict performance of any of the terms and conditions hereof, or to exercise any right or privilege
herein conferred, shall not be construed as a waiver of such terms, conditions, rights or privileges, but same shall continue to remain
in full force and effect. Any waiver by any party of any violation of, breach of or default under any provision of this Agreement by
the other party shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation of,
breach of or default under any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">20. <U>Successors and Assigns</U>. This Agreement shall be binding upon the Company and any successors and assigns of the Company. Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive. The Company may assign this Agreement and its right and obligations hereunder, in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">21. <U>Counterparts</U>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Additionally, a facsimile counterpart of this Agreement shall have the same effect as an originally executed counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">22. <U>Headings</U>. Headings in this Agreement are for reference purposes only and shall not be deemed to have any substantive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">23. <U>Opportunity to Seek Advice</U>. The Executive acknowledges and confirms that he has had the opportunity to seek such legal, financial and other advice and representation as he has deemed appropriate in connection with this Agreement, that the Executive is fully aware of its legal effect, and that Executive has entered into it freely based on the Executive&rsquo;s judgment and not on any representations or promises other than those contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">24. <U>Withholding and Payroll Practices</U>. All salary, severance payments, bonuses or benefits payments made by the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law and shall be paid in the ordinary course pursuant to the Company&rsquo;s then existing payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[SIGNATURES TO FOLLOW ON NEXT PAGE]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: left">NEONC TECHNOLOGIES HOLDINGS, INC.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Dr. Thomas Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Dr. Thomas Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">EXECUTIVE:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Patrick Walters</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Patrick Walters</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Operating Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">2.</TD>
    <TD STYLE="text-align: justify">Employment</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">a.</TD>
    <TD STYLE="text-align: justify">Title: Chief Operating Officer</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">3.</TD>
    <TD STYLE="text-align: justify">Base Salary: $195,000 per year.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6(e).</TD>
    <TD STYLE="text-align: justify"><U>Severance Period</U>: Three months</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">18(b).</TD>
    <TD STYLE="text-align: justify"><U>Executive Contact Information</U>:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patrick Walters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">1203 North Sweetzer Ave #313</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">West Hollywood, California 90069</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Restricted Stock Award Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Employee Proprietary Information<BR>and Inventions Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>CONFIDENTIALITY AND PROPRIETARY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>AND INVENTIONS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">In consideration of my Service (as defined herein) with NeOnc Technologies Holdings, Inc., and the compensation now and later paid to me, directly and indirectly, I hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-variant: small-caps"><B>1.</B></FONT>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Definitions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.1.</B>&nbsp;<B>Company. </B>As used in this Agreement, the &ldquo;<B><I>Company</I></B>&rdquo; refers to NeOnc Technologies Holdings, Inc. and each of its subsidiaries or affiliated companies. I recognize and agree that my obligations under this Agreement and all terms of this Agreement apply to me regardless of whether I am engaged by, employed by, or work for the Company or any other subsidiary or affiliated company of the Company. Furthermore, I understand and agree that the terms of this Agreement will continue to apply to me even if my Service is transferred at some time from one subsidiary or affiliate of the Company to another.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.2.</B>&nbsp;<B>Company Business. </B>As used in this Agreement, &ldquo;<B><I>Company Business</I></B>&rdquo; shall mean: (i) the development, manufacturing, distribution, marketing and/or sale of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain and (ii) any other business, product or service in which the Company engages during my Services with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.3.</B>&nbsp;<B>Competing Business. </B>As used in this Agreement, &ldquo;<B><I>Competing Business</I></B>&rdquo; shall mean any person or entity that engages in a commercial business that is the same or substantially similar to the Company Business, and only that portion of the business that is in competition with the Company Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.4.</B>&nbsp;<B>Confidential Information. </B>As used in this Agreement, &ldquo;<B><I>Confidential Information</I></B>&rdquo; shall mean, collectively, all &ldquo;Proprietary Information&rdquo; and &ldquo;Trade Secrets&rdquo; of the Company and/or any affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.5.</B>&nbsp;<B>Intellectual Property Rights. </B>As used in this Agreement, the term &ldquo;<B><I>Intellectual Property Rights</I></B>&rdquo; means all trade secrets, copyrights, trademarks, mask work rights, moral rights, patents and other intellectual</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">property rights recognized by the laws of any jurisdiction or country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.6.</B>&nbsp;<B>Invention. </B>As used in this Agreement, the term &ldquo;<B><I>Invention</I></B>&rdquo; means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments, designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.7.</B>&nbsp;<B>Proprietary Information. </B>As used in this Agreement, &ldquo;<B><I>Proprietary Information</I></B>&rdquo; shall include, without limitation, all technical and non-technical data, compilations, programs and methods, techniques, drawings, processes, financial data, actual and prospective customer lists, customer route books and materials, documents containing names and addresses of current or former customers that includes their past or present buying patterns or habits, sales reports, service reports, price lists and discount lists, methods and/or procedures regarding pricing, product cost and profit strategies or structures, product formulae, methods and/or procedures related to sales or services, methods and/or procedures of operation, special training of sales representatives, continuous market updates and merchandising strategies relating to the Company, any affiliate of the Company, and the Company Business, which is communicated to, supplied to or observed by me, either directly or indirectly, at any time during the Service relationship, whether or not received from the Company, any affiliate of the Company, or from any actual or potential customer of the Company or any affiliate of the Company, or from any person with a business relationship, whether contractual or otherwise, with the Company or any affiliate of the Company. The term &ldquo;Proprietary Information&rdquo; shall not include any information that I can prove: (i) was known or independently developed by me prior to the time of receipt from the Company or any affiliate, as long as such information was not acquired, either directly or indirectly, from the Company or any affiliate; (ii) is or becomes</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">publicly known through no direct or indirect act, fault or omission of my own; (iii) is or becomes part of the public domain through no direct or indirect act, fault or omission of my own; or (iv) was received by me from a third party having the legal right to transmit the same without restriction as to use and disclosure and such receipt was not in connection with any business relationship or prospective business relationship with the Company or any affiliate; <I>provided</I>, <I>however</I>, that a combination of features shall not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or otherwise within such exceptions, as previously described, unless the combination itself is in the public domain or otherwise entirely within any one such exception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.8.</B>&nbsp;<B>Trade Secrets. </B>As used in this Agreement, &ldquo;<B><I>Trade Secrets</I></B>&rdquo; shall mean information not generally known about the Company&rsquo;s business which is the subject of efforts that are reasonable under the circumstances to maintain its secrecy or confidentiality and from which the Company and/or any affiliate derives economic value from the fact that the information is not generally known to other persons who can obtain economic value from its disclosure or use, and shall include any and all Proprietary Information which may be protected as a trade secret under any applicable law, even if not specifically designated as such. Unless told otherwise, I shall treat all Proprietary Information as Trade Secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.9.</B>&nbsp;<B>Service. </B>As used in this Agreement, &ldquo;<B><I>Service</I></B>&rdquo; means any responsibility, duty or authority consistent with the role of an employee, consultant, advisor, officer or director of the Company, including any other responsibility, duty or authority assigned from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.10.</B>&nbsp;<B>Work Product. </B>As used in this Agreement, &ldquo;<B><I>Work Product</I></B>&rdquo; shall mean all discoveries, improvements, techniques, designs, artwork, trade secrets, Confidential Information, trademarks, data, analyses, materials, formulas, strategic plans, acquisition strategies, research, documentation, computer programs, information technology systems, communication systems, manufacturing systems, system designs, inventions (whether or not patentable), copyrightable subject matter, works of authorship, and other confidential or proprietary information or work product (including all worldwide Intellectual Property Rights therein), whether or not patentable, and in whatever form, which I have made or conceived, or may make or conceive, either solely or jointly with others, while providing Services to the Company or any affiliate, or with the use of the time,</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">material, resources, or facilities of the Company or any affiliate or relating to any actual or anticipated Business of the Company, or suggested by or resulting from any task assigned to me or work performed by me for or on behalf of the Company or any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>2.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Confidentiality</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.1.</B>&nbsp;<B>Protection of Confidential Information. </B>I recognize the interest of the Company and its affiliates in maintaining the confidential nature of its Confidential Information. Accordingly, I covenant and agree that I will not, at any time, other than in the performance of my Service for the Company or any affiliate, both during and after my Service with the Company, communicate or disclose to any person or entity, or use for my benefit, or for the benefit of any other person or entity, either directly or indirectly, any Trade Secrets and/or Proprietary Information. For the purposes of this Agreement, the prohibition against the disclosure of Proprietary Information is prohibited until the information becomes publicly available through no direct or indirect fault or act of my own, or otherwise no longer qualifies as a Trade Secret. I understand that misappropriation of a trade secret of the Company in breach of this Agreement may subject me to liability under the Defend Trade Secrets Act of 2016 (the &ldquo;<B><I>DTSA</I></B>&rdquo;), entitle the Company to injunctive relief and require me to pay compensatory damages, double damages and attorneys&rsquo; fees. Nothing in the foregoing covenant shall in any way limit or impair any of the rights of the Company or any affiliate with respect to any trade secret information, including, without limitation, any information that qualifies as a trade secret under the DTSA. Notwithstanding any other provision of this letter agreement, I understand that I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, in each case solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. I further understand that if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the trade secrets of the Company to my attorney and use the trade secret information in the court proceeding if I file any document containing the trade secret under seal and do not disclose the trade secret except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.2.</B>&nbsp;<B>Third Party Information.</B> I understand, in addition, that Company has received and, in the future, will receive from third parties confidential or proprietary</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">information (&ldquo;<B><I>Third Party Information</I></B>&rdquo;) subject to a duty on Company&rsquo;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my Service and thereafter, I will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information, unless expressly authorized by an officer of the Company in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.3.</B>&nbsp;<B>No Improper Use of Information of Prior Employers and Others.</B> I represent that my Service with Company does not and will not breach any agreement with any former employer, including any non-compete agreement or any agreement to keep in confidence information acquired by me in confidence or trust prior to my Service with Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict herewith. During my Service with Company, I will not improperly use or disclose any confidential information or trade secrets of any former employer or other third party to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party to whom I have an obligation of confidentiality, unless consented to in writing by that former employer or person. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>3.</B>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Work
Product and</B></FONT><B> <FONT STYLE="font-variant: small-caps">Inventions</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.1.</B>&nbsp;<B>Protection of Work Product</B>. I acknowledge and agree that all Work Product produced by me during my Service with the Company or any affiliate shall be considered &ldquo;work for hire&rdquo; as such term is defined in 17 U.S.C. &#xa7; 101 <I>et seq</I>. I hereby assign to the Company and all affiliates all right, title and interest whatsoever in and to any and all Work Product, including all worldwide Intellectual Property Rights therein. If, for any reason, any of the Work Product does not constitute a &ldquo;work made for hire,&rdquo; I hereby irrevocably assign to the Company, in each case without additional consideration, all right, title and interest throughout the world in and to such Work Product, including all Intellectual Property Rights therein. I agree to promptly disclose any and all such Work Product to the Company and any affiliate, as requested, and to perform, during or after the termination of my Service and</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">without requiring the Company or any affiliate to provide any further consideration, such further acts as may be necessary or desirable to transfer, perfect, and defend the Company&rsquo;s ownership (or any affiliate&rsquo;s ownership) of the Work Product as requested by the Company or any affiliate, including, without limitation the execution of such patent applications (including continuations and related materials), confirmatory assignments, instruments and documents as the Company or any affiliate deems necessary or desirable in order to effect such assignment and to protect and enforce such rights. The Company and all affiliates shall have the right to obtain and hold in its and their own name copyrights, patents, registrations, and any other protection available in the Work Product. My obligation to execute materials to effect assignment of Work Product shall survive the termination of my Service with the Company of any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.2.</B>&nbsp;<B>Prior Inventions.</B> I agree that I will not incorporate, or permit to be incorporated, Prior Inventions (defined below) in any Company Inventions (defined below) without Company&rsquo;s prior written consent. In addition, I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU GPL or LGPL or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company. I have disclosed on <B>Exhibit A</B> a complete list of all Inventions that I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my Service with Company, in which I have an ownership interest or which I have a license to use, and that I wish to have excluded from the scope of this Agreement (collectively referred to as &ldquo;<B><I>Prior Inventions</I></B>&rdquo;). If no Prior Inventions are listed in <B>Exhibit A</B>, I warrant that there are no Prior Inventions. If, in the course of my Service with Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.3.</B>&nbsp;<B>Assignment of Company Inventions.</B> Subject to the section titled &ldquo;Government or Third Party&rdquo; and except for Inventions that I can prove qualify fully under the provisions of California Labor Code section&nbsp;2870 (or</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">any similar law in an applicable jurisdiction) and I have set forth in <B>Exhibit A</B>, I hereby assign and agree to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, in the course of my Service with the Company. Inventions assigned to Company or to a third party as directed by Company pursuant to the section titled &ldquo;Government or Third Party&rdquo; are referred to in this Agreement as <B>&ldquo;<I>Company Inventions</I>.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.4.</B>&nbsp;<B>Obligation to Keep Company Informed.</B> During the period of my Service and for one (1) year thereafter, I will promptly and fully disclose to Company in writing (a) all Inventions or Work Product authored, conceived, or reduced to practice by me, either alone or with others, including any that might be covered under California Labor Code section&nbsp;2870 (or any similar law in any applicable jurisdiction), and (b) all patent applications filed by me or in which I am named as an inventor or co-inventor, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.5.</B>&nbsp;<B>Government or Third Party.</B> I also agree to assign all my right, title, and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.6.</B>&nbsp;<B>Enforcement of Intellectual Property Rights and Assistance.</B> During the period of my Service and thereafter, I will assist Company in every proper way to obtain and enforce United States and foreign Intellectual Property Rights relating to Company Inventions in all countries. In the event Company is unable to secure my signature on any document needed in connection with such purposes, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>4.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Records.</FONT></B> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Inventions or Work Product made by me during the period of my Service with Company, if any, which records shall be available to, and remain the sole property of, Company at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>5.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Return Of Company Property.</FONT></B> Upon termination</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">of my Service or upon Company&rsquo;s request at any other time, I will deliver to Company all of Company&rsquo;s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information of Company, excepting only (i) my personal copies of records relating to my compensation; (ii) my personal copies of any materials previously distributed generally to stockholders of the Company; and (iii) my copies of my agreements with the Company. I agree that I will not copy, delete, or alter any Confidential Information contained upon my Company computer immediately before I return it to Company. I further agree that any property situated on Company&rsquo;s premises and owned by Company is subject to inspection by Company personnel at any time with or without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>6.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Notification Of New Employer</FONT>.</B> In the event that my Service with the Company terminates, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement, by Company&rsquo;s providing a copy of this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>7.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">General Provisions</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.1.</B>&nbsp;<B>Governing Law</B>. This Agreement will be governed by and construed according to the laws of the State of California, without reference to conflict of laws principles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.2.</B>&nbsp;<B>Severability.</B> If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the other provisions of this Agreement will be unimpaired and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.3.</B>&nbsp;<B>Survival.</B> This Agreement shall survive the termination of my Service and the assignment of this Agreement by Company to any successor-in-interest or other assignee and be binding upon my heirs and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.4.</B>&nbsp;<B>Continuation of Service.</B> I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of Service with Company, nor shall it interfere in any way with my right or Company&rsquo;s right to terminate my Service at any time, with or without cause and with or without advance notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.5.</B>&nbsp;<B>Notices</B>. Each party must deliver all notices or other communications required or permitted under this Agreement in writing to the other party at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">requested), or by a nationally-recognized express mail service. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, any such notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, any such notice shall be considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of such change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.6.</B>&nbsp;<B>Legal Remedies. </B>I acknowledge and agree that the Company and its affiliates, as applicable, will suffer irreparable loss and damage if I breach or violate any of the restrictions and agreements contained in this Agreement. I therefore agree that, in addition to any other remedies available, the Company and its affiliates, as applicable, shall be entitled to a temporary restraining order, preliminary injunction and/or permanent injunction, without any bond or other security being required, to prevent a breach or contemplated breach by me and by any person or entity to whom I provide or propose to provide any services in violation of any of the covenants or agreements contained in this Agreement. Any rights created by this Agreement shall be in addition to, and not in lieu of, any other remedies that may exist under any applicable law or in equity.</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.7.</B>&nbsp;<B>Waiver.</B> Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or of such provision on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.8.</B>&nbsp;<B>Export</B>. I agree not to export, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, to countries outside the United States, because such export could be in violation of the United States export laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.9.</B>&nbsp;<B>Entire Agreement.</B> The obligations pursuant to sections of this Agreement titled &ldquo;Confidentiality&rdquo; and &ldquo;Inventions&rdquo; shall apply to any time during which I was previously employed, or am in the future employed, by Company as an independent contractor if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matters hereof and supersedes and merges all prior communications between us with respect to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and a duly authorized officer of the Company. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0.5in; margin: 0">[<I>Remainder of Page Intentionally Left Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">This Agreement shall be effective as of the first day of my Service with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>I have
read, understand, and accept this agreement and have been given the opportunity to review it with independent legal counsel.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Print Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">Date:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-variant: small-caps"><B>Accepted and Agreed To:</B></FONT></TD>
    <TD STYLE="text-align: left; width: 50%"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B>, a Delaware corporation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>[Signature Page to Confidentiality
and Proprietary Information and Inventions Agreement]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">EXHIBIT A</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">INVENTIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD>
    <TD STYLE="text-align: justify"><B>Prior Inventions Disclosure.</B> The following is a complete list of all Prior Inventions:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">None</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">See immediately below:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD>
    <TD STYLE="text-align: justify"><B>Limited Exclusion Notification.</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B><FONT STYLE="font-variant: small-caps">This is to notify </FONT></B>you in accordance with California Labor Code section&nbsp;2870 (or any similar law in an applicable jurisdiction) that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&rsquo;s equipment, supplies, facilities or trade secret information, except for those Inventions that either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>a.</B>&nbsp;Relate at the time of conception or reduction to practice to Company&rsquo;s business actual or demonstrably anticipated research or development; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>b.</B>&nbsp;Result from any work performed by you for Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent permitted by applicable law, this limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 24; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Restricted Stock Unit Grant Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>neonctechnologies_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EMPLOYMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Employment Agreement (the &ldquo;Agreement&rdquo;) is entered into as of the 4th day of January, 2024, by and between NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Thomas Chen, MD, PhD, an individual residing at the address set forth on Schedule A hereto (the &ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>INTRODUCTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company is in the business of the development and commercialization of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain (the &ldquo;Business&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Company wishes to employ the Executive under the title and capacity set forth on Schedule A hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">WHEREAS, the Executive desires to be employed by the Company in such capacity, subject to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOW, THEREFORE, in consideration of the premises and mutual promises herein below set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Employment Period</U>. The initial term of the Executive&rsquo;s employment by the Company (directly or through its wholly-owned subsidiary NeOnc Technologies, Inc.) pursuant to this Agreement shall commence upon the effective date of the Company&rsquo;s initial public offering if such public offering occurs on or before June&nbsp;30, 2024 (the &ldquo;Effective Date&rdquo;) and shall continue for and shall continue through and expire on that date which is seven months from the Effective Date (the &ldquo;Employment Period&rdquo;). Thereafter, the Employment Period shall automatically renew for successive periods of one (1) year each, unless either party shall have given to the other at least fifteen (15) days&rsquo; prior written notice of their intention not to renew the Executive&rsquo;s employment prior to the end of the Employment Period or the then applicable renewal term, as the case may be. In any event, the Employment Period may be terminated as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Employment; Duties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Subject to the terms and conditions set forth herein, the Company hereby employs the Executive to act for the Company during the Employment Period in the capacity set forth on Schedule A hereto, and the Executive hereby accepts such employment. The duties and responsibilities of the Executive shall include such duties and responsibilities appropriate to such office and as are normally associated with and appropriate for such position and as the Company&rsquo;s board of directors (the &ldquo;Board&rdquo;) may from time to time reasonably assign to the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive recognizes that during the period of Executive&rsquo;s employment hereunder, Executive owes an undivided duty of loyalty to the Company, and Executive will use Executive&rsquo;s good faith efforts to promote and develop the business of the Company and its subsidiaries (the Company&rsquo;s subsidiaries from time to time, together with any other affiliates of the Company, the &ldquo;Affiliates&rdquo;). Executive shall devote all of Executive&rsquo;s business time, attention and skills to the performance of Executive&rsquo;s services as an executive of the Company. Recognizing and acknowledging that it is essential for the protection and enhancement of the brand name, reputation and business of the Company and the goodwill pertaining thereto, Executive shall perform the Executive&rsquo;s duties under this Agreement professionally, in accordance with the applicable laws, rules and regulations and such standards, policies and procedures established by the Company and the industry from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) However, the parties agree that: (i) Executive may devote a reasonable amount of his time to civic, community, or charitable activities and may serve as a director of other corporations (provided that any such other corporation is not a competitor of the Company, as determined by the Board) and to other types of business or public activities not expressly mentioned in this paragraph and (ii) Executive may participate as a non-employee director and/or investor in other companies and projects as disclosed by Executive to, and approved by, the Board, so long as Executive&rsquo;s responsibilities with respect thereto do not conflict or interfere with the faithful performance of his duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>Place of Employment</U>. The Executive&rsquo;s services shall be performed at the Company&rsquo;s offices located at 8335 Sunset Boulevard, Suite 240, Los Angeles, California, 90069, at any other location at which the Company now or hereafter has a business facility, at employee&rsquo;s home office, or at any other location where Executive&rsquo;s presence is necessary to perform his duties. The parties acknowledge that the Executive may be required to travel in connection with the performance of his duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Base Salary</U>. The Executive shall be entitled to receive a salary from the Company during the Employment Period at a rate per year indicated on Schedule A hereto (the &ldquo;Base Salary&rdquo;). Once the Board has established the Base Salary, such Base Salary shall be payable in monthly installments in accordance with the Company&rsquo;s customary payroll practices. The Executive&rsquo;s Base Salary may be increased on each anniversary of the Effective Date, at the Board&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Bonus</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Executive shall be eligible to participate in any bonus or incentive program established by the Company for executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6. <U>Other Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Grant of Restricted Stock Units. The Executive shall be entitled to receive a number of restricted stock units (&ldquo;Restricted Stock Units&rdquo;) as in accordance with the terms of a separate Restricted Stock Unit Award Agreement set forth on Exhibit A hereto. Any additional equity awards to the Executive shall be at the option of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Restrictions. Any and all shares of stock, options, restricted stock units and other equity awards granted to or owned by the Executive will be subject to the share ownership guidelines and insider trading and blackout policies adopted from time to time by the Board of Directors for senior executives of the Company and will also be subject to applicable holding periods and transaction reporting requirements under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Insurance and Other Benefits. During the Employment Period, the Executive and the Executive&rsquo;s dependents shall be entitled to participate in any Company insurance programs and any applicable benefit plans, as the same may be adopted and/or amended from time to time (the &ldquo;Benefits&rdquo;). The Executive shall be bound by all of the policies and procedures relating to Benefits established by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) Vacation; Personal Days. During the Employment Period, the Executive shall be entitled to an annual vacation of such duration consistent with the Company&rsquo;s policies from time to time, as determined by the Board. The Executive shall be entitled to paid personal days on a basis consistent with the Company&rsquo;s other senior executives, as determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) Expense Reimbursement. The Company shall reimburse the Executive for all reasonable business, promotional, travel and entertainment expenses (&ldquo;Reimbursable Expenses&rdquo;) incurred or paid by the Executive during the Employment Period in the performance of Executive&rsquo;s services under this Agreement on a basis consistent with the Company&rsquo;s other senior executives, as determined by the Board, provided that the Executive furnishes to the Company appropriate documentation required by the Code and/or other taxing authorities in a timely fashion in connection with such expenses and shall furnish such other documentation and accounting as the Company may from time to time reasonably request. For purposes of this Agreement, &ldquo;Code&rdquo; means the U.S. Internal Revenue Code of 1986 (as it has been and may be amended from time to time) and any regulations and guidance that has been promulgated or may be promulgated from time to time thereunder and any state law of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. <U>Termination; Compensation Due Upon Termination of Employment</U>. The Executive&rsquo;s employment with the Company shall be entirely &ldquo;at-will,&rdquo; meaning that either the Executive or the Company may terminate such employment relationship by terminating this Agreement in writing delivered to the other party at any time for any reason or for no reason at all, subject, however, to the terms of this Section&nbsp;7. The Executive&rsquo;s right to compensation for periods after the date his employment with the Company terminates shall be determined in accordance with the provisions of paragraphs (a) through (e) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Voluntary Resignation; Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Voluntary Resignation</U>. The Executive may terminate his employment at any time upon thirty (30) days prior written notice to the Company. In the event of the Executive&rsquo;s voluntary termination of employment other than for Good Reason (as defined below), the Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, except as otherwise required by this Agreement or by applicable law, to provide the benefits described in Section&nbsp;6 for periods after the date on which the Executive&rsquo;s employment with the Company terminates due to the Executive&rsquo;s voluntary resignation, except for the payment of the Executive&rsquo;s Base Salary accrued through the date of such resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Termination without Cause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(A) If the Executive&rsquo;s employment is terminated by the Company without Cause (as defined below): the Company shall (x) continue to pay the Executive the Base Salary (at the rate in effect on the date the Executive&rsquo;s employment is terminated) until the end of the Severance Period (as defined below), and (y) pay any other accrued compensation and Benefits. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(B) If, following a termination of employment without Cause, the Executive breaches the provisions of Section&nbsp;10 hereof or that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, the Executive shall not be eligible, as of the date of such breach, for the payments and benefits described in Section&nbsp;7(a)(ii)(A) above, and any and all obligations and agreements of the Company with respect to such payments shall thereupon cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">(b) Discharge for Cause. Upon written notice to the Executive, the Company may terminate the Executive&rsquo;s employment for &ldquo;Cause&rdquo; if any of the following events shall occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) any act or omission that constitutes a material breach by the Executive of any of his obligations under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) the willful and continued failure or refusal of the Executive to satisfactorily perform the duties reasonably required of him as an employee of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) the Executive&rsquo;s conviction of, or plea of nolo contendere to, (i) any felony or (ii) a crime involving dishonesty or moral turpitude or which could reflect negatively upon the Company or otherwise impair or impede its operations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the Executive&rsquo;s engaging in any misconduct, negligence, act of dishonesty (including, without limitation, theft or embezzlement), violence, threat of violence or any activity that could result in any violation of federal securities laws, in each case, that is injurious to the Company or any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) the Executive&rsquo;s material breach of a written policy of the Company or the rules of any governmental or regulatory body applicable to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vi) the Executive&rsquo;s refusal to follow the directions of the Board, unless such directions are, in the written opinion of legal counsel, illegal or in violation of applicable regulations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(vii) any other willful misconduct by the Executive which is materially injurious to the financial condition or business reputation of the Company or any of its Affiliates, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(viii) the Executive&rsquo;s breach of his obligations under Section&nbsp;10 hereof or under that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">In the event Executive is terminated for Cause, the Company shall have no obligation to make payments to Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law, to provide the benefits described in Section&nbsp;6, for periods after the Executive&rsquo;s employment with the Company is terminated on account of the Executive&rsquo;s discharge for Cause except for the Executive&rsquo;s then applicable Base Salary accrued through the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Disability</U>. The Company shall have the right, but shall not be obligated to, terminate the Executive&rsquo;s employment hereunder in the event the Executive becomes disabled such that he is unable to discharge his duties to the Company for a period of ninety (90) consecutive days or one hundred twenty (120) days in any one hundred eighty (180) consecutive day period (unless longer periods are not required under applicable local labor regulations) (a &ldquo;Permanent Disability&rdquo;). In the event of a termination of employment due to a Permanent Disability, the Company shall be obligated to continue to make payments to the Executive in an amount equal to the then applicable Base Salary for the Severance Period (as defined below), payable in the form of salary continuation for the applicable Severance Period after the Executive&rsquo;s employment with the Company is terminated due to a Permanent Disability. A determination of a Permanent Disability shall be made by a physician satisfactory to both the Executive and the Company; provided, however, that if the Executive and the Company do not agree on a physician, the Executive and the Company shall each select a physician and those two physicians together shall select a third physician, whose determination as to a Permanent Disability shall be binding on all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Death</U>. The Executive&rsquo;s employment hereunder shall terminate upon the death of the Executive. The Company shall have no obligation to make payments to the Executive in accordance with the provisions of Sections&nbsp;4 or 5, or, except as otherwise required by law or the terms of any applicable benefit plan, to provide the benefits described in Section&nbsp;6 for periods after the date of the Executive&rsquo;s death except for then applicable Base Salary earned and accrued through the date of death, payable to the Executive&rsquo;s beneficiary, as the Executive shall have indicated in writing to the Company (or if no such beneficiary has been designated, to Executive&rsquo;s estate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Termination for Good Reason</U>. The Executive may terminate this Agreement at any time for Good Reason. In the event of termination under this paragraph (e), the Company shall pay to the Executive severance in an amount equal to the Executive&rsquo;s then applicable Base Salary for a period equal to the number of months set forth on Schedule A hereto (the &ldquo;Severance Period&rdquo;), subject to the Executive&rsquo;s continued compliance with Section&nbsp;10 hereof and with that Employee Proprietary Information and Inventions Agreement attached hereto as <U>Exhibit B</U>, payable in the form of salary continuation for the applicable Severance Period following the Executive&rsquo;s termination, and subject to the Company&rsquo;s regular payroll practices and required withholdings. Such severance shall be reduced by any cash remuneration paid to the Executive because of the Executive&rsquo;s employment or self-employment during the Severance Period. The Executive shall continue to receive all Benefits (either through the Company or an Affiliate) during the Severance Period. The Executive shall have no further rights under this Agreement or otherwise to receive any other compensation or benefits after such resignation. For the purposes of this Agreement, &ldquo;Good Reason&rdquo; shall mean any of the following (without Executive&rsquo;s express written consent):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) ;the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) removal of the Executive from his position as indicated on Schedule A hereto, or the assignment to the Executive of duties that are materially and negatively inconsistent with respect to Executive&rsquo;s position and are significantly different from, and that result in a substantial diminution of, the duties that he assumed under this Agreement, within twelve (12) months after a Change of Control (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iii) a reduction by the Company in the Executive&rsquo;s then applicable Base Salary or other compensation, unless said reduction is pari passu with other senior executives of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(iv) the taking of any action by the Company that would, directly or indirectly, materially reduce the Executive&rsquo;s benefits, unless said reductions are pari passu with other senior executives of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) a breach by the Company of any material term of this Agreement that is not cured by the Company within thirty (30) days following receipt by the Company of written notice thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f) <U>Notice of Termination</U>. Any termination of employment by the Company or the Executive shall be communicated by a written &ldquo;Notice of Termination&rdquo; to the other party hereto given in accordance with Section&nbsp;18 of this Agreement. In the event of a termination by the Company for Cause, the Notice of Termination shall (i) indicate the specific termination provision in this Agreement relied upon, (ii) set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive&rsquo;s employment under the provision so indicated and (iii) specify the date of termination, which date shall be the date of such notice. The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive&rsquo;s or the Company&rsquo;s rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) <U>Resignation of Executive Officer</U>. The termination of the Executive&rsquo;s employment for any reason will constitute the Executive&rsquo;s resignation from (i) any director, officer or employee position the Executive has with the Company or any of its Affiliates, and (ii) all fiduciary positions (including as a trustee) the Executive holds with respect to any employee benefit plans or trusts established by the Company. The Executive agrees that this Agreement shall serve as written notice of resignation in this circumstance, unless otherwise required by any plan or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8. <U>Section&nbsp;409A</U>. It is intended that
all payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A
provided under Treasury Regulations Sections&nbsp;1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed
to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions
hereunder) will be construed in a manner that complies with Section&nbsp;409A. For all purposes of Code Section&nbsp;409A (including,
without limitation, for purposes of Treasury Regulations Sections&nbsp;1.409A 2(b)(2)(i) and (iii)), Executive&rsquo;s right to receive
any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to
receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate
and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time
of Executive&rsquo;s Separation from Service (for purposes of this Agreement, &ldquo;Separation from Service&rdquo; means a &ldquo;separation
from service&rdquo;, as defined under Treasury Regulation Section&nbsp;1.409A-1(h))to be a &ldquo;specified employee&rdquo; for purposes
of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other
agreement with the Company are deemed to be &ldquo;deferred compensation,&rdquo; then to the extent delayed commencement of any portion
of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse
taxation under Section&nbsp;409A, such payments shall not be provided to Executive prior to the earliest of (i) the first date following
expiration of the six-month period following the date of Executive&rsquo;s Separation from Service with the Company, (ii) the date of
Executive&rsquo;s death or (iii) such earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon
the first business day following the expiration of such applicable Code Section&nbsp;409A(a)(2)(B)(i) period, all payments deferred pursuant
to this paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein
or in the applicable agreement. No interest shall be due on any amounts so deferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9. <U>Section&nbsp;280G</U>. If any payment or benefit Executive will or may receive from the Company or otherwise (a &ldquo;<U>280G Payment</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section&nbsp;280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<U>Reduced Amount</U>&rdquo; hall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&rsquo;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &ldquo;<U>Reduction Method</U>&rdquo;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &ldquo;<U>Pro Rata Reduction Method</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &ldquo;deferred compensation&rdquo; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change in control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive&rsquo;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other reasonable time as requested by Executive or the Company.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If Executive receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10. <U>Non-Competition; Non-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) For the duration of the Employment Period and, unless the Company terminates the Executive&rsquo;s employment without Cause, during the Severance Period (the &ldquo;Non-compete Period&rdquo;), the Executive shall not, directly or indirectly, except as specifically provided in the last sentence of Section&nbsp;2(c) hereof, engage or invest in, own, manage, operate, finance, control or participate in the ownership, management, operation, financing, or control of, be employed by, associated with, or in any manner connected with, lend any credit to, or render services or advice to, any business, firm, corporation, partnership, association, joint venture or other entity that engages or conducts any business the same as or substantially similar to the Business or any other business engaged in or proposed to be engaged in or conducted by the Company and/or any of its Affiliates during the Employment Period, or then included in the future strategic plan of the Company and/or any of its Affiliates, anywhere within North America; provided, however, that the Executive may own less than 5% in the aggregate of the outstanding shares of any class of securities of any enterprise (but without otherwise participating in the activities of such enterprise), other than any such enterprise with which the Company competes or is currently engaged in a joint venture, if such securities are of a class listed on any national or regional securities exchange or have been registered under Section&nbsp;12(b) or (g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) During the Employment Period and for a period of twelve (12) months following termination of the Executive&rsquo;s employment with the Company, the Executive shall not solicit or attempt to recruit any employee, or independent contractor of, or consultant to, the Company, or its Affiliates, to leave the employment (or independent contractor relationship) thereof, whether or not any such employee or independent contractor is party to an employment agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) The Executive recognizes and agrees that because a violation by the Executive of his obligations under this Section will cause irreparable harm to the Company that would be difficult to quantify and for which money damages would be inadequate, the Company shall have the right to injunctive relief to prevent or restrain any such violation, without the necessity of posting a bond. The Non-compete Period will be extended by the duration of any violation by the Executive of any of his obligations under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) The Executive expressly agrees that the character, duration and scope of the covenant not to compete are reasonable in light of the circumstances as they exist at the date upon which this Agreement has been executed. However, should a determination nonetheless be made by a court of competent jurisdiction at a later date that the character, duration or geographical scope of the covenant not to compete is unreasonable in light of the circumstances as they then exist, then it is the intention of the Executive, on the one hand, and the Company, on the other, that the covenant not to compete shall be construed by the court in such a manner as to impose only those restrictions on the conduct of the Executive which are reasonable in light of the circumstances as they then exist and necessary to assure the Company of the intended benefit of the covenant not to compete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11. <U>Inventions and Patents</U>. The Executive acknowledges that all inventions, innovations, improvements, know-how, plans, development, methods, designs, analyses, specifications, software, drawings, reports and all similar or related information (whether or not patentable or reduced to practice) which related to any of the Company&rsquo;s actual or proposed business activities and which are created, designed or conceived, developed or made by the Executive during the Executive&rsquo;s past or future employment by the Company or any Affiliates, or any predecessor thereof (&ldquo;Work Product&rdquo;), belong to the Company, or its Affiliates, as applicable. Any copyrightable work falling within the definition of Work Product shall be deemed a &ldquo;work made for hire&rdquo; and ownership of all right title and interest shall rest in the Company. The Executive hereby irrevocably assigns, transfers and conveys, to the full extent permitted by law, all right, title and interest in the Work Product, on a worldwide basis, to the Company to the extent ownership of any such rights does not automatically vest in the Company under applicable law. The Executive will promptly disclose any such Work Product to the Company and perform all actions requested by the Company (whether during or after employment) to establish and confirm ownership of such Work Product by the Company (including, without limitation, assignments, consents, powers of attorney and other instruments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12. <U>Executive&rsquo;s Representation</U>. The Executive hereby represents that the Executive&rsquo;s entry into this Agreement and performance of the services hereunder will not violate the terms or conditions of any other agreement to which the Executive is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13. <U>Arbitration of All Disputes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Agreement to Arbitrate</U>. To ensure the timely and economical resolution of disputes that may arise between Executive and the Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#xa7;1-16, and to the fullest extent permitted by applicable law, Executive and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or (ii) Executive&rsquo;s employment with the Company (including but not limited to all statutory claims); or (iii) the termination of Executive&rsquo;s employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EXECUTIVE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Arbitrator Authority</U>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Individual Capacity Only</U>. All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Arbitration Process</U>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by JAMS in Los Angeles, California, or as otherwise agreed to by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). Executive and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own expense. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute; (ii) issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions and a statement of the award; and (iii) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Injunctive Relief and Final Orders</U>. Nothing in this Section is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">14. <U>Governing Law/Jurisdiction</U>. This Agreement and any disputes or controversies arising hereunder shall be construed and enforced in accordance with and governed by the internal laws of the State of California without regard to the conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">15. <U>Public Company Obligations; Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Executive acknowledges that the Company intends to become a publicly reporting company whose shares of common stock will be registered under the U.S. Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and whose common stock will be registered under the Exchange Act, and that, after the Company becomes a publicly reporting company, this Agreement will be subject to the public filing requirements of the Exchange Act. In addition, both parties acknowledge that the Executive&rsquo;s compensation and perquisites (each as determined by the rules of the US Securities and Exchange Commission (the &ldquo;SEC&rdquo;) or any other regulatory body or exchange having jurisdiction) (which may include benefits or regular or occasional aid/assistance, such as recreation, club memberships, meals, education for his family, vehicle, lodging or clothing, occasional bonuses or anything else he receives, during the Employment Period and any renewals thereof, in cash or in kind) paid or payable or received or receivable under this Agreement or otherwise, and his transactions and other dealings with the Company, may be required to be publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) Executive acknowledges and agrees that the applicable insider trading rules, transaction reporting rules, limitations on disclosure of non-public information and other requirements set forth in the Securities Act, the Exchange Act and rules and regulations promulgated by the SEC may apply to this Agreement and Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) Executive (on behalf of himself, as well as the Executive&rsquo;s executors, heirs, administrators and assigns) absolutely and unconditionally agrees to indemnify and hold harmless the Company and all of its past, present and future affiliates, executors, heirs, administrators, shareholders, employees, officers, directors, attorneys, accountants, agents, representatives, predecessors, successors and assigns from any and all claims, debts, demands, accounts, judgments, causes of action, equitable relief, damages, costs, charges, complaints, obligations, controversies, actions, suits, proceedings, expenses, responsibilities and liabilities of every kind and character whatsoever (including, but not limited to, reasonable attorneys&rsquo; fees and costs) in the event of Executive&rsquo;s breach of any obligation of Executive under the Securities Act, the Exchange Act, any rules promulgated by the SEC and any other applicable federal, state or foreign laws, rules, regulations or orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">16. <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and thereof and supersedes and cancels any and all previous agreements, both written and oral, regarding the subject matter hereof between the parties hereto. This Agreement shall not be changed, altered, modified or amended, except by a written agreement signed by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">17. <U>Notices</U>. All notices, requests, demands and other communications called for or contemplated hereunder shall be in writing and shall be deemed to have been given when delivered to the party to whom addressed or when sent by telecopy (if promptly confirmed by registered or certified mail, return receipt requested, prepaid and addressed) to the parties, their successors in interest, or their assignees at the following addresses, or at such other addresses as the parties may designate by written notice in the manner aforesaid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(a)</TD>
    <TD STYLE="text-align: justify">to the Company at:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">NeOnc Technologies Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">8335 Sunset Boulevard, Suite 240</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Los Angeles, California, 90069</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: info@neonctech.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Manatt, Phelps and Phillips, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">695 Town Center Drive, 14th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Costa Mesa, CA 92629</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attn: Thomas J. Poletti, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Email: tpoletti@manatt.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(b)</TD>
    <TD STYLE="text-align: justify">to the Executive as set forth on Schedule A hereto.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All such notices, requests and other communications will (i) if delivered personally to the address as provided in this Section, be deemed given upon delivery, (ii) if delivered by facsimile transmission to the facsimile number as provided for in this Section, be deemed given upon facsimile confirmation, (iii) if delivered by mail in the manner described above to the address as provided for in this Section, be deemed given on the earlier of the third business day following mailing or upon receipt and (iv) if delivered by overnight courier to the address as provided in this Section, be deemed given on the earlier of the first business day following the date sent by such overnight courier or upon receipt (in each case regardless of whether such notice, request or other communication is received by any other person to whom a copy of such notice is to be delivered pursuant to this Section). Either party may, by notice given to the other party in accordance with this Section, designate another address or person for receipt of notices hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18. <U>Severability</U>. If any term or provision of this Agreement, or the application thereof to any person or under any circumstance, shall to any extent be invalid or unenforceable, the remainder of this Agreement, or the application of such terms to the persons or under circumstances other than those as to which it is invalid or unenforceable, shall be considered severable and shall not be affected thereby, and each term of this Agreement shall be valid and enforceable to the fullest extent permitted by law. The invalid or unenforceable provisions shall, to the extent permitted by law, be deemed amended and given such interpretation as to achieve the economic intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">19. <U>Waiver</U>. The failure of any party to insist
in any one instance or more upon strict performance of any of the terms and conditions hereof, or to exercise any right or privilege
herein conferred, shall not be construed as a waiver of such terms, conditions, rights or privileges, but same shall continue to remain
in full force and effect. Any waiver by any party of any violation of, breach of or default under any provision of this Agreement by
the other party shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation of,
breach of or default under any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">20. <U>Successors and Assigns</U>. This Agreement shall be binding upon the Company and any successors and assigns of the Company. Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive. The Company may assign this Agreement and its right and obligations hereunder, in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">21. <U>Counterparts</U>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Additionally, a facsimile counterpart of this Agreement shall have the same effect as an originally executed counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">22. <U>Headings</U>. Headings in this Agreement are for reference purposes only and shall not be deemed to have any substantive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">23. <U>Opportunity to Seek Advice</U>. The Executive acknowledges and confirms that he has had the opportunity to seek such legal, financial and other advice and representation as he has deemed appropriate in connection with this Agreement, that the Executive is fully aware of its legal effect, and that Executive has entered into it freely based on the Executive&rsquo;s judgment and not on any representations or promises other than those contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">24. <U>Withholding and Payroll Practices</U>. All salary, severance payments, bonuses or benefits payments made by the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law and shall be paid in the ordinary course pursuant to the Company&rsquo;s then existing payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[SIGNATURES TO FOLLOW ON NEXT PAGE]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: left">NEONC TECHNOLOGIES HOLDINGS, INC.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Amir Heshmatpour</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Amir Heshmatpour</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left"> Executive Chairman</TD>
    <TD STYLE="text-align: left">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="text-align: left">EXECUTIVE:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Thomas Chen</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left">Thomas Chen, MD, PhD.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="text-align: left">Chief Executive Officer and Chief Scientific Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">2.</TD>
    <TD STYLE="text-align: justify">Employment</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">a.</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer and Chief Scientific Officer</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">3.</TD>
    <TD STYLE="text-align: justify">Base Salary: $212,000 per year.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">6(e).</TD>
    <TD STYLE="text-align: justify"><U>Severance Period</U>: Three months</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">18(b).</TD>
    <TD STYLE="text-align: justify"><U>Executive Contact Information</U>:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Thomas Chen, MD, PhD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">740 Forest Green</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">La Canada, CA 91011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Restricted Stock Award Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Exhibit B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form of Employee Proprietary Information<BR>and Inventions Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>CONFIDENTIALITY AND PROPRIETARY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B>AND INVENTIONS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">In consideration of my Service (as defined herein) with NeOnc Technologies Holdings, Inc., and the compensation now and later paid to me, directly and indirectly, I hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-variant: small-caps"><B>1.</B></FONT>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Definitions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.1.</B>&nbsp;<B>Company. </B>As used in this Agreement, the &ldquo;<B><I>Company</I></B>&rdquo; refers to NeOnc Technologies Holdings, Inc. and each of its subsidiaries or affiliated companies. I recognize and agree that my obligations under this Agreement and all terms of this Agreement apply to me regardless of whether I am engaged by, employed by, or work for the Company or any other subsidiary or affiliated company of the Company. Furthermore, I understand and agree that the terms of this Agreement will continue to apply to me even if my Service is transferred at some time from one subsidiary or affiliate of the Company to another.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.2.</B>&nbsp;<B>Company Business. </B>As used in this Agreement, &ldquo;<B><I>Company Business</I></B>&rdquo; shall mean: (i) the development, manufacturing, distribution, marketing and/or sale of treatments for intracranial malignancies, i.e., aggressive cancers located in the brain and (ii) any other business, product or service in which the Company engages during my Services with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.3.</B>&nbsp;<B>Competing Business. </B>As used in this Agreement, &ldquo;<B><I>Competing Business</I></B>&rdquo; shall mean any person or entity that engages in a commercial business that is the same or substantially similar to the Company Business, and only that portion of the business that is in competition with the Company Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.4.</B>&nbsp;<B>Confidential Information. </B>As used in this Agreement, &ldquo;<B><I>Confidential Information</I></B>&rdquo; shall mean, collectively, all &ldquo;Proprietary Information&rdquo; and &ldquo;Trade Secrets&rdquo; of the Company and/or any affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.5.</B>&nbsp;<B>Intellectual Property Rights. </B>As used in this Agreement, the term &ldquo;<B><I>Intellectual Property Rights</I></B>&rdquo; means all trade secrets, copyrights, trademarks, mask work rights, moral rights, patents and other intellectual</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">property rights recognized by the laws of any jurisdiction or country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.6.</B>&nbsp;<B>Invention. </B>As used in this Agreement, the term &ldquo;<B><I>Invention</I></B>&rdquo; means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments, designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.7.</B>&nbsp;<B>Proprietary Information. </B>As used in this Agreement, &ldquo;<B><I>Proprietary Information</I></B>&rdquo; shall include, without limitation, all technical and non-technical data, compilations, programs and methods, techniques, drawings, processes, financial data, actual and prospective customer lists, customer route books and materials, documents containing names and addresses of current or former customers that includes their past or present buying patterns or habits, sales reports, service reports, price lists and discount lists, methods and/or procedures regarding pricing, product cost and profit strategies or structures, product formulae, methods and/or procedures related to sales or services, methods and/or procedures of operation, special training of sales representatives, continuous market updates and merchandising strategies relating to the Company, any affiliate of the Company, and the Company Business, which is communicated to, supplied to or observed by me, either directly or indirectly, at any time during the Service relationship, whether or not received from the Company, any affiliate of the Company, or from any actual or potential customer of the Company or any affiliate of the Company, or from any person with a business relationship, whether contractual or otherwise, with the Company or any affiliate of the Company. The term &ldquo;Proprietary Information&rdquo; shall not include any information that I can prove: (i) was known or independently developed by me prior to the time of receipt from the Company or any affiliate, as long as such information was not acquired, either directly or indirectly, from the Company or any affiliate; (ii) is or becomes</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">publicly known through no direct or indirect act, fault or omission of my own; (iii) is or becomes part of the public domain through no direct or indirect act, fault or omission of my own; or (iv) was received by me from a third party having the legal right to transmit the same without restriction as to use and disclosure and such receipt was not in connection with any business relationship or prospective business relationship with the Company or any affiliate; <I>provided</I>, <I>however</I>, that a combination of features shall not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or otherwise within such exceptions, as previously described, unless the combination itself is in the public domain or otherwise entirely within any one such exception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.8.</B>&nbsp;<B>Trade Secrets. </B>As used in this Agreement, &ldquo;<B><I>Trade Secrets</I></B>&rdquo; shall mean information not generally known about the Company&rsquo;s business which is the subject of efforts that are reasonable under the circumstances to maintain its secrecy or confidentiality and from which the Company and/or any affiliate derives economic value from the fact that the information is not generally known to other persons who can obtain economic value from its disclosure or use, and shall include any and all Proprietary Information which may be protected as a trade secret under any applicable law, even if not specifically designated as such. Unless told otherwise, I shall treat all Proprietary Information as Trade Secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.9.</B>&nbsp;<B>Service. </B>As used in this Agreement, &ldquo;<B><I>Service</I></B>&rdquo; means any responsibility, duty or authority consistent with the role of an employee, consultant, advisor, officer or director of the Company, including any other responsibility, duty or authority assigned from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>1.10.</B>&nbsp;<B>Work Product. </B>As used in this Agreement, &ldquo;<B><I>Work Product</I></B>&rdquo; shall mean all discoveries, improvements, techniques, designs, artwork, trade secrets, Confidential Information, trademarks, data, analyses, materials, formulas, strategic plans, acquisition strategies, research, documentation, computer programs, information technology systems, communication systems, manufacturing systems, system designs, inventions (whether or not patentable), copyrightable subject matter, works of authorship, and other confidential or proprietary information or work product (including all worldwide Intellectual Property Rights therein), whether or not patentable, and in whatever form, which I have made or conceived, or may make or conceive, either solely or jointly with others, while providing Services to the Company or any affiliate, or with the use of the time,</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">material, resources, or facilities of the Company or any affiliate or relating to any actual or anticipated Business of the Company, or suggested by or resulting from any task assigned to me or work performed by me for or on behalf of the Company or any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>2.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Confidentiality</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.1.</B>&nbsp;<B>Protection of Confidential Information. </B>I recognize the interest of the Company and its affiliates in maintaining the confidential nature of its Confidential Information. Accordingly, I covenant and agree that I will not, at any time, other than in the performance of my Service for the Company or any affiliate, both during and after my Service with the Company, communicate or disclose to any person or entity, or use for my benefit, or for the benefit of any other person or entity, either directly or indirectly, any Trade Secrets and/or Proprietary Information. For the purposes of this Agreement, the prohibition against the disclosure of Proprietary Information is prohibited until the information becomes publicly available through no direct or indirect fault or act of my own, or otherwise no longer qualifies as a Trade Secret. I understand that misappropriation of a trade secret of the Company in breach of this Agreement may subject me to liability under the Defend Trade Secrets Act of 2016 (the &ldquo;<B><I>DTSA</I></B>&rdquo;), entitle the Company to injunctive relief and require me to pay compensatory damages, double damages and attorneys&rsquo; fees. Nothing in the foregoing covenant shall in any way limit or impair any of the rights of the Company or any affiliate with respect to any trade secret information, including, without limitation, any information that qualifies as a trade secret under the DTSA. Notwithstanding any other provision of this letter agreement, I understand that I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, in each case solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. I further understand that if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the trade secrets of the Company to my attorney and use the trade secret information in the court proceeding if I file any document containing the trade secret under seal and do not disclose the trade secret except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.2.</B>&nbsp;<B>Third Party Information.</B> I understand, in addition, that Company has received and, in the future, will receive from third parties confidential or proprietary</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">information (&ldquo;<B><I>Third Party Information</I></B>&rdquo;) subject to a duty on Company&rsquo;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my Service and thereafter, I will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information, unless expressly authorized by an officer of the Company in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>2.3.</B>&nbsp;<B>No Improper Use of Information of Prior Employers and Others.</B> I represent that my Service with Company does not and will not breach any agreement with any former employer, including any non-compete agreement or any agreement to keep in confidence information acquired by me in confidence or trust prior to my Service with Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict herewith. During my Service with Company, I will not improperly use or disclose any confidential information or trade secrets of any former employer or other third party to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party to whom I have an obligation of confidentiality, unless consented to in writing by that former employer or person. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>3.</B>&nbsp;<FONT STYLE="font-variant: small-caps"><B>Work
Product and</B></FONT><B> <FONT STYLE="font-variant: small-caps">Inventions</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.1.</B>&nbsp;<B>Protection of Work Product</B>. I acknowledge and agree that all Work Product produced by me during my Service with the Company or any affiliate shall be considered &ldquo;work for hire&rdquo; as such term is defined in 17 U.S.C. &#xa7; 101 <I>et seq</I>. I hereby assign to the Company and all affiliates all right, title and interest whatsoever in and to any and all Work Product, including all worldwide Intellectual Property Rights therein. If, for any reason, any of the Work Product does not constitute a &ldquo;work made for hire,&rdquo; I hereby irrevocably assign to the Company, in each case without additional consideration, all right, title and interest throughout the world in and to such Work Product, including all Intellectual Property Rights therein. I agree to promptly disclose any and all such Work Product to the Company and any affiliate, as requested, and to perform, during or after the termination of my Service and</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">without requiring the Company or any affiliate to provide any further consideration, such further acts as may be necessary or desirable to transfer, perfect, and defend the Company&rsquo;s ownership (or any affiliate&rsquo;s ownership) of the Work Product as requested by the Company or any affiliate, including, without limitation the execution of such patent applications (including continuations and related materials), confirmatory assignments, instruments and documents as the Company or any affiliate deems necessary or desirable in order to effect such assignment and to protect and enforce such rights. The Company and all affiliates shall have the right to obtain and hold in its and their own name copyrights, patents, registrations, and any other protection available in the Work Product. My obligation to execute materials to effect assignment of Work Product shall survive the termination of my Service with the Company of any affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.2.</B>&nbsp;<B>Prior Inventions.</B> I agree that I will not incorporate, or permit to be incorporated, Prior Inventions (defined below) in any Company Inventions (defined below) without Company&rsquo;s prior written consent. In addition, I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU GPL or LGPL or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company. I have disclosed on <B>Exhibit A</B> a complete list of all Inventions that I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my Service with Company, in which I have an ownership interest or which I have a license to use, and that I wish to have excluded from the scope of this Agreement (collectively referred to as &ldquo;<B><I>Prior Inventions</I></B>&rdquo;). If no Prior Inventions are listed in <B>Exhibit A</B>, I warrant that there are no Prior Inventions. If, in the course of my Service with Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.3.</B>&nbsp;<B>Assignment of Company Inventions.</B> Subject to the section titled &ldquo;Government or Third Party&rdquo; and except for Inventions that I can prove qualify fully under the provisions of California Labor Code section&nbsp;2870 (or</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">any similar law in an applicable jurisdiction) and I have set forth in <B>Exhibit A</B>, I hereby assign and agree to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, in the course of my Service with the Company. Inventions assigned to Company or to a third party as directed by Company pursuant to the section titled &ldquo;Government or Third Party&rdquo; are referred to in this Agreement as <B>&ldquo;<I>Company Inventions</I>.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.4.</B>&nbsp;<B>Obligation to Keep Company Informed.</B> During the period of my Service and for one (1) year thereafter, I will promptly and fully disclose to Company in writing (a) all Inventions or Work Product authored, conceived, or reduced to practice by me, either alone or with others, including any that might be covered under California Labor Code section&nbsp;2870 (or any similar law in any applicable jurisdiction), and (b) all patent applications filed by me or in which I am named as an inventor or co-inventor, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.5.</B>&nbsp;<B>Government or Third Party.</B> I also agree to assign all my right, title, and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>3.6.</B>&nbsp;<B>Enforcement of Intellectual Property Rights and Assistance.</B> During the period of my Service and thereafter, I will assist Company in every proper way to obtain and enforce United States and foreign Intellectual Property Rights relating to Company Inventions in all countries. In the event Company is unable to secure my signature on any document needed in connection with such purposes, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>4.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Records.</FONT></B> I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Inventions or Work Product made by me during the period of my Service with Company, if any, which records shall be available to, and remain the sole property of, Company at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>5.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Return Of Company Property.</FONT></B> Upon termination</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">of my Service or upon Company&rsquo;s request at any other time, I will deliver to Company all of Company&rsquo;s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information of Company, excepting only (i) my personal copies of records relating to my compensation; (ii) my personal copies of any materials previously distributed generally to stockholders of the Company; and (iii) my copies of my agreements with the Company. I agree that I will not copy, delete, or alter any Confidential Information contained upon my Company computer immediately before I return it to Company. I further agree that any property situated on Company&rsquo;s premises and owned by Company is subject to inspection by Company personnel at any time with or without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>6.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">Notification Of New Employer</FONT>.</B> In the event that my Service with the Company terminates, I hereby consent to the notification of my new employer of my rights and obligations under this Agreement, by Company&rsquo;s providing a copy of this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B>7.</B>&nbsp;<B><FONT STYLE="font-variant: small-caps">General Provisions</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.1.</B>&nbsp;<B>Governing Law</B>. This Agreement will be governed by and construed according to the laws of the State of California, without reference to conflict of laws principles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.2.</B>&nbsp;<B>Severability.</B> If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the other provisions of this Agreement will be unimpaired and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.3.</B>&nbsp;<B>Survival.</B> This Agreement shall survive the termination of my Service and the assignment of this Agreement by Company to any successor-in-interest or other assignee and be binding upon my heirs and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.4.</B>&nbsp;<B>Continuation of Service.</B> I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of Service with Company, nor shall it interfere in any way with my right or Company&rsquo;s right to terminate my Service at any time, with or without cause and with or without advance notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.5.</B>&nbsp;<B>Notices</B>. Each party must deliver all notices or other communications required or permitted under this Agreement in writing to the other party at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="float: left; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">requested), or by a nationally-recognized express mail service. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, any such notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, any such notice shall be considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of such change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.6.</B>&nbsp;<B>Legal Remedies. </B>I acknowledge and agree that the Company and its affiliates, as applicable, will suffer irreparable loss and damage if I breach or violate any of the restrictions and agreements contained in this Agreement. I therefore agree that, in addition to any other remedies available, the Company and its affiliates, as applicable, shall be entitled to a temporary restraining order, preliminary injunction and/or permanent injunction, without any bond or other security being required, to prevent a breach or contemplated breach by me and by any person or entity to whom I provide or propose to provide any services in violation of any of the covenants or agreements contained in this Agreement. Any rights created by this Agreement shall be in addition to, and not in lieu of, any other remedies that may exist under any applicable law or in equity.</P> </DIV>

<DIV STYLE="float: right; width: 48%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.7.</B>&nbsp;<B>Waiver.</B> Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or of such provision on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.8.</B>&nbsp;<B>Export</B>. I agree not to export, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, to countries outside the United States, because such export could be in violation of the United States export laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>7.9.</B>&nbsp;<B>Entire Agreement.</B> The obligations pursuant to sections of this Agreement titled &ldquo;Confidentiality&rdquo; and &ldquo;Inventions&rdquo; shall apply to any time during which I was previously employed, or am in the future employed, by Company as an independent contractor if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matters hereof and supersedes and merges all prior communications between us with respect to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and a duly authorized officer of the Company. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</P> </DIV>

<DIV STYLE="float: none; clear: both; width: 100%"> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0.5in; margin: 0">[<I>Remainder of Page Intentionally Left Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">This Agreement shall be effective as of the first day of my Service with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>I have
read, understand, and accept this agreement and have been given the opportunity to review it with independent legal counsel.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Print Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; text-align: left">Date:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-variant: small-caps"><B>Accepted and Agreed To:</B></FONT></TD>
    <TD STYLE="text-align: left; width: 50%"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B>, a Delaware corporation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>[Signature Page to Confidentiality
and Proprietary Information and Inventions Agreement]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">EXHIBIT A</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0"><B><FONT STYLE="text-transform: uppercase">INVENTIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD>
    <TD STYLE="text-align: justify"><B>Prior Inventions Disclosure.</B> The following is a complete list of all Prior Inventions:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">None</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="text-align: justify">See immediately below:</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD>
    <TD STYLE="text-align: justify"><B>Limited Exclusion Notification.</B></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B><FONT STYLE="font-variant: small-caps">This is to notify </FONT></B>you in accordance with California Labor Code section&nbsp;2870 (or any similar law in an applicable jurisdiction) that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&rsquo;s equipment, supplies, facilities or trade secret information, except for those Inventions that either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>a.</B>&nbsp;Relate at the time of conception or reduction to practice to Company&rsquo;s business actual or demonstrably anticipated research or development; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><B>b.</B>&nbsp;Result from any work performed by you for Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent permitted by applicable law, this limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>neonctechnologies_ex10-17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.17</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants
         an Award of Restricted Stock, subject to the terms, conditions, and restrictions of
         the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement,
         including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix
         A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have
         the meanings set forth in the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="vertical-align: top; width: 25%; text-align: left">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify"><B>Richard Nanula</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">Grant Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>January 4, 2024</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Total Number of Shares of</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Common Stock (&ldquo;Shares&rdquo;) Granted</P></TD>
    <TD>&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left"><B>3,750</B></TD></TR>
     </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Lapse of Restrictions:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible
         to retain Shares of the Restricted Stock unless the Grantee has continued as a Director
         of the Company or one of its Subsidiaries through the applicable date set forth below.
         Such restrictions shall lapse with respect to:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering
(the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 3,750 Shares on that date which is seven months from the effective date of the
IPO</TD>
</TR></TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Termination of Service:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the event of Grantee&rsquo;s termination as Director of the Company and its Subsidiaries, whether such termination is by the Company
         or by Grantee, the Restricted Stock shall have been earned only to the extent that
         the restrictions on the Restricted Stock have lapsed in accordance with the schedule
         set forth above and shall not accelerate on a pro rata (or any other) basis. Upon such termination, Grantee shall forfeit the balance of such Restricted Stock
         as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited
         shall be returned to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions
         of this Award Agreement and hereby accepts same subject to all its terms and provisions
         hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
         interpretations of the Board of Directors or its duly appointed Committee upon any
         questions arising under the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">Dated:&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">January 4, 2024</TD>
                                                   <TD STYLE="width: 20%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Richard Nanula</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
                                 <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Grantee Signature</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPENDIX A</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock
         set forth in the Award Agreement, subject to the terms and conditions of the Plan,
         which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award
         Agreement, the terms and conditions of the Plan shall prevail.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided
         in the Plan, the restrictions set forth herein shall lapse in accordance with the
         provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either
         have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable,
         or otherwise transferable by Grantee other than by will or the laws of descent and
         distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant
         to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities
         law restrictions. The terms of this Award Agreement shall be binding upon the executors,
         administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted
         Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered
         by this Award, in the installments set forth in the Award Agreement, provided that
         Grantee&rsquo;s service as a Director of the Company and its Subsidiaries continues through the
         specified dates.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any
         actions permitted under Section&nbsp;11 of the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove
         any or all of the restrictions applicable to such Shares of Restricted Stock whenever
         the Committee may determine that such action is appropriate by reason of changes to
         applicable tax or other laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided
         that such fractional shares shall be aggregated and vested on the date when all restrictions
         lapse or expire.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares
         of Restricted Stock issued pursuant to the Award Agreement shall bear the following
         legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment
         and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement
         related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates
         representing Shares of Restricted Stock issued pursuant to the Award Agreement shall
         bear the following legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate,
         whether voluntary, involuntary, or by operation of law, is subject to certain restrictions
         on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive
         Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from
         NeOnc Technologies Holdings, Inc.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have
         been sold or otherwise transferred in violation of any of the provisions of this Award
         Agreement or (ii) to treat as owner of such Shares or to accord the right to vote
         or pay dividends to any purchaser or other transferee to whom such Shares shall have
         been so transferred.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation
         shall contain the same restrictions as set forth above as would otherwise be placed
         on any certificates and in each such case, the Company shall notify its transfer agent
         of the restrictions set forth herein.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the
         Committee may appoint, shall retain custody of the stock certificates or book-entry
         shares representing the Restricted Stock subject to the Award; provided, however,
         that in no event shall Grantee retain physical custody of any certificates representing
         Shares of Restricted Stock awarded to him or her.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award
         Agreement, he or she shall execute stock powers in favor of the Company with respect
         to the Shares of Restricted Stock granted hereunder in the form attached hereto and
         that he or she shall promptly deliver such stock powers to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect
         to the Restricted Stock, subject to the terms and conditions of this Award Agreement,
         including the right to vote the Restricted Stock and the right to receive all dividends
         or other distributions paid or made with respect to the Restricted Stock; provided,
         however, that any additional Shares of Restricted Stock to which Grantee shall be
         entitled as a result of stock dividends, stock splits, or any other form of recapitalization
         in respect of Shares of Restricted Stock shall also be subject to the terms and conditions
         of this Award Agreement until the restrictions on the underlying Shares of Restricted
         Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share
         of the Restricted Stock prior to the lapse of any restrictions with respect to such
         Share shall be compensation income rather than dividend income unless Grantee has
         made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect
         of shares of Stock or book-entry shares, Grantee shall also receive back the related
         stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate,
         if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following
         income tax consequences resulting from the receipt and vesting of the Shares of Restricted
         Stock:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">With respect to the Shares that are vested on the Grant Date, Grantee will be taxed
         currently on their Fair Market Value on the Grant Date.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">With respect to the Shares that are not vested on the Grant Date, Grantee will be
         taxed on the Fair Market Value of such Shares as and when the restrictions lapse in
         accordance with the provisions of the Award Agreement (such fair market value determined
         on such vesting dates), unless Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such an election is made, Grantee will be taxed currently on the full fair market
         value of the unvested Shares on the Grant Date. Any such election must be filed by Grantee with the Internal Revenue Service and,
         if necessary, the proper state taxing authorities, <B><U>within 30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY ELECTION UNDER SECTION 83(b) OF THE
         CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH
         ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS
         REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER BEHALF.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Grantee shall notify the Company immediately in writing in the event Grantee makes
         an election under Section&nbsp;83(b) of the Code (or any successor provision) or corresponding provisions of state
         or local tax laws with respect to the Restricted Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding
         any of the legal, tax, or business effects to Grantee with respect to the Plan or
         this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this
         Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the
         Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss
         the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the
         terms of the Plan and the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will assess its requirements regarding federal, state, and local income taxes, FICA
         taxes, and any other applicable taxes (&ldquo;Tax Items&rdquo;) in connection with the Restricted
         Stock. These requirements may change from time to time as laws or interpretations change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee acknowledges and agrees that the ultimate liability
         for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees that the Company:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">makes no representations or undertakings regarding the treatment of any Tax Items
         in connection with any aspect of the Restricted Stock, including any subsequent sale
         of Shares acquired under the Plan; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">does not commit to structure the terms of the Restricted Stock or any aspect of the
         Restricted Stock to reduce or eliminate liability for Tax Items.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding any contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry
         Shares will be issued or delivered to Grantee, unless and until satisfactory arrangements
         (as determined by the Committee) have been made by Grantee with respect to the payment
         of income, employment, and other taxes which the Company determines are to be withheld
         with respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify
         from time to time, may permit Grantee to satisfy such tax withholding obligation,
         in whole or in part (without limitation) by one or more of the following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having
         an aggregate Fair Market Value (as of the date the withholding is effected) equal
         to the amount required to be withheld, or (ii) by authorizing the Company to hold
         back a number of Shares otherwise deliverable to Grantee through such means as the
         Company may determine in its sole discretion (whether through a broker or otherwise)
         having an aggregate Fair Market Value (as of the date the withholding is effected)
         equal to the amount required to be withheld.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and
         may be modified, amended, suspended or terminated by the Company at any time;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual
         or other right to receive future grants of any Awards or benefits in lieu of any Awards,
         even if Awards have been granted repeatedly in the past and regardless of any reasonable
         notice period mandated under local law, and all decisions with respect to future grants
         of Awards, if any, will be at the sole discretion of the Company;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute
         regular compensation for services rendered to the Company or any Subsidiary or Affiliate
         and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes,
         including, but not limited to, calculating termination, severance, resignation, redundancy,
         end of service payments, bonuses, long-service awards, pension, retirement benefits,
         or similar payments;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">the future value of any Shares awarded under the Plan, if any, is unknown and cannot
         be predicted with any certainty;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">this Award is not intended to replace any retirement benefits or compensation and
         are not part of normal or expected salary or compensation for any purpose, including
         but not limited to calculating severance payments, if any, upon termination of employment
         (or other service to the Company and its Subsidiaries);</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">no claim or entitlement to compensation or damages arises from the termination of
         this Award or diminution in value of this Award or Shares received under the Plan,
         and Grantee irrevocably releases the Company from any such claim; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">nothing contained in this Award Agreement is intended to constitute or create a contract
         of employment, nor shall it constitute or create the right to remain associated with
         or in the employ of the Company or any Subsidiary or Affiliate for any particular
         period of time; this Award Agreement shall not interfere in any way with the right
         of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s employment or other service at any time, with or without cause, subject to applicable
         laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions
         of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares
         covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation
         of shares of stock of any class, the payment of any dividend or any other increase
         or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible
         into shares of stock of any class, shall not affect, and no adjustment by reason thereof
         shall be made with respect to, the number of Shares of Restricted Stock subject to
         the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way
         the right or power of the Company to make adjustments, reclassifications, reorganizations
         or changes of its capital or business structure, to merge or consolidate or to dissolve,
         liquidate, sell or transfer all or any part of its business or assets.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for
         in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently
         given if either hand delivered or if sent by fax or overnight courier, or by postage
         paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but
         in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted
         by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles,
         CA 90068 to the attention of Chief Executive Officer.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions
         may be determined to be illegal or otherwise unenforceable, in whole or in part, the
         remaining provisions shall nevertheless be binding and enforceable.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall
         be deemed an original, but all of which together shall constitute one and the same
         instrument. The parties hereto agree to execute such further instruments and to take such further
         action as may be reasonably necessary to carry out the purposes and intent of this
         Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments
         and modifications that may affect the tax status of the Award, provided that such
         action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with
         respect to the subject matter hereof and supersede in their entirety all prior undertakings
         and agreements of the Company and Grantee with respect to the subject matter hereof, and may not
         be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement
         shall be governed by the internal substantive laws, but not the choice of law rules,
         of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from
         this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction
         of the State of Delaware and agree that any such litigation shall be conducted only
         in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF SPOUSE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including
         any community property interest, in the Shares subject to the foregoing Award Agreement
         between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such
         Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably
         bind the undersigned as if the undersigned had made such decisions, executed such
         documents or performed such acts done by the undersigned&rsquo;s spouse.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">(signature)</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Date:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;)
         _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate
         Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock
         on the books of the said corporation with full power of substitution in the premises.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                   <TD STYLE="text-align: justify">[name]</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares
               of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(5)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer
               ceases to be a Director of the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company
               and taxpayer.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(6)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction
               other than a restriction which by its terms will never lapse) is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(7)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid for
            such property is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(8)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(9)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center
         with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>neonctechnologies_ex10-18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.18</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants an Award of Restricted Stock, subject to the terms, conditions, and restrictions of the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement, including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have the meanings set forth in the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Dr. Thomas C. Chen, M.D., Ph.D</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grant Date</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>January&nbsp;4, 2024</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Total Number of Shares of <BR>Common Stock (&ldquo;Shares&rdquo;) Granted</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><B>800,000</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Lapse of Restrictions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible to retain Shares of the Restricted Stock unless the Grantee has continued in employment or other service to the Company or one of its Subsidiaries through the applicable date set forth below. Such restrictions shall lapse with respect to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering (the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 266,666 Shares on that date which is seven months from the effective date of the IPO (the &ldquo;Initial Tranche&rdquo;)</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, twelve tranches of 22,222 Shares on the first date of each month commencing on the eighth month from the effective date of the IPO</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, 266,668 Shares, in whole or in part, on such date(s) as the Company&rsquo;s Compensation Committee, in its sole discretion, determines that all or some of the following metrics are met, it being understood that the Compensation Committee shall meet semi-annually on the second Monday of June and December of each calendar year to make such determination(s):</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- FDA Approvals: Successful completion of Phase 2 and Phase 3 for NEO 100; Phase &#xbd;, Phase 1, and Phase 2 for NEO 212.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Patient Enrollment: With respect to NEO100 and NEO 212, as applicable, meeting target numbers required to progress clinical trials.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Trial Outcomes: With respect to NEO100 and NEO 212, as applicable, attainment of primary and secondary endpoints in clinical trials.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Partnership Development: Formation of strategic partnerships or collaborations.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Oversight: Ensuring that drug development timelines are met and regulatory submissions are timely made.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Termination of Service:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">Except with respect to the Initial Tranche, in the event of Grantee&rsquo;s termination of employment or other service with the Company and its Subsidiaries, whether such termination of employment (or other service) is by the Company or by Grantee, the Restricted Stock shall have been earned only to the extent that the restrictions on the Restricted Stock have lapsed in accordance with the schedule set forth above and shall not accelerate on a pro rata (or any other) basis. Except with respect to the Initial Tranche, upon such termination of employment (or other service), Grantee shall forfeit the balance of such Restricted Stock as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited shall be returned to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Amir Heshmatpour</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Amir Heshmatpour</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Executive Chairman</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-indent: 0in; text-align: justify">Grantee
acknowledges and represents that Grantee is familiar with the terms and provisions of this Award Agreement and hereby accepts same subject
to all its terms and provisions hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations
of the Board of Directors or its duly appointed Committee upon any questions arising under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">January&nbsp;4, 2024</TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Grantee Signature</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">APPENDIX A</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock set forth in the Award Agreement, subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided in the Plan, the restrictions set forth herein shall lapse in accordance with the provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable, or otherwise transferable by Grantee other than by will or the laws of descent and distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities law restrictions. The terms of this Award Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered by this Award, in the installments set forth in the Award Agreement, provided that Grantee&rsquo;s service as an Employee (or other service to the Company and its Subsidiaries) continues through the specified dates (except with respect to the Initial Tranche as that term is defined in the Restricted Stock Award Agreement dated January __, 2024 by and between the Company and Grantee).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any actions permitted under Section&nbsp;11 of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove any or all of the restrictions applicable to such Shares of Restricted Stock whenever the Committee may determine that such action is appropriate by reason of changes to applicable tax or other laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided that such fractional shares shall be aggregated and vested on the date when all restrictions lapse or expire.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate, whether voluntary, involuntary, or by operation of law, is subject to certain restrictions on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from NeOnc Technologies Holdings, Inc.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Award Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation shall contain the same restrictions as set forth above as would otherwise be placed on any certificates and in each such case, the Company shall notify its transfer agent of the restrictions set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the Committee may appoint, shall retain custody of the stock certificates or book-entry shares representing the Restricted Stock subject to the Award; provided, however, that in no event shall Grantee retain physical custody of any certificates representing Shares of Restricted Stock awarded to him or her.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award Agreement, he or she shall execute stock powers in favor of the Company with respect to the Shares of Restricted Stock granted hereunder in the form attached hereto and that he or she shall promptly deliver such stock powers to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect to the Restricted Stock, subject to the terms and conditions of this Award Agreement, including the right to vote the Restricted Stock and the right to receive all dividends or other distributions paid or made with respect to the Restricted Stock; provided, however, that any additional Shares of Restricted Stock to which Grantee shall be entitled as a result of stock dividends, stock splits, or any other form of recapitalization in respect of Shares of Restricted Stock shall also be subject to the terms and conditions of this Award Agreement until the restrictions on the underlying Shares of Restricted Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share of the Restricted Stock prior to the lapse of any restrictions with respect to such Share shall be compensation income rather than dividend income unless Grantee has made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect of shares of Stock or book-entry shares, Grantee shall also receive back the related stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate, if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following income tax consequences resulting from the receipt and vesting of the Shares of Restricted Stock:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;With respect to the Shares that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;With respect to the Shares that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within 30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER BEHALF.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;Grantee shall notify the Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding any of the legal, tax, or business effects to Grantee with respect to the Plan or this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the terms of the Plan and the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;The Company will assess its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees that the Company:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;makes no representations or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any subsequent sale of Shares acquired under the Plan; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;does not commit to structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax Items.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding any contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and may be modified, amended, suspended or terminated by the Company at any time;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual or other right to receive future grants of any Awards or benefits in lieu of any Awards, even if Awards have been granted repeatedly in the past and regardless of any reasonable notice period mandated under local law, and all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute regular compensation for services rendered to the Company or any Subsidiary or Affiliate and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension, retirement benefits, or similar payments;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;the future value of any Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;this Award is not intended to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose, including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company and its Subsidiaries);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(g)&nbsp;no claim or entitlement to compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the Plan, and Grantee irrevocably releases the Company from any such claim; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(h)&nbsp;nothing contained in this Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s employment or other service at any time, with or without cause, subject to applicable laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares of Restricted Stock subject to the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently given if either hand delivered or if sent by fax or overnight courier, or by postage paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90068 to the attention of Chief Executive Officer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions may be determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The parties hereto agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments and modifications that may affect the tax status of the Award, provided that such action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Grantee with respect to the subject matter hereof, and may not be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the State of Delaware and agree that any such litigation shall be conducted only in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CONSENT OF SPOUSE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including any community property interest, in the Shares subject to the foregoing Award Agreement between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably bind the undersigned as if the undersigned had made such decisions, executed such documents or performed such acts done by the undersigned&rsquo;s spouse.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Rosa L. Chen</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(signature)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">Rosa L. Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">January 5, 2024</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;) _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock on the books of the said corporation with full power of substitution in the premises.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">[name]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer ceases to be an employee the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company and taxpayer.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(6)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is $________ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid
for such property is $____ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(8)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(9)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>7
<FILENAME>neonctechnologies_ex10-19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants
         an Award of Restricted Stock, subject to the terms, conditions, and restrictions of
         the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement,
         including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix
         A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have
         the meanings set forth in the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="vertical-align: top; width: 25%; text-align: left">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify"><B>Amir Heshmatpour</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">Grant Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>January 4, 2024</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Total Number of Shares of</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Common Stock (&ldquo;Shares&rdquo;) Granted</P></TD>
    <TD>&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left"><B>1,000,000</B></TD></TR>
     </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Lapse of Restrictions:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible
         to retain Shares of the Restricted Stock unless the Grantee has continued as a Director
         of the Company or one of its Subsidiaries through the applicable date set forth below.
         Such restrictions shall lapse with respect to:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0.5in; text-align: justify; width: 80%">Assuming that the Company closes its initial public offering
(the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 1,000,000 Shares on that date which is seven months from the effective date of the
IPO</TD>
</TR></TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Termination of Service:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the event of Grantee no longer
      serves as a Director of the Company and its Subsidiaries, whether such termination is by the Company or by Grantee, the Restricted
      Stock shall have been earned only to the extent that the restrictions on the Restricted Stock have lapsed in accordance with the
      schedule set forth above and shall not accelerate on a pro rata (or any other) basis. Upon such termination, Grantee shall forfeit
      the balance of such Restricted Stock as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited shall
      be returned to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions
         of this Award Agreement and hereby accepts same subject to all its terms and provisions
         hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
         interpretations of the Board of Directors or its duly appointed Committee upon any
         questions arising under the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">Dated:&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">January 4, 2024</TD>
                                                   <TD STYLE="width: 20%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Amir Heshmatpour</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
                                 <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Grantee Signature</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPENDIX A</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock
         set forth in the Award Agreement, subject to the terms and conditions of the Plan,
         which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award
         Agreement, the terms and conditions of the Plan shall prevail.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided
         in the Plan, the restrictions set forth herein shall lapse in accordance with the
         provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either
         have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable,
         or otherwise transferable by Grantee other than by will or the laws of descent and
         distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant
         to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities
         law restrictions. The terms of this Award Agreement shall be binding upon the executors,
         administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted
         Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered
         by this Award, in the installments set forth in the Award Agreement, provided that
         Grantee&rsquo;s service as a Director to the Company and its Subsidiaries continues through the
         specified dates.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any
         actions permitted under Section&nbsp;11 of the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove
         any or all of the restrictions applicable to such Shares of Restricted Stock whenever
         the Committee may determine that such action is appropriate by reason of changes to
         applicable tax or other laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided
         that such fractional shares shall be aggregated and vested on the date when all restrictions
         lapse or expire.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares
         of Restricted Stock issued pursuant to the Award Agreement shall bear the following
         legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment
         and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement
         related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates
         representing Shares of Restricted Stock issued pursuant to the Award Agreement shall
         bear the following legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate,
         whether voluntary, involuntary, or by operation of law, is subject to certain restrictions
         on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive
         Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from
         NeOnc Technologies Holdings, Inc.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have
         been sold or otherwise transferred in violation of any of the provisions of this Award
         Agreement or (ii) to treat as owner of such Shares or to accord the right to vote
         or pay dividends to any purchaser or other transferee to whom such Shares shall have
         been so transferred.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation
         shall contain the same restrictions as set forth above as would otherwise be placed
         on any certificates and in each such case, the Company shall notify its transfer agent
         of the restrictions set forth herein.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the
         Committee may appoint, shall retain custody of the stock certificates or book-entry
         shares representing the Restricted Stock subject to the Award; provided, however,
         that in no event shall Grantee retain physical custody of any certificates representing
         Shares of Restricted Stock awarded to him or her.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award
         Agreement, he or she shall execute stock powers in favor of the Company with respect
         to the Shares of Restricted Stock granted hereunder in the form attached hereto and
         that he or she shall promptly deliver such stock powers to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect
         to the Restricted Stock, subject to the terms and conditions of this Award Agreement,
         including the right to vote the Restricted Stock and the right to receive all dividends
         or other distributions paid or made with respect to the Restricted Stock; provided,
         however, that any additional Shares of Restricted Stock to which Grantee shall be
         entitled as a result of stock dividends, stock splits, or any other form of recapitalization
         in respect of Shares of Restricted Stock shall also be subject to the terms and conditions
         of this Award Agreement until the restrictions on the underlying Shares of Restricted
         Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share
         of the Restricted Stock prior to the lapse of any restrictions with respect to such
         Share shall be compensation income rather than dividend income unless Grantee has
         made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect
         of shares of Stock or book-entry shares, Grantee shall also receive back the related
         stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate,
         if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following
         income tax consequences resulting from the receipt and vesting of the Shares of Restricted
         Stock:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) With respect to the Shares
      that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) With respect to the Shares
      that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions
      lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless
      Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such
      an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any
      such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within
      30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE
      ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY
      ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION
      UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER
      BEHALF.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c) Grantee shall notify the
      Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor
      provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding
         any of the legal, tax, or business effects to Grantee with respect to the Plan or
         this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this
         Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the
         Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss
         the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the
         terms of the Plan and the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) The Company will assess
      its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax
      Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations
      change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee
      acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees
      that the Company:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) makes no representations
      or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any
      subsequent sale of Shares acquired under the Plan; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii) does not commit to
      structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax
      Items.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) Notwithstanding any
      contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be
      issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by
      Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with
      respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time,
      may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the
      following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as
      of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold
      back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion
      (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to
      the amount required to be withheld.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and
         may be modified, amended, suspended or terminated by the Company at any time;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual
         or other right to receive future grants of any Awards or benefits in lieu of any Awards,
         even if Awards have been granted repeatedly in the past and regardless of any reasonable
         notice period mandated under local law, and all decisions with respect to future grants
         of Awards, if any, will be at the sole discretion of the Company;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute
         regular compensation for services rendered to the Company or any Subsidiary or Affiliate
         and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes,
         including, but not limited to, calculating termination, severance, resignation, redundancy,
         end of service payments, bonuses, long-service awards, pension, retirement benefits,
         or similar payments;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(e) the future value of any
      Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(f) this Award is not intended
      to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose,
      including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company
      and its Subsidiaries);</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(g) no claim or entitlement to
      compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the
      Plan, and Grantee irrevocably releases the Company from any such claim; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(h) nothing contained in this
      Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain
      associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award
      Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s
      employment or other service at any time, with or without cause, subject to applicable laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions
         of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares
         covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation
         of shares of stock of any class, the payment of any dividend or any other increase
         or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible
         into shares of stock of any class, shall not affect, and no adjustment by reason thereof
         shall be made with respect to, the number of Shares of Restricted Stock subject to
         the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way
         the right or power of the Company to make adjustments, reclassifications, reorganizations
         or changes of its capital or business structure, to merge or consolidate or to dissolve,
         liquidate, sell or transfer all or any part of its business or assets.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for
         in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently
         given if either hand delivered or if sent by fax or overnight courier, or by postage
         paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but
         in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted
         by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles,
         CA 90068 to the attention of Chief Executive Officer.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions
         may be determined to be illegal or otherwise unenforceable, in whole or in part, the
         remaining provisions shall nevertheless be binding and enforceable.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall
         be deemed an original, but all of which together shall constitute one and the same
         instrument. The parties hereto agree to execute such further instruments and to take such further
         action as may be reasonably necessary to carry out the purposes and intent of this
         Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments
         and modifications that may affect the tax status of the Award, provided that such
         action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with
         respect to the subject matter hereof and supersede in their entirety all prior undertakings
         and agreements of the Company and Grantee with respect to the subject matter hereof, and may not
         be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement
         shall be governed by the internal substantive laws, but not the choice of law rules,
         of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from
         this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction
         of the State of Delaware and agree that any such litigation shall be conducted only
         in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF SPOUSE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including
         any community property interest, in the Shares subject to the foregoing Award Agreement
         between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such
         Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably
         bind the undersigned as if the undersigned had made such decisions, executed such
         documents or performed such acts done by the undersigned&rsquo;s spouse.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Kathy Heshmatpour</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">(signature)</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">Kathy Heshmatpour</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Date:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">January 4, 2024</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;)
         _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate
         Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock
         on the books of the said corporation with full power of substitution in the premises.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                   <TD STYLE="text-align: justify">[name]</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares
               of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(5)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer
               ceases to be a Director of the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company
               and taxpayer.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(6)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction
               other than a restriction which by its terms will never lapse) is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(7)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid for
            such property is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(8)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(9)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center
         with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>8
<FILENAME>neonctechnologies_ex10-20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.20</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants an Award of Restricted Stock, subject to the terms, conditions, and restrictions of the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement, including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have the meanings set forth in the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Keithly Garnett</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grant Date</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>January&nbsp;4, 2024</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Total Number of Shares of <BR>Common Stock (&ldquo;Shares&rdquo;) Granted</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><B>360,000</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Lapse of Restrictions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible to retain Shares of the Restricted Stock unless the Grantee has continued in employment or other service to the Company or one of its Subsidiaries through the applicable date set forth below. Such restrictions shall lapse with respect to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering (the &ldquo;IPO&rdquo;) on
    or before June&nbsp;30, 2024, 120,000 Shares on that date which is seven months from the effective date of the IPO (the
    &ldquo;Initial Tranche&rdquo;)</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, twelve tranches of 10,000 Shares on the first date of each month commencing on the eighth month from the effective date of the IPO</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, 120,000 Shares, in whole or in part, on such date(s) as the Company&rsquo;s Compensation Committee, in its sole discretion, determines that all or some of the following metrics are met, it being understood that the Compensation Committee shall meet semi-annually on the second Monday of June and December of each calendar year to make such determination(s):</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- R&amp;D Spend Efficiency: Meeting annual budget metrics as set by the board</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Accuracy of Financial Statements: Assuring Company financial statements are accurate
    and complete and not subject to restatement </TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 80%">- Coordination: Assuring coordination with Company independent public accountants and outside counsel on audits and periodic reviews</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Oversight: Ensuring that Company periodic filings with the SEC are timely made</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Termination of Service:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">Except with respect to the Initial Tranche, in the event of Grantee&rsquo;s termination of employment or other service with the Company and its Subsidiaries, whether such termination of employment (or other service) is by the Company or by Grantee, the Restricted Stock shall have been earned only to the extent that the restrictions on the Restricted Stock have lapsed in accordance with the schedule set forth above and shall not accelerate on a pro rata (or any other) basis. Except with respect to the Initial Tranche, upon such termination of employment (or other service), Grantee shall forfeit the balance of such Restricted Stock as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited shall be returned to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-indent: 0in; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions of this Award Agreement and hereby accepts same subject to all its terms and provisions hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors or its duly appointed Committee upon any questions arising under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">January&nbsp;4, 2024</TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Keithly Garnett</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Grantee Signature</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">APPENDIX A</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock set forth in the Award Agreement, subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided in the Plan, the restrictions set forth herein shall lapse in accordance with the provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable, or otherwise transferable by Grantee other than by will or the laws of descent and distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities law restrictions. The terms of this Award Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered by this Award, in the installments set forth in the Award Agreement, provided that Grantee&rsquo;s service as an Employee (or other service to the Company and its Subsidiaries) continues through the specified dates (except with respect to the Initial Tranche as that term is defined in the Restricted Stock Award Agreement dated January __, 2024 by and between the Company and Grantee).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any actions permitted under Section&nbsp;11 of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove any or all of the restrictions applicable to such Shares of Restricted Stock whenever the Committee may determine that such action is appropriate by reason of changes to applicable tax or other laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided that such fractional shares shall be aggregated and vested on the date when all restrictions lapse or expire.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate, whether voluntary, involuntary, or by operation of law, is subject to certain restrictions on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from NeOnc Technologies Holdings, Inc.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Award Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation shall contain the same restrictions as set forth above as would otherwise be placed on any certificates and in each such case, the Company shall notify its transfer agent of the restrictions set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the Committee may appoint, shall retain custody of the stock certificates or book-entry shares representing the Restricted Stock subject to the Award; provided, however, that in no event shall Grantee retain physical custody of any certificates representing Shares of Restricted Stock awarded to him or her.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award Agreement, he or she shall execute stock powers in favor of the Company with respect to the Shares of Restricted Stock granted hereunder in the form attached hereto and that he or she shall promptly deliver such stock powers to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect to the Restricted Stock, subject to the terms and conditions of this Award Agreement, including the right to vote the Restricted Stock and the right to receive all dividends or other distributions paid or made with respect to the Restricted Stock; provided, however, that any additional Shares of Restricted Stock to which Grantee shall be entitled as a result of stock dividends, stock splits, or any other form of recapitalization in respect of Shares of Restricted Stock shall also be subject to the terms and conditions of this Award Agreement until the restrictions on the underlying Shares of Restricted Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share of the Restricted Stock prior to the lapse of any restrictions with respect to such Share shall be compensation income rather than dividend income unless Grantee has made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect of shares of Stock or book-entry shares, Grantee shall also receive back the related stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate, if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following income tax consequences resulting from the receipt and vesting of the Shares of Restricted Stock:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;With respect to the Shares that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;With respect to the Shares that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within 30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER BEHALF.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;Grantee shall notify the Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding any of the legal, tax, or business effects to Grantee with respect to the Plan or this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the terms of the Plan and the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;The Company will assess its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees that the Company:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;makes no representations or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any subsequent sale of Shares acquired under the Plan; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;does not commit to structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax Items.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding any contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and may be modified, amended, suspended or terminated by the Company at any time;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual or other right to receive future grants of any Awards or benefits in lieu of any Awards, even if Awards have been granted repeatedly in the past and regardless of any reasonable notice period mandated under local law, and all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute regular compensation for services rendered to the Company or any Subsidiary or Affiliate and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension, retirement benefits, or similar payments;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;the future value of any Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;this Award is not intended to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose, including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company and its Subsidiaries);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(g)&nbsp;no claim or entitlement to compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the Plan, and Grantee irrevocably releases the Company from any such claim; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(h)&nbsp;nothing contained in this Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s employment or other service at any time, with or without cause, subject to applicable laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares of Restricted Stock subject to the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently given if either hand delivered or if sent by fax or overnight courier, or by postage paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90068 to the attention of Chief Executive Officer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions may be determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The parties hereto agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments and modifications that may affect the tax status of the Award, provided that such action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Grantee with respect to the subject matter hereof, and may not be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the State of Delaware and agree that any such litigation shall be conducted only in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CONSENT OF SPOUSE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including any community property interest, in the Shares subject to the foregoing Award Agreement between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably bind the undersigned as if the undersigned had made such decisions, executed such documents or performed such acts done by the undersigned&rsquo;s spouse.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Sherilyn Garnett</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(signature)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">Sherilyn Garnett</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">January 5, 2024</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;) _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock on the books of the said corporation with full power of substitution in the premises.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">[name]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer ceases to be an employee the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company and taxpayer.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(6)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is $________ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid
for such property is $____ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(8)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(9)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>9
<FILENAME>neonctechnologies_ex10-21.htm
<DESCRIPTION>EXHIBIT 10.21
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants an Award of Restricted Stock, subject to the terms, conditions, and restrictions of the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement, including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have the meanings set forth in the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>Patrick Walters</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Grant Date</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>January&nbsp;4, 2024</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="text-align: left; width: 25%">Total Number of Shares of <BR>Common Stock (&ldquo;Shares&rdquo;) Granted</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><B>300,000</B></TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Lapse of Restrictions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible to retain Shares of the Restricted Stock unless the Grantee has continued in employment or other service to the Company or one of its Subsidiaries through the applicable date set forth below. Such restrictions shall lapse with respect to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering (the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 100,000 Shares on that date which is seven months from the effective date of the IPO (the Initial Tranche&rdquo;).</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, twelve trances
    of 8,333 Shares on the first date of each month commencing on the eighth month from the effective date of the IPO</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes the IPO on or before June&nbsp;30, 2024, 100,004 Shares, in whole or in part, on such date(s) as the Company&rsquo;s Compensation Committee, in its sole discretion, determines that all or some of the following metrics are met, it being understood that the Compensation Committee shall meet semi-annually on the second Monday of June and December of each calendar year to make such determination(s):</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- FDA Approvals: Successful completion of Phase 2 and Phase 3 for NEO 100; Phase &#xbd;, Phase 1, and Phase 2 for NEO 212.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Patient Enrollment: With respect to NEO100 and NEO 212, as applicable, meeting target numbers required to progress clinical trials</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Trial Outcomes: With respect to NEO100 and NEO 212, as applicable, attainment of primary and secondary endpoints in clinical trials.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Partnership Development: Formation of strategic partnerships or collaborations.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 20%"></TD>
    <TD STYLE="text-align: justify; width: 80%">- Oversight: Ensuring that drug development timelines are met and regulatory submissions are timely made.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0in">Termination of Service:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">Except with respect to the Initial Tranche, in the event of Grantee&rsquo;s termination of employment or other service with the Company and its Subsidiaries, whether such termination of employment (or other service) is by the Company or by Grantee, the Restricted Stock shall have been earned only to the extent that the restrictions on the Restricted Stock have lapsed in accordance with the schedule set forth above and shall not accelerate on a pro rata (or any other) basis. Except with respect to the Initial Tranche, upon such termination of employment (or other service), Grantee shall forfeit the balance of such Restricted Stock as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited shall be returned to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-indent: 0in; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions of this Award Agreement and hereby accepts same subject to all its terms and provisions hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors or its duly appointed Committee upon any questions arising under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">January&nbsp;4, 2024</TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Patrick Walters</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Grantee Signature</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">APPENDIX A</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock set forth in the Award Agreement, subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided in the Plan, the restrictions set forth herein shall lapse in accordance with the provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable, or otherwise transferable by Grantee other than by will or the laws of descent and distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities law restrictions. The terms of this Award Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered by this Award, in the installments set forth in the Award Agreement, provided that Grantee&rsquo;s service as an Employee (or other service to the Company and its Subsidiaries) continues through the specified dates (except with respect to the Initial Tranche as that term is defined in the Restricted Stock Award Agreement dated January __, 2024 by and between the Company and Grantee).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any actions permitted under Section&nbsp;11 of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove any or all of the restrictions applicable to such Shares of Restricted Stock whenever the Committee may determine that such action is appropriate by reason of changes to applicable tax or other laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided that such fractional shares shall be aggregated and vested on the date when all restrictions lapse or expire.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates representing Shares of Restricted Stock issued pursuant to the Award Agreement shall bear the following legend:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0.5in 0in 1in; text-align: justify; text-indent: 0in"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate, whether voluntary, involuntary, or by operation of law, is subject to certain restrictions on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from NeOnc Technologies Holdings, Inc.&rdquo;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Award Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation shall contain the same restrictions as set forth above as would otherwise be placed on any certificates and in each such case, the Company shall notify its transfer agent of the restrictions set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the Committee may appoint, shall retain custody of the stock certificates or book-entry shares representing the Restricted Stock subject to the Award; provided, however, that in no event shall Grantee retain physical custody of any certificates representing Shares of Restricted Stock awarded to him or her.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award Agreement, he or she shall execute stock powers in favor of the Company with respect to the Shares of Restricted Stock granted hereunder in the form attached hereto and that he or she shall promptly deliver such stock powers to the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect to the Restricted Stock, subject to the terms and conditions of this Award Agreement, including the right to vote the Restricted Stock and the right to receive all dividends or other distributions paid or made with respect to the Restricted Stock; provided, however, that any additional Shares of Restricted Stock to which Grantee shall be entitled as a result of stock dividends, stock splits, or any other form of recapitalization in respect of Shares of Restricted Stock shall also be subject to the terms and conditions of this Award Agreement until the restrictions on the underlying Shares of Restricted Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share of the Restricted Stock prior to the lapse of any restrictions with respect to such Share shall be compensation income rather than dividend income unless Grantee has made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect of shares of Stock or book-entry shares, Grantee shall also receive back the related stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate, if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following income tax consequences resulting from the receipt and vesting of the Shares of Restricted Stock:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;With respect to the Shares that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;With respect to the Shares that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within 30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER BEHALF.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;Grantee shall notify the Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding any of the legal, tax, or business effects to Grantee with respect to the Plan or this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the terms of the Plan and the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;The Company will assess its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees that the Company:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;makes no representations or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any subsequent sale of Shares acquired under the Plan; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;does not commit to structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax Items.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding any contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to the amount required to be withheld.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and may be modified, amended, suspended or terminated by the Company at any time;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual or other right to receive future grants of any Awards or benefits in lieu of any Awards, even if Awards have been granted repeatedly in the past and regardless of any reasonable notice period mandated under local law, and all decisions with respect to future grants of Awards, if any, will be at the sole discretion of the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute regular compensation for services rendered to the Company or any Subsidiary or Affiliate and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension, retirement benefits, or similar payments;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;the future value of any Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(f)&nbsp;this Award is not intended to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose, including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company and its Subsidiaries);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(g)&nbsp;no claim or entitlement to compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the Plan, and Grantee irrevocably releases the Company from any such claim; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(h)&nbsp;nothing contained in this Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s employment or other service at any time, with or without cause, subject to applicable laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares of Restricted Stock subject to the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently given if either hand delivered or if sent by fax or overnight courier, or by postage paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles, CA 90068 to the attention of Chief Executive Officer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions may be determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The parties hereto agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments and modifications that may affect the tax status of the Award, provided that such action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The construction, interpretation, performance and enforcement of this Award Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the State of Delaware and agree that any such litigation shall be conducted only in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CONSENT OF SPOUSE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including any community property interest, in the Shares subject to the foregoing Award Agreement between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably bind the undersigned as if the undersigned had made such decisions, executed such documents or performed such acts done by the undersigned&rsquo;s spouse.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">(signature)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;) _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock on the books of the said corporation with full power of substitution in the premises.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 15%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">[name]</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer ceases to be an employee the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company and taxpayer.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(6)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is $________ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid
for such property is $____ per share.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(8)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; vertical-align: top"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: justify; text-indent: 0in; vertical-align: top">(9)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>10
<FILENAME>neonctechnologies_ex10-22.htm
<DESCRIPTION>EXHIBIT 10.22
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.22</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants
         an Award of Restricted Stock, subject to the terms, conditions, and restrictions of
         the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement,
         including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix
         A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have
         the meanings set forth in the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="vertical-align: top; width: 25%; text-align: left">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify"><B>Nasim Shomali</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">Grant Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>January 4, 2024</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Total Number of Shares of</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Common Stock (&ldquo;Shares&rdquo;) Granted</P></TD>
    <TD>&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left"><B>3,750</B></TD></TR>
     </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Lapse of Restrictions:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible
         to retain Shares of the Restricted Stock unless the Grantee has continued as a Director
         of the Company or one of its Subsidiaries through the applicable date set forth below.
         Such restrictions shall lapse with respect to:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering
(the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 3,750 Shares on that date which is seven months from the effective date of the
IPO</TD>
</TR></TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Termination of Service:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the event of Grantee&rsquo;s termination as Director of the Company and its Subsidiaries, whether such termination is by the Company
         or by Grantee, the Restricted Stock shall have been earned only to the extent that
         the restrictions on the Restricted Stock have lapsed in accordance with the schedule
         set forth above and shall not accelerate on a pro rata (or any other) basis. Upon such termination, Grantee shall forfeit the balance of such Restricted Stock
         as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited
         shall be returned to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions
         of this Award Agreement and hereby accepts same subject to all its terms and provisions
         hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
         interpretations of the Board of Directors or its duly appointed Committee upon any
         questions arising under the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">Dated:&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">January 4, 2024</TD>
                                                   <TD STYLE="width: 20%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Nasim Shomali</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
                                 <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Grantee Signature</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPENDIX A</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock
         set forth in the Award Agreement, subject to the terms and conditions of the Plan,
         which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award
         Agreement, the terms and conditions of the Plan shall prevail.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided
         in the Plan, the restrictions set forth herein shall lapse in accordance with the
         provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either
         have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable,
         or otherwise transferable by Grantee other than by will or the laws of descent and
         distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant
         to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities
         law restrictions. The terms of this Award Agreement shall be binding upon the executors,
         administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted
         Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered
         by this Award, in the installments set forth in the Award Agreement, provided that
         Grantee&rsquo;s service as a Director of the Company and its Subsidiaries continues through the
         specified dates.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any
         actions permitted under Section&nbsp;11 of the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove
         any or all of the restrictions applicable to such Shares of Restricted Stock whenever
         the Committee may determine that such action is appropriate by reason of changes to
         applicable tax or other laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided
         that such fractional shares shall be aggregated and vested on the date when all restrictions
         lapse or expire.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares
         of Restricted Stock issued pursuant to the Award Agreement shall bear the following
         legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment
         and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement
         related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates
         representing Shares of Restricted Stock issued pursuant to the Award Agreement shall
         bear the following legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate,
         whether voluntary, involuntary, or by operation of law, is subject to certain restrictions
         on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive
         Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from
         NeOnc Technologies Holdings, Inc.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have
         been sold or otherwise transferred in violation of any of the provisions of this Award
         Agreement or (ii) to treat as owner of such Shares or to accord the right to vote
         or pay dividends to any purchaser or other transferee to whom such Shares shall have
         been so transferred.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation
         shall contain the same restrictions as set forth above as would otherwise be placed
         on any certificates and in each such case, the Company shall notify its transfer agent
         of the restrictions set forth herein.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the
         Committee may appoint, shall retain custody of the stock certificates or book-entry
         shares representing the Restricted Stock subject to the Award; provided, however,
         that in no event shall Grantee retain physical custody of any certificates representing
         Shares of Restricted Stock awarded to him or her.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award
         Agreement, he or she shall execute stock powers in favor of the Company with respect
         to the Shares of Restricted Stock granted hereunder in the form attached hereto and
         that he or she shall promptly deliver such stock powers to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect
         to the Restricted Stock, subject to the terms and conditions of this Award Agreement,
         including the right to vote the Restricted Stock and the right to receive all dividends
         or other distributions paid or made with respect to the Restricted Stock; provided,
         however, that any additional Shares of Restricted Stock to which Grantee shall be
         entitled as a result of stock dividends, stock splits, or any other form of recapitalization
         in respect of Shares of Restricted Stock shall also be subject to the terms and conditions
         of this Award Agreement until the restrictions on the underlying Shares of Restricted
         Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share
         of the Restricted Stock prior to the lapse of any restrictions with respect to such
         Share shall be compensation income rather than dividend income unless Grantee has
         made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect
         of shares of Stock or book-entry shares, Grantee shall also receive back the related
         stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate,
         if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following
         income tax consequences resulting from the receipt and vesting of the Shares of Restricted
         Stock:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">With respect to the Shares that are vested on the Grant Date, Grantee will be taxed
         currently on their Fair Market Value on the Grant Date.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">With respect to the Shares that are not vested on the Grant Date, Grantee will be
         taxed on the Fair Market Value of such Shares as and when the restrictions lapse in
         accordance with the provisions of the Award Agreement (such fair market value determined
         on such vesting dates), unless Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such an election is made, Grantee will be taxed currently on the full fair market
         value of the unvested Shares on the Grant Date. Any such election must be filed by Grantee with the Internal Revenue Service and,
         if necessary, the proper state taxing authorities, <B><U>within 30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY ELECTION UNDER SECTION 83(b) OF THE
         CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH
         ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS
         REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER BEHALF.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">Grantee shall notify the Company immediately in writing in the event Grantee makes
         an election under Section&nbsp;83(b) of the Code (or any successor provision) or corresponding provisions of state
         or local tax laws with respect to the Restricted Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding
         any of the legal, tax, or business effects to Grantee with respect to the Plan or
         this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this
         Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the
         Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss
         the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the
         terms of the Plan and the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will assess its requirements regarding federal, state, and local income taxes, FICA
         taxes, and any other applicable taxes (&ldquo;Tax Items&rdquo;) in connection with the Restricted
         Stock. These requirements may change from time to time as laws or interpretations change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee acknowledges and agrees that the ultimate liability
         for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees that the Company:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">makes no representations or undertakings regarding the treatment of any Tax Items
         in connection with any aspect of the Restricted Stock, including any subsequent sale
         of Shares acquired under the Plan; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">does not commit to structure the terms of the Restricted Stock or any aspect of the
         Restricted Stock to reduce or eliminate liability for Tax Items.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding any contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry
         Shares will be issued or delivered to Grantee, unless and until satisfactory arrangements
         (as determined by the Committee) have been made by Grantee with respect to the payment
         of income, employment, and other taxes which the Company determines are to be withheld
         with respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify
         from time to time, may permit Grantee to satisfy such tax withholding obligation,
         in whole or in part (without limitation) by one or more of the following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having
         an aggregate Fair Market Value (as of the date the withholding is effected) equal
         to the amount required to be withheld, or (ii) by authorizing the Company to hold
         back a number of Shares otherwise deliverable to Grantee through such means as the
         Company may determine in its sole discretion (whether through a broker or otherwise)
         having an aggregate Fair Market Value (as of the date the withholding is effected)
         equal to the amount required to be withheld.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and
         may be modified, amended, suspended or terminated by the Company at any time;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual
         or other right to receive future grants of any Awards or benefits in lieu of any Awards,
         even if Awards have been granted repeatedly in the past and regardless of any reasonable
         notice period mandated under local law, and all decisions with respect to future grants
         of Awards, if any, will be at the sole discretion of the Company;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute
         regular compensation for services rendered to the Company or any Subsidiary or Affiliate
         and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes,
         including, but not limited to, calculating termination, severance, resignation, redundancy,
         end of service payments, bonuses, long-service awards, pension, retirement benefits,
         or similar payments;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">the future value of any Shares awarded under the Plan, if any, is unknown and cannot
         be predicted with any certainty;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">this Award is not intended to replace any retirement benefits or compensation and
         are not part of normal or expected salary or compensation for any purpose, including
         but not limited to calculating severance payments, if any, upon termination of employment
         (or other service to the Company and its Subsidiaries);</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">no claim or entitlement to compensation or damages arises from the termination of
         this Award or diminution in value of this Award or Shares received under the Plan,
         and Grantee irrevocably releases the Company from any such claim; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">nothing contained in this Award Agreement is intended to constitute or create a contract
         of employment, nor shall it constitute or create the right to remain associated with
         or in the employ of the Company or any Subsidiary or Affiliate for any particular
         period of time; this Award Agreement shall not interfere in any way with the right
         of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s employment or other service at any time, with or without cause, subject to applicable
         laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions
         of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares
         covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation
         of shares of stock of any class, the payment of any dividend or any other increase
         or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible
         into shares of stock of any class, shall not affect, and no adjustment by reason thereof
         shall be made with respect to, the number of Shares of Restricted Stock subject to
         the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way
         the right or power of the Company to make adjustments, reclassifications, reorganizations
         or changes of its capital or business structure, to merge or consolidate or to dissolve,
         liquidate, sell or transfer all or any part of its business or assets.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for
         in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently
         given if either hand delivered or if sent by fax or overnight courier, or by postage
         paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but
         in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted
         by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles,
         CA 90068 to the attention of Chief Executive Officer.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions
         may be determined to be illegal or otherwise unenforceable, in whole or in part, the
         remaining provisions shall nevertheless be binding and enforceable.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall
         be deemed an original, but all of which together shall constitute one and the same
         instrument. The parties hereto agree to execute such further instruments and to take such further
         action as may be reasonably necessary to carry out the purposes and intent of this
         Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments
         and modifications that may affect the tax status of the Award, provided that such
         action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with
         respect to the subject matter hereof and supersede in their entirety all prior undertakings
         and agreements of the Company and Grantee with respect to the subject matter hereof, and may not
         be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement
         shall be governed by the internal substantive laws, but not the choice of law rules,
         of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from
         this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction
         of the State of Delaware and agree that any such litigation shall be conducted only
         in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF SPOUSE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including
         any community property interest, in the Shares subject to the foregoing Award Agreement
         between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such
         Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably
         bind the undersigned as if the undersigned had made such decisions, executed such
         documents or performed such acts done by the undersigned&rsquo;s spouse.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">(signature)</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Date:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;)
         _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate
         Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock
         on the books of the said corporation with full power of substitution in the premises.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                   <TD STYLE="text-align: justify">[name]</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares
               of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(5)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer
               ceases to be a Director of the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company
               and taxpayer.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(6)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction
               other than a restriction which by its terms will never lapse) is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(7)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid for
            such property is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(8)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(9)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center
         with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>11
<FILENAME>neonctechnologies_ex10-23.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.23</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants
         an Award of Restricted Stock, subject to the terms, conditions, and restrictions of
         the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement,
         including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix
         A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have
         the meanings set forth in the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="vertical-align: top; width: 25%; text-align: left">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify"><B>Dr. Iyabo Tinubu-Karch</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">Grant Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>January 4, 2024</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Total Number of Shares of</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Common Stock (&ldquo;Shares&rdquo;) Granted</P></TD>
    <TD>&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left"><B>750,000, subject to adjustment as described below</B></TD></TR>
     </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Lapse of Restrictions:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible
         to retain Shares of the Restricted Stock unless the Grantee has continued as a Director
         of the Company or one of its Subsidiaries through the applicable date set forth below.
         Such restrictions shall lapse with respect to:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify"><FONT STYLE="font-size: 10pt">Assuming that the
Company closes its initial public offering (the &ldquo;IPO&rdquo;) on or before June 30, 2024, and QFE/QIA is an initial purchaser of
shares from the Company in the IPO, 750,000 Shares on that date which is seven months from the effective date if QFE/QIA purchases $75.0
million or more in the IPO; number of Shares will be proportionately reduced if less than $75.0 million is purchased by QFE/QIA in the
IPO of the IPO</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Termination of Service:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the event of Grantee no longer serves
as a Director of the Company and its Subsidiaries, whether such termination is by the Company or by Grantee, the Restricted Stock shall
have been earned only to the extent that the restrictions on the Restricted Stock have lapsed in accordance with the schedule set forth
above and shall not accelerate on a pro rata (or any other) basis. Upon such termination, Grantee shall forfeit the balance of such Restricted
Stock as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited shall be returned to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc.,<BR>
a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions
         of this Award Agreement and hereby accepts same subject to all its terms and provisions
         hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
         interpretations of the Board of Directors or its duly appointed Committee upon any
         questions arising under the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">Dated:&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">January 9, 2024</TD>
                                                   <TD STYLE="width: 20%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">Dr. Iyabo Tinubu-Karch</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
                                 <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Grantee Signature</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPENDIX A</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock
         set forth in the Award Agreement, subject to the terms and conditions of the Plan,
         which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award
         Agreement, the terms and conditions of the Plan shall prevail.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided
         in the Plan, the restrictions set forth herein shall lapse in accordance with the
         provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either
         have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable,
         or otherwise transferable by Grantee other than by will or the laws of descent and
         distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant
         to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities
         law restrictions. The terms of this Award Agreement shall be binding upon the executors,
         administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted
         Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="margin: 0in 0in 0in 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered
         by this Award, in the installments set forth in the Award Agreement, provided that
         Grantee&rsquo;s service as a Director to the Company and its Subsidiaries continues through the
         specified dates.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any
         actions permitted under Section&nbsp;11 of the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove
         any or all of the restrictions applicable to such Shares of Restricted Stock whenever
         the Committee may determine that such action is appropriate by reason of changes to
         applicable tax or other laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided
         that such fractional shares shall be aggregated and vested on the date when all restrictions
         lapse or expire.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares
         of Restricted Stock issued pursuant to the Award Agreement shall bear the following
         legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment
         and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement
         related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates
         representing Shares of Restricted Stock issued pursuant to the Award Agreement shall
         bear the following legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate,
         whether voluntary, involuntary, or by operation of law, is subject to certain restrictions
         on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive
         Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from
         NeOnc Technologies Holdings, Inc.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have
         been sold or otherwise transferred in violation of any of the provisions of this Award
         Agreement or (ii) to treat as owner of such Shares or to accord the right to vote
         or pay dividends to any purchaser or other transferee to whom such Shares shall have
         been so transferred.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation
         shall contain the same restrictions as set forth above as would otherwise be placed
         on any certificates and in each such case, the Company shall notify its transfer agent
         of the restrictions set forth herein.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the
         Committee may appoint, shall retain custody of the stock certificates or book-entry
         shares representing the Restricted Stock subject to the Award; provided, however,
         that in no event shall Grantee retain physical custody of any certificates representing
         Shares of Restricted Stock awarded to him or her.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award
         Agreement, he or she shall execute stock powers in favor of the Company with respect
         to the Shares of Restricted Stock granted hereunder in the form attached hereto and
         that he or she shall promptly deliver such stock powers to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect
         to the Restricted Stock, subject to the terms and conditions of this Award Agreement,
         including the right to vote the Restricted Stock and the right to receive all dividends
         or other distributions paid or made with respect to the Restricted Stock; provided,
         however, that any additional Shares of Restricted Stock to which Grantee shall be
         entitled as a result of stock dividends, stock splits, or any other form of recapitalization
         in respect of Shares of Restricted Stock shall also be subject to the terms and conditions
         of this Award Agreement until the restrictions on the underlying Shares of Restricted
         Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share
         of the Restricted Stock prior to the lapse of any restrictions with respect to such
         Share shall be compensation income rather than dividend income unless Grantee has
         made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect
         of shares of Stock or book-entry shares, Grantee shall also receive back the related
         stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate,
         if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following
         income tax consequences resulting from the receipt and vesting of the Shares of Restricted
         Stock:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"> With respect to the Shares
      that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">With respect to the Shares
      that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions
      lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless
      Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such
      an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any
      such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within
      30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE
      ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY
      ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION
      UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER
      BEHALF.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"> Grantee shall notify the
      Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor
      provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding
         any of the legal, tax, or business effects to Grantee with respect to the Plan or
         this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this
         Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the
         Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss
         the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the
         terms of the Plan and the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company will assess
      its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax
      Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations
      change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee
      acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees
      that the Company:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">makes no representations
      or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any
      subsequent sale of Shares acquired under the Plan; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> does not commit to
      structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax
      Items.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding any
      contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be
      issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by
      Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with
      respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time,
      may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the
      following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as
      of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold
      back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion
      (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to
      the amount required to be withheld.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="margin: 0in 0in 0in 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and
         may be modified, amended, suspended or terminated by the Company at any time;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual
         or other right to receive future grants of any Awards or benefits in lieu of any Awards,
         even if Awards have been granted repeatedly in the past and regardless of any reasonable
         notice period mandated under local law, and all decisions with respect to future grants
         of Awards, if any, will be at the sole discretion of the Company;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute
         regular compensation for services rendered to the Company or any Subsidiary or Affiliate
         and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0in 0in 0.5in; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes,
         including, but not limited to, calculating termination, severance, resignation, redundancy,
         end of service payments, bonuses, long-service awards, pension, retirement benefits,
         or similar payments;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in"> the future value of any
      Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">this Award is not intended
      to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose,
      including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company
      and its Subsidiaries);</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">no claim or entitlement to
      compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the
      Plan, and Grantee irrevocably releases the Company from any such claim; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">nothing contained in this
      Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain
      associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award
      Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s
      employment or other service at any time, with or without cause, subject to applicable laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions
         of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares
         covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation
         of shares of stock of any class, the payment of any dividend or any other increase
         or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible
         into shares of stock of any class, shall not affect, and no adjustment by reason thereof
         shall be made with respect to, the number of Shares of Restricted Stock subject to
         the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way
         the right or power of the Company to make adjustments, reclassifications, reorganizations
         or changes of its capital or business structure, to merge or consolidate or to dissolve,
         liquidate, sell or transfer all or any part of its business or assets.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for
         in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently
         given if either hand delivered or if sent by fax or overnight courier, or by postage
         paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but
         in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted
         by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles,
         CA 90068 to the attention of Chief Executive Officer.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions
         may be determined to be illegal or otherwise unenforceable, in whole or in part, the
         remaining provisions shall nevertheless be binding and enforceable.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall
         be deemed an original, but all of which together shall constitute one and the same
         instrument. The parties hereto agree to execute such further instruments and to take such further
         action as may be reasonably necessary to carry out the purposes and intent of this
         Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments
         and modifications that may affect the tax status of the Award, provided that such
         action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with
         respect to the subject matter hereof and supersede in their entirety all prior undertakings
         and agreements of the Company and Grantee with respect to the subject matter hereof, and may not
         be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement
         shall be governed by the internal substantive laws, but not the choice of law rules,
         of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from
         this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction
         of the State of Delaware and agree that any such litigation shall be conducted only
         in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF SPOUSE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including
         any community property interest, in the Shares subject to the foregoing Award Agreement
         between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such
         Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably
         bind the undersigned as if the undersigned had made such decisions, executed such
         documents or performed such acts done by the undersigned&rsquo;s spouse.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">(signature)</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Date:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;)
         _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate
         Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock
         on the books of the said corporation with full power of substitution in the premises.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                   <TD STYLE="text-align: justify">[name]</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares
               of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(5)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer
               ceases to be a Director of the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company
               and taxpayer.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(6)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction
               other than a restriction which by its terms will never lapse) is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(7)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid for
            such property is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(8)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(9)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 40%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center
         with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>12
<FILENAME>neonctechnologies_ex10-24.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.24</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2023 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESTRICTED STOCK AWARD AGREEMENT</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Company&rdquo;), hereby grants
         an Award of Restricted Stock, subject to the terms, conditions, and restrictions of
         the Company&rsquo;s 2023 Equity Incentive Plan (the &ldquo;Plan&rdquo;), and this Restricted Stock Award Agreement,
         including Appendix A attached hereto (the Restricted Stock Award Agreement and Appendix
         A are collectively referred to as the &ldquo;Award Agreement&rdquo;). The capitalized terms used in the Award Agreement but not defined herein shall have
         the meanings set forth in the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="vertical-align: top; width: 25%; text-align: left">Grantee:</TD>
    <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify"><B>Dr. Victoria Medvec, Ph.D.</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">Grant Date</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>January 4, 2024</B></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Total Number of Shares of</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Common Stock (&ldquo;Shares&rdquo;) Granted</P></TD>
    <TD>&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: left"><B>3,750</B></TD></TR>
     </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Lapse of Restrictions:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The restrictions imposed on the Restricted Stock shall lapse as set forth below. Except as otherwise provided in the Award Agreement, Grantee will not be eligible
         to retain Shares of the Restricted Stock unless the Grantee has continued as a Director
         of the Company or one of its Subsidiaries through the applicable date set forth below.
         Such restrictions shall lapse with respect to:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 80%">Assuming that the Company closes its initial public offering
(the &ldquo;IPO&rdquo;) on or before June&nbsp;30, 2024, 3,750 Shares on that date which is seven months from the effective date of the
IPO</TD>
</TR></TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Termination of Service:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In the event of Grantee&rsquo;s termination as Director of the Company and its Subsidiaries, whether such termination is by the Company
         or by Grantee, the Restricted Stock shall have been earned only to the extent that
         the restrictions on the Restricted Stock have lapsed in accordance with the schedule
         set forth above and shall not accelerate on a pro rata (or any other) basis. Upon such termination, Grantee shall forfeit the balance of such Restricted Stock
         as to which the restrictions have not yet lapsed, and the Restricted Stock so forfeited
         shall be returned to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURES APPEAR FOLLOWING PAGE(S)]</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>COMPANY:</B></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left">NeOnc Technologies Holdings, Inc., a Delaware corporation</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left; width: 50%"></TD>
    <TD STYLE="white-space: nowrap; text-align: left; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 45%">/s/ Thomas Chen</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Print name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Thomas Chen, MD, PhD.</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="white-space: nowrap; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Chief Executive Officer</TD> </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grantee acknowledges and represents that Grantee is familiar with the terms and provisions
         of this Award Agreement and hereby accepts same subject to all its terms and provisions
         hereof. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
         interpretations of the Board of Directors or its duly appointed Committee upon any
         questions arising under the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">Dated:&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">January 5, 2024</TD>
                                                   <TD STYLE="width: 20%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 10%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 50%">/s/ Victoria Medvec</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
                                 <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Grantee Signature</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPENDIX A</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TERMS AND CONDITIONS FOR RESTRICTED STOCK</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;<U>Grant</U>. The Company grants to Grantee an Award for the number of Shares of Restricted Stock
         set forth in the Award Agreement, subject to the terms and conditions of the Plan,
         which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Award
         Agreement, the terms and conditions of the Plan shall prevail.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;<U>Term</U>. Subject to earlier lapse of restrictions for the Shares of Restricted Stock as provided
         in the Plan, the restrictions set forth herein shall lapse in accordance with the
         provisions of Section&nbsp;4 below. This Award Agreement shall terminate when all of the Shares of Restricted Stock either
         have vested in accordance with Section&nbsp;4 or have been forfeited upon Grantee&rsquo;s termination of employment (or other service) with the Company and its Subsidiaries.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;<U>Restrictions on Transfer</U>. The Award shall be nontransferable and shall not be assignable, alienable, saleable,
         or otherwise transferable by Grantee other than by will or the laws of descent and
         distribution or pursuant to a &ldquo;domestic relations order&rdquo; (as defined in Code Section&nbsp;414(p)(1)(B)). Shares of Stock that have vested and are no longer subject to restrictions pursuant
         to Section&nbsp;4 may be transferred by Grantee, subject to applicable federal and state securities
         law restrictions. The terms of this Award Agreement shall be binding upon the executors,
         administrators, heirs, successors and assigns of Grantee. No non-permitted transferee of Grantee shall have any right in or claim to any Restricted
         Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;<U>Lapse of Restrictions</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;<I>Time Vesting</I>. The restrictions shall lapse with respect to the Shares of Restricted Stock covered
         by this Award, in the installments set forth in the Award Agreement, provided that
         Grantee&rsquo;s service as a Director of the Company and its Subsidiaries continues through the
         specified dates.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;<I>Change in Control.</I> Upon a Change in Control as defined in Section&nbsp;17 of the Plan, the Board or the Committee may make any determinations and take any
         actions permitted under Section&nbsp;11 of the Plan.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;<I>Action by Committee</I>. The Committee shall have the authority, in its sole and absolute discretion, to remove
         any or all of the restrictions applicable to such Shares of Restricted Stock whenever
         the Committee may determine that such action is appropriate by reason of changes to
         applicable tax or other laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;<U>Fractional Shares</U>. No fractional shares shall be delivered to Grantee. Any fractional shares shall be rounded down to the nearest whole number, provided
         that such fractional shares shall be aggregated and vested on the date when all restrictions
         lapse or expire.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;<U>Legends</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;If Restricted Stock is held in certificated form, certificates representing Shares
         of Restricted Stock issued pursuant to the Award Agreement shall bear the following
         legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&ldquo;<B>The Shares of Stock represented by this certificate have been acquired for investment
         and not with a view to, or in connection with, the sale or distribution thereof. No such sale or disposition may be effected without an effective registration statement
         related thereto or an opinion of counsel satisfactory to NeOnc Technologies Holdings, Inc. that such registration is not required under the Securities Act of 1933.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;If Restricted Stock is held in certificated form, until all restrictions lapse, certificates
         representing Shares of Restricted Stock issued pursuant to the Award Agreement shall
         bear the following legend:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify"><B>&ldquo;The sale or other transfer of the Shares of Stock represented by this certificate,
         whether voluntary, involuntary, or by operation of law, is subject to certain restrictions
         on transfer as set forth in the NeOnc Technologies Holdings, Inc. 2023 Equity Incentive
         Plan, and in the associated Restricted Stock Award Agreement. A copy of the Plan and such Restricted Stock Award Agreement may be obtained from
         NeOnc Technologies Holdings, Inc.&rdquo;</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;The Company shall not be required (i) to transfer on its books any Shares that have
         been sold or otherwise transferred in violation of any of the provisions of this Award
         Agreement or (ii) to treat as owner of such Shares or to accord the right to vote
         or pay dividends to any purchaser or other transferee to whom such Shares shall have
         been so transferred.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(d)&nbsp;To the extent any Restricted Stock is held in book-entry form, such book-entry designation
         shall contain the same restrictions as set forth above as would otherwise be placed
         on any certificates and in each such case, the Company shall notify its transfer agent
         of the restrictions set forth herein.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;<U>Escrow</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;Until all restrictions have lapsed, the Secretary or such other escrow holder as the
         Committee may appoint, shall retain custody of the stock certificates or book-entry
         shares representing the Restricted Stock subject to the Award; provided, however,
         that in no event shall Grantee retain physical custody of any certificates representing
         Shares of Restricted Stock awarded to him or her.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;Grantee further agrees that simultaneously with his or her execution of the Award
         Agreement, he or she shall execute stock powers in favor of the Company with respect
         to the Shares of Restricted Stock granted hereunder in the form attached hereto and
         that he or she shall promptly deliver such stock powers to the Company.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;<U>Rights as a Stockholder</U>. Upon the delivery of Restricted Stock to the escrow holder pursuant to subsection&nbsp;7(a), Grantee shall have all the rights of a stockholder of the Company with respect
         to the Restricted Stock, subject to the terms and conditions of this Award Agreement,
         including the right to vote the Restricted Stock and the right to receive all dividends
         or other distributions paid or made with respect to the Restricted Stock; provided,
         however, that any additional Shares of Restricted Stock to which Grantee shall be
         entitled as a result of stock dividends, stock splits, or any other form of recapitalization
         in respect of Shares of Restricted Stock shall also be subject to the terms and conditions
         of this Award Agreement until the restrictions on the underlying Shares of Restricted
         Stock lapse or expire. Grantee acknowledges that any dividends paid to Grantee with respect to any Share
         of the Restricted Stock prior to the lapse of any restrictions with respect to such
         Share shall be compensation income rather than dividend income unless Grantee has
         made an election under Section&nbsp;83(b) of the Code with respect to such Share.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;<U>Removal of Legends on Certificates and Return of Stock Powers</U>. When restrictions lapse and the Company delivers to Grantee the certificates in respect
         of shares of Stock or book-entry shares, Grantee shall also receive back the related
         stock powers held by the Company pursuant to subsection&nbsp;7(b) above. The distributed shares of Stock shall be free of the restrictions and such certificate,
         if any, shall not bear the legend provided for in Section&nbsp;6(b) above (but shall continue to bear the legend provided in Section&nbsp;6(a) above, if applicable).</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;<U>Code Section&nbsp;83(b) Election</U>. Grantee acknowledges that he or she has been informed and is aware of the following
         income tax consequences resulting from the receipt and vesting of the Shares of Restricted
         Stock:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a) With respect to the Shares
      that are vested on the Grant Date, Grantee will be taxed currently on their Fair Market Value on the Grant Date.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b) With respect to the Shares
      that are not vested on the Grant Date, Grantee will be taxed on the Fair Market Value of such Shares as and when the restrictions
      lapse in accordance with the provisions of the Award Agreement (such fair market value determined on such vesting dates), unless
      Grantee files an election pursuant to Section&nbsp;83(b) of the Code (and any similar state tax provisions if applicable). If such
      an election is made, Grantee will be taxed currently on the full fair market value of the unvested Shares on the Grant Date. Any
      such election must be filed by Grantee with the Internal Revenue Service and, if necessary, the proper state taxing authorities, <B><U>within
      30 days of the receipt of the Shares</U></B>. A form of Election under Section&nbsp;83(b) is attached hereto. <B>GRANTEE
      ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY&rsquo;S (i) TO DETERMINE WHETHER OR NOT TO MAKE ANY
      ELECTION UNDER SECTION 83(b) OF THE CODE, AND (ii) IF GRANTEE DETERMINES TO MAKE ANY SUCH ELECTION, TO TIMELY FILE SUCH ELECTION
      UNDER SECTION 83(b) OF THE CODE, EVEN IF GRANTEE ASKS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER
      BEHALF.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c) Grantee shall notify the
      Company immediately in writing in the event Grantee makes an election under Section&nbsp;83(b) of the Code (or any successor
      provision) or corresponding provisions of state or local tax laws with respect to the Restricted Stock.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;<U>Separate Advice and Representation</U>. The Company is not providing Grantee with advice, warranties, or representations regarding
         any of the legal, tax, or business effects to Grantee with respect to the Plan or
         this Award Agreement. Grantee is encouraged to seek legal, tax, and business advice from Grantee&rsquo;s own legal, tax, and business advisers as soon as possible. By accepting this Award and the shares of Stock covered thereby, and by signing this
         Award Agreement, Grantee acknowledges that Grantee is familiar with the terms of the
         Award Agreement and the Plan, that Grantee has been encouraged by the Company to discuss
         the Award and the Plan with Grantee&rsquo;s own legal, tax, and business advisers, and that Grantee agrees to be bound by the
         terms of the Plan and the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;<U>Tax Withholding</U>.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a) The Company will assess
      its requirements regarding federal, state, and local income taxes, FICA taxes, and any other applicable taxes (&ldquo;Tax
      Items&rdquo;) in connection with the Restricted Stock. These requirements may change from time to time as laws or interpretations
      change. The Company will withhold Tax Items as required by law. Regardless of the Company&rsquo;s actions in this regard, Grantee
      acknowledges and agrees that the ultimate liability for Tax Items is Grantee&rsquo;s responsibility. Grantee acknowledges and agrees
      that the Company:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(i) makes no representations
      or undertakings regarding the treatment of any Tax Items in connection with any aspect of the Restricted Stock, including any
      subsequent sale of Shares acquired under the Plan; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(ii) does not commit to
      structure the terms of the Restricted Stock or any aspect of the Restricted Stock to reduce or eliminate liability for Tax
      Items.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b) Notwithstanding any
      contrary provision of this Award Agreement, no certificate representing the Shares of Restricted Stock or book-entry Shares will be
      issued or delivered to Grantee, unless and until satisfactory arrangements (as determined by the Committee) have been made by
      Grantee with respect to the payment of income, employment, and other taxes which the Company determines are to be withheld with
      respect to such Shares. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time,
      may permit Grantee to satisfy such tax withholding obligation, in whole or in part (without limitation) by one or more of the
      following: (i) paying cash, (ii) delivering to the Company already vested and owned Shares having an aggregate Fair Market Value (as
      of the date the withholding is effected) equal to the amount required to be withheld, or (ii) by authorizing the Company to hold
      back a number of Shares otherwise deliverable to Grantee through such means as the Company may determine in its sole discretion
      (whether through a broker or otherwise) having an aggregate Fair Market Value (as of the date the withholding is effected) equal to
      the amount required to be withheld.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;<U>No Acquired Rights or Employment Rights</U>. Grantee agrees and acknowledges that:</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(a)&nbsp;the Plan is established voluntarily by the Company, is discretionary in nature, and
         may be modified, amended, suspended or terminated by the Company at any time;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(b)&nbsp;the grant of this Award under the Plan is voluntary and occasional and does not create any contractual
         or other right to receive future grants of any Awards or benefits in lieu of any Awards,
         even if Awards have been granted repeatedly in the past and regardless of any reasonable
         notice period mandated under local law, and all decisions with respect to future grants
         of Awards, if any, will be at the sole discretion of the Company;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(c)&nbsp;the value of this Award is an extraordinary item of compensation that does not constitute
         regular compensation for services rendered to the Company or any Subsidiary or Affiliate
         and which is outside the scope of Grantee&rsquo;s employment contract (or other service agreement or arrangement), if any;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(d)&nbsp;this Award is not part of normal or expected compensation or salary for any purposes,
         including, but not limited to, calculating termination, severance, resignation, redundancy,
         end of service payments, bonuses, long-service awards, pension, retirement benefits,
         or similar payments;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(e) the future value of any
      Shares awarded under the Plan, if any, is unknown and cannot be predicted with any certainty;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(f) this Award is not intended
      to replace any retirement benefits or compensation and are not part of normal or expected salary or compensation for any purpose,
      including but not limited to calculating severance payments, if any, upon termination of employment (or other service to the Company
      and its Subsidiaries);</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(g) no claim or entitlement to
      compensation or damages arises from the termination of this Award or diminution in value of this Award or Shares received under the
      Plan, and Grantee irrevocably releases the Company from any such claim; and</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; text-indent: 1in">(h) nothing contained in this
      Award Agreement is intended to constitute or create a contract of employment, nor shall it constitute or create the right to remain
      associated with or in the employ of the Company or any Subsidiary or Affiliate for any particular period of time; this Award
      Agreement shall not interfere in any way with the right of the Company or any Subsidiary or Affiliate to terminate Grantee&rsquo;s
      employment or other service at any time, with or without cause, subject to applicable laws.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;<U>Adjustment of Shares</U>. Upon the occurrence of events described in, and in accordance with the provisions
         of, Section&nbsp;10 of the Plan, the Company shall make appropriate adjustments in the number of Shares
         covered by the Award. Except as provided in Section&nbsp;10 of the Plan, Grantee shall have no rights by reason of any subdivision or consolidation
         of shares of stock of any class, the payment of any dividend or any other increase
         or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of any class, or securities convertible
         into shares of stock of any class, shall not affect, and no adjustment by reason thereof
         shall be made with respect to, the number of Shares of Restricted Stock subject to
         the Award. The grant of the Restricted Stock pursuant to the Plan shall not affect in any way
         the right or power of the Company to make adjustments, reclassifications, reorganizations
         or changes of its capital or business structure, to merge or consolidate or to dissolve,
         liquidate, sell or transfer all or any part of its business or assets.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;<U>Notices</U>. Except as may be otherwise provided by the Plan, any written notices provided for
         in the Plan and this Award Agreement shall be in writing and shall be deemed sufficiently
         given if either hand delivered or if sent by fax or overnight courier, or by postage
         paid first class mail. Notices sent by mail shall be deemed received three business days after mailed but
         in no event later than the date of actual receipt. Notice may also be provided by electronic transmission, if and to the extent permitted
         by the Committee. Notices shall be directed, if to Grantee, at Grantee&rsquo;s address indicated by the Company&rsquo;s records, or if to the Company, at 8335 Sunset Boulevard, Suite 240, Los Angeles,
         CA 90068 to the attention of Chief Executive Officer.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;<U>Severability</U>. The provisions of the Award Agreement are severable and if any one or more provisions
         may be determined to be illegal or otherwise unenforceable, in whole or in part, the
         remaining provisions shall nevertheless be binding and enforceable.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;<U>Counterparts; Further Instruments</U>. The Award Agreement may be executed in two or more counterparts, each of which shall
         be deemed an original, but all of which together shall constitute one and the same
         instrument. The parties hereto agree to execute such further instruments and to take such further
         action as may be reasonably necessary to carry out the purposes and intent of this
         Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;<U>Amendment</U>. The Award Agreement may be amended or modified by the Committee, including amendments
         and modifications that may affect the tax status of the Award, provided that such
         action may not, without the consent of Grantee, impair any rights of Grantee under the Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan and this Award Agreement constitute the entire agreement of the parties with
         respect to the subject matter hereof and supersede in their entirety all prior undertakings
         and agreements of the Company and Grantee with respect to the subject matter hereof, and may not
         be modified except by means of a writing signed by the Company and Grantee. The construction, interpretation, performance and enforcement of this Award Agreement
         shall be governed by the internal substantive laws, but not the choice of law rules,
         of the State of Delaware. For purposes of litigating any dispute that may arise directly or indirectly from
         this Award Agreement, the parties hereby submit and consent to the exclusive jurisdiction
         of the State of Delaware and agree that any such litigation shall be conducted only
         in the courts of Delaware or the federal courts of the United States located in Delaware and no other courts.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSENT OF SPOUSE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned spouse of Grantee agrees that his/her/their interest, if any, including
         any community property interest, in the Shares subject to the foregoing Award Agreement
         between Grantee and the Company shall be irrevocably bound by such Award Agreement. The undersigned further agrees that Grantee&rsquo;s decisions or execution of any documents with respect to the Shares covered by such
         Award Agreement shall be the decision, signature or deed of the undersigned and irrevocably
         bind the undersigned as if the undersigned had made such decisions, executed such
         documents or performed such acts done by the undersigned&rsquo;s spouse.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD COLSPAN="2" STYLE="text-align: left">Spouse of Grantee (if any):</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 5%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">(signature)</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Name:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">Date:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT SEPARATE FROM CERTIFICATE</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers unto _____________________&rdquo;)
         _____________ (_______) shares of the common stock, par value $.0001, of NeOnc Technologies Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U> standing in the undersigned&rsquo;s name on the books of said corporation represented by Certificate No. ____ delivered herewith, and does hereby irrevocably constitute and appoint the Corporate
         Secretary of the Company, as attorney-in-fact, to transfer the said shares of stock
         on the books of the said corporation with full power of substitution in the premises.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: left">&nbsp;</TD>
                                 <TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 10%">&nbsp;</TD>
                                                                                   <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                   <TD STYLE="text-align: justify">[name]</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 83(b) TAX ELECTION</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This statement is being made under Section&nbsp;83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section&nbsp;1.83-2.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in; text-align: left">(1)</TD>
    <TD STYLE="text-align: justify; width: 0.5in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Social Security No.: __________________</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property with respect to which the election is being made is ______________ shares
               of the common stock of NeOnc Technologies Holdings, Inc., a Delaware corporation (&ldquo;Shares&rdquo;).</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(3)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The date on which the Shares were acquired is __________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(4)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The taxable year in which the election is being made is the calendar year 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(5)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The property is subject to surrender and cancellation if for any reason the taxpayer
               ceases to be a Director of the issuer prior to specified vesting dates. This restriction lapses in accordance with the terms of an agreement between the company
               and taxpayer.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(6)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The fair market value at the time of transfer (determined without regard to any restriction
               other than a restriction which by its terms will never lapse) is $________ per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(7)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">The amount paid for
            such property is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per share.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(8)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">A copy of this statement was furnished to <B>[____________________]</B>, for whom taxpayer rendered the services underlying the transfer of property.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left; text-indent: 0in; vertical-align: top">(9)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">This statement is executed as of _________________, 20__.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.75in; text-align: left">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"></TD>
    <TD>&nbsp;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">Taxpayer&rsquo;s Spouse, if any</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOTE:</B>&nbsp;To make the election, this form must be filed with the Internal Revenue Service Center
         with which taxpayer files his/her Federal income tax returns. <B><U>The filing must be made within thirty (30) days</U></B> after the Grant Date of the Restricted Stock Award Agreement.</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

   </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>neonctechnologies_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the inclusion in this Registration
Statement of NeOnc Technologies Holdings, Inc. on Amendment No. 1 to Form S-1 (File No. 333-276124) of our report dated May 1, 2023, except
for the presentation of loss per share on the statements of operations, the net loss per share accounting policy disclosed in Note 2,
and Note 10, as to which the date is August 2, 2023, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue
as a going concern, with respect to our audits of the financial statements of NeOnc Technologies, Inc. as of December 31, 2022 and 2021
and for the years then ended, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to
the reference to our Firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia, PA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 12, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>14
<FILENAME>neonctechnologies_ex107.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
S-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeOnc Technologies Holdings, Inc</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered and Carry Forward Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Security<BR>
Type</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Security
    Class Title</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Fee<BR>
    Calculation<BR>
    or Carry<BR>
    Forward Rule</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount<BR>
    To Be<BR>
Registered</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Maximum<BR>
    Offering<BR>
Price Per<BR>
Share<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Maximum<BR>
    Aggregate<BR>
    Offering<BR>
Price</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Fee<BR>
Rate<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount
    of<BR>
    Registration<BR>
    Fee</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="9" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Newly
    Registered Securities</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fees
    to Be Paid</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">457(o)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$75,000,000.00<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00014760</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$11,070.00</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="9" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Carry
    Forward Securities</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Securities</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total
    Offering Amounts</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$11,070.00</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total
    Fees Previously Paid</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$7,380.00</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total
    Fee Offsets</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Net
    Fee Due</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$3,690.00</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price, includes the number of shares of Common
Stock issuable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
pursuant to Rule 457(o) under the Securities Act at a rate equal to $147.60 per $1,000,000 of the proposed maximum aggregate offering
price, subject to offset pursuant to Rule 415(a)(6).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &B 5T# 2(  A$! Q$!_\0
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M:_JG[0&MW4[>*-8TR"4:%X05A:V-GI#*K1QZ"@79<74IW$-N#E0Q  3T\_\
M!2']MQ0<_'C7%(# DZ%X5_A&3@'0R-W8#<P'7!.:_.?X9>#3\/\ X;^"O"=P
MRSZM9Z2FK^++I5\L/XO\1R_V[KE@J;F0Q>'FN[;PNDJ'9=MH;7L:A9P!]P^
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M5YSX_P#^"G'[=^BQZ5/IW[0VOVRSRZC!,B^'_!SAS%'92PN?-\/N0$624#+
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M7P_AZ%;+\UIXU4,JP"P=2I3JX;ZG&I3G1?+B6I57"K3C&34I0;DN5K[ O_\
M@I1^UM"R+_PN?5X S8+?V3X;_=,=P(=FTD+M^Z=S,1&%R20PSR>I?\%//VP;
M&,N/CAJK(/XDT?PS(X&,J<?V5M +'9N (QDCGD_E[K/BU[DR*MQ)%>0B5_,*
MG;-'&#YBE?E4,H!!1N"O*%CD'PW4OB-<7%Q=*UU\ENLFPD'#J I6#:H.7!.X
M$X8A<9X 'UV78C&5:49U,3BW^[CS2>(F_>:?1R=DK;[[;WT_-N*>&>$\IFH4
MN%,@@W+51R; -*"ZW="RN[\SOI:UWI?];]7_ ."J_P"VJU]9V.G_ !ZU>V?R
MP]Q*-#\*RQ<X($A?17VG#*' (*L&X'W:[CPG_P %"/\ @H3XP1TT;XU>(+EX
MRJ"X/A[PNL,K$-\P;^Q-A5'4AMN!C&1SFOR>^!WA;_A.M6DU+6C=)9L0=.BA
MPIO)6=5)G8*0EN$#*HF$8+;3DM@#];O GAS3?"^BQPVUO%;2(JH)0K85B"I5
ME "DDXP26W<YX!SZ%7%8BDXP]MB+\L9SO6J:4Y6M*6K2;5VFVGHWHE<^.J9=
MPSAJ;Q,N&>'ZDJTO9TH/*\&H*ZLIJ'L8WL[=-;V;3W]8LOVO/^"@\7E_VE\?
MY 63=.CZ)X8B-J1G[\@TE1(Y) "[5P5QSR*RK_\ ;G_;CTZ619?C_?2H&X*:
M)X94("K$C)TI@^TGAC@94+P,UYUXI\11X<#:LR1J0T; !GC<;2P)RI;<.I)Z
M$XQQX'KVMQNSAI=Y4!L#^%C&<ALY&3EU'.=Q!&0<UP?VGB(U&EB*\DIVUJ36
MC7;F>EMF]WU3:2Z<+P]DV.I^TJ<,<.TDXN4(TLIPL$X-7DY6H7YFU9:VZK7?
MZ0T3]OG]M_3?$LFJ:Q^T7XIUKPY-$=FCG0?!T<5I<AOF>2ZMO#ZSFV(8[8GE
M9D4 &4LF&^R/A5^W-^T=XG%[/J7Q,O+F"U6!EC%IH[/<&5OFA@6&SB?S5"G:
M@W=<#/W:_%35/%45F<O* 0I4@J2LBH",8Q@@C&X[3N/7&3NA\#_M&:?\/YO&
M.CZK>RQ0W]K9S>'9X [265\$D#1-&B&4K)(RA9#^[0*1D!B1Z%&OBJ]6E-XF
MO:,7**C4;A))7C"45*SDY:6ES/H[O0\;.N'>'L+EF+IX;(,GAC/:>TP\?J.'
M=2:E6IJKR5/9N=X4YMQBY<JM[L-&U_0/XY_:_P#C+!H[W.A_%N_T^^M_*GN+
M58-&GF",P+0NLMFYC^5MVY1Q@#=C=7WM_P $]?B[X^^,?PN\9>(?B%XFN?$^
MIV'CZYTJPNKJ&R@DMM,30]&NH[8)906\9!GN9Y]S(6;S<[MI '\?6L_M4W%R
MY8:@KP J)S*K F-5Q&TK_(=NX[I&SE2P!;C _IT_X(J:KJ&O_LU>-O$&I12V
MTFN?%*]U.SL[A?+NH]*G\,>'5TVZEB+%X8M3MXQ?V22K'))8SVUT$$5S$S>M
M@7B<1CG5O5]C1IU%53J3E#]Y&$:3G#X%)5%)1E:+=[:M,_'^*L!E^5\)U(5:
M&7T<;BLSP5+ S6&PU+&U/9RQ.(Q=*%2$(591IX=1G6BKVI\CDE!Q9^)O_!:Z
M75)?V[?%.GZ+IM]K&IW_ (+^&UE;V.F0O-=RB;PU;EV;&%@M8]ZFYOKAX+.S
MBD:2ZGBB5C7YC> /@=9>%O$\?CCQ>^BZYXNTR:6X\.:99S-JNB^![B6)HX=1
M:Y>*&QUSQ9:)<7'V62*&\T7P_?M;7MA?:AJEK#<6G]#/[<_[/GCKXX?MS_%W
M^R-1M_"W@BR\/?";3O$OBFXMQ<M-=IX*M;\:/:Z?#);76NW%M:7$%ZEA<WEO
MI-M+=133S1RW SQUK^P9\'+2P6VG\1>/[_4#'Y3:JNHZ;:#?LPTD.G1Z;-;1
MH&RR0/+,4X5IF4$U^HY!DF2X1T,US*NL96KM8K#X2,&J.&E%\D9XBTKUJL90
M<H135.+:<HRTB?Q]XB\?>(6>X;'<$\*9=_9&69=3GEF/SO%8Q4,5F491]M6H
MY>K*.'PKAB/82JI3JUGS1<J44K_D>X+$C<02X=RQWF1V)WM*Y.6=V8,Q.=YR
M^0QR?T*_8JUO7=:\*?ML6^M:YK&L0:!^P+\6=$T&#5]5U#5(-"T>&2SD@T?1
M(KV>:/2M+B9V>*PL4M[1"S.(@S U\R?'GX)7_P #/$]EI$FKKXBT+7K6;4/#
MNKM;"QNWM8+D6UY9:E9)-<Q0ZA8RM#%))#*(+Q)1/'' TC6\?LGP6_:[\)_!
M/P7K7A73?V5?A;XEU'QE\/-3^%_Q'\7ZO\0?B+8:M\0O">LOYFK6FJ:?9+<:
M9I;ZAMB20Z*()46$&WGA#L@_0,PC/&Y;)8*A]<E7E2=*4:F'I^S4*N&JRGS5
MW&2YX4'"U-QG=KF3I\R7\J<,QAD/$\HY[CGD\<!#'4\7"=',,6\15Q&!S3"4
MJ+AEL*[J<E?,:>+<L3&5*,8SJ4Y?6?9I^8_\$\[7[+_P4>^ 4^,"]\+?%>7Y
M.5+P?"#XA6[JA95)=42-GQPOF)D@C;7]!O[;?PQ\:_&#X3^%/ W@&_\ $&C>
M(+WXU?"344\1>'[O4+.;PLFA>()-8MO$^J3:5+!=MX>T+6+/2K[7X@)H+K38
MY[>>VGBE:%_YIK_XTZ[\-?C5I?[2?P1\#>#OAUKO@MM>;PUX"*ZYXT\(Z+I'
MBCPC<^#=>M(WU74M.U[4<V^H76KQO+>PO;7EQ+M1[:%8C[(O_!93]LL\!/@I
MQM(*_#G6#C@,N/\ BN@2I W9')QG&>G^<WTKOHP^.7BAX^< >,'A;A^!ZV'X
M0X1RK QP?%_$D,NYL[P.;<58N5+$8!93FE'&8*.&S^FW/FJTJU:G.BZ,J7/(
M_ISP*\7>"> N"ZV0Y[CL?/&PSO,*T*F RC&8FA5PTJ."H8>O%SE2J05:.'E4
M5&M3A5C'E4XK6*_1[1X/VN+_ .)OB?\ :,U[PC\8/AO=_%GX;?"?0O&?A[PY
M8V/C'Q+\(?!'A7XPWV@^)=.\$>%;^#7O"^H^/)]$35_'LCV6@ZYJ,7A3Q@;^
MWL-3UG3+?353XBZA^W/XJ\">*_#DFH_',7>K_ NZUK2U\(>#_#OP_P#&?AG4
MO!WQ OO$VD:]K&I67@^_T+Q/\2/BK\.;70]%O/!'@WQKX6U?P9XOT^_T%_ ^
MIZ3XBFU2R_.$_P#!97]LU3EX/@K,B%GFC7X>ZQ \ZKEFBCG?QQ*D$KH-J2R0
M7"1EM[P2JFUH-5_X+&_MQZ-XJOX9X/@5>?#^ZB&L>$O$EI\,O$<.J:OX?) N
MH=5MYO'TVGZ?XG\-7.='\1Z=;RS0Q7T<6HQ"WTS5=-#_ (AF_P!&KZ2>23P&
M<9KX5_1RBLM6"P.65Z?$F)QM/+L'EM*A0R7!4G6X-S#%1C@*.'>%C6Q&)Q'U
MO"S5+%4ZU7ZYC<P_IK@GQ6X2\0\UEDG#%7&8K-%1^L0PF+PD,KG6HPE"%2="
M6.Q5.%9T.:FZT*4G.-.4:CIN#E-?LA^V5%\</%VD:/X,\$I\:-9\!>+/A;82
MVT7A+X>>%=6U3QE\01\0/",]]H_Q??5-$TV[\ Z/%\.TU76Y)=#;P9)'J46L
MI9R3ZSIVA^%=5Y[QKXM_;4\$>#-6\26<OQC\<:WXVT?]N#0O#WAS0?AQX UF
MY^'_ ,0;#XS^'+3]D"2#3=-\-Z;>VWA _"+PWXZN7\2>*+S6K/5;_7--N?$S
MS7%_HRVWY.P?\%J?VE;RU>XL=3^$?F1!3):7/PXODN5)(_>*@\;9\OY@?,.0
M0/ES@UOZ1_P6'_:FU>)I1J7P?C ( Q\.;YP[="N7\;*2ZG[P4$#&,C.!^6X3
MP&\9\MR+)N&,7P/X%YCEV4XG,:^)EC<_S.IB\SGF.(QN*E.MF%+@=5\#BW5G
MED\1CL%.=7'/)L)3G2P>7U9Y12_H3!^%W'F91C/"Y)&479*-3.<AHR?,E9_O
M<<I6?Q>Z]+-.R=C[7?\ :4_:'\>_$K]I'1_ ?QGUYK_P?XH^(-C\./A3X+\)
MZ)XXO_$7AOX:?'35O">KW":AX?\ @IXAU3X,->:!'X2\ :5JOBR;XKW-_P"(
M-;U+QO<Z-I^B6&HPZ=]#_MCQ?'_QMIOAGPAX?T+XLVWA/Q9\-O!.H7GA;P=X
M2\%>+%U'XFP?%GP+J?BOPM\6/$RV%X/"VD>'/A_;ZCJD&K>$=4\/P:AJ-KK+
MZ3>ZS=6^D^&]5_-KP[_P4P_:1GN;_4K/4/@KIM]K=WI_]IZA;?"<07>JS0CR
M+635;J/QJLMW+9P2RQ6TET\S0QN\:%$9L_5GB7]LG]H/3M'TVY\+_&CX,^,=
M8GLC=ZMHVF?#&&6;0UC0R77]I&+Q^YLTA4J8C,/])#;4V$Y'T&9>"GB;BN+,
MCXFX2\,_!#*,-PW0KU*&75>(I03Q>/R/+,JE5Y<LX%PT*M/+<?@,1F65U\90
MS3.:7]H8^D\?@HXFA7P$X_PSXZRNMA<-C<AG"IBKQHN&9Y16IR]G&,I.M7I8
MBI1I*5U&#K58*<VX4^:6D?J/X/\ BG]K34-;^*4_CO\ X3Z62S^%OQ.O-3TC
MQ#X&\):#X:\*_'.R\<:Y!\//#WP+U32M'@O/'7@*^\ P0:@^L:YJ7BN2^<^%
MM0U&_L/$&N>(O#6D>3'Q!^VOX>\.:%9>,?%'QZU31+NQ^'^O^+?'?@3X1_"O
M7OBSI'B;Q-^S[<ZWJ'@OP[X3A\''PU<^$++XY6<FE:U/<^'KC5_#1O-&\.ZC
MX@BT34=2\0:3^27Q%_X+9_M;^!M<&E6J_!F]MOM,L1N;WX<ZI'<20P/L,JQV
MWCGRXRQYC$I.X(,?>S7B?C3_ (."?VQ_#]RT&DZ7\ ]3/F-A;SP'XA0(FT.A
M9K?QRHDD;+;MH3;C< %)->)1\ O&-9EC\?'P[^CY/#9E+*)O+UFF+3P-3)\!
MB<%3JX+%3X'K2PM2<\3B,4T\#7HRG'"4\=ALZEA8XNKU8OPGX^P*C+$9-0BI
M4U)1AGO#]1VE:44HPQSFJBB](+56M)-Q2/Z&_ABO[6OAWX??M>7_ (BE\<ZI
M^T+J'AW2?'7PU\*:O8:/JGPGL_%^I?LR?"^W-A\+]572X]/NDMOC/H?CKP_-
MX,N?$<^D6TNDV&I7EC ?$]]XG\18.IZO^U7=:)KOB7P'XX_:3OO#WAOX9>%9
M='L?''P@^%&B?$#Q7KGB'XSZYH/Q/UR?PR? ^F2WWBKX??"9)=:^&GAVS@T:
MPU74+#P_>ZUI7B=+S;K/\PVK?\',G[==G<+8Z=X#_9RU.^EE6&"SB\#>,WN+
MB65BL<<<$'CQGDD=P=H56R<="1G[S^ G_!5__@J#\3],MO$_Q)\-_LP_"3P[
M<AIK>P?X9^.-4\67EJ"R^9'IMQ\2;)+$2J!)&UW;2(R8.3NJE]'OQOCCLUS?
M$\$^ =3$YOB\LQ4Z%?-ZLL!0PN79'DV1ULMR_+J_ =;V."GA\FCB,%[&M'$9
M9BL;F%:6(SFMBOK-/R,1P)Q;ADW5RFDDK.3CF^224.;E<8S:QUHR=K*,FI:V
MU;1^MD7B_P#;/%YIT<7B/XN?V#JNA?''2_".J:C\$=#N?%GAGP[;WOCJ3X.?
M''XJZ!;>#K;0_'&OIIEIX9T^]^#6EZM\)O&\DC^&/$;^&]5O->\8>&M#]023
MX\>)O"'[&7B[Q#<?'#PMJ6B?'2.#XNZ?H']D:OJ/B3POJ5CXQ\+Z%JWCK3/^
M%=>$KY_AOKVL/X:N=2&H>!?">O>$O"NOR:UKVGZ3KVB+K.F_F!XC_P""JO[1
M>B@"T\2?#6Z(PDDL_P ,A'O8+\P6&'QM(RHI&-C3.RY"DELD?.WB[_@N'^U!
MX=9TL)_A#?['*D7'PXU&,8W!0W[GQQZY!!P,#E@>*VK?1^\:L5B\MQN7< >
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M+<W4DS1A6D9"Q 5OB#\=UV#_ (6]H3;G*-M^#FC * =N0#XU)!(.W! *L,]
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M365]"R36US<0LKM_05\1/VGR/!]MY6M)IL+6#P6UO;RE)51(T@*LB. ,C#'
MP6)!Q7X'>&_%;:%=1G5-,BUO3H8+J&UQ(MCK/AR.YD2623PEK)BEGTB9YM]Q
M_9MRMUX;O9FE^VZ.991=P^:_%;XE_$7PY);:WJL[>(?A_J.HR:;H_C2PCDM[
M.VOU"3V^C>+],BN;P^"O$US:D36NCZE<S6>K"UU%_#6K:Y;:=>S6_P#/7&'
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MKM=$_B?Q3>Z[KVD^$=%CGU+Q%K%\D;V&G1O<7OE(^Z-/+3+R23D*2%!RKER
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M]6>*SM5(.D\1*C./M)QE*"J0ER22.H_M;Q JX'PB^-IR<[?^%:>*,%0<GEK
M ] 5(R3G)&0!2_VOXARH_P"%/_&D$X+-_P *U\4@Y&$!4?8CSR <X &,9&:X
MZY_8W\?V,#75]XU^'%G:P)YDMW>3ZO;65N-N[=+=W5O#!$IVG:TDBA@"#SAA
MYU<?"/PYI\IM[S]H7X'Q2K@%(+W6]256()R9K*UEA3)(Y\YEY*DJ>:^DPOB_
M4QB<J&64L3"-U*6&CCZT%*-[J4HX":BTG=J^NR;=C@QW[+;@_*G%9KXRYEEB
MG9K^T,EX=P,I77NVCBN*Z4VFVHWY+7<;-W/=FU?Q#&5=O@_\:]C%BI_X5SXB
M]P00+8MD9+$D*Q)P1DFH5\0:RR,X^%/QLC525+?\*L\:$## LJ2KI#QG!49*
MD@;>H!!/G.A?LT3>*\?\(I\8?A%XG=E+?9](N=2N[U0O))TZ)TU! C?,6D@5
M45@2"1FNRB_9 ^*LLLBR>-/!<,"O&(I5N/$;EHT7 +6K1))!Y9("J9I @ #8
MZ%U/&.EAY<N(P>'PTVO@KO$4I>;C&K@(RM_>2:Z-W.C#_LJN'\=1AB<#XM9S
MCL/434:V%X:RC&4G))R=ZN$XEQ%+:UDY1<KWMU.LM'\17<$<\/P[^(BHQ4 7
M?A#5+><%0,B2*2%98V!(&R1493P<GIA>*9/B+:6L-OH?PE^)&L?:4ECN_P"S
MO#EQ;7%HLH9#+%)>V,MN+J!2)4$T$T1(P5((-9O_  Q7XWDED,OBGX>D.^YY
M9+#7)97RIWEQY8!E' #%F!)PQ)&:7_AB;Q>HV#Q9X!9<X+#2=:4[000" I'F
M98G .-O.01FN6IXTX65XNEA-792>)KVY;.^U&,5NVK0WU/4P_P"R@R"G.%2I
MXF<75N5<[A_J?DZI2E9/>>>-N/-?E35[*/,V<;X!L_B%X!U*R\6Q_LK_ !$\
M1?$S38I_#VC_ !1URQ^V>+M&^'=REU+-X*TRYGL+E;3S+BXCLK?Q'$3K5AX3
M%WX'TV6S\,7\]C7M\7QO^.__ "W_ &7OB#MQ.L,:V<J>3N<&'S"MB(Y2BA0R
MQI$';.&2O/Q^Q'XO#*K^+OA^H<,^5T;6>4)PA48QO*LK')YX!))!H_X8B\7\
M$^+? (YY_P")-J^=IP1M(CY!7G+$@;AC.<GGH>+V"PRJ4\/0P%%5*CKU72<H
MN=26]2<_J?OS:]V\W)VT3U/4S/\ 999'GDL-5S7Q)XTQ\L)A:>#PDL1PWETU
MA\)2O['#T8_ZQ\M*C3YI<L(0C92:DVE%1]!;XX?'5D _X9?^(?F!S\_V:Z9"
M@4 #ROLBE6#[B6\W[JA-J@!R-\<OCJ#\G[,7Q C7:HP]M<2!G  <L3;*JH7)
MQ'AB@!^8DECYVW[$_B]05?Q9X )PP)31M=D!DZA$:.-AU'4]<@<YQ7F6L_ _
MPGX=NY=.UGXW_!JPOX&$<UB;'Q#/<03<EHYH[*UN?*" '<DI60DDXQG/9A_%
MVKBI2CA<+#$2CJU0^L5&E?I[' R>OZZW/F\Q_99^&V40C/-O$W.LKIR:C"KF
M&29'@8SD[Z0EBN)J*J6LW>%TKI2<+J_T8/C?\?"ZD?LQ>/$^4J6^Q7'&0>"!
M9,<$X.UN ,GD#F&7XU_M!.3C]FSXAH"W+)IK/NRPX)>R)QC)#+DY/J#7SQIW
MP2\)ZQ*UMI7QT^!DT[*ABBO#JVD/O)"D :LED)%^]DQAV& WM7HL'[%OC*XC
M$T'BSX9312 ^7-#:ZM/#(003B6(.C*1]Q4?)QDOE@&K$^+-;#-?6\''#75HK
M$2QE'F72RGE])-ZZ+F37X*<M_99^&N;IU,I\3<WS+E?O/ 9/D&-4>K4XX;BN
MO*"ZWG"$5=7=I1OWC?&G]H;@#]G?XFJ000T6FQ<\'&&;326PN-Q8 ;@2"!S6
M=+\6_P!HF0LW_"A/BZ@. ##96B$ ,3QG26(('?)//0URS?L3^/#NV^)_AME>
M44V>N!&9R0X;$./NY^Z21CD <55?]BWXAJ7*ZW\,I%Y*#;K:-PQ.P;K%PK<A
M1N.."-I'3G7C)13NHX3WK)WQ->7I9>P=M->GJ>I']D_P:G)+CCBM6:4G_JCE
M*5WLH\V>RYD]V[>6YUK?%/\ :'E#%_@3\7U(8 %%CC()!(8>7I*XP,,2.=H(
M!/5:DOQ%_: F ,GP*^->6'(^V7"@ \D?N;*/ &0,'&5!4C#8KGHOV+?B1,TJ
MG4?AK''#$CL_FZFP+M((Q"JFR!+Y+EV!*JJG<5^4-?3]B7QLP&_Q)\.D!^8L
M+'6I#U4GG8@. ,DDYRNT=":;\9,,MOJ;O9**JU7=]-L/S:7ZOK;L5#]E)PA-
MR4./>*4X2Y9-\)Y/'EE:]ESYRNCM[KLK[NUD^7Q=\;)T)F_9[^+TYYVI//<S
M@G#;@0]EG^\>003@'ELBBOB#XP?*6_9K^)P89.UK=&"C 'RLNF!L].,%<XR#
MD-6@/V(_%V3N\4^ "#M QI.LM_%R6P>21D=R1R/O U2O_P!CZ[T2V:\\0_$?
MX7Z#9(Y0W>HV=Y90[U()7S-0O[%79%;<ZQM(PW\A<DDI>,U.=3V:IT9U)<L(
M0IO$2DW=.T5#"2;DK/K;2SL74_94<(86E.M6\1N),+0I+FJ5<1P]D6'I0Z<U
M2K7XBHTHJ[2O*<5>RU>@P>)?C9C _9G^)!P,*QC8'[O\0&CGDYZAL<\$L.:U
MQXB^-DT1B/[-/Q(0-)&<J;N&5'BF2>)TDBT:,Q.DL,;(0>2N#@X)YW_A2?PG
MA#QR_M*?" .BG*QZ-J$\3$+QMDAU=HFRV%.) N?]HG/3Z)^RSX;\3 +X7^-_
MPO\ $<I4NT&BZ-)=W&WK(&LD\1M> K@,1Y1X&XD(K5TU/%;$QHU)5LKK1I.,
MU)U*&,Y'&THR4_:8+DE"5.<HSC)2C*$Y)QE&4HOSL#^S-\-Z^,A2R_Q?Q^(Q
MD9IPHX7!<*5<2IPDG%TX4>+Y5.>,U%J5.,FI-)7;BG _B'X]E<+^SU\5%ZEL
MZGJ?)(7L=.*XSU 7.3DGD4Y-?^/;*,_L\_%,DX_YBFJ =0 <'35/7C ^4#G/
M.#U$G["U\<D^./"#LRJZG_A$M3C !!(#_P#$T8C  R=I((^@J%?V%M54DGQO
MX' !8 GPSJV>O# +>.,,<X4#=N& .6%?-P\1>%))?\8YPRFTG%O)LO5E9/ID
MO*E>^[]?+Z[_ (IAX%Q_Y.EQ[O+WEE.";W=M'Q"[QMU[[[:\\/$'QW?*G]GO
MXJJ<=%U340<8S@[]-;![YZ@$G:0 3*-=^.I(+?L]_%?'7G6+M,MG& TFG1J.
M".,\8!(P!6U<?L1:Q;H[CQYX&$4 #R@^%-?21(1M60HHN"CO&K>8!YHW!0"H
M05:7]AC68F:*;XA^ ) I8$V_A3Q [%2.2WG7$.&(YSE<D$8!R*I^(O"\7?\
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MK3:Q$OV3/ 55O$/CGB^LZO[YU*>3Y-5=7GNW5YUG,W-3;<N>-62DW+5G:?\
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MV4?#J"8P0S[54Y8@XR<X(=<YW$[0<;3DGTO6-%>2S AGDB6UE$T$&(I(([@
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M"&\1 ,3R?!?BQ"Q+95</I +;L\ #)YR.IK]"/^"P<B-^WMXHC).\>$O!$K#
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MIC(_F==2V=Q"6CT_Q%&S-)NBD\(>(92BEN0&^P(A*KD$;OWA9QD9Q7EGQ/\
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M8TR$6>@Z??7%Q-*USJ\6EPZ:FJ/9+9::E]%-';6T<49FD\A_:1B^+OP,^/\
M=^ ?'=Y!JWB3PA FG%I[N34%5#<7<;B&:*Y;RT.T[TWE9E9X]Z8+GF/A5\9O
M&7P?\=ZW=_#+5=0TG4='\0ZI;Z#K.@SK!<VMF;N5!;R2RQX:.%F"9"R-MB9U
M.<9Z.Z^'GQ?^/7C\^,]>AN]:U74IU-_K=]<$09W/)(TEZ(EDN)B92ODVT$H#
M[2JQ>8[G_.7 //.'O$',,WQ,*M#B;)N(\ZQ"SRE/#T<#[?#5\1A,-4RW!PI0
MHJI&5&K*G/ZO*,*,TH.%[K['C? \(YGX/Q\,,IS##YIPCCLCRGA?%<)T:F:8
MS,ZWU+-)/-JF;9Y7S'%5:N!JX;#TYJ$L1'&5,<Y5*E?$04:1V9D^)?Q;\*MI
M,ER-+T2ZB"W L3(#<0AT_<22SS3[89",&"%%,IRK.22*]1^"'P*GTF[>*UTZ
M]U'4$1%MH+/39;^\E;D*WV6QAD>(97'F3B.%3@R.-K8^[?@E\"/!?A#P]8'X
MAZ@+UK= 6T"PN;BVBGD5G*I=26;Q:C<1D;7DA%S:0RD$3J\:A&^G[;Q7H&D0
M_9/!VB:?X?L(\*I@L[:.218QL7]S'F(D8W*\YD=AR[A\EHXS\1>*>,,=+&\3
MYSBLUJJG+"TG-P4:&'52<U1H0IJG3I4Y2;E448OGJ7G*<I-(Z/![P'X \.,K
MP>&X X*P^44Y5(8_&UI1K?[5CITXTY8C$8S&UL3CL7548J$8U*U2C2BJD,/2
MPU&<Z<OF*+]EG7?$&BW5EXRTO1(-&O-.O(9M%UG6%6:]DO+6>!_[1ETY)H[1
M DTBQ?8[[[;#<LEW!=6DMM%-7Q_X_P#V -)T%KF:T\<>.9]'5T:#0=7N?#NK
M6<*MN(M6\:Z-8VTDEK:[0Q&J:/H5[/$@A6\FNY TGZB7?B!KMU>YNKBY?"@M
M.RO@@XY!8@*00.!]5)P36DU.SE)#Q@XP#RA!4GH1NVD8/.1G (#!@IK\Z6,2
M=-/"TZKC.4XSE%SFKS<KIN]FWJ[R]Z3YI7;;/W[%9)C,=&4Z]:<*DX.E)86+
MH1</>A[.<KQJ32C)ZWERNTE9^\_R&T']CB>[F9KG[3<6.Y A6X6>V94RL>W!
M,#A!D*_S(<84[2!7OGA/]DC3-,NH;EX'#0^271DBYP P!VQ@A<*<X^500,@$
M9^XGL-%8O/9K+I=ZS,1=Z8T<.YB6(%W9.DVG7T9Y9EN[&X/&Y7#Y-#:AJEIO
MDEB@U%2>;O0XD@U&-44;&DT>^D2WNER<&&QO?.&QE@MV,BJ=ZF;8UN?LO9X?
MVMI5(TZ<::G-6M.:II*4H\JY;/1MK7IX=#@7+</*A/%8>OC:E#3#SQN(Q.-]
ME25_<@\15JJCJVKPY>9)*UHI'ENJ_!SP_JG@V]\,ZI8--I]TB,&@ ANK2YMW
M5[34+"YV2"WO[.54DAE\J5#S%+!)!))%+Y/X9M_CK\"_[0A^'?C/SK6XMI89
MMB365]-:G=E;N".9[8S(5(9H/+1RI*QQ(PC7ZH'BC3]3AEMX;^&2[C79)"L3
M6EW$PP6$]A=B*X@..1OC? QACN(KES;6\E\EE:6TU]J<K$PVMN7FO'E9P8YO
M+?"" ELEYGCB5.=P)P?T/P^\:O$WPTP^8Y=PIG:PV69S.57&Y3C\NP.;9=6K
MR5**Q=+!YA1K4J&)Y*-!59T7"G7=&$J^'J5/WA]+F/#N4YO@Y?7*%"G*GA?J
MSE*%.5.>&A)RIX>O1K*>'K4J<TK*=&HXZQBXZ)?DU\*/@U\;/V[/BG/:Z'::
MGXC\9ZU-<:C;:/IE[+:&T,5T[&:2[\T2FZ1VR9E<R"0OY"HAVG0\*?LK^-/%
M?[3VF?!'XF:I?VGC<ZKIG@MM7\>:ZVJMHT*W$D$%LU[?32G[):,[R1Q.V6EE
M:25F# U^AOA;X _$SX%?$&^^,/P6^*%C\&-;OKBZU&311#%X@CMKK4I7N]5^
MQ,BK#90S73R3PZ;$UW:V$DC0V4L-LL40^+?C-X/\=2^,;OXF:QXQ\0ZKXNO]
M=LI=4\9QG[%=7%U=SM'%/!:VP-M OVL0Q0.L"LC2C=*Y<D^937&GB9Q'*EF.
M>9EF'$W%W$&&I8FIFN;U<+EV8NK47U6A*-)..'=*3=&@H8..$PD'0I83#TU%
M0?Y=QQQ)P7X893C..LVX>P6/RCA#AG'X_$9MDO"ZSKBO+,9A\-BUF>/J/$+!
MX>ODL,'_ &?&GEN%QM'$5JF'JT,4X81P</6_%'P0^-/[!G[7FF_"SX+?$>TO
M?B!KMO9Z;I6H^$KZRNK2_DUVW5I+=S;W!M"\4+2&297W)"C@X$?R_+G[>'[/
M'QP^#_Q)U*?X]0WL?Q'U>%O$][=S7L,W]H1Z@HO9&E$+LC1M),I,9P49MR,K
M*2?U2_9=_8#\;?M'^&]9^*>C^.+VV\=^#;=?%2^/-7UU;OQ'9WFEP.MI_9[7
M2/;&&")Y;>2P,1M+B-MKQF0B5?R4_;<\7_&/Q'\7+OPO\8?'LGQ(\0VH:T_M
MV>W2TNHK.QGDLK>R>&W;;&K^6KNRJ!(%1E8HU?I/'OT>N-?#S"T,PCF&"QU+
M#5,LQ&:4<MS=SP_#6)S2=6C]0Q.'QM#"XK,:M2$:<L/F.%C"&*H2Q'-A\.J4
M'5_E;PO^G9X.>,M;-.%<3D^88',9X+/<!ELLXX,K4<PX]604\)BJ&<9-4RC&
MX_*.'\OP^-GFD\=P_F]>K6P&(E@:N$Q=:MB*E.A<_9F\<L-0M=,5P5E, 2*3
MS+>YC)* QRV[;)XY2"/F"%),$HQ52*^M_B?\!?$^J^)-$^+G@*"'5->LK33H
M->\/:G<1VT>JV^DW4]QIUU87,[PP+>QI</;W5M=W4,=U;);""6*>(B7PK]F7
MX10W30:G?V22Q[H71IL_*"!(SHPVM$^_+*T;1&/=^[8, !^IFGZ=)IEHEOI6
MI/-!'$@&FZR\M];9*\Q1ZF5;6(5W*5033ZA'$S'8L:$(/Q;BBK0K8NK1HN?+
M+D]K'2RE&-/WXV3?-SQ<K7=G;FT3O_6'@_4SZAD5&IF-"I^ZFJN7J;3=*G">
M(4(2NDY14:BA:,M8VES*<M/E;]MK]IGXT_M._#GX7^ /$GPBT7P3#\.K6PM!
M-80V_P#:.IC3[:2))3)8W]_"PFDD(GF=MWEE]J;BK5\"6G@CXP2ZG?ZY8Z6)
M9-2E6>^TUG:"$F.(1QM;W4CXC*(0LWVABDV 796#$_L3JL.BR;!K6EQ:8HV^
M8]U$]WI4S<*KVNM6Z$P[ ,-'JMK8R-Y@_=X!>LJ\A\,*1:V,,.Q9"/,@;)O)
M  3;6:Q^8]PR;U5S"/+:0X4.!E?OO#[QMXY\-*U:IPSC849XG$X7%9C'$83"
MXE9E]3P\,+A:&*J1IPKQP]*CSJ-*C5HI3J3FI<SDGY&.\%<GS7C/*.+DZN5U
MN'\GSK)LEP^"QF88?"8# <0YDLXSJ"PE;%XBC7K8_-(PQF(K8J52;E3I4J#P
MU"E"G'\;_%&D?&:YM'_M'PS?:5$,QM+>36L^23C$,=K=7(=@0H#2-$JE@SJ5
MZ^7Z-\-]7\/Q:QXVUJVE9=.1)TCFB/\ I-]-<6UA91-_&8Y)YK=96#+L16V%
M"%V_OG_PIA=>@CGUN+3_  [HX8RL^HSM/J$D;JCC_0H2T-LS9 V7EPLW<P*<
MBN<^*/P)^$^O_"SQIX*\,Q2R>+M=TJW31O$M[-<"#3=9T[4;#6M-,41D2SL[
M*>XTU+*^:TLA.]M<SF25VD?=^B9]X^<1>)^?\*4?$*I@L)PUA<\RNKF>$P%&
MI##O!5,=AJ6/QM:53$5ZM25/!SK4Y*4Z:I8>MB535Y72S7PWC*K/%8/'X_.,
M9A^:>%@_@IXB$)NE-U'%0<E*R7(K-\L4Y+0_*[X:_![Q1\7]6M(IH=5\6ZMJ
M3"/3K/F90)0G^CV=L1Y%I;)DK'##"HBBCC1SA?F^G_!W[(]IX0^-O@OX-?M!
MVWB7P#X!^*>KVNAZCK1GM-,UGP7JABN)M*\::#J%[;7%C97&CWL222-JEM?:
M<',,VH6DEJ+M;A_[+_QEUC]F/XDZ)K'B7P\UAK?ABX,-YHNKVH2%WB*+(UG=
M2)]CO[>4H3;75K)+!<PL'5PKJ3J?\%,_V[(OVNM>TLV^B0Z4+MX])N/+LEL$
M6VNR!,#=:>BK%]IA#V@VSH\@DEWE0P)_T?XYS_@C@SPXQF9RRWA7&< O@;-W
M5EAL?EG/F.*Q. CALGX?RS+U+$QQ5/,'B</1:E2J_5Z4*^(JRA/".4ORSCC@
M'_7;+<'PQ4P]#!U,31>.P/&5?$5:?$?"/B!EV*I8GAO-\HH\U'$TL9EF:4,/
MBXUJ5:G[:E0K82JIX>O7I5?E/]M7X%^"?@+XUC\$_";]KOX6?M5Z!>ZFVGVE
M_P"!;;[)KVFQK9SW<O\ PE\-AJ^KZ+IFHV9A%G-]DNS%>W<R+:06ZL\$/]A'
M_!KUX3U7PK^Q%\6AJ,4Z0ZO^T-K6I:>\L0CBEMSX&\$VTIMV 'FHES!+&\GS
M'S5=2Q*FOYE?@Y^P/X(\>_LC_$;]H*/XG>$/#&I> Y/+L/!5U<(FI7CPSVT(
MDAB\MWW/YN^,*P 4*PSFOZC_ /@V>^(=QXX_8E^)>FNS-9^!OC[X@\,Z>'A6
M-EA;PEX2U68>8$1KB,W6H3-%,^X["$4[%4#_ "0X0K4,9QC@,7E7#L>'\GK9
M/CZD,-AL56S"G*LXJFJ^(Q&)E[>A*O[RIX=PA",J7)2BJ>B\+Z0V78[(O C/
M\IXO\0\1Q]QG@N->%LMJYCF.5X;(,1>C.68XK 8/ 9?AX8+&0P.#Q.$K/&TJ
MU95*.(G4KU9XNE)/X*_X+%/=I^WWXTN+:.SF2U\!_#CSH+K4WTYV%_X1CBC>
M%H]/U'S#&UJ=Z/'%E7S&[,I!^!? 7Q1^)_PQUW_A*OAIXBU+P#XG_L^[TD>(
M/"?CF_T;6QI>H2VK7UBE[:^%DGCMKN2TM7N%1\OY$>649K[9_P""PWQNN?!'
M_!3?6_AE_P ()I_C"S\7^ _@E>F^2SL]2UC2)]1L;O1)I'L;K3;Y+C2;."RB
MU"=!/9&-6N9?-7*M7S++8Z#=Y%WX5\)SEI) SV^G26X<DLC.DFG7EB4+*.#%
ML*KC.3G/%QYP=EN(XF_MG-LOISQM2$)99CZ.+SC"8J.%HRFZ3C/*\WP2I5*%
M6K7C&HX4:\HU$^>:C&9^V?1EQ>!S_P $.',GR[&8S%86AEJR_B;)JJR:IET\
M=.IBU5IU,)Q#PGFE#%X?$83#X*52BL1C<(YTW)4Z;E*$<77?V@_C]XHO_$NK
M^(?B7XRU?5/&&L>$?$'B?59_B5K:7^J:Y\/YGF\"Z@]Y:^&;>?3[CP=.[S^&
M5TJ2Q@T:X;SK*!)0'&K_ ,-9_M/>,/BUX2UZ]^,7Q!N/B/X8LM3L?"'C"\^*
M&J6Y\/:;?VBW6MV>G1V?AE;6&T\0QV,,?B"V_LB=?$;6MK_;PODMK9HZ$GA3
MP)<,BR>'M2LSO5Q_8OB74;4]3N"KJL6N0E"2,;E8@#*NH&#0L/AOX-LO%VD^
M(-.O/'&G_9O[4^WPWNH>']6BN[-='O6\JS<:!I3V%T/+V)<3&[CVR,\D#&-5
M/R]+A?)>>2J4L1>K5IXB7_&1\8Q<Z]"M5Q%*M-_ZR\U2K2KU:U:E5<G6IUJD
MZD)*<I2?[/BN%LHI8/VD,KM5PV#Q."HQEPKX9UJ5+!XS#8;+\5A*"CP/=X3%
M8/#X7!XC#0C&C7PU"AAYT_8TXTX]Q<?M)?M2^$?&WB7Q?:?''QS#X[\>:38V
M7B_Q1I/Q:\2IJVL:58&6+1;*^N6\+1+;1Z0GG_\ "-IIEO9MX>BFG;1I+#[3
M,DGF=E\7OBOIGQ";XN:?XLU.T^*+:U=^(I/B#:^.-1C\5OKVI036^HZM-J?_
M  BGF37=_;W5Q!>/,KI=6]Q+%-$\;LIZ?4/!W@#6;^?4[L^/I9KED#K#XC\.
M6J!8PJIMV>#Y9-OR\ !E!W!>2,6+7P[X!T\HMIX.;4"HPA\3Z]J^L D@!6DA
MTYM"M''!(7RR@YV@$-F:O"?#^)E#FPTJOU?&3QV']MQ!QC5=#&SFISQE)5>)
M6Z.,G/WWBJ?LZ\I^]*K-MM]6"X=P."I5UA\OQ5"MC<KHY-F4L+D'AOET,7E5
M&BJ,,HQ;I\&4UB<IHT4J,<OK_6,'"G#E6%Y5=0^%/VEOVB/ 9\7-X/\ BOXO
M\+GX@ZY?^*?&LEC\1]4'_"2^*]9FNKK5_%>H?:O"=WY/BG5+B^O)=0\2V!L]
M;NC-LFU)TA@6.L?VM_VD/#.F>$+;1OBSXREM_AC8RV_@/P_I?Q.%O9Z+:C2X
M]$^QVMEJ/AFUT*](T2--)@/B/^T?LVEHEA%+#:[8C9\3^)[+P1X8UO7M.\"Z
M)??V3I\U^=,\.>$[*_U6_$9VB"S:\34+MBFX&:9I)Q'"'E*.5P?S_P!5_;W^
M*45Y*NC>$/AYHEERL=GJ&AMJ%\B$@*;BXADTB-'QD )90@MN93M7GZ+A[PWH
M9Q>>5Y?6K87!RY94ZG%/%N I*^)>+E3IN/%<:W+4Q*GB*DJ45>NW6<75:F_R
MSQ&X@X X&JTY<48?#4<=FM-U*<X\*<%9UB:U*C@EE$*^)JT_#6G@H.E@(K+J
M4:V,=182/U6FE0C'D^DIO^"C_P"T+X0_X3@R>)/CQ9R?$.^EU7QY&WQ0TG4W
M\5:M=6$6D2ZI>M=/?I%JLFC06VD'5--:QO5T>UL]*2=+"UM88O,6_:ZUWXG7
M.AIKWAGQ_K,WAWPUHG@OP]/XE\3:/<KHWA#PW!]BT#P[I[QV\Y@TG1K3,%A:
MJC>5$S+O9B2?'&_;<^(-_<*GB3P5\.-9MF(\V*WT1M+N2F\,'BN;J75;<RJI
MV!I+5TD))([5][^"XM \2^&/#WBA?!^@6T/B+1K'6HK'5?#6E1:A9IJ$"W M
M[DV]G;/OC###J$\]"DRHF\*.SB[PVX>P5'#+-.%(X7#5G.G3HQXQXUSO#3J1
MG/%3<EF'$]>I"?MJ]7$J/L_81JSE4A+VKDWY/AIQ-@^,LZQ>(X#XGPN$Q.7T
M:-?'PAP-P5D.9_5JM.EEE&<<PH<"T:<E/!X*CERIT\1&7U2A2HU*4Z$(<OBN
MBZ/8ZE?ZKX@U6TMXY=6O(;F"U647TL-K':VUN(YIWL[,&0/%(^V.'RT#A0Y*
MDUH>+8-*2R@G%G;*T,T*K)]FC^5U=&MI@6B^26SE *.NUB@"8*Y2OH6?1/!]
MS&([GP;HD94MF33)-7TEV.WYF M-5\DD@  O!(O)^\*R+SX??#?5XEANO#WB
MF!-RL4L/&;PJ#D*2@N?#][(@4$N TD@R0V,9SX\L)0<:4855AZ.'IX;#X?#Q
MC6]E2P^$H4*&'I1]O5KSE&GA\/2AS5*M2;]Z4ZC;9^^9;E6%RO"NC+*\76Q-
M2IB:]?&NIE6(Q&)Q.-Q.(QF(Q%:I1^H+GJXG%5IR5*A0IQC*,(4X1A%/H?AI
MJ>E^%O FG>*8[33[/5]7TJVUG5KRTM8(IIGND!MM/CE$8D^QVT9BAMK<R&$R
MK)<&-)78#F-4^(^JZPS-?7TC(79HX3*_DA6+?NB@"(< 8+%"S9W;CCGH+;PY
MX-M/"OASP]<Z?XOU>QCT'1+N(R>)=/L%53;1SVT8:P\-)<2)!%)'"\C3(URT
M8GVQ;Q%4UGHO@K34"0^!=(D,B8\S7;_7]:E8 D8S+JMM;(^6&X):@$C+*!D4
M\3@Z$G']^KKI"\I.344[**49)I]UJM-%*V.5T(4O:8R635,35Q-1NE.MB,#0
M4*?--+E<ZU:49W34H>R;6\I7M;SN3Q-&FYI+I4&,MNDVC&5 ."%)QSP"">I(
MR"*W_"6VZX+7T*!5'2ZB.1N'+ LNW/(  ZX'3K[+%?6MJ@6R\/\ @_3U!8K]
MD\+:*2OR\L)+BWNGR "!\Y+;<$?+S\9?&K]I_P#:!\#>(-2T/PKX$7PWH%M-
M''8^,KGP>-:36$"1LM[I]W86L'A^P@D.88;>=;F]A5")@LIVKVY/PHL]Q/U/
M"5J4*L8N<ZN)J4L/123:UE5J1YI-W4(Q4I2?2VIYG&O&V#X$R=YYG&55W@Y5
MO80HY90Q>:XMU'"511DLNR^=.$.6+3J8B5*DI+65[)^V_P#"9V@(S>Q$G)"_
M;(U++@'(^<Y!R!E=P.3@D#F1/%MLXRMY"Q#?=$X+*PP< @\D#."1D$YX&"?A
M2W_;9_:9CD7=XCLKV,$@)<^#--D60L%R!Y4,+')W9V$$GG&%-?5/P0^//Q>^
M)UY=VGQ#^&>FV6CP6OVB#QH/"0TG37N056*QFM->MIUOI;L[C"^F7),'EL9X
M<.I'LYCX;X_*,-4Q>(Q& JTJ5-N3H8BA[1*3Y(^SHNK[6<[R2=FTKN2O%,^
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M]K;6B:AH#6UI;I9VWG>(O$E_+'!%@10B>_UB^N#'&@9%#O(450@<($0:]O\
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MCSP&@VG3M%/! +7'B!CA@""W[WD^N<L,]>>9O^&0?A^H'_$KT0\A6)?7?X2
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M2<#++SU8@'/N/_#)/@I5+?\ ".^$ S#(RNL#!Y!Y$*XSD$!3]""!EC_LE^#
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M/LLX>PTLUPU:,Z]*=/#J*P]&G>&(DX2M.$%))<E^5.SO[W-9'#G'T[^+O'W
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M,VR^E!RUQV 46ZL$H-_6<"Z]-/E52E"<TC[0XQP200#VZ=0?TP,CD8'0@TX
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MF?XQ?$OQ-KTBZC\2?'GB;XB^*8;=;728_$.MWNK)HUJR%FM-+LI)9-/T"Q&
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M-E/*;85\UG^5B[9P A*X/(^[M#1\GJP%9\?PI\^21UM([F)HU$T,T2LI,OF
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MX>$$"/\ \(_]K72)KB2YN;NSN9V1H_YZ3X)MU>$B.)H [P"RBM1OFN+DKP9
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MMV@*0 IP 3FO+/"_Q#O-./B;1(KR>*PN(UW)'<2HK&$S$YC#E'63?AHVW!0
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M^3#%DA5 /S,6D)<DU[A^TKJPOOBEXI@MI'>R/C?XB:P2"660WWBW48K-MJY
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MXKW5JP?4/-?3Y([G0?AM'>LVF:3X2BU2]3Q79Z3:^*O%=S++JR>&="\"\,>
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MN.X!&AM>1Q,5<3$&.9P5)&$8E5SC,9"D$ C/(KJIM0MHIDM9@YN-XPT8VA0
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M"I3FTE.$HZ/^$'0_^#4?]J70XHHH_C_\")EA!" 6'C.(!0QV1JHTME1$3 0
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MN6Y?1G[M3%)SY</"I6KU8^TC2C.K)M-Q2<JCA9\K5^FTW]FOXV7WA/P%)>?
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M4:2R10;F@0[T>;,:KE=HK_&[]L3]HWP!?_$OX*?$+XGZGX!^+/[/VF?\$_O
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M-ZU<2:O!J6F7.G:IH<,MEJ\RW5K\H>'?VPOB]\(/AKX?U#QI<^&_B18_$?\
MX7;=_#S7KF\UJZ\7?#Z+PA^W1X$_9WU#6/BUK'C#QCH^@>,O"7A+P]\>?#'B
M']QX@^%^D>&]/^'=UX5UGQ3H>@ZE!XKT3>APYAX1O&I+=>[R45=P?VK03OIJ
M]'R]F>]FGTD<]G6=.>78*G&-*$^:CB,UG1ITZD%[.E!?7)324?W:M!.%3W7)
M-RE#X%^#7[.G[2GAJ]N]%O\ ]E[XGK;VP+VEW+\-I[=)XI2N^*4K;*AD64L\
M;, 47C.!N7]!_A;\._VA-.NHX9?@%\0].C"JI2;P-,D90,B%"6B !95)#')
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M>%C! D,:*RX8C."#C[I')KP;XL? 'XT>+O&3:_-\"?%<DUYX=\+13FV\(M+
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MV?5%L[61RWDFY$<B#XLD_P""@'P%;='#HWCB&#<2L3>'-*G;<N IDD.J!69
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MX+9[V\@TW5?@_I%IX.N'US7;WQ9JU_-#K>NO8ZC<:IXHU2_\3ZC?77VBZO\
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MBI7P=2D\CR"O3K.E-T81R2A4>6X;#8K"8G"*-/&J;S3&8[$9;C:,*LY1I83
M9A2JXG"U*U/!KZN\>2>.M3T'0-;U272)=-\=?#;QI\3M+NK75UNO)TKP#8W6
MJ>+/#MZ8[?S+#QAIVCC3-83P_=QK-+HWB7P[JD4IL=2\V'X6\4>)S#)-!-O2
M,&51.SX58XR P;:H'R,"=Q*\#MBO8A\==:T'P[XS\/-H'A[6M,\:_"#2_AFV
MG7>L:I'!H&OZ-X8\7>%])^*^CW"6HE@\4:3H_CWQ?H<NFFW_ +-U[PYJ]UI&
ML7&#IUQI/P+\7/&]M'I]YIUM>?:M=UB3[)I5K;Y=_P#3KE(M[*AS%(0[,AD
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MEN-*G@:2.*W40HP,.T;^I?LW:5HAL_%/A[Q5!\0?B%X=N;*YT<^)?!.EZ)X
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M##U\9B\57XXQ,:6&PV'I2KXC$5)PR&K^[I4H2J3DDW%*W+)M(_-O5_A[HGB
M*FL_M('4HE='\BX^'_CHVZNH^5Q;[1"".<'9N7)(.0:]!^%$>B_""U^(D'AW
MXXZ4;KQUX13P]9WEQ\,?&DS^%=<BUW2KI/%^D*94-OKJ^%CXQ\$M<HK;M"\;
MZO!)&Q:WE@W)_&?[,L=PXLOV:KJ:V5OW,FH_%SXCM<.N3AI81XGN;="Q&54.
M^WW^7/1:'XO_ &/+MUC\4? '7= 1F)>\TCQSX\UN&-=P9I)K=?&^FW4@7&2L
M4<TBG)5'85]!B>+^-Y4U5KY/BZW*X5.6.$RS$54Z3C5I25+^T)U>:G4A&44H
M.<9).VEU^;Y;]$/Z!U'$RPV S[-L"IQQ&%YWQOQ7EF"G3Q5&IA,1!XK_ %3H
MX65"MAZU2G5=1QA4H5IQFW3FXF$GCWQY;'$?[5\<JL%5DD^%7BL@?>;Y3)&1
MP#M!&"<').*E7XD>/ R_\94VVW< 2?A/XF7 !'^RIZ 9Q@C'NJC[=T?]F']F
M'Q'I.F:WHGP^%UI&L6-MJ>F7L'CCXMVHN[*ZC\VWG,4GC>"XC#QO_JIHHY48
ML'48!J\?V3_V:K*.>YO?AF3;0(]U<2R?%#XW6XCM[=6EF?-G\4+)4C6)'8AP
M" &)9225^8?CAF:G.E.IB855*4'"> PJDJEY0<6O;WYE-VMK9KK8_4H?LK_H
MMSH4Z]#AC/*M"K1C6A6I>(69JE.A*BJL*\*BRMTG3E1:JJ:Y(.'))M1LU^6_
MP\\)>*_VF_C=I^A>)_%+:QK.J:DGA?3]:U#;:VT6F:?((83;6DC*+".X/F7[
MV3-YD5Y=3"Z,DT;E?L3]N+]A#QO^P9K/@]K'QW:27'C'3+1I)[*XM[FSN+9;
MC2M=M-+U:WTQRM]I4^HV]@;BUE27:8TD59"I5OCG1-.L?"GB6\\3>"KK5_#E
MW-KUYJ^F_9M6OM0331>7TL]M!9-KESJ]\L$<4L*$W>I7UXWS&XO+F5IGE]1\
M=?$3Q'\9?%/@C4_C?XGU_P =Z-X5U[1IKS3+W6=0T>U;0A?V-IJZ7DGABXTC
M5HUBTM+@QR66HV5Y!(&>UF2Y2"6+^Q\Q^D+P7C_".ED%+#XF..K<$YWP]Q/P
MLN'<1*>.S3,LHEEN'S7#\44<2L+EV6T:E:MC9-*&-E5BL)"C*I*=2?TO#?&7
M _#&0<#\!\*X3+\!D'"[H<+U.&,3P_0Q]"O/+,XP67\-YW3S[$*KEU'!X">#
MHYO6JXC"2QF(Q5Z\H2Q<OK,<'Q]\?OCI^U%\=K7XW_&_Q[H7PW\5:!X1LO"V
ME:SX?\)WFIV]_I]A9W>F0:6NB>&;UGA@%GJ%U/=7EY>1-),MJJQ,Z;1L/XDU
MN5AC]J(/(N-I;X3^,TQU/WSJY10H("EL#. 0"-I_0JY_9)_9MCEGCC^%B1K%
M))$PA^)OQRN?N2%=R&^^*M[E<8*G!1P<L<'FN/V1_P!G0,"/AD7.,CS/'?Q.
MD49W9)$OC9U(&U3N.3\QR>37\'\+>(U+@W+*F59)6S-8>MC:^/KSQ-'#UL1B
M,9B(TX5*U2=6:?,X4*4+0A!+DO+FE*Y]WXT?07\(/I <58+C'Q-X=KXS.,KX
M>RWA3*X93Q'7R/+LOX?RBKCZV P&&P&59:J%.%"OF>.JJ52K5;EB'"+IT7&F
MOS_3Q1XDB(3_ (:DN]G#2-%\*_$^T!LD?+)K(=FWC!(*]3GJ,N?Q9XE9@R_M
M7ZHFW#)&OPF\1 D@DC:W]IMD< $%L!>2,Y ZWQEXF_9&T._OM*\'? 4^+ET^
MXN;1M:U7QGX_TG3+B6UF:&5[""3Q3<ZG/:F6-EBN+F*R:>/9(D.QPS<$GCSX
M(K*JR?LR>#6@$B-(/^$\^)#W"H#AA'-+XAD ^0$*K1[-P!^5<@_JN&XT\0,3
M0AB(X'&TZ=2$:D%B*65T:DHRBIQ]R=9RBYQE&24G"34DW%71_'>8?0S_ &?6
M3XVK@:T<QQ-?#U*F'KSR_BCC#'8:%6G4G1KTWBJ&2?5YNG.E5A4G05:,91ER
M2J*.MN3Q)XGEPTO[5^O @8RGPO\ $'&2#_T%5(93R-H/ !*KCG^S/_@VUN;J
MZ_9&^,\EW\0[WXD2_P##0NK ZQ?:%?Z!+:?\4+X*8V*VNH7-S+(BEC.)D=8\
MS%%4%6K^6/X,^#OV4?C+%J5K9?!:'0-?T>**YO\ 2;SQ%XUN;=K.=_*BO]/U
M"W\4+%,GGXBF@GA@N(6*OY<D3K*?["_^"%GP[\$_#;]FWXI:/X%\/0>&]-O?
MC3J&I75G;ZAK6H++>R>$/"UNUPTFMZEJ=Q$S0P0H8H98H!LW"%7+$^!7X_SK
M-L?4X:S>.+HU;/$U*%?#X:FD\-&-6G/GHU)\T9*HW3<;PFM;Z79XE?0X^CGX
M7^%4O&7PBRRK+&?VID^3X#.%Q3FF;45A<XQN+R_-,// 8_ 85T\0OJ<*-6-7
MV5;#3C>5+]XK_P ]O_!5_P#;J^(GP/\ ^"AO[3O@GP+H+6$EC?>"+&[U^Q\4
M"PO=1@D\">$M;@?[--X=U+^S+O3KYX;K2]5TRZM-;TB_M8-3TC5=/O$69?RS
MU/\ X**?M#7>BV7A?3FM=.\+Z?<"]M]$NO$7B'4XKN\/C*Y^)#3^(M5DN8/$
M7C*&3XCWUS\1SI?C#6==T0_$.=O&S:8/$@74A],?\%K].:?_ (*=_M43%24?
M6_ G/ !Q\,?!X'4D$9!(.W).!G/7\M1HQR J=2/NME20 >@')SGD9P1GV'XE
MF6-JT<RS.$*]>G!8['ITXUJT::Y\3-U&HQG"*<Y*[:ZWLXZ\W^B_AKP)A<Z\
M-/#?,<=E&5XS$5N N!JBQ>*R3*,5B91P?#F I8&^*Q&68BO/ZK0FZ5#FK-*'
M+&:J1A35+W+Q=^W)^UKX[U<ZUXD^),6J:H5N(+:>\T/2[B#3+6_OCJ>H6VC:
M2;9?#^BKK&I;=2UV72=)L[OQ%JR0ZIKUUJE_%'<)XYH'[67[3ESXJN]1E^)T
MUZ=+M;JQMM.NM$T!=%DMKZ]C-P;K3X--ABNIUDTNS>"ZG/GV@B<121K-.K\=
MK]U#ID#Q0R1R7[!D"!MP@++M\^?#-LV]8HG.]FP5^57:LGPCX5U2"*^UFXL-
M1CL9C!:PW+Z?>K:EHGGDEN'OO)%J%:9HHTW2DL S@X))XO;3KNI4G&-2<XOF
MJS7--I*.CE-RE;EM%:V459)*Z/LH\+SRR6 RS+<1B,NP>%JU*L<%@<5]1P>'
ME*4JKG'#X98;#J<ZTO:SDZ<ZDZC3G4G))Q^H+']M#]HFV<_:=0\&:FH((2\\
M*P1<D$,=UE<V[ EOF/&< %?O 5W%A^WA\6(,#4?!G@'4"N#(8CK6G$GEMPV7
M=VJG!(R$)(_A.2*^7/[)*\&-FR?E*Q,3DY;H S8/)Y7L!R<$>L>(OV=_BQX1
M\"Z?\2->\ >)+#P9J:1M9:U)I-S':/'(67S/.FC10I9"%(SDD [<DCZ[@_PW
MXX\0IXN/!G">8\0RP"BL3+!4\-3I4ZU2G*M2PL*V-QV7T,3CZM*$ZM++\+4Q
M&/JTX2J0PJI\E2IZ^*^O954PM#&\28G"UL74=+!T,7CZ;JXF:BY.-"G6A.K6
M?(G)JG"I+E6G/:27>>*OVJ_#_P 0UM_^%@?L]>#_ !!=V<;Q6>J0>+]4T_5K
M6*0[FAM]3AT;[>L)*[_LTD\UOYF)%C#,QKS?_A8_P9#!O^&?]7SN),8^,FJK
M!@894 /A8S#/*R8DS@#!4DFO,[:PBND2:WE2:.0$JZE6 ^8%E?)4QRH0R30N
M!)!('21%<$"4:2P[8& 3GD YSQ]T9P1QGD9..0:\'^T\^R.K7RN6)S7*J^!K
M5L)B<!5J8S"U<%B:%6I2Q&'JX2M:6&K4JT*D*M*5*G.$DU**?Q>5F?AMDG$=
M=9EFW#_#^=8FMRU7F.-R+)\7B*Z<81A4J8I8"%3$^Y&,8SJRKM*"5[P45]*>
M!_VGOAWX OOMWAS]F[0-%NFL[R(:U%XPN=9\2+</:SBUC34M9T1IX+*:Z\J/
M4193V\KV;3-$LD@2(V==_;J^+5^)8]!\*^!_#BMNV2S)JNO3IN "8-S/:0EL
M%23Y"\JIV=A\Q'2G.-@.2 3@.,?4D@L-N<#D8&X':"::=)8#F+).<%E9CP1@
MYQDC=N)]>#R.1Y-?%U,75=?%U:N+KRLG6Q-6O7J./\O-5J3:C'HERPCNH*Y[
MV!X:QN4X-9?E"I9/@%)RAA,JP&7Y7AHSDE%R5/ X'#/F=ESU)>TG*R<IM1C
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MR;)9B%8*0=R@CS74/BS^R;K#///^SYX[T*5CROAGQ/I-M:]&!"6_]MVEK$O
MW"*V5,')CWYQ\[MH[[\%6XSG*G&2H.3]T'CGUZ88X% TAE!R"3N&0JLN1R.
M"%ZA5)"G(P#D<5_/F%S+&9?+_8,7C,(I2NX87%UZ"FX^ZW4ITZD8MJSBW*$F
MFE%R3M!?O.;\&4^(HP7$.3Y+Q!&DO90JYOD&59A4I*3=3V4,36P3K4X2=ZGL
MXXN,9.\U2:<JB]TMOB%^R=:S^>/@Q\7-10%BUI?>,="2S8C)'F&TU<3NG) 4
M."3DD\@'V6W_ &Y?#'AS3+?1O WP,&BZ18Q&*RT]_$VEZ386RL-V8[/0_#\Z
M9=SF9VG,LTC&25W?+GXH&D.#TSTZ \\\ X)*[<$?[(()'JTZ3("NU5X)&&!
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M*[O)-)*Z/4-'_:\_:-TT8N?%NCZZ$P?^)YX7TB29@"<@S6%OI[LS@'S"2"Q
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M\(>!_#?[5!G^*7@SX=^)O&?@O4?A[=Z+XP^!UO\ %B+Q-I6GZG>.9?#^I_\
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M%K!;PB&-20OD6]I!!9VBA,#9!#M7 VD8P>/F\527#F2YGEN)"<>9/<22OCD
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M\;?%;XU?$M+G2M*U>7X0>!I$FM[;P/\ #*>YTIYM/F8%1XI\9R2-XT\9ZO<
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M2VBB\_S-/U[68?&VA7'VEX&G^U^'?'-OXBT.X,IBB!DFL6D7;^[90Q#?J?\
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M^*_PN^,WAD>,OA%X^T'XA^&%81W=[I+76GZQH5UM'FZ;XN\(ZU;Z?XI\)ZG
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MV!/J> 3C)XY (/?+ CDUX1\?;F)?#6D6[$>;<:T2@SR4M[.<2N%(/0S1+D$
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MD=O,5=V\R-8RH20J=IE(8MA05)/S?D#XR^&^MZ+=7,5O#)=P0'"HXV3M&5!
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M2\/7=U<3V*R075[9WGH<_P -O%-XA,[:JPY8[XYPP"JHSN:$*1@?Q# Q]T\
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1D4EHDHJT4DM$E%)+1)(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '\ ZP# 2(  A$! Q$!_\0
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M?:H[+5;74+J>&UD258D1C(C!E.XMQQ_N_K1S+N'LJEFW%Z>1>HHHIF84444
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M_P#?#?XT?\)OJG_/*U_[X;_&CVT0_LO$>7WGH-%>??\ ";ZI_P \K7_OAO\
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MH3@X R?TYI\D&M&2L1B8R7-'97V[Z7_7U70HZ[IM_J*"*UN$CA:&2-T9BO+
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MN/\ P';_  I_5_('CZC35UKY+S_S9M2Z1<&;4A%/"+?4%/F!T)=6,>S@YY'
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M*$$E2Q!'/^T>*ADT"]GU$SSZ@)(Q)*R!E;*AT90N,[0!NZ@9-9O_  M+PO\
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MY!>E_P#7.3_T8:SZT+W_ )!>E_\ 7.3_ -&&FMF9S^*/K^C,^BBBD:!1110
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MG0ZVZ2W4O]G7*0J^Q=C!L<L<Y!Y[#TK=.LZ/IEC9Z>FKMJ#/K"7LDKQLOV=
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M?\AF^_Z[O_,T="/^7GR_4IT444C4**** "BBB@ HHHH **** "BBB@#0N?\
MD!:=_P!=)OYK6?6A<_\ ("T[_KI-_-:SZ;,Z6S]7^84444C0**** "BBB@ H
MHHH **** "M"]_Y!>E_]<Y/_ $8:SZT+W_D%Z7_USD_]&&FMF9S^*/K^C,^B
MBBD:!1110 4444 %%%% !1110 4444 =/X&_Y#$__7#^HKOZX#P-_P AB?\
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M]_SWM?\ OL_X4?\ ")WW_/>U_P"^S_A76T4>QB']J8CR^XY+_A$[[_GO:_\
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M+6[+5E:?[39V/V"(%QM\KGJ,<GGK4WAOP]8^%=%BTG3C,;:)F=?.8,V6.3R
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M* 3CGOQ0!V-':D1M\:N.-RAOS%+VH GN/]<?H/Y5%4MQ_KC]!_*HJ "BBB@
MHHHH .._ KC=*N[4O?\ BS5&^7SC!;<;O+0'&%'J3_6NRP""#T/!K@[#3I;[
M1[K0$DCBU#3;XSHL@^5USD9]N?Y5O22L[^7W?U8RJ7NOZU.YDCCN(&CD7='(
MA5@1U!%<79Z<+S3;_P ,79_TS3F,EE+_ !;#RA!^O'XU9U*_\0VD8;4=3TG2
MXVR Z*TC,?8&J*ZJLVI6NKQO++!IELZW5_)'Y8N"1\J =^2*N$)):/\ X?\
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M0\SO]KMQ.)T1BJ[L%!C&3N!SGH.]:@\8>'SJXTK^U(?MYG>W\CG<'098'C@
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M2&FD-*:0TBT----.---!2&]J0TO:D-(I#324II*1:&&D-*:0T%(0=1]:)?\
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M+\0,>@;T-8?PXLIXO#)U6]&+[6IWU"?/4!S\B_@N/SKSO6?^15^*?_84B_\
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M]Z/_ +[%'V=_[T?_ 'V* '7'^N/T'\JBJQ-"QE)W)T'5AZ4SR&_O1_\ ?8H
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M3IO]?)_O&GK VX?-'U_OBG2P,97.Y.6/5A0!7HJ7[.W]Z/\ [[%'V=O[T?\
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M&6ZGF\@^4@\@H$VYR%P ,YSDU=TKPR=-U*VU!KSS9T:ZDGQ'M$DD[*Q(&?E
MV@ <_6NE\A_[T?\ WV*/L[?WH_\ OL4 <O#X6>(VUJ;U6TNUOSJ$4'E?O-^X
MN%+YP5#L3TR>!5=/!C06FHPP:DZ&XD00?)@0VZN7\@X()4EGR00<$#M78?9V
M_O1_]]BC[.W]Z/\ [[% ')Z9X6;1[A[T3K,XO7O_ "(8MH),'E>6N6/UR35S
MPYIE_IFGV\=S.F#&\DT 3)6:20R$A\] &VXQVSFN@^SM_>C_ .^Q1]G;^]'_
M -]B@"*BI?L[?WH_^^Q1]G;^]'_WV* )M/\ ]>W^[6C5&RB9)225/'9LU>H
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M "BBB@ J1_\ 51?0_P ZCJ1_]5%]#_.@".BBB@ HHHH **** "BBB@ HHHH
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M0?\ "0P?\\)?S%)_PD4'_/"7\Q7/FFTO:2*^IT>WXG0_\)';_P#/O+^8I/\
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M_P!:P8/AT]E\3H?$]E>Q1Z<)))WL2IR)70J[+V )P: ,GP7XTU;7O$GV:_\
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M=P@):*&4,P ZG'?\*H:3XQL+G0[;4-5N]/L&N998XPMT'C;RR<X?@$X&3Z4
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M7#8L?^6@_*D^P-_ST'Y4K,KVD>Y2---7O[/;_GH/RI/[.;_GH/RHLRO:P[E
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M X(4X-8WVJ?_ )ZM6S=?\>LO^Z:P: )?M4__ #U:C[5/_P ]6J*B@"7[5/\
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MW_/5JBHH E^TS?\ /5J/M,W_ #U:HJ* )?M,W_/5J/M,W_/5JBHH E^TS?\
M/5J/M,W_ #U:HJ* )?M,W_/5J/M,W_/5JBHH E^TS?\ /5J/M,W_ #U:HJ*
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M?G;[_K[5"7?^^WYTN8?U=]S<HK!,C_WV_.F&1_[[?F:.<KZL^YT-%<V9)/\
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M HHHH **** ')_K%_P!X4LO^N?\ WC_.D3_6+_O"EE_US_[Q_G0 RD(S2T4
M1$8-,-3-C'-0FDS2+&'I3#UIYZ4P]:DT0TTPT\TPTC1##UIIIQZTTTC1"_\
M+N?]_P#I4!J?_EW/^_\ TJ TC1#6IAI[4PTC1##UICD*I9B H&23V%//6J][
M_P >%U_UQ?\ ]!-(M%2RUK2M3F,5AJ5I=2#DI#,K'\@:=9:C::G"\UE.LT:.
MT;,N>&'4<UYEX&\/W^I1>&KY-,L[&VLIFF:_C<>=<C)&T@<^W/:J]G=:OH_A
M&]UJRU62*.#5F06@C79("XW;CC)ZC\!3<3*-9V3:/7#TIAKSGQ?XGOHKG5)=
M(OKZ,Z=Y:2J'B2%7)Y^5LL^?:I/$&LZM:7T=_-J-Q!HY@A+?8'C+0NP!/F(P
MR0<\8QQBERFWMXJ_D=^U-ZUYUJFN>(KSQ%K%OIEQ)&MD8Q BS11)@C.Z0/RP
M/MBNYGM?[4TD6UR\D1N(E$IMWVD$@$A3Z=1]*EJQM"IS726Q);W=M=EC;7$4
MPC?8YC<-M8=0<=ZDE_UC?4UR'P[ACM['5H(5VQ1:G*B+G. , "NOE_UC?4U+
M5F:TI.45)C%=HW#HQ5U.01U%=7I.KI?*(I<+< =.S^X_PKDS30S*ZLA(<'@C
MKFB,W%DU\/&M&SW[GH5%5K!KE[*-KM0LQ'('I[^]6:[%J?.27*V@HHHH)"BB
MB@ HHHH **** )7_ ./:+ZM_2HJE?_CVB^K?TJ*@ HHHH **** "BBB@ HHH
MH **** "I9/]3#]#_.HJED_U,/T/\Z (J*** "BBB@ HHHH **** "BBB@ H
MHHH N:;_ *]O]VM2LO3?]>W^[6I0!%=?\>LO^Z:P:WKK_CUE_P!TU@T %%%%
M %6/3;&%;I8K.!%NV+W("#$S$8);U)'%5'\,:#)IL>FOHUBUC&YD2V,(\M7/
M5@/7DUJT4 4;/1=+T^QDL;/3K6"TD)+P1Q (Q/7(Z'H*33]$TG28I(M.TRTM
M$E_UBP0JF_ZXZU?HH Q(/!OABUN([BW\/:;%/$P>.1+=0RL#D$'L:TVL+-M1
M746M83>I&8EN"@WA#_"#Z58HH PU\%^%TG$Z^'=,$H;>'%NN0V<YSZYK<HHH
M *#THH/2@"Q<_P"O/T'\A452W/\ KS]!_(5%0 4444 %%%% !2.BR(4=5=&&
M"K#(/X5A^*/%%MX7LK>62WFN[J[F%O:VD&-\TA[#/0>]9^C>-)[K7ET/7-"N
M-%U*6%IX$DE65)47KAE[@ G'M0!JMX4T!IO-.DVN[TV<?ETK5BBC@B6*&-(X
MUZ(BX _"LJ'Q7X>N59H=:L9%2 W#E9@=L0."Y]!FJMUXQTN3PYJ^J:+?V>HR
M:?;/,T<<F1D D!L<@'%4Y-[L2BELCHJ*S?#^I2:SX<TW4Y8UCDN[9)F1"2%+
M#.!FM*I&%%%% !1110!*O_'M)_O+_6HJE7_CVD_WE_K45 !1110 4444 %%%
M% '$_$_2(;KPE?:J;F]ANM/MG> V]PT:Y)'W@/O5GZ#.?"Q\'V-H9KD>(PKW
M<EY.TK(PB#?N^>.6/'-=SK&E6^N:/=Z7=%Q;W49CD,9PV#Z&LK4_!FFZII^D
MVKSWMN^D[?L=S;3;)8\*%ZX] .U '-ZA\1-0L=)\37JV-K(VD:I'91)EAYB,
MV"2<_>_3VILWB_QM#J^J:0=)T/[98V8U!I//D,:PXSM]2_;L.#6R/AOH8T;4
M-+\V^,%_<I=3L\VYS(O?<1W/)^M:\OAJQFUG4=59IOM%_8_89@&&T1^PQP?>
M@#F(_'&LZO#X;M=$TZQ_M+6+-[QS=R,(8E0D$#;R22#5-_B7J9TK37AT>W?4
MY=5DTJZMC*0@F4<%&[#)'7/&:Z&3P!I)T_2;:"YU"UFTJ-HK6\MI]DRH<Y4M
MC!!SZ4L/P_T.WLM*M81<(FF79O8V\S+2RGJTA(^;/X4 87B#QMXF\/7NG6-]
M::/9O/;EY;ZX\YK4R[B!&K+]WC!RU>APN9((W8H2R!B4.5)(['N/2L'Q!X0M
MO$<DOVO4]5AMYD6.:TM[G9#* >ZX//O6[!!':VT5O"NR*)%C1?10, ?D* )*
M*** "BBB@ HHHH <G^L7_>%++_KG_P!X_P Z1/\ 6+_O"EE_US_[Q_G0 R@G
M%%,:@!K')IAIYIAJ35##TIAZT\]*8>M(M#33#3S3#2-$,/6FFG'K332-$+_R
M[G_?_I4!J;_EW/\ O_TJ$TC1#6IAI[4PTC1##UICJ&4JP!5A@@]Q3S332+16
MM;6WL;=+>T@C@@C^Y'&NU5[\"JK:-IC63V9T^V-J[^8T/EC8SYSN(]<UH&F&
MD6DC-N=!TBZN7N;C2[.6=UVM(\(+,,8P3].*CFT#1I[E;F;2K.2=-H61X06&
MWA>?; K4-,-*Y:BNQFWVB:3J4XFOM-M+F4# >6(,<>F:N8V@ < =,=J>:::3
M-4DM2M;6=M9[Q;6\<(DD,CB-<;F/4GWJ67_6-]32C[P^M#@M,54$L6P .]2:
M+0BP2< $D\ #O73:/HHMMMQ<J#-U5#T3_P"O3])T<6@$\X!G/0=D_P#KUKUO
M"G;5GDXO&<WN4]NX4445L>6%%%% !1110 4444 %%%% $K_\>T7U;^E15*__
M ![1?5OZ5%0 4444 %%%% !1110 4444 %%%% !4LG^IA^A_G452R?ZF'Z'^
M= $5%%% !1110 4444 %%%% !1110 4444 7--_U[?[M:E9>F_Z]O]VM2@"*
MZ_X]9?\ =-8-;UU_QZR_[IK!H **** "BBB@ HHHH **** "BBB@ H/2B@]*
M +%S_KS]!_(5%4MS_KS]!_(5%0 4444 %%%% ''^.]%U2^?1-8T:%+F]T>[,
MXM78+YR$ , 3T/ Q]:HV]IK_ (E\;V&MZAHDFCV6EVL\<4<\RO+/)(N/X> !
M_3WX[ZB@#RS0?#&N:#\(IX=-T>&#Q1)O#B2.-I'4R="3D'Y.@)Q5*V\+^(I;
M[Q+=2Z;J>V^T![6 WLL+2R39&%(CP%[X'IWKV"B@#'\)V=QI_@_1K.[B,5S!
M9QQRQMU5@O(XK8HHH **** "BBB@"5?^/:3_ 'E_K452K_Q[2?[R_P!:BH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ')_K%_WA
M2R_ZY_\ >/\ .D3_ %B_[PI9?]<_^\?YT ,HHHH **** #\*,#THHH ,#T%&
M!Z"BB@ P/04F!Z"EHH D 'V4\#[X[>U18'H/RJ8?\>I_WQ_*HJ $P/0?E1M'
MH/RI:* $VC^Z/RHVC^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[J_E2T
M4 )M7^ZOY4;5_NK^5+10 (J[U^5>H[4^95%Q)A0/F/:FI]]?J*?/_P ?$G^\
M: (Z*** "BBB@ HHHH **** "BBB@ HHHH E?_CVB^K?TJ*I7_X]HOJW]*BH
M **** "BBB@ HHHH **** "BBB@ J63_ %,/T/\ .HJED_U,/T/\Z (J***
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MZ "BBB@ HHHH **** "BBB@ HHHH *D?_51?0_SJ.I'_ -5%]#_.@".BBB@
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MH **** "BBB@ HHHH **** "BBB@"1O]1']34=2-_J(_J:CH **** "BBB@
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MN;PQRV5_I\5FT7.[Y<Y/Z\5R]A\/-2LM \1:;+J,$[ZBL202MN^58\@;N/3
MXSTIZ$VJ=/,O1:WK^E:AHBZM-:7UCJY6-)(83$\,C*" 1D@CFK/C37KW0XM.
M^S216T-S/Y<][-$9$MQC@E1Z_P!*BLO"^KW-]I=UX@U&UEBTL VUK9Q%5+@
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M?L]OZV&44459S!1110 4444 %%%% !1110 4444 2-_J(_J:CJ1O]1']34=
M!1110 4444 %%%% !1110 4444 %2/\ ZJ+Z'^=1U(_^JB^A_G0!'1110 44
M44 %%%% !1110 4444 %%%% %FR_UK?[M7ZH67^M;_=J_0!'/_J)/]TUEUJ3
M_P"HD_W3670 57N[&TOTC2\M8;A8W$B+*@8*XZ,,]"/6N9^(FN7.CZ#;6VGW
M:VFHZG=QV=O.V,19.7<Y[!?YUB:;X_N=,^&FI:K?;=3U'1;LV=SB0*)OW@57
MR 1RK \>E 'I#JLJ,DBJZL,,K#((]Q5.RT?2]-BEBL=-L[6.7/F)# J!\^H
MYKDH/B#=I?:C8ZIX?ETZ[ATY]2M(WN%<3Q*,X)4?*WMS2:#\1;G4]4T&*^\.
MRV5CK:_Z%=?:%DWNHRP*CD#T)YZ'% '66^AZ39A1;:790;$:-?*@5<(WWEX'
M0]QWI&T+1VMK:V;2K%K>U;?;Q&W4K$>N5&./PKR_1O$5^VB>&7NK[4)IKGQ)
M-;%UNBNY <!7R#N7VXKL-+\9:EKVNR0Z5X=DFT2&[:TEU-[E4PR_>*QGD@4
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M2- BC/0 8% $Z_ZA_P#>']:CJ1?]0_\ O#^M1T %%%% !1110 4444 %%%%
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M]!^5 &9/_KC]!_*HZU]H]!1M7T'Y4 9%%:J-%)G84;:2IVD'!'44[:OH/RH
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M116JC12 F-D< E25(."."/K3MJ^@_*@#(HK678ZAEVLIZ$<@TCF., N54$@
MGCDG 'YT 95%:^U?0?E1M7T'Y4 9%%:PV%B!M)'4>E V%BHVDCJ/2@#)HK7V
MKZ#\J:S1(R*Q0,YPH) +'&>/7@4 9S?ZB/ZFHZU]H]!1M7T'Y4 9%%:R['4,
MNUE/((Y!I=J^@_*@#(HK1GN;6VC>2>>&)$(#-(X4*3TR34JF-U#(593T(Y%
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M8W>G2!3\S)OG/F+N\M00 %)&" >];>D7VMOXM:UFN0D,=S-&]M*#\T"@^6R
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M7^O:JVN7BV!O4"QWD;1.N\*8XSL<#8-N67(^8[@?R]!HH X&:XUNTC>%]6N
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?KVW$\!8QEF7YD*G*D@\$ ]0:FHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (F \\# 2(  A$! Q$!_\0
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MA=[?WC1O;^\:;WI: LAV]O6C>WK3:*!V0[>WK1O;UIM% 60[>WK1N;UIHI:
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M&]O6DI* LAV]O6C>WK3:* LAV]O6C>WK3:* LA****!A1110 4444 %+244
M+1129H 6BDS2T %%%+0,*!12T %+2"E% PI<444@$Q12T4 )12TE @I*6DH
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MDABTG<.IX'YTK:%^T:FT]DB6?4$B8J@WL.OI4 U1\\QKCZTW3[=92TCC(7@
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MI2WQ6!WM$8G*G'&X^W8#BK_P5T>:S\/7FI3(4%[*!%D?>1,\_3)/Y5UOCO\
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MW7SKB$R2<!68G!)]#Z^]*VK&ZC<(ZVN=SX7A^)=MXEMH->N!-IC M-(?+<
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M.0.F<5TOBKPO:>+=.CLKV>:&-)?-#0XSG!'?ZUN44[L2A%*UCS3_ (4GH/\
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MC \3>#=&\61(NIVY\V,8CGB.UU'IGN/8USFF_!KPQ872SS-=7NTY$<[ +^(
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M*E'2F@8%+FD4@-%)UI1TH*"@TE(30(44M)24#'T4VEH #0.**2@!U+30:7-
MA:*,T4 !% HI:!!3@*04O2F(#R*A85-367B@1#12D44#$HI:* "BBEH 2BBB
MF(7-%%)2&+11FC- !1110 4444#"BBEH **** $HHHH 6BBB@ %+110 M%%
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M8I*6@0HI<TVEIB"EI** "G"DZTO04""HWJ3--84 1TE.-(:!B444M @HHI*
M"BBB@ HHHH *44E**!A2T4M "4444##&:0\4X=:7;F@0RC!J0)BEP*!$>#1S
M4N!1@4 ,'-' IVW%-84 9.GZ5+::SJ-Y(\;176-JCJ/K65;^%)K/Q EY#-']
MD20NL9)W#/:NJI34\J.E8FHF[/=6.:N]%U8:_<:EI]S;Q>:H7$@).,#VJ[/I
M,^IZ(;/5)D:X+;A+$.%/;BM:EHY4#Q$W;:ZZVUT.6;0M?FM!83:K#]DQM)"G
M<5]*Z'3[*+3;*&TASY<8QD]2>YI;N\@L81+</M0NJ XSR3@5.>#0HI!4K3G&
MSV\E;4Y_P]H%SI&K:M=SRQ.EY)O0)G(&2>?SK)G\':K"U[:Z9J<,.G7K[I(W
M4EESU KMJ*N[./V<;6.7U'P@)-*TV#3[@076G',,K#()ZG/XU)HGAV]MM8GU
MC5KN.YOI$V+Y:X51724478_9QO<*2B@TBQ****8!1110(!2T@I:0!1110 HI
M<TF:2@!P-+FFYHS0,?13 :=F@ HI,T9H 6BDS2YH 2ES2&DH 7-)FBDH ***
M*! :2E-)3 *,T4E !1110(**** "DHI<4 )11BEQ0 E%+M-+L.* &44NTTF*
M "BBC% !24M)0 4444 %%%% @I*6@T#$HHHH ****!"4444 %%%% #J,4F:<
M#0-"J*4T"BI+04M&*#0,*,4"EH 2BEI": %S124M !12$T T +0#244 +124
M4 +3A30*6@0M% H[4"%HI*6F #K3J04Z@0VANE*::U ##2444#"BBFNZQHSL
M<*H+$^PH 6BL&WU;6;V!;BUTF!H).8R\^"1ZXJ7[9X@_Z!%K_P"!-3S(W="2
MT;7WHV:*QOMGB#_H$6O_ ($TGVSQ!_T"+;_P)HYA>PEW7WHVJ4"L7[;X@_Z!
M%K_X$THO?$/;2+7_ ,":.8/82[K[T;.WFEQBL;[;XB_Z ]K_ .!-'VWQ%_T!
M[7_P)HYA^PEW7WHV:*QOMGB'_H#VO_@32_:_$7_0'M?_  *HYA>QEW7WHV>U
M1SSPVMN\]Q(L<2#+,W:LO[7XB_Z UK_X%5SWBZYU>6R@2^LX[:'>?]7+OW''
M>IE.RN:T<,YS46U]Z-B/QII#W'EDS*N<>8R?+_C71)(LD:NC!D895@>"*\]O
M;B.X^'EB!#;Q217[1_NU 9@$ZMW))-:/AJ[UM-%C6VL(KB ,P1Y)MIQZ8]*F
M,W>S.BMA(J'-#2S:U?ZG9!LFGXK!%[XB_P"@/:_^!5+]N\1?] >U_P# JM.8
MXO82[K[T;@HK#^W>(O\ H#VO_@51]N\1?] >U_\  JGS"]A+NOO1NTA&:P_M
MWB+_ * ]K_X%4OVWQ'_T!K7_ ,"J7,@]A+NOO1M8I"*QOMOB/_H#VO\ X%4?
M;O$7_0'M?_ JCF'[&7=?>C6QBE%8YO/$1_Y@UK_X%4?;/$7_ $!K7_P*HY@]
MC+NOO0SQ7_R"8O\ K[A_]"K;8_,?K7)>(+G69-.C%UIL$,?VB,ADGW$MNX&/
M>M-KSQ#N.='M>O\ S\TE+5FTJ+]G%777JO(V:4=:Q1>>(?\ H#VO_@32_;?$
M.?\ D#VO_@33YC'V,NZ^]&T>E-K':]\0_P#0'M?_  *IGVWQ!_T"+7_P)HY@
M]C+NOO1MTE8OVWQ!_P! BU_\":/MOB'_ *!%K_X$T^9#]C+NOO1M45B_;/$/
M_0(M?_ FE^V>(?\ H$6O_@31S(/8R[K[T;-%8WVSQ#_T"+7_ ,":/MGB'_H#
MVO\ X$T<R%["7=?>C8DD2&-I)&"(HRS$\ 5S[>--)%QY>9BN<>8$X_QK.\3W
M6LOI!6ZL8K> R#<T<V\GT!'I4D"S#X>WD5ZJQH(4:VDD:-E?YLX0#Y@_J36;
MF[V1UT\+!04JFMW;1_U?T.KAFBN84FA</&XRK+T-25Q'A6ZU>/3I4L[*.XA$
MG!DEV;3CD"MW[;XA_P"@/:_^!-5&=U<PJX5PFXIK3S1M45B_;?$/_0'M?_ F
MC[;XA_Z ]K_X$T^8S]A+NOO1M4E8WVWQ#_T![7_P)H^V^(/^@1:_^!-','L)
M=U]Z-G-+FL3[;X@_Z!%K_P"!-'VWQ!_T"+7_ ,":.8/8R[K[T;5&:Q?MOB#_
M *!%K_X$T?;?$'_0(M?_  )HY@]C+NOO1MYHS6)]M\0?] BU_P# FG6^JWR:
MC!::C8QV_P!H#>4\<N\$CG!HYD'L9=&OO1LYHHHJC$****!!1110 4E+2&@
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M)$?\F%1+9F^'_BQ_K?0VCUHIJG<JMZ@&G51@%%%% !1110 4444 )12XI,4
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M/[/U/_GC:_\ ?YO_ (FE^P:G_P \;7_O\W_Q- 77=?>1[:-M2?8-3_YY6O\
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M8Z;L'YOQH#E9MQLSPHSKL9E!9?0XY%.H[44BA*HZU_R!;O\ W/ZBK]9^M?\
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M !.D_P"O7_V<UMUB:G_R&4_Z]?\ V<U,MC>A\7R9%124M0=(4444 %(:6BF
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MM9FWL6Y>$DY.WL<^_2G07S6-[)9ZE>PE517CE<!&;)(.>Q(QVJ5H:2:DM/\
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M=F6Z3%5?[3L/^?VW_P"_@H_M.P_Y_;?_ +^"BZ'R2[,M8HJM_:=A_P _MO\
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M7N:%,95;[RJWU&:I'6]-_P"?I?\ OD_X4W^V]-_Y^E_[Y/\ A3NC/V4^S+^
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M44 %+FDHH 6C-)12&)1113$+1112 ****8!2TE+2&%%)13$+1244 +2TE I
M.HI*7- PHHS29H 6DHHH ***2@ H-%)3$%%%% "TE%% "T4E+2&.09-*Q[4B
M'!I&Y- " G-/7CK2# I"<T#)@0:Q-"_X_P#6_P#K]/\ Z"*V5&!6-H1_T_6O
M^OP_R%0]T;T_X<_E^9M&B@TF:HQ#%**** $-**** $-)3J2D,3%&*6EIB&XI
M0*7%%( -)2FFF@89HIM179(LIB#@[#S3&E=V)84NKP%K2W#Q9QYDC[%;Z<$F
MIOL&I_\ /O;_ /?\_P#Q-;D4:Q0QQH %50 !Z4^JY3F==WT1@?8-3_Y][?\
M[_G_ .)I/L&I_P#/"W_[_G_XFN@-)3Y4+V\NR_KYF#]@U/\ YX6__?\ /_Q-
M)]@U/_GA;_\ ?\__ !-;]0SW=M:KNN+B*(?[;@4N5![:3Z(QC8:G_P \+?\
M[_G_ .)H%AJ?_/"W_P"_Y_\ B:W@00"#D'I2T<H>WEV7]?,P/[/U/_GA;_\
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M5H"Q'25)MI-M 6&44[%)B@0E+24M, I:**0PHI:* "BBB@ HQ110 8HQ110
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MQJ<'FE/-.P<\NY7^PVO_ #R_\>;_ !IDMO80)OF543(&6<@9/0=:M5B^*O\
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MII#0 VBBB@D2BBBF 4444 %%%% !1110 4444 %%%% !1110 5D:&,WVL_\
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MZC)I]MJEG->Q_?MXYU:1?J <T<J%[>??\$5O[&N?^@A_Y '^-']C7'_00_\
M( _QJ5/$FAO=1VJZS8&XE=HTB%PNYF4X*@9Z@\53L_%5M<ZYXAT^X1;2+16B
M$MS+* CAUW9YQMQTZT<J#V\^_P""+']CW/\ T$!_WX'^- T:Y_Z"'_D ?XU8
ML]=TC4+.6\L]4LKBUB_UDT4ZLB?4YXJ.'Q+H-S:27<&M6$MM&P1YDN%*JQ.
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ML)+B[EM(()9@6E=&Q\O3)/I1RH/;R_I(M_V+<_\ 00_\@#_&D_L6Y_Z"'_D
M?XU:?6]*C6[9]2M%6S<)<DR@"%CT#^A^M5SXK\.K%/(VO:8$@8)*WVI,(Q['
MFGRH/;R_I(;_ &+<_P#00_\ ( _QH_L6X_Z"'_D ?XUI&\MA8M>B9&MA&9?-
M4[E* 9R".HQ7-:'X]LM<<NFE:K:6!B::/4;N );NB]3NSQ^-'*@]O+^DC2_L
M6X_Z"'_D ?XT?V+<?]!#_P @#_&H-'\;>'M;TPZA:ZI;K"K!9!+(%:,EMJAA
MGC<>GK5V7Q%H<%F]Y+K%@EK'*87F:X4()!U7.>OM1RH7MY?TD0_V+<?]!#_R
M /\ &C^Q;C_H(?\ D ?XU9NM>T>QL8KZ[U6R@M)O]7/).H1_H<\TRY\2:%90
M6\UUK-A#%<C,#R7"@2#U4YYHY4'MI?TD0_V+<?\ 00_\@#_&C^Q;C_H(?^0!
M_C6PCK(BNC!E89# Y!'K2T<J#VT_Z2,7^Q;C_H(?^0!_C1_8MQ_T$/\ R /\
M:V:*+(/;3_I(YR[M;G3]KRR+/ Q"F15VE">F1Z>])6IKG_(%NO\ ='\Q66?O
M'ZU.S-XRYHW8E%%% PHHHH **** "BBB@ HHHH ***44 &.:<!0*44BD+BEH
M%+2+$-)2T4 )1110 M%%% "T4E% !1110 444E $5&*4"G 4S,;BDIY%-(H
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M"O'!YH%9G*WVMWX74+F34'L[VU6 VU@ ,3%D4G*D9;+%EXZ8J9KO4R^HW_\
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M110 4E+10 E%%% @I*6DI@%%%% @HHHH$%%%% PHHHH *6DI:  ''2CJ:**
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MM[J]T3Y4,:#EF Y/TK4XCK:*Y.3Q)J/AK1H7\4QP7.I7%U]GM(-)1F-P2.
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ME3C  ]<UV0I*HP:N>.>*/"%WX1\%>,PEZUSI-\(9HC<2EYQ-O4,6.,'/KG/
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ML4?:K?\ Y^(O^^Q7/?9;;_GWB_[X%'V6W_Y]XO\ O@4<S'[&/=_@=#]JM_\
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M@04M)1VIB"BBEH ::8PJ0TTB@9 W%-S4C"HR*!"4444 %%%% !1110 4444
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_004a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'D \0# 2(  A$! Q$!_\0
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M/+XTA\0?:P%BCV>1Y?)^0K][/OGI6]L*$$BNB$&KW,)S3M8\Y^'*YO\ 7?\
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M_P!>E_X0UO\ G^7_ +]__7JO;0[D>PF<K@&CK75?\(<W_/\ +_W[_P#KT?\
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MV?\ &C_A#&_Y_E_[]?\ UZ/;4P]C/L<D5 IN?FQ77'P6W_/^/^_?_P!>F_\
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M1),[&:Z0!L'!P<\X/%.EUK2H$BDFU2QB29=T3/<HHD7U4D\CZ4@+M+4;3PK
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M7_=:N: ZUTOBW_6VO^ZW\ZYL5Z%#X$<=7XA0/2BEQ16QD7?%1_XJ:[_X!_Z
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M<?CBBX%K%&*KV5['?0&6-750Y7#C!X[U9H 0UPNO_P#(;N?J/Y"NZ-<+K_\
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MXR0L#['/S.,\] .3Z5!1THHKFKWQA9PW426RW%R@&]S!"'\T&WDG"(2XPVU
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MJ"?^^B!^M9C,^;27EMH;<31;$;>SO#NDW$Y+(VX;3R>QIRZ;,TUTUS<1R)<
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M8@(I*=330 4444 +0*2E%!2%-%+14C&FFTX]:::=Q"9]Z*2E%%Q"BG4@I32
M*6D%% PI,4M% #<4O>C%'2@!31115 +B@BES14C&D4E.--Q2&%*:*".*I":$
M-5[[_D'W/_7)OY58QTJO??\ 'A<_]<F_E3(9YD>5JM)$P.<5>4 8%(XR,8KU
MW&Z/)C*S.K\&+C1I0>OG'^0K8U+38=5T^2SG>9$<JPDA?8\;*P964]B" ?\
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M_!0(EKGK[5M2M/$/V=T*64@$=J?LV\3RF-FV[]PVG(_NG.*W/M-O_P _$/\
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MR<*"1@<]!45YHL=S--.GDQS2!1N,((('7=R"V?KQCZYNM>VJ(SM<PJJ@DL9
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MAN)[!XBMQ%%Y0D21-PRN3@@AAP>1BJ,_Q!\/V\LL;R7I,4CQLR6<C+N5BIY
MP>011=!9G4T=ZXU?B?X79PHGO=Q[&QE']*T8O&.G7"AH+/6)5/0QZ9,P_1:I
MII7:)4DW:YT)I#UK#/BFU'_,,UW_ ,%,_P#\32?\)5:Y_P"09KO_ (*9_P#X
MFE=#-RDK!B\76,\8DBL-;=#T9=*G(/;^[3_^$IM1_P PS7?_  4S_P#Q-%QF
M[2BL+_A*K3_H&Z[_ ."F?_XF@>*K3_H&Z[_X*9__ (FE=#-ZEK!_X2JT[:9K
MO_@IG_\ B:9%XPL)HQ)%8:W(A) 9=*G(X.#_  ^HHT&;YZ4VL0^*K0_\PW7?
M_!3/_P#$TG_"4VO_ $#-=_\ !3/_ /$T:"-LT#BL3_A*;0?\PS7?_!3/_P#$
MT?\ "4VO_0,UW_P4S_\ Q-&@K&Z*=7/1>+K&9 \5AK;IDC<NE3D9!P?X?4$5
M*/%5I_T#-=_\%,__ ,32'8W<48K#_P"$KM/^@9KW_@IG_P#B:7_A*K3_ *!F
MN_\ @IG_ /B:=T%C:Q28K&/BJT/_ ##-=_\ !3/_ /$U''XOL)DWQ6&MNN2N
M5TJ<C()!'W>Q!%(#>IIK$/BJT_Z!FN_^"F?_ .)I/^$JM/\ H&Z[_P""F?\
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M^A?TG_P!B_\ B:?/_P C/I__ %YW/_H<%:8HL%S)_P"$6\.?]"]I/_@#%_\
M$TH\*^'/^A>TG_P!B_\ B:UJ6BPS"N_#'A^.QN)(_#6E2.L3,J+91@L0. "%
MSD].*99Z3INF^*8#8:;:69DTZ7?]G@6,G]Y%UP!FMB__ .0==9F\@>2_[[_G
MG\I^;\.OX52/_(SVG.?^)=+SZ_O(JA_$:?8^?Z&KBDQ3J2K,Q*XO6Q_Q-[GZ
MC^0KM#7&:U_R%[C_ 'A_(5O07OF57X3+(]:M:1_R&;3_ *Z"H&&15G2%_P")
MQ:G_ *:"NN:]UF$7[R.YI11BEQ7FG659[""YO+*ZD#&6RD:2$AL %D*'([\,
M:QAX(T;%PD@NI8)(I8HX))R4MUD8,_E#JN2 0<Y&!C KHS24P,[2=&@TCSS'
M+<7$]S())[BYDWR2$ *,G X    '\S6!X'MH+C1M2\Z"*7_B<WP^= ?^6S5V
M ZBN4\ _\@;4O^PS??\ HYJEQ3T8TVM4:TWA[2ILDV<:$]3'\M9<W@32&8O
M'MY,Y#Q@*<_50#^M=/Q2U"HP6L=/2Z_)E.I)Z2U];/\ -')?\(_XBL<G3?$$
MC+VCN29%_P#'\D?G5F#5?$EB1_:6CQW:@\R6+$-C_<.1^HKI.U/0?./K0XSZ
M2?SL_P!$_P 1)Q_E^ZZ_S7X'/^&M3LSHUO ]PD4Z[MT4K!6&7)_'KVKH!R 1
MR#WK!TC3;/4O#5K'>6Z3+\^"PY7YVZ'J/PK/G\-:II,AN-#U">6'J;*:7!_X
M ^,?@P/UJ5[7R?X?G=#DZ?FOQ_R9UM(<US6FZ_>7$[6NP2W42[I+.Y7R+E1Z
M@<JX]QQ6M%K%JTHAGWVLQZ1W"[,_0]#^=#KQB^6HN5^?^>WXC5-R7-#WEY?Y
M;_@:"_>'UK+\/_\ ($A_ZZ3?^C7K47[PK+\/?\@2'_KI-_Z->MNIF:=)BEH/
MM3 *!U'UHI5^\*0&7H'_ "!X_P#KK/\ ^CGK4K,T#_D#I_UVG_\ 1SUI]*$
M\=*=48.*<#0 [N*R=!/_ !*3_P!?5S_Z/DK4S\PK(T(XTHC_ *>KG_T?)2&:
M6:,TW-**: <>E(>M+VI#UIDF9H?_ "#Y/^ORZ_\ 1\E:.:S=$_Y!TG_7Y=?^
MCY*T.E25<DS13<THI%7'"E[4VEQ3$%5[[_D'W/\ UR;^56<5#>C_ $"X_P"N
M;?RH \V;/Z5'C%7Y+?%5F3;QBO43.1QNCK?"?.F2_P#74_R%;U8/A/C39?\
MKL?Y"M_O7!4^-FT5:*%/2L.Z\,VUS%=[;JXAFGODU!)DVEH9E55&T$$$83!!
M!SN-;E)WJ"CE)? MJ\+JFJZA%-<1S0WLZ^7NNTE;>X;*X4Y) *@;0<"F>/(D
MA\,6$,:@1IJE@BKZ*)T %=;7*_$#_D7K3_L+6/\ Z4)2L-&U?:#I.H%OM6FV
MLI/&XQ@-_P!]#G]:R)/!-BA+6-[?6C?W?,$J?]\R _H174'[Q^M)BG;2S_3_
M ")MK=')G1O$-D0;:[M[I!V262U?^;H?R%']O:I8'_3H]2M5'WGN;43Q#_MI
M"<X]R*ZVG#VK-T:7\MO1M?EI^!?/4_FOZI/_ (/XG*?\)";^YTR6-[>[$=PQ
M_P!!G$A8^4XQM/*G!)Y]*W8=;LY7\LW)AE_YYS@QM_X]C-9>N:'IE_J6EF>S
MB,DEPZM*@V2$"*0CYEP>H!ZTDWA_4H(3'9:O]IA XMM5B%POTWC##\<U/LFO
M@G\I+]5_D5[5?;A\XO\ 1_YG1[FQG<?SI"[_ -YOSKC6NKK1\F]L[W2TZF>T
M?[5:_BN-RC\*U[36I)+<7!6&]M3TNK!MX'U7J/UI.<Z?\6-EW6J^]?JAQ4)N
MU.5WV>C^Y_HS:WM_?;\ZS+MF_P"$@TKYC_J[CO[)5RVN[>\B\RVE25.Y4]/K
MZ53N_P#D/Z5_USN/Y)6BE&2O'8AIIV9J!FQ]YOSI-[_WV_.@=*:*IH2';W_O
M-^=&]_[S?G28HQ2&9\C-_P )+:G<<_8IN_\ TTBK1WO_ 'F_.LZ0?\5+:_\
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M5OD_K^%6\5-]31K1#<44[%!%-,EHRYQ_Q5&G_P#7E<_^AP5J5F3_ /(T:?\
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M_(2T?_KZ?_T1)6C0 4X'FFTHH&AXK.O/^1ATK_KG<?R2M &LZ[/_ !4.E?\
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M.?W4O3FMVL[5/^/K1_\ K_'_ *)EH$2_VBW_ $#[_P#[]#_XJC^T#_T#[_\
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M8X_"N<^(!)\/V?\ V%K#_P!*$I6'U-YKG4-Q_P"):G7_ )^A_P#$TGVG4/\
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MT6NI_"S!?$CK*2EI*XSI"BCK7'ZAXV>UNM5%O9+-:VEKO@E9ROGS>;Y1 /9
MQ W=<AL< 9>P'8#J*Y3P!_R!M3_[#-]_Z.:M/0]2OKF^U'3M3BMEO;%X]SVI
M;RY$D7<I ;D$88$<],]\5A^!M0LK;2M3CGO;:&0:S?'9),JG'G-V)I-@=I1T
MJE_:^E_]!.R_\"4_QI?[7TO_ *"=E_X$I_C1<9;-"_>'UJF=7TO_ *"=E_X$
MI_C0NKZ7N'_$SLNO_/RG^- %;P[SH%I_P/\ ]#:M/I6#X?U33DT*V5M1LU8;
M\@W"#^-O>M+^UM,_Z"=C_P"!*?XT("Y2XJE_:VF?]!.R_P# E/\ &E_M?3/^
M@G8_^!*?XT[B+J_>'UK+\/\ _($A_P"NDW_HUZL#5]+W#_B9V/7_ )^4_P :
MS- U735T:)6U&S4B2;@W"#_EJ_O1U WLT9JE_:^F?]!*Q_\  E/\:/[7TS_H
M)V/_ ($I_C3N*Q>S5#5()'A2YMQFYM6\V,?WA_$OXC-.&KZ9_P!!.Q_\"4_Q
MI1J^EY&=3LO_  (3_&LJL%4@XLN$G&297\-N)-!@D (#O*X!&#@RN1_.M:N1
MTJ33C8?:+?6X+6Z:6;=_I"%7_>MC<I/ICIBK\?B6"W=8KZ>S?<<+-:3!U/U7
M.X?K6*KN&E56\^G_  /G]YHZ:D[TW\NO_!^1O]Z*I#6-,('_ !,K,<9P9U!_
M4T?VQI?_ $$[+_P)3_&NE2C)73,FFG9EP=167H/_ ""C_P!?-S_Z/DJP-7TO
M/_(3LO\ P(3_ !K,T/5=-72R&U&S4_:;DX-P@ZSN1WH W<THJC_:VF?]!.R_
M\"4_QI1J^F?]!.Q_\"4_QIZ"- &C-4?[8TO_ *"=E_X$I_C1_;&F?]!.Q_\
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M>WY'0[1Z4[ ]!56SU"UO@?L\H9U^]&>'7Z@\BK5;PG&:YHNZ,9)Q=F(0/2C
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MUW96@U[2P+2WP8[C(\I>>$]JV*SKO_D/Z5_USN/Y)28RX+&SQ_QYVW_?E?\
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M (4TV%G_ ,^=O_WY7_"K.::::$RO]@LO^?.W_P"_*_X4?8+/_GTM_P#ORO\
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MVW#:CD\!"1EL\8!^E<-);Z/;V<2ZK/97.FO87[V:VQ+VT-RTH/E0\??52 O
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MYY6'_?U__B:S[MM4_MO2\QV.[;/M_>/C[JYS\M%QF]3A5#=JW_/*P_[^R?\
MQ-*&U;_GE8?]_9/_ (FG<1?%.K/#:M_SRT__ +^R?_$T[=JW_/+3_P#OZ_\
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M5_5:TOLEW_T%)_\ OS%_\32 NTT]ZJ?9+O\ Z"D__?F+_P")IIM+O_H*3_\
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MRPXK'O1_Q/M*_P!VX_\ 05H&C0I0:2EQ5 *#3LTSI1F@#/G/_%4:?_UY7/\
MZ'!6EUK+G/\ Q4^G_P#7E<_^AP5K(.,U+=AI";,TA3%24'FHYAV(0>:S9/\
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M(?[,N1M7RY%S_J_5A^==7N8'DG\ZY[Q1?ZW;/91Z3#=LC"5[B6VMXYF15 P
M'91R3ZY^7@4 /_X3'1?[]_\ ^"NZ_P#C='_"8Z+_ ,]+_P#\%=U_\;K5TV\3
M4-*L[V"<SPW$"2I+MV[PR@AL=LYSCM5OGU/YTK@<Z?&&B_\ /2__ /!7=?\
MQNC_ (3#1?\ GI??^"NZ_P#C==%SZG\Z82?4TTP.3O?%.E2WVF2(;]DAN&>0
M_P!F7/R@Q2*#_J_5A5Y?&.B@_P"LO_\ P5W7_P ;K+F\0ZY%'K$,QLXKJ/5+
M2PMFB#.D23^4-[9P6(WDXX&<#I6QX>O[ZY_M2TOYUGGT^^:V\]4V>:OEQR*2
MHX#8DP<<<9XSBF(4>--$_OZA_P""NZ_^-TO_  FFB_WM0_\ !7=?_&ZV1(P[
MG\Z7S6]319B,1O&FBX^_J'_@KNO_ (W6;=>*M*DU>PG4WYCB68.W]F7/&X #
M_EG[&NL+L>I./K7*W.L:_%=>)[=(()9K.QBFTV&W!=F9_-"[LXR<HO X]Z +
M7_"8:+WDO_\ P5W7_P ;IW_"8Z+_ '[_ /\ !7=?_&Z=X;U*YNX[VWOI[EKZ
MUF"RQW%ND+H&4%>$9E8$9((/J.U;F6QU/YTU<# /C#1?^>E__P""NZ_^-TG_
M  F&B_\ /2__ /!7=?\ QNN@RWJ?SHW'/).*-0.2E\4Z4VO6=ROV\PQVL\;/
M_9ESPS-$5'^KSR%;\JTAXRT4#&_4/_!7=?\ QNN=O?$_B#39]1/VFSO&AMYF
MEABA)BL)2ZK K2#[[$-EE.#QG@8ST^@WFHC4]6TK4;I;N2R:)DN5B$9=9%)P
M5'&05/([$5+U*(O^$RT7^_J'_@KNO_C='_"9Z+_?U#_P5W7_ ,;KHMS>IJ*1
MF'<U/*%SGSXQT4M_K+__ ,%=U_\ &ZCL]6M-6\2H]G]I*1V,BLTMG-" 3)&0
M,NHR>#P/2M/59KR/2[A[*:WAG '[ZY/[N)<C<Y]=J[C@X!( )%<A_;GB>YL(
MC9K=7D!NY@E_;V,>^>V2-2KA'95&79@"/O!,@<U0CNJ*J:7>1:AI-G>P3^?%
M/ DJ2E-F\%0<[>WT[5=5,TP&UY_XAF=/$5RJ\GY>/P%>C;!7$Z]: ZG<S <Y
M _05O05YF56?+&YEPD%1YN![5H:4Z_VQ:+'C'F5STTTF\JW&*O>'IF;7[)<Y
M!?\ H:ZYVY68QJ7:/2V.*;NIS'@4VO.L=5PP#2X]Z,BC-,0=",UQGAUM8T&U
MO[2;PYJ$_F:E=7"2036^UDDD+*?FE!Z'N*W/%6H7.E^$-9U"S(6YMK.66)BN
M[:P4D''?'7\*J:#YEIXDUC21J-U?6D%M:7$;W,OFNKR>:&&[T(C5L=MQQ@8I
M/<9/_;>I9_Y%75O^_MK_ /'J=_;>I?\ 0J:O_P!_;7_X]6WM%.Q3$8/]MZE_
MT*FK?]_;7_X]2C7-2!!_X135^O\ SUM?_CU;>*AN9Q:VD]PQ0"*-I,R,%48&
M>3V'O2 YW2M0U6QTR"VE\*ZJ73=DK-:XY8G_ )[>]7O[<U+_ *%/5_\ O[:_
M_'JRO!LU_;7+:7J\DT]^;&"Z,_\ :!NHY 25)&578=P/ R".AXKL.U!1B_VY
MJ7_0IZO_ -_K7_X]1_;NI?\ 0IZO_P!_K7_X]6WFC-*S&8HUW4L@_P#")ZO_
M -_K7_X]5'2M1U:QTZ.WE\*:J75Y&)6:UQ\SLP_Y;>AJ;QC)J%OIMI<V.H-:
MI'?6JSHL8)F5[B--N[^$88YQUSBL6[U"^&M7=^NI7*R6_B"WTV.R$G[HP.L6
MX%.['S&?=U&!@X%(#H/[<U+_ *%35_\ O[:__'J3^W-2_P"A4U?_ +^VO_QZ
MMLTF:H1A_P!MZEG_ )%35O\ O[:__'J<-<U($?\ %*:O_P!_;7_X]6U6%XR>
M_A\'ZM<:=?M8W$%K+,)EC#MA4)P,]#[]J&!5TS4M5LK!()/"VJEP\C966UQ\
MTC,/^6WH15W^W-2_Z%35_P#O[:__ !ZL#Q%?7]K?2:EY[OIFG65O+<06^IF"
M4%F8LQC"G?E0,!BN<$#FN[QS0@N89US4O^A4U?\ [_6O_P >I/[<U+_H5-6_
M[^VO_P >K<-)0!BC7-2!_P"14U?_ +^VO_QZJ>F:CJUE9>3)X5U4MYTTF5FM
M<8>5G'_+;T85=\32K%ID;2:C<641N$$GV5"T\X.<11[?F#,<<CG /3J..N)M
M=CM+NWU#5KZQFT_19]1@ G7S-WFR>7YS#B0HBQAARI+'.>#4C.P_MS4O^A4U
M?_O[:_\ QZC^W-2_Z%35_P#O[:__ !ZM2QE>XT^UGE7;)+"CNOH2H)'YU/30
M&+_;FI8Q_P (GJ__ ']M?_CU']N:E_T*FK_]_;7_ ./5N#D5R'B\W\MXMMIF
MI7JZB]J3965F=@63=_KYVZ>6.!M;@_, &)&&Q&UH*7":7FZM9+65[B>0PR,K
M,H>5V&2I(Z,.AK5'>N'AO=0MO%2W-],T]E=:DUC;_9M1)2)A%]UX N.J.3\Q
M()'&*[@4@'XS36I<^](2* &$4#I030.E4(6JM\/] N?^N;?RJU5:^_X\+C_K
MDW\J!'GBJ%'2GJ26VK0L;, 6^44I<+PE>N>>=9X87;I\H)S^]/\ (5MYXK"\
M+9.G2_\ 77^@K=%>74^-G=#X4(.M%. H-061XYKG/'%G=7GA^%;.UEN98M0M
M9S%$ 6*),K-C)'8&NFQ7+^(I[^76X].M-3GTZ--,N+TRP*A+NC(J@[U(VC<2
M1QG(YI,9:/B1R2?^$=U_K_SZK_\ %T?\)))_T+NO?^ B_P#Q=7M$NY=2T#3;
MZ9566YM(IG"C #,@)Q^)J_B@1A?\)(__ $+VO?\ @(O_ ,72CQ+)_P!"[K__
M ("K_P#%UN8I5'- CEKS6[B:\T^5/#NN[;>=I'S:KT,;KQ\_JPJU_P )(_\
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MJ2&V^490*6 )W#.W!)!JGH2=/_PDC_\ 0N:__P" J_\ Q='_  D<G_0NZ_\
M^ J__%TOANXNG.K6=U=279L+]K>.XE"AW38C@-M !(+D9QV]:W,TP,+_ (22
M3_H7-?\ _ 5/_BZ/^$DD_P"A=U__ ,!%_P#BZW,^]9/B*9X-*$BZF=.C\Y!+
M/''OE*$_<C&#EV. .">N!G% #-(N9K[6KZZ?3KZSB-O#&OVN,(6*M(3C!/\
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M6Y@$$UW;1S/&O0%@#QR>#U&3G!YYK7;BF!!:VD%E:0VMM$L5O!&L<4:]%4#
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M9VNE2POYLI5417=RKY9MHQC.0<@47 [NDKC-9\:7%K#+]ELS;W5NEU]HM[Q
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M*R6\2Z(MDEXVJVJV[NT:NSXRZC)3'7<!_#UIVE^(-.UB\O+6QG:66T?9("A
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ML*G""@!M)FD6>VD<)'<1,Y+ *K@G*G#<>Q(!]":?M.:!BIT-(WWJ51C.:1V
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MB ,DB("P4%V R2< #/<GH*<* '#K3>YI5ZFD_B-  >E)37D1&16D56D;:@+
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M0GSX5\' 4DKD#GBQX>\-RZ<!'?I!(C:-9:=)M.=QB602#I]T[QCUK1D\3Z)
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M8VMT*R/_ 'F&.3[GFE9A<P[K5M5L? @U"Y-NFHJL:RRKAXX]T@0RG!Q@*=Y
M.!@]JP?$4UW/::EH[ZS+=P6]UI;BY$<._,MRJM&^$VG 57''\0SD=>_6&&*
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M#@\T?VIK(:34&U(&W37O[/%H+= K0F<1<MC=N&[(((' R#R:Z8VFF7E\M_\
M9K.XNX"8EN1&CR1D$@J'Z@@YX[5-]EMMA3[-#L,OG%?+&#)G=N_WL\YZYYH
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ME6>..5S%,J $!""H!^[QG(R>.=G2_$4^H_9(+.QFNMMM;2W=Q+*D?EF5 P&
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M(P4@%6WC'0@C&3G(M-X=6:75K>X8BTNKR/4+::%]LL$X502.,<,@8'G.\@C
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MU&V:>8+?W:7<A&,JR>5@#CI^Y'YFIM6TF/4WMIQ<36EW:NSV]S!M+)N&&!#
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ME\BO>SVE@;@H/)9N(U!QE]HZ=ZV3KEM:>$9-;^TMJ-O;V[S-+&@1I=N=PV\
M-D$8XP1@T0:+-8Z)8:9I^JW-H+*)8A*L<;F10,?,&4CMGC%#>';4^&+C01-/
MY%Q'*DDS$&1FD8L[DXQDLQ/3'M0!0NO&$MF]^D_A_4%>PMQ>7 \V'Y;<[OG'
MS<M\C_)_LGGIFQ<>*X;9[MUL+J:PLY4BN[U"@6)F"G[I.Y@H=2Q XSWP:M7^
M@P:A-JTDDTJG4[ 6$H7'R(/,^9??]Z>O' JM/X4M[AKE!?7<=E=NDEW9ILV3
MNH49)*[E#!%# $9QVR<FH#4\4JUV4.EWBVBZ@=.:[W1[1+OV A<[BI) SC@G
MIP:RT\4:M<P:/<G3'B,^JS6A@@E1C.J+<* 2?NX:-23GL2/2M[^P(#:F#SY=
MIU(:EGC._P T2[>GW<C'KBH[7PS';36["]N'@MKV2]@A=4Q&T@E#KD#)4F9C
MSR, >M%F!3?QC$B0(=.F6[EN);9H)IXHU22/&5\PMM).X%0.2,],''2IN9 2
MA0D E6QD'TXXK%NO# N+6\MH]1GBAO;B6>XC,$4JOO !&'4XQMX/N<YK2T_3
MO[.C,*75Q+ $CCBCE(/E*B!< XR<XR22>::$6N!UH!H*TF*8#C29Q2J.M-H%
M87@^QII7'O0:0$BI*%R1WIP;/O2##=N:<!BFA7%XQZ4X#(--I1Z46'<7@=Z;
MD4M)Q3"X9]A7$:_=/%J]RH) R.@]A7;Y KSWQ)*QUZY0+P"#G\!71AW:?R.;
M$+W#/>YFF;@OCZUI:%#)_;%HS= XXJA'+Y8^Z/J:O:-=-)K=FO\ "9/Z&NVI
M\#.*'QH]"'>FFA3UIIKRCU10>>!5>RU"&^N+^"(.'L9Q!-N&!N*(_'J,.O-8
M_BRVFNM/L@+:6ZM([Z*2^MHEW-+ -V1M'WQNV$KSD C!Z5R<FC7GV>\-II5Q
M;Z2^N_:'M)+)I=]O]D15;R-P+()!]SM@?+\N!+8SU$*>E.V^U>?Z;X8BNKO3
M8=0M)[[3X]/O-HO+5HD1GG1D3RV)V[5W! >0!QC%4HO#^K0:!IC:;:W-OJ]U
MX>G2^F)*227.("HE<_\ +3_6A2QR.>1BE<5CTMA[5&0?2O.K[2&NH-070M&O
MM.TV6WMHY+?R&MVDF%PA+*G7<J;MSCKQR<5:U;P[;P7NJV\%E<6VEL;.>**T
MLC/ \P,P??"OWU($>X#G[IZ\T7"QVAFB6Y%N9$$S(9!&6^8J" 6QZ9(&?>GX
M/I7!6>F?\3/2[^[\,I YTV>VB\BRR()1+F,XY,6Y<L,GY=Q7.>J1Z0--\,>'
M[/\ L"*<3PH^HR7%BUXZS+$H&^,$%B267<QPN,>E!1W1FB%R+8R()RAD$6?F
MV@X)QZ9(&:EP?0^E><:/HM[;OI$]WI4@U(Z+):PW4EMYAMKE7.S>WS%,*>&)
MQ@8SZU++0=171;GR(+^*\^QQ17EK'8-;?:<2HTN92Y$LI02*&!YWGGI0!Z-'
MJ$$FK7&FJ'^T6\$4[DCY=LA<+@]SF-L_A4&C:W::ZM\UD)@+*\ELI?,0+^\C
MQNQR<CD<UC>&K*&#Q3J]S8:1/IVFS6EJD*R6Y@5F5IMVU#]W&Y<C Y.<<Y/#
MCPE?PRW.L1:9J":LOC%I8I%\P$6;.-S!1QL()R<<T >LV%_#J4<[P).JPSO
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M#$ 9( SV0'L&CZI;ZWH]IJMGY@M[N(2QB0;6VGU )P?QJ_R>"N:\WN]*U/\
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MJ.O 'XU8HH **** "CITHHH 7=G[PS[T]>^#VZ&HZ* '$.>X_.DVGU'YTE%
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MI:Y$>,Y#_P N2?\ ?9IQ\8R ?\>:?]]FJ]C/L3[>'<ZND-<D?&D@_P"7)/\
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MMTVN,_X3N15^>QC+=R'(%,_X3U_^@>O_ '\/^%<#A);G<IQ9VU%<3_PGS_\
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M?_6H_P"$^?\ Z!Z_]_/_ *U')(.9';45Q/\ PGK_ /0/7_OY_P#6H_X3U_\
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M:**!!FBBB@ HHHH&%%%% !1110 4444 %%%% !1110 4444 !ZT444 %%%%
M!4D;'%%%5'<F1(#Q2 X-%%:F(_M]:9BBBF) #CBIXQWHHIQW%(G7I0WW:**T
MZ&2*4HYI%-%%9=3;H/'.:4?>HHJUN0/4#=4ZL<4452)D(S$9JKDEC]:**F0T
M.S1U%%%"&.7I3T )HHIH3)/2H9#BBBFR5N5R,"CK1161L,8 TL9(XHHJ>I70
MLQ'YA5KJ***WCL82*UP.":IT45E/<TAL':@>E%%0:CU)#8%64^\M%%:(RF6@
@>*@G^Z3116KV,H[E4GBJ[N2:**YIG3 <O2BBBD,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_004c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004c.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .W!9$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[X0U:ZUWPU;7MXBK.VY92G <KP&'L>M+H5K<WJ*0=*7%0;!11BC% !11BC%
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M>E-AE!_A]*RY_!WA^[O)[F;3D,]S_K,'\3Q6[@<\=:*.9ARH;%&D$:QQ+L1
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M%+113*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU);_ /'Q']:BZ]0:DM_^/B/C^*J5^9$3:Y6;-+3>AIU=IP!1110!$[;%))Z
MG K@)O'&GQSR1^3+E&*FN_E_U3_[I_E7@=W_ ,?MQ_UU;^=>?CZDH)6ZGM9+
M@Z>(E+GZ6.Z_X3O3_P#GC+^5'_"=:?\ \\9?RK@**\QXF:1[[RG"K9,[[_A.
MM/\ ^>,M+_PG6G_\\9?RKSZBF\140?V3ANS/0?\ A.M/_P">,OY4?\)UI_\
MSQE_*O/Q2T?69]Q_V1A^QW__  G6G_\ /&7\J/\ A.M/_P">,OY5P%%'UF9*
MRG#/HSO_ /A.M/\ ^>,OY4?\)UI__/&7\JX"BCZS+N/^R<-:]F=__P )UI__
M #QE_*C_ (3K3_\ GC+^5>?_ (4M)XJ:&\GPR>IW_P#PG6G_ //&7\J/^$ZT
M_P#YXR_E7GQZT4_K,Q?V3A?,]!_X3K3_ /GC+^5'_"=:?_SQE_*O/J=2^LS!
MY3ANQW__  G6G_\ /&7\J/\ A.M/_P">,OY5P%%'UF8?V1ANQW__  G6G_\
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M #QE_*C_ (3K3_\ GC+^5<!1^%'UF8_['P_8[_\ X3K3_P#GC+^5'_"=:?\
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M /GC+^5'_"=:?_SQEKS\]*2F\3/H']D89;IGH/\ PG6G_P#/&7\J/^$ZT_\
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M?UN6Z>@?V3AKV/0?^$ZT_P#YXR_E1_PG6G_\\9?RKSZBG]9G</[(PSV/0?\
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MK^)->3_:KZ>XV[?-<MM],U$**6N=N[N=\8\J4>P4444AA6EH6J_V/J0N&7?
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M]XGCBM7ATKMOL81Q]2=FH;WZ]CG?#NGP:EJIM[@%H_+8A0<'(%9DBA)G4!U
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MI %%%% !1110 4<444 )Q2T44 )Q2T44P"DXI:* :N%%%%%[C"BBBD(****
M&L0,$]*Z6'3-(TO2[:\UHR3278W1PQ' "^M<V1NX]N3[5TMIK.G3Z?!8^(+!
MV6$8@F7@A:Z*%M;G!CN?E7+>U];;_(IZWI^G16MO?:1(SPS':8B?F0^N*I:E
MILNF30Q2D,94#@CC K5U"PMM-AMM9T6Z::V:38/-'*-]*M^+[ZYFU"QLW421
MNB.8T49<]QFM9TDXMK38YJ.)J+DC%WCKOOIW.3[;@&*>OH*.<XZ\] <X':O1
MK2"YN;HVUW'8P630D?9%P9!QU/K6'H4J6&@:S<^1'*T,F(]R@]^*/JJYM7I8
MN.92E%V6JM^+,&#3;BXTZZO0"L-N!ORIR3["J?.!@=?6NRTWQ!?W/AC5;B1H
M!-$5V%4 &#ZUR4$?VJ]C1C@SR!6/;\*QJPC[L8/H;86O4J<_M%I%D7."RAB!
MU)'%:.A:>NJZQ!:2%A$P)D*]0!6YJFMG1M:CTRUMX/LD&Q) 4!:0GKFK]D#H
M_CDVEJ%6UN8C,5*Y*G&>#6].@O:*_<YJN/J2HO2S:;7H<CJ_]GK?R+IL$D,2
M$J5D/.1WK>L?#5G?^$1>(&_M @E<'[V*Y[4[V>^OY9Y]OF!V5=HQD9[UT45^
M^E>%M#NT8C9<D$#H5/45-!0E.;:T16(]K"C347[UU^39D:%IT%^;_P"TKS#;
MEUP>C"KNCV6C+X;DU/58)92)_* C/(]*V8[".SU35I[<?Z)>632QD=,]Q6?H
MQT]? \IU196MS=8_=<D'M6T:48*[7?\ ,Y:N*G5BY)NUX[;[:HR=6FT)[53I
MEK-%.&P2QR,5>CTK2-'LXIM=$LUQ.-RP1=%6J-^^AO+;_P!EQ3H_FJ9/-'&W
M-6_&V[_A(Q\ORB%=@'IBL=()MJ_Y'0N:<H48<T4[O5ZD>K:38C3%U;2I':S)
MV2(_6-JET;PK_:%@]W=7(B4H6BC3EFQW-2Z-@>!]:\SE=ZXST!]JC\'/(VIS
M(TCL5M6 R>@JHQIRJ6:W5Q2E6C1J)2^![]>A0T;25U&2XEN)?)L[?)DD'I[5
M)JNCVUKI\.I:?=-<V3G:6888'WJW8C9X%U8KU^U 'Z9I+(;O %[D?+]J3J,=
M^:7)%QY4MU<;KU7/G4M$U&WZA:^'K!;:U.I:@UO<W8S#&!P!VS6/J%C+INHS
M6<OWHSU]16QXR 76K, 97[-%MQ1XV &MQGCS&MX]V/7%*O&*4DE\+L7A:U64
MXN4KJ:;]+'.@TM!QGBBN,]0****!A1113N G%+112 **** L%%%% "<4<4M%
M-:"LF)Q1Q2T4#$XHP*6B@+(3BC I:*!604444AA1110 4G%+10,3BEHHIB$X
MHXI:* $XHXI:* L%%%%(+"48%+10%A,"EHHH!Z[B<4<4M%,'KN)Q1Q2T47!I
M,3BCBEHH"R"BBBD 4444 '6MS2=)LCI;:QJTC):!ML<:]7-83#<I'M72:V2?
M"&B,AQ"6;=CUK>C%6E-]#BQDFW"DG;F>XY]+T75[*YFT4317-L-[P2?Q+ZUS
M'/H3VSBNC\$AO^$B;Y?E^SMO)]/>K>C7*67A?5;KR8WD2Y(0NH.TYX_"M?9Q
MJQ4MKI_@<RKSPTIT_BVM?S.1) ?9T[?-P3]*.#@J"1T/?'U-=5J,O]N>$K;4
M)XXH[H7(@WQ* "":LZIJ?]A:Q;Z5:VL)ME1!,KIRY/>I6'BKJ_8T6-DXI*'O
M:W5_Y=_S.-9L=>.F"1@G\*#G(RI //*D9]A7=3:?;3>/+J66%&AMK42A,>U4
MM*U9_$=Q<6%];PF&2(M#M3!3'2CZOJU]WR)68.RDH>ZDF_*YSRMIPT=U=7.H
M;QA@/D4>A-4Q][!1L^BC)_\ U5T"1HG@*_!X=+K!.!VK1U+5GTG1M':UMX&G
MDCRSNH.1Z53HIZ^29/UN46U%7U:W\CC>@P?O8[T[GY1M;)/3')^E=I<Z9:WG
MB_3SY2K'+!Y[Q@8!;%&AZZVHZ_-:S6T!@VN(@J#*8I?5K()9E)QO&/2[.*X/
M/..P)YHXI\@(GE###!B/UIM<KC9GIQ?-:3[!11106(>E:?AS_D9M._Z["LP]
M*T_#G_(S:=_UV%71_BQ.;&?P)^C/<:?3*?7TY^=H**** (I?]4_^Z?Y5X'=_
M\?MQ_P!=6_G7ODO^J?\ W3_*O [O_C]N/^NK?SKR\RVB?2<._%/Y$6*,445Y
M!]2&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444#"M7PW<"UU^$2
M'"3 Q,3VR*RJ0,0V5)'?/<$54)<LN8QK04X.#ZFYI=S;Z-=:O#<%E+HT* #M
MGBH=(U"WL]%U*WD8K).H$84=?K6227)9F+L>2QZFDQ6GMI?H8+!P:N]W;\#9
MLM0M8/"-]I\C,+B612H'0UIWLMC?:?ILVM+<V\Z($0HF1,!T&>U<GMS6O:>(
M]0M+-+9#%-!%POF+N(_&M:=96M+M8PQ&#G\5'>[?WJQT/B"]MK#6/-&Y95L!
M'"G]TL.]8&@:I;V"W=G>@FUNEV.RC)![&LV[NY[ZY:XN'WR-UYZ>U05%3$\U
M3F15'!15+V=3>R_ Z>"^T/3=#U"QM)YY9)TXE=?TQ3?M^BZCH]C#J#S12V0Q
MY2#*2#_&N:X]*7:*:Q+[#>70>\G>][_@;6OZK#>:Y;7]@7 0($##H1VK5\=7
MJ.UK:(H3<!/< ?WB.]<E&YBG24?,4((7MFIKV^GO[M[FX(:1NPZ!:7MVU)=Q
M_4DJM.VT4:;-]D\%JG22[N-V/516(1P*-[$*OF,P3[JGH ?2EK.<^:WD=%"C
M[+F3ZL*,445F;ABC%%% &LNH6X\(MI^X_:/M D ]JT_"GB.WTVRFLKYF$1RT
M# 9*'N*Y3 '-&<ULJ\D[I''5P<*L'"_Q.[[W\C>T;4[%+&^TR_:2.WNG++*@
MR5/O4VHZCI \)_V1I\DA=)MQ9U^_[US8]^:./2FJ[<>6W2P2P4'54[O>_E>V
MYM:_J-O?6^EK;N2;>'8ZD<#FEUS4K:]U6PN(&8QPHBOE>F,5B\4GTI>UD[M_
MU8<<)2CRQ71/\=SK5UZP3QH^I%V-L8=OW>IQ45IJ.AZ5<7.HVDD\ES*K".%E
MX0GOFN7XI>/2J>)E>]NK?WF;RZF]$WLE\D;MGJ%E=Z-_9FHR26[1.9(YHL\Y
M/>B?4--CU#3A9B4PVI!DF?[TE8.,T8QQ2>)ERVMV_ J. IJ3=^^GJ:&LW,=[
MK-U<0L6B<Y4FI]"U.#3Y)X;I&:VNEVR;>U9(H/2H51J;DNILZ$94O9/8Z/[=
MI&C:==Q:9+-/<W(V>8Z\(OI5(W]N?":V&YC<+<;AQQCUK(Q15.LV91P4(];N
M]_N%QU]>^*7%(*6LCL>]PQ1BBBD 8HQ110 8HQ110 8HQ110 8HQ110 8HQ1
M10 8HQ110 8HQ110 8HQ110 8HQ110 C+N4@D@8[>M=0NI:'J^E6L&L>;;W-
MNNT/"O!KER:3&36M.JJ=]+W,*^'5:VMFMFC;U?4['[!;:7IB/]DB;<\C_><U
M;U'5M.FNM.U.%Y)+JW54> C"X'<&N:SGCBC[O/%-XB6NG;\#%X&'*E&6U_G?
M>YV-OJOAZVU^35EFN'FF4Y5E.(R1VK&MM1MXM"U6T9V,EQ-O0#N,UCX'7UI,
M"J>(DU]_XDT\#"#W;>GX;&YH=[8QZ7?Z=?R/$DZJ0Z+GFL<-Y,X>(D^6VY"?
M:HZ=6?/HE;8WIT%!R=_BW.IGO?#^I7<.J7<LT5R@!>%$R'(JM;:[%/XN_M6Z
MS'"5*HH[#&!FN>(&<FDR#5NO-V,5@()--MW5EY+R'RD-<2LAR"Y9=W;)K4NK
MZ"7PO9:>CMYL4C,P[5D45G&;BFNYTNC&?+?I_P ,=9HWB2V@\.7.GW9(F"%(
M#C(P>V:KZ1>:0?"\NF:E<2Q,9]X,:US>,BEQ["MOK,K+38X_[/IN#LVKN_W&
MKJ5OH<5H#IMW-)/N'#KC'O6D=4T;7+*!-8\ZWNX!M\V+^(5S'X"DQFIC6M?3
M1FLL&I12E)W6SZF_J^K6/]EII&DQNMH&WRNXP9#4/AS4+?3[ZXEN"P$D!3CU
M-8U%)UIN7,BE@Z:I.EWW?5FUH>IVUJEW87X8V5U_$O53G@T_5M1L%TJ+1]*,
MA@W;Y99.KGTK"HQ0Z\G#E)>!I.?/KZ=+]SJ8M3T748+.;5/.6[LU"80?+*!T
MS6)JVH-JNIS7K+M#<(OHHZ51I1THJ5G-695'!TZ4^>-_\@QTI<445B=5@Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
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M6B@!.**6B@!.*6BB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@
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M^J?_ '3_ "KP.[_X_;C_ *ZM_.O+S+:)])P[\4_D14445Y!]2%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^?R6C_A75E_S^2UV= ZXH^KTNL0_M+%?SLXS_A75E_S^2T?\*ZL_^?R6NS.
M0#P3TH]P.*/J]+I$/[2Q7\[.,_X5U9_\_DM'_"NK/_G\EKLZ*/JU/^4/[2Q7
M\[.,_P"%=6?_ #^2T?\ "NK/_G\EKLZ*?U:G_*']I8K^=G&?\*ZL_P#G\EH_
MX5U9_P#/Y+79T4?5J?\ *']I8K^=G&?\*ZL_^?R6C_A75G_S^2UV=%'U:G_*
M']I8K^=G&?\ "NK/_G\EH_X5U9_\_DM=G11]6I_RA_:6*_G9QG_"NK/_ )_)
M:/\ A75G_P _DM=G11]7I_RA_:6*_G9QG_"NK/\ Y_):/^%=6?\ S^2UV>,]
MOQH^G4=12^KT?Y0_M/%?SLXS_A75G_S^2T?\*ZL_^?R6NSXVD_SXHXQD\'TH
M^KT>U@_M/%?SLXO_ (5U9_\ /Y+2_P#"NK/_ )_):[/C(ST/:CT_6CZO1[!_
M:>*_G9QG_"NK/_G\EH_X5U9_\_DM=G11]6I_RA_:6*_G9QG_  KJS_Y_):/^
M%=6?_/Y+79T4?5J?\H?VEBOYV<9_PKJS_P"?R6C_ (5U9_\ /Y+79T4?5J?\
MH?VEBOYV<9_PKJS_ .?R6C_A75G_ ,_DM=G13^KT_P"4/[2Q7\[.,_X5U9_\
M_DM'_"NK/_G\EKLZ*/J]/^4/[2Q7\[.,_P"%=67_ #^2T?\ "NK+_G\EKLZ#
MG' R:7U>C_*']I8K^=G&?\*ZLO\ G[EH_P"%=67_ #^2UV0(//8]*6CZO2Z1
M#^TL5_.SC/\ A75E_P _DM'_  KJS_Y_):[.BG]7I_RA_:6*_G9QG_"NK+_G
M\EH_X5U9_P#/Y+79T4?5Z?\ *']I8K^=G&?\*ZLO^?R6C_A75G_S^2UV=%+Z
MM3_E#^TL5_.SC/\ A75G_P _DM'_  KJS_Y_):[.BCZM3_E#^TL5_.SC/^%=
M6?\ S^2T?\*ZL_\ G\EKLZ*/JU/^4/[2Q7\[.,_X5U9_\_DM'_"NK/\ Y_):
M[.BCZM3_ )0_M+%?SLXS_A75G_S^2T?\*ZL_^?R6NSHH^K4_Y0_M+%?SLXS_
M (5U9_\ /Y+1_P *ZL_^?R6NSHH^K4_Y0_M+%?SLXS_A75G_ ,_DM'_"NK+_
M )_):[.BCZO2ZQ#^TL5_.SC/^%=67_/Y+1_PKJR_Y_):[,\#<>GH!DT$'.!C
MCKGTH^KT?Y0_M/%?SLXS_A75G_S^2T?\*ZL_^?R6NRZX&#DC)QV%*1C.> 3\
MI]:?U:B']IXG^=G&?\*ZL_\ G\EH_P"%=6?_ #^2UV=%'U:G_*']I8K^=G&?
M\*ZL_P#G\EH_X5U9_P#/Y+79T4?5J?\ *']I8K^=G&?\*ZL_^?R6C_A75G_S
M^2UV=%+ZM3_E#^TL5_.SC/\ A75G_P _DM'_  KJS_Y_):[.BCZM3_E#^TL5
M_.SC/^%=6?\ S^2T?\*ZL_\ G\EKLZ*/JU/^4/[2Q7\[.,_X5U9?\_DM'_"N
MK+_G\EKL^.IH/ [9H^KT?Y0_M+%?SLXS_A75E_S^2T?\*ZL_^?R6NSXSCU&0
M1S2 @_3U'-'U>C_*']I8K^=G&_\ "NK/_G\EH_X5U9?\_DM=GC'6BCZO1_E#
M^TL5_.SC/^%=67_/Y+1_PKJR_P"?R6NSHI_5Z?\ *']I8K^=G&?\*ZL_^?R6
MC_A75E_S^2UV=%'U>G_*']IXK^=G&?\ "NK/_G\EH_X5U9?\_DM=G11]7I_R
MA_:6*_G9QG_"NK/_ )_):/\ A75G_P _DM=G11]7I_RA_:6*_G9QG_"NK/\
MY_):/^%=6?\ S^2UV=%'U:G_ "A_:6*_G9QG_"NK/_G\EH_X5U9_\_DM=G12
M^K4_Y0_M+%?SLXS_ (5U9_\ /Y+1_P *ZL_^?R6NSHH^K4_Y0_M+%?SLXS_A
M75G_ ,_DM'_"NK/_ )_):[.BCZM3_E#^TL5_.SC/^%=6?_/Y+1_PKJS_ .?R
M6NSHH^K4_P"4/[2Q7\[.,_X5U9_\_DM'_"NK/_G\EKLZ*/JU/^4/[2Q7\[.,
M_P"%=6?_ #^2T?\ "NK/_G\EKLZ,<XSQCKBCZO2ZQ#^T\5_.SC/^%=6?_/Y+
M1_PKJS_Y_):[,X R<@=.G6@X!(YR*/J]'M8/[3Q7\[.,_P"%=6?_ #^2T?\
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MG_"NK/\ Y_):/^%=6?\ S^2UV?&T$'.>@Q0<#(SS_*CZO1_E#^T\5_.SC/\
MA75G_P _DM'_  KJS_Y_):[.BCZM3_E#^TL5_.SC/^%=6?\ S^2T?\*ZL_\
MG\EKLZ*?U:G_ "A_:6*_G9QG_"NK/_G\EH_X5U9_\_DM=G11]6I_RA_:6*_G
M9QG_  KJS_Y_):/^%=6?_/Y+79T4?5J?\H?VEBOYV<9_PKJS_P"?R6C_ (5U
M9_\ /Y+79T4?5J?\H?VEBOYV<4?AU9]KR6K6F>!+6RU*WNEN79HG# &NK/TI
M8^7%..'IIWL3/,,5.+4IZ%L#&.]24S&>]/KN5K:'E_,**** &'@'BJ1ZGZU?
M;H:H'J?K6=0TII!11169J<MXT\63>&K0)8Z?+?:C(A>-%7Y8U'4L>U.?Q7]D
M\!VOB&\A\RYFC7;"G=V. !6AXG5?^$4U9R!N^R2 L!\P&/6N%U'(\!^!T<_N
MS=0[AZ\]Z<;M7(;LS?T_Q-KEMK5CI_B73H(4U'_CU>!]P!ZX;T-:WBWQ!_PC
M>A37:)YMXQ*6T&/]8W^%9/Q#4F;PYL)\S^U$QZ[>^*S?[4L]?U_5]7N[VWBM
MM,AEM;*WDD4$R8^9\$_E56%S,ZWPKJL^N>&++4KJ-8[B>/<R+T%:_7FN6^'5
MQ#/X)L%BN$DDC!$F&!(^M=34LI-A1114W?<H****+ON 4444:]P"BBBC7N 4
M444:]P$-1W=Q%8VLUS+NV0KN; R2/;UJ7GMC/O2<="I*GVR#3N[ <7X5\:WW
MB+Q7>6$NG&SLDA\VW:08=QZD=J[0=,UQMB<?&'4P.,:<@'' Y'2NSSD],#U]
M:J6Q,6V%%%%1=]R@HHHHN^X!1111=]P"BBBB[[@%%%%%WW ****+ON!F>(-9
M3P_HEQJ3PR3>4 %BC&6=CP *Y>/Q7XDTY[&Z\0Z5;0Z;>R*BF!\M!N^[N^M=
MUA21N (!Y!Q7G/BQ=7B\06%QXADCF\-)=KY*6XPR.3\N_P!1FK1+;-G4?$.M
M7GB*YT?PU9V\DEHH:XN;I\(N>P]35_POXAEUI+RVO+86NIV4GEW$8Y!]P?2N
M9U"+5;[Q]J+^#IHK6ZCB5;^YG&8I#_"H']ZJFE:['X7\.Z\US&W_  D*W82X
M>1N))7X5@?[M,GF9N:GXVG@\=V&@V-NLMJ\GEW,Y[.?X1[BNT( )&>AKRN2+
M3]'O/"$)U.WFN#=M/>3"53N=ADY.?PKU,,' =6#*W(([TFM!IBT445%WW+"B
MBBB[[@%%%%%WW ****+ON 44447?< KG/%/B&ZTB6PL=,M1<ZE?N4A#\)'CJ
MS'TKHZK7DUG9027]XT4<4"%FD?JH]C338NA@>'O$6HW.LW.@ZY9Q6VIP1B8&
M%MT<J'N*ZBN*\(0W.MZ_?>,+M&ACN$$%E$W7RA_%^-=KWIRT>XE<****F[[E
M!1111=]P"BBBC7N 4444:]P"BBBC7N 4444:]P"BBBB[[@%%%%%WW ****=V
M!5U*9[;2;NXC;$D<3.I]"!Q7G>CCQYJ/A>+7XO$<$A9&E%HT&-P';=]!7H.L
M8_L+4">4^SOD#KG%>9>%[#QWJ'@>TM+._P!-MM,GA*!@O[U%).3]:J/F2][&
MGJOBS6-4\,^'+K1[A-.NM3N?)F9DW ,.HJ34KSQIX,A74M2OK;5],5PMRJQ;
M7C4GJ*9X@TB+0+;P9I4#%XX+X9=^KM@Y:NL\:-%_PANM&X8>7]F<$'N<<4-D
MQO?4UK>:*ZMHKB$YBE0.A'H>E28K!\#B0>!]$\W.[[.N<^F.*W1]T9J9774M
M"T444M>XPHHHHN^X!1111=]P"BBBC7N 8^;N3C@>M</XT\=77AZX6RTO3GN)
MT*&YF=?W<:L0.OK7;D9X_$>F:Y#XF@+X+N2 ,F:+) QD[AQ339+9I^)?$/\
M8.BV]S';_:+NZ=8K>)3@,Y'\JRX/$>O:5K%C8^)["VCCU!BD$]K)D(V,[6I/
M'?V9_#.G0/$\E_++&M@$."DV.#^%8C0:[8^*M$G\;W$-W"7\NT>U&%CF_P!H
M?2K)39Z:1C@Y_'K12MG<<]<TE2VRT%%%%3=]QA1111=]P"BBBB[[@%%%%%WW
M ****+ON 44447?< HHHHN^X!1111KW ****+ON 44447?<!#C@D9 /(KEK#
M5K]?B+J6B7DV^U^SI/:J!T]:ZH]*XOQ,5TSQ[X;U?.U)/,MICZ@C(S^5--B9
M1U3Q=J5K\3+?3XW']B!T@G)'/F,"<#\JW?$>JWUMXET#2M/E$9NIF:<8SF,"
MN-N;62\\!ZQKX7]\^I?:X_4(K #]":Z/2)DU[XBOJ(.^*RT^,+Z!G&<U9%V:
M<8UBRMM?N;N^AG0*SV:1]80%)PWOFI/!NHW.K>$K&_O'$EQ*A9Y.F<&N:\/%
MO(\=J7)"S/@9S@;#67%<W!^'?A/1[:9H!J4QCEE0\A V2/RH2N.[.L\7ZU=:
M=+H8T^YC*7-^L,S*0P ].*ZIRB"1G8*J<G)Q7E_BGPE9>'-3\.2Z6\\4#:D@
MDA9]P=NS<UZ5?6D-]:SVMTA:&13N3.,#ZU+34;B4C.T+Q'8Z_8RW=O(L:12M
M$P=@",=ZUL@*S$@*HR6)X%>6>%O"6GW_ ($UN*" QWCS3(DH/3:<J*GNM<GU
MKX;Z-IT+$:CJ,JV4H!P05/SG]*;3[C<G:YZ4)(V.!*AXW?>'3U^E*KHZ[DD1
MU)P"K C]*\_UC1%NOB%H6E":5+.'365XU<@NH.*?96</@[X@0Z=IKRC3;VS>
M5[=FW;&7T)[&CE?<;E9G>-)&CA&E17/168 G\*?@CJ"/8UXI:ZAHVL:;?:AJ
MHU276YI)1#-$C%8<$A0G;%>G^#[J[OO">GW%^CK=-'A]X^8X.,FDT^X*1N44
M45-WW*"BBBB[[@%%%%&O< KE?B!J>HZ5X<CFTN=(+J6YCA$C+G 8UU5<9\31
MGPU:?]A"'^=--B90OE\?>&K)M5FU.VU:VA^>>W$6QMG<@]Z[72-2@UG2;34K
M8_N;B(2*#U3U%2:D4_LB[\T@1?9VWL>BC;UKR*VU26Q^&/A^S>6XCMKZ]=)6
MMQEC"#V^M63=GLB.D@S'(CXX.Q@<?E0\D<;!7E16/0,P!/T%>7Z-=Z?8^,=,
M_P"$9M-1AL9D=;V*6-@@ Y#DGOGBK6B:!%XTTG4-9O;N<7\US(MM,KD?9PI(
M7:/3BDXON',ST<D*"6(4 9)8XQ0C)( T;JZGH5;(->:>+;XVE]H&@:Y<W<UK
MY!DO#:@EIV'"YQVJ7P?=0Q>,[FUT:*]AT.:V+LMPA412KZ$]J.5VW#F/1/-B
MWA#-&&(R%+C)_"G,RHI9W55'4L< 5XUK+:6=,U6]L8-6U'4$E,@U9.$C;(X'
M^R*W/%1NYHO#NH:A:W5YH1M\WD=IG/F'HQ ZBCE?<.8])4JX!1@X(R"ISFD#
MQM(8UEC,@ZH'&1^%>>:7J6GZ7X0\0:GH&J2SPH"T=K."&LVQCIU]ZY:2YTN+
M0K6\TR/5V\2*T<KSF-L2L<%@?]GK1RN^X.1[:[)&I:1U10<$LV!FN9&KWI^)
M']DK,IT]K#S0@YR^?6LC4X1XM\;V^C:BTBZ=;Z>MS- K%0\C<<GVJ'1=&30_
MBW):P22/:MI^Z-)&W%!GL:$FQ.3/0P/P]O2EH'0<Y]Z*G7N:!1112N^X!111
M1=]P"BBBB[[@%%%%&O< _'\Z\V\2^+]8T/XAQ0HP;0T1/M*;>4W'&17I/7MF
MN$FT^#6/B%K^F7(#17.F*O\ NG/!JDWH)FKXTU>YTK3-/N=/F \^\B3/7<C'
M_"KWB.^N+&VLH[,XNKJY2)<^AZYKSB?4KB3PA:Z)J!/V_2-5AMW)ZLH;Y3^6
M*[^Z_P!.\<6-LQWQV5N9W _OL,"KZ$*3*OCS6-2T?1X(-(93J]U((X >_P#>
MK0\)ZLVN>&K.^?(G9"LX[[QP<UR.I^)]&_X6Q_Q-=0CM[;2K8B,2 D>:_7IW
MI_PXUC3WU_Q%HMC<K/;+.;NV=<C*M]X4M0YCT6BBBL]>YH%%%%%WW ****+O
MN 44447?< HHHHN^X!3H_OBFTZ/[XIQW$]BYCTIU)2UT'.%%%% "-T-4#U/U
MJ\>AJCG)/UK.9I3"BBBLC4HZU9R7^A7]G#S-<0-&N>F2*P9/"<M]\/K/0KN0
M17ELBE)4Z)(IRI^E=91BA.RL2UJ<1IOA[Q'J6N6-_P"*IK18=.!^SQVQ)$C=
M S9J]J/@#PQ?1W<YT6#[7,&8.W]\]_SKJ<<8ZC.>:*KF8<J.:\$>&(O#'A]+
M<V\4=ZY'VED_B;UKI:.X/I12;&D%%%%(84444 %%%% !1110 4444 %%%%)@
M<[;:)>1?$&\UM]GV2:S6( =<BNBSGKUH[ =A15-W)2L%%%%(H**** "BBB@
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M\]_:HJ*.9ARHE\]_:CSW]JB_+\:3(SM+9)Y"D@$?A33;8K(F\]_:CSW]JA)
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M^H6=G:_&/1)HHTBFFLY/,5>/H?K3L).YW@)(YZT4#I_C14-&@4444@"BBB@
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M@\1O-K&HO#H,,6V*WAE,99S_ !,167X9;5I;#Q-H^DW[7$=K(8M-NY^=N1R
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M]K@9OP]UR?7/"4$]V=UW S02GN64XS^E=6.F?6N'^%=E+:^#EN)T*/>7$EP
M1V9B1^E=P!CBG( I:.]%2@"BBBF 4444 %%%% #7[9Z>]>>7_@^74M4U/5/$
MVLRPP9Q8K!.8UB0#J>>37H;=JX^_'AGX@6U[IUVS/_9TQ656)C:-P/O=>10!
MC:*/$GB'X>?9;.^\NY^TM MY("&, ; 8>^.]5I=+A\'^*="@T'4;FXN+N4Q7
MEN\QDWKC)<Y/RFKOA+Q;!I/A,R:M<;K2"]:RMKE$^^H.%)QV]ZJZ[ING^%?%
M6D:KH3!;W4[KRIH@^_S$;DL,]/7B@#T]  ..E.I%[TM !1110 4444 %%%%
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MA#2'NH/TQ0'2YZ512"E'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT.:1K&&TFBN9(IX[?[C.#RP^M '6T444 %%%% !1110 4444 %%%% !1110
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MO-1N;^\U)11=A9"[F_O-1N;^\U)11=A9"[F_O-1N;^\U)11=A9"[V_O-1O;
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M=SVKG_"7AUM!L9IKR43ZM>N9KN7.?F/\(]A7054MQ1V"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH HZR ="U X_Y=W_E7F^@^&O"$GPRC
MO+Z"SCN_LSR-.L@$N[G!]<YKTG6"?[#U''#_ &:3;GZ5Y]X(^'OAK4?".F:A
M=V4DDTL>Y]TIVDY]*M.R(>YF3(=:\&^!X]67SQ+>[")?XT . :WO%_@?3M(T
M2;5_#MO_ &=?Z?\ OD\EL"11RP8=ZM^.(HH;WPG%&B)#'?A54<!0 < 5H_$#
M6+72_"&H*\R&XND,,$>?F=SQP*=[B6ALZ)J*ZOH5CJ0Z3PJ[?4CFKPZ5D>%K
M*33?">EV<H*RQP+N4^I&3FM<]?:HD7$****0PHHHH **** "BBB@ ]#[]*QO
M$=IJ]_IOV32+I+625B)IV&2B>WO6S_.DQ\I'7"G^5#%T9Y[X#355\ ZA;:?=
M&344O984FN3NQAL;J=\.K:ZT_7_$EG>:A)>RPR(6=B2-S#)V^@J_\,.-!O/?
M4IP!U_BIOA/CQSXM4#/[V/./]VM'N_ZZ$([3IQCCM10.F!THJ&6@HHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #D'(KB8D&E_&*5
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M6S_&35A:,A862>=M[OFDE:_H%SNL\T4<=NE%06@HHHH&%%%% !1110 4444
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M,;;N>>N.N:Z;X8:J^H>#H;:X;_3+!VM9QG/S+P/TQ0([.BBB@ HHHH ****
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M&CDT9-&,45.H6#)HR?6BBG<+!D^M&3111<+!D^M&3111<+!D^M&3U[#K[44
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M:75?M22M)''AH4[[S7IY.3USC@G&,GO6CV(6XE%%%9F@4444 %%%% !1110
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M@ )2@P"_?'M3^R):R):*!14=#1[A1112 **** "BBB@ HHHH **** "BBB@
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MVSZ^E%NHT>F]#12GJ:2H92"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M[TBQ@,:M^4_]VCRG_NT*XM"K<V5I>A1=6L$X4Y42H&"_3-3*B(H5%"*!@*O
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MZ"@#T'%&*B@N(KFWCN(7$D4BAT=3P0>]2@T6"X8I:** "BBB@ HHHH ****
M"BD/.!7,:UX[T;0;\V5R\TMPHW2+;Q%_+7U;'2@#J**YO4/&6EZ?HD&L*)[N
MTN2/+:TC,C'CT%9=C\4="O=3M;$6^I02W3^7"T]JR*QH [BBD'O2T6 ****
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MTY;&[$BW4Z;/,VC[L7KFO45YR:\JU;7C\0)]*T[2])OHIH+I)[B>>,QB#;U
M/<UZJO?^=,!U%%% !1110 4444 %%%% !1110 4444 -=0>HK@O&I&K^)=!\
M,1 !99?M5WM7_EFG(!^I%=Z[!1D]._M7!>#8IM6\8^(/$=S#)& XL[99%P=B
M]2/J: ,1-:N(/B-XA:QT>35=0@5(8H@=JQ1XSG<>E/G32?$'@?7FLHUT:\^T
M>;J$,W 65<95O9JNSWP\#>-]6O;VRN)-.U-4DCGMX]Y1AU4CTK+GT+5]9\.Z
M]K<-@Z37]Y'=0V3\-)$AZ$>IH BO/$7_  EYT+1Y-)DT<"9)/M5TFU"5_@B;
MOFO8(S\JCGIWKRK7/$!\<:98Z'I&DWL=XL\;S--#L%KMZ\^M>JQJ555/4*!G
MUH ?1110 4444 %%%% !1110 4444 <EXYT#3;[1;[4[JW$UQ;6<@AW\A#CJ
M!ZU3T70M/USX?:(VI0_:!;VWFHKGY2V#U'>M[Q8&D\):LB*S,;9P% Y)QVJI
MX25H_A]IT;HRN+/!4C!!P:0%'X5\^!K?_KM)@>GS=*[2N-^%\4L/@BW2:)XW
M\V0[7&#]ZNRJGN 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH RO$6F-K6@7^F)($:XB*!O[I-<!IGC&_\ ">D0Z1XG\,W<5O;Q^4;JV3?&
MZ#C<0.E=_P"(8M0FT*^32Y?+U Q$P-CHW:N'A^(DG]CC3]4T+4WUL1&.2V\C
M*2-C&<^AI/8$.\;/I3_#2WDT5(3I[W$+1"+A5&\5W.I6L6H:)=6MR@DBE@96
M4]""*\QU?1K[0?@ZEO=0,;@7(N)((EW% 7!V@>PK3U'XEQZCI,ECX=TK4;G4
MID\E \!54)&,DFJ>PEN:OPKGEF\#6\,A8^1))"I)S\JL0*[<=*P/!FA/X=\+
M66G2G,R+OE.<_.>3^M;XHEY"0M%%%(H**** "BBB@ HHHH :QQBN9N]/T+PK
M%K6OSH UR-T[RG=GC 4?7TKIF&2!^M>-Z_XJLM3\;26NO6]]'H^F/F.VC@9A
M<RC^)O8>E)@=G\-K"XM/"$7VN$QF>:2>.%A_JD8Y4?E5%@-?^*ZQ*J_8]$M]
MSC'!E?I^0-=%I_B:RU'PY-K-E',((D8A'C*M\HZ;:QOAG8S1Z#<:O>(RW>J7
M#W#[Q@A<_*#^%5U [=>G/6EI!2U(!1113 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 1AFO,O'6F+K/C6ST]NLVG3[?8C!'\J]--</JT<
MK?%?0Y!$YB%I*&?;\HSC@FEU_KL!D_\ "037?PCM44G[;<,MA[[PV#^@IWA.
M :/JGBZ&VPK6<,80^ZQDYK/T?2+Z/XG3:(T+C2+2X;48G(^4LW:MO1+6>7Q1
MXVC,3*UP%6+<,!B4(X--@6=-\0ZC<?"I]<DD4WRVTD@8#C(SCBN>\9_VMK'@
M'0[YM16'S7@,R!/ONQ&"/I5.UU^6R^'%]X7&E7KZO!!+$\?E'9CGD-Z5L:U#
M./A'H[1P2R&W%O))&JDN I&<#U%*VOW#;TT\SH-4;Q!I^A64%M>VQG+!;G4)
MQM6-/4+WK+\/Z_J=_JNJ>'VU:WO9([<2P:A"F I/\)'J*S_%.HQ:@_A[5[BS
MN[KPR QN(DC.X.1A2Z^F:F\(+#)\0=0N[+2)+&PDLD$.4V[^3DD=C5+J+L1?
M#B+4-,LM;OKS5/-L8+N??#Y>,L,$MGW]*7_A(?$\NA?\)6FHV2VHS*FF;1N:
M+/\ >S][%+X78R0^*?"\T-Q#?R7$\J,\9V,K=,-WKGK.Q\/V.B+I=UX6N[C7
MX0(3 0VR5L_>W=,=Z0WN=MJ_B;4]2N](TGP]Y<%SJ%M]KEN)5W""+Z>N:Q[#
M^V$^+6GVVLO'//#IS!+B-=JRJ6]/6KFJQ2^%_$VD>(&T^3[#]A^QW$=L-_V<
M]0<=QVJ.TU.?6?BK87J6,\.G+8ND,LD97S&SD_04"/21P*6FKTIW>@$%%%%
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MQQG/KVI1R<<9/2C4- HH!!Z<C^GK29Z<CZ9HU#06BDS^OKQ63%K\4OBN?0!
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M]Q-'M^S =1GO7IS8+$@@^]-[$K<2BBBI+"BBB@ HHHH **** "BBB@ HHHH
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MKL%1 2Q)X [T@)*/RKF?"'C.U\7G43:6\L<=I/Y0=^D@]173T[ )^5'Y4M%
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M+10 GY4?E2T4 )^5'Y4M% "?E1^5+10 GY4?E2T4 )^5'Y4M% "?E1^5+10
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M#2WD"2S6R[6BSQG%.P[GH-%,21)8DDC;<CJ'5O4&GU PHHHH **** "BBB@
MHHHH **!RP'?T]:XCQ=\05\/ZA%I]E8O=W'F(MPY!$<2L>.?6F([>BN>\8Z_
M>>'=&M[FQM8KF[GF6%(I&(7+>]0Z1>^,Y=26/6='L+>R(^:6"5F93[ ]:?**
M]SIZ***FY2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HH'49Z5S.D:U?S>.=8T*^*B.*-)K3"X.T]?K30F=-17!7'C+48OB=%I
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M'\"S>(U3_2!K'VP'N$W8_D:ZK2776OB9>:@"6ALK2.)".F7&XUIC01_P@_\
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MZDR;UMH6D*_WL=JX2TTWQMK>BQZ_'XB6&YFC\Z&RCC'E;>H4GUH ]-S[4F_
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M]UXFU9/BO&J7!_L))%LGB[>:03G]*Z+7M2O?^$YT'2+.<QQN'N+@#^)!Q@T
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MC+=7$4$8_BD<*/UKDK/5KFX^)UW9"Z$FG?V<DR(IRN23SF@#LP<_A2T@Z4M
M!1124 +1124 +1112 **** "FAB>HQ[TIZ5Y+X@\4:WHOQ.>87#/H=LL:74)
MZ('P WYFF%CUK/M02>.*Y'QKJES91:(]C<%$N;Z-'9?XD.*T/%%[<6\-E;6C
M[+BZNDC!'9<_,: -W=TX/-+FN'^(FIZI!IUGI&ASF/5;Q_E<=0B#+5M^$-8_
MMWPO9:@S S.FR;V=>"* L;U%%%( HHI*8"T444 %%)2T %%%% !1244"%HI*
M6@84444 !I!TI32#I0 M)2T4 >97/B#2=1^(DQU;4;:VL]&&R"&60#S)FZMC
MV%<W#J5I=?"35K>VN(YI4O&>:-6^81E^N/2O5[KPOH%],\]SH]C+,_61X06)
M^M8/AWP%9Z;X=O\ 2[N"V,MX7$DL*8;83P"?:A#;(?B'L/PV3;@@^0(_KQBN
MDOX]0NM#-KI>H16NH^4N)&4/L..I6N3L_ ^N3SV-GK6LPW6BZ?*)+>)$(DD*
M_=#GOBK^M>%M:'B)M>\-:C%;74L0BG@N06B<#ITZ4VQ(J_#Q6L=0UO3+_,FM
M0RJ]U<ALB<,/E(!Z5Z .@KE_"GAJ?0VN[W4;P7NJ7K;KB<+M4>BK[5U(Z4@"
MBBB@ HHHH **** "BBB@ HHHH #TKD?B#KYT'PUNBD6*>[D6VCF<X$6[JQ_#
M-==52^TVQU. P7UI#<Q$YV2H&'Y&D!Y8-2\.:5XH\)VMGJ]I);VR.DLJR YD
M(ZL?4FO6XF#(&4_*>17%WWP\TJ?Q)IM_;:;816EJ#YL(A WGL2,<XKM(U"KM
M4 *.@'I3$/HHHH&%%%% !1110 4444 %%%% !3>IYQ3J:<#KTS0!PW@,9UWQ
M=TP=0'7TVTFG?\EAU7 Z:>@P>PW=JU_#?A^?1M3UVZGFCD2_N1-&%_A &.?>
MDM= N8O'5[KS3(8)[58$0=5(.<T@,.Y\%:MJ'BK6;P:XUC9W84(+3_69 [FK
M_@74[^:+5-)U2<7,VEW)@%P1S(F,AF]ZBU?PQXAB\13ZMX;U>*![I D\%TI9
M./XEQT-1R>"]0M/!5_I6FZF%U;4)"]Q>R X9CUQCD"F!6GF/C[Q=;V]HV[0=
M'F\R:4#Y9IQT5?4"O0UZ_P">:\]T'0O'6B16-A%<Z*FG0<.J1MO8=S]:]"7/
M&?3M0 ZBBB@ HHHH **** "BBB@ HHHH 2O._&,4^K^--.T[1)/L>M0PF9K\
M\^5$>VW^+->BUR'B7PO?WNM6VNZ%?1VFJV\9B/FKF.5#V:EU!&/X1AN-'\=7
MVG:W+]NUBX@$R:ATWQC^';_#BO1N]<CX<\+ZA:ZY/KVO7T=WJDT0A40KMCB0
M=A]:Z^J8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AJZ
MV3Z5=1ZB46R:,K,6.!M/O7 IX,\1Z!:&?PEXE,EJ!OBM+M=Z;>N%/:N^U?3(
M-:TNZTVZ'[BYC*/Z@>HKAK?PGXVL[-=&MO$ML-+5/+65HLSJGH/PH H>(]?E
M\2_"R+4)81%.+R.*95.0&5P#7I5TZ)I,TCD",0$L3Z;:Y+6/ SOX"3P[I$T:
M2QNLBS3Y^9P<ECCUJA=>%_'FN6O]G:OKVGPZ>_RR_8XV$CKW&30]8V!+4N_"
M=''@:)L_(]Q*T?\ NES7=BJ>EZ;;Z3IEO86J;8($"*/85<%#U$E86BCO10,*
M*** "BBB@ HHHH *0]*6B@#D?&^BWVJVMA=Z4T8U/3[@7$$<AXD[%?RKD=8G
M\0:AXL\*7>K62Z>!=-&MLC;F8[>N:[KQ9H-QKUC ME?O97EM*)H95/!(['U%
M9FD^&=9DUR#6O$VHPW5S;(4MH;9-L<>>K'/5J .T'>EIJ?=Z@^].H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-<%XG*Z-\0=#
MUHL$BFBDM9F/3.,K7>MTKE/B!X5G\7^'/[/M9UM[A95D25OX<?2D!QD]E+-\
M,YM;P?M U/\ M!6'4KO 'Z&NE\/RIK?C_4]77#106T4$1'(!8;C6Z="0^$?[
M#^7'V7R-P^[G'7\ZS/ 'A2?PAX>%A=SI<7;2%Y98\X8?PCGT%5<3.>\/$#P_
MX[/!_P!(GSC_ '#5.9YIO 7@W1UD>.#4I52=E;!*#DKGWKJ],\)7EEI?B2VD
MN(F;5)9'B*@_(&! S^=13>"9KGP9IFE->"/4M-VO;W*C@./;TI=?N*1@^+_"
MNEZ'JWA>YTN!;5/[02-X8SA9/0D=S7I-];07=E/;W,2RPLIRC#(QBN(U#PEX
MBUJ^T>_U;4[3S-.NEF6&)2$8#J?7=7?. R-GN",^U)_");GE/AGPO8:I\+-3
M@M[.*.XF>4*X7YLJ<KC\J?=ZNWBKP9X=T=7/G:C,L-VHX8+']_/IR!74^#O#
MNK^&FN;.XO+>XTLRM);@*1(I8YY[8KG_  +H\3>/O$NIQ.SV<$YB@!Z*[<OC
M\15=09-JFAVFH_%:RLY@?LL6ED&')VR ,, TVTM(?"/Q!GL=)3R;*[TU[DVP
M/R)*IZCTI==M+ZY^+5LVFW:6]U'IS.N_E7&[H16WHGAB\AU:[UG7;J.ZU&ZB
M\C9$I\J./T7/-#&><:<]EJ?AFXFNO#VJWFKW;2,+]5!*ODA2ASPHXKUSPE)>
MR^%M.?44:.\\D"56ZY''/Y5S4?A/Q-IUG-H^E:U;1Z3*S;'D4^= C=0I''<U
MV>FVHL;&&T\R24Q(%\R0Y9\=R:"2Y1112&%%%% !1110 5POQ/\ ^09H_P#V
M%(?YFNZKEO'7A[4/$6DV\&FSPPW-O<QSJTPROR_2@#6UV2*+P[J#S,JQBV?<
M6Z ;37D"W3P?#_P;ITT%W+:7DQ::&V.'=!DA?I757GA'QIXCB%AX@UVR7368
M&6.RC8-(!_"2>U=#KOA5=0T_3TTR<65WIK!K27&0N!C!'H120SD=% 3QU97.
MB>'[[2[%H'CO5>,)&V!E3@=ZD\,>';#QAH6HZGJV9;R[N)42<M\UNJD@;3VQ
MBNETG1M??64U/7M3CD,2%8K2TRL?)^\V>IK(F\%>(+)[^QT/5[>WTF_D:25)
M$)EBW?>V'ISUYIB,CQ))]F\1Z#HNHQ7FL65K:F5TA /FMT4L.XXJ[X2=K?Q9
MJ$EGI5WIFB2VOF,LZ[520=2!TZ5M:AX0NXCIUWH=^+?4=/B\E'G&]9XR.0W>
MI].\/:G-)J%SK^H":2\A\GR(21%$OL#W]Z.@(\WUA;$^%KV^TC0+R55D\[^V
MYI,2!MP^93UQ[5U/BVSU&>;0-5ETV76-,@@S=6B=2Q P^WO4<G@/Q+/X;E\-
M2:U;#2XU M66,^80&R%D[8^E;VLZ#KDD^FZAHNJ1VU[:P^2\4N3!.,=P._%'
M0#E[75-,L?!'B:_\/2W4$F<O8W *M:NW' [ @G%9$D5O_8FGMHGAO58=:B>.
M3[68QF0Y&[><\@\UW6G^"I#9ZP=;NEN+_5P!<20KM1 !A=OT]ZAA\,>*YH+7
M3+W781IMLR_O8 RSRJO16/3M3!%2>QA\5_$:6QU=#-9Z=9)+]D;[AE8\DCOQ
M3/#VD6VB_%K4[6U)%NUC'(D7:/YN@]JV]9\-ZDWB&/7=!O(H+T0B":.=24E3
M.><=ZBT'PKJ6G^,;S7;^_2Y:Z@6-U48",#T'M2Z =FHP*6D7D4M !1110 44
M44 %%%% !1110 AZ5YTNF0ZUX_\ %FFW0!@N+&-,=P3W_"O13TKG+'09[7QI
MJ>M/*C07<"1H@Z@K0PN>=_VE<2:1I6B:@V=0T?5X[>0'K(@/R/\ EBO0;@_;
M_'EK%UCT^!I&_P!Y^!_*L;Q-X!FU?QGI>O6%W';&"13=1L#^^"G/YUT=CI-Q
M:7VK7IEC,]X_[D\_(H' /XTQ6.!N?&&C6_Q6U"XU2>9(M/M_LT 2(NI8_?.0
M*M_"_7;*YUGQ#I-E,SVBW'VFU#(5^1NO!KI_"/A;^P-%:WOO(N;N69YIY=OW
MF8^]1WWA:4^.-,\0:?)% L,;0748&/,0]/QI(;.MHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $)HS2$X!-9YOY Q&U>#42GR[E1@Y;&CFBLW[?+
M_<6C[?+_ '%J?:HOV$C1QSUI-@/&>!TYK/\ M\O]Q:/M\O\ <6CVJ#V,C0"@
M <\T;1C&>*S_ +?+_<6C[?+_ '%H]J@]C(T0!ZY^M+FLW[?+_<6C[?+_ '%H
M]J@]C(TLT9K-^WR_W%H^WR_W%H]J@]C(TLT9K-^WR_W%H^WR_P!Q:/:H/8R-
M+-&:S?M\O]Q:/M\O]Q:/:H/8R-+-&:S?M\O]Q:/M\O\ <6CVJ#V,C2S1FLW[
M?+_<6C[?+_<6CVJ#V,C2S1Q6;]OE_N+1]OE_N+1[5![&1I4#CO6;]OE_N+1]
MOE_N+1[5![&1I9HS6;]OE_N+1]OE_N+1[5![&1I9HS6;]OE_N+1]OE_N+1[5
M![&1I9HS6;]OE_N+1]OE_N+1[5![&1I9HS6;]OE_N+1]OE_N+1[5![&1I9HS
M6;]OE_N+1]OE_N+1[5![&1I9I,>]9WV^7^XM'V^7^XM'M4'L9&B!@=:,#G&!
M6=]OE_N+1]OE_N+1[5![&1?$8 (!///6G$ ]ZSOM\O\ <6C[?+_<6CVJ#V,C
M1P/8TM9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9O
MV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V
M^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFBLW[?+_<6C[?+_<6CVJ#
MV,C2''>C-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC
M-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^X
MM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM
M'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&E
MFC-9OV^7^XM'V^7^XM'M4'L9&B5!S[]:0J#GGKWK/^WR_P!Q:/M\O]Q:/:H/
M8R- J"1D]/>EP.QQ6=]OE_N+1]OE_N+1[5![&9I?C16;]OE_N+1]OE_N+1[5
M![&1I49K-^WR_P!Q:/M\O]Q:/:H/8R-+-&:S?M\O]Q:/M\O]Q:/:H/8R-+-&
M:S?M\O\ <6C[?+_<6CVJ#V,C2S1FLW[?+_<6C[?+_<6CVJ#V,C2S1GWK-^WR
M_P!Q:/M\O]Q:/:H/8R-' ]J0(,D]2?6L_P"WR_W%H^WR_P!Q:/:H/8R-(<>E
M&:S?M\O]Q:/M\O\ <6CVJ#V,C2S1FLW[?+_<6C[?+_<6CVJ#V,C2S1FLW[?+
M_<6C[?+_ '%H]J@]C(TLT9K-^WR_W%H^WR_W%H]J@]C(TLT9K-^WR_W%H^WR
M_P!Q:/:H/8R-+-&:S?M\O]Q:/M\O]Q:/:H/8R-+-&:S?M\O]Q:/M\O\ <6CV
MJ#V,C2S1FLW[?+_<6C[?+_<6CVJ#V,C2S1FLW[?+_<6C[?+_ '%H]J@]C(TL
MT9K-^WR_W%H^WR_W%H]J@]C(TLT9K-^WR_W%H^WR_P!Q:/:H/8R-$\]Z,>]9
MWV^7^XM'V^7^XM'M4'L9&C@4%03UK.^WR_W%H^WR_P!Q:/:H/8R-''O2;?>L
M_P"WR_W%H^WR_P!Q:?M4'L9%\QJ3DXI=HXYZ5G_;Y?[BT?;Y?[BTO:H/8R-$
MJK @]#[U4T_2[+2XY([*%8EDD,C@'[S'J34/V^7^XM'V^7^XM'M4'L9$S:79
MMJ@U(PK]L$?EB7N%]*M;!D<]#GK6?]OE_N+1]OE_N+1[5![&1HD \=N]"C:,
M9X_E6=]OE_N+1]OE_N+3]J@]C(TLT9K-^WR_W%H^WR_W%I>U0>QD:6:,UF_;
MY?[BT?;Y?[BT>U0>QD:6:,UF_;Y?[BT?;Y?[BT>U0>QD:6:*S?M\O]Q:/M\O
M]Q:/:H/8R-''O1@9SFL[[?+_ '%H^WR_W%H]J@]C(T H!SFEP./;WK.^WR_W
M%H^WR_W%H]J@]C(T-HQBC:,'FL_[?+_<6C[?+_<6CVJ#V,C0VCUHVCVQZ>E9
M_P!OE_N+1]OE_N+1[5![&1H;!QSP.U+@>M9WV^7^XM'V^7^XM'M4'L9&@5!.
M<_K1M&*S_M\O]Q:/M\O]Q:/:H/8R-(?6C-9OV^7^XM'V^7^XM'M4'L9&EFC-
M9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&EFC-9OV^7^XM
M'V^7^XM'M4'L9&EFC-9OV^7^XM'V^7^XM'M4'L9&D>128'M6=]OE_N+1]OE_
MN+1[5![&1HX]Z,#/6L[[?+_<6C[?+_<6CVJ#V,C1P/RHQQUK.^WR_P!Q:/M\
MO]Q:/:H/8R-+-&:S?M\O]Q:/M\O]Q:/:H/8R-+-&:S?M\O\ <6C[?+_<6CVJ
M#V,C2S1FLW[?+_<6C[?+_<6CVJ#V,C2S1FLW[?+_ '%H^WR_W%H]J@]C(TLT
M9K-^WR_W%H^WR_W%H]J@]C(TLT9K-^WR_P!Q:=%>.\BJ5 R>U-58L7LI+<T,
MTM)2UH9A1110 UONFL5OOM]:VF^[6*WWV^M85CHPXE&/>BBN>QTACWHQ[T44
M##'O1CWHHH#4,>]&/>BBBPKA^-%%%%AA11118 HHHHL 8]Z,>]%%%A7#'O1C
MWHHHL%PQ[T8]Z**!ACWHQ[T44 &/>C'O11185PHHHHL,****+ %%%%%@"BBB
MBP!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 **
M**+ %%%%%@"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118
MHHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****+ %%%%%
M@"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 444
M46 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!1
M1118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****+
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M9?"XO;N[G.^<3A<(/NJN>U$?B"7PES7;?4+GQJ;3PK)';ZG;6.VYGF&4\L]
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ML=BK?)&#U''?'/%&E@UYCMZ*CB,AB0R##E5,@_NGOBGUGU-4+1112*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
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MG.:T ,  =!1CGFB[#E,Z\T'2M0*M>V4<WEIY:;N<+Z5/I^F6.DV:VEC;1PP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:GLA
MFZ4>E0=Q5[3T&YG[U4%>2,JKM%E__&EI*6NPX0HHHH *@NH1-$0>HZ5/2&I:
MNK#3L[F$ 5)!'(I:T+JUW_.@^;O6>058@C&/6N25-IG9"HFA,TN:3K14ZFN@
MM%)FC-+4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06B
MDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU 6BDS1
MFC4!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4
M-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!
M:*3-&:-0%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3
M-&:-0T%HI,T9HU#06BDS1FC4!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:
M-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0
MT%HI,T9HU#06BDS1FC4!:*3-&:-0%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI
M,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T
M9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU 6BDS1FC4!:*3-&:-0T%HI,T9HU#
M06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06
MBDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4!:*3-&:-0T%HI,T9HU#06BDS
M1FC4-!:*3-&:-0T%HI,T9HU#06BDS1FC4-!:*3-&:-0T%HI,T9HU#06BDS1F
MC4-!:*3-&:-0%I* >>1BE57<X1=WO56;$VD"H78*!UZUKP1"*,*.U1VML(AN
M;EC5G%=-*-CDJU.;1!BEI*6M3$**** "D[TM% "8J*2W24?,HSZU-12:N-.V
MQ0;3LG(<TG]G'^^:T**GV<2_:R,_^SC_ 'S1_9I_OFM"BE[.(>UD9_\ 9Q_O
MFC^SC_?-:%%'LXA[61G_ -G'^^:/[./]\UH44>SB'M9&?_9Q_OFC^SC_ 'S6
MA11[.(>UD9_]G'^^:/[./]\UH44>SB'M9&?_ &<?[YH_LX_WS6A11[.(>UD9
M_P#9Q_OFC^SC_?-:%%'LXA[61G_V<?[YH_LX_P!\UH44>SB'M9&?_9Q_OFC^
MSC_?-:%%'LXA[61G_P!G'^^:/[./]\UH44>SB'M9&?\ V:?[YH_LX_WS6A11
M[.(>UD9_]G'^^:/[./\ ?-:%%'LXA[61G_V<?[YH_LX_WS6A11[.(>UD9_\
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M>SB'M9&?_9Q_OFC^SC_?-:%%'LXA[61G_P!G'^^:/[-/]\UH44>SB'M9&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_004d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004d.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ."!40# 2(  A$! Q$!_\0
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M +P_*J]%'/(/90[%C[;/_>'Y4?;9_P"\/RJO11SR#V4.Q8^VS_WA^5'VV?\
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ME"&/##L:Z+QF0;KPX&XSJ"YW?[II615V9*ZQ>:3XS\3FRTF2_E4QO,$;;L0
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MY*,/?O6MFN6\%D>=X@ .<:D_?^5=3425F:Q;:U#-&:**109HS110 9HS110
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MVY1 #M].*;'IMC$9S'90()_]:%C \SZ^M6OQH_&B['9%6WTVQM2K6]G!"RC
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M?C0 M%)^-'XT +12?C1^- "T4GXT?C0 M%)^-'XT +12?C1^- "TG>C\:.]
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M:*B^U0?\]H_^^Q1]J@_Y[1_]]BBZ[ARLEHJ+[5!_SVC_ .^Q1]J@_P">T?\
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MKN'*R6BHOM4'_/:/_OL4?:H/^>T?_?8HNNX<C):*B^U0?\]H_P#OL4?:H/\
MGM'_ -]BBZ[ARLEHJ+[5!_SVC_[[%'VJ#_GM'_WV*+KN'(R6BHOM4'_/:/\
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M8HNNX<C):.]1?:H/^>T?_?8H^U0?\]H_^^Q1==PY67+'_CZ_"M85CZ?-%)>
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M="OA)YM\=MJMI-=*"6@!YXZXKGBI1S&PVLIVD'U]*)J29-*M0JW<.F^@9/\
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MBKPUW\/?H*#XJ\-'IX>Q^ H^KT_YQK&UKZ8=_@<3YB_WA^E'F+_>7\Q7;?\
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M>,I)[&V%O"+;;LP.N:]&%>M@HJ-*R=SYG.)N>)NXVT6C%HHHKK/*$KQ_Q_\
M\C6_^XM>P5X_X_\ ^1K?_<6N#,/X7S/;R+_>7Z?Y',BEI!2UX9]F%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"^9[61/_ &E^G^1S(I:3C_)HX_R:\2Q]G="T4G'^31Q_DT6#06BDX_R:./\
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M+29 _P#UT<?Y-<UKZG?:R3%HI./\FCC_ ":+!="T4G'^31Q_DT6"Z%HI./\
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MD_W:/M7^S3YT+E9/Y4>"-BX)R1CO2[5W;L#=TSCFJ_VK_9H^TG^[1SH.1EC
M]*:(HPH41J #D#'?UJ'[2?[M'VG_ &:.=!R,L!%!)"@$]2!UIHC169U10S=2
M!R:A^T_[-!N<_P -'.@Y&3,B. &16&<\C-*0&!# $'L15?[1_LT?:/\ 9HYX
MAR2+(  P *;Y4?S?NT^;EOE'/UJ'[2?[M'VD_P!VCF0<C)WC21=KHK+Z$9%*
M44KM*@KTP1Q5?[2?[M'VD_W:.=!RLL  #   '&*" PPP!!Z@U7^T_P"S1]I_
MV:3D@Y63JJJH55  Z #I0J*HPJA1UX&*@^T_[-'VG_9HYD'*RP0&!! (/4&D
MV*,84#'3CI4'VD_W:/M/^S1SH.1D^Q2X<JNX# ;'(I#%&5VF-=N<XQQFH?M)
M_NT?:3_=I\Z#D9.45B"R@E3D$CI1L7<&VC<.,XYJ#[2?[M'VD_W:7.@Y&3^6
M@!&Q<-U&.M!C1E"E%*CH".*@^TG^[1]I/]VCG0<K)]B;MVT9QC..U'EIOW[%
MW_WL<U!]I/\ =H^TG^[3YT'(R=XTD #HK '(R,T!%!)"@$]3CK4'VD_W:/M)
M_NTN=!R,G*(65BH++T)'2C8NTKM&#VQ4'VD_W:/M)_NT<Z#D9,(XUVX11MX7
M Z?2AT20 .BL!R-PS4/VG_9H^T_[-'.@Y66" P((!!X(-(40H%*KM'08XJ#[
M3_LT?:3_ ':.=!RLL #TI#&C,&9%)'0D=*@^TG^[1]I/]VCG0<C+!1202H)'
M0D=*0HA(8JI(Z$CI4'VD_P!VC[2?[M'.@Y&3E$9@Q521T)'(I<"J_P!I/]VC
M[2?[M/G0<C)RB,X<JI8="1R*5E5U*L 0>H(JO]I/]VC[2?[M+G0<C+"JJ@!0
M !T %($15*A5"GL!Q4'VD_W:/M)_NT^=!R,L!548"@#T IHBC4 *B@#H .E0
M_:3_ ':/M)_NT<Z#E98"J"2  3U..M-\J/##RTPQR1CJ:A^TG^[1]I/]VCG0
M<K+!52"I (/4$4*BHH55"J.@ QBJ_P!I_P!FC[2?[M+G0<K)@B*I554 ]@*3
MRH]JCRUPOW1CI]*B^T_[-'VG_9I\Z#D=BQ2U6^T_[-'VD_W:.=!R,LT56^TG
M^[1]I/\ =HYT'*RS15;[2?[M'VD_W:.=!RLLT56^TG^[1]I/]VCG0<K+-%5O
MM)_NT?:3_=HYT'*RS15;[2?[M'VD_P!VCG0<K+-%5OM)_NT?:3_=HYT'*RS1
M5;[2?[M'VD_W:.=!RLLT56^TG^[1]I/]VCG0<K+-%5OM)_NT?:3_ ':.=!RL
MLT56^TG^[1]I/]VA23#E99HJM]J_V:/M)_NT<Z#E99HJM]I/]VC[2?[M'.@Y
M66:*K?:3_=H^TG^[1SH.5EFBJWVD_P!VC[2?[M'.@Y66:*K?:3_=H^TG^[1S
MH.5EFBJWVD_W:/M)_NT<Z#E99HJM]I/]VC[2?[M'.@Y66:*K?:3_ ':/M)_N
MT<Z#E99HJM]I/]VC[2?[M'.@Y66:*K?:3_=H^TG^[1SH.5EFBJWVD_W:/M)_
MNT<Z#E99HJM]I/\ =H^TG^[1SH.5EFBJWVD_W:/M)_NT<Z#E99HJM]I/]VC[
M2?[M'.@Y66:*K?:3_=H^TG^[1SH.5EFBJWVD_P!VC[2?[M'.@Y66:*K?:3_=
MH^TG^[1SH.5EFBJWVD_W:/M)_NT<Z#E99HJM]I/]VC[2?[M'.@Y66:*K?:3_
M ':/M)_NT<Z#E99HJM]I/]VC[2?[M'.@Y66:*K?:3_=H^TG^[1SH.5EFBJWV
MD_W:/M)_NT<Z#E99HJM]I/\ =H^TG^[1SH.5EFBJWVD_W:/M)_NT<Z#E99HJ
MM]I/]VC[2?[M'.@Y66:*K?:3_=H^TG^[1SH.5EFBJWVD_P!VC[2?[M'.@Y66
M:*K?:3_=H^TG^[1SH.5EFBJWVD_W:/M)_NT<R#E99HJM]I/]VC[2?[M',@Y6
M6:*K?:3_ ':/M)_NT<Z#D99HJM]I/I1]I/\ =HYT'(RS15;[2?[M'VD_W:.9
M!RLLT56^TG^[1]I/]VCF0<C+-%5OM)_NT?:3Z4<Z#D99HJM]I/I1]I/]VCG0
M<C+-%5OM7^S1]I/I1S(%%LLT56^TGTH^TGTHYT'(RS15;[3_ +-'VG_9HYD'
M(RR:2HHYO,;&,5+33N)JPM%%%,053G_UIJY5.?\ UIJ)E0W(\T4=Z*QN;V"B
MBBC<-@[@>O2DR!U=1]6%#9V/@X^0\'GM7DWA/POX9UG19;S6+UTNWN9%<&\*
MGAN.,T6$V>M9XSN'YT$XY/  R2:P+S7-,\-Q6>G(ES<.8\P6]NGF.4'<U3U7
MQE;1^$+K6]*CFF9,IL$>6A8=G';%.P)G5$@ DG '<\4 DG&#GZ5P]WK&FZYX
M*TZ\UR*_MDDGB7Y%V,TIQ\PY^X370ZQXCT_0FM[>=9IKF=0(;:W3?(P'?Z4W
M&PE*YKY[Y&/7-&>Y.!ZUA:;XOTK59;^.T,I>PC\R<-'M*C'3'K4R^)M/;PP?
M$0\[[ $+\K\Q .*5F/F-CZG%'/\ DUDWWB+3M.TJVU&XED$=T 88U7,DA/10
M*-&\1V.MR310+-#=P &2VN$VR*#WQ2Y6',:WXT=^^*/ITK%U?Q3I^C7D=G(L
M]Q>2+O6"WCWL%_O'T%%AW-KFDR/7/TYK"T_Q=I.J6^IW%F\KQZ:/WY*;2#C)
M IND>,=+UQ7DM%N1;)#YYN7CVH!W&?44<HN8Z#(]:#D9X/'6N;LO'&DWEU#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(?3\J&"./
MUPX^)WAG_KA-_*NQ(YS4$EG;RW45U);J\\7W&/5<^E6#Z%LGKSVIW]VQ-O>N
M)1112*"BBB@ HHHH **** "BBB@ HHHH 0YPVWC(QGOGUKE)='\:F1V3Q5;(
MA8E5-FI*CM]:ZRB@10TF'4;>P2+5;V.]NPQ+3(FP8[<5?HHH&%%%% !1110
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MZU7TW4I]-O\ 0+:TUFU\0:9<R+'!;R*OGVRXX;/; XKTJWM+:TMEMK>WAB@
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M ]HRIY$GH*/(D]!5NBCD#VC*GD2>@H\B3T%6Z*.0/:,J>1)Z"CR)/05;HHY
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MS@>M:6L^#H=4U-=3M=3O-.OO+$+S6TF/,0=B*Z7<GJ*-R>JT70S.T31+/0;
M6=FK;"Q=V8Y9W/5F]ZQ]3\%0ZAJLNJ6FIW^FW,Z[;C[++@2J.Q%=3N09P1SU
MI=R>HHN*QS6IZ98Z!X"O;"VM'FMTMV41 ;F=B.I]3FF^!]!CT3P/8Z<\?SR0
M[I5;J2PR0?SKIMR>H_.C<@_B'YT[H=CC(OAOI\3K"VI:@^E))YJ:<\N8E;.?
MYUJ:AX6@O?$EKKD5[<VEU;IY;B%\+,F<[6'I6_N3U%+O7^\*5PL<Q>^#(;G4
M;B]M-3OK![L@W,=O)A)>,=.W%2W/@S3)M,TRPA,L-OI\PGB56R68>I/6NAW+
MC&X?G2[T]10F#1D:CH%OJ6N:;JLDLBS6!8HJ]#N'>E&@6_\ PE7]O^8_VDVW
MV?RP?EQG.?K6KO7^\/SHW)ZBG="LS/UO1+/Q!IDEA?*3"V&!4X9&'1@>Q%87
M_"!6LUYI]Y>ZG?W=U83"6&263. !C%=;O3U%&Y,YR*5PLS%C\.6<>L:IJ4CN
MYU&)8IHV^Z !CBL>T^'=E;20H^HW]SI]M)YD%A-+F*-@<C\J[(,@[BD'ECH1
MSU]Z+CL<WK'@V#4M3?5+34;S2[V1 DLMH^#*HZ BI(_!VFP>&;O0H3(L-XI\
MZ9FS(['JQ/K71;D]12;D_O#\Z+A8H+HUJVA+H\ZF:U\GR6#]6&,5S5Q\.+6[
MTY;"ZU2_GM865K:*27B+;T'O7:;DSG*YI=Z_WA^=%PL8.K^%[?5)[:ZCNKBR
MO[=/+CNK=L,5[@^M1VW@^RMM&U*P\^XD?45(N;F5]SN2,9_*NAW)C&X?G1O7
M^\/SHN%C+.A1GPQ_8<=Q-'$(! )D.' ]1[U;TZR&FZ=;62R22B%!'YDARQ '
M4U9WI_>'YT!D'\0].M%Q69)VHIGF+_>%'F+_ 'A1<=A]%,\Q?[PH\Q?[PHN%
MA]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q
M?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q
M?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%
MA]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q
M?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q
M?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%
MA]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN%A]%,\Q?[PH\Q?[PHN@L/HIGF
M+_>%'F+_ 'A1=!8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*
M/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*
M+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13
M/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*
M/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*
M+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13
M/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*
M/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*
M+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+A8?13/,7^\*/,7^\*+H+#Z*
M9YB_WA1YB_WA1="L/HIGF+_>%'F+_>%%T.P^BF>8O]X4OF+_ 'A1="L.HIOF
M+_>%)YB_WA1=!8?13?,7^\*/,7^\*+H+#J*9YB_WA1YB_P!X47'8?13/,7^\
M*/,7^\*+A8?13/,7^\*/,7^\*+H5A]%,\Q?[PI?,7^\*+H+#J*;YB_WA1YB_
MWA1=!8<:2DW@\ BG4P"BBB@!*J3?ZPU<JG/_ *TUG,N&Y'11WHK,VT"BBB@0
MF?\ Z]&>N5P*1VVH[8SM4M@]^*R/">M2>)-%34)8(XBTKQ[5/]TXHU%H;/X4
M5A>'M?DUN[U:*2%8Q87/D*0?O#UK>*D#)!HU"Z$HI0"QP.3Z4F#G&"#[T:CT
M#N..**P_$NNS:#_9ABMDF^V72VYW'[H-;I7!QVSQ3U%H)2#D9 I>0V,'-4]8
MNY--T>]OUC61[>%I%5N,D=J-0T+E%4-#OWU;0;'46B$9N(1(4'1<]JT "2 !
MR:6H[H2BCIUHH&%%*%8]!WQ28QUX_I1J*Z"BC!XX/-*5(!)'2C4>@E)GC.._
M%.52YP*P?#^O2ZU<ZQ%);+&-/NFMT_V@,<T:B;1NT<=R!2E2O4<>O:FLRHI8
MN%4 DL>@ HU%="Y&,T=^G'K7+:-XZT_7?$TVCV$$SI'$9/M+C"/@X(7U^M=2
M._<=J-1Z!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "C_)HHR!SW'KT'O0 #GM29!_E7+67CK3M
M2\8#P_9PS395F^UXPF5Z@9ZUU([<<_Q&GK:XM!:***0PHHHH **** "BBB@
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MSFMH<_AFI8T%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7XT?C5W:/[HQ1A1U _*CV8>T*1 .>G(QTHP/6KH4=U%+L7T%'LP]H41P, T
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M#@GK7G7@Z._3XB>)$U-DDN5A@42J,>8H'!Q6CX\UZ\T?^S(8KDV%I=2LMSJ
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MD^O!H ZF/Q='/IFC7]OIUU/%J3A5\M<^4#_$WH*Z0' .6S[UY=INJWNF^$_
MT=I*8H[F41S#'4;3P:L:YXBOF\67VER:VN@I J_8S)'E;DGJ2>F.U 'I18 9
MHW =>*X74==UR.WT/1XI+5-8U,D27,8WQQHHY<#N:?;WFL>'/%6G:7J>H?VE
M9ZF'6*9D"O'(HSCZ$4 =ON!Z&FD]>3QS7G^ES>(]=\5:W;)JYM;#3[U0FV,,
MSKW3Z4^SO/$/BO5-0NK#5!86%C.UO# L8;SG7J6/IF@#J?#^O0>(+&6[@B>)
M(YGAP_7*]ZUMPQG/!KR+0-?N/#OPTN;P^4E[-JLD(=ON(['[V/08Z5I:=XDN
M+'Q)IEFWB"+6[?4"8Y%"8,+XR"/]GM0!Z7N% 8'O7GVC3>(=;\4ZS;?VNUO8
M:?? (JH"SKCE/I[U0O/$FIW7B/5K*378M%N+:41V-K/'\EP.SECQ@TD!Z@&!
MI:YXVNO7-UH]R+Z&WCB7-]!&-RS$C^$^E= ISS3 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #24II* %HHHH *0=32TE
M"TCG"FBB@#C?$.D^(8/$=OK^@2QSE8?)N+&=R$D'8KZ&H]/TC7]7\46FN>((
MK:S2Q1EM[6!]Y+-U8GZ5VV*" >HH \SN?!&J31:Q?0!+;5EU'[9ILJMG<,#Y
M6] >AK:.E:O?>+]!UJYMXX4@LGCNE#@E9"1P/45V6!Z48%.X'*^%]%OM+U/Q
M#/=(BI>W?FPD-G(V@<^E/\#:->:'H,UI?*HE:[EE 4_PL<BNGP*" >M) <+J
M>CZ[:>-9-<TVRM=1AN(%@V7#[6MB.ZYZ@U6MO"VM1^"?$6FSB%[Z_GDEB,9P
MK;L?ETKT/%&*2T XOQ#X>U+4?!.G:;;11F[MY+=G1GPN$(W<_A2ZCI.LZ9XK
M_MW1H(;H7,"PW5M(^T_+T8&NR*@]12[1Z4[B.*\,Z+K=KXOUG5]6$7EWL<8B
M\ILA0!TQUS6CXGAU]A:2Z,EM<QHQ^TV5P !,N.,$]#71[1SQUHVCGCK0QGGF
ME>"KR73_ !$]Y#;::=7C"+9P',<1 X)]\^E4M1T3QGJOA>VT.>RM(([22(&5
M9=WGJA';MTKU'%&!0(X?7="UN7Q;H^L:6D!6RMG25)7P') ^7_Z]+9:!JVLZ
M_/K/B"&&U5K1K."UB?>45NK,>AS[5VVT8QBEP/2@;U/.K'2/&NGZ?!X=MFMH
M[*!PJ:F&^?RLYQL]>U7;W2_$.E>,+O6-%MK:^AU"*..5)7V&)EXW9[_2NX"@
M#I2;1G..:$!P_AKPUJ]GH_B&UU-H5N-1N))$DC.5PRXSCM68WAGQ'?\ @&WT
M>ZM[6WNM.E1H4\S=%=*IZ-Z UZ9@>E)M'I0P1PEEI7B.]\7Z1K&HV-I9V]K#
M)&T$#[BI(X.?TK2\-Z+?:;J'B.:[CC6.^O&EA*MG<I&.?2NJP*3:/2BX'GEM
MX)OY_ <ND7(BBODO7NX0QW+G?N4'V-7=+TW7)]5MIKK2-+TJW@R9O*4.T[=@
MI'W17;%03G%+CVHN!P$&F^*O"UQ?6FBVEM?:?=3O/"\TFUK=FZ@CN,TK^ [K
M_A7\NBK=1MJ,DOVIYB/D:;=NQZX[5WV!Z48'I2"YYS>Z9XNUZ[T*:_L;2TBT
M^[$DD<<VXL ,;L_TJYXAT_Q--?WD2Z9INLZ;<#]RL^%:V.,'KU'?BNYVCGCK
M1M![4[@8GA/19/#WAFRTN:;SI(5(9N2,DYP,]A65;Z9K&G_$.\U&"UBGTS4(
MU667S,-$5'IW%=CBC ]* .#TOP_XAT[P_J\-G-#;ZA/?O<P%^5=#CY3Z9J'1
M_#NKW7BVWUW4-*LM(^S1-&5M""9V;N<=A[UZ%@>E&,4 >8:QX;\5:[;R:1J%
MAID^Z3Y-:Z21KNR"%'.X#CTK7U71M<TWQ-:ZYHL,.H,;,6DT4[[#@$8<'^8K
MM]B\\=>:7:...E ' Z/X6UB6\\3OK)@4:NJA6BY"C;@C%5K30/$4-I;Z2FE:
M3#Y!53J@0,60'LO7/;FO1\48% %>6%9;5[>3E'0HP'N*X.UT?Q9IGAZY\,6T
M%I+;"-X[:_+XPK9(!7KGGKTKT0 #H*0J&!!'!H \]3PIJRZ-X.M3'$TNES![
MH%\?+C&1ZG-6O$%AXFFU"[B73-.UC3+CB%;@*K6WKUZ_A7<X [48H \['@C5
M--T'0GL)HI-7T=F95<G9(&ZIGL*OV&E:[K7B6SUG7[>"R@L$86]K')O)=N"Q
M/3I7:X%)M [>U '+^&-&O=,UOQ%=7*((KZ[\V##9)&.]9UEI/B+PUJ&HV^EV
MUM=V%].T\4LDFTP,WW@P[C/I7=8'I2;1GI[4 >:V7@?5&\#/I=[)#_:4>H->
M0L1F-SG(!'H>?>M?2=-UN?6;>>ZTC3=*M+<'S!"JL\[8XP1]T?K79[1Z4N :
M .6\,Z/>Z9K/B"YND58[V[\R%E.25P.M8FOZ1XHOWO\ 3I=,TS5;.YW?9;F<
MA6M0PQR.N1UXKT3 I-HR3CK20',65GKFC0Z#I5H(;FRAC\N]N'?YQ@<8'?FN
MG7'..E+B@#'2F M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)1
M0 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 II*** %HHH
MH *JS2.LA ;BK54Y_P#6FHD[%05V)YLG]ZCS9/[U,[T5E=FUD/\ -D_O4>;)
M_>IE%%V*R'>:_P#>H\V0?Q4S(YR>!R?:N3'Q*\)F0QKJ$F=Q3?Y1V@CKS33;
M"R.P\V3^]2>;)_>K+N-?TNT.GB:[!_M!]EJ5&1(?K4T6J6<VJW&F)+_I=N@>
M5"/NJ>AHU#W2_P";)_>H\V3^]3,_GV'<T$XZ_A[TKL+(?YLG]ZCS9/[U,R#P
M.N,XH'/3IZT[L+(?YLG]ZCS9/[U,SQD<T=,Y.,47860_S9/[U)YLG]ZFYQU.
M.,G/:J.H:S8Z7-917<I5[V7R8,#(9O2B["R-'S9/[U'FR?WJ8> 2>@[T9&,]
MJ+L+(?YLG]ZCS9/[U1Y'K2TKA9#_ #9/[U'FR?WJ9WQW]*!SCCK1<=D/\V3^
M]1YLG]ZH\\=^F<4;@3@<_P!:+L5D2>;)_>H\V3^]3"0IY_#WJGJ>J6>CV?VN
M^E\N$N(PV,_,>E.["R+_ )LG]ZCS9/[U1@ANA'0&E^O'U[T7860_S9/[U'FR
M?WJ@FN(;:!Y[B18847<[R' 4>]);W,%W;I<6TJRPNNY70Y!%&H618\V3^]1Y
MLG]ZF44KL+(?YLG]ZCS9/[U,HHNPLA_FR?WJ/-D_O4RBB['9#_-D_O4>;)_>
MIE%%V%D/\V3^]1YLG]ZF447860_S9/[U'FR?WJ911=BLA_FR?WJ/-D_O4RBB
M["R'^;)_>H\V3^]3**+L+(?YLG]ZCS9/[U,HHNQV0_S9/[U'FR?WJ911=A9#
M_-D_O4>;)_>IE%%V%D/\V3^]1YLG]ZF4478K(?YLG]ZCS9/[U,HHNPLA_FR?
MWJ/-D_O4RBB["R'^;)_>H\V3^]3**+L=D/\ -D_O4>;)_>IE%%V%D/\ -D_O
M4>;)_>IE%%V%D/\ -D_O4>;)_>IE%%V*R'^;)_>H\V3^]3**+L+(?YLG]ZCS
M9/[U,HHNPLA_FR?WJ/-D_O4RBB['9#_-D_O4>;)_>IE%%V%D/\V3^]1YLG]Z
MF447860_S9/[U'FR?WJ911=A9#_-D_O4>;)_>IE%%V*R'^;)_>H\V3^]3*#Q
M1=A9#_-D_O4>;)_>JFVH6:7ZV+740O&7>(-WSX]<59[GVIW860_S9/[U'FR?
MWJ912NPLA_FR?WJ/-D_O4RBB['9#_-D_O4>;)_>IE%%V*R'^;)_>H\V3^]3*
M*+L+(?YLG]ZCS9/[U,HHNPLA_FR?WJ/-D_O4RBB['9#_ #9/[U'FR?WJ911=
MA9#_ #9/[U'FR?WJ911=A9#_ #9/[U'FR?WJ911=BLA_FR?WJ/-D_O4RBB["
MR'^;)_>H\V3^]3**+L+(?YLG]ZCS9/[U,HHNQV0_S9/[U'FR?WJ911=A9#_-
MD_O4>;)_>IE%%V%D/\V3^]1YLG]ZF4478K(?YLG]ZCS9/[U,HHNPLA_FR?WJ
M/-D_O4RBB["R'^;)_>H\V3^]3**+L=D/\V3^]1YLG]ZF447860_S9/[U'FR?
MWJ911=A9#_-D_O4>;)_>IE%%V*R'^;)_>H\V3^]3**+L+(?YLG]ZCS9/[U,H
MHNPLA_FR?WJ/-D_O4RBB['9#_-D_O4>;)_>IE%%V%D/\V3^]1YLG]ZF44786
M0_S9/[U'FR?WJ911=A9#_-D_O4>;)_>IE%%V*R'^;)_>H\V3^]3**+L+(?YL
MG]ZCS9/[U,JO?7UMIEC/>WDOE6T"%Y'(Z"G=A9%OS9/[QH\V3^]7*6GQ%\+7
MUQ##'J#(TQ C:6,HK$].3749!^OI1J&@_P V3^]1YLG]ZH\CGVI<CN<?6E<+
M(?YK_P!ZCS9/[U1YZ>]4KC6;&TU:TTJ:4K>78)A3:3N Z\T7861H^;)_>H\V
M3^]5"RU6SU"XO(+67S)+.3RI@!]UO2G:CJ-KI-A+?7LGE6\6-[D=,T[L+(N^
M;)_>H\V3^]4,4B31))&<JX#+[@]#3\'.,47860_S9/[U'FR?WJ9SC@$TF1V.
M?I2NPLB3S9/[U'FR?WJB>18T+L?E )/^'UJKIFJ6FL6"7UC+YMN[%5;'4CK1
M=A9%_P V3^]1YLG]ZF9XS29'KSZ>E.["R)/-D_O4>;)_>J/.<8[G I>,XSSZ
M4KL+(?YLG]ZCS7_O50CU6RFU>;2DF!O88Q+)%CHIZ&KE.["R)X9&:3!.1BK%
M5;?_ %GX5;[UK#8RFK,****HD#5.?_6FKAJG/_K36<RX;D?>BCO161L%%%%"
MW!C)/]5)DD?(W\J\F\+>,='T_P '3Z5/IUU=71DF79':%E<DG'S8Q7K,@_=R
M8!W%&X]>*YGX>VMS8^$HX+N!X)A<RG:ZX."W%..S)ENC#T:2_P#"^A>$]+NK
M.%IKRY82)+R85)R,>_.*TK"6.V^*'B2>4[4CLHW=O10#5CQ=9W=UKOA>2&"2
M58+XR3,H^ZN.IJ%-*GO/'7B7S(I$M;NP2&.?'R$D$55R6B&+Q/XFOM)DU^RT
MRS_LE0S)#(Y$TJ*?O#L*OW_BU5TC2KC2H8YKC5B!;),=JH?XF8^U85GJ>N:1
MX8/A<^'[R;5(HC;0S(,P.IZ,7Z#CM2:OX/DM=!\-*;1]1CTHG[5;1,0SANI4
MCDD'M3L@U-[2M?O_ .WY-!UE;4W9@-S!+;2$HZ@X((Z@BJGA?Q%K_B&-M1EM
M[*WTV"65)I,G>X7H5J/POIUM_;TEY8>'9K"TBA*BXNRWFL_=0">E6/ VF7,?
M@RYLKJ*2VEEFG&)%(X8G!%&@:E'_ (3+6I=-FUZ"VL?[&A<XA>3]_)&#RW]<
M5K7WB:ZN+S3]-T&"*2\O8/M.^=B$AB/0G'<UQ=KX>AT_23H]QX1N[O54;RTD
MWMY$PS]]F!P/I717]G?>'/$NGZ[;Z9)=6JV(M;B"S&YHF[;1W%&E@U*7BC4_
M$=UX)U%7MH;"ZM)@EPV25D7(PT9]ZT[C5-1TV#PM#J$-E<7%Y.(RP7(C7;D%
M?]JHM3;7O$/@?67GTWRS*X-E:D$2% 0?F'8^U1:@]YK,?@VZBTV\A%O=@SI+
M'AHP%QD^U+0'N:MYKVKWOB&ZTCP];6Q:R -S=73'8&/10!WING^*KBZT766N
M;9+75M*5Q-#G<F0I*L/8U1DDOO"/BS5KUM+NK_3]499 ]JFYHW'8CT]ZCL-*
MU*;2O%.KWMJ\%YJL;+%:9!9452%_$TN@UN0CQIXFA\-67B:?2[3^RI%7S80Y
M$P!.-P[8]J] C=9(T=#E64,/H:X+4=/OI/@U!8K:.;W[/&A@VG<"&]*Z$ZY]
MBU71]$%I))/=6^^1@0/)"CN*J270$R]KNK0Z%HESJ4ZLZ0@$(G5B>@KDM3\4
M>+-$TRSO[W3K#R[V9$"Q.28 Q[YZ\5N^-=+EUGPK=V<#()_EEB+O@%E.<9[5
MQGBSQ#J&J>&=-MWT:ZL]EW MP]P,+D$<)_>_"DD@;9TVL^(=9A\7PZ!H]K;2
MM/:F:.64X$9!YW59U74=?M6M+:"/3X':'=/>7<FV%7_NJ*@FL[EOBO;7@@E^
MR#3"HGQ\N[/0_A6;K]O-'XX-YJ>B76JZ2]NJ6RPJ66*7OO7MGUINQ.I>LO&Z
MGPEJ&K7D"K+82-"Z0/E97S@;3Z&N;\97OB63PQ!)K%C:1VMU=0LAMV)>WR<@
M-ZU+I_AG4+SP)KFGBP%C=/?F>" MA6VG<%!_#%2>)]3U;Q#X9MK*WT"_BDCF
MA-T'3&T*>=I[_6C2PU<Z/5-?U%M=&@Z,EH+F&W6:XFNI"$C!Z#'<FK7AG7I-
M:BO8;N&.*_L9O)N$B;='G&05]B*YGQ!HD,/B^76=1TFYU"PN;=(]UJQWPNHQ
M@J.H-;O@S3Q96MY,-'72TGDW)"7+2,O9GSWHT!7)/&'A^WUW2)OMDLWDVT,D
MAA1L"0[3@FF_#["> -& P%$1'ZULZHC2:/?1HI=VMI-H'<E3@5E>![>:T\$:
M7;W41CFCCPZ'L<TNA74Z =.>O>BCKSZT5!04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUQ/HUW-:7-YYD+0)EFX]*JSZ'JO_  K[Q#-/:.M]JEQ]H%LG+(F>/QQ1IIZ
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M9$!.[<,YR<G':E!(Z&IOLRX W' [4OV<>II.#ZASHKGYCD\G&/PI<G.<U/\
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M11VT'#2;LYWG\*]*'WOPH0#J***8!1110 4444 %%%% !1110 4444 %%%%
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ML;=0LDH"_>)QEMU>I26=M+<17$D$;319\N0J"RYZX/:H9M'TVXO1>S6%O)=
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MC?\ B:[\B-KDZE(JR,N<@#C'I0XA<Z*^\2Z-I]\=/N=2@BO&3Y4)R0<=ZR_
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M9:G-$S7-IN,#!L 9ZY%9UUX,T"\U*34)[,F>4'S0DA5)#_M+T)KH?*;GY>M
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MT>4_]VCE8<R&44_RG_NT>4_]VCE8<R&44_RG_NT>4_\ =HY6',AE%/\ *?\
MNT>4_P#=HY6',AE%/\I_[M'E/_=HY6',AE%/\I_[M'E/_=HY6',AE%/\I_[M
M'E/_ ':.5AS(913_ "G_ +M'E/\ W:.5AS(913_*?^[1Y3_W:.5AS(913_*?
M^[1Y3_W:.5AS(913_*?^[1Y3_P!VCE8<R&44_P I_P"[1Y3_ -VCE8<R&44_
MRG_NT>4_]VCE8<R&44_RG_NT>4_]VCE8<R&44_RG_NT>4_\ =HY6',AE%/\
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MN55))  Y.3P*=@'45%%<P3@F&>.0#J48''Y4C7=NDPA:>)93T0N 3^% $M%
M-!(]:5@%HJ#[;:[G7[3#E/O#>/E^M.>X@C(#S1J2"PW,!P.]%@)<48J%KNV2
MW$[7$0A/20N-I_&GK+&ZAD=64]"IR*+ .SS0.:YKQEX@;1O#-_>Z?-"]W;[?
MER"1D@<BMRWNU_L^"XN)$3=&K,S$ 9(!HL!9/%&13(Y8IT#Q2*Z'HRG(-8WB
M77CH&G"6&QGO+F4[88(1DLWN>PHL"-O(I:Y_P=KT_B7PU;ZI<VZP2RE@T2G.
MW!Q70CH*+ %&***+ %%%%%@#%&***+ &*,4446 ,48HHHL 8HHHHL 44446
M*,4446 ,48HHHL 8HQ1118 Q1BBBBP!11118 Q11118 HHHHL 8HQ1118 HH
MHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2 <4M07
M4JV]M+.Y(2-"[8ZX R: )=PQD@T!L]1@UYY'X]UA;*#7;K0TBT&601AS)B9
M3@,5]*]!C<.JNO*N,@^U $E%%% !1110 4444 %%%% !1110 4444 %%!.*3
M<,XS0 M%&1G%% !1110 4444 %%%% !1110 4444 %%%% !11D49!H ****
M"BBB@ HHHH **** "BBB@ HHHH *3(%+6#XH\0'P_8B:*SGO;F3*PP0KG<<9
MY/84 ;H(-+6!X-UR?Q'X9MM3N8%@FE+!HE.=I!QBM^@ HHHH **** "BBB@
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MU9HV3:_N 36OH&K76KV\DMUI%UIK*V!'<,I9O?@UKT4 %%%% !1110 4444
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M;[YI*DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HS^8Z9Z"BD(R.02.A'3(-(3.:M/'6E:CXN'AZS62>78S&Y4?NP
M5Z@'UKILD\'@]_K7%75M!9_%/0H;:%(8A9S'8@QD\\UVO<UHU[MR4];!1114
M%A1110 4444 %%%% !1110 4444 %&::[*B,YZ*-Q('.*Y5_B1X;1Y$:2^W(
M2&Q9R$<?AS0!UG;-%4],U*VU:Q2]L]Y@?IYB%#^1JY0 4444 %%%% !1110
M4444 %%%% !1110!S_BKQAIGA*R\^^,DDS#,<$0R[>I^E;%C<K?:?;WB(42:
M,2!6ZC/K6)XXMH&\(ZM=&"-KA+1U20KE@/0'M6AX<'_%,:7D'/V5.ISVJN@C
M3HHHJ1A1110 4444 %%%% !1110 4444 '?%%'H.YK U7QGHVBZ@;.]>Z$P4
M-B*W=Q@^XH WZ*Q=$\5:7X@EEBT]K@O&-S>; R#'L3UK;]J=@$HHHI %%%%
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M;:G807MK('MYUW1MTR*LY&<46078WRD_NBD\I?[HI)[B*VMI)Y6VQQJ68^@
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M7V5W<^(O"\MO;O+%!=NTK+_ -O4TP.OSS3J;C)S[TZD 4444 %%%% !1110
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M8^$=4U#6] CU.^BCB,[,T2)_SSS\I^I'-8UQK_B*Z\9:AH.E6]F%MHXY//N
M> W4<'FNRM+6.SM(;:%0(H46- .P Q7+:/97</Q(UV[DMY!:RP1".5NA('(%
M #+[7]7O-?N='T;[#$UDBFYN+HY!8C.U1G]:P/$GB!O$7P\>>:-8;FVU%()T
M1MRAU<9P>XJ35_#]O9>+=2U'4M FU:TO]KQR6_+Q$#!4C(X[YINIZ%>_\*]:
M"WT*.SGDOHYA9VYR0FX<M[XZT(&=7XAU+5[5[2'3DLH8G3=+>WK_ +M/10HY
M)-<^_B/5=?\ !6NB"2TBOK)VAEGB):)U SN0@YS2^)[&Y3QC:W]_HUSJ^C_9
MA%%#"01#*3U921GCC-1^&M$U!="\56S:<+"6[FD,$ ^Z%*_*!0!+I&OZCX?^
M&]A>ZB8;NYE6..T5,C);@!B:OVOB'6-.U[3[#7182QZB66":T8_NY ,[&!//
MUK"?2M0\2?#>QL6T::&[TUX]UI<X43[.NT@]#_6K.AZ9:W/B"RFL/"!L88-S
M3W-WPT;=A&,G/?F@9?3Q!XBUC4[\Z%:V9TVPE,+F<DO<..H0C@#MS1\*)&F\
M*SS21^7(][,67T.[D57T>35/"%SJ>E'2+B[CN;I[BRGBP5._G#DG@@UH?#6Q
MU"P\-31ZG;F"Z>[E=E/?+9X]J!'9&DHHH 6BBB@ I.]+5>69D<@8Q2;2&E<G
MS]*,_2JIN']J//?VJ>=%<C+6?I1GZ55\]_:CSW]J7.@]FRU^5(<&JWGO[4>>
M_M1SH/9LM$ C!I,#I5;[0_M1]H?VHYPY&60 .E! (JM]H?VH^T/[4^=!R,LX
M&:#5;SW]J//?VHYT'(RG=Z%;7NO6&K2,XN+)66,#[I#=<UJX&>U5?/?V]Z7S
MW]J.=!R,LD ]<48&,=JK>>_M1Y[^U'.@Y&6N,D]S2  56\]_:CSW]J.=!R,M
M4<"JOGO[4>>_M1SH.1EG I'19(WC;E7!!&>QJOY[^U'GO[4<Z#V;%L["UTZS
M2UM(5B@3HBUE:[X6M-;N+:\,]Q:WML"(KBW;# 'J,=ZT_/?VI/.<=Q^5'.@Y
M&4-"\-6>A?:)8GEGNKE@T]S.VYWQTK:VC_)JJ9WQQC/TI?/?VHYT+D99(!.3
M2_E57[0_M1Y[^U'.A\C+5)@8Q5;SW]J//?VI\Z#D99  Z4M5?/?VH\]_:ESH
M/9LM49^E5?/?VH\]_:AS0>S9:S]*,_2JOGO[4>>_M2]H@]FRUGZ49^E5?/?V
MH\]_:CG0<C+6?I1GZ55\]_:CSW]J.=![-EK/THS]*J^>_M1Y[^U'.@]FRUGZ
M49^E5?/?VH\]_:CG0>S9:S]*,_2JOGO[4>>_M1SH/9LM9^E&?I57SW]J//?V
MHYT'LV6L_2C/TJKY[^U'GO[4<Z#V;+6?I1GZ55\]_:CSW]J.=![-EK/THS]*
MJ^>_M1Y[^U'.@]FRUGZ49^E5?/?VH\]_:CG0>S9:S]*,_2JOGO[4>>_M1SH/
M9LM9^E&?I57SW]J//?VHYT'LV6L_2C/TJKY[^U'GO[4<Z#V;+6?I1GZ55\]_
M:CSW]J.=![-EK/THS]*J^>_M1Y[^U'.@]FRUGZ49]Q57SW]J//?VHYT'LV6L
M_2C/TJKY[^U'GO[4<Z#V;+6?I1GZ55\]_:CSW]J.=![-EK/THS]*J^>_M1Y[
M^U'.@]FRUGZ49^E5?/?VH\]_:CG0>S9:S]*,_2JOGO[4>>_M1SH/9LM9^E&?
MI57SW]J//?VHYT'LV6L_2CKZ55^T/[4?:']J?.@]FRUBC\JJ_:']J/M#^U'.
M@]FRUFC/TJKY[^U'GO[4<Z#D9:S]*,_2JOGO[4>>_M2YT'LV6L_2C/TJKY[^
MU'GO[4<Z#V;+6?I1GZ55\]_:CSW]J.=![-EK/THS]*J^>_M1Y[^U'.@]FRUG
MZ49^E5?/?VH\]_:CG0>S9:X]J./:JOGO[4>>_M1[1!R,M?E1FJOVA_:C[0_M
M3YT'(RUGZ49^E5?/?VH\]_:ESH/9LM9^E&?I57SW]J//?VHYT'LV6L_2C/TJ
MKY[^U'GO[4<Z#V;+6?I1GZ55\]_:CSW]J.=![-EK/THS]*J^>_M1Y[^U'.@]
MFRUGZ4'!ZXJKY[^U'GO[4<Z#V;+7'M1^55?/?VH^T/Z"GSH.1EK-&?I57[0_
MM1Y[^U'.@Y&6L_2C/TJKY[^U'GO[4N=![-EK/THS]*J^>_M1Y[^U'.@]FRUG
MZ49^E5?/?VH\]_:CG0>S9:S]*,_2JOGO[4>>_M1SH/9LM9^E&?I57SW]J//?
MVHYT'LV6LT55\]_:CSW]J?.@]FRU157SW]J//?VHYT'LV6L_2C/TJKY[^U'G
MO[4N=![-EK/THS]*J^>_M1Y[^U'.@]FRUGZ49^E5?/?VH\]_:CG0>S9:S]*,
M_2JOGO[4>>_M1SH/9LM9^E&?<55\]_:CSW]J.=![-EK/THS]*J^>_M1Y[^U'
M.@]FRUGZ4'FJOGO[4>>_M1SH/9LM<>U! /6JOGO[4?:']J?.'LV6<#.?;%*0
M#UJK]H?VH\]_:ESH/9LLX&,<4  '(JMY[^U'GO[4^=!R,M<"BJOGO[?E1Y[^
MWY4<Z%R,L]JR9M!MI_$=MK4CR-/;Q-%$G\*@]3]:N&=_:CSWQVHYT/V;+0ZX
M[>M+503/WQ[<4OVA_:CG0>S99P*,#.>!]*K?:']J//?VHYT'LV6< G-&![56
M\]_:C[0_M1SH.1EG SGO2U5^T/[4?:']J.</9LLX'M2U5^T/[4>>_M1SH.1E
MJBH(I6=\''2IZI.Y+5A:***8@-4Y_P#6FKAJG/\ ZTUG,N&Y'WHH[T5D;!11
M10 $@=35>UOK2^#FTN8I_+;8_EL#M/H:F<XCD/'W6R3].E>/>#,^$[RUU8,P
MTS5[J6VO"3D12AOD;\>E-";/7EN8&F>%94,L8W/&#\P'KBI>AQWKD-+&WXG^
M("!M/V.++Y]Z2;QO/:PM?3:!=1Z0DWEFY=L/UQNV=<9-.PKG8=\=_2DR.N1C
MUK U/Q,UKJ\.DZ=8-J%])!YYC#[%6/U)/>D@\4QR>'9M5;3KQ)89#$]GY>9?
M,!QCZ>]+E8<QT//H:BBN;>=I%AFCD:)ML@1LE#Z'T-86E^*)[C6X=*U/27TZ
MYG0RV^9 ZR =>1T/M6?X&&W6?%N./^)EGD<YVBG8?,=E^!J(W, N?LQF3S]N
M_P K=\VWUQ63X@\1IHLMK:P6DE]J-WDVUHAP3CJ2>PKE]-U.74OBW ;K3Y;&
M[ATQQ)!(<XY/(;N*+"<CO;>\M;Q'>UN(IU1BK&)@V".HXJ;TQS[BN+TGQ)H^
MF>%M2U>&P-C;P7LD;Q1MN,LF0,GTW$BM/3/$ES<ZM#INI:)/8/<1F6%R=T9
M[$CH?:AH.8Z$<C-&0?\ &N/F\=D+-?6VCW-SI%O*8I;Y#D@@X)"]P":NZCXJ
M\C48M,TK3Y=2OI(A.8E^58T/0L?X?I2Y6',=%D<<CDX'O1N'J,5@Z7XGBU*V
MU$RVTMI?:<I^T6DGWEP,@J?0^M847Q(EDT>#6V\.W2Z2?]=.&!$7.,@=Q[T<
MK#F.\R,9R,57O+^ST^-7O;J&W5CM4RN%W'T'K7,'QTT5Q:37&BW,6CWKB*&_
M)!R6^[E>PK$U]K^_^*&G07&@I>0P6S&)'FRK<C]YCU%.P<QZ2&!Q@YR,C'<>
MM&1Q[]/>N:NO%,@U2YTO1='FU)[,#[2RMLCC)'W >Y]J1_&EF?"%YK\=M(WV
M1BEQ:MP\;@@%3Z=:.47,=/Z>_2BO._$GBWQ WA>6_P!/T66U@?R_*O))ANVL
M1_#CBNVTBXNKK2X);VU^RS%!F,ON[=<^])JPU*Y>H_#'UJ*XGCMK:6XF8+%$
MA>0GL ,FN+N_B%+;:/)K<GAZZ_LHC]S<9Y?G .WL#2'<[@," 1WI>P]^E<SK
MGC!-'72/] EN7U,?NXXSSNQD"IKGQ!?VFGV<DF@SMJ5VQ1;17W!!W+MT48JN
M4.8Z#\*9++'!&TLKJD: EG8X50/4UB:/XE34'OK>]M6L+S3EW3HQW*$/.Y6'
M7I7*^(_&$^I^#=6E70KE-'F@=(KW=RW;.WT-'*Q<QZ+'*DT:21.'1QN5EY!'
MK3B0#COZ#O7*6^O+HWAK0;2"TDO;^[MT6&W0X)P.2Q[ 5H:)XC;5+RZT^[L9
M;'4;50\ENQW95NA4^E'*',;E(KJXRK!AG&0<UG:Y87FI::]I97YLG<@23(,M
ML[@?6N<^%\(MO#=Y;>;+(L-_,BM*VYC@]Z5@N=K12#( !H[TBD+1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137Z>_KZ4 +N4$ L
MH+#(!/)%+7G%II-YI?Q8TZ2^U.:]N+JVF=U)PB@?= 7MQ7H_;T _G3:]VY*>
MM@HHHI%!1110 4444 %%%% !1110 4444 '2D9E5=S.JKG&2>*7KD#CCKZ5Y
MO\2M*O&$&K2ZG.+>.ZA2"TB.T<L,D^M-*XF>D?@:*4\$@ #MD&DI-6!,****
M!A1110 4444 %%%% !1110 4444 %%+M;T/Y4$$=010 E%%% !1110 4444
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MM]ZN&QG/<****L@#5.?_ %IJX:IS_P"M-9S+AN1]Z*.]%9&P4444 -?/E28
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MNX#\* -"BN)31O'@=-_B:Q*@C</LN,UV,0<(@D(9P &(& 30!+1110 4444
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MW5K%<1JVV1 P!&#@C->1Z6)[Z[LOA_-N;^S+YIKEB.&@4[D'ZX_"O8>!D#@
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MZ*/QS12U&%%%%+4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU
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M$3L?XBOK0Y7&E8YBXBBE\->!#-&CLTL8=G0-N7'<GM6WJ*JGQ;TC8JKMTZ8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7>*.*/9A[0I;'_NFC8_]TU=XHXH]F'M"EL?^Z:-C_P!TU=XHXH]F'M"EL?\
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M7>*.*/9A[0I;'_NFC8_]TU=XHXH]F'M"EL?^Z:-C_P!TU=XHXH]F'M"EL?\
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M1[=8+L2(3%-CG=QR"#TJ4>%;B[\.ZEIVL:I+=S:@27D PL6>@0=@#74  #%
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MVEF[AV@A6,N. <#%<]JGAG5(]?EUKP[J$-I=W*A+B*Y0M%(!T;CD&NNP.]&
M1@T7 Y#3_!DUMI&IPSZI*=2U1S)/>0C:R-VV>PJM;>$]<NM3TVZ\1:M:W,.E
MMOMQ!'M=VQC+D_TKN>*:44G-%P.$O_!_B*ZBOM+77HI=&O79G6XCW31JQR54
M^GI6F_A<Q>(M#U"&X5;32[4VXC;[S#;@'/05U.!CGF@@'K_^NG<#AH?"FOZ9
MJVL:GI.JVR2:E.9?*F0LBCL?K2R^ B/!=[HT5]F]O)A<3W4B\-(6W'CT]*[?
M:N0>X[T;1CDY^M*X'#?$FVC'@)86E*7L;Q):.@Y\[H,>G>NE\.Z4NB^'[+3T
MY,,8WN?XF_B/US6A/:V]R$$\22A&#KN&<,.AJ7 SG-.X-'/ZWH$NJZ]HNH).
MJ1Z=*TC(1][(Q1XB\/W&J7-GJ&G78M-1LF/E2,NY64]58>E=!@8ZGZT8&<CB
MI6PSF;#1-8+7MQJVJ^?<7,)A6&)=L,?N!US66W@.Y'A+2M-345CU#3)?/@N
MF8R^3P5/;FNZVC/4T8%.^I-M#C]-\,ZPOBNWU[5=2@N)TMC \42%47GC9_\
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M78:"[C_>-&X_WC2'CK1T.*-0T%W'^\:-Q_O&D]?:E )Z"C46@;C_ 'C1N/\
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MLJJ3%%!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
M8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ1
M10 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8
MHQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ11
M0 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8H
MQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
M 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ
M110 8HQ1S1S2N,,4<#DTE/BB:615'0')IQ5V3+:[+VGH5C+$8S5VFHH50!TI
MU=D8\JL<,G=W"BBBJ)"DI:,4"()X%F7D<UF2P20G!7Y?6MK%(5##!&:B4$S6
M%1Q,'/N*7/TK8:UA?J@I/L<']RL?8OH;^WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1
MGZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K
M_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/
M[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V
M.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y
M1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1
MGZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K
M_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/
M[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V
M.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y
M1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1
MGZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K
M_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/
M[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V
M.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y
M1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1
MGZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K
M_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/
M[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V
M.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y
M1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1
MGZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K
M_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/
M[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V
M.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y
M1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0
M>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9&?I1GZ5K_8X/[E'V.#^Y1[&0>WB9
M&?I1P#U!K7^QP?W*5;6%>B"CV,A>WB9D5O),?E&!WK3A@6)<#KWJ4*%& ,"E
MK6$.4QG4<@HHHK0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_004b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '6 [\# 2(  A$! Q$!_\0
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M_P"><G_?UO\ &C^PK#_GG)_W];_&M*B@#-_L*P_YYR?]_6_QH_L*P_YYR?\
M?UO\:TJ* ,W^PK#_ )YR?]_6_P :/["L/^><G_?UO\:TJ* ,W^PK#_GG)_W]
M;_&C^PK#_GG)_P!_6_QK2HH S?["L/\ GG)_W];_ !H_L*P_YYR?]_6_QK2H
MH S?["L/^><G_?UO\:/["L/^><G_ '];_&M*B@#-_L*P_P"><G_?UO\ &C^P
MK#_GG)_W];_&M*B@#-_L*P_YYR?]_6_QH_L*P_YYR?\ ?UO\:TJ* ,W^PK#_
M )YR?]_6_P :/["L/^><G_?UO\:TJ* ,W^PK#_GG)_W];_&C^PK#_GG)_P!_
M6_QK2HH S?["L/\ GG)_W];_ !H_L*P_YYR?]_6_QK2HH S?["L/^><G_?UO
M\:/["L/^><G_ '];_&M*B@#-_L*P_P"><G_?UO\ &C^PK#_GG)_W];_&M*B@
M#-_L*P_YYR?]_6_QH_L*P_YYR?\ ?UO\:TJ* ,W^PK#_ )YR?]_6_P :/["L
M/^><G_?UO\:TJ* ,W^PK#_GG)_W];_&C^PK#_GG)_P!_6_QK2HH S?["L/\
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MN_7H*H^&?^1@\1_]?0_D:U]9UBWT6P:XF^9S\L42_>D;L!0!D^&]4U%]6O\
M1M3D2>:U 99E7&X'U_,5T]<]X8TFYM1<ZGJ./[0OFWR*/^6:]EKH: "BBB@
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M95N/M^KR71YAM<Q1>A?^)OZ?G0!:T^R^Q6^&;?-(=\LAZLQ_I5NBB@ HHHH
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MSPZ?6[_4]JHHS17S! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8FL^([?1]1L+27!-R^'.?N+T!_/'ZUMUPNO\ A"74]:^TW&JH
MCW+[(8_*)P "<=?0&NPTZ">UT^""YF$TL:!6D QNQWH M4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:N
M/L[6VH+UMY,/_N-P?Z'\*TZANX!<V<T!Z2(5_2H-)G-QI5M(WW]@5OJ.#_*@
M"$?O/$C>D5L,>Q9O\!6G69:\Z_J!](XA^AK3H **** "BBB@ HHHH **** "
MBBB@ HHHH *\8M?^3I[[_L'C_P!%)7L]>,6O_)T]]_V#Q_Z*2@#TG7].LXM&
MNIH[:)90 =P7G.15[0_^0'9_]<A4NIVGV[3IK;?LWC[V,XP<_P!*R/"#NUA.
MK.S!)-JY/08[5&TCQN54,TCRQLIP:TLM4[O\SHNHKP75BFB?$&9K:V&+6YWQ
MVZ\9'7CVKWJO%?%T6H67Q.N=3CT.?48!&JA-C;&RF.H':N7'4^>"MN?:Y'5Y
M)U(-74H[-VOJ9'AC7463Q=%-&(_[11I 22=K!F(7IS][K[5NKIND^(/"FB6]
MUKGV":R\W*B$N3N8'\.E>=6^IK::G?32VCJ)F<&%?X"2>.?0_P JZG0/&FCV
M6FFVO_#US>S*Q*R1'&%]#^.:^TQ^$S*I"<L*DW>#5^J]FD^O?N>33KX:E1BF
M[/6Z5]'S2\K;6)FLDT;QAH4-GK]QJ,<MS&78[D"_.!C!/->\@@]"#7S+=:O8
M:E,CS6^IQ.G""!58_KWK9\$>.AX9GOVFL;^^6;:%"MDH!GKGO7##*\PQ&'A.
MM"TTM5IW_P 78BOB<._AGMY/_(^@B0 23@#O3(Y8YEW12*Z],J<BO*-1^,%O
M=Z9=VJ^'M2#30O&"<<$J17)_"[QT?!/A)M*O=#OY9C<O-N0 #!"C^E8/)\<I
M*/LW=^G^9S?6*=KW/H:BO+O^%TVO_0NZG^E'_"Z;7_H7=3_2J_L7'_\ /O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NG?\A+4_P#K
MJO\ Z"*TJS=._P"0EJ?_ %U7_P!!% "6?_(>U/\ W8?Y&M.LRS_Y#VI_[L/\
MC6G0 4444 ><>)?BU;:=JUQHOA_1[W7M6@8QRI;H1'$PX(9L'D'T'XUACQ_\
M5@V]OAXIB_N@MNQ_WU_2O2='UOP_>W]_8Z7<VGVRWG=;N",!)!(#AB1P3SWK
MS7Q7XY\2-XVU72-,\0:%H-MIGE@?VE]^Y+*&)&5/'..* .B\,?%>TUC5H=%U
MG2+[0]7F.V*&ZC.R4^BM@?J/QKT*N0^'^N2>,_!]AJ^J6EL;M)77>J90LC%?
M,3/3/^-=?0 4444 %%%% !1110 5XQ:_\G3WW_8/'_HI*]F) ZD#ZUXS:$']
MJ>^(.?\ B7C_ -%)0![/1110!FSZ#IMS.\TUN&D<Y8[CS4?_  C6D_\ /H/^
M^C_C6M12Y5V.267X23;=*-WY(Y?7=$T^STB6>"W"2*1@[B>]<UIFE^-;&*5M
M)-JEK<2&8;V4DY ]?I7?:S92:AIDMM$5#MC!;IUK-\+7%Q)'=6\\FX6[+&HQ
MTZ_X5MA\0\/)VBFGW5UIJ<-'DP69\L*:4:D;*R5KIMO\#S;QJWB98;2+Q \#
M(69HA%CJ!@YQ]:YJ/6]1LK&PL6M$6U\Z0PS'.7RPW8^G%>B_%:-I9=(C12S,
M9 % R2?EXKSB]@U.^TZS6WL69--D=7?/1W((!!_W37#G5*,N2LTDIQ>BT5XN
MW^7W'Z5EDX5L!R32M&7HE=/]?S/H?3"3I5H22285R3]*S_$V@:=K^D2PW\ <
MHA:.0</&<=0:\D?XE>,-,LXUDMK2.) $4M%Z#CO7M-N\E]HL3M@23VX)],LO
M_P!>JPF(C))P>UCYS%8.KAK3DU9MVL[G"?!V>:30+^&25WCANML:L<A1M!P/
M3FO1Z\CT[X?>-M(26/3=<MK6.1][+&[#)]?N^E7_ (>ZGKDOB_5M+U?4I;O[
M)$5PS97<' R.*]6O2C.4JD))]3"I%2;DF>FT445PF 4444 %%%% !1110 5Y
M?\'?O>)?^O[_ .*KU"O+_@[][Q+_ -?W_P 57J83_<<1_P!N?^E,QG_$A\_R
M/4****\LV"BBB@ HHHH IWD5N]W8M-+LD24F%<_>;:01^635RJ=Y#!)>6+RR
M[)(Y28E_OMM((_(D_A5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K-T[_D):G_ -=5_P#016E6;IW_
M "$M3_ZZK_Z"* $L_P#D/:G_ +L/\C6G699_\A[4_P#=A_D:TZ "BBB@#Q'X
MC:S\.)/$<T%S%J,&N6K8DU+2(MKPO_M,"-Q&>>OUJM+;7_V.TUG7=!LO'>@O
M'NAU2WAVWB1_[:?Q8].W/-/N[:&?QEX@L_#?Q$BT1KN\D-]I]Y %;S>C%&;[
MP/;%>K>%],TWPKX7L=&MKZ.2"TCV^:[@%B26)Z\9))H ?X2UC1M;\.6UWH"J
MFGC,<<8B\ORRO!7;VQ6W7+CQOX3MM:MM%M-2M9;^\F*K!9X?YCDEF*\#IR37
M44 %%%% !1110 4444 <;X^^'L'CR.Q6;5+JQ^R%R#  =^['7/TKRSP-X8C\
M(_M"2Z-%>37:06+,)IOO-NC4\_G7T+7C%K_R=/??]@\?^BDH ]GHHHH ****
M "N)TW68M(O+\30ROYLQP5 [$^OUKMJY[QA_R#(?^NP_D:B>UT>-G,*D:2Q5
M*5I4[O:][V1@^/6SKOAA_6YS_P"/+6)8V0T;X@SZ9JMU ;&Y9[F16;;&2<E,
MY[C-;/Q$MIYK'3]3LYHLV)W$ Y;)VXP._2IY_#6G>(/#L6MZE'++J#6(9G$A
M4%@N1P.*Z\QH^UP5"I&SY;IKYW_(^QRS%TH0<*C]V:Y7:S:=U9[]+F#\4-.T
MMO"UM/H\$#[KH*7MOG_A.1Q5:R^*^JV]G#;)X;+^3$%R';HHZ_=]JO?#SQ)9
M6MI;:#/:RM<3W#,K%!M&0/7Z5?\ $EIJ<.NZA<6.FRS(]LT2[(R5.Y-IQCO7
MS\JKA%5*2T;2:2V_ [:T(X:?U2O#F2;<6W:Z;2OHSH/!/BB3Q9HCZA):K;E9
MFCV*^X<8YSCWKD;OP#XJC\2:CJFD:O;V?VN5FRK,&VDYP>*Y[PSK'C'P=HLE
MG!X8F> .TS23P2#;QST[<5Z%\/\ Q?=^+K*[GN[>"%H7"J(LX((/K7J8;&.%
MH]7W1PXS!3H2G5I6Y+]T_3N<KX)\:/IVIZI;>*-==O+811>=E@6#$-C KUI6
M#*&4Y!&0:\X\:_#A;^.&7P]96\5VT[27#O*5W \]\]ZJKIGQ450HU"TP!@?O
M%_\ B:]*I"E6M.$DO)_\ \^2C/WD['J5%>,^(+_XB^&M/%[J.IPK$S^6#&58
MY()Z;?:O7--E>?2[2:1MTCPHS'U)4$USU:#IQ4KII]C.4.57N6J***Q("BBB
M@ KR_P"#OWO$O_7]_P#%5ZA7E_P=^]XE_P"O[_XJO4PG^XXC_MS_ -*9C/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR5DN[2WEFV@,S1@_SK'B\,QQ^*9-0\BU%F80J1A>0X/7&,4 ='1110 4444
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M&S(I91["L*PL[EOAA\1U2TU,&>\9H4OD8W#J53!;N30![7H?_(OZ;_UZQ?\
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MTO[I@[S'+;][;LGOSG'MBNSK.T+1;'P]HEKI6FQE+2V3;&"<D]R2>Y)YK1H
M**** "BBB@ HHHH Y[Q3X(T'QDMLNMVC7 MBQBVR,F-V,]#["O)?"WA_3?#/
M[2%QI>E0F&TAL"R(7+8+1J3R>>I->]UXQ:_\G3WW_8/'_HI* /9Z*** "BBB
M@ HHHH Q_%$#3Z#.%(&PJYSZ UC>'M?M['3?L][+(9!(VP!<X7L*Z/6AG0[_
M /Z]W/\ XZ:\[T0!_ -M,XW2F\8%SRV/3-;>RD\/*LGHFE]^OZ'CYG3Q%!2Q
M]&2]V-FFF[ZW[H]14AE##H1FL?Q58IJ'AN^C:V6XD6)GB4KN(< X(]ZUHO\
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M6$7EQ%\[<9Z?45Y/X2\1Z=XI_:-GU;2Y'>TFL"J,Z%3E8U!X/N#0![[1110
M4444 %%%% %'6?\ D!W_ /U[R?\ H)KC/!6EC5O D,!E,6VY=L@9KNKZW-W8
M7%L&VF6-DW>F1BN"M?A[K5C (;7Q+)#$#G9&K 9_.O1P_L9X:=&I-1;:>M^B
M?8J=*E7H2HU=GZ_H=!_PBT__ $%[C]?\:S]0TZXTFZL3_:$\PEF ()(Z$>_O
M57_A"?$?_0V7'_CW^-0W'A;7;-09=3N-2+?=QG,1]1D_YQ7-6PE"$'*-5-]K
M2/G\RRC"T,+*K0OS*UK.;?Q*^EWTN+\1_#>FIH]YK20-]N>2/<^XD=0O3ITK
MH]&G_M'P%;/!&V7L?+5#U)"[?YBO/M2TO6OLES;7&J7S,(&D:&=^'4#.#^5,
M\"7M^GB#2;8WTS6DD;L(-YVJ!GC'ZUSTL)3EBI1I337(WLUL]=_4^SP^-AF&
M5>TA)R]G.VJ:M[JTL_0J>&7\=^%M-EL;3PPTT4LIE;SHR3G '8^PIVO>,_%4
M-LMEJ^@VMBEV0JL8R&.",XY^E>VUY;\8+&]NY=&>SL[BY\MI"WE1EL?=ZXZ5
MQ5J#C2:3;.K"XRGBL2E5I13=]=>WK8[KPM_R+5C_ +A_F:V*\.A\;>,M+L1&
MFDW$-M"I.7MFPHZY)(KJ?#NM>,?$6CIJ-NT C=F4?='0^]94L5[.G&#A)M)+
M1?\ !.+$9=5IIU)-6OW7Z'1_$'_D0]6_ZX_^S"HOAO\ \B!I7^X__H;5R_BF
MY\2?V=+I>HE9/M<1VQ1*"7YZ#'?-4- \4>+/#^AVVF1>$[F5( 0'>"0$Y)/I
M[UZN#K+%T)0@K.,M4[+IZG/*BU"UT>PT5Y/=?%'Q%8>6;[PV+97;:K3!T!^F
M17J-M>6]Y'NMYXI@,;O+<-@_A55*$Z:3EU,)0E'<GHHHK(@*XSQQX&F\77-A
M/!J?V)[3<0PC+')Q@@@C&,5V=%;8?$5,/456D[-$S@IJS/+O^%8^)/\ H>K_
M /.3_P"+JMJ'P\\1Z?IEW>GQOJ#BWA>79ND&[:"<9W^U>M5F>(_^18U;_KRF
M_P#0#7I4LWQ4JD8MK5K[,>Z_NF,J$$F_U9SOPJO+F^\!VT]W<37$S32@R3.7
M8C><<FNUKA/A!_R3RT_Z[2_^AFN[KES-)8VJE_,S2C_#CZ%.\M5N+RQE,H0P
M2EPI'W\J1@?GFKE4[NT^T7=C-Y@7[/*7VG^+*D8_6N$\7RV"^-XUUJZU*#3A
MI^Y#:22JOF;SUV>U8X7#^WFX7Z-[7V\M!SGRJYZ/17%WH/\ PK>Z/@^]FNB4
M+13>>9)",_. S'.[&<9Z5@^&;C3[WQ5I9\*7M_+"D+/JJW,[NH!&%!#'[^[/
M2NB&!YH3GS6Y;].ROKVOLM]275LTK;GJ5%>3V.IO8ZS!>W5U>IJ$%U<OJXE+
M^6EN-VW@_+C[FW'7-==X69KW4+K5M1N$74KI!Y=CYH+6MOU52N>&/4GWQ2KX
M!T8N3=U;MU_RZW[6[A&KS.QU5%%%<!J%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7#>.K76-5GAL[*QFEM8AO9UQAG/X]A_.NYJ
MCJQNQ8$V(8S^8GW<9V[ANZ^V: *WAJ6^?1(4U*WDAN8AY;;_ .(#H?RK7HHH
M **** "BBB@ HHHH **** "BBB@ HHHH \NO?BIJMK?7%NOAF5UBD9 ^YOF
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MJ?15L&)N)Y0B;HL8\H!3\V347_"[/#/_ #PO_P#OVO\ \51_PNSPS_SPO_\
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M/&A^,&KVL-K821):0DP27CA$AWG$@&W[Y'48_&@#U*.Y@FEEBBFC>2(@2(K
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M\(,Y' Z$[@HQUQW)K1^*_B2T\5^!O!=U80_9K*[N9/,MEP!&Z[5(X]-S8^M
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MU\(GPXLL@ 21E,DX X9@I.W&2,$UUM% !1110 4444 %%%% !6;IW_(2U/\
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M44 %>,6G_)T]]_V#Q_Z*2O9Z\8M?^3I[[_L'C_T4E 'L]%%% !1110 4444
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MRG4J.R3W^3,JT7*FTCJ8/^/>+_<'\JDKR\>!/'2@ >-7 ' 'S4O_  @OCO\
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M,M(U/XE2:S9)J-BJ633*)V\E!A,\]&]*]-K*K2=-V;3]")1Y1KL51F"EB!G
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MRO#$EGY<;.2J9BYP.@S0!WU%>)2:A>CX1>/I_MEQYT6L72QR>:VY )$P <Y
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M $$5I5FZ=_R$M3_ZZK_Z"* $L_\ D/:G_NP_R-:=9EG_ ,A[4_\ =A_D:TZ
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M5%"\8( ^8XP-Q[?6O0:* .+U?X?O=>(KC7-%U^^T2\O$5+S[,JNLX7@$ANC
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MXP??.>]=I63X9URS\2^'++5[".2.UN4)C210&4 E<$ D=JUJ "BBB@ HHHH
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M  H_L'1_^@59?]^%_P */:Y;_P ^Y_\ @2_^1#EK=U]QR/\ PN+PE_SVNO\
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MY&M.LRS_ .0]J?\ NP_R-:= !1110!A^+Y] M_#%Y)XG6)M( 7SEE0L#R-O
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M>GM0!Y?X;2:U\'?%/3WLH[".W68I8Q3>;';EH&RJM@<<#L*].\ ?\D^\/_\
M7A#_ .@BH]-\ >'M)TO5M-LK66.VU5"EVIF9BX*E2<DY!()R?4YK=TS3K?2-
M+M=.M%9;:VB6*)68L0H&!R>M 'E%EHNLZS\2_'::3XCFT8++;+(8K=9"Y,7!
MR>F.>E<I<SM#\)[[1Y+:)XO#OB"..\N+?)6Y0.=TASW)(S^%>NZG\-/#NK:Q
M>:I.+^.ZO"IG-O>R1*^ %&0I Z"M?3?"VB:3H+:)9Z="FG.I$D!&X29ZEL]2
M?>@"_'?6CV$=ZMQ%]D= ZS;P$VGH<],5YAJGAZV\5_$KQ?H]R<)<:-;;).\;
MAB58?0X-;UO\(O"-O,C"VNY+>.3S$M)+R1H%;.?N$XKIX-!L+?Q#=:Y'&POK
MF!()6WG:47H .@H \A\)Z_=ZO\3?#%CJH*ZUI-G>65\I[LH&U_?<,'/UKK?A
MM*B>(_'5HS 7"ZTTIC/7:RC!^AP:Z?\ X0_1!XO'BE;3;JWE&(RJY 88QRO0
MG'&:I:[\/=!U_5?[4F2ZM=0*;'N;*Y>!W7T8J>: ,3PHRW'QD\<W$)#PI%9P
MLZ\@.$Y7ZC%>BUD^'O#6E>%].-CI-J((F<NY+%GD8]69CR3]:UJ "BBB@ HH
MHH **** "BBB@ HHHH *S=._Y"6I_P#75?\ T$5I5FZ=_P A+4_^NJ_^@B@!
M+/\ Y#VI_P"[#_(UIUF6?_(>U/\ W8?Y&M.@ HHHH \(T?Q%8?#WXU>*X_$9
M:U@U9Q-;W;(2H4DL.G.#NQGU6M_XB?%;P@?!>I6-EJ,&I7=Y T$<$(+#+#&Y
MCC  Z^M=_P"(?">A>*K98-:TV&[5/N,P(9/HPY'YUB:1\)O!&B7R7EGH<1G0
M[D::1Y0I]0&)&: '?"K2[K1_AIHUI>HR3^49"C<% S%@#^!%=E110 4444 %
M%%% !1110 5XQ:_\G3WW_8/'_HI*[7Q[X$E\;)8K%KMWI7V4N2;<$^9NQU^8
M=,?K7EO@?PX_A;]H6727U&;4&AL68W$PPS;HU.#R>F<=>U 'T)1110 4444
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M'_XFC_A;L_\ T+-Y_P!]'_XFL/J=;M^*_P R/8S['J%%>7_\+=G_ .A9O/\
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M#@T =O17FD?Q3ODATS5;WPI=VGA^_ECA2]DG7>K/T8QCG:3T/XUZ70 4444
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M5YOU!T9JI0BKZ^7^9W_7<%.+C.F[?XO^ <U_PNK1O^@=>_FO^-'_  NK1O\
MH'7OYK_C72?\(!H7_/*7_OL?X5@^*_"^EZ-I\,]K$V]Y0AWD$8P3Z>U56KXN
MC3=2459>?_ %">73DHJF_O(/^%UZ+_T#[S\U_P :/^%UZ+_T#[S\U_QK;@\5
M>'8[>)'M3N5 #_HZ]<5)_P );X;_ .?0_P#@.M4L;2M_&B+_ &7_ )\2_P#
MO^ 8'_"Z]%_Z!]Y^:_XT?\+KT8]-.O/S7_&M_P#X2WPW_P ^A_\  =:P/&GB
M/0[SPAJ-O:VY29XP%;R0N/F'>CZ[3Z54V72AA9S4/825W;XO^ =YH.L0Z_HE
MKJD$;QQ7"DJC]1@D<_E6C7DO@_XEZ!H?A.PTV\-U]H@1@^R+(Y8G@Y]ZW/\
MA<'A?UO?^_/_ ->NN->'*KO4YZ^6XE59*%-VN[>AWU%<#_PN#POZWO\ WY_^
MO2CXO^%N[7@^L'_UZKVU/^8R_L[%_P#/M_<=[17!?\+?\*_W[S_OQ_\ 7H_X
M6_X5_OWG_?C_ .O1[:G_ #(/[.Q?_/M_<=[17/>&_&>D^*I;B/33.6@56?S(
M]O!SC'Y5T-:1DI*Z.6I2G2ER35F%%%%,@*BN8C/:S0@[3(C+GTR,5+10!Y1;
M?";5[./R[;Q,85/)$<;*"?7AJH^#M7DT+6M=AU6_-TELR0+]HE.UCYF"1N]
M"?H*]EKP[QQ\+]9N5U.[BO+8Q7=SO50Q!4L2%)_[ZQ^)KNCB'4A-5&MM-#=5
M'*+4F>WQR)-$DL3J\;@,K*<@@]"*9=6T=Y:RVTP8QRJ48*Q4X/N.15;1+26P
MT'3[.8*)8+:.)PIR,JH!Q^56;E9GMI5MY$CG*D([KN"MV)'&:XEN8'(^&+*U
MT[QMXBM+.!(+>.&U"QH, ?*U17%IJ^C:SK>HIH5OJ5I<2+,#YRB0*JX( (JU
MIOAWQ#9:_/JDVLV,INS&+E%LBNY4! "G?P>3SS5C4-*\4W,ES#;Z[:16<Q8
MFTS+&I[ [L'ZD5U.2Y]T[I7W-KZ[E29I];_L/Q+HMI'=0I!*GV65Q&0' &0>
M1D%<?0FN>TVYBA&EVMXDUW9:<S+!!:1E_M5PN6=P.,QQYP#W-=G)X?EM?"L.
MA:3=?9D55A:=N7$?\9&/XCS^=1WOAF2)M,ET.:&SET^)X(TEC+H8V !R 0<Y
M .:(U(;=-;?C_F"DMC:T^_M]4T^"^M'WP3+N0D8./<>M6:S]$TM=%T:VT]9#
M+Y*X+D8W$DDG';DFM"N65KNVQD[7T"BBBD(**** "BBB@#DM1\%M?ZC/=C47
MC\U]VP+T_6JW_" -_P!!63_OC_Z]=M17!++,+)N3CJ_-_P"9NL342LF<5_P@
M3[=O]JOC_KG_ /7I/^$ ;_H*R?\ ?'_UZ[:BAY9AGO'\7_F"Q-1;,XR#P(T-
MQ'+_ &G(=C!L;.N#]:[.BBMZ&%I4$U35KF<ZDI_$QKL5C9E4L0"0H[^U>,6U
MO,_C33+SPCX>U_0[N6\#:O#<1F.S:+G>2,E2QXQMKVFBN@@\LM]1U;P9XU\4
MHWAK5-235KA+FQELXPR.VP*5=B<)@]ZPAX?UP_ J;3I=)N5U)M4,K6JH2P'V
M@,2!W&.<^E>X44 >9_&3S9M.\/VELDLMQ+JB-'#;,%N6*JQS$Q!"D'!)/%5_
M \]OIOC&:VUJSUV/Q'J=N?+N=5>.02Q1\E$,?RC'7&*[?Q+X3T_Q3%:B[>Y@
MN+23S;:ZM93'+"V,95A531/ UCI&L?VQ<7^HZIJ2QF)+B_G\PQ(>H08 &: /
M-[?PSKT'PWT*\@TNXDO]%UR2_:Q9=LDL?FMT![X((KK[_P 5Z_XD\-ZU'X<\
M/ZMI]U'9EH+B^B$3-+GE$4DY.,X/KBO0:* /!;/1VN_$/A"ZT_P_XG$MK?QO
MJ-[JC2'#;3D;68CKDE@ !QZUZ%X;T^\M_BEXQO9K66.UN8K,0S,I"R%5;=M/
M?&:[BB@#B/&FGWEWXR\$W%M:RRPVU]*\\B*2(U,> 6/85D?%#PY)>Z]H&NR:
M5>:KIUD)8;RULI&68*X&'7:03@CD UZ=10!YEX5M- MI=5U+1?!FNQRQV3*7
MU#?FY'7RD$CMG./85E>%;&5/'=F?"NCZ[H^A21RG5;74$,<"L5.WRU).&W'M
MQBO8J* / -(\,:7X>MKK1_$W@_Q%?WL<\GE3Z<\S0W4;,2N L@4'!P1CZUU6
MK:;<^&-=\)^)=*\/WDFE6=@]E<6%NOF3VRN-P."?F()P>>WO7JM% 'G?B6ZU
M/QU\,O$4-IH%_9R.@6TBNU"2W !5B0G;H0 >M9WB"ZO?%?PZTY+30M5@GMM1
MLT>&YM]CD(5+,!DY4>OM7JM% 'F-S+J'@GXE:WK$NC:AJ.DZS#"5FL(?->&2
M,;=K+G.#Z_3WJA!HFLZEH'Q#\07.EW%I/KMJT=G8./WVQ(BJEE'1FSTKUVB@
M#R_Q;I&I77P?T.P@L;B6\B:Q\R!4)==I7=D>W>O4*** "BBB@ K-T[_D):G_
M -=5_P#016E6;IW_ "$M3_ZZK_Z"* $L_P#D/:G_ +L/\C6G699_\A[4_P#=
MA_D:TZ "BBB@ HHHH **** "BBB@ HHHH **** *E]JNG:8$-_?VMH'SL^T3
M+'NQUQD\UXYI5Y:W_P"T_>7%G<PW$+:?A9(9 ZG$29P1Q7H_B_P%H?CA;1=:
MCG<6I8Q>5*4QNQG/KT%>4^$?#>G>%?VC)](TM)%M(; L@D?<<M&I//U)H ]]
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B="UNUTM;I+@
M2$O+D;5S6_8^(K+4+M;>$2AV!(W+@<5I_9X/^>,?_?(KG614\<1!5"CR>@&.
MQK/6-CYZ-/%Y="E3]HG#F4;<NNK?6YTU%%%:'T(C*&4JPR",$5SY\"^&223I
M$//^TW^-=#14RA&7Q*YK2Q%6E?V<FK]FU^1X5XPT>.U\67-CI=FXC5$*Q0JS
M$<<G')KL8/B#J,-O%%_PBE^=B!<_-S@8_N5'/J5GI7Q8N[F^N%@A^S!=[9QD
MJ.*ZC_A./#/_ $%X/R;_  KKQ>6U.>$\.FDX1VCI>S\MSV)9AST84Z]+VEM;
MN4NOH<__ ,+&U'_H4[__ ,>_^(H_X6-J/_0IW_\ X]_\170?\)QX9_Z"\'Y-
M_A1_PG'AG_H+P?DW^%<W]GXW^]_X#_P#'ZQA?^@7_P FF<Q<?$35 \4H\-WT
M,43%I0P;#+@]RG'.#GVKL?#>MCQ#HL6HB P"1F&PMNQ@XZXKG]>\7Z/>V@M+
M/6+<+.LD<I(. "C 9XZ9Q7!C5=4\/:4D.F^)K26)6PL%N"2,\D_,O2L:M'%X
M?WZD9.*6ONVL=5+"X;'4^2E!4JEU:[D[JS\CW*BN9M/'/A[['!Y^L0>=Y:[\
M@_>QSV]:F_X3GPS_ -!>#\F_PKKC1JRM:+^X\26'JQ;3B]/)_P"1T%%<_P#\
M)QX9_P"@O!^3?X4?\)QX:_Z"\'Y-_A5_5,1_S[?W/_(CV<^S.@HI%8.@93E2
M,@TM<Y 4444 %13VT%R@6>&.50<@.H8 _C4M%)I-68%/^R=._P"?"U_[\K_A
M1_9.G?\ /A:_]^5_PJY14^RI_P J^Y?Y%<TNY3_LG3O^?"U_[\K_ (4V31=+
MEC,<FFVCH>JM"I!_2KU%'LH?RK[E_D'/)=3)_P"$6\/_ /0#T[_P%3_"C_A%
MO#__ $ ]._\  5/\*UJ*?+'L7[>K_,_O?^9BS^%] %M*5T33]VPXQ:IGI]*\
M_P!(BM=-MY(I_"D-VS/N#R6W(&.G*FO6J*Y<1A'4E&<)<K5^B>YI3Q4XIIMN
M_F_\SS;[9IW_ $(]I_X"C_XB@7FG9'_%#VG_ ("C_P"(KTFBLOJ=?_G]_P"2
MQ+^MOL__  *7^9X=X!UB;2=?UV2VTUI1(P_=1@CRP&;C@>]=W+X[NH5!ET=X
MP>A=B,_F*P/A=_R.'BK_ *Z#_P!#>NQ\8Z7>:K96\=G%YC)(68;@,#%85(8F
M-%U*4WITLOZ\SNS"5-XNTUTCK?\ NHZ)&WHK=,@&G5PL6M>(K/6;&QU#R469
ME&T(#E<XZBNZKOP^)C73LFFM'=6/)J4W"U^H4445TF852U:[CLK S2PB9?,1
M=A]2P /X9S5VL3Q-XATCP[81S:O/;I'+(J1I,P 8Y'3/IU_"@#;HI%8.H92"
MI&01WI: "BBJ5_!J$S(;*]CMP =P>'?G]1BIE)Q5TKC2NR[17+1:MJ<":Q)+
M/%<Q62A$<1; 9._?H*L0:S-8R7B7\ZW"PQ1RH\:;22V0$P.^>GUKF6,INU[K
M^G_DS1T9'0T53TP7GV-7OF!GD)<H!Q&#T7WQ5RNF,N:*=K&;5G8****H0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6;IW_(2U/_KJO_H(K2K-T[_D):G_ -=5
M_P#010 EG_R'M3_W8?Y&M.LRS_Y#VI_[L/\ (UIT %%%% !1110 4444 %%%
M% !114-W=V]C:R75W/'!;Q+NDEE8*JCU)- $U%86B^,_#?B*Y>VTC6;2[G09
M,<;_ #8]0#U'N*W: "O&+7_DZ>^_[!X_]%)7L]>,6O\ R=/??]@\?^BDH ]G
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&U+P]'J-[]J
M-S+$^T+A!6S12:3W,,1AJ6)AR5HW6YSG_"))_P!!&Y_.C_A$D_Z"-S^=='12
MY(G%_8N!_P"??XO_ #..ETXZ5X@TV)+J:59'!.\^]=C7.Z_:WSZG975G;F8P
M GKQG-)_:7B/_H%Q_G_]>I3Y6T<6%JT\!6K4N27+S*UHR:MRKKKU+E]X6T34
MKMKJ\TZ&:=P SMG)QT[U6_X0CPU_T![?]?\ &F?VEXC_ .@7'^?_ ->C^TO$
M?_0+C_/_ .O72L96BK*<K>K_ ,SO6=07V:G_ (!(?_PA'AK_ * ]O^O^-'_"
M$>&O^@/;_K_C3/[2\1_] N/\_P#Z]']I>(_^@7'^?_UZ?UZO_/+[W_F/^VH?
MRU/_  "16N_!FAI=V*P:- 8GE(F(4G"[21WXYQ4MW\/_  W=0^6M@(#D'?"Q
M5OI]*)-2\2>9%C3E7YN0!D-QW.>*D_M+Q'_T"X_S_P#KU%3%5:D7"<FT^C;_
M ,RH9ZJ<E.*J)K^Y(SO^%7^'O^GO_O\ ?_6KBKFT\/\ AKQO=6NH6LMSIT<0
M"H?G.X@'/;WKT;^TO$?_ $"X_P __KU!)-K,KEY-"M78]69 3_.N%T8Q:G1]
MV2=[V/4P_%]N:.)C5G&2M;EDNVNQR7]N?#O_ * <O_?H_P#Q54_$!\-WWAD7
M^AZ=]F>.[2)V92"<C/J:[<MJQ'_(OV?_ '['^-<9J&@RZ/HCVU]O@M);H2[V
MP3OQ@ 8[5Z6!QV,ABH.I-RC?5*]_NOJ)Y]EDH/DI58RNK7C*2??HCUFU_P"/
M.#_KFO\ *IJXF;6O$-E;PIY$(9UVPAD^^<<=_I53^UOB-C_D"VGYC_XNN.I7
M47L_N(RUPS'G]E)1Y6DU/W'KKLST&BO/O[5^(W_0%M/S'_Q=4M4\6>.-%M!<
MZAIEG!"6"!B,_,03CA_8UF\5%*[3^X]:&35IR483@V_[Z/3J*9$Q>%&;J5!-
M/KI/(:L%%%% !1110 4444 %%%% !1110!Y5\+O^1P\5?]=!_P"AO7>3^*]#
MM?$</A^;4(TU:90T=L5;+ @GKC'8]^U>?M\-/%%MJM]>:9K\%H+J5G/EEU)!
M)(!P/>H](^%7B*W^(NG^*-4UVWN_LHVLIWEV&UA@$_6N>AS17*UW/5S)4:DO
M;4ZB>B5M;[6[6.W\1^';W5M2MKNTN8H6A3:"V<@YSD8JE_PCGB?_ *#H_P"^
MV_PKLZ*RG@*,YN;NF^S:.!5YI)::>1QG_".>)_\ H.C_ +[;_"C_ (1SQ/\
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M"CT Q3JUHTW3ARMW(G+F=PHHHK4D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M-T[_ )"6I_\ 75?_ $$5I5FZ=_R$M3_ZZK_Z"* $L_\ D/:G_NP_R-:=9EG_
M ,A[4_\ =A_D:TZ "BBB@ HHHH **** "BBB@ KQ?]HF^N%T/1-)BE*0WUVQ
ME _BV@8!]LMG\!7M%>/?M!Z/>W?AO2]7M(6E73+EFF51DJK ?,?8%1GZT <M
M\1O#NG?#KQ-X+U;P_!]C8N$E",?WFPIDGW(8@^M>]:SKFG>'](EU35+C[/9Q
M8WR;2V,G X )ZFOG_P 5>);?XM^+O"&E:##<.ENPDNB\>/+R5+_@ O7I7T-?
MZ;9:K8O9:A:PW5J^-T,R!E;'(R#0!Q7_  NOX??]!\?^ LW_ ,17F5O\0/#"
M?'ZZ\3-J6-(DLQ$MQY,G+>6HQMV[NH/:O9O^%=>"_P#H5M)_\!$_PKR>V\+:
M W[1UYH[:-8G35L0ZVAA7RPWEH<[>F<DT =__P +K^'W_0?'_@+-_P#$4?\
M"Z_A]_T'Q_X"S?\ Q%;/_"NO!?\ T*VD_P#@(G^%'_"NO!?_ $*VD_\ @(G^
M% &-_P +K^'W_0?'_@+-_P#$4?\ "Z_A]_T'Q_X"S?\ Q%;/_"NO!?\ T*VD
M_P#@(G^%'_"NO!?_ $*VD_\ @(G^% &-_P +K^'W_0?'_@+-_P#$4?\ "Z_A
M]_T'Q_X"S?\ Q%;/_"NO!?\ T*VD_P#@(G^%'_"NO!?_ $*VD_\ @(G^% &-
M_P +K^'W_0?'_@+-_P#$4?\ "Z_A]_T'Q_X"S?\ Q%;/_"NO!?\ T*VD_P#@
M(G^%'_"NO!?_ $*VD_\ @(G^% &-_P +K^'W_0?'_@+-_P#$4?\ "Z_A]_T'
MQ_X"S?\ Q%;/_"NO!?\ T*VD_P#@(G^%'_"NO!?_ $*VD_\ @(G^% &-_P +
MK^'W_0?'_@+-_P#$4?\ "Z_A]_T'Q_X"S?\ Q%;/_"NO!?\ T*VD_P#@(G^%
M'_"NO!?_ $*VD_\ @(G^% &-_P +K^'W_0?'_@+-_P#$4?\ "Z_A]_T'Q_X"
MS?\ Q%;/_"NO!?\ T*VD_P#@(G^%<K\2? _A73?AUKEY9>'M-M[F*WW1RQ6R
MJRG(Y! XH T?^%U_#[_H/C_P%F_^(H_X77\/O^@^/_ 6;_XBLOX9>"/"VI_#
MC1;R^\/:;<7,L),DLMNK,QW'DDBNM_X5UX+_ .A6TG_P$3_"@#&_X77\/O\
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M_0K:3_X")_A7DWBGPMH%M\>/#.E0:-91:?/ #+;)"!'(?GY*]#T'Y4 >@?\
M"Z_A]_T'Q_X"S?\ Q%'_  NOX??]!\?^ LW_ ,16S_PKKP7_ -"MI/\ X")_
MA1_PKKP9_P!"MI/_ (")_A0!TJL&4,IR",BEI  H  P!P!2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5FZ=_P A+4_^NJ_^@BM*LW3O
M^0EJ?_75?_010 EG_P A[4_]V'^1K3K,L_\ D/:G_NP_R-:= !1110 4444
M%%%% !1110 4C*&4JP!4C!!'!%+10!5M-,L+!G:SLK:W+_>,,2IN^N!5JBB@
M KSF#P9J\?QRN?%K+#_9<EH(5/F?/NV*OW?J#7HU9,/BC0;G4CIT&LV$EZ#C
MR$N%+Y],9Z^U &M1110 4444 %%%% !1110 4444 %%%% !7/>.M&N_$'@C5
MM)L0ANKJ#9&';:N<@\G\*Z&JU]J%GIEJUU?W4-K;KUDF<(H_$T 8G@'1;SP[
MX&TK2;\(+JVB*2!&W+G<3P?QKI*HZ9K.F:U T^EW]M>1*<,T$@<*?0XZ5>H
M**** "BBB@ HHHH **** "BBB@ HHJCJ>LZ;HL"3ZG?6]I$[[%>9PH9O09H
MX:\\%ZO/\<+'Q8BP_P!EPVGE.3)\^[8X^[]6%>CTTR((O,+J(\;MQ/&/6LFS
M\5^'M0OOL5GK>GSW6<"*.X5F)]AGG\* -BBBB@ HHHH **** "BBB@ HHHH
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M=_%;Q/>>'HI(O#+(VU=I5-Q9=F!V/WR!V!KWN@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYV2MA3M'&.K,.O\ #72D@#)( ]Z\6L9YC^T;XHB\Z0Q#2B0F\[1^[AY KD/
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MB--W4^I/N3D_C6C10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.^B'=?DD_+H:>FMV>[9.7MG_ +LZ%?UZ4 :-%1QSQ3 &.5'![JP-24 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445!->VMN,S7$48_VG H GHK,.LI*=ME;3W3>J
MKM7_ +Z-)]EU&]_X^[A;:(_\LK<_,?JQ_I0!-=ZI%!)Y$*M<71Z0Q\D?4]A]
M:B@TZ2:9;K4F624<I$O^KB^GJ?>KEK9V]E'Y=O$J*>3CJ3[GO4] !1110 44
M44 %%%% !1110 4444 %-=$D7:ZAAZ$9HHH I2:+ITC%C:1JQ[I\I_2H_P"P
MK0?<>Y3Z3M_C110 O]B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_
M #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%
MY_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0
M?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44
M']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\
MT44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7
MG_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_
M #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_
M8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_
M #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%
MY_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0
M?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44
M']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\
MT44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7
MG_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_
M #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_
M8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_
M #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%
MY_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0
M?\_%Y_W_ #1_8D'_ #\7G_?\T44 ']B0?\_%Y_W_ #1_8D'_ #\7G_?\T44
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "G 9D# 2(  A$! Q$!_\0
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M_6_QK6HH R?^$;TW^Y+_ -_6_P :/^$;TW^Y+_W];_&M:B@#)_X1O3?[DO\
MW];_ !H_X1O3?[DO_?UO\:UJ* ,G_A&]-_N2_P#?UO\ &C_A&]-_N2_]_6_Q
MK6HH R?^$;TW^Y+_ -_6_P :/^$;TW^Y+_W];_&M:B@#)_X1O3?[DO\ W];_
M !H_X1O3?[DO_?UO\:UJ* ,G_A&]-_N2_P#?UO\ &C_A&]-_N2_]_6_QK6HH
M R?^$;TW^Y+_ -_6_P :/^$;TW^Y+_W];_&N9US4->UOQV?"^B:L-'@M+%;R
MZNUMTFD=F8JJ*'X XR3U[5<\ :WJNI6^KZ;K4Z7.H:1?O9O=I&(Q<* "K[1P
MIP>0*%K_ %YV!Z&U_P (WIO]R7_OZW^-'_"-Z;_<E_[^M_C6M10!D_\ "-Z;
M_<E_[^M_C1_PC>F_W)?^_K?XUK44 9/_  C>F_W)?^_K?XT?\(WIO]R7_OZW
M^-:U% &3_P (WIO]R7_OZW^-'_"-Z;_<E_[^M_C6M10!D_\ "-Z;_<E_[^M_
MC1_PC>F_W)?^_K?XUK44 9/_  C>F_W)?^_K?XT?\(WIO]R7_OZW^-:U% &3
M_P (WIO]R7_OZW^-'_"-Z;_<E_[^M_C6M10!D_\ "-Z;_<E_[^M_C1_PC>F_
MW)?^_K?XUK44 9/_  C>F_W)?^_K?XT?\(WIO]R7_OZW^-:U% &3_P (WIO]
MR7_OZW^-'_"-Z;_<E_[^M_C6M10!D_\ "-Z;_<E_[^M_C1_PC>F_W)?^_K?X
MUK44 9/_  C>F_W)?^_K?XT?\(WIO]R7_OZW^-:U% &!J&@V-OIMS-&LH>.)
MF4^:W4#ZUR_VVZ_Y^9O^^S7=ZO\ \@>]_P"N#_R->>T =QX;_P"0,G_71_\
MT(UK5D^&_P#D#)_UT?\ ]"-:U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <3XA\,^(H_%8\3>$[S3DO9;46ES;:DCF&1
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MV5PHHHJ2@HHHH **** "BBB@ HHHH **** *>K_\@>]_ZX/_ "->>UZ%J_\
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M$6L!;*Q#&0&("&0@G<X^\55 NQ0 4444 %%%% !1110 4444 %%%% !1110
M4444 4]7_P"0/>_]<'_D:\]KT+5_^0/>_P#7!_Y&O/: .X\-_P#(&3_KH_\
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M4 %%%% %/5_^0/>_]<'_ )&O/:]"U?\ Y ][_P!<'_D:\]H [CPW_P @9/\
MKH__ *$:UJR?#?\ R!D_ZZ/_ .A&M:@ HHHH **** ,_4]$T[6/*:]M]TT.?
M)N(W:*:'.-VR5"'3( !VD9'!R*\S^)'PQMM8BTV\N=6NY4BO;6TS-&CSK!+.
MD7EI, "0/,+9E$K94<C+[O7*Y_QE_P @.V_["NF_^EL- %S0/#FD>%M+73=%
ML8[2T#E]BDL68]2S,26/09)/  Z 5J444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7'_%&RNM0^'FI6ME;37-P[0;8H8R[MB9
M"< <G@$_A7844?U^*?Z#3L>16GAK5M#^,MC';V4TGAZ66XU&.9(B4MY98BLB
M,P&%RR@@<=:]=HKDSK]]:7Z'4&CCBT]V@U0(NV,(Z!XKU<Y<195D(Z*6DRQ$
M)8BV2[$VUN=91110,*Y_P]_R'/%G_85C_P#2*UK(^+I;_A6.KA7=-QA4LC8.
M#,@.#7%^%+^:+QAX=\/7S+_:NDWEY;W3@8:Y06ZB&9O7,:JH)R<(*(ZNW];!
M+17/:Z*** "BBB@#G_&7_(#MO^PKIO\ Z6PUT%>/_$;7]5T;XC65Q'*\VC:=
M8PWM]8,-R.GV@J9 IXWH=C ]BH/&*[3P+J4^ICQ#)+=/<QQZQ/' S/N"Q@(5
M"^W/ZT+57_K>P/1V.LHHHH **** "BBB@"GJ_P#R![W_ *X/_(UY[7H6K_\
M('O?^N#_ ,C7GM '<>&_^0,G_71__0C6M63X;_Y R?\ 71__ $(UK4 %%%%
M!1110 5A^+()KG1[=((I)7&IV#E44L0JW<+,>.P4$D]@":Y;Q["=>\;>%_"E
MW/-'I-ZMQ<7<44AC-QY:C;&2"#MYR1_D9OC_ $J'P=X7\-6FAP7,L,/B&V>"
MT-P6)^\?*5F/ )'<]Z%T;ZNWXV'ULNU_P;_0]7HKS#PCK&H:E\5M>N-2TJYT
MMTTJ#_1)9!*V [?,-N<Y]!S7:>'/$]IXEANFM[6_M);6;R9K>^MS#*IP&!VG
ML001['M0ME_75H75_P!=+FW1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<_XEL-L3:M#:?:FAB9+VS6/>;^UVMNAV\AF!;<
M@(Y.4RHD<UT%% '-VFO:1H>EV%C=:]'J%P;=7MO*)GNKN'D)((TW/*=HRSJ,
M$AFPHX$G]K:[J/&F:)]EA/2ZU641_*?NND*;G; Y*2&%N@X).W8M;"SL?/\
ML=I!;^?*T\WDQA/,D;[SMCJQP,D\FK% '/ZCX9D\0>&KK2->U%YS=2*[R6D(
M@"!65E5%;>0,H"=Q8DEL$# 5EQX)TFX\;V?BTF=-2M83  C*$D4@C+#&20&/
M(([5T=%"TU_K:WY ]58R]2U:;2[A6ETR[GL"@+7-HAF:)LGAHE&\@_+@H'ZM
MN"A<G0@GANK>*XMY8YH)4#QR1L&5U(R""."".<U)7'ZYISZ5K6D2^'7@TV[U
M/4'BN2T3/!*#!-*S/"KHK2%HU_>9#\ $E<J0#K)YX;6WEN+B6.&")"\DDC!5
M10,DDG@ #G-8\&N3:O<1+HUK(]GO!DU&>,K R Y(B!(:4L,;7 \O#;@S%=C9
M>AVMYK.M:O-X@N//DT[4$2VLX7*VT'[B&8?+QYS!GR'D!P4#*L9XKL* .<O?
M",&H>*[C6+J826]QI1TR2T,?#*7+%MV?0XQC\:@\ >"QX%T*;2UU!KU7N6G6
M1HMA4$* O4YP%Z\?2NJHH6FW]:W_ #!Z[_UI8PX/$#6]Q%::]:QZ7<3.(X)#
M<+);W+D\)'(0I+\CY75"3NVA@I-;E1SP0W5O+;W$4<T$J%)(Y%#*ZD8((/!!
M'&*R['1KC2[R-;#4-NDC(.GS0AQ",':L#@J47)SM;>  %0(!B@#8HKR_0+76
M?'&JZKKLGB?5-.BL=4DM+&RLV"PA(B 3*A'[S=Z'I^@JW_CN;0O'WC.QNQJ]
MU L%M]D2T@:9+=C"2QX^YDD'/L?2DW97\K_@G^HTKMVZ:?C8]:HK@?"_C.PT
MGX8>'M6\3ZN(WNXE0SW!9FD<D]<9/U/0=Z[U'61%=&#*PR&!R"/6J:LVNQ*=
MTF5-7_Y ][_UP?\ D:\]KT+5_P#D#WO_ %P?^1KSVD,[CPW_ ,@9/^NC_P#H
M1K6K)\-_\@9/^NC_ /H1K6H **** "BBB@# \4>$+#Q5%:FYGN[2[LY#):WE
ME+Y<T+$8.UL'@CJ,54;P'8RZ9IUE=:GJMVUCJ*:DMQ<W DEDE3H&)7&WM@ =
M.*ZJBA:; ]3&7P[;V_B2^\0V\DIO[JT6V*2,/* 0DJ>!D<GGD_2LWP7X;O/#
M[ZO)=+# E]="X2VAO);H(=@#,TLJAF9B,\C P*ZNBA:?U\P>H4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7/\ B'_D.>$_^PK)_P"D5U705RGC?5+'0W\/ZMJ=U%;65GJ3232.>0#:
MSH,*.6.YU&%!/.>@) "5RWX>_P"0YXL_["L?_I%:UT%<CX&UG3M>G\1ZEI=Y
M%<VMSJ221LIPVT6L"?,I^9?F1AA@#QGI774 %%%% !1110!PB> M6T[6KZ?0
M/%4VF:9J%R;JYLOL:2D2,?G,;L?DW?0XK6MO"7V?Q%XFU;[=N_MN*&+RO*QY
M/EQE,YS\V<YZ"NEHI6TM\OD.^M_Z[GGFL>%-1T[X6P>$]..I7TB6S0&:P>"
MOP<!_-;B,DX;:2V!Z$UW=C'-%I]M'<>7YR1*LGE#";@!G:/3/2K%%5??S)ML
MNQ3U?_D#WO\ UP?^1KSVO0M7_P"0/>_]<'_D:\]I#.X\-_\ (&3_ *Z/_P"A
M&M:LGPW_ ,@9/^NC_P#H1K6H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\[\:7%O9?$[P3=ZF\<6FJ+M1+,0(TG*#9DG@'KC]*]$JIJ.EV&KVAM-2LK
M:\MR03%<1+(N1T.".M'5/M_P?\PZ-'#>%9K2_P#BWXKO]*>*6Q^R6T4\T!!1
M[@;B>1PQ"\&O1*JZ?IEAI-HMIIME;V=LI)$5O$(U!/4X QFK5'1)=/\ @_YA
MU;_KI_D%%%% !1110 4444 %%%% %/5_^0/>_P#7!_Y&O/:]"U?_ ) ][_UP
M?^1KSV@#H=-\16FEVAM)XIS(DCYV*I'WC[U<_P"$RT[_ )XW7_?*_P#Q5%%
M!_PF6G?\\;K_ +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJ
MC_A,M._YXW7_ 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%44
M4 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% !_PF6G?\\;K_
M +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_
M 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%444 '_  F6G?\
M/&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% !_PF6G?\\;K_ +Y7_P"*H_X3
M+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_ 'RO_P 5110
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MYXW7_?*__%444 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%%
M!_PF6G?\\;K_ +Y7_P"*H_X3+3O^>-U_WRO_ ,5110 ?\)EIW_/&Z_[Y7_XJ
MC_A,M._YXW7_ 'RO_P 5110 ?\)EIW_/&Z_[Y7_XJC_A,M._YXW7_?*__%44
M4 '_  F6G?\ /&Z_[Y7_ .*H_P"$RT[_ )XW7_?*_P#Q5%% %>^\5V-U87$"
;17(>2-D!95QDCZUA_8+K_GE_X\/\:** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &V 9$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HI&8*,L0!ZFHA>6I;:+B+/INH
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M0 4444 %%%% !1110 4A&Y2#T(Q2T4 9RZ6R'Y;@XPHP1Z?XTATIB<_;)/\
M6!__ *WTK2HH SUTV15*BZ;G=G(]?QH3371\_:W(VJN"/2M"B@"E:V#VTL;F
MX+[ P((^]DY_2HQI;[L_:Y#\^[!^G2M&B@#/_LV0NK-=-PFW@8SSGUI!I;J^
MX7DG^LW\C/X5HT4 5K>VDAA:$R[D(;!QR"35<:6PE9_M3G<%&TC(X_QK1HH
MQ-5T*;4YTE^V>5M7;A5ZU0_X1";_ *"3?D?\:ZJB@#E?^$0F_P"@DWY'_&C_
M (1";_H)-^1_QKJJ* .5_P"$0F_Z"3?D?\:TM&T232IY9'NC,)%"X(Z<UL44
M % ZBB@=10!9HHHH K4444 %5YOO_A5BJ\WW_P *N&YG4^$B---.---=!R,R
M[QRNOZ<GVA4#))^Z*Y+].A[8K2K-O&(U[35\V)0R291ER[<#[I[5I5,-WZF]
M=>[#T_5B&FTV>9+>!YI#A$!8GVKD+C4;[69B+9C';AACYAM(*\<CG.32K5X4
ME>1R6;=DM3;URX2.WM_],2 _:8P3PV>?NX[9]:TP0>001Z@YKS+Q!X0N[R"W
MFMFDDE5@C9&W*\?,?4\]:Z#1+^;2&CTVZ7-N@(5@.%&[ P3]X&N*AC8SJM-6
MN>GBJ%*G@Z4U*\FW=6V^?Y'6FDI325ZIY(TTE*:2F0S3LO\ CW'U-6*KV7_'
MN/J:L5PS^)GJTO@04445!H%%%% !12X)Z4T,I8J&!(Z@'D4 +1110 44@922
M RDCJ >13L$]* $HHHH ** 01D$$>HHH **** "BBB@ HHHH **** "BBB@
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M/8W&%[PR'^$^A]*XR:&2VF:*92KKU!KBE&VQ[%.?-N-HHHJ#4**** "BBB@
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M]5)RT9VFN99F;&YB<# R:U?#\FVYDBSPRY_*M.=N1A[)0AH=%4EO_P ?4/\
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2"BBNB/0X9[L\7HHHKTSYL__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M ; # 2(  A$! Q$!_\0
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M7L?G&+RR7F VX&> ,<TV/Q)#Y4*2/<2*FC"R*-RIE#AO7IQUK&4Z+_SPU/\
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MW9A[%6]XN"\C RKMGTI8[Z.7Y7R#ZCK4-MI<V_Y\;<\$<[OI5IX+*!OG^_\
MW5Y/X^E="<6<%2"6P%IE( 'FQMQP,_I3)((XP95)+#DPQG^M3QL9%\N,!(FX
M*KW^IJCY30SB/=@YQ51W."HK%BWU<L#&0%C(P4']:Y;Q+X>U"*)]0T:^O'@'
MS26_GL6C'JO/(K;_ '=X7&1%<1G!;LU6H&N;/$APR?WE.0*NRB^:.C[=SEE>
M:Y9ZKNNAY"=3U'_H(7?_ '_;_&FG5-2_Z"%W_P!_V_QKM_&'A>.:)]9TN(
M;KF!!T_VU'\Q7 D5W4I0J1ND>16C4HRY6_1DQU34?^@A=_\ ?]O\:8=4U+_H
M(7?_ '_;_&HB*816O)'L9JI+N3'5-2_Z"-W_ -_V_P ::=4U+_H(WG_?]O\
M&H"*:12Y8]BU4EW)CJNI_P#01O/^_P"W^--.K:G_ -!&\_[_ +?XU 13"*7+
M'L:*I+N23:A?3QF.:]N9(SU1YF8'\":ID5,13"*+);%<S>Y]3WETME93W3_=
MB0O]<5\^3W5W<:B]W(Y\VXD+'&&#9/3->J?%'4?L?A06ZN4:[F6/*]=HY/\
M*O'(FFBB62)VV#C*GE3GN*^ Q4M5$_:^'<-:C*L]V[?)?\$L;9$G$4T?ER9X
MS_GI5ZVM7\TI(1@^O&#2O&[6 E:4R7'F?>S_  8ZXI$*%O-9][8Y(XXKE/H&
M[HU;2.,QAG9G*OL( P!^=:$#1MDQHNSIR<<^U9-J5G7AF!;D ^O:MG2B ^)"
M61U/R=B16D3SJ[LFSH-!1Y;A5)) Y&?2NQ*D2?9U *D9.:QO#EMY:>85((4
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M+9(ZGH*F*'6J*QO6%K]H=0!^\5<$GO786Z+8VQD(_>%?E']:S-(L]B1,P 4
MEV]O2I-5NE:,R;\+]T**[H+E5SY+$2=:IR+8S+ZZ,TFTD9<X'/4UY]XD\/W0
M\0IJUG+ 9HMHD64X4D=,5U<]R&W,&PHXR,5BW%SNDW(@8;OF<C=SZUS3:9[>
M$IRIN\3GM2UR&[6_?4+:+^T)V525&%15]/7/K6=IEJ!:F5;9 Y8[9".5%:E]
M"9I7\R.,%<G<$R1[52+@V[QQ22; ,G* ?KWKLK8Y2PZH4XVMYF.79)5HXZ>,
MJU>;FT2M9)=+]-%HOS+EO=V5O<V[W*2):;@9B/O8!YQ]:?XUO[%=1M;WPXBO
MISP^63(I(WJ3N7!Y'!7\ZR)X))-.CD88!(W9.3_GFNZ7PYI \(E?M*![@ @L
M?NR#[I_7!^M>AE>$P\J/M:NK;M8]3'25.I&7,UTT\^_H<-I-['>LZF';,!EX
MU. 0.<CWZUT6GP)<V\X(RK$KGKO'UKB[7S;#6B3$WF0AE9 <$'D5VWANZANX
MYRI*D &2,C&P\\CZURYE@'1J<U->Y^1A_:=%5'AI37M-[=;?D0OIUS9WGER_
M,J\0D= IY.?QKH;2,HNT"IKRU\TQR2X"I]W)ZCMGUJ2V4$YKRN74N=?G@KFA
M;1E0 !DL<5M0HEM&"?O5GV2;1YC=ONU.\Q<YYKJA:*N>'6O.5B9Y2YR34#/2
M,Q[\5 [^]9SF*,"IJC9A1<?Q5E;*NW\N&1?J:J>8/2E%W5S3;0;LHV4[S!Z4
M>8/2J"XW91LIWF#TH\P>E 7&[*-E#3J#@#+>@J58"8S+=2+#".3DXH"Y ,NV
MR)2[>U.N(+2RMS<:I/&D8_A8_P"<UF:EXOM[2)HM(A61NGFL/E_#UK@+VZO-
M6O6:\N':0GY2W0#T [4[,S52+=D=!JOBBTN6:WTNSBAC/!FD49(]0.U5-(M!
M<:@ 3B&(?,Y].]9<&EVXE0S7#G/M707I:SMTAM<F';G<!G=4./5G;2KQC[E/
M=]3J3I]_XJTZY;3C"EK8K@JYY.!G ]_K4?AK3!;QRW3X+2%3M'1<=/Q-9>C7
M3VVDB,>9NO92KX<KE$'.<=LG]#7::1 LMELB38O#,!T..E--O1=32HY4H.+^
M&^GZW?74;<7+.<$U%$KRS*GJ<47*^7*14MK]]2#WK@H<TJGO!I&%T/O9(UD6
MUB^ZGWO<U;L8(<[YG  ' ]:IWEL4O'?DACG\Z%<J.37OT;J3N<%:SI)19!J]
MNT=^TQ'RN 0>V*2RBBNV,#D*6'RGWK1#+=VSPOR0,H?2N>=S%-\F00>*]""L
M[GCU)N4>1[HLS:5+ _EO]TFM%+6ST^$/=-\QY$8Z_P#UJ;)K(MM/B,Z!Y6/R
M$]0*P=2N&;9,&)27^\<D'TKLBCP:SE+<OZG<PWUK,L>]!&NY44_+QZUG:)-L
M$S$9Q&QQZ\4^R'[B?=U:)@/RJOHPS,RXSE6&/PKIBM&CR:K)[&4R-+<D8(0X
MQV]*W-,C$VDR1>N2/J!FL..,V>F%9!AYL*![=ZW-(9HX8/0R?TJZFL;HX(6Y
M[/S-71I]K(?0UYKXDL18>(K^W48192R_[K<C^=>AVO[J[=1TW9%<O\0H NMV
M]P!Q/;J3]5)%947:OZK_ ((8F/-A?\+_ . <:149%3$5&17IGD)D1%1D5,PJ
M-A2-4R)AS49%3$5&:EFJ9[#\5M.%SHMI>[<FWF*G'HP_Q KSFVCA"1/EGEQN
MP3^8KW/7M.&K:%>61&3)&=O^\.1^M>)V\$BMY4GRF,\9_E7YYB(VG?N?NN18
MA2PKI-ZQ?X/_ ()?MX]\C#<Q7/*M_*NHT>P5BN 2"P& ,5F:7:/,Y9E^4'"C
M'6NUAA2P@0X^8C@^]*G#J+'8BWNK<?<3"&-+=" 0.3Z5C37*L3')R&P#CT[B
MH[J]$DSL> ^0.^!W-9S3QI)YN\J@P02?NC_.:N4SEH8>RU(;X-;S?+" !GF0
M\ 5@7U_)YI,4JQC'*J<"M+6+Q)$22.)G9LH68X"@=.*YNZD!!46HP.N>H_&N
M:;/H,+2NDY(;/<.I&P[ 5W.XY))[<U5FN)1*$2<;6/S8 '(Z#%1O=,%/[DE0
M>A'\S5B" S7'" NQW;@>.?3Z5D>HHJ*U-?1(4\VY-PI>&--Q9NAP.:YN[>9;
M2:0O,MJAR$!P.>@%;FH7*VFF-91%_,F.Z0GK@=OQJM#,]U8O!<L?+E7:YV@E
ME]*ZZ&*JX?\ A2M<Y90<KS:]"WI#H_AZ3Q'*;6:6,"&[MY%^:0=%<'J#CCZC
MWJSX8TZ:*6ZU!@8HI2$5".2,YS6;X>\,FUU(&:Y\RQDB^>%^-ZG^$_3KD=P*
M]!CM/LMX\,;@PE04&.,8X(^HKH6,KRI.G)W3[GR^)RW"+&1Q25IJ_E?U[M=/
M)^1)>1J]EP>@S@]<'M4-K%N;'0=Z=+*[PL&499LCV%30#RX^>N*Y[)LZ$W&%
MBV9. B]* V.E0!NE*6R:B<SGY1\CG/6H6-(S$GTJ*20(I9CP!DUQSG=FD8V,
MS4)\W17^X *J^;522Y,LC2'JQ)IOFUWQ5DD8-W9=\VCS:HF< 9)HC:6X.(A@
M?WC5 76G"CDT^*.:XY_U<?\ >-9]Q?6.EC,K>=/_ '%Y/_UJPKS6[S5%="WE
M1#I&AZ_4UK"E*>VQRUL53I:2>O8Z*Z\0Z?I9,5J!<W/<@\#ZFN3U'5K[59LW
M,Q*9XC7A1^%5[>#]X":G6WS+TKH=%11P?69U7;9">4?+4>U32:5]JMPRD@]]
MOK6DM@66, <E16O;V*P0$<ECUKGJ73?8Z*.EFMSC1IMVC[2ID /RMGD5T<UE
M<'28A&&$I!'TK8M+:)IAYA 4'GBNHLA8SR)"P^4<_0#FN*E-S33:78]B57DY
M7R[:G*V^G/#/!!+M'D1*A"C'S'YF/YFNQTYDB15' Q@UGZCILJ,TZG<');<.
M^:AM;HI@,>17/3J5*==JHO0TJM5Z2<63ZE P<G'(_6J]J^T\UJI=Q3J(Y5##
ML>XJ"YTUD7S83O0]QU%>C'#^_P"T@8*NHQ]G4T+@VWEL%S^\4?+[^U9+V\_F
ME=A^I[5/;NR'%4M9N);B^2!)&VA!O&>,UZT5HF>:Y-3<5L3POY-PJ@@MGG!H
MG@T^.X?>[;P<[*CC$6FVC7,F-P^ZI[FN?\^2:229R2SDDFNR'8\JL^9MICM5
MG:XN0_&Q1M50>%%11MYQBC;[H;-0R/FDB;#BNN"/*KRTL7'N?(U!E PJG 'J
M*?IA2"]9P<* S#/..*BO(Q*1+GDC-5XI?+<9/7@UU15T>)5G9EVY\V6822L'
M5_N.O3Z>U;FF ND0!&8SR*Y^RE55,,G*;JVH9HH1MC<[V&,XJIKW>4XTUS<S
M-0N/MI^@S6-\0$W6FES=_P!XG3Z&KL9/VDY.2<5!XYYT+3O^NS?^@US6Y:L/
MZ[ERES4*G]=4>?$4PBI2*817J'BHA85&14Q%1L*1K%D+"F-4K"HR*1JF?3>:
M\XU_0/LWB.22)2(KG]ZI[*>X_.O1JIZE9+?6NP_?4[E/]/QKX:I#G5C]0P6*
M>'J<RV>C.8TRW2*#S'X '/\ A45]?&4L=S9Z  <?G2W=T-YAC^15X/'W:QYI
ME;*NPV ;<LVW/L*Y6[*R/H*5-SESR&SW9A^8'<>F6Y7UK,N+Q;C8%9%7U1AR
M3T&.U)J,S"U:%-DAS\RQD-M'N:QF<1HYB9HW8#<Q R?]T=OK7/*1[="@M^I=
MF8+:^26D=0!M!X)]SZ&LV>!T<!+=01SRV21]:MV_^F0E8SC:A"D'G\:(YO*4
M<AQNQD+T_/UJ'J=\5RZ=2I'8O(OS* I!VKM)SZ\>M3G;IZ*0I,N,*G]T>I]J
MMW-Z@4"&5 W.X]-N.OU-8]L9C*6::4IU9#SDFE8?,Y+4DC>>>X=QM61N&9EX
M!]B>E7[2QD9HY)=Q^;:BA<CMS]*C2*50/.$C#[S*PXZUT%E";FREF8)R.%')
M/;\!["KBKG+7JN*T'Z7 5D)G4@[L ]2<'M[<5TB(AM3",F2/)4CG*CJ/SY_.
MLRTADC59'ZJ,X'I4[73V\/G1JP"L%P!^-;QT1XE>]25T2V2K<+,,C]S&6?CO
M3[6TEN8 ZO&OS[%#-@LW7 I]K%Y&B3W8W*EU\RJW5?;\Z2VOA;Z?M14,PFWK
MN7.T8QD>]4[):F#E)\SAWM_G^(^*PF?:6:.,N2$5VP6/3C\:B>WE7R]P"^8Y
M0 GD$'!_G5GS;:Y6V>6X\MX5VR*5)+8.<C\Z<^J9,3($&9W=PR [02,=:Y*G
M+W(YJE]OZU*:6K///&SJGD@EV;H,<?SJCJMC,RV]E#<VIGNR B^9R5]>G3BM
M#4KF&VL9Y=X"W$K2,WHBGC\S7)-XAL[C7=)NBY"0P%)0%)VG+8'OU%30IQE/
M7I_7Y"J5)\MUU\O+_,AMM)OKO4I["-%$\ 8R;FP!M]Z2+39KFQENK>YM9!"F
M^1!)\RC.,$8ZUIP^(-.MH[*]NIC#/(5-^S#C$:E5QZYR"?<5S&J^*-,3PW':
M:+JMM')@RW"R0R;Y).RCC& .F3WKTX4W/2.IPU<2J6M1V_K7_@&G#811VOVR
M_O;:VAW^6KW$FQ6?^Z/6N6U7Q%J4RSQV-N\5K"Q1YXUW#(_VAP*K0WMCKOAR
MVL-3U0V=W:7,DJR2Q-(DJ.!D?+T8%>G0@UN:;K>FVME8%-4D%M96D]M+IWE,
M/M3-NP^/NX;<I.>1MKMAA5'62NSR*^9SG=0?*OQ,/3[:Y:P:66*4*9/]8ZG!
M)'J:U(M,DAO9(>)"#L#Q@E6/MQ71:?J0U2PN[6.>6>)K2UMX(L$CS%"[@!ZY
M#<UN3362:R_VB[\AK74S<'Y"V]=H! QWR.]="3M:QP*2WN<5'I<Y5G2"1D7@
ML$) ^IK1T_1+B[FCA2%Q,_W%=2N[W%=O;C[1H:"$NDDMO*68!A'L+DGD<;L#
MOS3'U&RMIK,QW#LL5WYA;+LPC*XY)[^H%1-7Z'92E;0QHM.EB@!>%PT?#$J>
M*/*XKI+/4XFT[RQ<))- 7#NX?$@/0@=_3FL6% [[3TKEK4^961ZF&J6;YBCY
M;*>!S5JV$R6MQ* =S8B7\>3^@_6M5CI]JXCD):7:#M[59FEBM+&*65H[>(_-
MPNYB3TQGV%>7++E>[D>HL?HDH[CK%B+)(;DG<[ (O?Z_2JEQI#/,Q@=&P>0#
MS5[3&LY9Q)'N8_WW.2:);:VDD9SL?!YP>?I7I+"QE!*6IP_7'"HW'3Y%&/3)
MXL-(P4#NQQ4LE\\02WMF#J.9'QP?84V::-'"Q6\>!W;DU*+F$0K\BB0]AWKH
MA24-$95,0YZSU(6=3DE0#[5581))YTGZ]33IIQ@N5.T=AU-<]J>H":0K%D#&
M#S^@]JZD<C;99U6ZCO+3SHSDB3:P]!VQ[50M[N.,%)4W(>_<57BF W(WW7&#
M560E6(/:NF$3BK327*:,L2-\T3!E]JK[-ARQ 'O559V0\$BJ\D[.^2<UV11X
M]:9<DNM\N>0 ,#Z5%YN7JKNIP;!S75!'C5YW-2*4 COWK2M':24X!/M7.Q3)
M&6DE<)&@+.Q[ 5@7?B*_U<NMK(UIIR' *_>D^OJ?THG-0TW;.6G3G5N]DCU>
M!M]P/F7/H&!--\<D#1--4_>,KG'X"O(()4BF5DGNMV>7##(]\?\ UZ[.74;^
M]T^WLKZ=9_(4S6\H_P"6J' //J,=/K6'+S3B^QM-^SI36]U^IG$5&PJ4BHR.
M*[SQTR(TPBI&IAI&R(349J9NM1-2-HGTO129I<YKXD_1#FO$VEDPO>V\88J,
MN@'?^]7 7<N93&4C,N-VX+D<_6O9#TYZ5P7BKPO)&#>:<I\G):2->J>I'J/:
MN6M3;]Y'T64XZ,6J-5V[/]#A/.\KY(E)ZC>>-V?Z5"92\R,Z*7&0-Q^ZO^)I
M9TE=@"6*#ACFK 6'3X1<7>5S@*I&YL>]<.Y]JDHKS+EO;?9+%I&C5(WX8AN>
MO)K+DD:20!740H=RJ!SQWJ2:]%Y(K)*/+CP?+'0Y[538.MPV-Q)&=V.,>E#%
M"+U<MRQ%;"9$B9 !OW9!QD_U%7G2SB*N[J64]5'Z8%9R2'>@<L@/ VCI]*LD
M+-(2(P%)^[_6FB*CU-*WDM#M.)1GJ/4?C6E#<6ZD+"C$G QTK%CB)E103_=
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MJB+];@>6H:+'51@[A3HKLH,1Q-@=V  KSYTE+1['JTZO*[K?IY'1V,WV2/*
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M;W&N,BJ4\>15XX(ZU"R9IB/G_P")$6/&MR/^F4?_ *#7*K%7:?$U,>.;D?\
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M4F:,T +FDS3<T9H =FC--S1F@!V:3/O244 +FC\:2DS0 M%)FC- 'A?Q./\
MQ75S_P!<HO\ T&N26NL^)W_(]7/_ %QB_P#0:Y(&OJ<-_!CZ'RV*_C2]28'%
M/%1 U(.E=".)DH-2 U"*D4TS*2)14@-1*:D!IF+1*#4BG-0J:E4U9E)&SX<O
MA8:W;R.<1.?*D_W6XK ^(UP)-7N%4Y"MM&/;BM334$E_"&^ZAWM]!S7*>*;C
MS[QW8\LQ-<N(2492\K'7@FW4C'L[F#;(35SR^.:+*-2!4L^W=@&N&$+1N>S.
MI>=BG+!D9[4D4!%;>G0K.P1E#*>"*K7$ L[^:V/1&X^AJG05E(A8IMNGU1$J
MX%1RID5;"J1Q3'2J<-"54U,QD.:5(R35IH^:6-.:Q]GJ=#K:#[>+D<5K6\>!
M56!.E7XQ@"N^C"R/+Q%1R+"<"G[ZAW4TM73<X.6Y91^:O0-G%94;<UI6W)%5
M%F%:-D=!I<7F3**[". 16V<=JY_P[;F28''%=-K4BV=C@\';FN?$3O44$:X&
MFE2G69YGXKO ]RR@\#BN8MY-TM6-=N_,N7.>]9UF^913E)<UCHH4W['F?4]:
M^'C[=4C-=EXOT9-<LWA7 O(26@8]_53['^=<!X*N/)O8FSU(KT36;@QS;P?>
MN'%QE]8C*.]CKR^4'A*D);7U/&94>*1XY%*NA*LIZ@CM4)-=[XBT9=<B:_L5
M'V]!^]B'_+8#N/\ :'ZUP+<'!X(ZBO1I5.=:[]3R:M'V;TU3V8TFHR:<:C8U
MH)(8QIC&G,:C)I,V2/HZBFYHS7Q1^A#J*;FC- #J*;FC- #LBC(IN:,T +FC
M)I,TGXT .R:,FF_C29H =Q29IN:* '9]J,TVC- 'AOQ./_%<W/\ URB_]!KD
MA75_$T_\5S<_]<HO_0:Y(5]1AOX4?0^7Q/\ %EZDPJ134(J1370<;1**D!J(
M&G@U1DT3 T\&H0:D!IF31*IJ45 #4BFJ,FC0TZ58[K#-M#JT>X]LBN7\0:3<
MO=;0ISFMP&M&WU-HT"3P17*#IY@PP^C#FLZD%./*PHU949\\3E;'P[>.J@*Q
M)'04Z7188)L7-Y&C?W5!<_\ CH->NZ>=)E\'S7\=HID&4FC9B0".0,^AXKSC
MQ-?FZLEN[&*.UBSL:.(8 -<ZC!I\JV[G9[6MSQYFO>[>?G8MVMOH.C6*WUWJ
M:.<9%NBGS"?3!Z5PE[J;7^ISW979YKY"CL.PJC,[.Q+L2?4U$'P:XZE=RTZ'
MJ4,)&FW)ZMFU!/D5:'S"L2&;!%:<$N0*UISOH9UJ?+JB5D!I4C&:DQFE4<UM
MRZG-S.Q-$N!5E3TJ%*F%=,=CEGN.S3:6@"F0/B'S5KV2985GV\9)%=-HFGO<
MW"(HSDUI'35G%B)7]U;L[;PEI_[L2,, #)-8GC75E+2(K<#BNOU&XC\/Z#Y8
M($\B]/05XMXDU,R,^6Y-<%!^TG*N]MD>C7A[.G#!QW>LCEM0N/,F)SWHL&S*
M*S9Y2SDYJ[IS?O!6<9\U2YZ,J?+2L>B:!.8YH2#_ !"O1]:N T ;/\->5Z1)
MMDC/H17<:C?"2R SU%=M2GSR@^QX%.M[&-6/<SK?5I;6Z#JY&#5[4=#M?$\9
MO-/9(-2(R\9X28^OLW\ZY.>?#GFK6GZI);RJR.0<UI5I*3O'21AAZ\J:M-<T
M7T_R,:[M;BQN'M[J%X9D.&1Q@BJI->KF;3/$]BMMJD89U&$F7B2/Z'^E<+XA
M\)WVA$S?\?-BQ^2XC' ]F'\)K"%;7DJ*S_/T/1=%./M*3YH_BO4YXFF$TI-,
M)K9D)'T;FC--_&BOC#] '9HS3<T9H =FC--S1F@!:*;NHS0 ZBFYHS0 M&::
M31F@!<T9IN11D4 .S29I,BDS0!X?\33_ ,5S<_\ 7*+_ -!KD@:ZOXF'_BN+
MG_KE%_Z#7)@U]1AOX4?0^9Q/\67J2@T\&H@:>M=!R-$RFG@U$#4@Z4T8M$BF
MI :A!Q4@-,S:)0:D!J$&G@U2,FB8&G@U"#3P:HR:.F\/W\!TZ^T>ZF\A+L!H
MI6^ZKCL?0'UKG=5TNYL;:739(B'W9R>](#GBNKN=3:XT33YC''/Y4?DOYBY(
M*^_7IBL>6TM-F4ZEHIO=6_/]#R6;0+W)(7(]JIOI5W&?FC;\J]-N/%*V<9\K
M3;56]2F?YUR=_P"--0>1A'%"N?2%?\*X:M"E'5W1ZV'Q6)J;13_ Q+;3)W8#
M81^%;,6A7@B\P1.5'4[:H_V[K<XXF\L>H0#^E+#?ZJMPDLE_<,5.<%SBI@Z:
MV3-:JKRW:7WLNB-X^&!!I0.:M^<MTNYOO=Z9Y8SQ7=RKH</.^NX1BIP*1%J5
M5S6B1A*0T+FIHXLFI(X<]JTK.Q:5U55R35J-SEJ55%"6-DTLBJJY)KU#P_I4
M.B:>=0O, @953WJ#0/#T&EVHU#4<* ,JA[USWBSQ4U[(8XVVPKP%'2N.I-UW
M[*G\/5_HCIHTUADL165Y/X8_JS/\5^(GO[F1RWR_PBO,=6O#)(PS6GJE^3DY
MYKE;B4LQYJ<144(J$=CLP5"4I.K4U;&%LFM/3OOBLA3\U:UAU%<=%^\>G77N
M'8Z8^&6N@FN"80">U<QI[X*UJSS8BZU[L'H?'8FG>H4;N?#&H8;O:<YJA?7.
M&/-4XYRS 9K"52S/1AAKPU.RL=4=&!5B*[71O$9V^3/M>-QM97&58>A%>86A
M(QS6W;3E<<UI*$:L>6:.)RGAI\])G3:[X"M]0C:^\.E5DQN>R8\'_</]#7G$
M\4MO,\,T;1RH<,CC!!]Q7HVD:U);NOSG'K6_JFD:3XQM1]IQ!?!<1W:#GZ,/
MXA7%)U,.[2UCWZK_ #/5H5*6+7N^[/MT?^7Y'1YHS3<T9KY<^W'9%&13<TF:
M 'Y%)D4TFDS0 _-&:9FC- #\TFZFYHS0 [-&:9FC- #LBC(IF:,T .S1FFYI
M,T >(?$P_P#%<W/_ %RB_P#0:Y,&NJ^)A_XKBY_ZY1?^@UR8/%?3X?\ A1]#
MYO$K][+U)0:>#40-/!KH.1HE4U(IJ$&I :9FT2@T\&H@:>#5&31,#3P:A!IX
M-!DT2@T\&H@:<#5(S:)@:U-$OHK74(UND\RSE8+-&3V/&1[CK60#3L\4-75B
M;6=SN]7\+>'A.\9NY(6'\+X(_.N4O?#>EVSDPD2_[5;_ (AD%U9V%R.3-:HQ
M/OC!_E7"7\L\ )1SCTK*%E!2EJ-\\ZCA3?+9]+A=6L2$A5&*S9$ :J,VK3$G
M)JO]N=CS7).O!O0]>EAJB6K-F([>AJXC@XYK!CNF)K2M2\A%:4ZB>B,ZM)K5
MFHG-7(8BQZ5':V[-CBNKT3P[<7[@A=L8^\[< 5V:)<TMCR*DVY<L%=E+3M,E
MNI52-"S$] *]$TW1K+P];"ZO]K3XRL9[?6JIU32/#%L8[4K/=8YD[ ^U<1K7
MB:>_D9GD.,],US2<Z^B]V'XLUIQIX=\TO?J=ND?7NS7\3>*Y+Z1D5\1CH!7G
M^H7Y;=EJ9=WI8G)YK#NK@DGFJE*-*'+#1&]&C.K/VE5W;(+RX+L>:S';)J65
MR34!/->34GS,^@I0458<G6M:RX(K*B'-:MIP15T=S/$;'2V+8Q5RYFQ%UK.M
M6PHHOI]L1KV5*T3YR5/FJ&-?7&92,U)9C)%9CN9;C\:V["+@$UPTVYSN>M52
MITTC6MQ@"K\;8JI"O%65XKT8G@U-6:$,I'>MS3=4>!A\W%<RC5;BD((K2RDK
M,XFI0ES0W/7\T9IE%?"GZL/S1FF49H ?FDS3<T9H =FC-,S1F@!V:,TW=29H
M ?FBF;J-U #LTF:;FDS0 _-&:91F@#Q+XEG_ (KBY_ZY1?\ H-<D#75?$L_\
M5O<_]<HO_0:Y05]-A_X4?0^=Q"_>R]204\&H@:>#70<K1*#3U-1 TX&F9M$P
M.*D!S4(-.!IF;1,#3P:B!IP-,S:)@:<#4(-/#4S-HF!IP-:6D>&=9UMA]AL)
M7C/_ "U8;4'XFN\TKX?Z9I 6XUNX6\G'(MX^(P?<]6K&>(A#2]WV1I##5)J]
MK+N]C TRUNM2\)LQMY/+M)"$E*_*RMS@'V.?SKE[^T.&R*]7U/Q&D:"&!42-
M!A8U "@>F*Y6XGT>\)-PLELYZE%W+^745=)S</?C9''6=.-7]U*[Z]/N/)+S
M3V60X6H([!R>AKTB?2=.G<^3J%NW/ <["?SJ)-"M4.7O+15'4F5:P>&@W>YW
MQS&2C9IW./M-+8D96NETS19)758XRQ/8"M)6T6RZS-<O_=A7 _[Z/_UZZSP?
MJ*W5Q=1I;10JL.Y-HRP((ZG\:UM&E%RBKG-*I5KS46^6YE_8[#08P^H9EGQD
M6Z=?^!'M63J?C6>9?)0B"$=(H^ /\:[;Q;H']IZ<NJVJY<#$RCU]:\FO=-Q(
M2V:(2]I'G6K_ "$Z4:4W3EHGU[KU_0?+JS3<Y/-49KDG/-,>+RQBJDSXI3FU
MN=-*C#[*&S3$YYK.F?)J:5ZJ-DFN"I)L]2E!(B/6HSUJ9AQ4/>N9G9$EA%:=
ML<8K.BJ] V*WI:'-6U1MP/A:IZI<83&:=#)\M96IS;GVYKLJU+4SAHTKU1MF
M#)+GWKJ+*+Y16#I4.2#76V</ XIX2'NW,L?52=BQ''@4_::G6/ I"E>A8\%S
MN1J,5,AINVGJ*:(D[GKV:,TS)HR?6OAC]3'YHIF3ZTF3ZT /S1FF9HS0 _-&
M?>F9HS0 _P#&DS3<TF: ';J7=3,T9H =FC-,S[TF?>@!^:3--S1Q0!XG\2C_
M ,5O<_\ 7*+_ -!KE :ZGXDG_BMKG_KE%_Z#7*"OIL/_  H^A\_B%^\EZD@I
MX-1 TX'%;G,T3 TX&H@:>#3,VB4&G@U"#3U.2 .2:9#1*#BKNGZ?>ZK<BVL+
M66XE/\,:YQ]?2NV\)_#">^BCO]?9[.S(W+ .)9![_P!T?K7I$-QIN@VGV32[
M6*WB7^X.3[D]2:Y)XK7EIJ[_  -XX:RYZKY5^)P6D?"2\D59=:OH[1.IBB^9
M_P 3T'ZUV-CX<\*Z" 8+%)YE_P"6MP=YS^/ JA?^(B2<OFL"ZUN23.#BB.&K
MUM:DK+RT.6IF.%H:4HW?GK_P#L-0\1D1[(V"(. %X%<=J&L23,<.<?6LJ>_9
MSRQ-49;C=WKNHX:G16BU/'Q.-KXIZNR)I[DL3S6=-*3WI7DS4#\ULW<BG32*
MLK$DU#^%6'3-,$?-9,[HM)"Q+DBO0O %HTE_*P''DL#^5<+;1;G KV#X>V(A
MMY)".66L,5/DH29>&A[7%0AYW+/AZ]1Y;G3Y<%6R-IK@_%FCK:WLFQ?D)R*U
M=1N7TCQ2[*2,/FK_ (G1+ZS2ZCY5QGZ&HIQY*JDOAFOQ%6J>TH2A+XJ;?W7/
M'KR,J36-,#N-=;J-M\S<5SMS!ALUI6@S;"54T94BU%Y=76CR>E!BPO2N%P9Z
MBJ6,R48J #FK-QP34 KFDM3K@]"1>*LQOBJHZ4Y6YJHNQ,E<TTDVIG-9<K&6
MY'UJQ)+MBQFHK*,R3@^]7.7-:*,Z<>1.1T6DV_RKQ756D.%'%9>F6^%7BNC@
MBPM>U1A:-CY3'5[R8WR^*C9*N%.*C:.NBQYBF5"M&*G,=-V&E8TYCU+-(33-
MU&ZO@S]9'49INZDS0 _-&:9FC- #\T9IF:0F@!^:-U,W4;J '[J3=3"11N%
M#LTN:CR:-U #R:3--W4F: /%OB2?^*VN?^N47_H-<H#74?$@_P#%;7/_ %RB
M_P#0:Y4&OIL/_"CZ'@UU^\EZD@-/!J,&E!K<YVB4&G U&#3@<4$-$J99@J@L
MQ.  ,DFO:?!/@.W\/P1ZOK<:R:DPW16[<K /4^K?RK)^&'A*.&!?$VIQ@_\
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EC.<55E8U4(:DU*NA%-+UYJG)-BEG<C-9\TA%>A3IW/&KUK'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V ;,# 2(  A$! Q$!_\0
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M$D<2!5.T*0<#C/)Y]ZU*SKG_ )&'2?\ =G_]!6@:-FJFIO(E@_E.49BJ;AU
M9@"1[X-6ZIZI_P >)_ZZ1_\ H:TBB :98J,?9D;W;+$_4GDTO]FV/_/K%_WS
M5H]:*9!5_LVQ_P"?6+_OFC^S;'_GUB_[YJU10!5_LVQ_Y]8O^^:/[-L?^?6+
M_OFK5% %7^S;'_GUB_[YH_LVQ_Y]8O\ OFK5% %7^S;'_GUB_P"^:/[-L?\
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MB?\ KI'_ .AK5RJ>J?\ 'B?^ND?_ *&M(HD/6B@]:*9 4444 %%%% !1110
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M^'/^1?M/]T_S-:E<4_B9Z=/X$%9US_R,.D_[L_\ Z"M:-9US_P C#I/^[/\
M^@K4FB-FJ>J?\>)_ZZ1_^AK5RJ>J?\>)_P"ND?\ Z&M(HD/6B@]:*9 4444
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MG_7>7_T-JT*S[/\ U4G_ %WE_P#0VIB98HHHH)"BBB@ HHHH **** "BBB@
MHHHH *X+Q;_R'6_ZY+7>UP7BW_D.M_UR6MZ'Q'+BOX9A444^*&2>01Q(78]A
M78>:E<91706OAY/+)NG)<C@(>%_QK.OM)N+++@>9%_?4=/J*S52+=DS:5"I&
M/,T4****T,3T;PY_R+]I_NG^9K4K+\.?\B_:?[I_F:U*\Z?Q,]FG\""LZY_Y
M&'2?]V?_ -!6M&LZY_Y&'2?]V?\ ]!6I-$;-4]4_X\3_ -=(_P#T-:N53U3_
M (\3_P!=(_\ T-:11(>M%!ZT4R HHHH **** "BBB@ HHHH **** "L3Q?\
M\BM>_1?_ $(5MUB>+_\ D5KWZ+_Z$*F7PLWP_P#&AZK\SRFM72]=FTF&1;>W
MMS*P(69E^=<GZ\BLJBN).VQ]A.$9JTEH;">)=0_L^:SG?[1%+L'[P]%4_=X[
M'I3K3Q-?64DH@(2V976.W!^2+=W7OQ6+13YF9^PIZKEW-U_$\K6HC6RA6X^S
M?93<;F+;._'3)K"HHI-M[EPIQA\*.Y^'?34?^V?_ +-7<5P_P[Z:C_VS_P#9
MJ[BNNG\*/E\P_P!YE\OR"BBBM#A*NB?\>,W_ %]W'_HYZTJS=$_X\9O^ONX_
M]'/6E2+"BBB@ K/L_P#52?\ 7>7_ -#:M"L^S_U4G_7>7_T-J8F6****"0HH
MHH **** "BBB@ HHHH **** "N!\6_\ (=;_ *YK7?5@ZA:P-JK7#H&E"J 3
MSCCM6E.:B[F56FZD>5'+V.B37.'FS%%[_>/X5T5M:PVD>R% H[GN?J:DW5E_
M\)+HPUO^QO[1A_M#./(R<[L9VYZ;L<XSFE.I*6Y5.C&GMN:U%4M2U:QTBV6X
MU"Y2WB:18E9OXF8X  [FJO\ PD^B^;?Q_P!HP[]/4M=#)_=@<'Z\\<9YXK,U
M%OM#AN,R6^(I/3^$_P"%<]<6TUK)Y<R%6[>A^E=HL@=%89PP!&1BF3117$9C
MF0.I[&MX5G'1G+5PT9ZQT9H>'/\ D7[3_=/\S6I5/2X$MM-AA0G8H.,_6KE9
M2=VV;15HI,*SKG_D8=)_W9__ $%:T:SKG_D8=)_W9_\ T%:1:-FJ>J?\>)_Z
MZ1_^AK5RJ>J?\>)_ZZ1_^AK2*)#UHH/6BF0%%%% !1110 4444 %%%% !111
M0 5B>+_^16O?HO\ Z$*VZQ/%_P#R*U[]%_\ 0A4R^%F^'_C0]5^9Y314UM:S
MW<HBMXFD<]E'3ZUTVG^$T7$E^^X_\\D/'XFN.,'+8^JK8FG17OOY=3F[2QN;
MZ3R[:%I#W(Z#ZFI[_1[W3N9HLQ_\]$Y7_P"M7H,4,4$8CAC6-!T51@4\@$$$
M @\$'O6WL58\EYK/GNHZ'EE%=OJ/ABTN\R6W^CR^@'RG\.WX5RE]I=WISXN(
MB%[.O*G\:RE!Q/3H8NE6TB[/L=;\.^FH_P#;/_V:NXKA_AWTU'_MG_[-7<5T
MT_A1\_F'^\R^7Y!1116APE71/^/&;_K[N/\ T<]:59NB?\>,W_7W<?\ HYZT
MJ184444 %9]G_JI/^N\O_H;5H5GV?^JD_P"N\O\ Z&U,3+%%%%!(4444 %%%
M% !1110 4444 %%%% !6+J!Q>/\ 0?RK:K#U(XO7^@_E0!!FO.;OPQJ,GC)1
M91WR:8-575)VE$0B+A>?+8'>23Q@@ <UZ%FLJT\2Z5?ZJ^FVERTUPA96*1,8
M]R_>7?C;D=QFG8+G'^,M%\3^);:'4+>RA146/RM.N#F6!_,!9\J=I. .<\+G
M')HUKP1J#7]Q-IKS,Q@>Y(++Y7GE]XBCSS]_+_-Z**["S\2Z/?V=[=V]]&;>
MQ=H[F1_E$97KG/;WJLGC/1'TRYU$7$PM;?;O=K:1<[CA2H(^8$^E%@N6/"G]
MJKH$8UDSF[\V3'VEE:7R]QV;RO!;'6MK-9NEZS8ZU;//83&1$<QR*R%&1AU5
ME."#5[=185S?LO\ CSC^A_G5BJUA_P >,7T/\ZLTAA6=<_\ (PZ3_NS_ /H*
MUHUG7/\ R,.D_P"[/_Z"M T;-4]4_P"/$_\ 72/_ -#6KE4]4_X\3_UTC_\
M0UI%$AZT4'K13("BBB@ HHHH **** "BBB@ HHHH *H:S;QW>ER6\P)CD(#
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M_P#LU=Q793^%'RF8?[S+Y?D%%%%:'"5=$_X\9O\ K[N/_1SUI5FZ)_QXS?\
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M^\R^7Y!1116APE71/^/&;_K[N/\ T<]:59NB?\>,W_7W<?\ HYZTJ184444
M%9]G_JI/^N\O_H;5H5GV?^JD_P"N\O\ Z&U,3+%%%%!)E^(_^1?N_P#='\Q7
MG->C>(_^1?N_]T?S%><UV4/A/.Q?QKT"BBBMSD"BBB@ K9\+?\C!!_NM_*L:
MMGPM_P C!!_NM_*HG\+-*7QKU/0:***\\]@*X+Q;_P AUO\ KDM=[7!>+?\
MD.M_UR6MZ'Q'+BOX9A4445V'FA1110 4444 >C>'/^1?M/\ =/\ ,UJ5E^'/
M^1?M/]T_S-:E>=/XF>S3^!!6=<_\C#I/^[/_ .@K6C6=<_\ (PZ3_NS_ /H*
MU)HC9JGJG_'B?^ND?_H:U<JGJG_'B?\ KI'_ .AK2*)#UHH/6BF0%>??$+_D
M)6?_ %Q/\Z]!KS[XA?\ (2L_^N)_G6=7X3T,M_WA?/\ (X^BBBN,^I"BBB@
MHHHH ]:\+?\ (KZ?_P!<OZFM>LCPM_R*^G_]<OZFM>NZ.R/C*_\ %EZO\PK$
M\7_\BM>_1?\ T(5MUB>+_P#D5KWZ+_Z$*)?"QX?^-#U7YGE-%%%<)]D%%%%
M!1110!W/P[Z:C_VS_P#9J[BN'^'?34?^V?\ [-7<5V4_A1\IF'^\R^7Y!111
M6APE71/^/&;_ *^[C_T<]:59NB?\>,W_ %]W'_HYZTJ184444 %9]G_JI/\
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MW6)XO_Y%:]^B_P#H0HE\+'A_XT/5?F>4T445PGV04444 %%%% '<_#OIJ/\
MVS_]FKN*X?X=]-1_[9_^S5W%=E/X4?*9A_O,OE^04445H<)5T3_CQF_Z^[C_
M -'/6E6;HG_'C-_U]W'_ *.>M*D6%%%% !6?9_ZJ3_KO+_Z&U:%9]G_JI/\
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M?_T%:T:SKG_D8=)_W9__ $%:12-FJ>J?\>)_ZZ1_^AK5RJ>J?\>)_P"ND?\
MZ&M(HD/6B@]:*9 5S/B?PU<ZY=P303Q1B-"I#YYYSVKIJ*32:LS6E5E2ESPW
M//?^%?7_ /S^6WY-_A1_PKZ__P"?RV_)O\*]"KG=9\96&A:G'9WEGJ7ELT:2
M7B6Q-O$9#A S^YXXSCOBL_91.S^TL1W7W'/_ /"OK_\ Y_+;\F_PH_X5]?\
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M.:],HH'<YSP3I=YHV@_8[W3X+.82L[&.[-PT[-RTCN57YB<]JZ.BB@04444
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M@"2">@P ::-7TXE M[ YD *A'!)!. >.V:K_ /"/VALWM7>1HFD:3;P N1C
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-0/SJY112&%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &% ,\# 2(  A$! Q$!_\0
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M * VG?\ @*G^%:-% &=_PCVB?] ;3O\ P%3_  H_X1[1/^@-IW_@*G^%:-%
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M7:6]I<P["K01A,Y<*<XZ\$]:Z:N<\>_\B3J/TC_]&I0!I>'O^19TG_KRA_\
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MBB@ HHHH *YSQ[_R).H_2/\ ]&I71USGCW_D2=1^D?\ Z-2@#2\/?\BSI/\
MUY0_^@"M&L[P]_R+.D_]>4/_ * *T: "BBB@ HHHH **YK5_&VGZ5J[:5'9:
MEJ5_'&)9H-.MC*84/0OV&>PZU5UGXC:7HFHR65QI^JRO#:+>W#06VX01-_$_
M.1CO0!U]%<Y%XWT:?Q19^'XWE-U>6BWD$FS$;HP) SZX!.,5-X>\6Z9XFOM5
MM-.\TOIDPAF=UPK-DC*GN.#0!NUFWOA[1=2NUN[[2;*YN%&!+- K,!]2*Y^/
MXEZ*U_);RVNIP6\=X;%K^2V_T<3 XVEP>.>Y]:Z.?7-)MIGAGU.SBEC+!T>9
M0RX7<<C/&%.?I0!3'AJWM_$EKK&GF.SV0O!<P11A5N$/*YQC!4]#[D5MU3.K
M::K!3J%J&,'VD R@?NO^>G^[[]*;IVLZ7J^_^S=2M+S9@O\ 9YE?;GIG'2@"
MX(T61Y%10[XW,!RV.F3WIU<I8_$30;_1M:U1&GC@T9V2Z$B8;(SC:,\Y(('O
M5ZR\7Z)>:!8:U+?0V-I?#,'VR18BW.,<GKQ0!NT52FUC3+>989M1M(Y6V;4>
M906WG"X&><D''K5#0?%FF:_IEA>12?9FOC(+>WN&42OL8JV #SC':@#<HK*E
M\3:''97]W_:UG)#IZEKHQS*YBQV(!Z]L>M6-)U>PUS3HM0TVZCN;:495XV!P
M?0^A'<=J +M%%% !1110 5SGCW_D2=1^D?\ Z-2NCKG/'O\ R).H_2/_ -&I
M0!I>'O\ D6=)_P"O*'_T 5HUG>'O^19TG_KRA_\ 0!6C0 4444 %%%% 'F'B
MCPKXG35_$,^AP-<0ZVL3I-;ZA]DFM)HT*@D_QISG -8_B?P!XAU/5S.VD+J;
M2Z)!8_:3J(A$5POWI&&<N,\X(.:]GJO>7UKI]LUQ>3I#"#C<Y[^@]3[4 >8Z
MSX)\3MJB:M8B";4['3K)+:;S%199XRXE&.P*N?2NA\!^$KGPIJFKK(B_9)H;
M-() P)D9(\2$CM\Q-=7::E9WS*MK<+*6B$R[<\H20#^8(_"IEGB>YEMU?,L2
MJSK_ '0V<?R/Y4 >4-X/\57VG:OX9DTVVMM-U#69+Z347NU8B$R!P%C SN^7
MOZULS^!9[W4O'EU+:6RW&KQK%I]R^&8+Y 1O=1NZ^M=[/<16JQF9P@DD6-,]
MV8X I6N(5N%MVD43,AD5">2H(!/TY'YT >(>)=%UN#19[_7M+@LK>/P_'H\8
M2[60M.)4V,Q'"J2,\\ #FNO^%L\+76OPO;2KJ7GQ2WEQYL,L4C%,*$,0"C 7
ME>O-=C+K6C2,+6:\MI/-A,OEM\P:/!.3VQ@$\^E+I%_H]U9LVD2VWV=.6$"A
M O&<D8';O2 \PT_X<Z_#<VL4T42V%Y<3'54\Y22B3M+!CGG.0#Z"GS>#/%W_
M  BOA_1Q:0R006,\-S"EQ&ACF<G:Q<J24P>0O->F6GB#2;^)I;6_AE12 2N>
M_(X]#@\]*GM]3LKID6"X5V< J #R"H;_ -!(/XTP.#\*^![NS\3:7J&L:?;2
M)9:!;V:.[+(8[A&.[:/8?Q5E>#O 'B+P^V;I4D:_LI[260R*7TPEF*&,YY1M
MP) YR*]=P?0U#<W,-G;M/<2".)<98CU.!0!Y#HGPTU:/1[^PO;1XKH:-+IT4
M[74+V\A;E2$1 XY&<N21[UZ1X1@O+7PQ96U_I<>FW,$:Q/#'*L@;: -^5XYQ
MGUK;HH **** "BBB@ KG/'O_ ").H_2/_P!&I71USGCW_D2=1^D?_HU* -+P
M]_R+.D_]>4/_ * *T:SO#W_(LZ3_ ->4/_H K1H **** "BBB@ K*UBUNI);
M*\LX4GEM7=O)9PA8,I7*D@@,/?WK5HH XY]&UVX'VBY_?2&%$DC,ZJ\JK*[>
M664  [67D8!(J)?#NL+=I*$"R-Y(2879)ME21F*D?Q_*=N?Z5VU% ''0Z+K+
M7CW5S'&BFXAF>))BRDI(6+*/=2,#K6I=1ZC+=6&L6MB'D^RO#):RRB-DWE6!
MR1CC;@CWK=HH XR3P]JD$8MK&)8RUGY%U.9QY=QB,J!LQD,"1AN..N>E:&F:
M;J$DYO+RWCM)%TX62PB42%R#G<Q'&/0>YKHZ* .&TSP[K,447F1>1L@B@=9;
MOS6?8&R0W9.?N_I4X\.ZRD,203) P@V,RRD?-Y"(.G^TK<]NM=E10!QC^'-1
MN8)OW;VL1MY_L]J+QF\J4A-A+ \_,K'VS5^QTF_.J79O$)MIX0LLKS[G9\+]
MP#[J\'@CZ5TE% !U-%%% !1110 4444 %<YX]_Y$G4?I'_Z-2NCKG/'O_(DZ
MC](__1J4 :7A[_D6=)_Z\H?_ $ 5HUG>'O\ D6=)_P"O*'_T 5HT %%%% !1
M110 4444 %%%% !1110 4444 %%8?BOQ&/"^D)?FU^T[IA%LW[<9!.<X/I7%
M_P#"XT_Z A_\"?\ [&M(TIR5TB7.*T9ZA17E_P#PN-/^@(?_  )_^QH_X7&G
M_0$/_@3_ /8U?L*G8GVD>YZA17E__"XT_P"@(?\ P)_^QH_X7&G_ $!#_P"!
M/_V-'L*G8/:1[GJ%%>7_ /"XT_Z A_\  G_[&M_PEX]7Q5JDMD-.-MY<)EW^
M=OS@@8Q@>M2Z,XJ[0U.+=D=C1116185SGCW_ )$G4?I'_P"C4KHZYSQ[_P B
M3J/TC_\ 1J4 :7A[_D6=)_Z\H?\ T 5HUG>'O^19TG_KRA_] %:- !1110 4
M444 %%%% !1110 4444 %%%% '"_%G_D48?^OQ/_ $%Z\3KVSXL_\BC#_P!?
MB?\ H+UXF>E>EAOX9RU?B)1:W!MOM(@E,&[;Y@0[<^F:DN=.OK.**6ZL[B".
M49C>6,J'^A/6O0C<O??#U8;K4H;,Q1+';"SN@5N3@8CDCZAL]?SJ'7=*UM-
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M "+.D_\ 7E#_ .@"M&L[P]_R+.D_]>4/_H K1H **** "BBB@ HHHH ****
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M](__ $:E='7.>/?^1)U'Z1_^C4H TO#W_(LZ3_UY0_\ H K1K.\/?\BSI/\
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MI0!I>'O^19TG_KRA_P#0!6C6=X>_Y%G2?^O*'_T 5HT %%%% !1110 4444
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M***\D[ KG/'O_(DZC](__1J5T=<YX]_Y$G4?I'_Z-2@#2\/?\BSI/_7E#_Z
M*T:SO#W_ "+.D_\ 7E#_ .@"M&@ I&^ZWT-+2-]UOH: /ER7_6M]:;3I?]:W
MUIM>V< 4444 %%%% $EO_P ?$?\ O"OJ,]:^7+?_ (^(_P#>%?49ZUPXOH=%
M'J)1117$;G"_%G_D48?^OQ/_ $%Z\3KVSXL_\BC#_P!?B?\ H+UXG7I8;^&<
MM7X@HHHKI,@HHHH *] ^$7_(T77_ %YM_P"AI7G]>@?"+_D:+K_KS;_T-*RK
M?PV7#XD>S4445Y)V!7.>/?\ D2=1^D?_ *-2NCKG/'O_ ").H_2/_P!&I0!I
M>'O^19TG_KRA_P#0!6C6=X>_Y%G2?^O*'_T 5HT %(WW6^AI:1ONM]#0!\N2
M_P"M;ZTVG2_ZUOK3:]LX HHHH **** )+?\ X^(_]X5]1GK7RY;_ /'Q'_O"
MOJ,]:X<7T.BCU$HHHKB-SA?BS_R*,/\ U^)_Z"]>)U[9\6?^11A_Z_$_]!>O
M$Z]+#?PSEJ_$%%%%=)D%%%% !7H'PB_Y&BZ_Z\V_]#2O/Z] ^$7_ "-%U_UY
MM_Z&E95OX;+A\2/9J***\D[ KG/'O_(DZC](_P#T:E='7.>/?^1)U'Z1_P#H
MU* -+P]_R+.D_P#7E#_Z *T:SO#W_(LZ3_UY0_\ H K1H *1ONM]#2TC?=;Z
M&@#Y<E_UK?6FTZ7_ %K?6FU[9P!1110 4444 26__'Q'_O"OJ,]:^7+?_CXC
M_P!X5]1GK7#B^AT4>HE%%%<1N<+\6?\ D48?^OQ/_07KQ.O;/BS_ ,BC#_U^
M)_Z"]>)UZ6&_AG+5^(****Z3(**** "O0/A%_P C1=?]>;?^AI7G]>@?"+_D
M:+K_ *\V_P#0TK*M_#9</B1[-1117DG8%<YX]_Y$G4?I'_Z-2NCKG/'O_(DZ
MC](__1J4 :7A[_D6=)_Z\H?_ $ 5HUG>'O\ D6=)_P"O*'_T 5HT %(WW6^A
MI:1ONM]#0!\N2_ZUOK3:=+_K6^M-KVS@"BBB@ HHHH DM_\ CXC_ -X5]1GK
M7RY;_P#'Q'_O"OJ,]:X<7T.BCU$HHHKB-SA?BS_R*,/_ %^)_P"@O7B=>V?%
MG_D48?\ K\3_ -!>O$Z]+#?PSEJ_$%%%%=)D%%%% !7H'PB_Y&BZ_P"O-O\
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M_0'N?^^:/^$&\3?] >Y_[YKWHZOIBZ:NI'4+46# %;GSE\LY.!\V<=>*N Y
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,0#D <#'(%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ .8# 2(  A$! Q$!_\0
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M/^ASUS_OS9?_ "/7044 <_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\
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M (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@Q
MA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .
M@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A
M._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ #P;_R [G_ +"NI?\
MI;-14?@:>&Z\-R7%O+'-!+J>H/')&P974WDQ!!'!!'.:* .DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N O0# 2(  A$! Q$!_\0
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MB(0'!^7+X;^!6IO_ #_K]/4%_D>A0N988Y&C>)F4,8WQN4D=#@D9'L33ZS=
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M ,_TW_@._P#A0!V]%065Y#J%A;WMNQ:"XB66,D8RK#(X^AJ>@ HHHH ****
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M\A\(:]KGA;13IY\(ZE<DRM)O".G4 8QL/I0!Z]17 ?\ "P=;_P"A'U/\W_\
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MO:=874]K<3N)X+4WCQI"[D0@X+ *#GGL.?:M%&#HK#.&&1D$'\CTH 6BBB@
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M#D8+11*I(].!4)T+2"23I5B2>I-NG^%&@#)/$&EQ:3'JCW0%G(=J/M/S')&
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MST&30!/1110 4444 %%%% !1110 4444 %%%<Y?>/?#&FZA'8W>JHEP]T;,
M1NRB8",E2P4J,>='DD@ MC.0< '1T444 %%%% 'F>F>$U\+_ !.T0+KFMZI]
MHL+W_D*7?G^7M:'[G QG=SZX%>F5RFJ_\E/\-?\ 8/O_ /T*WKJZ "BBB@ H
MHHH **** "BBB@ HHHH XOP'_P A/Q7_ -A:7_T(UVE>6V&L:YX9UK7TA\*:
MC?176HRS)*B.HQN.,80Y!ZYK:T?Q]>ZAXDL]&OO#EQISW(<JT\K @*K-D*4&
M?NXIB.XHHHI#*Z1L-1FE(^1HHU!V+U!?//4]1P>!VZFN=^(5C<ZEX:BM;:.Z
M=GU"T+?92P=4$Z%F!7D8 )R.F,UT21L-1FE(^1HHU!V+U!?//4]1P>!VZFK%
M 'D7ASPG/HGB[3;BTLM4BBAU>]M%,DDSQQV/E%D4!B0$,F"#W;N:?X4T75X/
M%NJ:A<S7\6K3M=I,K6%P(YUW'R6,[.82%&W:$4$ X[&O6JX?6;KQ#K7C"]T/
M1-;&C1:?8I.\HM4F::60L%!WY 4;,G !.>M2]K>3_+4?GZ?F>>Z9H-\NAZRU
MMHFNQW<_AF2&Z:[BF+3WQ8&38'))))S\O!YQGFM>?3M2D^)MMJ,&E7]O+&[6
MLLJPW3"6W^S$AC(6\H*9"!Y:J"&7).35J[\<:U=>'O#.LSWL^C:9=VTAOM0M
M+);E(K@,%02!@2D3'=R.<D#(ZUZPK!E# @@C((Z&KDM_FOP?^>W:Q*=G_7=?
MY'F7PV\/7.@WNG2&VU&$7>A1-??:6D(^T*P4 A^%8)P%&, =*].HHH;NP2L%
M%%%(84444 %%%% !5>_&=.N1YOE9B;]YYGE[.#SNP=N/7!Q5BJ]^,Z=<CS?*
MS$W[SS/+V<'G=@[<>N#B@"Q1110 4444 %%%% !1110 4444 %%9^N:S:^']
M&N-4O!*T, 'R0QEWD9F"JBJ.K,Q 'N>U97A[QQI?B76-0TVSBNXY;,MB2>,+
M'<H)&C+Q,"=RAD(SQ0!TM%%% !6+XE\)Z)XOLHK/7+/[5;Q2>:B>:\>&P1G*
MD'H36U10!PGP;18_A9I*(,*LER /;[1)7=UPWP?_ .27Z7_UUNO_ $IEKN:
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M*^&_^?S5?^_L?_Q%>CT4 ><?\*5\-_\ /YJO_?V/_P"(H_X4KX;_ .?S5?\
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M/,\O9P>=V#MQZX.*L57OY%ATZYE<X1(F9CO9> #W7)'U'/I0!8HHHH ****
M"BBB@ HHHH **** .0^)=QCP1J-G!JEE8WL\6Z(75XMN)45T\Q Q(QN!V9R
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M+=R++N&-TG&6')X/'I]*UJYGP8"+;5@1@C4Y@0?HM '34444 %%%% !1110
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MW-:%9^E7,MS]M\UL^7=R1K^]1\*,8^X!M_W6RP[FM"@ KE/B3_R(&I_]LO\
MT:E=77/>.=.N]5\'7]E8PF:YD\O8@(&<2*3UXZ T 7/"_P#R*6C?]>,'_HM:
MU:\WT_4_B!IVFVMC'X9MF2VA2%6:09(4  GY_:K/]O\ Q#_Z%>U_[^#_ .+H
M [^BN _M_P"(?_0KVO\ W\'_ ,71_;_Q#_Z%>U_[^#_XN@#OZ*X#^W_B'_T*
M]K_W\'_Q=']O_$/_ *%>U_[^#_XN@#OZKW\BPZ=<RN<(D3,QWLO ![KDCZCG
MTKB/[?\ B'_T*]K_ -_!_P#%UDZ[>_$+44T]I=,_LZTM+V.ZNWMKHQF2!,[T
M)5B<$'L.PH ]5HHHH **** "BBB@ HHHH **** ,C7-9N=%^SS+I<][:,2LS
M6SJ98CQM(C.#(.N0I+<#"MGCB/AC<>(]0U;4+V_U?[;8!&CF5KM)<W&X$%(A
M&K6X"[@8WP<D<<9K=\=^!/\ A-A9#^T%M/LRRK\]OYOW]OSK\R[77;\K<XR>
M*Z&#0],M=7EU:"SCBOYH_+FFC^4S#(Y<#AB,#!() R 0": -"BBB@ K&\1^(
M!X=LHKDZ1JVI^9)Y?E:9:^>Z\$[B,C XQGW%;-% '"?!MM_PLTEMI7=)<G##
M!'^D2=:[NN&^#_\ R2_2_P#KK=?^E,M=S0 4444 %%%% !1110 4444 %%%%
M !1110!BW>J6T/BK3]->S62XFB=TN#C,8P>!QGG:<].U;5<GJT,L?C[2[]XV
M6SAMW\V<C")\K_>;H.HZ^M;7_"0:-_T%K+_O^O\ C3 TJ*ISZMIUJ(S<7]M%
MYB[DWRJ-P]1SR*2WUC3+J98;?4+665L[4292Q[\ &D!=HJA)KFDPRM')J=FC
MH2K*TZ@@CJ#S4L6I6,\'GQ7MN\6_9O64%=WIG/7VH M4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#2
M:UI6L?$[P]_9FIV5[Y6GWWF?9IUDV9:#&=I.,X/Y&NYKSZ+PQHGASXG:!_8V
MF6UCY^GWWF^2FW?M:#&?ID_G7H- !1110 4444 %%%% !1110 4444 %%%%
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MW_\ Z%;UU=>>P^'X="^)V@^5J&J7?G:?>Y^WWLEQMPT'W=Y.WKSCK@>E>A4
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M)?I?_76Z_P#2F6NYKA/@XBQ_"S244859+D >@^T2UW= !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<=\2?^1<@_Z^U_\ 0'KL:R/$=R;73XY!
MHYU4^<!Y(3=MX)W?=/3&.G>F@-?M17,6GBF^N+R&"3PWJ,*2.$,C(V$R<9/R
M]!4VJ>([S3]0DMH= O[M$ _?1(=K9&>, ^N*+ =#16-I>MW&H6UU+-H][:M
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M7_0ZV'_@D'_QZC^P_'7_ $.MA_X)!_\ 'J .PHKC_P"P_'7_ $.MA_X)!_\
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MGT+X=Z?;:%X^\=:#IJ-!I5H]C);VP=F6-I(27(R2<D@9^@H ])HHHH ****
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MDX% !12*P90RD%2,@CH:6@ K,U#P_I>J:KINIWEKYMYIC.UI)YC+Y9< -P"
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MCDCM]Y?SK1H YS6/ /A77]7BU75=$MKJ]C  D<'YL=-Z@X?_ ($#71
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M$C@T <M\%]?U/Q'X0OKS5;^6^F74I8TEE4*=@5"!@<#J>/>O*]#L-2\,^$M
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #^ A4# 2(  A$! Q$!_\0
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M .2*Z"B@#G_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_ )(KH** .?\
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M5/\ H3-<_P"_UE_\D4?\)#JG_0F:Y_W^LO\ Y(KH** .?_X2'5/^A,US_O\
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M6PUT%<_XR_Y =M_V%=-_]+8:Z"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KV]];W<]W#!)ODM)1#.-I&
MQRBR <]?E=3QZ^N:L5CZ--;R:KXA2"U\F2+4$2=_,+><_P!E@(?!^[\I5<#^
MYGJ30!L4444 %5[^^M],TZYO[R3R[6UB>:9]I.U%!+' Y. #TJQ6/XLFM[?P
M;KDUY:_:[6/3[AYK?S#'YJ"-BR;ARN1D9'3- &Q1110 4444 %%%% !1110
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M!-"X="]S,X##H2K.0?Q%=S13#<**** "BBB@ HHHH Y_P;_R [G_ +"NI?\
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MS_V%=2_]+9J*/!O_ " [G_L*ZE_Z6S44 'C+_D!VW_85TW_TMAKH*Y_QE_R
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M ZSPIX T+P?+<75C'/<:E=9^TZA>2F6>;+%CEN@R3S@#. 3DC-=110 4444
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MGV!J*Y&@VWB"TEN4T^/6;E&BMI)%03R*!EE4GYB!GH*U:J[Y4F39<S://_\
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MM_Y)#KO_ &[_ /I1'0!Z!1110 4444 %%%% 'S_HO_)(?A;_ -C7!_Z43U]
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ML>=D,$8C1<DDX4<#))/XT 9_ACPQI?A'0X=(TB#RK>/EF;EY7/5W/=C@?D
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M%U&I$T1N(R =Q)4<YZKT%=5X"U*?[?KGAD[#8^'FM[&S<C]XT8B RYZ$_+V
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MNH:YJ.CVTY>^TX1FYC*, F\97DC!X]*\V\:G7E^-.B?\(TNG'4!I$NT:AO\
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M,O\ D!VW_85TW_TMAKH*Y_QE_P @.V_["NF_^EL-=!0 4444 %%%% !1110
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ME>I(T#.C_NY7B8,CAU(9"&!#*#D$=*R_^$-TO_GZUS_P>WO_ ,>H Z"BN?\
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M Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J .@HKG_\
MA#=+_P"?K7/_  >WO_QZC_A#=+_Y^M<_\'M[_P#'J .@HKG_ /A#=+_Y^M<_
M\'M[_P#'J/\ A#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\
M>H_X0W2_^?K7/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\
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M>WO_ ,>H Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J
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M_'J .@HKG_\ A#=+_P"?K7/_  >WO_QZC_A#=+_Y^M<_\'M[_P#'J #P;_R
M[G_L*ZE_Z6S45J:7I=IHU@ME9)(L"N[_ +R5Y6+.Y=B6<EB2S$Y)/6B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' GP# 2(  A$! Q$!_\0
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M#\CMQTP3P0QI#/6O^&CO!_\ T#=<_P"_$/\ \=H/[17AJ<&*PT77+F]?Y;>
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M'CYCZFO0/!W@#0O W]H_V+'.OV^422>=*7VJ,[47_97<V,Y;GDGC'#_LX_\
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M,@L2<DDXR0, D5Q?A[_DZ'Q9_P!@I/\ T&UKV"O'_#W_ "=#XL_[!2?^@VM
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MFM#PMX@'B#1+&_,8B:YMXYC'NW;-R@XSQG&>N*TJX3X7L?\ A%])'_3E#_Z
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M7^'7B&X\5?#_ $?6+Q<74T128Y'SNC-&S\  ;BI; '&<=JZB@ HHHH ****
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MHHHH **** "BBB@#Q_X0?\E#^)W_ &%1_P"C;BO8*\?^$'_)0_B=_P!A4?\
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ME))VLF=N_GD$'M2>XT-\(?$+5]3\5)H$GV#7K4%EDUC2XIDCAPF1YN5*98C
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M4.W_ ,:YN3X=3>'K:_\ $2>,I++Q"T[W!U1B+:"0NR-Y<R9*E"X/ME^5; %
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MGCZ2\%SS77@3P]<7$LDT\NFVSR22,69V,2DDD\DD]Z -RBBB@ HHHH ****
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M:G8FYY_X2_Y*]\1?^X9_Z3M7H%>?^$O^2O?$7_N&?^D[5Z!2&%%%% !1110
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MZKV"O'_$7_)T/A/_ +!4G_H-U0![!1110 4444 %%%% !1110 4444 %%%%
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MMDCCC4*J*)XP  .  .U='X#_ .2>>&O^P5:_^BEK ^-G_)(==_[8?^CXZW_
M?_)//#7_ &"K7_T4M '04444 %%%% !1110 4444 %%%% !7FGQ#3X:2ZY;K
MXRNVCOTA5HD\ZX4!,M@@)QG.[GK7I=<SXA\6V6AWZ6MSHVL7KM&'$EGI[3H
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M@VM 'L%%%% !1110 4444 %>/^(O^3H?"?\ V"I/_0;JO8*\?\1?\G0^$_\
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M_)T/BS_L%)_Z#:U[!7C_ (>_Y.A\6?\ 8*3_ -!M: /8**** "BBB@ HHHH
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M2_\ 8*NO_134 <]\$O\ DD.A_P#;Q_Z/DKT"O/\ X)?\DAT/_MX_]'R5Z!0
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M,J!XY(V#*ZD9!!'!!'>HH=.L;:\N+R"SMXKJYQY\T<2J\N.FY@,MCWH6CO\
MUIL#U5OZ\SS/2=*NM;U?QK;S76BI/)?R1745_IK3S?9]J^4=PF3";0".."">
MM-3PYIUSXQ\%Z9J,EMKMK;:+,8YI$#1S8*!7VY8$8/')'?TKT34/#FA:O<"X
MU+1=.O9@NP27-JDC!?3+ G')JS'IMA%-!-'96R2V\7DPNL2@Q1\?*IQPO X'
M'%"TMY?HFOU_,):W\_\ @?Y'E.J6EMIOAOXH6%C!';6<11HX(E"HA:!"V%'
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M"KK_ -%-0!SWP2_Y)#H?_;Q_Z/DKT"O/_@E_R2'0_P#MX_\ 1\E>@4 %%%%
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MOB+_ -PS_P!)VKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC(XX(Q1NKAL3T444 %%%5[:^M+QYTM;J"=H)#%,(I QC<=5;'0^QH L4444
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M.:\Z^&FCZBGB'Q/,WB&]>*VUJ5)H3%#MN6V+\SG9D'D?=P.*]5KB]$\/^(-
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M;.G!:-<*&7 /WLY..V:T/$6N:[>^(?"EAH&H16,6L6L\LKRQ++L4*C!@".6
M)QSC)YSTJ"]\.>/->T!/#6JW>BV^GN%ANK^U:1IYHACA490JLV.3D@9.!707
MOAF>7QAX;U2U:%++2H+B%XV8[SO157:,8.,<Y(J]+^5_PL_UL9INWG;\;K_@
MF9X=O-;TKQ_>^%]3U>35K9M/2_MIYXD22/YRC(=@ 89YSBNZKG/[ NO^%CGQ
M%YD/V/\ LH66S<?,W^:7SC&,8]\^U='2Z+^NK_2Q3W?]= HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7&G65W<VUS<VD$T
M]JQ:"21 S1$C!*D]#CTHHH LT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5Y+&TFO8+R6VA>ZMPRPS,@+QAOO!3U&<#-6*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )$ @<# 2(  A$! Q$!_\0
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M6ZO'@4B,R.V<*#SM VJ,\X6O,M0TG3=&_:6\*6^EZ?:6,+:;*[1VL*Q*6V7
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M44 9UWHFFWTYGNK.*64@+O8<X%0_\(QHG_0-A_(UC>(;JXBU=DCGD1=B\*Q
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MK;5+QW?R[!+B9@,LV(PS'Z]:YZ+XJZ#*+9A::PL=Y'NL7-@^+QN,I%CDMSW
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M U>*2?1KV&)2TCP.JJ.Y(.*\F'A/7@/^09-^G^-<&*E537)<[,/&FT^<VO\
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M_P##_P!]4?\ "0:3_P _\/\ WU42I*7Q1O\ (B4*<OB2?W$O]D:=_P ^-O\
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M^/\ P D]_P /Z^\]#HHHI %%4]5U6QT/2[C4]2N4MK.W7?+*^<*.G0<DY(
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M )"EW_UV?_T(UZF6_%+T/B>,7?#T?\3_ /23S#4O^0K>?]=W_P#0C7T;:_\
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MR#&, <=/PKA=2_Y"EW_UV?\ ]"-=9X8_Y%NQ_P!P_P S7)ZE_P A2[_Z[/\
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MW6OG\J_@OU_1'Z9Q5_OD?\*_-A1117JGRH4444 %%%% !1110 4444 %%%%
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ML$9T&03^'VUZWWJ9;)51F*@YW!7(#$8''4UMT4GJ!Y%'K?P;63R+_1=.TR[
M^>UO]',4B>QRF/R-3VGBSX5:;J*2^'=*M[W5HP6BBT?26>8Y!!VD*!T)'4=:
M]3EABG7;+&DB^CJ"*(H8H4V11I&OHJ@"J J:/>W6HZ7%=WFG2Z=-)N/V:9U9
MT7)V[MN0"1@X[9Q5ZBBD 4444 %%%% !7D/B+_DYWPC_ -@N3_T&YKUZO(?$
M7_)SOA'_ +!<G_H-S0 _X]>+I-!\,PZ*EFLRZU%-&TI?:8MAC.0,<YW>W2NA
M^%WCR7Q]H=U>RV"69M9Q %24ON^4'/0>M><_M-?\RM_V]_\ M&G? W7K;PY\
M/M7O[N"ZE@&HA7-O%O*#RP=S>B\=?<5<(2J24(*[8FTE=GOU><^.O^0]'_U[
MK_-J[ZPO%U"QANTAGA65=PCGC,;K[%3TK@?'7_(>C_Z]U_FU>'GJ<<*T^Z_4
M^>XC=\#\U^IS=S_K1_N)_P"@BMFW_P"/:+_<'\JQKG_6C_<3_P!!%;-O_P >
MT7^X/Y5]_@O]PH?X8_\ I*+XX_Y$.7?+_P!-H\^U+_D*WG_7=_\ T(U]&VO_
M !Z0_P#7-?Y5\Y:E_P A6\_Z[O\ ^A&OHVU_X](?^N:_RKX+ ?QZWJ_SD?I6
M=?\ (OP?^"/_ *13):***]<^4"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /$_B7\4M#L?%>EZ5+:Z@9]$U:.ZN66-
M-KJ(FX0[\D_..H'>O8-)U*'6=&L=4MUD6"]MX[B-9  P5U# '!(S@^IKY#^+
M_P#R5?7_ /KLG_HM:^J/ G_)//#7_8*M?_12T =!7--J5BOC/SC>VXB%AL+F
M5=H;S,XSGK[5TM>+W/\ Q]S?[[?SKQ,VQ<L.J;2OK?[O^'/G<\QTL(J3C&^M
M_N_X<LV6H7IU.%C>7!9W16)E;+#/0\\BKEY_R#KS_KVE_P#0#658_P#(0MO^
MNJ_S%:MY_P @Z\_Z]I?_ $ U^BYA%*E.R^R_R9Z_'45'-<MLOM+_ -+IG._#
MW_D>M-_[:_\ HIZ]UKPKX>_\CUIO_;7_ -%/7NM? 95_!?K^B/M>*O\ ?(_X
M5^;"BBBO5/E0HHHH **** "BBB@ HHHH **** "BBB@#S[Q-XKF\*>,;FXOT
MU&6TFTQ4TR"WB>2.:YWMN0A1@.?DP3VS69I.F:OX?\2^%IKW7=1NM9UAIFU2
MSEG+PA/+9R53H@1MB@CUQWQ6WKU_XGU3QQ_PC>A:G:Z1#;V*WDUU+:B>23<[
M*%520,#;R?I5[2-#\86>J0SZIXSBU"S7/F6JZ3'"7X('SAR1@X/3M1'H_P"K
M:_K^2"75?UT_KYG5T444 %%%<3X[\6ZIH&IZ%I>D#2TN=3:<F?5'9((DB0,=
MS+R"=P Z\T =M17#ZAKWBZWM]#TFVMM$E\1ZDL\SS;Y39111$<_WR2'C ]R>
MU5)/'FL7VG:#9:7IUK#XBU:6ZAV7C,UM;M;,1-N*_,<D?*!_>&2,<@'H=>0^
M(O\ DYWPC_V"Y/\ T&YKT/PMK-SK6D/)?010:A;7$MK=Q0L619(V()4D E2,
M,,]FKSSQ%_R<[X1_[!<G_H-S0!SO[37_ #*W_;W_ .T:Y[X=^(--T[X4^(]+
MN9REW>SGR$",=V$3N!@?C70_M-?\RM_V]_\ M&O*O#__ "!?^WA__04KV,DP
M\:^-A"?37[M3FQ4W"DVCZ_\ #VOZ;XCTTW>ESF:&-_)9BC+A@ 2,$#L17'^.
MO^0]'_U[K_-J9\$O^1,O/^P@_P#Z+CI_CK_D/1_]>Z_S:OFN+*$<.JE&&T9)
M'A9[-SRU2?5K]3F[G_6C_<3_ -!%;-O_ ,>T7^X/Y5C7/^M'^XG_ *"*V;?_
M (]HO]P?RK[/!?[A0_PQ_P#24;\<?\B'+OE_Z;1Y]J7_ "%;S_KN_P#Z$:^C
M;7_CTA_ZYK_*OG+4O^0K>?\ 7=__ $(U]&VO_'I#_P!<U_E7P6 _CUO5_G(_
M2LZ_Y%^#_P $?_2*9+1117KGR@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\;_%__ )*OK_\ UV3_ -%K7U1X$_Y)
MYX:_[!5K_P"BEKY7^+__ "5?7_\ KLG_ *+6OJCP)_R3SPU_V"K7_P!%+0!T
M%>+W/_'W-_OM_.O:*\7N?^/N;_?;^=?,<0_#3^?Z'QO%/PTOG^@6/_(0MO\
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M5>'_ /D"_P#;P_\ Z"E?0<.?\C"/H_R./&_P7\CO?#'_ "#9/^NQ_D*ZQ?\
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M_016S;_\>T7^X/Y5][@O]PH?X8_^DHCCC_D0Y=\O_3://M2_Y"MY_P!=W_\
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M ,+_ "9[W'?_ "-<M_Q?^WTSG?A[_P CUIO_ &U_]%/7NM>%?#W_ )'K3?\
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M5/#.0>">U:75[_TO(SL[?UJ=A1114E!1110 4444 %>0^(O^3G?"/_8+D_\
M0;FO7J\A\1?\G.^$?^P7)_Z#<T <[^TU_P RM_V]_P#M&O*O#_\ R!?^WA__
M $%*]5_::_YE;_M[_P#:->5>'_\ D"_]O#_^@I7T'#G_ ",(^C_(X\;_  7\
MCO?#'_(-D_Z['^0KK%_X];;_ '#_ .A-7)^&/^0;)_UV/\A76+_QZVW^X?\
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MKL;#[._@_7V/FL^1I\O<*/[OM7LY'B*6'QD:E5V5G^1S8J$ITW&*U.O\,?\
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M9'+!^%_W?^^:[3S#Z-L[D7MC;W2QRQ+-&L@CF0HZ@C.&4\@C/([5-7S VO\
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M2,!EM4;<%EFYRD9*,-^, CG%6M;UBUT#2)]2O!*T,.T;(4+N[,P5551U)9@
M/4UP%WKT]QJ!GUKP]!I6IPI(MS!>[95OM*)S*J,N5=T&&*<XY[.: #4/$EEX
MCCWW%II^M#3-4NHKC18F2:5X49XTF6)C\[C (&.0YQSBG>']DVH76CPV5S:^
M&]8$\0TB]B\JXMAL^:6.//R6S?,NT@8=EP &Q6MX<^'OAW3II;BWL=)O].E<
M7>GRR6D<DL!<ERJ2XYC&5*=QD\GBC7;S3M%U>2V\.:19'Q-?Y62:"W0.H;YB
M78#DG[V"<<;CQC-TZ<JDN6),I**NQVH:S-X>TS3O"^DR/J&MK;QVXD;YBNU
M-[YXW$#=SP.IXZZOACPQ%H,#S3/]IU.XYN+EB222<E03SC/?J3R>P!X8\,1:
M# \TS_:=3N.;BY8DDDG)4$\XSWZD\GL!T%;5*D8Q]G3VZOO_ , B,6WS2W_+
M_@A1117,:A5>]OK33;5KJ]N(K>W4JK2RL%52S!1DGIDD#\:L5Q7B?Q3&+J[T
MA/#-]KFGVVV/5_(A$@C61,JJH2#(W*$A0=JG/7% $<GQ*TY+G28;G9I;7%U)
M;ZA%J,J12V.(I&3>,X&\HNTDX8'CKQR-C"L%C86]CHQT;Q-98\SQ#%;@Z?.J
MC+O+<#'FI(H.0WS!R,X()K4CT"Q\:6\5PESI.H>(]&;8+N2$2VM_"X(1Y5'^
MM!CW#((VRK)C@$'N/^$-\+_91:_\(WH_V</Y@B^PQ;-V,;L;<9QQF@!GAY4U
M**V\2_8VL;K4K&+[5;NF'R.5R>#\NYQSU!'3%;U%% !1110 445F:YKEKH%E
M'<7*R2/-,EO;P1 &2>5C\J+D@9/)Y(  )) % %.;Q=ID&NQ:;(Y"2R&W6\W*
M85N1C_1V.<K(000"/F!X.>*X.YUO2O$&IZ=X@O=+MO$>FW&EPPR:;9HM_-I]
MT279C#_"-K!68#=E%!%7!K%GJ>K/:Z]I=Q9-J02RU+1YD5MLN0(KQ"IYC)/E
M>:/XEB'&VN@\-^ =*T6$1W>F:3=S6LN+&\-C&+@0@#9YCXYD!R-PQD 'KF@#
MGO#']IWT6I>$KL2) UG]OTR:6,M)IBO(WV>*7)_UB!8W SD8(S\H->H#ISUJ
MII^E:=I,3Q:;86ME&[;W2VA6,,V ,D*!DX Y]JMT %%%% !1110!1U74TTRT
M\P0O<7#[A!;1%1).X5GVKN(&=JL>O:N2UWQ3I^OZ'/I^F^(+72Y=0L7-I=3W
M'D2"8-M*8.&4J00P'(S[<P>(O%EKJMN]OY5_9:,TQCB\31.@A@N8WP#U)$>\
M%"Y !)*]#FGV7AC2_%%_;^(Y-)MH))RT6K:;J%JDH9UR-V#G:X8+AOXD()'2
M@#E]4U"72UAUSPIX:;PU)IB2RZE#>VXM+.[3;M6/,?$[[C^[*D@%N<;L'U73
M=*;3M0U2X6X+0WTZSK!MP(6V*K8_WBNX^Y)[TU?#6@HEHBZ)IJI9$FU46J 0
M$G<2G'RY//&.>:U* "BBB@ HHHH *Y/Q#XYL]&@U1%C;[1;Z?-=VLTN/L]R\
M8?=$K@\R*4.Y.&QSZXTO$FN3Z-9(+'3I]1U*Y+1VMK#M^9PI.YR2 L8( +=M
MP[D5PUNNB^*3?Z%JVGI9V6INSRVMRP%Q8:D5.Y4## WKF1&7.XB4\[L4 1WM
M_HFHWM]?7ND-XDCO8D>TU#2(H[N6Q81*K0JP):$A@9%;( :0DD$9.UX2CU;5
M] 2QU>\MI-3T:\@"7<1\UTVK&7CD;=_KMIDC<@]'SCFM71O"&BZ)I4AO]-T5
MIQ#)%<WJV,<7G0\@F4XYRH!?^$G/ %<E ;KQG+=:-X3CAT/PK%N2>XAME3[0
MYY.%&.O' (^4DMU"UE4J*&F[>R.["8*6(O)M1A'>3V7^;?1+5^FI<UO6[[QS
MJDGAKPU+LT].-0U(<J5[JI[@\CC[W/102>XT31+'P]I<>GZ?%LA3EF/+2-W9
MCW)_P P !1HFB6/A[2X]/T^+9"G+,>6D;NS'N3_@!@ "M&E3IM/GGK)_AY+^
MM37&8R,XK#X=6I+[Y/\ FEY]ELEHNK"BBBMCS HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J6KZK;Z+IDM_<K,\<>T".",
MR2.S$*JJHY))( 'O6/JOBI+'71IX:VM[>UC2XU*]OI/*B@B<E4"DXW,S#'H,
M'/. 6:E9Z%X_TLK9:HAN+257AO;*13-:2@@CKG;G'((Y'X&@#D]1U'5/%GAV
M]N62[EL_-;[?H,4(BU.RC5R8)(AG(F^5)</D,/N]/FGUNRUS4]0M=,U.VFU.
MX,/FZ=J%GIOV>&TD)7$LSO(2'7;]Q0,AB,'.!U6DZ'<2W-EK>K116>N(CQWB
MZ;*1!=?PJSY +@*,J&^[N(J'Q/XGELITT?1T^TZS<<*J@$0@C[Q[9QS@\ <G
MCK=.G*I+EB3*2BKL9XA\0_V5Y&@:!;I)JDBB.*&)1MMUQQQT&!T'0#D\=;GA
MCPQ%H,#S3/\ :=3N.;BY8DDDG)4$\XSWZD\GL >&/#$6@P/-,_VG4[CFXN6)
M)))R5!/.,]^I/)[ =!6U2I&,?9T]NK[_ / (C%M\TM_R_P""%%%%<QJ%%5-4
MU"+2=*N]1G5WBM86F98\;F"C.!D@9.,#)%9$?BEK;6+?3-;T]]-DN@#;7#2A
M[>1R<+#YG'[X\G9@@@'#&@#+U_QK FK1Z-9SW-I&)_*OM:^S@VMEA2=AE?Y!
M(6V+@Y W^N!67:P>*M/U;6[M!Y>J^6DEX5L'GL]0501&]N/-4I,$ 5T+8)"X
MXYK6M?!?]DZO<6UI#;WOAK5I7EU"POB'6VDQE3"FW;L)&"IZ84CH173Z3IRZ
M1I<%@MU=W2P@@37<QEE?DGYF/7K0!R/PUT&71[>]GBM[JSTJX2".PLKU0MQ"
ML:%7,@'"EW+/@'JY; +$5W=%% !1110 445S=WXHN4O=5BL-%N+V/265;O9(
MHD<F-9 ($Y\P[6&0Q3G@9[ &AKVO6GA[3_M5S'<3,[>7#;6L1DFG?!(1$'4X
M!/L 2< 5P5_<W_B32;?5//>^L5NUDDAMK0?;=$ND;*'9R7V9VR(PW$$D<'%=
M'J5A9>-]+T_6=*G$.JZ?)]HLY&(5H9@IS!/C+*N3MD08/&*TM*T(0:@FM3K]
MFU.>U$5]!:2$6TLO!,FW^)A@@.?FVG!]@#B+[0=<U/QY83SBX;5;22W9]2M[
M=K6R:R20NT62SL\K;B"F0O"],9/J=%% !1110 4450U?4QI-A]I\B2X=I8X8
MX8RH+N[A%&6( &6&3Z ]>E %^N#N/&,FO>(DT70K]].PLQAO;JRW07\B;?DA
M<L ZK\^_'/ *G&36W:>(8;S59O#^LV'V*^=/DCF8/!>J02X@8@&3:N-P*@C/
M3'-9-CX':WT^X\,W3>=X?CQ-IERLK"\M)=Q9LOZAFRC#D $-GN <Y=:?J?\
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M/U1["P>6T\+VT@^T7.,-<L.<#/X$ ].&;G:M>C6%A:Z98PV5E L%M"NU(UZ
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MWX<FMDN9U5RRVMY(6+P6V!A8D&T;#RNX=\BO1GBCD9&>-69#E21DJ?4>E/
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M-T<^;G<P;GK6Y?\ AO4_$K75QJ<\>GW%K<E]$>W =[1DW 3,>-^_()C/R[0
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M?X;+0****V/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME]J!\.>'#OOFR+BY!PMNO?GL1W/;H/F/&WX>\/6?AW3Q;6PWRM@S3D8:1OZ
M=AV^I))X>\/6?AW3Q;6PWRM@S3D8:1OZ =AV^I).O6E2HK>SI_#^?]=$3"#O
MS2W_ ""BBBN<U"BBB@ HHHH **** "BBB@ HHKD?%7C&X\.7\D/V.#R(]/DO
MEFGFV"X,9^>!.,!PN&R>O3'4J =:K!E#*05(R"#P17 >,;3Q/Y$,B:8FMBRO
MAJ-G+9RBWE@9"2L3QL<2*5+1E@V</G82.:<_B'6+'10QN6TFQMKV0)>&Q-SF
M%E22WC>)1N5-DA1F&"#$!D%J[_2+R;4-$L+VX@-O-<6\<LD)SF-F4$KR >"<
M<@&@"#0M.?3[>Y)DF\NZN&NTMY<$VQD 9X\@G(WEV]MV!P!6I110 4444 %%
M%% !1110 4444 %%%% !112.ZQHSNP55&2Q. !0 I.!D]*X;4]6U+6?%.GZ;
MI6N/I>G7VDM>65Y#!%)]JEW#Y?WBGA4*OM !(8\C%=#HGBO0?$DES'H^JVUX
M]LY258FY7'?'=?1AP>QKD]6-EIKG1/&9SI4MZ)M&U15,2VS[B8X2RG,<D?.U
MS@,O?@@@&YHNOWZ->Z-J]OYNMV$7FHL#+F_@^ZLZCA8RS*P*$_*1UP15G^R]
M'\/3S^(;RXG\V*W,1N;NX>3RH2P;RU&?[P'8L3@9/%16VFZ;X?-SXDU+59;R
M?[.(CJ%UL!6W#;EC C55(W,3G!9BW4\ <K;6U]\4-46_OTEM/"UK(?L]OG#7
M+#C)Q^()'3E5YW-6-2IR^['63_J[\CT<'@U63JU7RTX[O_VV/>3_  W>@6UM
M??%#5%O[]);3PM:R'[/;YPURPXR<?B"1TY5>=S5Z7%%'!"D,,:QQ1J%1$&%4
M#@  =!1%%'!"D,,:QQ1J%1$&%4#@  =!3Z=.GR:O5O=DXS&/$-0@N6G'X8]O
M-]V^K_0****U. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH H:IHFE:U&B:IIEE?+&28Q=VZRA">X# XKG=&T/Q/=:
MK9WOB>[TR--,=FLK71A(D4A9&0F429Z*3M"XQDY)XKL:Y+Q/K.I3:@GAS0XI
M%OITWRW+ JL49[@_^S#IT&6Z:4Z;J2LB9245=D7B'Q#>7VH'PYX<.^^;(N+D
M'"VZ]^>Q'<]N@^8\;?A[P]9^'=/%M;#?*V#-.1AI&_H!V';ZDDGA[P]9^'=/
M%M;#?*V#-.1AI&_H!V';ZDDZ]:5*BM[.G\/Y_P!=$1"#OS2W_(****YS4***
M* "BBB@ HHHH **** "BBN,\7ZW&]AJ5H/[4ACTV>W;4#8EDN#;O\PDA*'=M
MW##'CY8Y0.@- &[XDTZ\U71'L[&X:WF>:!F=)WA/EK*C2*'0$@E R\>M<=J^
MAW^B7DDT.G>'I?#7]H6\@T^YB>212<(SP _(DA+85 ,$]P3@ZFG-<Z%J^G+9
MZG-J_AW5W98I9[DW#VLFQG4K*22\;!2.22#C!P:V(-'AU*>/4=<TBQ&H0R?N
MMKF=5",3&XW*,..H.,C)P: +B:<\>OSZF+J39-;1P&V(^0%&=@X]SO(/T'I5
M^BB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?$'B8ZWX9\2V]KIEU)IL7
MVG2KFZCPTL4FTH\@B'+1+G)(.[@X0CFM[Q7>Z_90Z:_A^TCNYC>?Z3#(#AX!
M%(S -_"Q*J%)XW$9XS6+I(EN;J3Q#X/-OY%[-_Q-](O&,)BG ^=OE#>7<#Y0
MRD8;@Y'4@&!+K.F7GAVUOXS#I?BK3(4%DML%A75@BY2*#^*:UD;@(,'.. 17
MI6JSZ?%HEQ-K*0+8^5FX2X4.F#_"1SN],<Y/%8OAZP'@_P -WLVLW4$47VN>
M\V(Q:*T21R5BC) ) S@  9).!S7-6UM??%#5%O[]);3PM:R'[/;YPURPXR<?
MB"1TY5>=S5C4J<ONQUD_ZN_(]'!X-5DZM5\M..[_ /;8]Y/\-WH0:3I$GC^Z
MAD-F-+\'63G[)8PH(A.P/)PO [Y(Z<JO.YJ]2BBC@A2&&-8XHU"HB#"J!P
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M>A&3@T 9^D:5?V^H7.HZK>6US>31) /LML88UC1G(X+L227.<G'H!R3LT44
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M;Y3744UM)(MAJD8VQLLZXWYC4KM&3@N".K"@!T^FWZ:E9:%JUW.NIPEF\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <#JNC6^M_%>WMM3>6YM+?3/MD5LY'EJ_F;,8QR#P3GJ0 3@8KOJ
M**QI)7D_-_H>GCZDG&C%O10C9>O-?[^H4445L>8%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &J DT# 2(  A$! Q$!_\0
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M44 %%%% !1110 445S/C/P]K7B&RMH=%\2SZ')%(7DDABW^:,8 /((Q]?Z4
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MK=31:.TA9F:W\Y1!@GYB-W"YYQBO9X]PB3?]_:-WUH$.HHHH **** "BBB@
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MD_-\Q!['O5JVT&'P7JG@[4+">Z,^IS"RU0R7#R"\9X6<2.&)^8.N01CAB.E
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MV&(P<[0..^S7FVHZ[XIN];\&XTR"QDFO+E)K:2^;9*5ADP=RH=R;1O4D=<#
M^]6I<>/)(?A]<^)QIZ,\5XUL+?S2 0+KR,[L?\"Z>U ':T5POB7Q;XF\/WMO
M;QZ+I-W)?71M["WCU"3SYQG[Q7R<*%7YF);"^O3-[_A,9/[$\6Z@;%-V@2SQ
MJGFG$WEPK)DG'&=V._2@#K**\[G\>Z_<7>H0:1X?LYET_3H-0FEGO2@(DC+^
M6H"'+'! )P.#G'%6-(\=:M?:CH+7>AQ6VEZ]'(]DZ7/F3ILC,@,B[0/F4$@*
M3CO0!WE%>=_\+!UBSU+1_P"U]&L;.UU:[2UBM?MV;Z N2$>2(J!CID DC=6/
MH7BC6_#N@ZMJ1T6*?0;+6+S[3,;DBX9#<-N>--N"JYY!8$X/2@#URBN<\<ZY
M/H'@?4]4LN;I8@EL0 <22,$0\]<,P/X5A#5-3\.:UI_@3PWI-K=O%I2W?VN\
MNC$J@.59G"HQ8LV#QR2Q)Z4 >@45P]KXS\0:GX>L-1TOPO#<SRO-%=V\NI+#
M]GDC?80"5.\$AN1TXJS%9W/C33YK3Q=X>6P@@D26%;?5F<NV&!):+81C/0Y!
MS[4 =?17E'@7P;I.MZ?KVK117$.DZLLEE80M<RRXMU./.^=B0[.NX?W0JXZF
MNS\ ZQ=:YX)TZ\OO^/T*T%R3CYI8W,;-QZE2?QH Z2BBB@ HHHH **** "BB
MB@ JK>Z?:Z@JK<Q;PARO)&/RKBOBQXRU3P7HFFW>E"W,MS?+;OYZ%AM*L>,$
M<\"N_IIN+NB*E.%2+A-)I]'J8T_A/0[J(Q7&GQS1DYV2$L,_0FI/^$;TK_GU
M_P#(C?XUJT5I[:I_,_O.3^SL':WLH_\ @*&11)!$D4:[410JCT KA?%DMWIO
MCO3M9AL+FZCLM'OFVPQ,VY\QE4R!U8C %=[161VI)*R/'#\-_$+_  WQ_P )
M#?#4=G]J?8OLL/%[_K<;]N_=OXSN_3BM[QY/>>)?@A>7$.G70O;RUA=K,0N9
M$?S$++MQNX(/;H,UZ+10,\?^+WAC5(8+W5M M);F+5DAM=5M84+,2CJT4ZJ!
MDD;=A]F''4B/4;'0$^)GBVX\3^%[[4HIWM/L<T>F2W"X$"A\,H(ZX'X>U>R4
M4 >7W5I;G2-%U[P?X?NXH_#^H22/IKVC6\DL4D>V7RT<#<V'!'J00.>*7Q3K
M'_"Q=*C\*Z-IFJ;+V:+^T+NZLY(([.%'5VR7 W2': %&>_/%>GT4 <;\0+6X
MNIO"1M[>680^(;:63RT+;$"299L= ,CD\<UGSWP\&?$'Q#J5]9:A/9:S;VTE
MO+9VCS@S1*R&$[0<,PVD9P#SSQ7H5% 'COAS3;[P'<>&];UFRNC#+I=S:7QM
MH&F-G))<?:$WJ@+8^9DR <$>]=E\/K6[%IK6JW=K+:_VMJLUY!#,A218<*B;
MU/W6(3./<5V%% 'BVJV5U)\.OB7I,5O+-J']N2RB")"\C)*\4B-M'."I_0^E
M=MXAL;RX^(7A][02PJNGW\?VI(MZP,PBV$Y&W.02 >N*Z*/1;:'Q%-K4321W
M%Q;K;SHI&R4*Q*,PQG<N6 .>C$'.!C1H X^U\->+H;N"6?Q]<7$*2*TD)TNV
M42*#DKD+D9'&1ZUYW<:-9Z7X7\3^%)O#%W<>(+V]F:QECLV<7 =LPS"8#:@0
M$$Y88VMZFO=** ."U.&:;XH^"K;SQ+<:?I][/=D=2K+'&&_%_P"5=[6=:Z+;
M6NM7^KAI9+N]6.-FD;(CC0':B#'"Y+,>Y+'GH!HT %%%% !1110 4444 %%%
M% !1110 4444 >9:7\-KQX_#^GZZ+"YTG37O;F:VR9%GFED8QY5E PJ,3GU/
M3O6S!X&BT/QQIVL^&[2PL+(VTMKJ5O&OE^8IPT;*JC!8,.2<<5VE% '.VGA^
M9/&6N:I<B"2QU"TM[=8C\Q.SS-P8$8P=X[GO7 -\)-7L]#\8:38W]M+!J368
MTPW,KYBBAE+^7(<$X .U2,Y '3I7L-% '(V<WQ#-];B]LO#*VAD7SFANIRX3
M/S;04 )QG&>]4H]"\5^&-1U$>&O[+O=*OIWNEMK^5XGM9GY<*55@T9.3C@C.
M/<]W10!S?A'PY<Z'!?7>J7:7FLZG/]IO9HU*H#@*L: \[% P,\]?H,E_ UW=
M>"]?T2>ZBAGO]2N+ZVFB)81DS>;$3D#H0N1]:[JB@#@7\)ZYXHO[BY\5?8+5
M!I<VG00V$C2X:8 2S995QPH"KSWR?5=*\.>*+K4?#_\ PD+Z<+/0E9D:UD=V
MO)MAC1V!4; %8G )^;VKO:* *^H6<>HZ;=6,S.L5S"\+E#A@&!!Q[\U'I.G0
MZ/H]CIENSM#9V\=O&TA!8JBA03@ 9P/2KE% '.Z9H-W9>.=?UJ1X3:ZA!:QP
MJK'>#&'#;AC ^\,<FL;PCX%N?#WBC4+ZXG@?3XDD@TB"(D?9XI96FD# C&=Q
M5003PM=W10 5YO'X!U9/@Q_PAYFL_P"T?,+>9O;RL?:O.Z[<_=]NOYUZ110!
MP/BSPAJ&J^,+;68],T?6;2.P-HMEJLC+'!*7+>:HV.IR, \ _*,&LRS\#^)=
M.T&"PD@\/ZK;)?W,USIUS'M@N$D;<CH3&QB=3GY0",'KP*]1HH \OTOP#K^A
M:?H\VGMIK7=CJMQ>_87FD%O!%-&R&*-]I;Y=V>0.2?QCO_!/B^;P]>^%[9]'
M_LJ34&NX[J263S6C,_G>65"X#!OXLD8&,<Y'JE% 'G,6@^-[;QCJFO\ V70;
MZ>9C#9O<7DJ?9K8'Y451$<$]6.>3Z5%J?A/Q>;?Q1INF'1_L7B M,T\\LF^!
MWB5)$VA<,#MX.1C.2#TKTNB@#B-*\(:C8S^('EDMB-0TNTLX=KL</%$Z,6XX
M&6&.M,3P;J:Z9X+MENH(9=%MGAN)8V)(8VK0AH^.<,0><<5W5% 'C]A\,]:A
MA\/P_P!E^'+.32KZ"ZN;^%WDN+_RW!)+% 5R"6();+8^Z*TI/!WC";0]4\,M
M/I::5J5]/,]VLKF:""25G9 A3#,0>N0!N(YP#7IU% '+?$'1[G5OA_J=CIRD
MW21I-;HHR6>)UD50/4[,?C4.E63:QXUM/&MG-"^E76A);Q@D^9N:7S 2,8 P
M<=<Y[5U]16]M!:0B&VACAB!)"1J%4$G)X'J23^- '':9\/-,GT5+/Q)IUEJ$
ML-Y=SPDY8(LTS/QG'.-N?<5=E\%Z=I?AK6['PM86NFW>H6CQ!TR@W[&"$D9/
M!8FNIHH QK..U\(^#8([EU2UTJQ42..FV-.3[]*S_AUIMWI?@73H[]=EY/ON
MID((*-*[2;2#T(W8/N*Z2XMH+N!H+F&.:%L;HY%#*<'(R#[@&I: "BBB@ HH
MH/ H **\\T+QIKNM?$B/3;G29M)TF32Y+J""[51<2D2(H=P"?+ZL O7J3U&)
MIM4\3>)O%.LZ=X?U.TTJRT9HX6FEM/M#7,[+N93DC:JY XYSGGT .]HKS&+X
MA:OK&B^'["QAM;3Q'JMY-93EU+Q6Q@SY\BKG+8 !52?XL$\<[?A_6-;L?&=Q
MX3U^[@U"0V(U"TOH8/)+IOV,CIDC<"1C':@#D_VA?^16T/\ ["J?^@/7K]>.
M?M!S1/X9T5$D1F75DRH8$CY'KV S1@X,B9_WA0 ^BF>=%_ST3_OH4>=%_P ]
M$_[Z% #Z*9YT7_/1/^^A1YT7_/1/^^A0 ^BF>=%_ST3_ +Z%'G1?\]$_[Z%
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M7=M')V (2 ,C)XX-=5HCR>)?B?+XEMK2[BTBTTK[##-=6[PFXE:0.S(K@,5
M&,D#FN_HH ^>/C9X T+0K:WUNRCG%[J>JG[07E)4[P[M@=N:[/\ X9\\$?\
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M* "BBB@ HHHH **** ,_7/\ D"W?_7,UY!\7/^0%X&_["2_TKU_7/^0+=_\
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M_:%_Y%;0_P#L*I_Z ]>OT %%%% !1110 4444 %%%% !1110 4444 9^N?\
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M@_4&J?\ 8>D_] NR_P# =/\ "O2HXF@L/["M%OWN;1I=+=4S*4)<W-%G,_\
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M6\.I-&#<1VQ)C5O1<Y/ZG\:OU3TF^DU/2[>\ELKBR>5=QMKD 21\]& )JY0
M4444 %%%% 'D'[0O_(K:'_V%4_\ 0'KU^O(/VA?^16T/_L*I_P"@/7K] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >/\ QS_X^O!?_85'\UKV
M"O'_ (Y_\?7@O_L*C^:U[!0!D^)_^1:O_P#KD:3PO_R+-A_UR_J:7Q/_ ,BU
M?_\ 7(TGA?\ Y%FP_P"N7]379_S"?]O?H=__ #!?]O\ _MIKT445QG %%%%
M!1110 5YK\(ON^)/^PDW]:]*KS7X1?=\2?\ 82;^M>IAO]RK_P#;G_I3,9_Q
M(_,]*HHHKRS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*XUW_H?]9_[Z;_XNO1**O^U,3W7_ (##_P"1(]C#^F_\SSO_ (5QKO\ T/\
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M "*VA_\ 853_ - >O7Z\@_:%_P"16T/_ +"J?^@/7K] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<^?^1U7_ *X?T-=!7/G_ )'5?^N']#71
M0^UZ/]#R<S_Y<_\ 7R/ZE'XH_P#),/$7_7FW]*9\*?\ DEOA[_KU_P#9C3_B
ME_R3#Q#_ ->;?S%4/AW<W=I\/M%@LK!KZV2WQ'<K(L8D&3R%;D?C7)*:CO\
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M;Z6]Q'@'S!,B\^F"<TW-)7?Y$Q@Y.R_-%^BLZVO;^6X5)M)>",YS(9T8+QZ
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M$@6RRODFU,O3G=N Z_2HDTK7[EPBW>W8T****L@**** "BBB@ HHHH ****
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ME., CW]ZN&&IU'RQJ:^C]2Z>$HU)<L*MWK]E]$W^AW]%%%<)YP4444 %%%%
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M )</^N_^%=!7/^)_^7#_ *[_ .%=&&_BKY_DSRLX_P!RG\O_ $J)P'_-T/\
MW"O_ &6O7Z\@_P";H?\ N%?^RUZ_7.>J%%%% !7)>,_^/O1/^OH?S6NMKDO&
M?_'WHG_7T/YK79@OXZ^?Y,[\N_WF/H__ $EG6T445QG %%%% !1110 4444
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MZ,C*PZAE8 J?8CTJS5F,HN+Y9*S"BBB@D**** "BBB@ HHHH$%<_XG_Y</\
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MG_/'_P "7^1U-%<MY_C/_GTT[\S_ /%4>?XS_P"?33OS/_Q5'U5_SQ_\"_X
M?4G_ #Q_\"7^1U-%<MY_C/\ Y]-._,__ !5'G^,_^?33OS/_ ,51]5?\\?\
MP+_@!]2?\\?_  )?Y'4T5RWG^,_^?33OS/\ \51Y_C/_ )]-._,__%4?57_/
M'_P+_@!]2?\ /'_P)?Y'4T5RWG^,_P#GTT[\S_\ %4>?XS_Y]-._,_\ Q5'U
M5_SQ_P# O^ 'U)_SQ_\  E_D=317+>?XS_Y]-._,_P#Q5'G^,_\ GTT[\S_\
M51]5?\\?_ O^ 'U)_P \?_ E_D=317+>?XS_ .?33OS/_P 51Y_C/_GTT[\S
M_P#%4?57_/'_ ,"_X ?4G_/'_P "7^1U-%<MY_C/_GTT[\S_ /%4>?XS_P"?
M33OS/_Q5'U5_SQ_\"_X ?4G_ #Q_\"7^1U-%<MY_C/\ Y]-._,__ !5'G^,_
M^?33OS/_ ,51]5?\\?\ P+_@!]2?\\?_  )?Y'4T5RWG^,_^?33OS/\ \51Y
M_C/_ )]-._,__%4?57_/'_P+_@!]2?\ /'_P)?Y'4T5@^%=8NM9L[B6[6)7B
MF\L>6I Q@'N3ZUO5A5IRIS<);HYJU*5&HZ<]T%%%%9F04444 %%%% !1110
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M-M3D$PC)*'-NH"HO]U\Y^Z<[C7H5%0J+LE<ZO[1A?F]GTMT_RV_(\]L7CM_
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M[&C- "T4FX>HHS0 M%)N'>C- "T&DR.]&0: .4\!?\@^_P#^OH_^@BNLKDO
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MY0PU2479J+L_DSR#XDHNF:?X/^Q#ROM]_&MSCGS &1AUZ<^F*]E73+-#$5A
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M#7_0$\1?^ L?_P <IDG[0_A>,J'T?7UW' W6\0S_ .1* /7**\F_X:"\-?\
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M W6\0S]/WE/_ .&@O#7_ $!/$7_@+'_\<H ]9HKR;_AH+PU_T!/$7_@+'_\
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MRQ<[8MK$L7('8;??K7I]% PHHHH$%%%% !1110,**** "BBB@ HHHH ****
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MZ*CRH_[L:* J#//USZG.GX5\.V_A/PU9Z':S2S06H8+)+C<=S%N< #JU;%%
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L;NF<YXZUM44 %%%% !1110 4444 %%%% !1110,**** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &5 I0# 2(  A$! Q$!_\0
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M\]/P.FHKY0^''P?_ .%@>'KC5O[=^P>3=M;>5]D\W.$1MV=Z_P!_&,=JZ_\
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MHW_J8O\ R2_^V4?4\O\ ^@G_ ,D8>TJ_R?B>O45Y#_PHW_J8O_)+_P"V4?\
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M^V4?\*-_ZF+_ ,DO_ME'U/+_ /H)_P#)&'M*O\GXGKU%>0_\*-_ZF+_R2_\
MME'_  HW_J8O_)+_ .V4?4\O_P"@G_R1A[2K_)^)Z]17D/\ PHW_ *F+_P D
MO_ME'_"C?^IB_P#)+_[91]3R_P#Z"?\ R1A[2K_)^)Z]17D/_"C?^IB_\DO_
M +91_P *-_ZF+_R2_P#ME'U/+_\ H)_\D8>TJ_R?B>O45Y#_ ,*-_P"IB_\
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MOOLOVFZ0NXM5947YB,88DY&,'GJ#CBNBJY*SL2G=7"BBBI&%%%% 'C_[./\
MR3S4/^PK)_Z*BKV"O'_V<?\ DGFH?]A63_T5%7L% !1110 4444 %>=?&#_D
M5I_^O*Z_] %>BU7O+*VU"W,%U$)(\@X/&#Z@CD5SXFDZM)PCOI^#3_0X\;0E
M7HNG%ZZ/[FG^AX!\%/B)X5\(^#;RPUS5?LEU)J#S*GV>63*&., Y12.JG\JZ
M?X(ZI971U80W",9?*V#D$[=^1SWY!QZ<UT<OP6^'LLKR-X=4,[%B%NYU&3Z
M/@#V%>+_  *_Y#5U_P!?%I_Z$]9XJ7LXJKU37XM+]3MJYG/!X*K!134W!/R]
MY?YL^I:***[!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"$;#>2RV$ZD<M&\9D /T:,'\3ZT+97W_ ,T$M&^W^3.QHHHH **** "BBB@
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M/X>V2:ZF36+"'49K!Y\74-M]KD38WRQ9(W9QCJIXZ\=*XW_A=OP\_P"AA_\
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M=_[8?^CXZ[\=*X#XV?\ )(==_P"V'_H^.N_'2@ HHHH **** "BBB@ HHHH
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M/_)/-0_["LG_ **BKV"O'_V<?^2>:A_V%9/_ $5%7L% !1110 4444 %%%%
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M^1V&D>/KU]26S\3>&Y_#_GV\EQ:RRW*3)*B#<P.T#8P7G:>P-0Z3\1KZ]O\
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MQ"1H4D((P67*MQSC\ZZRBCK</(****  @$$$9![5GV&A:/I7G?V=I5C9^?\
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MU]%=-/%XBE'EIS:79-HAPC)W:.0_X5?X-_Z _P#Y,S?_ !=;&A^%]&\-^?\
MV39_9OM&WS?WKONVYQ]XG'WCTK7HIU,9B*D>2=1M=FV"IP3ND<WX^TJ]UOP3
MJ.G:?#YUU,$$<>X+G#J3R2!T!K%UGP-#XU\832^)]-,NBV%JD-A']H*^;*QW
M22?NV!&,*N#COQ7?45R6_KY6+_K\;G$>$O"<G@SQ/J=CI5F8_#-W#'<0_O\
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M5-G1Q'4E..78F]I2<H2LW9J*LKKNNYV-%%%>X<X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0RVMO.P::WBD8# +H"?UIG]G6/\ SYV__?I?
M\*LT4 -CCCA0)&BH@Z*HP!3J** "BBB@ HHHH \?_9Q_Y)YJ'_85D_\ 145>
MP5X_^SC_ ,D\U#_L*R?^BHJ]@H **** "BBB@ HHHH *\_\ C;_R2'7?^W?_
M -*(Z] KS_XV_P#)(==_[=__ $HCH \K@_Y)#X'_ .W_ /\ 2BO8_#__ ".F
MJ_\ ;;_T8*\<@_Y)#X'_ .W_ /\ 2BO8_#__ ".FJ_\ ;;_T8*\3$?[W3_Q+
M_P!)9IQ!_NN5_P".H=C1117MF84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNST[5T/PX^&K>)/ .EZJVLF$S"0>6;??M"R.@YWCLOI7??&W_DD.N_\ ;O\
M^E$='P2_Y)#H7_;Q_P"E$E9SIQJ*TD=F$QM?!S<Z$K-JW]7,O_A3/_4?_P#)
M/_[.N?\ %_P__P"$4TF*^_M/[5YDXAV>1LQE6.<[C_=_6O=*X#XO?\BG:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /'_V<?\ DGFH?]A63_T5%7L%
M>/\ [./_ "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** //_ (V_\DAU
MW_MW_P#2B.CX)?\ )(="_P"WC_THDH^-O_)(==_[=_\ THCH^"7_ "2'0O\
MMX_]*)* /0*X#XO?\BG:_P#7\G_HN2N_K@/B]_R*=K_U_)_Z+DK#$?PI'KY)
M_P C&C_B_1G5>&/^13T;_KQ@_P#1:UJUE>&/^13T;_KQ@_\ 1:UJUK#X4<&)
M_CS_ ,3_ #9S7C?_ ) L/_7PO_H+5LZ1_P @6P_Z]X__ $$5C>-_^0+#_P!?
M"_\ H+5LZ1_R!;#_ *]X_P#T$5Y]/_?JG^&/YL^=H_\ (TJ_X(_FRY1117I'
MM!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/\ [./_
M "3S4/\ L*R?^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_145>P4 %%%% !1110 4444
M %%%% 'G_P ;?^20Z[_V[_\ I1'1\$O^20Z%_P!O'_I1)1\;?^20Z[_V[_\
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MM]::=%?01/NN9EB3>R;MH+$<\'CVH6JOZ?CL#T=OZT//OV<?^2>:A_V%9/\
MT5%7L%>%_ +Q+H.C>!;ZWU36]-L9VU.1UCNKI(F*^5$,@,0<9!&?8UZI_P )
MWX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\
MZ&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_
M /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
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M5D8( 006R"#QBM'_ (3OP?\ ]#7H?_@QA_\ BJUA\*.#$_QY_P")_FR+QO\
M\@6'_KX7_P!!:MG2/^0+8?\ 7O'_ .@BN2\2^)=!UG38[?2];TV^G68.T=K=
M)*P7!&2%).,D#/N*T=/\:>%;73;6WN/$NC0SQ0HDD<E_$K(P !!!;((/&*\^
MG_OU3_#'\V?.T?\ D:5?\$?S9U%%<_\ \)WX/_Z&O0__  8P_P#Q5'_"=^#_
M /H:]#_\&,/_ ,57I'M'045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
M^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8
MP_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '
M045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#P
MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]
M#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)W
MX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
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M ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%% SS_ /X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^
M3MQ_\<KT"FR2)%&TDCJD: LS,<!0.I)H X'_ (4E\//^A>_\G;C_ ..5S?AS
MX#:/;:SKLOB"QM+O3IKC=I<4-W.&@BW/\K_=R=IC'5NAY]?2-#\6Z1XATJ\U
M2QG)L+2:2)[AP K; "S Y^[SUK%TCXHZ+J^JVED+#6+.*];;97MY9&*WNCU
MC?/.1R,@4=;!?2Y5_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRKVL
M_$6VTG6[G2X?#GB/59;7:)I=,L1/&C,H8*3N&#@@XQWKKK>7S[>*;RY(_,0-
MLD7#+D9P1V-"U5P>CL<'_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\
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MVB]O+2S,L%ID9_>.#QP0> :.WF!VE%-BE2:))8G#QNH964Y!!Z$44 .HHHH
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ML Y'3>H(5_\ @0-2T[Z#35M3GO#&IS:AX]TV_P!4V0WE_P"&()(XSQEO,+2
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M4TJ@8PS*">.W6LS5OAUX1US6EU?4M#MKB^!!,A+ .1TWJ"%?_@0-=.JA5"J
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M7CV4OFJ!N=0"2N"<CYAUP?:ISJ6-<72_L5X=UN9_M8B_<##!=A?/W^<XQTH
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M:I]O\[_\ SAF"47S+WFDKZ.]N;?;1W7W+316OT445N>2%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y K4# 2(  A$! Q$!_\0
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M >P45X__ ,(]\<_^AST/_ORO_P CUD^'?^%T>)M/DO;+Q=I,<:2F(B:WC!R
M#V@/'S"ES).QHJ4Y0=1+16N^U]OOL>[45\_:]JOQ>\+:_P"'M,U+Q5ITKZS=
M"WA,%O&54[D4[B800/W@Z9[UW']B_%C_ *&?2?\ OVO_ ,9KMP^&C63;J1C;
M^9O]$S"4W'HV>DT5YM_8OQ8_Z&?2?^_:_P#QFC^Q?BQ_T,^D_P#?M?\ XS73
M_9]/_H(A]\O_ )$CVK_E?]?,])HKS;^Q?BQ_T,^D_P#?M?\ XS1_8OQ8_P"A
MGTG_ +]K_P#&:/[/I_\ 01#[Y?\ R(>U?\K_ *^9Z317FW]B_%C_ *&?2?\
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M_P#?M?\ XS1_9]/_ *"(??+_ .1#VK_E?]?,])HKS;^Q?BQ_T,^D_P#?M?\
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MX8_]A4_^C;>O8*W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_P"$'_)0
M_B=_V%1_Z-N*]@KQ_P"$'_)0_B=_V%1_Z-N*]@H **** "N#^$O_ "*MU_U^
MO_Z E=Y7!_"7_D5;K_K]?_T!*PG_ !8_/]#UL/\ \B^O_BA^<CF_B_\ \E#^
M&/\ V%3_ .C;>O8*\?\ B_\ \E#^&/\ V%3_ .C;>O8*W/)"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Q_X0?\ )0_B=_V%1_Z-N*]@KQ_X0?\ )0_B=_V%
M1_Z-N*]@H **** "N#^$O_(JW7_7Z_\ Z E=Y7!_"7_D5;K_ *_7_P#0$K"?
M\6/S_0];#_\ (OK_ .*'YR.;^+__ "4/X8_]A4_^C;>O8*\?^+__ "4/X8_]
MA4_^C;>O8*W/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!&W%>P4 %%%% !1110!Y+\9='OM5UGP<^DW4=MJD%VYM))1E%<O#@MP>A
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH CG@ANH'@N(HYH9!M>.10RL/0@]:Y.3X6>"))6<^'K9=S
M;C&C.D9/^X&"_ABM#Q9H7A_5-.:^\06AG@T^*2;(D=-BXRWW6&>%'6O$I-4\
M.?9KVZM_A==R6UI;1WDC'6&#""091RH8G!')QG'>E?4JSL?0EAIUEI=HEII]
MI!:6R?=B@C"*/P'%6:S?#QB;PUI;00);PFUB*0I-YJQKM&%#_P 0'KWK2JI)
MIM,B+NKA1112&%%%% 'C_P (/^2A_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\
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M%W';VYG2,/L$@QD?-@XSZXKDKCQ[XSTVT>_U3X;S0:="OF7$T.L0S.D8Y+!
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MR0H) X/)XXK1CUS3)DT^2*\C>/4?^/21<E9?EW8#=,X!.#UP?2A:AL:%%%%
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MMQ7L% !1110 4444 %>/_LX_\D\U#_L*R?\ HJ*O8*\?_9Q_Y)YJ'_85D_\
M145 '2?"7_D5;K_K]?\ ] 2N\K@_A+_R*MU_U^O_ .@)7>5AA_X43ULZ_P"1
MA6_Q?H@HHHK<\D**** "BBB@ HHHH **** "BBB@"MJ-S+9:9=W4-N]S+#"\
MB0)G=*P4D*, \G&.AZUY_P#\+)\2?]$[U;\Y/_C5>DT5V8>O1IIJI24_5R5O
MN(E&3V=CQO1/'/Q"L]3U:;5O"VIZA:7$VZQMUMVB-JF6.TL(<OP5&3_=]Z[;
MPMXNU?7M3DM;_P *7VDQ)"9!/.7VLP91MY1>>2>O:NNHJYXG#NFXQHI/OS2;
M7Z$J$KW<OP0'H:\1DU=[/X+:1I4%M>W4^K7<MNT-C%YLS0"9VF*J.IV C_@7
M:O;JYC1/ NF:%?65W!/>3/96\MO;K.ZE4$DA=V&%'S$\9] *\^VOW?@[_P"1
MM?3^NUCG/AAK<1U77=!72]1TJ!9?M]C::C;&"412'YP%R1M$@.,?WJU_$<:S
M_$GP?%.JM;JMY*BMC!E5%"GGN 6(_&MV[\/VEWXCT_73)/%>64<D2^6P"RHX
MY5P1R 0",8YJ+Q-X5L/%5E#!>27-O+;R>;;W=G+Y4\#XQE&[<''^13;V?;_@
MK^O05MUW_K^O4QM 18?BAXMBMU"PO!9RRA1@><0X)^I4+G\*M^(+>XN[?4XO
M"0T#^W)"L=^UV,D(4.T/L!.[&,;N,9Z]*-+\"6&CZ/+86FHZLLT]TEU<7[76
M;F=U(.'?'*D*%(P."?4FF>(/A]INOZJ=374=7TN\D01W$FF79@^T(.BR<'('
M/H:36BC\OZ\N@T[-O^OZZG(Z'H%SJ?A&WN-$6W@272)-#O(]0F):W*.X9P54
MK)@E_EPH/'(Z5/INNSV-[]OL]._M%_[-9[,37'D[-.AVC>#M;,DK?-@XX"Y(
MQ7=?\(OIL7A4>'+19+/3A%Y.VW;#;,_,-QR?F&03UY)R#S4.L^$;'5WB=;B[
ML)([9K0O9LJEX&QF,[E(QP.1@CL152;NVOZW_7IV;%%+2_\ 6J_3\4CC?$FF
M6_CCQ=HSVLSV\LNA2WNGW.,/!+YL+1O^N"/0D4_2O$3^(/&OA87D0M]6LHK^
MVU"V_P"><RK%DC_98?,#Z&NXA\.6%MJ]EJ, DB:SLFL885(\L1$J>F,Y&P#K
MZU6D\'Z4_C2'Q6JR1ZG';M;ML("2*>[#&21T!R/QXHT4E;;7];?@U?\ X M6
MM=[+]+_YK_@G ^$?^%C_ -B2?V!_PBO]F_;KOROM_P!H\[_CXDSNV?+USC';
M%;/DS7WQ2T6W\2K:27%OHC3PQQ F#[5Y@$C1AN20N,9Y -2?\*HMXY)C:^,/
M%]G%)*\OD6NIB.-"[%CM4)P,DUK7'@'3+[P[::3J%[JEY)9NTEOJ4]T3>1N2
M3D2@ ]\=,8 ]*2T2?:WY6&]6_._YW,_X@0V\&J>%=0@54U<:Q!!#(@Q(\39$
MJ$]2NW)/;@54\=:%8P^)/#.M;9)+^;7;:+S))&81Q[&^1%)P@) )P.3UK:T#
MX?Z9H6IC5)+[5=7U%%*17>JW9G>)3U"< #/TS6QK&AVNMOIS7,DR&PO$O8O+
M(&74$ -D'CYCTP?>FM+>MQ/6_I8YWP]!'<?$+QI)=1H\H-K H< XA\G./H26
M^IKC_"*">]\#6\RAK&&;56M0V,$I(5CP#Z*6Q7<>)/A[IGB34O[1:_U73;MH
MO(GDTRZ\DW$?99.#N')_SBI]3\!Z+J7AZPT9%N+&+3MILI[.8QS6Y QE7Y.2
M,YSG/7K4QTL^UOUU_$;UNN_^2_R*.@(L/Q0\6Q6ZA87@LY90HP/.(<$_4J%S
M^%87Q1UGQ-%:2V5OX2\_3$N[1H]1_M&-?,82QL%\LC<,M\N?QZ5VOACPK8>%
M+*>"TEN[F:XE,UQ=WDOFS3OC&6;C/  _R:T=2TRSU>T^RWT/FP>8DFW<5^9&
M#*<@@\$ T[;>5OSO_P ,">_G_E8I^'=0UC4M.:?6]#_L:Z$A46_VM+C*X&&W
M*,<\\>U<=H^AQ^(] \<Z3(=OVC6;E4?^XX"%6'T8 _A7I%9FCZ';:*VH-;/,
MYOKM[R7S"#AVQD+@#CCOGZT/5OT_5?Y M/O_ ,_\SB8]1D\:VOA+3K@E9Q,;
MO5(MO1K4[60CMF;;^ KJO&NHMI7A#4;J.]ELI1&$BF@M_/D#LP50D>1N8D@#
MD#)J33/"VG:3X@U36;8S?:-2*F5&8&-"!SL&.-QY/7)JUKNB6?B+1;G2K]7-
MO. "8VVLI!!#*>Q! (^E*6J]=7^ 1LGY(\7L[[Q)HFN/ \_BF&SOM+O7!UR_
M260O'%N#1HG,1!QSGG/M6UI>GZ]H]KX,\0R^+=7OIM2GMK>\M;F;=;F.5"?E
M3'## ^8DD]:Z&#X3:1'>)>W.L:]?WBQ2P"XO;T3/Y<B%"O*X &XD8 Y]1Q71
MOX7LGTO1M/,MQY6DRPRP$,NYC$,+NXY'KC'X52Z?UI=_HR6F_P"O)?J>6'3;
MGP]X>^(5_9Z[K+SQ:BL"-+=DX_U+;^ #OPVW/]T 5V5WXYNK^RUFPLO#7B6S
MNX+*X:&\NK#RX&=$.W:^[G)QCCFKU[\/-,OKC6Y&OM3CBUG8;FW2<>4'4J=Z
MJ5.&.P GGBNM PH';I4-7AR^7Z6+O:?-YW_%,Y7P)I>CK\.M)M[.W@DLKFR1
MIOE!$S,HWE_4DYSFL-?[%6]\ 1>'91)I45[<Q0,'9QA8)00"W) ((]/3BK4_
MPET1[B8VFJ:]IUC.Y>;3;&_,5JY/W@4QP#Z CVQ6IK7@+3-6TO2]/M[O4-'B
MTMMUJ^ES"%T^4KC<03T)]SGFM'*\N;^NOY7T)M9<OD]?Z_$SOB,D%M-X:U.*
M /J<.KP) 8US*R-GS$7N04SQ[5H:+XG'B]+VP.@^)=&'DD&>^M3:D[N/W;!C
M\PZ^U1Z%\/--T75H]5GU+6-8OX598)]6O#.T 88;8, #/KC-==4V25AMN]SR
M_1/#%H-2^(OAS3%%I#/%!!&<EMK/;G+$DY8DDDDG)YK%U27Q9:Z5X9TK4O#&
MFZ7%8:K90PW<-VLAG8/C]S&HRF0"3N/3->IP^&["'4=:O&\V4ZP$6ZBD(*85
M-@"@ $9'7)-86B_#'1M%U:VOQ>ZM??8\_8;:^O#+#9YX_=KCC X&<_GS3B[-
M7\OPO_78'LTO/\4/^*N[_A6FL[,;MD>,],^8M<QJUCKGA35XV3Q1JNH#5=-O
M3<1W$GRQS1Q;U:!0!Y8SG@=..37HVOZ);>(M$N=)O'E2"X"AVA(###!N"01U
M'I3=0T"SU/4;"]N3(S622HD8(V.)%VL&&,GCT(J&G9VZ_P"37YV&GJO+_-/]
M&<G/J=V/!_@2=;Z?S;N[L5FD$QW3!D)8,<_,#U.>M<A>OXBC\/:UXIA\4:DD
M^F:Y+#:6?FEK=D-PJ%95/+CYL 9   P*[73?A3H>FSV4J7^L3BPN5N+..YO/
M,2VP<[$4C 4\9[\#FM27P/IDWA[4-$:>[%M?7C7DK!UWAS()"%.W&,@=03CO
M6C:<G+S_ %7Z7)2:5OZV?ZV.:M5U'PAXJU.WO/%.H7EE+HLFH22W^)OL\JO@
MLB@#"8.0@^GI7):3?>)=/\2^&]0-QXN:UU"]CM[F76KF-()MX/"6HR4Z9!S\
MN,=Z]@O_  SI^IZG)?78DD,M@]A)"6&QHG()[9SQUS7,6GPDT>WN[&YEUG7[
MV33YTFLQ=WWF+!M(.U5*X"G !XS@<$5,=))O^M7^EARU3M_6B_4YN;2M=UFW
M\9ZNOC#6[,Z7?W/V&VM[C;$IC4-AP02RG@;<X'/K7H%QJ%_<?#>34H23J$FD
MF="@_P"6IBW# ^M6+?PO96UAK-FDMP8]7FFFG)9<JTB[6V\<# XSFM.PLH].
MTVVL8BS16\2PH7()(4 #/OQ4M7@X^2_+4:=I\WF_S5CG/ FEZ.OPZTJWL[>"
M2SN;)&F^4$3,RC>7]23G.:Y3Q9JVD6/PUT_1?"T=Y?66H3_8HHK!7N)3 C$S
M[ QR<*&7K@9[ 5LS_"71'N)C::IKVG6,[EYM-L;\Q6KD_>!3' /H"/;%;]GX
M0TJPU>QU"V1XQ869LK2V4CRH4)!8@8SN. "23TJY/F=]K_\ #_Y)$KW59:_U
M^?4X;P/K<1C\5Z"FE:CI4"I)?V-KJ-L8)1%(IW@+DC:) <8_O5B0:Q\1=$^&
M^CW#Q^&!H#V<$37'DSRR6\#( 'E7.#@$9P"/;%>L:IX8LM5UFTU626XANK:"
M6WS"X DCD&"K@@Y .".F"*L66AV=EX<@T':T]C%:BTVS8)>,+MPV  <CKP*E
MZK[OG:_YHI:-?UNE^I#X4TB+0?"NF:7!<BZCMX%43@ "3ON '0'/ ]*Q_BE_
MR3?5_P#=C_\ 1BUN^']$B\.Z);Z3;W-U<6]L-L37+AG5,\+D < <#V I=?T2
MV\1:)<Z5=O*D%P%#M"0&&&#<$@CJ/2JD[N_G^J)CHM?ZW-!/]6OT%>3ZY?7;
M>&?B%K5I=36^H)?)90S1N5:)(O+"@$<CEW/_  (UZR!@ >E<3<>%A=:IX@T6
M[%R-)US9>I-!UBE7:)$)((7.U&&>N6]*G=_UW7Z)C6B^[]?UL9]AI>K^%_'6
MB12>)]5U6#5H+@7<5]('19$0,&B4 !!DG@?K7$R?ZU_^2W]3]WI^'M7MEUHM
MM>:OIFI2/*)M.\SRE4C:V]=IW<9/ XP16C3_ .#^8+16]/R/%_#2^+)=8UVZ
M\/:=:R7*&V@>X\32O]I,0MT*Q%4&0_)9B2!D]\<;EYJ,6I?!>YU2RTV#2;G3
M@\Z6T*KLM[B"0EMNW P65OJ&KH/$/P_T[Q!J9U)=1U?2KR1!%/+I=V8#<(.B
MR<$-C)]ZBUWPW#'X3L_!VD6<D=C=.MO(Z9(A@!W2,S'^)@"!GDEO8T;KST_,
M-$[]-?R_KY'5VD_VFS@GQCS8U?'ID9HJ5%5$5%&%48 ]!13=KZ"5[*Y4U;[%
M_8][_:/_ !X^0_VCK_J]IW?=YZ9Z<UXGXEC^%4N@7@T5+I]6\IOL:6RWC,TN
M/E&#P03P<]J]JUJ^?3-"U#4(XC+):VTDRQ@??*J2!^.*\:?QUXIU:R5[/Q!!
M;_V?H+:O?7%O;QLIF<EH[<AMV !@=03R34.VO]?UM_5RTGI_7;_,]@\.1R0^
M&=*CFM1:2K:1![<$D1-M&5R>>.G/-:=9WA_4)=6\.:9J,\7E375K%,Z8(VLR
M@D8/UK1K2?Q.YG#X58SM>U3^Q-"O-2$/GM;QEEBW;?,;HJYP<9) S@]:KKJN
MH6&EWVH>(+.RLX+6(S$VEV]QE5!+9W1)@\<8SFD\5VL-YX?FBN=,;4[<21O+
M:I(RLR*ZL2 O+%<;@G\6,=ZY)O#ZZIIWB>U\/:<VG:5>Z6+>"V:S:R5[K]YN
M81NJD<&,%L ' Y.WB.YHDKJ_]:G2:3XCO;G5H-/U72X["6[M3=VACN?.#JI4
M,K_(NUQO4X&X<GGBNCKC+"6XU_Q;I&H+I]]:0Z;8S)<&ZMWA_?2F,>6H8#?@
M(Q++E>G)S5_QK9>*[[1H8O!^IVFGZ@+A6DENE#*8MK9491^=Q4].QY]:?^?Y
MZ$+S\O\ @G!_"#_DH?Q._P"PJ/\ T;<5[!7B?P*COH?%7Q BU2:.?4$O8ENI
M8QA7E#S[V' X+9/0?05[92&%%%% !1110 5X_P#LX_\ )/-0_P"PK)_Z*BKV
M"O$[#X9_$CP@]YI_@OQ5IL&BR7!GB6[C!ER54?-^Y89 4#@X.,X&<4 =A\)?
M^15NO^OU_P#T!*[RO*/V?K^YU'P%?374OF2#4Y%!V@<>5$>P]S7J]9TH.$%%
M]#MS#$1Q.*J5H;2=]?D%%%%:'$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% $-W=06-G/=W4@CMX(VDE=NBJ!DG\A6'!I
MOA&+PW/>0:=I4>C74:WDS+;(L4JCYP[#'..O--\:^'?#NNZ%<2^(K-9K>S@E
ME$H^_"-OS,I]<#/IP*\PT/POIM_H]G=Z?\)!<V<D:M!<7FJ1I+,F.'9>Q/6E
MW'V/:[&\MM0L+>]LY!);7$:RQ. 0&1AD'GVJQ533%9-*M$:R2Q984!M48,L/
M ^0$<$#IQZ5;JG:^A*V"BBBD,**** /'_A!_R4/XG?\ 85'_ *-N*]@KQ_X0
M?\E#^)W_ &%1_P"C;BO8* "BBB@ HHHH **** /'_P!G'_DGFH?]A63_ -%1
M5[!7C_[./_)/-0_["LG_ **BKV"@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *6KPK<:+?0/.D"26\B-+(@=8P
M5(W%3P0.N#7AFA>(M0T>R;3=/\6ZY_9ECI_VR"670H&#VPD";TR^\J,D_,/N
MJ<=L^ZZII\6K:3>:=.6$-W \#E3R%92IQ[\UX\_@3Q;!, VJ>'UT]-'.@"^>
M1P1"9,;BF,>9CY<;L9[]J2O=E:6U_K;_ (/W(]ATJ0RZ19R->+>EX4;[4J!!
M-D#YP!P,]<>]6ZIZ1IL6C:-9:9 S-#9P) C/U(50 3[\5<JY6N[$1O97"BBB
MI&%%%% 'C_P@_P"2A_$[_L*C_P!&W%>P5X_\(/\ DH?Q._["H_\ 1MQ7L% !
M1110 4444 %%%% '@WP'\5Z)H7@>]M=2O?(F?4GD5?*=LJ8XAG*@CJ#7J/\
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M_P "C_D9?_"Q?"G_ $%?_)>7_P")H_X6+X4_Z"O_ )+R_P#Q-:G_  C6@_\
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M_D9?_"Q?"G_05_\ )>7_ .)H_P"%B^%/^@K_ .2\O_Q-:G_"-:#_ - 33?\
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M_P 31_PL7PI_T%?_ "7E_P#B:U/^$:T'_H":;_X")_A1_P (UH/_ $!--_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >/_"#_DH?Q._["H_]&W%>P5X_\(/^2A_$[_L*C_T;<5[!
M0 4444 %%%% !1110!X_\7_^2A_#'_L*G_T;;U[!7C_Q?_Y*'\,?^PJ?_1MO
M7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'C_P@_Y*'\3O^PJ/_1MQ7L%>/_"#
M_DH?Q._["H_]&W%>P4 %%%% !1110 4444 >/_%__DH?PQ_["I_]&V]>P5X_
M\7_^2A_#'_L*G_T;;U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_\(/^2A_$
M[_L*C_T;<5[!7C_P@_Y*'\3O^PJ/_1MQ7L% !1110 4444 %%%% 'C_Q?_Y*
M'\,?^PJ?_1MO7L%>/_%__DH?PQ_["I_]&V]>P4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5;4
M;^#2M,NM0NF*V]K$TTA R0JC)P/PJS6/XLTR;6?".KZ;;X,]U9RQ1@G +%3@
M9[<XI/8J*3:N5-)\1WMSJT&GZKI<=A+=VIN[0QW/G!U4J&5_D7:XWJ<#<.3S
MQ71UQEA+<:_XMTC4%T^^M(=-L9DN#=6[P_OI3&/+4,!OP$8EERO3DYJ_XU\-
MZEXHT:&RTOQ#=Z%.EPLK7-J&W.H5AL.UU."6!Z_PCBJ?^?YZ$+S\O^"<'\(/
M^2A_$[_L*C_T;<5[!7S)X$\":]K?BKQC967CC4M,GTZ]$5S<PA]UZV^4;WQ(
MISE">2WWSSZ]W_PJ#QA_T5G7/RF_^/TAGL%%>/\ _"H/&'_16=<_*;_X_1_P
MJ#QA_P!%9US\IO\ X_0![!17C_\ PJ#QA_T5G7/RF_\ C]'_  J#QA_T5G7/
MRF_^/T >P45X_P#\*@\8?]%9US\IO_C]'_"H/&'_ $5G7/RF_P#C] !\7_\
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MA_T5G7/RF_\ C] 'L%%>/_\ "H/&'_16=<_*;_X_1_PJ#QA_T5G7/RF_^/T
M>P45X_\ \*@\8?\ 16=<_*;_ ./T?\*@\8?]%9US\IO_ (_0![!17C__  J#
MQA_T5G7/RF_^/U0UWX9^,-$\/:GJO_"T]<F^Q6DMSY69EW[$+;<^<<9QC.#0
M![?17S_X(\#^,/&/A"QU[_A9VN6?VKS/W&^:3;MD9/O><,YVYZ=ZZ#_A4'C#
M_HK.N?E-_P#'Z /8**\?_P"%0>,/^BLZY^4W_P ?H_X5!XP_Z*SKGY3?_'Z
M/8**\?\ ^%0>,/\ HK.N?E-_\?H_X5!XP_Z*SKGY3?\ Q^@#V"BO'_\ A4'C
M#_HK.N?E-_\ 'Z/^%0>,/^BLZY^4W_Q^@#V"BO'_ /A4'C#_ **SKGY3?_'Z
M/^%0>,/^BLZY^4W_ ,?H ]@HKQ__ (5!XP_Z*SKGY3?_ !^C_A4'C#_HK.N?
ME-_\?H ]@HKYPT_PUXPO_BAJW@O_ (61KB?V?:+<_;/-F/F9$1V[/-X_UO7<
M?N^_'7_\*@\8?]%9US\IO_C] 'L%%>/_ /"H/&'_ $5G7/RF_P#C]'_"H/&'
M_16=<_*;_P"/T >P45X__P *@\8?]%9US\IO_C]'_"H/&'_16=<_*;_X_0![
M!17C_P#PJ#QA_P!%9US\IO\ X_1_PJ#QA_T5G7/RF_\ C] 'L%%>/_\ "H/&
M'_16=<_*;_X_1_PJ#QA_T5G7/RF_^/T >P45X_\ \*@\8?\ 16=<_*;_ ./T
M?\*@\8?]%9US\IO_ (_0![!17@GB_P &>,O WABZ\2I\3-9O7L&B=;>02;7)
MD5>=TK CYLX*D'&#UKV/PE?7.I^#=#O[R3S;JZT^":9]H7<[1J6.!P.2>E &
MQ1110 4444 %%%% !1110 4444 %-DD2&)Y975(T!9F8X"@=23V%.KE_'Y)\
M,I&W^HEO[.*X]#$UQ&&!]B#@^QH\@-W3M5T[6+8W.F7]K>P!BAEMIED4,.V5
M)&>15NN5LAY7Q0U=(0!')I5K)/M[R"255)]]HQ] *ZJCHG_7]:!UL%%%9?B.
MSO=1\.W]CI[0+<W,)A4W!(0!N&SCG.TG'OBDW97+IQ4YJ+=DVM>WG\CA?!WC
M:75OB)JMK+=;[&\W?8EP^!Y?W=H)^7<FYFR!DCMTKTZOG[PMX-UF[\1W?V":
MP%UHEVF_SV?8[J[8QA<D90^E?0-<F#G.4'S]SZ+B/#X:CB(?5VOA5TNEDK/;
MJK,****[#YH**** "HYYXK:"2>XE2*&)2\DDC!510,DDG@ #O4E9?B&#29]$
MG.N;/[-AVSS>8Y51L8."<'D9 X[],&@:)+77M'OM/FU"TU:PN+*#/FW,5RCQ
MQX&3N8' P"#S2Z9KFD:T)#I6JV-^(L"0VMPDNS/3.TG'0UQ%_IVH:W8Z[JI%
MMI(U@6ME;1:@QCWQ*^-T@'(=PY54ZXV@X)P.GTC4M277KO1-4>UN)H;:.Z2Y
MM;=H4*NSKL*,[G(*$YW<@]!CEH7H;]%%%( HHHH **** "BBB@ HHHH RY?$
MFA0:H-+EUK3H]0+!!:/=()2QZ#9G.3D8&.]376LZ78WMO97>I6=O=W!Q!!-.
MJ/+SCY5)R>>.*X^"YU?P]%?ZT;W2;W3[K5SO@M8W>0AY5@&)=^T,@VY78>5(
MR,Y%35DBGT?XFR784RIE5+'E42U1XL>F&+$>YS2OI?\ KI_F4HW=O.WXV/2:
M*KV#ROIUJ\^?.:%#)G^]@9_6K%4U9V(3NDPHHHI#"BBB@ HHHH **** *6I:
MQIFC0I-JFHVEC$[;%>ZG6)6;&< L1D\&JT7BCP_-I\VH1:[IDEE P66Y2[C,
M<9/0,V< \CKZU-KNJ)HF@7^J2*66U@>7:/XB!D#\3@5R4GAR^MO#NAV$6H:?
M%JD^H)>WDU[EOM$P#2-M0$%R&"X7</E3J,4+_+^ONNP?]?U]QV6G:KIVL6QN
M=,O[6]@#%#+;3+(H;TRI(SR*MUB:!JEY>7&J:?J'DO=:=.L+SP1F..4-&L@(
M0LQ7 ?!&X],]\#;I@%%%%( HHHH **** "BBB@!DTT5M!)//*D4,:EWDD8*J
MJ!DDD] *CN;VTLK-[RZN88+5%W/-+(%11ZECP!7,?$S3(M2\ ZMY\UPJ6]K+
M/Y<4I19&5&VA\<LH.#CH2!G-)K_S7/@R&3_CV?4%,@/0LMO(R9_X$ ?J!0M?
MO2!Z:^OX'0KK.EOI1U5=2LSIP4M]K$Z^3@'&=^<8SQUJ>ROK34;2.[L;J"ZM
MI,[)H) Z-SCAAP>:\TDX\>R68 &FMXEC=E'W3+]A+_GO"M]>>#74^%QY?B7Q
M=#$ +9=0C=0O02-;QE_QS@GW-"U5_P"NG^8/33^NIU-%%% !1110 4444 %%
M%% !48N(#<M;":,SJ@D:(,-P4D@$CK@D$9]C4E<3H>E0Z?\ $KQ J37,S7-A
M;S2R3S,[$M)-P/[H P !@  ?6CK;U#I<Z:UUW1[W49M.M-5L9[Z#/FVT5PC2
M1X.#N4'(P3@YJ.7Q)H4&J#3)M:TZ/4"P06KW2"4L>@V$YR<C''>N9TZQM-0U
MC1[70+00:%X>DDQ=C.)9=K1F*,GE@"Q+OR"P R3G$<%QJ_AZ+4-:-[I-[I]U
MJWSP6L;O(0\JP#][OVAD&W*[#RI&1G(:U:_KJDOO!]?Z[_Y'?4444@"BBB@
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MY.4G=L****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' U # 2(  A$! Q$!_\0
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MR\.?]!FS_P"_@H_X3+PY_P!!FS_[^"CVM/\ F7WA]4Q'_/N7W/\ R-RBL/\
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M_09L_P#OX*/^$R\.?]!FS_[^"CVM/^9?>'U3$?\ /N7W/_(W**P_^$R\.?\
M09L_^_@H_P"$R\.?]!FS_P"_@H]K3_F7WA]4Q'_/N7W/_(W**P_^$R\.?]!F
MS_[^"C_A,O#G_09L_P#OX*/:T_YE]X?5,1_S[E]S_P C<HK"_P"$R\._]!FS
M_P"_@KEOAO\ $6]\;:KK=K<V=O#%8,!$\);]X"S#)S]!51G&6SN9SHU:?QQ:
M]4U^AZ-1115&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7A_BK7]3N_BCH.M0>"_%+VNBM/%+MTYC
MYN<J&C(X([YR.*]PHHZI]@Z-=SR3Q.=4T/XEZ+X[M]"U2_TZXTW[+<V]K!ON
M("<L-R=CR._4$9Z4SPMX3UC6]!\=ZCJ%E)IEUXG+BVM[@8>- K!-X[<MCGGC
M->O44K*S7JOO=QW=T_3YVT/GKR?$OB?P3H'P]?PMJMG<VERBWMY<0;+=84)Y
M5^YP1]<<9S7T(H"J%'0#%+157_'7]/T)M^'_  Y5U#3+#5K<6^HV5M>0JV\1
MW$2R*&P1G!'7D_G7%>/O"_A_3_ &O7=GH6F6]S#92/%-%:1JZ,!P00,@^]=_
M7+?$K_DFGB/_ *\)?_0:0[V>AQ_P4TRPU7X;V]UJ-C;7EP;B4&6XB61R W R
M1FO1/^$:T+_H"Z=_X"I_A7#? 3_DEMK_ -?,W_H5>G5/)'LC;ZQ6_G?WO_,R
MO^$:T+_H"Z=_X"I_A1_PC6A?] 73O_ 5/\*U:*.2/8/K-;^=_>_\S*_X1K0O
M^@+IW_@*G^%>3?$NRM-/^(?A2VL[6"W@FDC\V**,*LG[Y1\P'!XXYKVZO&/B
MO_R4WP=_UTC_ /1ZUZ>5TX.NTXKX9=%_*_(QK8FMR_&]UU?^9ZE_PC6A?] 7
M3O\ P%3_  H_X1G0O^@+IW_@*G^%:HHKS.2/8V^LUOYW][_S,K_A&="_Z NG
M?^ J?X4?\(SH7_0%T[_P%3_"M6BCDCV#ZS6_G?WO_,RO^$9T+_H"Z=_X"I_A
M1_PC.A?] 73O_ 5/\*U:*.2/8/K-;^=_>_\ ,RO^$9T+_H"Z=_X"I_A1_P (
MSH7_ $!=._\  5/\*U:*.2/8/K-;^=_>_P#,RO\ A&="_P"@+IW_ ("I_A1_
MPC.A?] 73O\ P%3_  K5HHY(]@^LUOYW][_S,K_A&="_Z NG?^ J?X4?\(SH
M7_0%T[_P%3_"M6BCDCV#ZS6_G?WO_,RO^$9T+_H"Z=_X"I_A1_PC.A?] 73O
M_ 5/\*U:*.2/8/K-;^=_>_\ ,RO^$9T+_H"Z=_X"I_A1_P (SH7_ $!=._\
M 5/\*U:*.2/8/K-;^=_>_P#,RO\ A&="_P"@+IW_ ("I_A1_PC.A?] 73O\
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MG?WO_,RO^$9T+_H"Z=_X"I_A1_PC.A?] 73O_ 5/\*U:*.2/8/K-;^=_>_\
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M_ 5/\*U:*.2/8/K-;^=_>_\ ,RO^$9T+_H"Z=_X"I_A1_P (SH7_ $!=._\
M 5/\*U:*.2/8/K-;^=_>_P#,RO\ A&="_P"@+IW_ ("I_A1_PC.A?] 73O\
MP%3_  K5HHY(]@^LUOYW][_S,K_A&="_Z NG?^ J?X4?\(SH7_0%T[_P%3_"
MM6BCDCV#ZS6_G?WO_,RO^$9T+_H"Z=_X"I_A5NSTVQT\.+*SM[8/RPAB";OK
M@5:HH48K9$RK59*TI-KU?^844451D%%%% !1110 4444#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y;XE?\ )-/$?_7A+_Z#74URWQ*_Y)IXC_Z\)?\ T&@1S7P$_P"26VO_ %\S
M?^A5Z=7F/P$_Y);:_P#7S-_Z%7IU !1110 5XQ\5_P#DIO@[_KI'_P"CUKV>
MO&/BO_R4WP=_UTC_ /1ZUZF5?[P_\,O_ $EF-;X?FCV<44"BO+-@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 55O]3L-*MC<ZC>VUG #@RW$J
MQKGZL0*M5YWJWP<T#Q#XJN]=UVZU"^:9ALM3-LBC4 #:,?-CKT(Z]*6MQ]"Y
M=_&'P#92>7+XC@9O6&*64?FBD59T[XI>!]4<+;^);%6/07#&#_T8%IMK\*O
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M+_T(T )_PF6G?\\;K_OE?_BJ/^$RT[_GC=?]\K_\56I10,R_^$RT[_GC=?\
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M_P#A,M._YXW7_?*__%4?\)EIW_/&Z_[Y7_XJM2B@#+_X3+3O^>-U_P!\K_\
M%4?\)EIW_/&Z_P"^5_\ BJU** ,O_A,M._YXW7_?*_\ Q5'_  F6G?\ /&Z_
M[Y7_ .*K4HH R_\ A,M._P">-U_WRO\ \51_PF6G?\\;K_OE?_BJU** ,O\
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MK4)U33P<&^ML_P#79?\ &FDWL@N&QO[I_*C8W]T_E1_:FG_\_P#:_P#?Y?\
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MLIZ!B 26/7 [>O.)?#7B^_O=?NO#GB#3$T_6((A<)Y,OF17$1.-Z'J.>Q_\
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M>9:S_>C8%@1[].#W&#78^+O%H\,PV-O;63ZAJVH2^396:-MWMW9CV4<9/O\
M4@Z._>WX(75>E_Q9TU%<$GC+Q%HFL:=:>+=%L[:UU*4007EC<&18Y3T1PP!Y
M]1Q]>W>T=+AY&)KWB:VT&[TJSDAEN+G4[D6\,41&[IEG.2/E48S]:VZ\W\S^
MV/CYY3D-%HFE%HU_NRR$9/UVMBKWBSX@S^&O%ECH<&C2ZE->VQD@2!\.TF2
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M2/4:***0!1110 4444 %%%% !7+?$K_DFGB/_KPE_P#0:ZFN6^)7_)-/$?\
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MO_7S-_Z%7IU>8_ /_DEMM_U\S?\ H5>G4""BBB@ IDO$;_[II],D&Y&7U!%
M'CG[/CH^DZUM=6Q+#G!S_":]E'2O'O!WPS\9>![>ZATC7=,"W3*TOF0LW*@@
M8X]S72_V;\2_^@_HW_@,W^%>IB5]9JRK2G%.72[_ ,C*'NJUF=[17EOB2[^(
MGAKP_=ZO<:UI4L5L%+)';'<<L%XS]:ZOX?ZU>^(?!&G:KJ#HUU/YN\HNT';*
MZCCZ**YZN$E"E[923C>VG>U^R*4TWRG3T445QEA1110 4444 %%%% !1110
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M$?\ R2_1_K/_ .CY*D^*_P#R3/6O]R+_ -&I4?PC_P"27Z/]9_\ T?)7L?\
M,M_[?_\ ;3;_ )??+]3MQ10**\HV*FJW3V.D7MW$%,D$$DJANA*J2,^W%5/#
M.J3ZUX>M=0N5C667?N$8(48<KQDGL*D\0_\ (M:K_P!><W_H!K-\!?\ (E:?
M_P!M/_1C5%_>L<;G+ZVH7TY6_G='244459V!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %35/^01>_]<'_ /0365X>_P"0';_\"_\
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M6\"VMC?#%W,S7$Z?W&?^'\!@'WS61\1P%\9?#\   :F0 /\ @-7))5$O-?\
M!(3?(WY/_@'H-]<M9:?<W2P2W#0Q-((85R\A SM4=R>@KS?4_&?Q$TK2Y->N
MO"&GQ:7%^\EM3=EKE(^Y)''Z9'<5ZA7"?%37OL/AB31+-/M&L:R#:6MJO+,&
MX9L=@ >I[_C6;NMMS16>C.JT'6K;Q%H5EJ]GN$%U$)%#CE?4'W!R/PJ'Q1K<
M?AOPOJ.KR8(M8&=5)QN?HH_%B!^-,\(Z&?#7A+3-':02/:P!78="W5L>V2:Y
M'XV.S>"K2S'W+S4X('YQP23_ #45517?+'J[?>TB:;T3EZ_<F_T.J\%C5/\
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M>-S.3T!]<9]17I-%*VEGL'6_4Y+X?^%9/!GA$6ES(;B_E=KJ[9.=TK=0/7
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M8GL*!G0T5F?\)!I?_/U_Y#;_  H_X2#2_P#GZ_\ (;?X4 :=%9G_  D&E_\
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M#;_"C_A(-+_Y^O\ R&W^% &G169_PD&E_P#/U_Y#;_"C_A(-+_Y^O_(;?X4
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M5S]U3P#P.QZ$M7/[+W_(^:EE=\?S6]SXO^!]_P"!TE%%%=!]*%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (Z+(C(ZAE88*D9!%5?[
M*T[_ )\+7_ORO^%6Z* *G]E:=_SX6O\ WY7_  H_LK3O^?"U_P"_*_X5;HH
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MJ5[+7C7B3_DXC1?^N$7_ +4KU<L^.I_@E^1C5V7JCV6BBBO*-@HHHH ****
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5S_X#M_A77_V98?\^5M_WZ7_  H_LRP_Y\K;_OTO^% '(?\ "W/"?_/U<_\
M@.W^%'_"W/"?_/U<_P#@.W^%=?\ V98?\^5M_P!^E_PH_LRP_P"?*V_[]+_A
M0!R'_"W/"?\ S]7/_@.W^%-?XO>$8T+M=W 51DDV[ "NQ_LRP_Y\K;_OTO\
MA6'XP\-)K'@_5=.TZTM5N[FW:.)F0* 3[@<4 9,7QA\'S('CO)V4]U@8BG_\
M+<\)_P#/U<_^ [?X4GPR\&S>&?!5OI>LVMH]Y'+(Q90'&"V1R178?V98?\^5
MM_WZ7_"@#D/^%N>$_P#GZN?_  ';_"C_ (6YX3_Y^KG_ ,!V_P *Z_\ LRP_
MY\K;_OTO^%']F6'_ #Y6W_?I?\* .0_X6YX3_P"?JY_\!V_PH_X6YX3_ .?J
MY_\  =O\*Z_^S+#_ )\K;_OTO^%']F6'_/E;?]^E_P * .0_X6YX3_Y^KG_P
M';_"C_A;GA/_ )^KG_P';_"NO_LRP_Y\K;_OTO\ A1_9EA_SY6W_ 'Z7_"@#
MD/\ A;GA/_GZN?\ P';_  H_X6YX3_Y^KG_P';_"NO\ [,L/^?*V_P"_2_X4
M?V98?\^5M_WZ7_"@#D/^%N>$_P#GZN?_  ';_"C_ (6YX3_Y^KG_ ,!V_P *
MZ_\ LRP_Y\K;_OTO^%']F6'_ #Y6W_?I?\* .0_X6YX3_P"?JY_\!V_PIK_%
M[PBB,[7=P%49)-NV!78_V98?\^5M_P!^E_PK$\7^&TU?PAJVG:?:6JW=S;/%
M$S(% 8CUQQ0!D1?&'P?,@>.\G93W6!B*?_PMSPG_ ,_5S_X#M_A3?ACX,F\,
M^"H-+UFUM'O(Y9&+* XP6R.2*['^S+#_ )\K;_OTO^% '(?\+<\)_P#/U<_^
M [?X4?\ "W/"?_/U<_\ @.W^%=?_ &98?\^5M_WZ7_"C^S+#_GRMO^_2_P"%
M '(?\+<\)_\ /U<_^ [?X4?\+<\)_P#/U<_^ [?X5U_]F6'_ #Y6W_?I?\*/
M[,L/^?*V_P"_2_X4 <A_PMSPG_S]7/\ X#M_A1_PMSPG_P _5S_X#M_A77_V
M98?\^5M_WZ7_  H_LRP_Y\K;_OTO^% '(?\ "W/"?_/U<_\ @.W^%'_"W/"?
M_/U<_P#@.W^%=?\ V98?\^5M_P!^E_PH_LRP_P"?*V_[]+_A0!R'_"W/"?\
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M+_A0!R'_  MSPG_S]7/_ (#M_A1_PMSPG_S]7/\ X#M_A77_ -F6'_/E;?\
M?I?\*/[,L/\ GRMO^_2_X4 <A_PMSPG_ ,_5S_X#M_A1_P +<\)_\_5S_P"
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MZE'I]S87JW:3/%YF"H...G4CK7,^#_$WBW3/B9<>"O%5_!JF^U^T6]W%"L9
M S@A0.,!NHSGO1#>SWU_+_APEM=;:?G_ ,,3:_\ $KQ$WB35-(\'^&DU5='
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M8*@XXZ=2.M'V8OSU^\/M27E^@OA#Q#XLUB^N(O$'A3^QH$BW1R_:1)O;(&W
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MRI1UBEW:5_N3?WCD[2;[)MK[VC6T/XE^(HO%FFZ'XQ\-1Z4-6!-C-%,'^BL
M3ST'8@D9'-7_ !=X_P!9LO%*>%O"6A)JVL"W^TS^;,$CB3/'4CGD=2.HZYK%
M^+2E_'GPX6(9D_M(GY>NW?%G\,9I?">?^&B/&7F8W?8X]O3.,152]ZW_ &]^
M%K?F)^[KOM^+:_30ZSX>^.?^$VTN[>XL38:C83FWN[8MNVL.X/IP>.Q!^M=A
M7D?PE5O^$_\ B,ZC]R=2 4CIG?+G^E>N4/5)]TG^ 6LVNS"BBBD 4444 %%%
M% !1110!Y5XP^)/B[0[S4)M,\&/-HVG2[)[ZX<CS0.K(!C"@\;OF''..E=+:
M^/8=0^&$WC*SM"1':23FV=\8=,@J6QTR#SCI6#\7/$KM8)X(T6,W6O:T/*$*
M?\LH3]YF],@'\,GMSM6/@,:?\*7\&P7*B62RDA:X*DKYCY+-CKC)/X5.O)+\
M/U&[<Z_'TZ&-X8\>^-O$%SILLG@80:5>%6-Z+P$+&W\>,9/':M7QUXZO/#NH
MZ;H>AZ4-4UW4MQ@@:0(BJHY9C^![@<'GBN$NKOQO\)+KP[;WNN6VK^'YIDLO
MLXM51XUX'&!N)QTY/3D5KZIG_AIK1M^-O]DMLSCTDJ])-);7?X*Y-W%-O>R_
M%V.A\!>/;WQ+J6J:%KFE#3-<TS:9H4?>CJ>X//MW/4$$UW=>1Z K']I;Q,R#
M]V--C#XZ9VPXS^M>N4;QC+NO\_\ (;5I-?ULF%%%%( HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N3
M\>^!H/&^FVL8O9;"_LIA/:7<0W&-O<9&1P.X.0/QZRBDU<:=CA/"'P[GT+Q#
M<^(M<UV;7-9FB$"3R1"-8H_0+D\\=>._')KNZ**JX@HHHI %%%% !1110 44
M44 %%%% ',>,/#FL:^ED^B^);C0[FV=B7BC\Q900.&7(!QCC.:R_!GPX/AS7
M+OQ!JVMW&MZW<IY1N9DV!$XX"Y/H.<]!@ <UW=%"TU0/7<\QUWX47USXCU/5
MO#OBJYT0:LNV^A2#S Y[D'<,9Y/L2<$9Q7:>%/#-CX0\.6NBV&YH8 29'QND
M8G+,?J?TP*VJ*%HK('J[L**** "BBB@ HHHH **** "JFJVMQ?:3=VEI>/97
M$T+1QW*+N,3$8# =\=:MT4FKZ G8\@L/@WX@L?$;ZZOQ#NC?3;5N)18X:5!C
MY2?,/91VKJ?''P^;Q5J.FZQIVKS:1K.GY$-U''O!4]BN1[_F<@UVU%/HEV#O
MYG'>!_ 2^$I=1O[S4Y=6UC47#7-[*FS('10,G Y]?3I@5RMY\%KOS]2M-)\7
M7>G:#J<WFW.G+!OSDY(#;AQVZ=,9SBO6Z*'J[A<IZ3I=KHFD6FF6,>RUM8EB
MC7O@#'/J?4U<HHIMW=V)*VB"BBBD,**** "BBB@ IK@LC*K;200&';WIU%)J
M^@'CDWP7\1SZY%K4GQ'NVU*%#''<FP^=5.> ?-_VC^==MXE\+:YJ^GZ6FE>*
M[K2[ZR&)+A(MXN<J =Z;@.HSWZUUM%/I8.MSA/!GPW/AS7;OQ!JVMW&MZW<I
MY1N9DV!$XX"Y/H.<]!@ <UF:[\*+ZY\1ZGJWAWQ5<Z(-57;?0I!Y@<]R#N&,
M\GV).",XKTZBAJ]O(%H8OA3PS8^$/#EKHMAN:* $M(^-TC$Y9C]3^F!6U113
M;;=V)*VB"BBBD,**** "BBB@ H/2BB@#QBR^!^NZ7>WEWIWQ$O+2:\??.\-D
M5,AR3\Q$O/)/YUVNI^ 1KWP]C\+ZWJUQ>W" ,-1*XD,@)(8J2<\'&">GIV[*
MBE;W>7I_D._O<W4\W\.?"^]L?$MEKGB/Q-<:[<:?%Y=E')#Y:Q<8W'YCD_UY
MR>*L>*_AM=:OXI3Q-H'B&?0]5,/D32)%YJRIVXR,'IZC@=",UZ!13>MO(2T.
M8\#>"K7P1HLEG%<R7EU<2F>ZNY1AII#WQDX'MD]_6NGHHIMW ****0!1110
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M@@9.0O/K7;:)H>F^'-+CTW2;86UG&S,D0=F +$D\L2>I->4?%_\ Y*;\._\
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MMZHZC[SLVWE^  ,8Y/3H>O\ BIX$O?&^C6*Z7=0VVHV%QYT+S$A3QR,@$@\
MCCM7?44WK]]_F)*WW6^1P\/A[Q9J/PSU31?$6J6=YK=Y#-$DZ+LB4,,*#M0=
M.YV]^]9=I\+I;CX.0^"M5NH%O(B\B7%OET1_,9U(W $C!P>G4UZ910];^=OP
M!:6\OU/"6^&'Q,UC2;3PQK?B73E\/VY13Y(W.R+]T#Y 6Q_M$?CBO4]9\,B?
MX?7GAC2C'$&L#9VYF)"K\FT;B ?QP*Z.BB6J:?4%HTUT/.]+\!:I9?!>;P;+
M<69U%[>:(2J[>5EW9ASMSC!':M_P!X>N_"O@C3=%OI()+FV5P[0,2ARY;@D
M]#Z5TM%-MMM][?@*VR[7_$****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( \\# 2(  A$! Q$!_\0
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M[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\
MGTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.
MLO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP
M*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I
M#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G6
M7_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *
MW]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6
M:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_
M[X%6:* *W]G67_/I#_WP*/[.LO\ GTA_[X%6:* *W]GV0ZVD/_? IOV*P_Y]
M8?\ OU5IONFJ_P")JE&Y+=AOV*P_Y]8?^_5'V*P_Y]8?^_5._&C\:?*+F&_8
MK#_GUA_[]4?8K#_GUA_[]4[\:/QHY0YAOV*P_P"?6'_OU1]BL/\ GUA_[]4[
M\:/QHY0YAOV*P_Y]8?\ OU1]BL/^?6'_ +]4[\:/QHY0YAOV*P_Y]8?^_5'V
M*P_Y]8?^_5._.C\31RAS#?L5A_SZP_\ ?JC[%8?\^L/_ 'ZIWXFC\31RAS#?
ML5A_SZP_]^J/L5A_SZP_]^J=^-'XT<H<PW[%8?\ /K#_ -^J/L5A_P ^L/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:FI/')8:3]J\Y8-I!;YSP-WI0[@K'>GQMHBZ';ZO))=);7#^7&OV20R,X&2
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M_M6#_GC+_P!]"IHKZ&6*63RY (P"1D<YHYD'*R?)Q15?[?!_SSE_,4?;X/\
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ME_E5FJVG?\@RT_ZY+_*K-24%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S;\;?\ DHDG
M_7K%_*O.N]>B_&W_ )**_P#UZQ?RKSH5[^'_ (4?0\ZI\3"BE(XS@_E16I'*
MQ**4@@_XB@#GI1==Q\K$HIW8DBO5O!_P=_M'3H]3\17,MI#(H=+:,A7V_P!Y
MV/W?I6<ZL8*[92IR;L>3T5[R_P )?!6JP21Z3J<JSH/OQ7*S;3[K7D?BOPK?
M^$-7-A?A75AO@G3[LR^H]_4=JFG7C4=EN$J3B85%'((R",]R,4HZ="3["MOF
M182BC![Y!^F*LVNGWM\";.RN+@+U,43./T%#MW#E>Q6HI\T,MO*8YXI(I!_!
M(I4_D:90G?9BL=C\+?\ DH%B/^F<O_H)KWJO!?A;_P E L?^N<O_ *":]ZKR
M<;_$7H=U#X0HHK UO7;[3]7L-,T_3XKN>\1W422^6!MZ\UPHW-^BL'2_%5E>
MZ"^JW>+%(IF@E61\[9 <8!'6K:^(M';3_P"T!J$)M!((S*<@*Q[$=1^-.S T
MZ*SK/7M*U"*XEM;^&1+;_7MG'E^YSV]Z2QU_2M268V=]%+Y*[I!R"H]<$=*+
M,#2HK,LO$>C:BTJVNH1R-$A=Q@@[1U.".1]*BT/Q-IOB)9?L,C;XR=R.I!QG
M ;/3FBP&Q1112 LVG^JN?]U?YTM):_ZJY_W5_G2T %%%% !16)KWB Z1/9V5
MM9M?:C>L1!;J^P8'5B>P%0Z;XFEDU*[TS6+#^SKZW@-QA9/,1XAU8$>G>G8#
MH:*R8O$^B3Q3RPZE"\<$8EE9<D(K="?\.M03^)[&;0-2U+2KB&Z>SB+F,@C!
M'(!!P0#19@;M%5=+NVOM)L[R155YX5D95Z D9P*M4@"BBB@!9O\ CQ/_ %U'
M\JJ&K<O_ !Y'C_EK_2N(U'Q;J%KJ>JV]MI4$\&FHKS2/<[&*D9X!ZFFE<#K*
M*QSXHTF'3+&^O+D6JWD8DCCD!+X]P.WO5R#5K"YNTM(+N.2=X?/15YW1_P!X
M&BS N45D2>*-$CM$NGU!!"[LB-M8[BOW@,#G'>K$VMZ7;Z:NHRWT*V;_ ')=
MV0Q] .I-%F!?HK%;7X;BYTHV%S:R6M[(Z,S[@YVC^#CK]<4MOXKT*[NQ:P:@
MK3D,=FQ@<+RQY'M18#9HK/37=,>UL[I;M##>R>7;O@XD<]%'%5YO%6@V]P;>
M;5((Y1(865B?E8=0?3\:+,#8HK.LM?TG4I9X[*_BE> ;I0I/RKZ^X^E-L/$&
MDZK.\%C?1S3*I;8 5) [C.,BBS TZN6?_'I=_1?YUQOA_P 96.J6UNEY=6T&
MH3.ZK I.#@X')[D5V=I_QZW?T7^=%@&4444@"BBB@ HHHH **** "BBB@"6W
M_P!>/HW\JSQT%:%O_KA]&_E6>.@H 6BJVH7\&EZ=<7]TQ6"!"[X'/T%9&E:S
MK>I26\SZ"MO87'*RO< R(N.&*^_I18#H**RV\1Z.NI?V<=0B%WNV>6V1\WIG
M&,^U-O/$^B:?<R6]WJ,,4T3!7C;.02,\^WO3LP-:BLRT\0Z/?WKV=IJ,,TZ*
M7*IG[HZD<<U73Q?X=D=%75[;+@L.2!@=1G&,^U%F!MT5FV_B#2;K3YK^&_B>
MU@.)9!D;#[C&:DT[6-.UA)&T^[2<1G#@ @KZ9!YHLP+U%%%(#7N/^/A_J/Y5
M%4MQ_P ?#_7^E14 %%9?B'7;;P[I+W]Q')+\ZQQPQ_>E<G 456TS4_$$[RG5
M- AL(!"TB2+=B0[@,A66G8#=HKDM)\5W>HV'ARYD6R@;5)9$EC9FW87/$?!R
M>.]:X\3Z&=5_LPZE"+S?Y?ED$?/_ '<XQGVHLP-:BN9\3^,].T&TOHH[RV?5
M[>$RQVDA/)[ XZ?3.:MR^*=)L+.QEU2^AMIKJ!9O+Y. 1UP,X&>YHLP-NBL,
MZ\[>,+/2(5ADM+FP:[$ZG).#QC'&,5N4@"GZQ_R++?1?_0J93]8_Y%EOHO\
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M+Q ]">QS[5R==U)02M#8YYWO[QV/PM_Y*!8_]<Y?_037O5>"_"W_ )*!8_\
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M.A64J7]JLD)MY) [B.3.06X!P>:[RJ]W>Q67D>8&9IY1%&BC)9C_ $ Y-/F
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M]);Z-?P^$Y=2@LI8IK/4S?:=:,,.L61E<=LCM19 >BM>6B&;=<PJ8/\ 79D
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M/^%H>-O^AAN?^^$_PH=.LURM*P*</,V/&_ASXAMITFK^*)5DM+;'RK.I5,G
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MDE8G)9O_ *PXJ:D 5=L_^/2[_P!U?YU2J[9_\>EW_NK_ #H 91DYR"<^M%%
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MWKWQ(M-.AAOK+3WTQYWM+R (Y?(PV>X(/:O0:8!1110(**** "BBB@#'UO\
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M%PY6:/V2?_GG_P"/"C[)/_SS_P#'A6=11<.5FC]DG_YY_P#CPH^R3_\ //\
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MN_K1L;^[^M5** +>QO[OZT;&_N_K52B@"WL;^[^M/56\MQCKBJ-30_ZJ7\*
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M[FI;OQ+>1ZE# D%O;0RQ)(DEWN <GJ 1T(Z<TN9%_5YG3T4?E^%%4<X4444
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M6V:U6SN9@4CC;C P.2.Q/2HM'^'MAH^I:9?_ -J:E=S:8C16PN)%*K&RXV
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MB&W51%,I D0KW!]^0?4&I;S04N+E[BWOKNQDEB6&<V^/WJ 8&<]"!D9%:U%
M$-I:06%E!:6R;((4"1IUP!_6IJ** "BBB@ J:'_52_A4-30_ZJ7\* $HHHH
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M4WJO_?5&*,47"QEZO:O+<1$/$,1X^9\=S6?]@D_YZP?]_*T-6_X^(>/^6?\
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MJI,48H C^SOZI_WU4L43+'("5YQWI,4].(I,>U #/);U7_OJCR6]5_[ZHHH
M/);U7_OJCR6]5_[ZHHH /);U7_OJCR6]5_[ZHHH /);U7_OJCR6]5_[ZHHH
M/);U7_OJCR6]5_[ZHHH <D9W]5[]ZA\A_5/^^JFC^^/QIM $?V=_5/\ OJC[
M._JG_?528HQ0!']G?U3_ +ZH^SOZI_WU4F*,4 1_9W]4_P"^J/L[^J?]]5)B
MC% $?V=_5/\ OJC[._JG_?528HQ0!']G?U3_ +ZH\A_5?SJ3%% "O$QD/*_G
M2>2WJO\ WU3G_P!8U-H /);U7_OJCR6]5_[ZHHH /);U7_OJCR6]5_[ZHHH
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MC?8/X6(^\./U-=%10!AOX0T.9-9CGM#-'J\@EO$D<D%@, K_ '<=L55T_P
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MNH6R6Q$%_-Y\R!B,/ZI_=((R,=ZLZ=H]MILTT\;W$]S,%62XN)3)(RKT7)Z
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M46"Y+MC_ .>@_(T8C_YZ#\C45%%@N4M5$'GQ;[D(?+_N$YY-4=MK_P _B_\
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M4RYB<@9+*?O FES&GU=OJ=I12!@R@@Y!&0:6K.9[V"BBB@04444 :&C?\?\
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M %5M;_Y%Z7ZK_P"A"K-5M;_Y%Z7ZK_Z$* )K7_D$6?\ UR7^5+26O_((L_\
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M%8P-RGJ,=L^U:%% %.PTG3]+#BPLX;;?]\QK@MZ<^GM5RBB@ HHHH ?']_\
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M]EC_ +[?E4U% $/V6/\ OM^5'V6/^^WY5-10!#]EC_OM^5'V6/\ OM^5344
M0_98_P"^WY4]+=51P&)!QVI].'^K:@"'[.G]]ORH^SI_>;\JDHH C^SI_>;\
MJ/LZ?WF_*I** (_LZ?WF_*C[.G]YORJ2B@"/[.G]YORH^SI_>;\JDHH C^SI
M_>;\J/LZ?WF_*I** &) H;(<GCTIGV2/^^WY5.O7\*2@"'[+'_?;\J/LL?\
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M>]0Z9/!%;^&+_3]1GGUZ^ND34(GN"S2@@F8.A.%"'IP,8 H ]/HHHH ****
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M0/\ 9.LZ8L5TJC(@N<823'H_W6]P#ZUT=W]AO-<U&'Q#?R6D%II\$E@OVDP
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M)86<MF+.2SMWM0 !"\2E!CI\N,58HH 1$2-%2-%1%&%51@ >@%+110 4444
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M^TP8_P"N@I/[1L/^?F#_ +^"BB@ _M&P_P"?F#_OX*/[1L/^?F#_ +^"BB@
M_M&P_P"?F#_OX*/[1L/^?F#_ +^"BB@ _M&P_P"?F#_OX*/[1L/^?F#_ +^"
MBB@ _M&P_P"?F#_OX*/[1L/^?F#_ +^"BB@ _M&P_P"?F#_OX*/[1L/^?F#_
M +^"BB@ _M&P_P"?F#_OX*/[2L<$"Y@Y_P"F@HHH /[1L/\ GY@_[^"C^T;#
M_GY@_P"_@HHH /[1L/\ GY@_[^"C^T;#_GY@_P"_@HHH /[1L/\ GY@_[^"C
M^T;#_GY@_P"_@HHH /[1L/\ GY@_[^"C^T;#_GY@_P"_@HHH /[1L/\ GY@_
M[^"C^T;#_GY@_P"_@HHH 4:C8#I<P?\ ?P4G]HV'_/S!_P!_!110 ?VC8?\
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F_OX*** #^T;#/_'S!_W\%5-09=5MC9V;JY;&YU.54#GFBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
